<SEC-DOCUMENT>0001125345-18-000022.txt : 20180227
<SEC-HEADER>0001125345-18-000022.hdr.sgml : 20180227
<ACCEPTANCE-DATETIME>20180227160701
ACCESSION NUMBER:		0001125345-18-000022
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		86
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180227
DATE AS OF CHANGE:		20180227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MACROGENICS INC
		CENTRAL INDEX KEY:			0001125345
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36112
		FILM NUMBER:		18645107

	BUSINESS ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			Rockville
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-251-5172

	MAIL ADDRESS:	
		STREET 1:		9704 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>mgnx-123117x10k.htm
<DESCRIPTION>10-K
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s34E1ABEDF72B5CA4856F427A955EFCB7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C.&#160;&#160;20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM 10-K</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Mark One)</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9746;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the fiscal year ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OR</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:682px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:61px;"></td><td style="width:621px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#9744;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to &#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commission File Number 001-36112</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Exact name of registrant)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Delaware&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">06-1591613</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(State of organization)&#160;&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(I.R.S. Employer Identification Number)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9704 Medical Center Drive, Rockville, Maryland 20850</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">(Address of principal executive offices and zip code)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(301)&#160;&#160;251-5172</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant's telephone number)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Securities registered pursuant to Section 12(b) of the Act:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:4%;"></td><td style="width:48%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title of Each Class</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Name of Each Exchange on Which Registered</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, par value $0.01 per share</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Nasdaq Stock Market LLC</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Securities registered pursuant to Section 12(g) of the Act: None</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745; </font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;&#9744;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font><font style="font-family:inherit;font-size:10pt;">&#160;No&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font><font style="font-family:inherit;font-size:10pt;">&#32;No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein and will not be contained, to the best of the registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font><font style="font-family:Wingdings 2;font-size:10pt;">&#32;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company.&#160;&#160;See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:25%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer </font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer&#160;&#160;&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Yes&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font><font style="font-family:Wingdings 2;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">No&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#222222;">&#9745;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate market value of the registrant's common stock, par value $0.01 per share, held by non-affiliates of the registrant on June&#160;30, 2017, the last business day of the registrant's most recently completed second fiscal quarter, was approximately $642 million based on the closing price of the registrant's common stock on the Nasdaq Global Select Market on that date.&#160;&#160;Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, direct or indirect, to direct or cause the direction of management or policies of the registrant, or that such person is controlled by or under common control with the registrant.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The number of shares of the registrant's common stock outstanding on </font><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">36,918,852</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of MacroGenics, Inc.'s definitive proxy statement for the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual meeting of stockholders are incorporated by reference into Part III of this Annual Report.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="sB3A83A76A29D562C890EFFB7837A8AFF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ANNUAL REPORT ON FORM 10-K</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">TABLE OF CONTENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s445763FFBF165FC9AC40A5B1A6466CE2"><font style="font-family:inherit;font-size:10pt;">Business</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAE8F9604B73F5B8B926EF1BC43AC1B81"><font style="font-family:inherit;font-size:10pt;">Risk Factors</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 1B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sCBC601E3B783596BA534583A321D00E7"><font style="font-family:inherit;font-size:10pt;">Unresolved Staff Comments</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD454CFCAA22D575DA192E1BE7CCB4EB6"><font style="font-family:inherit;font-size:10pt;">Properties</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s239BF47AAB2E5C86B0E7F6EBF17595A4"><font style="font-family:inherit;font-size:10pt;">Legal Proceedings</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 4</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB2B23833C4BA5FA897AC2F69BB96350E"><font style="font-family:inherit;font-size:10pt;">Mine Safety Disclosures</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 5</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0308C1C10C70577399B9ECF0A721B287"><font style="font-family:inherit;font-size:10pt;">Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 6</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE5151942094551EFB1E3089E9E8E92CB"><font style="font-family:inherit;font-size:10pt;">Selected Financial Data</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5ABE223BD5D559E38E28F4BC5875A5F8"><font style="font-family:inherit;font-size:10pt;">Management's Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 7A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB1470B487EAB5424A58B9F04010623FA"><font style="font-family:inherit;font-size:10pt;">Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 8</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sB0AA3C9392245881B47B5BA212F3F3F8"><font style="font-family:inherit;font-size:10pt;">Financial Statements and Supplementary Data</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0497764479FB59E082151BDB87E42D84"><font style="font-family:inherit;font-size:10pt;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC5F5A12ABBF95689B0BE2842A573224C"><font style="font-family:inherit;font-size:10pt;">Controls and Procedures</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 9B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s25BE8DF7C4DE53CA840AEF2D4516088F"><font style="font-family:inherit;font-size:10pt;">Other Information</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 10</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s19A814EAD55753199995AE423E03858D"><font style="font-family:inherit;font-size:10pt;">Directors, Executive Officers and Corporate Governance</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 11</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD6947B3F94A75F0B82EF972B5CF42729"><font style="font-family:inherit;font-size:10pt;">Executive Compensation</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 12</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s47CFF52B44275E4CBBA902ED9445B13E"><font style="font-family:inherit;font-size:10pt;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 13</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0F931FC496715003BE06FAC1A339838F"><font style="font-family:inherit;font-size:10pt;">Certain Relationships and Related Transactions, and Director Independence</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD577C939F9E8551D92A705E6AFEB7121"><font style="font-family:inherit;font-size:10pt;">Principal Accountant Fees and Services</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1AB9B15FF1F75D6CA9260CF1C7F597A1"><font style="font-family:inherit;font-size:10pt;">Exhibits and Financial Statement Schedules</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Item 16</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE104D8107D875334B4C5236128B87D0A"><font style="font-family:inherit;font-size:10pt;">Form 10-K Summary</font></a></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;" href="#sC0A27E47A81356B98E9056687DE9247B"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><hr style="page-break-after:always"><div><a name="sD7E92B5E8C605E8B9509F5394AC253CC"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This report includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations". Forward-looking statements can often be identified by the use of terminology such as "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All forward-looking statements, including, without limitation, our examination of historical operating trends, are based upon our current expectations and various assumptions. We believe there is a reasonable basis for our expectations and beliefs, but they are inherently uncertain. We may not realize our expectations, and our beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements. The following uncertainties and factors, among others (including those set forth under "Risk Factors"), could affect future performance and cause actual results to differ materially from those matters expressed in or implied by forward-looking statements:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our plans to develop and commercialize our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the outcomes of our ongoing and planned clinical trials and the timing of those outcomes;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to enter into new collaborations or to identify additional products or product candidates with significant commercial potential that are consistent with our commercial objectives;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to recover the investment in our manufacturing capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the rate and degree of market acceptance and clinical utility of our products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our commercialization, marketing and manufacturing capabilities and strategy;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant competition in our industry;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of litigation and the failure to successfully defend lawsuits and other claims against us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">economic, political and other risks associated with our international operations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to receive research funding and achieve anticipated milestones under our collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to protect and enforce patents and other intellectual property;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">costs of compliance and our failure to comply with new and existing governmental regulations including, but not limited to, tax regulations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss or retirement of key members of management;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to successfully execute our growth strategy, including any delays in our planned future growth; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our failure to maintain effective internal controls.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consequently, forward-looking statements speak only as of the date that they are made and should be regarded solely as our current plans, estimates and beliefs. You should not place undue reliance on forward-looking statements. We cannot guarantee future results, events, levels of activity, performance or achievements. Except as required by law, we do not undertake and specifically decline any obligation to update, republish or revise forward-looking statements to reflect future events or circumstances or to reflect the occurrences of unanticipated events.</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s441149F5FAD95D62BF154DD59D048707"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I</font></div><div><a name="s445763FFBF165FC9AC40A5B1A6466CE2"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1.</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">BUSINESS</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Except as otherwise indicated herein or as the context otherwise requires, references in this annual report on Form 10-K to "MacroGenics," the "company," "we," "us" and "our" refer to MacroGenics, Inc. and its consolidated subsidiaries.</font><font style="font-family:inherit;font-size:10pt;color:#1f497d;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">MacroGenics, the MacroGenics logo, DART</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(R)</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, TRIDENT</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;and the phrase "Breakthrough Biologics, Life-Changing Medicines" are our trademarks or registered trademarks. The other trademarks, trade names and service marks appearing in this report are the property of their respective owners.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms, which also have broad applicability across other therapeutic domains, including autoimmune disorders and infectious disease. We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our most advanced clinical product candidate is margetuximab, a monoclonal antibody directed against human epidermal growth factor receptor 2, or HER2, that has been enhanced using our proprietary "Fc Optimization" platform described in greater detail below. The HER2 protein is expressed by certain breast, gastroesophageal and other cancers. We have an ongoing Phase 3 clinical trial, which we call SOPHIA, to study margetuximab in patients with HER2 positive metastatic breast cancer that has progressed despite treatment with other HER2-directed therapeutic agents. In January 2018, we announced the completion of a pre-planned interim futility analysis with the recommendation of an independent data safety monitoring committee to continue SOPHIA as planned without modification. This analysis was based on a pre-specified assessment of progression-free survival as determined by independent central review. We anticipate that a successful outcome from the SOPHIA study would allow us to seek approval of the product from the U.S. Food and Drug Administration, or FDA. We are also conducting a Phase 2 clinical trial by treating patients with HER2-positive gastric or gastroesophageal junction cancer with margetuximab in combination with an anti-PD-1 monoclonal antibody, an immune checkpoint inhibitor molecule that plays a critical role in modulation of the immune system's response to cancer. Encouraging interim clinical data from this study were presented in January 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Flotetuzumab is one of several clinical-stage molecules developed using our proprietary platform technology for making DART</font><font style="font-family:Arial;font-size:10pt;">&#174;</font><font style="font-family:inherit;font-size:10pt;">&#32;molecules, which is described in greater detail below. Unlike standard monoclonal antibodies, DART molecules are bispecific, which means they can be directed against two different biological targets, and therefore lend themselves to a variety of different applications. Flotetuzumab is a bispecific, humanized DART molecule that recognizes both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, has been reported to be over-expressed on cancer cells in a wide range of hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). AML and MDS are thought to arise in and be perpetuated by a small population of leukemic stem cells (LSCs) that generally resist conventional chemotherapeutic agents. LSCs are characterized by high levels of CD123 expression that is low or absent in the corresponding hematopoietic progenitors and stem cell populations in normal human bone marrow. Flotetuzumab was designed to redirect T lymphocytes to kill CD123-expressing cells. To achieve this, the DART molecule combines an arm that recognizes CD123 on the target cancer cells, with a portion of an antibody recognizing CD3, an activating protein expressed by normal T cells, which are specialized white blood cells in the human immune system. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Updated dose expansion data from an ongoing Phase 1 study of flotetuzumab were presented at a scientific conference in December 2017. Consistent with dose escalation data that had previously been presented, flotetuzumab demonstrated acceptable tolerability as well as evidence of anti-leukemic activity, with three of eight evaluable patients in the dose expansion cohort experiencing complete remission with or without platelet recovery (CR/CRi) or morphologic leukemia-free (MLF) state as of the data cut-off date. Our collaborator, Les Laboratoires Servier and Institut de Recherches Servier, or, collectively, Servier, has development and commercialization rights outside North America, Japan, Korea and India for flotetuzumab.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are pursuing multiple approaches for targeting an immune system protein known as programmed cell death protein 1 (PD-1). Marketed antibodies targeting this checkpoint molecule have shown clinical efficacy in the treatment of various tumors by releasing the "brakes" on the immune system which is often seen when tumors evade detection by the immune system. In 2016, we commenced a Phase 1 clinical study of MGA012, a humanized, monoclonal antibody directed against PD-1. MGA012 is being developed for use as monotherapy as well as in combination with other potential cancer therapeutics. We licensed MGA012 to Incyte Corporation in 2017 under a global collaboration and license agreement. We retain the right to develop our own pipeline assets in combination with MGA012.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to MGA012, we use the anti-PD-1 specificity as we continue to develop additional bispecific and trispecific molecules that engage this target together with other immune regulatory molecules. Monoclonal antibodies that target the immune checkpoints PD-1 and lymphocyte-activation gene 3 (LAG-3) have shown enhanced clinical antitumor activity when given in combination. Recognizing the therapeutic potential of dual checkpoint blockade, we have engineered MGD013, a bispecific DART&#160;molecule, to bind PD-1 and LAG-3 concomitantly or independently and disrupt these non-redundant inhibitory pathways to further restore exhausted T-cell function. We anticipate that MGD013, if approved, could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. MGD013 has demonstrated an acceptable preclinical safety and toxicological profile and is currently being evaluated in a Phase 1 dose escalation study. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Approved monoclonal antibodies that target the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4 </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(</font><font style="font-family:inherit;font-size:10pt;">CTLA-4) have shown enhanced clinical antitumor activity when given in combination in various cancers, including renal cell carcinoma and non-small cell lung cancer with high tumor mutational burden. MGD019, a second DART molecule in our pipeline designed to enable co-blockade of two immune checkpoint molecules co-expressed on T cells, recognizes both PD-1 and CTLA-4.  We anticipate submitting an Investigational New Drug (IND) application for MGD019 in 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. B7-H3 is widely expressed by a number of different tumor types and may play a key role in regulating the immune response to various types of cancer. There are no currently approved therapeutic agents directed against B7-H3. We have two clinical product candidates directed against B7-H3, enoblituzumab and MGD009, and we also have ongoing research efforts underway to advance MGC018, an antibody-drug conjugate, or ADC, directed against B7-H3. Our most advanced candidate in this franchise, enoblituzumab, is a monoclonal antibody that has also been enhanced using our Fc Optimization platform. Enoblituzumab is being evaluated clinically in multiple studies either as monotherapy, or in combination with an anti-PD-1 antibody across multiple tumor types.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009 is directed to both B7-H3 expressed on tumor cells as well as CD3, expressed on normal T cells. In preclinical models, MGD009 has re-directed T cells to reduce or eliminate B7-H3 expressing tumors. We are currently conducting a Phase 1 clinical trial with MGD009 in patients with B7-H3 positive tumors and in a separate study that combines MGD009 and MGA012.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Two additional CD3-targeting DART molecules, MGD007 and PF-06671008, are currently in Phase 1 clinical testing, with each targeting a specific tumor antigen known to be expressed on certain cancers. MGD007, which recognizes glycoprotein A33 (gpA33) and CD3, is being tested in patients with colorectal cancer. Our collaborator, Servier, has an option to gain development and commercialization rights for MGD007 outside North America, Japan, Korea and India. PF-06671008, which targets p-cadherin and CD3, is being advanced by our collaborator Pfizer, Inc. (Pfizer) and is being studied in certain undisclosed solid tumors. The DART molecules that redirect T cells against cancer targets are manufactured using a conventional antibody platform without the complexity of having to genetically modify T cells from individual patients, as would be required by approaches such as chimeric antigen receptor (CAR) T cells.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beyond oncology, we believe our antibody-based technology platforms have broad applicability across other therapeutic domains. For example, MGD010, a clinical-stage DART molecule, has a different mechanism of action than the other DART molecules currently in development. MGD010 recognizes two proteins expressed by B cells, which are specialized white blood cells that play a role in modulating the human immune system's inflammatory response. We believe that MGD010 may be able to reduce the harmful inflammatory effects seen in a variety of autoimmune and inflammatory disorders by modulating the function of human B cells while avoiding their depletion. In 2017, we completed a Phase 1 clinical study in healthy volunteers and observed acceptable safety and pharmacodynamic activity consistent with the expected mechanism of action of MGD010.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As another example of our DART platform's versatility, MGD014 is the first DART molecule designed to target an infectious agent. MGD014 targets the envelope protein of HIV-infected cells (Env) and T cells, via their CD3 component, to redirect the immune system&#8217;s T cells to kill HIV-infected cells. An IND for MGD014 was cleared by FDA in 2017 and we expect to commence the Phase 1 study in 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We continue to invest in our clinical-stage programs, advance additional preclinical product candidates, primarily using our proprietary technology platforms, and expand the potential of our platforms using our antibody and protein engineering expertise. We develop new therapeutic product candidates internally using our proprietary platforms and also in collaboration with other biopharmaceutical companies, when such relationships are advantageous for strategic or financial reasons. These arrangements have allowed us to expand and accelerate the breadth of our product candidates and also have generated a significant portion of the funding we have received to date. We also have our own manufacturing facility, primarily </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for generation of earlier-stage clinical trial material, and have been investing in expanding our manufacturing capacity to meet later-stage clinical and future potential commercial requirements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We estimate that in 2017, 2016 and 2015, we spent approximately </font><font style="font-family:inherit;font-size:10pt;">$147.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$122.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$98.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;on research and development activities, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Strategy</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our goal is to be a fully integrated biotechnology company leading in the discovery, development and commercialization of breakthrough biologics for the treatment of patients with cancer.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:54px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Key elements of our strategy are as follows:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Therapeutic focus, science driven.</font><font style="font-family:inherit;font-size:10pt;">&#160; We create therapeutic biological products primarily to treat various types of cancers, including both solid tumors and hematological malignancies.&#160; Our proprietary DART and Fc Optimization technology platforms are particularly useful for targeting and harnessing specific elements of the human immune system, allowing us to design molecules that (1) directly target cancer cells and enhance the ability of the immune system to destroy those cells, (2) re-direct effector cells to attack tumors or (3) affect mechanisms that regulate the immune response to cancer, either by stimulating pathways that enhance this response or by blocking pathways that inhibit this response, including checkpoint molecules.&#160;This field of scientific discovery, broadly known as immuno-oncology, has been developing rapidly in the last few years, and most therapeutic products to date are largely focused on affecting individual biological pathways.&#160;We believe that cancers are sufficiently complex that effective treatments must simultaneously affect more than one pathway.&#160; We believe that we are well-positioned, particularly through the adaptability of our DART platform, to be able to create and develop therapeutic molecules designed to simultaneously target more than one pathway.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This same flexibility in our platforms allows us to create therapeutic molecules that may be useful for other unmet medical needs beyond cancer, such as for autoimmune disorders and infectious diseases.&#160; Our core strategic focus is on development of cancer therapeutics, but we may also opportunistically pursue such possibilities when they arise.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fully integrated with a deep pipeline.</font><font style="font-family:inherit;font-size:10pt;">&#160; Our objective is to be a fully-integrated biotechnology company, and we intend to continue to grow and establish all necessary functions from early-stage research through commercialization in at least the United States.&#160; At our current stage of development as a company, we have established early-stage discovery, process development, clinical development and clinical-stage manufacturing functions, we are completing the build-out of a facility that will support commercial manufacturing, and we intend to build a U.S.-based sales and marketing infrastructure as our development pipeline matures.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have a broad portfolio of product candidates and we are not dependent upon the success of any one of them for the overall success of the company.&#160; We continue to augment our pipeline through the discovery and development of new product candidates, primarily through utilization of our internal scientific expertise and strategically seeking external collaborations that can augment our own skills.&#160; From 2015 to 2017, we advanced four programs into clinical development.&#160; Our goal is to continue to advance one or more programs into clinical development per year to ensure a robust pipeline and to replace product candidates that fail to progress.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leveraging collaborations.</font><font style="font-family:inherit;font-size:10pt;">&#32;Throughout our company's history, we have entered into collaborations with other biopharmaceutical companies and intend to continue to do so.&#160;We enter into collaborations when there is a strategic advantage to us to do so and when we believe the financial terms of the collaboration are favorable for meeting our short-term and long-term strategic objectives.&#160;We are not dependent upon any one of these collaborations, but in many cases we have rights to receive sales royalties and other significant financial payments if the partnered product candidates achieve certain development and sales milestones.&#160;Some of the collaborations also preserve our right to participate in future commercialization, for example by securing co-promotion or profit-sharing rights under certain circumstances.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investments in talent and culture.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;One of our most valuable assets is the quality of our employee base. We invest significant effort in selecting and retaining high caliber, talented individuals who reflect our values.&#160;As we continue to grow, we continue to seek and develop employees who are strongly committed to delivering life-changing medicines for unmet medical needs through a collaborative work environment.</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Therapeutic Areas We Target</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cancer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is a broad group of diseases in which cells divide and grow in an uncontrolled fashion, forming malignancies that can invade other parts of the body. In normal tissues, the rates of new cell growth and cell death are tightly regulated and kept in balance. In cancerous tissues, this balance is disrupted as a result of mutations, causing unregulated cell growth that leads to tumor formation and growth. While tumors can grow slowly or rapidly, the dividing cells will nevertheless accumulate and the normal organization of the tissue will become disrupted. Cancers subsequently can spread throughout the body by processes known as invasion and metastasis. Once cancer spreads to sites beyond the primary tumor, it generally becomes more difficult to treat and may be incurable. Cancer cells that arise in the lymphatic system and bone marrow are referred to as hematological malignancies. Cancer cells that arise in other tissues or organs are referred to as solid tumors. Cancer can arise in virtually any part of the body, with the most common types arising in the prostate gland, breast, lung, colon and skin.&#160; We believe that our platforms position us very well strategically to actively develop approaches for the treatment of both solid tumors and hematologic malignancies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cancer is the second leading cause of death in the United States, exceeded only by heart disease.  An increasing number of people are also living longer with cancer. The American Cancer Society has estimated that by January 2026, the population of cancer survivors in the United States will increase to almost 20.3 million people. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Therapeutic Areas </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We believe our proprietary technology platforms also have broad applicability across other therapeutic areas, including autoimmune disorders and infectious disease.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Autoimmune disorders, including rheumatoid arthritis, Crohn's disease, systemic lupus erythematosus and multiple sclerosis, collectively affect more than 20&#160;million people in the United States. Autoimmune disorders involve self-reactivity and destruction by T cells, B cells and antibodies due to a lack of self-tolerance. Anti-inflammatory therapies, such as tumor necrosis factor inhibitors, have been able to improve diseases like rheumatoid arthritis.&#160; However, in addition to T cells, more evidence indicates that B cells play an important role in many common autoimmune and allergic disorders by initiating and amplifying the pathological disease processes. Current B cell targeted therapies either cause depletion of B cells, thus limiting their applicability due to the potential for infections (e.g., rituximab), or exhibit a delayed onset of action and limited efficacy across patient populations (e.g., belimumab).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a wide variety of infectious diseases, and the epidemiology for each varies significantly with the type of pathogen and patients who are affected. However, in order to avoid being recognized as foreign by the human immune system, many infectious agents have found ways to evade detection. In this way, they may behave similarly, at a biological level, to certain types of cancer. Accordingly, our expertise in designing protein-based therapeutics that are designed to activate the human immune system to eliminate foreign substances may have applicability to various types of infectious diseases, and we explore those possibilities opportunistically.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Product Candidates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below depicts the current status of product candidates that are in or near human clinical development and for which we retain all or some commercial rights:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">4</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="pipelinechart201710k.jpg" alt="pipelinechart201710k.jpg" style="height:383px;width:684px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Oncology</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Margetuximab</font><font style="font-family:inherit;font-size:10pt;">&#32;is a monoclonal antibody that targets HER2-expressing tumors, including certain types of breast and gastroesophageal cancers. HER2 is critical for the growth of many types of tumors. Using our Fc Optimization platform, we have engineered the constant region, or Fc region, of margetuximab to increase its ability to kill tumor cells through an Fc-dependent mechanism, including antibody dependent cell-mediated cytotoxicity, or ADCC. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our Phase 1 data for margetuximab, in addition to demonstrating margetuximab was well-tolerated at the dose levels studied, demonstrated that anti-tumor activity had been observed at a range of doses tested, including the lowest dose level of margetuximab, even in patients who were heavily pre-treated (frequently with other anti-HER2 agents). We are currently studying margetuximab in a Phase 3 clinical trial, which we call SOPHIA, in patients with metastatic breast cancer expressing HER2 at the 3+ level by immunohistochemistry (IHC) or 2+ level by IHC with gene amplification whose tumors have progressed despite therapy with other HER2-directed therapeutic agents.&#160; In January 2018, we announced the completion of a pre-planned interim futility analysis with the recommendation of an independent data safety monitoring committee to continue SOPHIA as planned without modification. This analysis was based on a pre-specified assessment of progression-free survival as determined by independent central review. The FDA has granted Fast Track designation for the investigation of margetuximab for treatment of patients with metastatic or locally advanced HER2 positive breast cancer who have previously been treated with anti-HER2-targeted therapy.</font></div><div style="line-height:120%;padding-bottom:12px;padding-left:78px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also conducting a Phase 2 clinical trial combining margetuximab with an anti-PD-1 antibody in patients with HER2-positive gastric or gastroesophageal junction (GEJ) cancer.  In January 2018, MacroGenics presented interim clinical data from this study, including acceptable tolerability and an objective response rate (ORR) that was higher in patients with gastric vs. GEJ cancer (32% vs. 4%). ORR across all patients in the study was 18% (six confirmed and three unconfirmed patients). Similarly, disease control rate (DCR), which includes partial responses and stable disease, was higher in patients with gastric vs. GEJ cancer (72% vs. 38%). Median progression-free survival was also higher in patients with gastric vs. GEJ cancer (5.5 vs. 1.4 months). Based on these results, MacroGenics is expanding the study by enrolling 25 additional gastric cancer patients and will continue to evaluate biomarkers, including HER2 and PD-L1 expression, to determine the patients who are most likely to benefit from margetuximab plus anti-PD-1 therapy.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Flotetuzumab </font><font style="font-family:inherit;font-size:10pt;">is a DART molecule that targets both CD123 and CD3. CD123, the Interleukin-3 receptor alpha chain, is expressed on leukemia and leukemic stem cells, but only at very low levels or not at all on normal hematopoietic stem cells. T cells, which express CD3, can destroy tumor cells. In preclinical studies, we have demonstrated the ability of flotetuzumab to recruit, activate, and expand T cell populations to eliminate leukemia cells. In a Phase 1 dose escalation study of flotetuzumab, acceptable tolerability and evidence of anti-leukemic activity were demonstrated. We are currently enrolling patients in the United States and Europe in a Phase 1 dose expansion study of flotetuzumab in patients with AML or MDS and expect to commence a combination study with flotetuzumab and MGA012, an anti-PD-1 antibody, in 2018. Under the terms of our collaboration with Servier, Servier has the exclusive right to develop and commercialize flotetuzumab in all countries outside North America, Japan, Korea and India, and MacroGenics retains exclusive rights in those countries. The FDA granted orphan drug designation to flotetuzumab for the treatment of AML.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGA012</font><font style="font-family:inherit;font-size:10pt;">&#32;is a monoclonal antibody targeting PD-1. Antibodies targeting PD-1 have shown efficacy against various tumors by releasing the "brakes" on the immune system that are often seen when tumors evade detection by the immune system. MGA012 is being developed for use as monotherapy as well as in combination with other potential cancer therapeutics. We licensed MGA012 to Incyte Corporation in 2017 under a global collaboration and license agreement. We retain the right to develop our own pipeline assets in combination with MGA012. Patients with a variety of different solid tumors are currently being enrolled in the dose expansion portion of a Phase 1 clinical trial of MGA012. We anticipate that MGA012 will be used in combination studies with several of our other product candidates. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD013</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that is intended to enable the co-blockade with a single recombinant agent of two immune checkpoint molecules, PD-1 and LAG-3, which may be co-expressed on T cells. We anticipate that MGD013, if approved, could be used for the treatment of a wide range of cancers, including both solid tumors and hematological malignancies. MGD013 is currently being evaluated in a Phase 1 dose escalation study. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD019</font><font style="font-family:inherit;font-size:10pt;">&#32;is a preclinical DART molecule designed to recognize the immune checkpoints PD-1 and CTLA-4, which have shown enhanced clinical antitumor activity in various cancers when given in combination. We anticipate submitting an IND application for MGD019 in 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Enoblituzumab </font><font style="font-family:inherit;font-size:10pt;">is a monoclonal antibody that targets B7-H3. We engineered enoblituzumab to utilize the same Fc Optimization enhancements that we incorporated in margetuximab to target B7-H3 that is over-expressed on differentiated tumor cells, cancer stem cells and supporting tumor vasculature and underlying tissues. We are currently evaluating enoblituzumab in patients with multiple solid tumor types in an ongoing Phase 2 clinical trial in combination therapy with an anti-PD-1 antibody.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD009</font><font style="font-family:inherit;font-size:10pt;">&#32;is the second molecule in our B7-H3 franchise. This DART molecule recognizes B7-H3 and CD3, and has an Fc domain, which is designed to provide extended pharmacokinetic properties. We have demonstrated that this molecule is able to mediate T&#160;cell killing of cancer cells in preclinical experiments. We are currently enrolling patients with a variety of solid tumor types in a Phase 1 clinical trial of MGD009 and in a separate study that combines MGD009 and MGA012.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGC018</font><font style="font-family:inherit;font-size:10pt;">&#32;is a B7-H3 ADC for which we have completed IND-enabling activities. MGC018 is based on a MacroGenics proprietary B7-H3 antibody and a duocarmycin-based, linker-drug technology licensed from Synthon Biopharmaceuticals B.V. We expect to submit an IND for MGC018 in 2018.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD007</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets both gpA33 and CD3, and has an Fc domain, which is designed to provide extended pharmacokinetic properties and convenient intermittent dosing. gpA33 is expressed on gastrointestinal tumors, including more than 95% of human colon cancers. We have demonstrated that this molecule is able to mediate T&#160;cell killing of gpA33-expressing cancer cells and cancer stem cells in preclinical experiments. We are currently enrolling patients with colorectal cancer in a Phase 1 clinical trial of MGD007 and plan to commence a combination study of MGD007 and MGA012 in 2018. Under the terms of our collaboration with Servier, Servier has an option to obtain exclusive rights to develop and commercialize MGD007 in all countries outside North America, Japan, Korea and India.&#160; If the option is exercised, MacroGenics would still retain exclusive rights in those countries.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Autoimmune Disorders</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Teplizumab</font><font style="font-family:inherit;font-size:10pt;">&#32;is an anti-CD3 monoclonal antibody being developed for the treatment of type 1 diabetes. Teplizumab has been engineered to alter the function of the T cells that mediate the destruction of the insulin-producing beta cells of the islets of the pancreas. Teplizumab potentially represents an advance in the treatment </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:78px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">of type 1 diabetes by addressing the underlying disorder, rather than treating the symptoms through insulin replacement therapy. Teplizumab is being evaluated in a Phase 2 clinical trial for potential application to patients at risk of developing Type 1 diabetes. We have elected to collaborate with NIDDK/TrialNet to execute this clinical trial. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:78px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:54px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD010</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule designed to address limitations of existing B cell-targeted therapies by binding to the CD32B and CD79B proteins found on human B cells. In preclinical studies, this DART molecule modulated the function of human B cells without B cell depletion. In normal conditions, B cells utilize CD32B as one of the key checkpoints or negative regulators to ensure that tolerance to self is maintained and autoimmune disease does not occur. MGD010 is designed to further exploit this mechanism by triggering this inhibitory "immune checkpoint" loop. We believe this molecule preferentially blocks those B cells that are activated to produce the pathogenic antibodies that promote the autoimmune process. In 2017, we completed a Phase 1 clinical study in healthy volunteers and observed acceptable safety and pharmacodynamic activity consistent with the expected mechanism of action of MGD010.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Infectious Diseases</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:84px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:60px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MGD014</font><font style="font-family:inherit;font-size:10pt;">&#32;is a DART molecule that targets the envelope protein of human immunodeficiency virus, or HIV-infected cells (Env) and CD3-expressing T cells. We are developing MGD014 under contract number HHSN272201500032C awarded to us in September 2015 by the National Institute of Allergy and Infectious Diseases, or NIAID, part of the National Institutes of Health. In 2017, NIAID exercised the first of its two options, pursuant to which NIAID will fund our advancement of MGD014 into Phase 1 clinical trials as well as the development and testing of a second DART molecule. MGD014 is our first DART molecule targeting an infectious agent that is planned for clinical testing. The work under this contract will build on preclinical studies demonstrating that DART molecules targeting the Env and T cells, via their CD3 component, are able to redirect the immune system's T cells to kill HIV-infected cells. DART molecules could be used independently or become a key part of a "shock-and-kill" strategy in conjunction with HIV latency-reversing agents currently under development. Our IND submission for MGD014 was cleared by FDA in 2017 and we anticipate that a first patient will be dosed in 2018.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Platforms and Technology Expertise</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We apply our understanding of disease biology, immune-mediated mechanisms and next generation antibody technologies to design specifically targeted antibody-based product candidates based on our DART and Fc Optimization platforms.&#160;Through these platforms we have designed antibody-based product candidates that have the potential to improve on standard treatments by having one or more of the following attributes: (1)&#160;multiple specificities; (2)&#160;increased abilities to interact with the body's immune system to fight tumors; (3)&#160;capacity to bind more avidly to antigen targets: (4)&#160;increased potency; (5)&#160;reduced immunogenicity or (6)&#160;the ability to target cancer cells that are resistant to standard treatments. Moreover, these technology platforms are complementary and can be combined.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">DART and TRIDENT</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">TM</sup></font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#32;Platforms: Our Proprietary Approach to Engineer Multi-Specific Antibodies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We use our DART platform to create derivatives of antibodies with the ability to bind to two distinct targets instead of a single one found in traditional monoclonal antibodies. DART product candidates are therefore bispecific. An example of a bispecific molecule is illustrated below:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="form10k2017dart.jpg" alt="form10k2017dart.jpg" style="height:208px;width:466px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because cancer cells have developed ways to escape the immune system, we have created DART molecules, which are alternative antibody-like structures with more potent immune properties than the parent antibody molecules from which they are derived. The two variable regions of an antibody are mono-specific and are able to target only a single type structural component of an antigen. For many years, researchers have sought to create recombinant molecules that are capable of targeting two antigens or epitopes (i.e., specific part of an antigen bound by the antibody) within the same molecule. The challenges in creating such molecules have been the instability of the resulting bispecific molecules and their inherently short half-lives, as well as the inefficiencies in manufacturing these compounds. We believe our DART platform has overcome these engineering challenges by incorporating proprietary covalent di-sulfide linkages and particular amino acid sequences that efficiently pair the chains of the DART molecule. This is designed to provide a structure with enhanced manufacturability, long-term structural stability and the ability to tailor the half-lives of the DART molecules to their clinical needs. This engineered antibody-like protein has a compact and stable structure and enables the targeting of two different antigens with a single recombinant molecule.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The DART platform has been specifically engineered to accommodate virtually any variable region sequence with predictable expression, folding and antigen recognition. We believe our multi-specific platforms may provide a significant advantage over current biological interventions in cancer, autoimmune disorders and infectious disease by enabling a range of modalities, including those described below.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also advanced beyond our DART platform to establish a TRIDENT platform, which reflects the continuing evolution of our multi-specific antibody-based targeting expertise. Built on the DART module, the trivalent TRIDENT platform incorporates in an Ig-like format an additional domain capable of engaging an independent antigen. With the inclusion of a third targeting arm, TRIDENT molecules enable a broader range of mechanisms of action than bispecific targeting, allowing, for instance, the engagement of multiple antigens on a single or on different cells or enabling enhanced target selectivity by modulating the avidity of one of two antigens.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:79%;"></td><td style="width:21%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Redirected T cell activation and killing</font><font style="font-family:inherit;font-size:10pt;">. In this version of the DART molecule, we are enabling the cancer-fighting properties of the immune effector cells, such as T lymphocytes to: (1)&#160;recognize and bind to structures expressed on a cancer cell (e.g., CD123, the first specificity in the example on the right), (2)&#160;enable the recruitment of all types of cytotoxic, or cell killing, T cells, irrespective of their ability to recognize cancer cells (e.g., CD3, a common component of the T cell antigen receptor, is the second specificity in the example on the right) and (3)&#160;trigger T cell activation, expansion, and cell killing mechanisms to destroy a cancer cell. The outcome is that any of the body's T cells, in theory, could be recruited to destroy a cancer cell and thus, are not limited to the small numbers of specific T cells that might have been generated in response to cancer to kill tumor cells. Furthermore, since any T cell could be recruited for this killing process, only small amounts of a DART molecule are required to trigger this potent immune response. Additionally, the compact structure of the DART protein makes it well suited for maintaining cell-to-cell contact, which we believe contributes to the high level of target cell killing. Similarly, DART molecules targeting CD3 and a viral antigen can be used to recruit T cells to eliminate cells infected by a virus, such as HIV-infected cells.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="form10k2017image1.jpg" alt="form10k2017image1.jpg" style="height:246px;width:134px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Simultaneous targeting of multiple co-inhibitory receptors or checkpoints, such as those involved in inhibiting T cell responses and B cell responses.</font><font style="font-family:inherit;font-size:10pt;">&#160;The immune system generally prevents the development of autoimmune phenomena by regulating activated immune cells that have responded to non-self or foreign antigens. This negative feedback loop is triggered by the interactions of co-inhibitory receptors, or checkpoint molecules, expressed on the immune cells with ligands expressed by other cells, such as antigen-presenting cells. This phenomenon is exploited by cancer, whereby tumor cells express checkpoint ligands that block the development of an immune response against the tumor. Antibodies that block the interaction of checkpoint molecules with their ligands have been shown to significantly improve the clinical outcomes of patients with certain advanced cancers. Because of the diversity of immune checkpoint pathways, blockade of a single axis, while clinically significant, as shown in the case of the blockade of the PD-1/PD-L1 axis with pembrolizumab or nivolumab, will not benefit all patients. In fact, combinations of checkpoint inhibitors, such as nivolumab and ipilimumab, a CTLA-4 blocker, have resulted in significantly enhanced benefit compared to ipilimumab or nivolumab alone. We believe that DART molecules targeting two immunoregulatory pathways, such as two checkpoints in a single molecule, could afford the clinical benefit of the combination together with the potential for synergistic activity, as well as significant advantages in manufacturing, simplified clinical development, and enhanced patient convenience.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="form10k2017image2.jpg" alt="form10k2017image2.jpg" style="height:250px;width:137px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Modulation of receptor signaling</font><font style="font-family:inherit;font-size:10pt;">. In another configuration of the DART molecule, we have taken advantage of the two different specificities engineered in a DART structure to bind to particular cells involved in autoimmune processes, such as autoimmune B cells, and to usurp the immune checkpoint signaling pathways programmed within the cells to impede the pathogenic autoimmune responses. Our MGD010 product candidate targets both CD32B, a co-inhibitory molecule, and CD79B, part of the B cell antigen receptor complex, two proteins expressed on the immune system's B cells. Using a single DART molecule, we attempt to promote the interaction of these two receptors, a step required to interrupt the B cell activation and immune response that single antibodies directed against CD32B, CD79B or both cannot accomplish independently.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="form10k2017image3.jpg" alt="form10k2017image3.jpg" style="height:178px;width:130px;"></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Enhanced effector cell selectivity. </font><font style="font-family:inherit;font-size:10pt;">T lymphocytes with lytic effector function belong preferentially to the CD8 lineage, while CD4-positive T cells preferentially provide immune regulatory function, such as the secretion of cytokines or the differentiation into regulatory T cells. Greater selectivity in the recruitment of effector T cells is an example of the range of applications of our TRIDENT technology. By encoding a CD8 recognition arm in addition to the CD3- and tumor antigen-specific arms, our TRIDENT technology allows the preferential engagement of CD8-positive T lymphocytes and redirects them against tumor cells. This strategy allows for retention of lytic effector function, while limiting the CD4 cell engagement and associated effects, such as inflammatory cytokine release.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="form10k2017image4.jpg" alt="form10k2017image4.jpg" style="height:190px;width:110px;"></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the ability to tailor a DART molecule's valency, we have the capacity to modify the strength by which the binding sites attach to their targets and the molecule's half-life in the blood circulation after delivery to a patient. Furthermore, when an Fc domain is coupled with a DART molecule, additional changes can be included that can modulate the DART molecule's engagement with different immune cells.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are developing specific product candidates using this technology, including flotetuzumab, MGD009, MGD007, MGD010, MGD013 and MGD014, among others. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fc Optimization Platform: Our Proprietary Approach to Enhance Immune-Mediated Cancer Cell Killing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To enhance the body's immune ability, we developed our Fc Optimization platform which introduces certain mutations into the Fc region of an antibody and is able to modulate antibody interaction with immune effector cells. Such interaction enhances the body's immune ability to mediate the killing of cancer cells through ADCC.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ADCC</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><img src="form10k2017adcc.jpg" alt="form10k2017adcc.jpg" style="height:185px;width:216px;"></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Fc region mediates the function of IgG antibodies by binding to different activating and inhibitory receptors, referred to as Fc&#947;Rs, on immune effector cells found within the innate immune system. By engineering Fc regions to bind with an increased affinity to the activating Fc&#947;Rs and with a reduced affinity to the inhibitory Fc&#947;Rs, we have been able to impart a more effective immune response and improve effector functions, such as ADCC. This is another example in which small changes in antibody structure can confer improvements on normal immune processes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have established a proprietary platform to engineer, screen, identify and test antibodies' Fc regions with customizable activity. In particular, we have licenses to use transgenic mice that express human Fc&#947;Rs. These mice can be used for in vivo testing of antibodies that incorporate Fc domain variants, including those antibodies intended for cancer therapy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To date, we have successfully incorporated our Fc variants in two of our clinical-stage antibody product candidates, margetuximab and enoblituzumab. We have preclinical data demonstrating that these Fc variants have substantially improved the activity of these antibodies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Our Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products.&#160; Each of our collaborations has a unique set of terms and conditions, but in general, they fall into two categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">MacroGenics-Originated Programs</font><font style="font-family:inherit;font-size:10pt;">.&#160; We have a number of collaborations relating to product candidates that we have created from our internal research efforts. These include Incyte for MGA012; Servier for flotetuzumab and MGD007 and Green Cross Corp., or Green Cross, for margetuximab.&#160; In the case of these product candidates, we entered into collaborations because we believed that our collaborator could further enable development of the program or provide additional capabilities and funding to supplement MacroGenics' investment, or both.&#160;We obtained financial terms and retained certain rights that we believed were beneficial to us.&#160; For example, under the Incyte agreement, we retained the right to develop our pipeline assets in combination with MGA012 and to manufacture a portion of the global clinical and commercial supply needs of MGA012.&#160; Under the Servier agreement, we retain full commercialization and development rights in the United States, Canada, Mexico, Japan, South Korea and India, and regain worldwide </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:54px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">rights if Servier opts not to continue co-developing MGD007. Under the Green Cross agreement, we retain full commercialization rights worldwide except for South Korea.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:54px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:30px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Joint Research Programs.</font><font style="font-family:inherit;font-size:10pt;">&#160;We have several programs under which collaborators have sought to utilize some aspect of our protein engineering platforms with new product concepts that are jointly directed, sometimes employing a collaborator's own proprietary technology.&#160;These collaborations give us the ability to expand the breadth of our potential products, develop greater scientific expertise and obtain additional funding for research.&#160;F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche, and Pfizer, Inc. are currently advancing projects in their own pipelines based on these types of programs.&#160;With these collaborators, we have more limited development or commercial rights related to the product candidates that may emerge from joint research programs, although we are eligible to receive royalties from these programs as well as other consideration upon the occurrence of specified development and sales milestones.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Intellectual Property</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We strive to protect the proprietary technologies that we believe are important to our business, including seeking and maintaining patents intended to protect, for example, the composition of matter of our product candidates, their methods of use, the technology platforms used to generate them, related technologies and/or other aspects of the inventions that are important to our business. We also rely on trade secrets, confidentiality and invention assignment agreements and careful monitoring of our proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend significantly on our ability to obtain and maintain patent and other proprietary protection for commercially important technology, inventions and know-how related to our business.&#160; In addition, there is cost and risk to our business in defending and enforcing our patents, maintaining our licenses to use intellectual property owned by third parties and preserving the confidentiality of our trade secrets and operating without infringing the valid and enforceable patents and other proprietary rights of third parties. We also rely on know-how, continuing technological innovation and in-licensing opportunities to develop, strengthen and maintain our proprietary positions. We currently use multiple industry-standard patent monitoring systems to monitor new United States Patent and Trademark Office, or USPTO, filings for any applications by third parties that may infringe on our patents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted by the courts after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, narrowed, circumvented or invalidated by third parties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A third party may hold patents or other intellectual property rights that are important to or necessary for the development of our product candidates or use of our technology platforms. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize our product candidates, in which case we would be required to obtain a license from these third parties on commercially reasonable terms, or our business could be harmed, possibly materially. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, should a court find that they cover margetuximab or enoblituzumab and we are unable to invalidate them, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because patent applications in the United States and certain other jurisdictions can be maintained in secrecy for 18 months or potentially even longer, and because publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain of the priority of inventions covered by pending patent applications. Moreover, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention. In the ordinary course of business we participate in post-grant challenge proceedings, such as oppositions, that challenge the patentability of third party patents. Such proceedings could result in substantial cost, even if the eventual outcome is favorable to us.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pipeline Patent Protection</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we held 87 patents in the United States with 41 patent applications pending and 349 patents in other countries of the world with 528 patent applications pending. In addition to patents and patent applications generally providing protection for various aspects of our Fc Optimization, DART, and TRIDENT platforms, we have patent and patent applications for the composition of matter of each of our clinical pipeline product candidates and, in some cases, we also have </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">other patents and patent application related to various aspects of the technology underlying these product candidates or their methods of use.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent terms may be adjusted or extended, as described in greater detail below, in certain circumstances. However, assuming no adjustments or extensions, the primary composition of matter patent for each of our clinical pipeline product candidates is expected to expire in the following timeframes:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:66%;"></td><td style="width:34%;"></td></tr><tr><td style="vertical-align:top;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Product Candidate</font></div></td><td style="vertical-align:top;background-color:#d9d9d9;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">margetuximab</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2029</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">enoblituzumab</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2031</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">flotetuzumab</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2034*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGA012</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD013</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD019</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2036*</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGC018</font></div></td><td style="vertical-align:top;padding-left:92px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2037*</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">* pending</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Patent Term Extension and Reference Product Exclusivity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Hatch-Waxman Act permits a patent term extension for FDA-approved drugs, including biological products, of up to five years beyond the expiration of the patent. The length of the patent term extension is related to the length of time the drug is under regulatory review. Patent extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Similar provisions are available in Europe and other jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our pharmaceutical product candidates receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We intend to seek patent term extensions to any of our issued patents in any jurisdiction where these are available, however there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, collectively the ACA, created a regulatory scheme authorizing the FDA to approve biosimilars via an abbreviated licensure pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. Under the ACA, a manufacturer may submit an application for licensure of a biologic product that is "biosimilar to" or "interchangeable with" a previously approved biological product or "reference product." The "biosimilar" application must include specific information demonstrating biosimilarity based on data derived from: (1) analytical studies, (2) animal studies, and&#160;(3) a clinical study or studies that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed, except that FDA may waive some of these requirements for a given application. Under this new statutory scheme, an application for a biosimilar product may not be submitted to the FDA until four years after the date of first licensure. The FDA may not approve a biosimilar product until 12 years from the date on which the reference product was first licensed. The law does not change the duration of patents granted on biological products. Even if a product is considered to be a reference product eligible for exclusivity, another company could market a competing version of that product if the FDA approves a full Biologics License Application, or BLA, for such product containing the sponsor's own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of their product. There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect these provisions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Trade Secrets</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also rely on trade secret protection for our confidential and proprietary information. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Thus, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual's relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In many cases our confidentiality and other agreements with consultants, outside scientific collaborators, sponsored researchers and other advisors require them to assign or grant us licenses to inventions they invent as a result the work or services they render under such agreements or grant us an option to negotiate a license to use such inventions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">In-Licensed Intellectual Property</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into patent and know-how license agreements that grant us the rights to use certain technologies related to biological manufacturing for our clinical product candidates. We anticipate using these technologies for future product candidates. These licensors have businesses dedicated to licensing this type of technology and we anticipate that licenses to use these technologies for our future products will be available. The licenses typically include yearly maintenance payments and sales royalties, and may also include upfront payments or milestone payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Manufacturing</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently manufacture our drug substance for our clinical trials at our manufacturing facility located in Rockville, Maryland. For our antibody product candidates, we have supplemented our drug substance manufacturing capacity through an arrangement with AGC Biologics, Inc., or AGC (formerly CMC Biologics, Inc.), a contract manufacturing organization, and plan to commercially produce margetuximab at AGC assuming the success of the Phase 3 SOPHIA clinical trial on the expected timeline. We are also completing the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which has been designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with current Good Manufacturing Practices (cGMP) to be able to sell commercial product. In addition, we currently rely on and will continue to rely on contract fill-finish service providers, primarily Ajinomoto Althea, Inc. and Baxter Healthcare Corporation, to fulfill our fill-finish needs for our current and future product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Most of the principal materials we use in our manufacturing operations are available from more than one source. However, we obtain certain raw materials principally from only one source. In the event one of these suppliers was unable to provide the materials or product, we generally seek to maintain sufficient inventory to supply the market until an alternative source of supply can be implemented. However, in the event of an extended failure of a supplier, it is possible that we could experience an interruption in supply until we established new sources or, in some cases, implemented alternative processes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Production processes for biological therapeutic products are complex, highly regulated, and vary widely from product to product. Shifting or adding manufacturing capacity can be a very lengthy process requiring significant capital expenditures, process modifications, and regulatory approvals. Accordingly, if we were to experience extended plant shutdowns at one of our own facilities, extended failure of a contract supplier or contract manufacturing organization, or extraordinary unplanned increases in demand, we could experience an interruption in supply of certain products or product shortages until production could be resumed or expanded.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commercialization</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We cannot market or promote a new product until a marketing application has been approved by the FDA. We currently have no approved products in the United States. We have not yet established a&#160;sales, marketing or product distribution infrastructure.&#160;We believe that it will be possible for us to access the United States oncology market through a specialty sales force.&#160;Subject to receiving marketing authorization in the United States, we expect to commence commercialization via&#160;our then-in-place&#160;sales and marketing organizations. We believe that these organizations will be able to serve the oncology community in treating the patient populations for which our oncology product candidates are being developed. Outside the United States, we expect to enter into arrangements with third-party commercial partners for any of our product candidates that obtain marketing approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Competition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In particular, margetuximab is directed against HER2 and several companies have cancer therapeutics directed against HER2 marketed or in development, such as Roche, particularly through its affiliate, Genentech, Inc., as well as Puma Biotechnology, Inc., Daiichi Sankyo Company, Limited, and Cascadian Therapeutics. Market competition may limit the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">utilization of margetuximab as a therapeutic, even if market approval and adequate reimbursement is obtained, and competition among development-stage programs for patients enrolling in clinical trials for HER2-directed therapies may delay expected timelines for our clinical trials.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the immuno-oncology field is competitive, with treatments currently approved and on the market or in development for various tumor types and patient populations from a variety of different companies such as Merck &amp; Co., Inc., or Merck, The Bristol Myers Squibb Company, or BMS, and Roche, all of which have significantly greater resources than we do. Many of our pipeline programs, if successful, will likely face significant competition both by therapeutics that are already being marketed as well as those that will be approved for marketing before our programs. In particular, we are developing a franchise of PD-1-directed product candidates, which includes a monoclonal antibody and two DART molecules. Merck, BMS and Roche all have approved products that target either the PD-1 receptor or its ligand, PD-L1, and there are several other companies that have anti-PD-1 or anti-PD-L1 antibodies in clinical development, all of which would compete with our PD-1-directed programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, several companies are also developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. Amgen Inc. has obtained marketing approval for one product that works by targeting antigens both on immune effector cell populations and those expressed on certain cancer cells, and has other product candidates in development that use this mechanism. In addition, other companies are developing new treatments for cancer and autoimmune diseases that utilize multi-specific approaches, including Roche, Genmab A/S, Merus B.V., Abbvie Inc., Affimed Therapeutics AG Corporation, Eli Lilly and Company and Xencor, Inc.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Mergers and acquisitions in the pharmaceutical, biotechnology and diagnostic industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining top qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The key competitive factors affecting the success of all of our therapeutic product candidates, if approved, are likely to be their efficacy, safety, dosing convenience, price, the effectiveness of companion diagnostics in guiding the use of related therapeutics, the level of generic or biosimilar competition and the availability of reimbursement from government and other third-party payors.&#160; In addition, the standard of medical care provided to cancer patients continues to evolve as more scientific and medical information becomes available.&#160; These changes in medical care relate to pharmaceutical products, but are also affected by other factors, and such changes can positively or negatively affect the prospects of our product candidates as well as those of our competitors.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop, or the standards of care for cancer patients change while our clinical trials are ongoing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, a trastuzumab biosimilar has been approved in the U.S. by FDA.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The most common methods of treating patients with cancer are surgery, radiation and drug therapy. There are a variety of available drug therapies marketed for cancer. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third party payors. In many cases, these drugs are administered in combination to enhance efficacy. While our product candidates may compete with many existing drug and other therapies, to the extent an approved drug is ultimately used in combination with or as an adjunct to these therapies, our product candidates will not be competitive with the approved drug.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Government Regulation and Product Approval</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government authorities in the United States, at the federal, state and local level, and in other countries extensively regulate, among other things, the research, development, testing, manufacture, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United States and in foreign countries, along with subsequent compliance with applicable statutes and regulations, require the expenditure of substantial time and financial resources.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">FDA Regulation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of our current product candidates are subject to regulation in the United States by the FDA as biological products, or biologics. The FDA subjects biologics to extensive pre- and post-market regulation. The Public Health Service Act, the Federal Food, Drug, and Cosmetic Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of biologics. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending BLAs, withdrawal of approvals, clinical holds, warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, or criminal penalties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Preclinical Studies</font><font style="font-family:inherit;font-size:10pt;">. Drug development in our industry is complex, challenging and risky; failure rates are high. Product development cycles are long - approximately 10 to 15 years from discovery to market. A potential new biological product must undergo many years of preclinical and clinical testing to establish it is pure, potent and safe.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preclinical studies include laboratory evaluation of product chemistry, formulation and toxicity, pharmacology, as well as animal trials to assess the characteristics and potential safety and efficacy of the product. The conduct of the preclinical tests must comply with federal regulations and requirements including FDA's good laboratory practice, or GLP, regulations and the U.S. Department of Agriculture's regulations implementing the Animal Welfare Act. After laboratory analysis and preclinical testing in animals, we file an IND with FDA to begin human testing. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical trial protocol, among other things, to the FDA as part of an IND application. Certain preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold or agrees on an alternate approach with us. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Clinical Development</font><font style="font-family:inherit;font-size:10pt;">. Clinical trials involve the administration of the investigational new drug to human subjects (healthy volunteers or patients) under the supervision of a qualified investigator. Clinical trials must be conducted: (i) in compliance with all applicable federal regulations and guidance, including those pertaining to good clinical practice, or GCP, standards that are meant to protect the rights, safety, and welfare of human subjects and to define the roles of clinical trial sponsors, investigators, and monitors; as well as (ii) under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing of a new drug in the United States (whether in patients or healthy volunteers) must be included in the IND submission, and FDA must be notified of subsequent protocol amendments. In addition, the protocol must be reviewed and approved by an institutional review board, or IRB, and all study subjects must provide informed consent prior to participating in the study. Typically, each institution participating in the clinical trial will require review of the protocol before any clinical trial commences at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their ClinicalTrials.gov website. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and there are additional, more frequent reporting requirements for suspected unexpected serious adverse events.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A study sponsor might choose to discontinue a clinical trial or a clinical development program for a variety of reasons. The FDA may impose a temporary or permanent clinical hold, or other sanctions, if it believes that the clinical trial either is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial subjects. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB's requirements, or may impose other conditions.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials to support BLAs for marketing approval are typically conducted in three pre-approval phases, but the phases may overlap or be combined, particularly in testing for oncology indications. In Phase 1, testing is conducted in a small group of subjects who may be patients with the target disease or condition or healthy volunteers, to evaluate its safety, determine a safe dosage range, and identify side effects. In Phase 2, the drug is given to a larger group&#160;of subjects with the target condition to further evaluate its safety and gather preliminary evidence of efficacy. Phase 3 studies typically last multiple years for oncology indications. In Phase 3, the drug is given to a large group of subjects with the target disease or condition (several hundred to several thousand), often at multiple geographical sites, to confirm its effectiveness, monitor side effects, and collect data to support drug approval. In some cases, FDA may require post-market studies, known as Phase 4 studies, to be conducted as a condition of approval in order to gather additional information on the drug's effect in various populations and any side effects associated with long-term use. Depending on the risks posed by the drugs, other post-market requirements may be imposed. Only a small percentage of investigational drugs complete all three phases and obtain marketing approval.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Approval</font><font style="font-family:inherit;font-size:10pt;">. After completion of the required clinical testing, a BLA can be prepared and submitted to the FDA. FDA approval of the BLA is required before marketing of the product may begin in the United States. The BLA must include the results of preclinical, clinical and other testing and a compilation of data relating to the product's chemistry, manufacture and controls. The cost of preparing and submitting a BLA is substantial. Under federal law, the submission of most BLAs is additionally subject to a substantial application user fee, and annual product and establishment user fees also apply. These fees are typically increased annually.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA has 60&#160;days from its receipt of a BLA to determine whether the application will be accepted for filing based on the FDA's threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins a substantive review, and the review period under the Prescription Drug User Fee Act begins. The standard for reviewing a BLA is whether the product is safe, pure and potent, which has been interpreted to include that the product is safe and effective and has a favorable benefit-risk profile. FDA's current performance goals call for FDA to complete review of 90 percent of standard (non-priority) BLAs within 10 months of receipt and within six months for priority BLAs, which is 12 months and eight months, respectively, if the 60-day review of the initial application is included in the timeline.  In addition, the FDA has developed approaches intended to make certain qualifying products available to patients rapidly - Priority Review, Breakthrough Therapy, Accelerated Approval, and Fast Track.   While the timelines for approval under these pathways may be shorter, there are requirements and conditions associated with each pathway, and there can be no assurance that any of our investigational products will be able to meet the conditions or requirements necessary to receive any such designation or be able to receive the review or approval benefits associated with such designations. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes outside clinicians and other experts, for review, evaluation and a recommendation as to whether sufficient data exist in the application to support product approval. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Before approving a BLA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will typically inspect the facility or the facilities at which the drug is manufactured. FDA will not approve the product unless compliance with cGMPs is satisfactory.&#160; FDA also reviews the proposed labeling submitted with the BLA and typically requires changes in the labeling text.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After the FDA evaluates the BLA and the manufacturing and testing facilities, it issues either an approval letter or a complete response letter. Complete response letters generally outline the deficiencies in the submission and delineate the additional testing or information needed in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA's satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. The FDA has committed to reviewing 90 percent of resubmissions within two or six months from receipt depending on the type of information included.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An approval letter authorizes commercial marketing of the drug for the approved indication or indications and the other conditions of use set out in the approved prescribing information.&#160; Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a condition of BLA approval, the FDA may require substantial post-approval testing and surveillance to monitor the drug's safety or efficacy and may impose other conditions, including labeling restrictions that can materially affect the potential market and profitability of the product. As a condition of approval, or after approval, the FDA also may require submission of a risk evaluation and mitigation strategy, or REMS, to mitigate any identified or suspected serious risks. The REMS may include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Other U.S. Post-Marketing Regulatory Requirements</font><font style="font-family:inherit;font-size:10pt;">. Once a BLA is approved, a product will be subject to certain post-approval requirements, including those relating to advertising, promotion, adverse event reporting, recordkeeping, and cGMPs, as well as registration, listing, and inspection. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">FDA regulates the content and format of prescription drug labeling, advertising, and promotion, including direct-to-consumer advertising and promotional Internet communications. FDA also establishes parameters for permissible non-promotional communications between industry and the medical community, including industry-supported scientific and educational activities. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion for uses not consistent with the approved labeling, and a company that is found to have improperly promoted off-label uses or otherwise not to have met applicable promotion rules may be subject to significant liability under both the FDCA and other statutes, including the False Claims Act. See "Other Healthcare Laws and Compliance Requirements" below for more information.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All aspects of pharmaceutical manufacture must conform to cGMPs after approval. Drug manufacturers and certain of their subcontractors are required to register their establishments with FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the FDA inspects manufacturing facilities to assess compliance with cGMPs. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMPs and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMPs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Products may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, product formulation or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, in some cases before the change may be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers are subject to requirements for adverse event reporting and submission of periodic reports following FDA approval of a BLA. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, or failure of Phase 4 studies to meet their specified endpoints, may result in revisions to the approved labeling to add new safety information, the need to conduct additional post-market studies or clinical trials to assess new safety risks,&#160; imposition of distribution or other restrictions under a REMS program, or recall of the product and withdrawal of the BLA.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Noncompliance with postmarket requirements can result in one or more of the following consequences:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Warning letters;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Holds on post-approval clinical trials;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;text-indent:-24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license approvals;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Product seizure or detention, or refusal to permit the import or export of products; or</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">Injunctions or the imposition of civil or criminal penalties.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Approval of Biosimilars</font><font style="font-family:inherit;font-size:10pt;">. The ACA authorized the FDA to approve biosimilars via a separate, abbreviated pathway. In many cases, this allows biosimilars to be brought to market without conducting the full suite of clinical trials typically required of originators. The law establishes a period of 12 years of data exclusivity for reference products in order to preserve incentives for future innovation and outlines statutory criteria for science-based biosimilar approval standards that take into account patient safety considerations. Under this framework, data exclusivity protects the data in the innovator's regulatory application by prohibiting others, for a period of 12 years, from granting FDA approval based in part on reliance on or reference to the innovator's data in their application to the FDA. The law does not change the duration of patents granted on biological products.  There have been recent proposals to repeal or modify the ACA and it is uncertain how any of those proposals, if approved, would affect the provisions governing biosimilars.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Healthcare Laws and Compliance Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, our activities are potentially subject to regulation by federal, state, and local authorities in addition to the FDA, including the Centers for Medicare and Medicaid Services, other divisions of the U.S. Department of Health and Human Services (e.g., the Office of Inspector General), the U.S. Department of Justice and individual U.S. Attorney offices within the Department of Justice, and state and local governments.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, certain financial interactions with healthcare professionals may be subject to the anti-kickback and fraud and abuse provisions of the Social Security Act and the False Claims Act, and in addition our activities may be affected by the privacy regulations issued under the Health Insurance Portability and Accountability Act, as amended, and similar state laws.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">International Regulation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to regulations in the United States, a variety of foreign regulations govern clinical trials, commercial sales, distribution of product candidates and other areas outlined above. These regulations can vary between jurisdictions and can be more onerous than regulations in the United States.&#160; Penalties for violating such regulations also exist in these jurisdictions. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA approval.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing, and Reimbursement</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States and other countries, sales of any future products for which we receive regulatory approval for commercial sale will depend in part on the availability of adequate reimbursement from third-party payors, including government health administrative authorities, managed care providers, private health insurers, and other organizations. Third-party payors are increasingly examining the medical necessity and cost effectiveness of medical products and services in addition to safety and efficacy and, accordingly, significant uncertainty exists as to the reimbursement status of newly approved therapeutics. Third-party reimbursement adequate to enable us to realize an appropriate return on our investment in research and product development may not be available for our products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Drug prices have become a subject of increased focus in recent years. Although there are currently no direct government price controls over private sector purchases in the U.S., federal law requires pharmaceutical manufacturers to pay prescribed rebates on certain Medicaid-reimbursed drugs to enable them to be eligible for reimbursement under certain public healthcare programs such as Medicaid and Medicare Part B. Various states have adopted further mechanisms that seek to control drug prices, including by disfavoring certain higher priced drugs or by seeking supplemental rebates from manufacturers. Managed care has also become a potent force in the market place that increases downward pressure on the prices of pharmaceutical products.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Public and private healthcare payers control costs and influence drug pricing through a variety of mechanisms, including through negotiating discounts with the manufacturers and through the use of tiered formularies and other mechanisms that provide preferential access to certain drugs over others within a therapeutic class. Payers also set other criteria to govern the uses of a drug that will be deemed medically appropriate and therefore reimbursed or otherwise covered.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Facilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our headquarters building, located in Rockville, Maryland, currently houses laboratory and office space and we are also completing the build-out of a suite for manufacturing at commercial quantities and scale. This space is occupied under a lease that expires in 2027 and may be extended for up to two additional seven-year terms. We also have a smaller-scale manufacturing facility, also in Rockville. The lease for a portion of that facility expires on March 31, 2023 and may be extended for a five-year term, and the lease for the remainder of that facility expires on December 31, 2019 and may be extended for up to two additional five-year terms. Finally, we have additional laboratory and office space in Rockville under two leases that each expire in 2020, and each of those leases may be extended for a five-year term. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also lease office and laboratory space in South San Francisco, California under a lease that expires on February 28, 2018. In December 2017, we moved the South San Francisco operations into different space in Brisbane, California, which is leased until 2023.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employees</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February 27, 2018, we had 330 full-time employees, 274 of whom were primarily engaged in research and development activities and 60 of whom had an M.D. or Ph.D. degree.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Legal Proceedings</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time we may be involved in various disputes and litigation matters that arise in the ordinary course of business. We are not currently a party to any material legal proceedings.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Available Information</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our website address is www.macrogenics.com. We post links to our website to the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the Securities and Exchange Commission, or the SEC: annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, proxy statements, and any amendments to those reports filed or furnished pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. All such filings are available through our website free of charge. Our filings may also be read and copied at the SEC's Public Reference Room at 100 F Street, NE, Washington, DC 20549. Information on the operation of the Public Reference Room may be obtained by calling the SEC at 1-800-SEC-0330. The SEC also maintains an internet site at www.sec.gov that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">19</font></div></div><hr style="page-break-after:always"><div><a name="sAE8F9604B73F5B8B926EF1BC43AC1B81"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1A.</font><font style="font-family:inherit;font-size:5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">RISK FACTORS</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business and results of operations are subject to numerous risks, uncertainties and other factors that you should be aware of, some of which are described below.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Any of the risks, uncertainties and other factors described below could have a materially adverse effect on our business, financial condition or results of operations and could cause the trading price of our common stock to decline substantially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business and the Development and Commercialization of Our Product Candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">All of our product candidates are in preclinical or clinical development. Clinical drug development is expensive, time consuming and uncertain and we may ultimately not be able to obtain regulatory approvals for the commercialization of some or all of our product candidates.</font></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The research, testing, manufacturing, labeling, approval, selling, marketing and distribution of drug products are subject to extensive regulation by the U.S. Food and Drug Administration, or FDA, and non-U.S. regulatory authorities, which regulations differ from country to country. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of a Biologics License Application, or BLA, from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in drug development. We have not submitted an application for or received marketing approval for any of our product candidates. We have limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA. Obtaining approval of a BLA can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and non-U.S. regulatory requirements may, either before or after product approval, if any, subject our company to administrative or judicially imposed sanctions, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">restrictions on the products, manufacturers, manufacturing facilities or manufacturing process;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">warning letters;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">civil and criminal penalties;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injunctions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspension or withdrawal of regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product seizures, detentions or import bans;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">voluntary or mandatory product recalls and publicity requirements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">total or partial suspension of production;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">imposition of restrictions on operations, including costly new manufacturing requirements; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refusal to approve pending BLAs or supplements to approved BLAs or analogous marketing approvals outside the United States.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The FDA and foreign regulatory authorities also have substantial discretion in the drug approval process. The number of preclinical studies and clinical trials that will be required for regulatory approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address, and the regulations applicable to any particular drug candidate. Regulatory agencies can delay, limit or deny approval of a product candidate for many reasons, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may not be deemed safe or effective;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the results may not confirm the positive results from earlier preclinical studies or clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies may not find the data from preclinical studies and clinical trials sufficient;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies might not approve or might require changes to our manufacturing processes or facilities; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory agencies may change their approval policies or adopt new regulations.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delay in obtaining or failure to obtain required approvals could materially adversely affect our ability to generate revenue from the particular product candidate, which likely would result in significant harm to our financial position and adversely impact our stock price. Furthermore, any regulatory approval to market a product may be subject to limitations on the indicated uses for which we may market the product. These limitations may limit the size of the market for the product.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to obtain regulatory approval and commercialize our product candidates on a timely basis, which would require us to incur additional costs and delay our receipt of any product revenue.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently enrolling patients in clinical trials for margetuximab, enoblituzumab, flotetuzumab, MGD007, MGD009, MGA012 and MGD013, and anticipate initiating or continuing clinical trials for these product candidates as monotherapies or in combination with other product candidates in 2018. In addition, our collaborators are currently enrolling patients in clinical trials for PF-06671008 and teplizumab.&#160; The commencement of new clinical trials could be substantially delayed or prevented by several factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">further discussions with the FDA or other regulatory agencies regarding the scope or design of our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the limited number of, and competition for, suitable sites to conduct our clinical trials, many of which may already be engaged in other clinical trial programs, including some that may be for the same indication as our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any delay or failure to obtain regulatory approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to obtain sufficient funds required for a clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to manufacture sufficient supplies of the product candidate for our clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or clinical research organizations, CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delay or failure to obtain institutional review board, or IRB, approval to conduct a clinical trial at a prospective site.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The completion of our clinical trials could also be substantially delayed or prevented by several factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">slower than expected rates of patient recruitment and enrollment;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of patients to complete the clinical trial;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues, including severe or unexpected drug-related adverse effects experienced by patients, including possible deaths;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of efficacy during clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">termination of our clinical trials by one or more clinical trial sites;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to monitor patients adequately during or after treatment by us and/or our CROs; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the need to repeat or terminate clinical trials as a result of inconclusive or negative results or unforeseen complications in testing.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in regulatory requirements and guidance may also occur and we may need to significantly amend clinical trial protocols to reflect these changes with appropriate regulatory authorities. Amendments may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us, due to a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">unforeseen safety issues or any determination that a clinical trial presents unacceptable health risks;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of adequate funding to continue the clinical trial due to unforeseen costs or other business decisions; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">upon a breach or pursuant to the terms of any agreement with, or for any other reason by, current or future collaborators that have responsibility for the clinical development of any of our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any failure or significant delay in completing clinical trials for our product candidates would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The results of previous clinical trials may not be predictive of future results, and the results of our current and planned clinical trials may not satisfy the requirements of the FDA or non-U.S. regulatory authorities.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical failure can occur at any stage of clinical development. Clinical trials may produce negative or inconclusive results, and we or any of our current and future collaborators may decide, or regulators may require us, to conduct additional clinical or preclinical testing. Success in early clinical trials does not mean that future larger registration clinical trials will be successful because product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and non-U.S. regulatory authorities despite having progressed through initial clinical trials. A number of companies in the pharmaceutical industry, including those with greater resources and experience than us, have suffered significant setbacks in advanced clinical trials, even after obtaining promising results in earlier clinical trials.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, our product candidates may not be approved even if they achieve their primary endpoints in Phase 3 clinical trials or registration trials. The FDA or other non-U.S. regulatory authorities may disagree with our trial design and our interpretation of data from preclinical studies and clinical trials. In addition, any of these regulatory authorities may change requirements for the approval of a product candidate even after reviewing and providing comments or advice on a protocol for a pivotal Phase 3 clinical trial. In addition, any of these regulatory authorities may also approve a product candidate for fewer or more limited indications than we request or may grant approval contingent on the performance of costly post-marketing clinical trials. The FDA or other non-U.S. regulatory authorities may not approve the labeling claims that we believe would be necessary or desirable for the successful commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We use new technologies in the development of our product candidates and the FDA and other regulatory authorities have not approved products that utilize these technologies.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our products in development are based on new technologies, such as Fc Optimization, DART molecules and TRIDENT molecules. Given the novelty of our technologies, we intend to work closely with the FDA and other regulatory authorities to perform the requisite scientific analyses and evaluation of our methods to obtain regulatory approval for our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted by the FDA and other regulatory authorities. For some of our product candidates that are based on these technology platforms, the regulatory approval path and requirements may not be clear or evolve as more data becomes available for this product candidates, which could add significant delay and expense. Delays or failure to obtain regulatory approval of any of the product candidates that we develop would adversely affect our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in our efforts to use and expand our technology platforms to build a pipeline of product candidates. We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A key element of our strategy is to use and expand our technology platforms to build a pipeline of product candidates and progress these product candidates through clinical development for the treatment of a variety of different types of diseases. Although our research and development efforts to date have resulted in a pipeline of product candidates directed at&#160;various cancers, as well as autoimmune disorders and infectious diseases, we may not be able to develop product candidates that are safe and effective. Even if we are successful in continuing to build our pipeline, the potential product candidates that we identify may not be suitable for clinical development, including as a result of being shown to have harmful side effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval and achieve market acceptance. If we do not continue to successfully develop and begin to commercialize product candidates, we will face difficulty in obtaining product revenues in future periods, which could result in significant harm to our financial position and adversely affect our stock price.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize our products outside of the United States, which would limit our ability to realize their full market potential.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and may require additional preclinical studies or clinical trials or additional administrative review periods, which could result in significant </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays, difficulties and costs for us. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although all of our product candidates have undergone or will undergo safety testing, not all adverse effects of drugs can be predicted or anticipated. Unforeseen side effects from any of our product candidates could arise either during clinical development or, if approved by regulatory authorities, after the approved product has been marketed. All of our product candidates are still in clinical or preclinical development. While our clinical trials for our initial product candidates to date have demonstrated an acceptable safety profile, the results from future trials may not support this conclusion. The results of future clinical or preclinical trials may show that our product candidates cause undesirable or unacceptable side effects, which could interrupt, delay or halt clinical trials, and result in delay of, or failure to obtain, marketing approval from the FDA and other regulatory authorities, or result in marketing approval from the FDA and other regulatory authorities with restrictive label warnings or potential product liability claims.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates receives marketing approval and we or others later identify undesirable or unacceptable side effects caused by such products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require us to take our approved product off the market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require the addition of labeling statements, specific warnings, a contraindication or field alerts to physicians and pharmacies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to change the way the product is administered, impose other risk-management measures, conduct additional clinical trials or change the labeling of the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to limitations on how we may promote the product;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of the product may decrease significantly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be subject to litigation or product liability claims; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us, our collaborators or our potential future partners from achieving or maintaining market acceptance of the affected product or could substantially increase commercialization costs and expenses, which in turn could delay or prevent us from generating significant revenue from the sale of our products.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if approved, if any of our product candidates do not achieve broad market acceptance among physicians, patients, the medical community, and third-party payors our revenue generated from their sales will be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The commercial success of our product candidates will depend upon their acceptance among physicians, patients and the medical community. The degree of market acceptance of our product candidates will depend on a number of factors, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations or warnings contained in the approved labeling for a product candidate;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the standard of care for the targeted indications for any of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limitations in the approved clinical indications for our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">demonstrated clinical safety and efficacy compared to other products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">lack of significant adverse side effects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales, marketing and distribution support;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability and extent of reimbursement from managed care plans and other third-party payors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">timing of market introduction and perceived effectiveness of competitive products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the degree of cost-effectiveness of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">availability of alternative therapies at similar or lower cost, including generic and over-the-counter products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the extent to which the product candidate is approved for inclusion on formularies of hospitals and managed care organizations;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">whether the product is designated under physician treatment guidelines as a first-line therapy or as a second- or third-line therapy for particular diseases;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity about our product candidates or favorable publicity about competitive products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">convenience and ease of administration of our products; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">potential product liability claims.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved, but do not achieve an adequate level of acceptance by physicians, patients and the medical community, we may not generate sufficient revenue from these products, and we may not become or remain profitable. In addition, efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The manufacture of our product candidates is complex, and we may encounter difficulties in production.&#160; If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale could be delayed or halted entirely.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The process of manufacturing our product candidates is extremely susceptible to product loss due to a variety of factors, including but not limited to contamination, equipment failure or improper installation or operation of equipment, vendor or operator error, contamination and inconsistency in yields, variability in product characteristics, and difficulties in scaling the production process. Even minor deviations from manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are in the process of completing the build-out of a manufacturing suite that could support future commercial production of our product candidates, if and when any are commercialized. We have no experience in large-scale or commercial manufacturing, and there can be no assurance that we will be able to complete our manufacturing facility or, if completed, we will be able to manufacture commercial products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are in the process of expanding our manufacturing capacity to support future commercial production and are building a suite with additional capacity at our current headquarters for this purpose.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although some of our employees have experience in the manufacturing of pharmaceutical products from prior employment at other companies, we as a company have no prior experience in large-scale or commercial manufacturing. Designing and building a manufacturing facility is time-consuming, expensive, and may be subject to delays or cost overruns. In addition, government approvals will be required for us to operate a commercial manufacturing facility and can be time-consuming to obtain, and there can be no assurance that such approval will be obtained. As a manufacturer of pharmaceutical products, we also will be required to demonstrate and maintain compliance with cGMPs which include requirements related to production processes, quality control and assurance and recordkeeping. Furthermore, establishing and maintaining commercial manufacturing operations may require a reallocation of other resources, particularly the time and attention of certain of our senior management. Any failure or delay in the development of our commercial manufacturing capabilities could adversely impact the commercialization of our product candidates or one or more of our collaborations. </font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our manufacturing facilities are subject to significant government regulations and approvals, which are often costly and could result in adverse consequences to our business if we fail to comply with the regulations or maintain the approvals.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must comply with the FDA's current Good Manufacturing Practice, or cGMP, requirements, as set out in statute, regulations and guidance. We may encounter difficulties in achieving quality control and quality assurance and may experience shortages in qualified personnel. We are subject to inspections by the FDA and comparable agencies in other jurisdictions to confirm compliance with applicable regulatory requirements. See "Other U.S. Post-Marketing Regulatory Requirements" above for additional information. Any failure to follow cGMP or other regulatory requirements or delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or storage of our product candidates as a result of a failure of our facilities or the facilities or operations of third parties to comply with regulatory requirements or pass any regulatory authority inspection could significantly impair our ability to develop and commercialize our product candidates, including leading to significant delays in the availability of drug product for our clinical trials or the termination or hold on a clinical trial, or the delay or prevention of a filing or approval of marketing applications for our product candidates. Significant noncompliance could also result in the imposition of sanctions, including fines, injunctions, civil penalties, failure of regulatory authorities to grant marketing approvals for our product candidates, delays, suspension or withdrawal of approvals, license revocation, seizures or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">recalls of products, operating restrictions and criminal prosecutions, any of which could damage our reputation. If we are not able to maintain regulatory compliance, we may not be permitted to market our product candidates and/or may be subject to product recalls, seizures, injunctions, or criminal prosecution.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have no marketing, sales or distribution infrastructure. If we are unable to develop sales, marketing and distribution capabilities on our own or through collaborations, we will not be successful in commercializing our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have no marketing, sales and distribution infrastructure and we have limited sales and marketing experience within our organization. If any of our product candidates are approved, we intend to establish a sales and marketing organization with technical expertise and supporting distribution capabilities to commercialize our product candidates in the United States and, potentially, to outsource this function to a third party outside of the United States. Both of these options would be expensive and time consuming. These costs may be incurred in advance of any approval of our product candidates. In addition, we may not be able to engage a sales force in the United States that is sufficient in size or has adequate expertise in the medical markets that we intend to target. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our products.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">With respect to certain of our existing and future product candidates, we have entered into collaboration or other licensing arrangements with third party collaborators that have direct sales forces and established distribution systems. To the extent that we enter into additional collaboration agreements, our product revenue may be lower than if we directly marketed or sold any approved products. In addition, any revenue we receive will depend in whole or in part upon the efforts of these third party collaborators, which may not be successful and are generally not within our control. If we are unable to enter into additional arrangements on acceptable terms or at all, we may not be able to successfully commercialize certain approved products. If we are not successful in commercializing approved products, either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we may incur significant additional losses.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face significant competition and if our competitors develop and market products that are more effective, safer or less expensive than our product candidates, our commercial opportunities will be negatively impacted.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The life sciences industry is highly competitive and subject to rapid and significant technological change. We are currently developing therapeutics that will compete with other drugs and therapies that currently exist or are being developed. Products we may develop in the future are also likely to face competition from other drugs and therapies, some of which we may not currently be aware. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, universities and other research institutions. Many of our competitors have significantly greater financial, manufacturing, marketing, drug development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing pharmaceutical products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA approval or discovering, developing and commercializing products in our field before we do.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Specifically, there are a large number of companies developing or marketing treatments for cancer and autoimmune disorders, including many major pharmaceutical and biotechnology companies. These treatments consist both of small molecule drug products, as well as biologic therapeutics that work by using next-generation antibody technology platforms to address specific cancer targets. In addition, several companies are developing therapeutics that work by targeting multiple specificities using a single recombinant molecule. See "Competition" above for additional information.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third party payors seeking to encourage the use of biosimilar products. Biosimilar products are expected to become available over the coming years. For example, certain HER2 biosimilar products are approved in certain countries and others may be approved prior to margetuximab. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive biosimilar products if any have been approved by then.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller and other early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that our products will be widely used.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if our product candidates are approved for sale by the appropriate regulatory authorities, market acceptance and sales of these products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will reimburse and establish payment levels and, in some cases, utilization&#160;management strategies, such as tiered formularies and prior authorization. We cannot be certain that reimbursement will be available for any products that we develop or that the reimbursement level will be adequate to allow us to operate profitably. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. Our ability to commercialize our products may depend, in part, on the extent to which reimbursement for the products will be available from government authorities and third-party payors.  If reimbursement for our products is not available or is available on a limited basis, or if the reimbursement amount for our products is inadequate, we may not be able to successfully commercialize any of our approved products.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Actual or anticipated changes to the laws and regulations governing the health care system may have a negative impact on cost and access to health insurance coverage and reimbursement of healthcare items and services. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The United States and several foreign jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our future approved products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives, including the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Affordability Reconciliation Act, collectively the ACA, which became law in 2010. While it is difficult to assess the impact of the ACA in isolation, either in general or on our business specifically, it is widely thought that the ACA increases downward pressure on pharmaceutical reimbursement, which could negatively affect market acceptance of, and the price we may charge for, any products we develop that receive regulatory approval.   Further, the United State and foreign governments regularly consider reform measures that affect healthcare coverage and costs.  Such reforms may include changes to the coverage and reimbursement of healthcare services and products.  In particular, there have been recent judicial and Congressional challenges to the ACA, which could have an impact on coverage and reimbursement for healthcare services covered by plans authorized by the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In September 2017, members of the United States Congress introduced legislation with the announced intention to repeal major provisions of the ACA. Although it is unclear whether such legislation will ultimately become law, executive or legislative branch attempts to repeal, reform or to repeal and replace the ACA will likely continue. In addition, various other healthcare reform proposals have also emerged at the federal and state level. In addition, recent changes to United States tax laws could negatively impact the ACA.  We cannot predict what healthcare initiatives, if any, will be implemented at the federal or state level, however, government and other regulatory oversight and future regulatory and government interference with the healthcare systems could adversely impact our business and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to experience pricing pressures in connection with the sale of any products that we develop, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative proposals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If any product liability lawsuits are successfully brought against us or any of our collaborators, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face an inherent risk of product liability lawsuits related to the testing of our product candidates in seriously ill patients, and will face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities. Regardless of their merit or eventual outcome, liability claims may result in:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased demand for our future approved products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">injury to our reputation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial participants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">termination of clinical trial sites or entire trial programs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased regulatory scrutiny;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant litigation costs;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial monetary awards to or costly settlement with patients or other claimants;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product recalls or a change in the indications for which they may be used;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">diversion of management and scientific resources from our business operations; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize our product candidates.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity. We could also be adversely affected if any of our products or any similar products distributed by other companies prove to be, or are asserted to be, harmful to patients. Because of our dependence upon consumer perceptions, any adverse publicity associated with illness or other adverse effects resulting from patients' use or misuse of our products or any similar products distributed by other companies could have a material adverse impact on our financial condition or results of operations.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently hold $20 million in product liability insurance coverage in the aggregate, with a per incident limit of $20 million, which may not be adequate to cover all liabilities that we may incur. We may need to increase our insurance coverage when we begin the commercialization of our product candidates. Insurance coverage is becoming increasingly expensive. As a result, we may be unable to maintain or obtain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. A successful product liability claim or series of claims brought against us, particularly if judgments exceed any insurance coverage we may have, could decrease our cash resources and adversely affect our business, financial condition and results of operation.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The contract with the National Institute of Allergy and Infectious Diseases (NIAID)&#160;makes us a government contractor. Laws and regulations affecting government contracts&#160;may&#160;make it more costly and difficult for us to successfully conduct our business.&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts.&#160;Failure to comply with these laws could result in significant civil and criminal penalties. &#160;Among the most significant government contracting regulations that&#160;may&#160;affect&#160;our&#160;business&#160;are:&#160;&#160;the Federal Acquisition Regulation, or FAR, and&#160;NIH-NIAID-specific regulations supplemental to the FAR, which comprehensively regulate the procurement, formation, administration and performance of government contracts;&#160;&#160;business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act,&#160;and&#160;the False Claims Act;&#160;&#160;export and import control laws and regulations; and&#160;laws, regulations and executive orders restricting the use and dissemination of&#160;sensitive&#160;information&#160;we may receive pursuant to our performance of the government contract. &#160;&#160;U.S. government agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. If we are audited, such audit could result in disallowance of expected cost reimbursement, or if such audit were to uncover improper or illegal activities, we could be subject to civil and criminal penalties, administrative sanctions, including suspension or debarment from government contracting and significant reputational harm.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, Public Law no. 115-97 (the Tax Act), was signed into law. The Tax Act introduced significant changes to the Internal Revenue Code of 1986, as amended.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">current year taxable income in respect of losses arising in taxable years beginning after 2017 and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future, we continue to examine the impact the Tax Act may have on our business. As a result, the overall impact of the Tax Act is uncertain and our business and financial condition could be adversely affected. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Position and Need for Additional Capital</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred significant losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We have no products approved for commercial sale, and to date we have not generated any revenue or profit from product sales. We may never achieve or sustain profitability.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company. We have incurred significant losses since our inception. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, our accumulated deficit was approximately </font><font style="font-family:inherit;font-size:10pt;">$312.3 million</font><font style="font-family:inherit;font-size:10pt;">. We expect to continue to incur losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for, our product candidates, prepare for and begin to commercialize any approved products, and add infrastructure and personnel to support our product development efforts and operations as a public company. The net losses and negative cash flows incurred to date, together with expected future losses, have had, and likely will continue to have, an adverse effect on our stockholders' deficit and working capital. The amount of future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. For example, our expenses could increase if we are required by the FDA to perform trials in addition to those that we currently expect to perform, or if there are any delays in completing our currently planned clinical trials or in the development of any of our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To become and remain profitable, we must succeed in developing and commercializing products with significant market potential. This will require us to be successful in a range of challenging activities for which we are only in the preliminary stages, including developing product candidates, obtaining regulatory approval for them, and manufacturing, marketing and selling those products for which we may obtain regulatory approval. We may never succeed in these activities and may never generate revenue from product sales that is significant enough to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Our failure to become or remain profitable would depress our market value and could impair our ability to raise capital, expand our business, develop other product candidates, or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will require substantial additional funding, which may not be available to us on acceptable terms, or at all, and, if not available, may require us to delay, scale back, or cease our product development programs or operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are advancing our product candidates through clinical development. Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. In order to obtain such regulatory approval, we will be required to conduct clinical trials for each indication for each of our product candidates. We will continue to require additional funding beyond what was raised in our public offerings and through our collaborations and license agreements to complete the development and commercialization of our product candidates and to continue to advance the development of our other product candidates, and such funding may not be available on acceptable terms or at all. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, combined with the proceeds from collaboration payments we anticipate receiving, will enable us to fund our operations for approximately two years, assuming all of our programs and collaborations advance as currently contemplated. Because successful development of our product candidates is uncertain, we are unable to estimate the actual funds we will require to complete research and development and to commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future funding requirements will depend on many factors, including but not limited to:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the number and characteristics of other product candidates and indications that we pursue;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the scope, progress, timing, cost and results of research, preclinical development, and clinical trials;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">28</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs, timing and outcome of seeking and obtaining FDA and non-U.S. regulatory approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the costs associated with manufacturing our product candidates and establishing sales, marketing, and distribution capabilities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to maintain, expand, and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make in connection with the licensing, filing, defense and enforcement of any patents or other intellectual property rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our need and ability to hire additional management, scientific, and medical personnel;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the effect of competing products that may limit market penetration of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our need to implement additional internal systems and infrastructure, including financial and reporting systems; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the economic and other terms, timing of and success of our existing collaborations, and any collaboration, licensing, or other arrangements into which we may enter in the future, including the timing of receipt of any milestone or royalty payments under these agreements.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through a combination of public or private equity offerings, debt financings, strategic collaborations, and grant funding. If sufficient funds on acceptable terms are not available when needed, or at all, we could be forced to significantly reduce operating expenses and delay, scale back or eliminate one or more of our development programs or our business operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish substantial rights.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Debt financing, if available at all, may involve agreements that include covenants limiting or restricting our ability to take specific actions such as incurring additional debt, making capital expenditures, or declaring dividends. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, product candidates, or future revenue streams, or grant licenses on terms that are not favorable to us. We cannot assure you that we will be able to obtain additional funding if and when necessary. If we are unable to obtain adequate financing on a timely basis, we could be required to delay, scale back or eliminate one or more of our development programs or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our ability to use our net operating loss carryforwards and other tax attributes may be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to utilize our federal net operating losses, or NOLs, and federal tax credits is currently limited, and may be limited further, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended. The limitations apply if an ownership change, as defined by Section&#160;382, occurs. Generally, an ownership change occurs when certain shareholders increase their aggregate ownership by more than 50 percentage points over their lowest ownership percentage in a testing period, which is typically three years or since the last ownership change. We are already subject to Section&#160;382 limitations due to acquisitions we made in 2002 and 2008.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had federal and state NOL carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$239.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and research and development tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section&#160;382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us. </font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Dependence on Third Parties</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our existing therapeutic collaborations are important to our business, and future collaborations may also be important to us. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have limited capabilities for drug development and do not yet have any capability for sales, marketing or distribution. We have entered into collaborations with other companies that we believe can provide such capabilities, including our collaboration and license agreements with, for example, Les Laboratoires Servier and Institut de Recherches Servier, or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collectively Servier, Pfizer, Inc., or Pfizer, Green Cross Corp., or Green Cross, Incyte Corporation or Incyte, and F. Hoffman La Roche Ltd and Hoffman-La Roche, Inc, or Roche.  These collaborations also have provided us with important funding for our development programs and technology platforms and we expect to receive additional funding under these collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not perform their obligations as expected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators' strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such product or products;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborations may be terminated for the convenience of the collaborator and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of our collaboration and license agreements may be terminated for convenience upon the completion of a specified notice period.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our therapeutic collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development of our technology platforms and product candidates could be delayed and we may need additional resources to develop product candidates and our technology platforms. All of the risks relating to product development, regulatory approval and commercialization described in this report also apply to the activities of our program collaborators.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us. If one of our collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For some of our product candidates, we may in the future determine to collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator's resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator's evaluation of a number of factors. These factors may include the design or results </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our technology platforms and our business may be materially and adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Aside from our agreement with Green Cross, subject to certain specified exceptions, each of our existing therapeutic collaborations contains a restriction on our engaging in activities that are the subject of the collaboration with third parties for specified periods of time.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Independent clinical investigators and CROs that we engage to conduct our clinical trials may not devote sufficient time or attention to our clinical trials or be able to repeat their past success.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to depend on independent clinical investigators and CROs to conduct our clinical trials. CROs may also assist us in the collection and analysis of data. There is a limited number of third-party service providers that specialize or have the expertise required to achieve our business objectives. Identifying, qualifying and managing performance of third-party service providers can be difficult, time consuming and cause delays in our development programs. These investigators and CROs will not be our employees and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if their performance is substandard, it may delay or compromise the prospects for approval and commercialization of any product candidates that we develop. In addition, the use of third-party service providers requires us to disclose our proprietary information to these parties, which could increase the risk that this information will be misappropriated. Further, the FDA requires that we comply with standards, commonly referred to as current Good Clinical Practice, or GCP, for conducting, recording and reporting clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial subjects are protected. Failure of clinical investigators or CROs to meet their obligations to us or comply with GCP procedures could adversely affect the clinical development of our product candidates and harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure of third-party contractors to successfully develop and commercialize companion diagnostics for use with our product candidates could harm our ability to commercialize our product candidates.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We plan to develop companion diagnostics for our product candidates where appropriate. We expect that, at least in some cases, the FDA and similar regulatory authorities outside the United States may require the development and regulatory approval of a companion diagnostic as a condition to approving our product candidates. We do not have experience or capabilities in developing or commercializing diagnostics and plan to rely in large part on third parties to perform these functions.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In most cases, we will likely outsource the development, production and commercialization of companion diagnostics to third parties. By outsourcing these companion diagnostics to third parties, we become dependent on the efforts of our third party contractors to successfully develop and commercialize these companion diagnostics. Our contractors:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may not perform their obligations as expected;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may encounter production difficulties that could constrain the supply of the companion diagnostic;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may have difficulties gaining acceptance of the use of the companion diagnostic in the clinical community;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may not commit sufficient resources to the marketing and distribution of such product; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may terminate their relationship with us.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any companion diagnostic for use with one of our product candidates fails to gain market acceptance, our ability to derive revenues from sales of such product candidate could be harmed. If our third party contractors fail to commercialize such companion diagnostic, we may not be able to enter into arrangements with another diagnostic company to obtain supplies of an alternative diagnostic test for use in connection with such product candidate or do so on commercially reasonable terms, which could adversely affect and delay the development or commercialization of such product candidate.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We expect to contract with third parties for the manufacture of some of our product candidates for clinical testing in the future and expect to continue to do so for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have a manufacturing facility located in Rockville, Maryland. We manufacture drug substance at this facility that we use for research and development purposes and for clinical trials of our product candidates. We believe we currently have capacity to produce some but not all of the material required for our clinical trials. Our current facility will be insufficient to support our needs for our Phase 3 clinical trials for our antibody product candidates and for commercial quantities of such candidates.  We are also completing the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which has been designed to increase our internal capacity to manufacture more drug substance lots, at larger scale and in full compliance with current Good Manufacturing Practices (cGMP) to be able to sell commercial product.  We do not have experience in manufacturing products at commercial scale. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have entered into agreements with contract manufacturing organizations to supplement our clinical supply and internal capacity as we advance our product candidate pipeline. We expect to use third parties for the manufacture of certain of our product candidates for clinical testing, as well as for commercial manufacture of some of our product candidates that receive marketing approval and that are not manufactured by one of our third party collaborators. We have entered into two long-term supply agreements with manufacturers for commercial supply, and may in the future enter into one or more additional supply agreements for our product candidates. We may be unable to reach agreement with any of these contract manufacturers, or to identify and reach arrangements on satisfactory terms with other contract manufacturers, to manufacture any of our product candidates. Additionally, the facilities used by any contract manufacturer to manufacture any of our product candidates must be the subject of a satisfactory inspection before the FDA and other regulatory authorities approve a BLA or marketing authorization for the product candidate manufactured at that facility. We will depend on these third-party manufacturing partners for compliance with the FDA's requirements for the manufacture of our finished products. If our manufacturers cannot successfully manufacture material that conforms to our specifications and the FDA and other regulatory authorities' cGMP requirements, our product candidates will not be approved or, if already approved, may be subject to recalls.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reliance on third-party manufacturers entails risks to which we would not be subject if we manufactured the product candidates ourselves, including:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility of a breach of the manufacturing agreements by the third parties because of factors beyond our control;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility of termination or nonrenewal of the agreements by the third parties before we are able to arrange for a qualified replacement third-party manufacturer; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the possibility that we may not be able to secure a manufacturer or manufacturing capacity in a timely manner and on satisfactory terms in order to meet our manufacturing needs.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these factors could cause the delay of approval or commercialization of our product candidates, cause us to incur higher costs or prevent us from commercializing our product candidates successfully. Furthermore, if any of our product candidates are approved and contract manufacturers fail to deliver the required commercial quantities of finished product on a timely basis and at commercially reasonable prices, and we are unable to find one or more replacement manufacturers capable of production at a substantially equivalent cost, in substantially equivalent volumes and quality and on a timely basis, we would likely be unable to meet demand for our products and could lose potential revenue. It may take several years to establish an alternative source of supply for our product candidates and to have any such new source approved by the FDA or any other relevant regulatory authorities.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A disruption in our computer networks, including those related to cybersecurity, could adversely affect our financial performance.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely on our computer networks and systems, some of which are managed by third parties, to manage and store electronic information (including sensitive data such as confidential business information and personally identifiable data relating to employees, customers and other business partners), and to manage or support a variety of critical business processes and activities. We may face threats to our networks from unauthorized access, security breaches and other system disruptions. Despite our security measures, our infrastructure may be vulnerable to external or internal attacks. Any such security breach may compromise information stored on our networks and may result in significant data losses or theft of sensitive or proprietary information. In addition, a cybersecurity attack could result in other negative consequences, including disruption of our internal operations, increased cyber security protection costs, lost revenue, regulatory actions or litigation. Any disruption  could also have a material adverse impact on our operations.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our commercial success depends significantly on our ability to operate without infringing the valid patents and other proprietary rights of third parties.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our success will depend in part on our ability to operate without infringing the proprietary rights of third parties. Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import our future approved products or impair our competitive position. For example, certain patents held by third parties cover Fc engineering methods and mutations in Fc regions to enhance the binding of Fc regions to Fc receptors on immune cells. Although we believe that these patents are not infringed, invalid, and unenforceable, if a court should find that they cover margetuximab or enoblituzumab and we are unable to invalidate their patents, or if licenses for them are not available on commercially reasonable terms, our business could be harmed, perhaps materially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents that we may ultimately be found to infringe could be issued to third parties. Third parties may have or obtain valid and enforceable patents or proprietary rights that could block us from developing product candidates using our technology. Our failure to obtain a license to any technology that we require may materially harm our business, financial condition and results of operations. Moreover, our failure to maintain a license to any technology that we require may also materially harm our business, financial condition, and results of operations. Furthermore, we would be exposed to a threat of litigation.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the pharmaceutical industry, significant litigation and other proceedings regarding patents, patent applications, trademarks and other intellectual property rights have become commonplace. The types of situations in which we may become a party to such litigation or proceedings include:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our collaborators may initiate litigation or other proceedings against third parties seeking to invalidate the patents held by those third parties or to obtain a judgment that our products or processes do not infringe those third parties' patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if our competitors file patent applications that claim technology also claimed by us or our licensors, we or our licensors may be required to participate in interference or opposition proceedings to determine the priority of invention, which could jeopardize our patent rights and potentially provide a third party with a dominant patent position;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if third parties initiate litigation claiming that our processes or products infringe their patent or other intellectual property rights, we and our collaborators will need to defend against such proceedings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if a license to necessary technology is terminated, the licensor may initiate litigation claiming that our processes or products infringe or misappropriate their patent or other intellectual property rights and/or that we breached our obligations under the license agreement, and we and our collaborators would need to defend against such proceedings.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These lawsuits would be costly and could affect our results of operations and divert the attention of our management and scientific personnel. There is a risk that a court would decide that we or our collaborators are infringing the third party's patents and would order us or our collaborators to stop the activities covered by the patents. In that event, we or our collaborators may not have a viable alternative to the technology protected by the patent and may need to halt work on the affected product candidate or cease commercialization of an approved product. In addition, there is a risk that a court will order us or our collaborators to pay the other party damages. An adverse outcome in any litigation or other proceeding could subject us to significant liabilities to third parties and require us to cease using the technology that is at issue or to license the </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">technology from third parties. We may not be able to obtain any required licenses on commercially acceptable terms or at all. Any of these outcomes could have a material adverse effect on our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pharmaceutical and biotechnology industries have produced a significant number of patents, and it may not always be clear to industry participants, including us, which patents cover various types of products or methods of use. The coverage of patents is subject to interpretation by the courts, and the interpretation is not always uniform or predictable. If we are sued for patent infringement, we would need to demonstrate that our products or methods either do not infringe the patent claims of the relevant patent or that the patent claims are invalid, and we may not be able to do this. Proving invalidity is difficult. For example, in the United States, proving invalidity requires a showing of clear and convincing evidence to overcome the presumption of validity enjoyed by issued patents. Even if we are successful in these proceedings, we may incur substantial costs and divert management's time and attention in pursuing these proceedings, which could have a material adverse effect on us. If we are unable to avoid infringing the patent rights of others, we may be required to seek a license, defend an infringement action or challenge the validity of the patents in court. Patent litigation is costly and time consuming. We may not have sufficient resources to bring these actions to a successful conclusion. In addition, if we do not obtain a license, develop or obtain non-infringing technology, fail to defend an infringement action successfully or have infringed patents declared invalid, we may incur substantial monetary damages, encounter significant delays in bringing our product candidates to market and be precluded from manufacturing or selling our product candidates.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The cost of any patent litigation or other proceeding, even if resolved in our favor, could be substantial. Some of our competitors may be able to sustain the cost of such litigation and proceedings more effectively than we can because of their substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Patent litigation and other proceedings may also absorb significant management time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to obtain and enforce patent protection for our product candidates and related technology, our business could be materially harmed.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issued patents may be challenged, narrowed, invalidated or circumvented. In addition, court decisions may introduce uncertainty in the enforceability or scope of patents owned by biotechnology companies. The legal systems of certain countries do not favor the aggressive enforcement of patents, and the laws of foreign countries may not allow us to protect our inventions with patents to the same extent as the laws of the United States. Because patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, or in some cases not at all, and because publications of discoveries in scientific literature lag behind actual discoveries, we cannot be certain that we were the first to make the inventions claimed in our issued patents or pending patent applications, or that we were the first to file for protection of the inventions set forth in our patents or patent applications. As a result, we may not be able to obtain or maintain protection for certain inventions. Therefore, the enforceability and scope of our patents in the United States and in foreign countries cannot be predicted with certainty and, as a result, any patents that we own or license may not provide sufficient protection against competitors. We may not be able to obtain or maintain patent protection from our pending patent applications, from those we may file in the future, or from those we may license from third parties. Moreover, even if we are able to obtain patent protection, such patent protection may be of insufficient scope to achieve our business objectives.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our strategy depends on our ability to identify and seek patent protection for our discoveries. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. Despite our efforts to protect our proprietary rights, unauthorized parties may be able to obtain and use information that we regard as proprietary. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The issuance of a patent does not ensure that a court or agency finds or will find the patent valid or enforceable, so even if we obtain patents, they may not be valid or enforceable against third parties. In addition, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from marketing our own patented product and practicing our own patented technology. Third parties may also seek to market biosimilar versions of any approved products. Alternatively, third parties may seek approval to market their own products similar to or otherwise competitive with our products. In these circumstances, we may need to defend and/or assert our patents, including by filing lawsuits alleging patent infringement. In any of these types of proceedings, a court or agency with jurisdiction may find our patents invalid and/or unenforceable. Even if we have valid and enforceable patents, these patents still may not provide protection against competing products or processes sufficient to achieve our business objectives.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent position of pharmaceutical or biotechnology companies, including ours, is generally uncertain and involves complex legal and factual considerations. The standards which the United States Patent and Trademark Office, or USPTO, and its foreign counterparts use to grant patents are not always applied predictably or uniformly and can change. There is also no uniform, worldwide policy regarding the subject matter and scope of claims granted or allowable in pharmaceutical or </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">biotechnology patents. The laws of some foreign countries do not protect proprietary information to the same extent as the laws of the United States, and many companies have encountered significant problems and costs in protecting their proprietary information in these foreign countries. Outside the United States, patent protection must be sought in individual jurisdictions, further adding to the cost and uncertainty of obtaining adequate patent protection outside of the United States. Accordingly, we cannot predict whether additional patents protecting our technology will issue in the United States or in foreign jurisdictions, or whether any patents that do issue will have claims of adequate scope to provide competitive advantage. Moreover, we cannot predict whether third parties will be able to successfully obtain claims or the breadth of such claims. The allowance of broader claims may increase the incidence and cost of patent interference proceedings, opposition proceedings, and/or reexamination proceedings, the risk of infringement litigation, and the vulnerability of the claims to challenge. On the other hand, the allowance of narrower claims does not eliminate the potential for adversarial proceedings, and may fail to provide a competitive advantage. Our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products, or provide us with any competitive advantage.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may become involved in lawsuits to protect or enforce our patents, which could be expensive, time consuming and unsuccessful.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even after they have been issued, our patents and any patents which we license may be challenged, narrowed, invalidated or circumvented. If our patents are invalidated or otherwise limited or will expire prior to the commercialization of our product candidates, other companies may be better able to develop products that compete with ours, which could adversely affect our competitive business position, business prospects and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following are examples of litigation and other adversarial proceedings or disputes that we could become a party to involving our patents or patents licensed to us:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we or our collaborators may initiate litigation or other proceedings against third parties to enforce our patent rights;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may initiate litigation or other proceedings seeking to invalidate patents owned by or licensed to us or to obtain a declaratory judgment that their product or technology does not infringe our patents or patents licensed to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may initiate opposition, reexamination or inter partes review proceedings challenging the validity or scope of our patent rights, requiring us or our collaborators and/or licensors to participate in such proceedings to defend the validity and scope of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">there may be a challenge or dispute regarding inventorship or ownership of patents currently identified as being owned by or licensed to us;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the U.S. Patent&#160;and Trademark Office may initiate an interference between patents or patent applications owned by or licensed to us and those of our competitors, requiring us or our collaborators and/or licensors to participate in an interference proceeding to determine the priority of invention, which could jeopardize our patent rights; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">third parties may seek approval to market biosimilar versions of our future approved products prior to expiration of relevant patents owned by or licensed to us, requiring us to defend our patents, including by filing lawsuits alleging patent infringement.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These lawsuits and proceedings would be costly and could affect our results of operations and divert the attention of our managerial and scientific personnel. There is a risk that a court or administrative body would decide that our patents are invalid or not infringed by a third party's activities, or that the scope of certain issued claims must be further limited. An adverse outcome in a litigation or proceeding involving our own patents could limit our ability to assert our patents against these or other competitors, affect our ability to receive royalties or other licensing consideration from our licensees, and may curtail or preclude our ability to exclude third parties from making, using and selling similar or competitive products. Any of these occurrences could adversely affect our competitive business position, business prospects and financial condition.</font></div><div style="line-height:120%;padding-top:9px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The degree of future protection for our proprietary rights is uncertain because legal means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may be able to develop a platform that is similar to, or better than, ours in a way that is not covered by the claims of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">others may be able to make compounds that are similar to our product candidates but that are not covered by the claims of our patents;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to make the inventions covered by patents or pending patent applications;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we might not have been the first to file patent applications for these inventions;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any patents that we obtain may not provide us with any competitive advantages or may ultimately be found invalid or unenforceable; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not develop additional proprietary technologies that are patentable.</font></div></td></tr></table><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with our obligations under our intellectual property licenses with third parties, we could lose license rights that are important to our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are currently party to various intellectual property license agreements. These license agreements impose, and we expect that future license agreements may impose, various diligence, milestone payment, royalty, insurance and other obligations on us. For example, we have entered into patent and know-how license agreements that grant us the right to use certain technologies related to biological manufacturing to manufacture our clinical product candidates. These licenses typically include an obligation to pay yearly maintenance payments and royalties on sales, and may also include upfront and milestone payments. If we fail to comply with our obligations under the licenses, the licensors may have the right to terminate their respective license agreements, in which event we might not be able to market any product that is covered by the agreements. Termination of the license agreements or reduction or elimination of our licensed rights may result in our having to negotiate new or reinstated licenses with less favorable terms, which could adversely affect our competitive business position and harm our business.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to patent protection, we also rely on other proprietary rights, including protection of trade secrets, and other proprietary information. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual's relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we may not obtain these agreements in all circumstances, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, such inventions may become assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual's assignee. Such assignment or license may not be available on commercially reasonable terms or at all.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is common in the biotechnology and pharmaceutical industries, we employ individuals who were previously or concurrently employed at research institutions and/or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that these employees, or we, have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or concurrent employer. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign patent offices at various points over the lifetime of our patents and/or applications. We have systems in place to remind us to pay these fees, and we rely on our outside counsel to pay these fees when due. Additionally, the USPTO and various foreign patent offices require compliance with a number of procedural, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, it could have a material adverse effect on our business. In addition, we are responsible for the payment of patent fees for patent rights that we have licensed from other parties. If any licensor of these patents does not itself elect to make these payments, and we fail to do so, we may be liable to the licensor for any costs and consequences of any resulting loss of patent rights.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Amendments and similar foreign legislation for extending the term of patents covering each of our product candidates, our business may be materially harmed.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.</font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Legal Compliance Matters</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development involves, and may in the future involve, the use of potentially hazardous materials and chemicals. Our operations may produce hazardous waste products. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by local, state and federal laws and regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations and fire and building codes, including those governing laboratory procedures, exposure to blood-borne pathogens, use and storage of flammable agents and the handling of biohazardous materials. Although we maintain workers' compensation insurance as prescribed by the States of Maryland and California to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws commonly referred to as "fraud and abuse" laws have been applied in recent years to restrict certain marketing practices in the pharmaceutical industry. These laws include false claims and anti-kickback statutes.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. In addition, under the Sunshine Act provisions of the ACA, pharmaceutical manufacturers with one or more products for which payment is available under a federal health care program are subject to federal reporting and disclosure requirements with regard to payments or other transfers of value made to </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">physicians and teaching hospitals. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which may apply to items such as pharmaceutical products and services reimbursed by private insurers. Some state laws also prohibit certain gifts to healthcare providers, require pharmaceutical companies to report payments to healthcare professionals, and/or require companies to adopt compliance programs or codes of conduct. Administrative, civil and criminal sanctions may be imposed under these federal and state laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Over the past few years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. At such time, if ever, as we market any of our future approved products and these products are paid for by governmental programs, it is possible that some of our business activities could also be subject to challenge under one or more of these "fraud and abuse" laws.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are subject to the U.S. Foreign Corrupt Practices Act and other anti-corruption laws. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, which could adversely affect our business, results of operations and financial condition.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our operations are subject to anti-corruption laws, including the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business. The FCPA and these other laws generally prohibit us and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We and our commercial partners operate in a number of jurisdictions that pose a risk of potential FCPA violations, and we participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA or other anti-corruption laws. There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws. If we violate provisions of the FCPA or other anti-corruption laws or are subject to an investigation or audit pursuant to these laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures and legal expenses, which could have an adverse impact on our business, financial condition and results of operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are exposed to the risk of employee fraud or other misconduct. Misconduct by employees could include intentional failures to comply with FDA regulations, to provide accurate information to the FDA or other agencies, to comply with federal and state health care fraud and abuse laws and regulations, to report financial information or data accurately or to disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We have adopted a code of conduct, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Employee Matters and Managing Growth</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent on the research and development, clinical and business development expertise of Scott Koenig, M.D., Ph.D., our President and Chief Executive Officer, as well as the other members of our senior management, scientific and clinical team. Although we have entered into employment agreements with certain of our executive officers, each of them may terminate their employment with us at any time. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. In addition, we will need to expand and effectively manage our managerial, operational, financial, development and other resources in order to successfully pursue our research, development and commercialization efforts for our existing and future product candidates. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">experience required to successfully develop, gain regulatory approval of and commercialize products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to grow our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of February 27, 2018, we had 330 full-time employees. As our development and commercialization plans and strategies develop, we expect to expand our employee base for managerial, operational, sales, marketing, financial and other resources. Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit, maintain, motivate and integrate additional employees. Also, our management may need to divert a disproportionate amount of their attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations which may result in weaknesses in our infrastructure, give rise to operational errors, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of existing and additional product candidates. If our management is unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize our product candidates and compete effectively with others in our industry will depend, in part, on our ability to effectively manage any future growth.</font></div><div style="line-height:120%;padding-top:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Relating to Our Common Stock</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our stock price may be volatile and fluctuate substantially, which may subject us to securities class action litigation.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our stock price is likely to be volatile.&#160; The stock market has experienced significant volatility, particularly with respect to pharmaceutical, biotechnology, and other life sciences company stocks. The volatility of pharmaceutical, biotechnology, and other life sciences company stocks often does not relate to the operating performance of the companies represented by the stock.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit and divert the time and attention of our management, which could seriously harm our business.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Provisions of our charter, bylaws, third-party agreements and Delaware law may make an acquisition of us or a change in our management more difficult.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain provisions of our restated certificate of incorporation and amended and restated bylaws could discourage, delay, or prevent a merger, acquisition, or other change in control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. Furthermore, since our board of directors is responsible for appointing the members of our management team, these provisions could prevent or frustrate attempts by our stockholders to replace or remove our management by making it more difficult for stockholders to replace members of our board of directors. These provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">allow the authorized number of directors to be changed only by resolution of our board of directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish a classified board of directors, providing that not all members of the board of directors be elected at one time;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">authorize our board of directors to issue without stockholder approval blank check preferred stock that, if issued, could operate as a "poison pill" to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that is not approved by our board of directors;</font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish advance notice requirements for stockholder nominations to our board of directors or for stockholder proposals that can be acted on at stockholder meetings;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limit who may call stockholder meetings; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require the approval of the holders of 75% of the outstanding shares of our capital stock entitled to vote in order to amend certain provisions of our restated certificate of incorporation and restated bylaws.</font></div></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, in the ordinary course of our business, from time to time we discuss and enter into collaborations, licenses and other transactions with various third parties, including other pharmaceutical companies and biotechnology companies. When we deem it appropriate, our agreements with such third parties may include standstill provisions. These standstill provisions, several of which may be in force from time-to-time, typically prohibit such parties from acquiring our securities for a period of time, which may discourage such parties from acquiring MacroGenics even if doing so would be beneficial to our stockholders.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us for a prescribed period of time. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCBC601E3B783596BA534583A321D00E7"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1B.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNRESOLVED STAFF COMMENTS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><a name="sD454CFCAA22D575DA192E1BE7CCB4EB6"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTIES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We lease approximately 200,000 square feet of manufacturing, office and laboratory space in Rockville, Maryland under five leases that have terms that expire between 2019 and 2027 unless renewed.&#160; We also lease office and laboratory space in South San Francisco, California under a lease that expires in February 2018.&#160; In December 2017, we moved the South San Francisco operations into different space in Brisbane, CA which is leased until 2023. We believe that our properties are generally in good condition, well maintained, suitable and adequate to carry on our business.&#160;&#160;We believe our capital resources are sufficient to lease any additional facilities required to meet our expected growth needs.</font></div><div><a name="s239BF47AAB2E5C86B0E7F6EBF17595A4"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">LEGAL PROCEEDINGS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the ordinary course of business, we are involved in various legal proceedings, including, among others, patent oppositions, patent revocations, patent infringement litigation and other matters incidental to our business.&#160;&#160;We are not currently a party to any material legal proceedings.</font></div><div><a name="sB2B23833C4BA5FA897AC2F69BB96350E"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MINE SAFETY DISCLOSURES</font></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40</font></div></div><hr style="page-break-after:always"><div><a name="s686EC8AEA8EC599ABD1A47F74D7ECAA7"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II</font></div><div><a name="s0308C1C10C70577399B9ECF0A721B287"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MARKET FOR REGISTRANT'S COMMON EQUITY,&#160;RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Market Information</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our common stock has been listed on the Nasdaq Global Select Market under the symbol "MGNX" since October 10, 2013.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On </font><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2018</font><font style="font-family:inherit;font-size:10pt;">, the closing price for our common stock as reported on the Nasdaq Global Select Market was $23.46. The following table sets forth the high and low intra-day sale prices per share of our common stock as reported on the Nasdaq Global Select Market for the periods indicated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">High</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Low</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.29</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.36</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">First Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30.66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.84</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Second Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28.37</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Third Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33.30</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fourth Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.22</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shareholders</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">February&#160;23, 2018</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">36,918,852</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding held by approximately 79 holders of record, which include shares held by a broker, bank or other nominee.&#160;&#160;We have never declared or paid any cash dividends.&#160;&#160;We do not anticipate declaring or paying cash dividends for the foreseeable future.&#160;&#160;Instead, we will retain our earnings, if any, for the future operation and expansion of our business.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Performance Graph</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following graph compares the performance of our common stock to the performance of the Nasdaq Composite Index (U.S.) and the Nasdaq Biotechnology Index since October 10, 2013 (the first date that shares of our common stock were publicly traded).&#160;&#160;The comparison assumes a $100 investment on October 10, 2013 in our common stock, the stocks comprising the Nasdaq Composite Index, and the stocks comprising the Nasdaq Biotechnology Index, and assumes reinvestment of the full amount of all dividends, if any.&#160;&#160;Historical stockholder return is not necessarily indicative of the performance to be expected for any future periods.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;"><img src="perfchart201710k.jpg" alt="perfchart201710k.jpg" style="height:366px;width:673px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The performance graph shall not be deemed to be incorporated by reference by means of any general statement incorporating by reference this Form 10-K into any filing under the Securities Act of 1933, as amended or the Exchange Act, except to the extent that we specifically incorporate such information by reference, and shall not otherwise be deemed filed under such acts.</font></div><div><a name="sE5151942094551EFB1E3089E9E8E92CB"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SELECTED FINANCIAL DATA</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated statement of operations and comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;and the consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;presented below have been derived from our audited consolidated financial statements and footnotes included elsewhere in this Annual Report on Form 10-K.&#160;&#160;The consolidated statement of operations and comprehensive loss data for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;and the consolidated balance sheet data as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2014</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2013</font><font style="font-family:inherit;font-size:10pt;">&#32;have been derived from our audited consolidated financial statements which are not included herein.&#160;&#160;Historical results are not necessarily indicative of future results.&#160;&#160;The following data should be read in conjunction with Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" and the consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Statement of Operations and Comprehensive Loss:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,742</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,880</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,854</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,797</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58,035</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,232</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,091</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,271</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,653</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,765</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,926</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,087</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,922</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,036</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,112</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57,669</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income (loss) from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,315</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">366</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(627</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(38,313</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(261</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted&#160;net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.04</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,384,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,847,697</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">As of December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2013</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Consolidated Balance Sheet Data:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash, cash equivalents and marketable securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">305,121</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">284,982</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">339,049</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,591</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">116,481</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,883</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">359,269</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173,886</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,782</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,839</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,306</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30,720</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,403</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,286</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,914</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">43</font></div></div><hr style="page-break-after:always"><div><a name="s5ABE223BD5D559E38E28F4BC5875A5F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">The following discussion of our financial condition and results of operations should be read together with our selected consolidated financial data and the consolidated financial statements and related notes included elsewhere herein. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors including, but not limited to, those set forth under the sections entitled "Risk Factors" and "Forward-Looking Statements", our actual results may differ materially from those anticipated in such forward-looking statements.</font></div><div><a name="s71F64B0C151E5B6DABC33076CE22451E"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics to modulate the human immune response for the treatment of cancer.  We currently have a pipeline of product candidates in human clinical testing that have been created primarily using our proprietary technology platforms, which also have broad applicability across other therapeutic domains, including autoimmune disorders and infectious disease.  We believe our programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We commenced active operations in 2000, and have since devoted substantially all of our resources to staffing our company, developing our technology platforms, identifying potential product candidates, undertaking preclinical studies, conducting clinical trials, developing collaborations, business planning and raising capital. We have not generated any revenues from the sale of any products to date. We have financed our operations primarily through the public and private offerings of our securities, collaborations with other biopharmaceutical companies, and government grants and contracts.&#160; Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, combined with collaboration payments we anticipate receiving, will enable us to fund our operations for approximately two years based on our current business plan.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$312.3 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;We expect that over the next several years this deficit will increase as we increase our expenditures in research and development in connection with our ongoing activities with several clinical trials.&#160;</font></div><div><a name="s94E92C57FC5F50DA928573919672A158"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Strategic Collaborations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We pursue a balanced approach between product candidates that we develop ourselves and those that we develop with our collaborators. Under our strategic collaborations to date, we have received significant non-dilutive funding and continue to have rights to additional funding upon completion of certain research, achievement of key product development milestones and royalties and other payments upon the commercial sale of products. Currently, our most significant strategic collaborations include the following:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Incyte. </font><font style="font-family:inherit;font-size:10pt;">In October 2017, we entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while we retain the right to develop our pipeline assets in combination with MGA012. The transaction closed in the fourth quarter of 2017 and we received a $150.0 million upfront payment from Incyte upon the closing. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the collaboration, Incyte will lead global development of MGA012. Assuming successful development and commercialization by Incyte, we could receive up to approximately $420.0 million in development and regulatory milestones, and up to $330.0 million in commercial milestones. If commercialized, we would be eligible to receive tiered royalties of 15% to 24% on any global net sales and we have the option to co-promote with Incyte.  We retain the right to develop our pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing our asset(s), if any such potential combinations are approved. In addition, we retain the right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012, through utilization of our commercial-scale GMP facility, which is expected to be fully operational in 2018.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finally, Incyte will fund our activities related to our ongoing monotherapy clinical study until such time as we can transfer the Investigational New Drug application (IND) to Incyte. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Servier. </font><font style="font-family:inherit;font-size:10pt;">In September 2012, we entered into an agreement with Les Laboratoires Servier and Institut de Recherches Servier (Servier) to develop and commercialize three DART&#174; molecules in all countries other than </font></div></td></tr></table><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-left:72px;padding-bottom:12px;"><font style="font-family:inherit;font-size:10pt;">the United States, Canada, Mexico, Japan, South Korea and India. We received a $20.0 million upfront option fee. In addition, we will be eligible to receive up to approximately $700 million in additional license fees and clinical, development, regulatory and sales milestone payments if Servier exercises its remaining options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. Additionally, assuming exercise of its options, Servier may share Phase 2 and Phase 3 development costs and would be obligated to pay us low double-digit to mid-teen royalties on product sales in its territories. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, Servier exercised its option to develop and commercialize flotetuzumab, for which we received a $15.0 million license option fee.&#160;&#160;We also received two $5.0 million milestone payments from Servier in 2014 in connection with the IND applications for flotetuzumab and MGD007 clearing the 30-day review period by the U.S. Food and Drug Administration (FDA). As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, Servier still retains an option to obtain a license for MGD007, but has notified us that they have terminated their rights to license the third DART molecule.</font></div><div style="line-height:120%;padding-bottom:16px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we have sought to complement our internal expertise and capabilities with collaborators that may help us advance our programs. For example, in December 2017, we entered into a research collaboration and license agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (collectively, Roche) to jointly discover and develop novel bispecific molecules to undisclosed targets. During the research term, both companies will leverage their respective platforms, including our DART platform and Roche's CrossMAb and DutaFab technologies, to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.</font></div><div><a name="sFD96EE3077EF5F41A02196A369D2A64D"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists primarily of collaboration revenue, including amounts recognized relating to upfront nonrefundable payments for licenses or options to obtain future licenses, research and development funding and milestone payments earned under our collaboration and license agreements with our strategic collaborators. In addition, we have earned revenues through several grants and/or contracts with the U.S. government and other research institutions on behalf of the U.S. government, primarily with respect to research and development activities related to infectious disease product candidates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense consists of expenses incurred in performing research and development activities. These expenses include conducting preclinical experiments and studies, clinical trials, manufacturing efforts and regulatory filings for all product candidates, and other indirect expenses in support of our research and development activities. We capture research and development expense on a program-by-program basis for our product candidates that are in clinical development and recognize these expenses as they are incurred. The following are items we include in research and development expense:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related expenses, such as salaries and benefits;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employee-related overhead expenses, such as facilities and other allocated items;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based compensation expense to employees engaged in research and development activities;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation of laboratory equipment, computers and leasehold improvements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to consultants, subcontractors, clinical research organizations (CROs) and other third party vendors for work performed under our preclinical and clinical trials including, but not limited to, investigator grants, laboratory work and analysis, database management, statistical analysis, and other items;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts paid to vendors and suppliers for laboratory supplies;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs related to manufacturing clinical trial materials, including vialing, packaging and testing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">License fees and other third party vendor payments related to in-licensed product candidates and technology; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs related to compliance with regulatory requirements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is difficult to determine with certainty the duration and completion costs of our current or future preclinical programs and clinical trials of our product candidates, or if, when or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. We may never succeed in </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">achieving regulatory approval for any of our product candidates. The duration, costs and timing of clinical trials and development of our product candidates will depend on a variety of factors, including the uncertainties of future clinical trials and preclinical studies, uncertainties in clinical trial enrollment rates and significant and changing government regulation. In addition, the probability of success for each product candidate will depend on numerous factors, including competition, manufacturing capability and commercial viability. We will determine which programs to pursue and how much to fund each program in response to the scientific and clinical success of each product candidate, as well as an assessment of each product candidate's commercial potential.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist of salaries and related benefit costs for employees in our executive, finance, legal and intellectual property, business development, human resources and other support functions, travel expenses and other legal and professional fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income (Expense)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) consists of interest income earned on our cash, cash equivalents and marketable securities, offset by other expenses.</font></div><div><a name="s85AB1CC0915D51629194268E8794FCC8"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Significant Judgments and Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management's discussion and analysis of financial conditions and results of operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the balance sheets and the reported amount of the revenue and expenses recorded during the reporting period. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable. We review and evaluate these estimates on an on-going basis. These assumptions and estimates form the basis for making judgments about the carrying values of assets and liabilities and amounts that have been recorded as revenues and expenses. Actual results and experiences may differ from these estimates. The results of any material revisions would be reflected in the consolidated financial statements prospectively from the date of the change in estimate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While a summary of significant accounting policies is described fully in Note 2 in our consolidated financial statements, we believe that the following accounting policies are the most critical to assist you in fully understanding and evaluating our financial results and the effect of the estimates and judgments we used in preparing our consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We enter into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to our technological platforms, such as our Fc engineering and DART technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to us under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to us from these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. We follow the provisions of the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Multiple-Element Arrangements,</font><font style="font-family:inherit;font-size:10pt;">&#32;and ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, we must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had two types of agreements: i) exclusive development and commercialization licenses to use our technology and/or certain other intellectual property to develop compounds against specified targets, which we refer to as exclusive licenses; and ii) option/research agreements to secure on established terms development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by us during an option period, which we refer to as right-to-develop agreements.&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to our technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, we may have an option to participate in the co-development of product candidates that result from such agreements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that we will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases, grant us an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on our intellectual property rights and whether we exercise any co-development and co-commercialization rights.&#160;We do not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, management evaluates whether the exclusive license has stand-alone value from the undelivered elements to the collaborator based on the consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of technology platform and product research expertise in the general marketplace. In addition, we consider whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items.&#160;&#160;If we conclude that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, we then determine the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of our previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use our technology platforms, our pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by our collaborators and the nature of the research services to be performed on behalf of our collaborators and market rates for similar services. The upfront payment is recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses are deferred if facts and circumstances dictate that the license does not have stand-alone value, and revenue is then recognized throughout the period of performance. We reassess the period of performance over which we recognize deferred upfront license fees and make adjustments as appropriate. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use our technology to develop an alternative product candidate to the same target or a target substitute, we would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. We recognize revenue related to the rights to future technological improvements over the estimated term of the applicable license.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We typically perform research activities and preclinical development services, including generating and engineering product candidates, on behalf of our licensees during the early evaluation and preclinical testing stages of drug development under our exclusive licenses. We record amounts received for research materials produced or services performed as revenue from collaborative agreements.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the FDA or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, we evaluate whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">assessment of whether (i) the consideration is commensurate with either (1) our performance to achieve the milestone, or (2) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from our performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. We evaluate factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of our efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because we did not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by us under agreed upon research and preclinical development programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to us (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) upon the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license, referred to as exercise fee, for a program, or (iv) some combination of all of these fees.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, we are at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, we do not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defer any upfront payments received and recognize this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. If a collaborator exercises an option and acquires a development and commercialization license to a product program, we attribute the exercise fee to the development and commercialization license.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, we would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license. We then apply the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This method is consistent with our accounting policy for upfront payments on exclusive licenses (discussed above). In the event a right-to-develop agreement were to be terminated, we would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, we consider the development and commercialization licenses to be a deliverable at the inception of the agreement and apply the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. All of our right-to-develop agreements have been determined to contain substantive options. We do not directly control when any collaborator will exercise its options for development and commercialization licenses.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense and related Accrued Expenses</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the process of preparing our consolidated financial statements, we may be required to estimate accrued expenses. In order to obtain reasonable estimates, we review open contracts and purchase orders. In addition, we communicate with applicable personnel in order to identify services that have been performed, but for which we have not yet been invoiced. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In most cases, our vendors provide us with monthly invoices in arrears for services performed. We confirm our estimates with these vendors and make adjustments as needed. The following are examples of our accrued expenses:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to CROs for services performed on clinical trials;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid to investigator sites for performance on clinical trials; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fees paid for professional services; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Development expenses incurred by our collaborators that we share. &#160;</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of expenses related to clinical trials performed by our CROs are dependent on the successful enrollment of patients. These expenses can vary from site to site and contract to contract. We base our estimated accruals on the time period over which the services are to be performed and the level of effort to be expended in each period based on the estimated enrollment of patients in each trial. We also receive estimates from our collaborators when we are sharing development expenses.  We use these estimates to record an increase or decrease in research and development expense, depending on how much we have each spent during the period.  We will adjust accordingly should the estimates vary from the actual expenses. However, we do not anticipate that our actual expenses will differ materially from our estimates.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more than 50% likely to be realized upon ultimate settlement. Our policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recorded net deferred tax assets of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, which have been fully offset by a valuation allowance due to uncertainties surrounding our ability to realize these tax benefits. The deferred tax assets are primarily comprised of federal and state tax net operating loss (NOL) carryforwards and research and development tax credit carryforwards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had federal and state NOL carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$239.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and research and development tax credit carryforwards of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;available. The federal NOL carryforwards will begin to expire at various dates starting in </font><font style="font-family:inherit;font-size:10pt;">2025</font><font style="font-family:inherit;font-size:10pt;">. We are already subject to Section 382 limitations due to acquisitions we made in 2002 and 2008. Future changes in stock ownership may also trigger an ownership change and, consequently, another Section 382 limitation. Any limitation may result in expiration of a portion of the net operating loss or tax credit carryforwards before utilization which would reduce our gross deferred income tax assets and corresponding valuation allowance. As a result, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards and tax credit carryforwards to reduce United States federal income tax may be subject to limitations, which could potentially result in increased future cash tax liability to us.</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize stock-based compensation expense in accordance with the provisions of ASC Topic 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation&#8212;Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using a Black-Scholes model. The resulting fair value is recognized on a straight-line basis over the requisite service period, which is generally the vesting period of the option. The use of a Black-Scholes model requires us to apply judgment and make assumptions and estimates that include the following:&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value of Common Stock</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#8211;</font><font style="font-family:inherit;font-size:10pt;">&#32;Before our entry into the public market on October 10, 2013, our Board of Directors determined the fair value of the common stock. The Board of Directors made determinations of fair value based, in part, upon contemporaneous valuations to determine fair value. The contemporaneous valuations were performed in accordance with applicable methodologies, approaches and assumptions of the technical practice-aid issued by the American Institute of Certified Public Accountants Practice Aid entitled </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Valuation of Privately-Held Company Equity Securities Issued as Compensation</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period. As we do not yet have sufficient history of our own volatility, we have identified several public entities of similar size, complexity and stage of development and estimate volatility based on the volatility of these companies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; We have never declared or paid dividends and have no plans to do so in the foreseeable future.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of ten years and we have estimated the expected life of the option term to be 6.25 years. We use a simplified method to calculate the average expected term.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:61px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:37px;"><font style="font-family:inherit;font-size:6pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected Forfeiture Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested. We estimate the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">See Note 2, Summary of Significant Accounting Policies, to the consolidated financial statements for information under the caption "Recently Issued Accounting Standards."</font></div><div><a name="s0B30CCB02FE1564B893DBFFDAD59F610"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Years Ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development revenue for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.1</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">157.7</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">65.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">72</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;includes the $150.0 million upfront payment recognized under the Incyte agreement. Revenue from collaborative agreements for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes the $75.0 million upfront payment recognized under our MGD015 agreement with Janssen Biotech, Inc. </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Janssen).  The remaining change in revenue from collaborative agreements is primarily due to a $2.0 million milestone payment from Pfizer, Inc. in 2016 and a decrease in revenue recognized under the our  MGD010 agreement with Takeda Pharmaceutical Company, Limited (Takeda) of $2.1 million for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements decreased for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily due to lower costs incurred under our cost plus fixed fee contract with the National Institute of Allergy and Infectious Diseases. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Margetuximab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enoblituzumab</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Flotetuzumab (a)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGA012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGC018</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">189</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other immune modulator programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">320</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Discovery and other pipeline programs, collectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total research and development expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">147.2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">25.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">21</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) - Expenses are shown net of reimbursements from collaborator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;our research and development expense increased by </font><font style="font-family:inherit;font-size:10pt;">$25.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. This increase was primarily due to the continued enrollment in our various clinical trials, including two margetuximab studies, multiple enoblituzumab studies, and the flotetuzumab and MGD007 Phase 1 studies.  Also contributing to the increase was the initiation of the Phase 1 clinical trial of MGA012 in late 2016, as well as IND-enabling activities for both MGC018 and MGD019.  These increases were partially offset by decreased spending on MGD010 due to the completion of a Phase 1 study and decreased spending on MGD013, as IND-enabling activities ended and the dose escalation study began in 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our general and administrative expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense increased for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;by </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily due to an increase in labor-related costs, including stock-based compensation expense, and information technology-related expenses, partially offset by lower patent expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in other income for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to an increase in interest income earned on marketable securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations for the Years Ended December 31, 2016 and 2015</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development revenue for the years ended December 31,  </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2015:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">253</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total revenue</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">91.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">100.9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(9</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The decrease in collaboration revenue of $12.8 million for the year ended December&#160;31, 2016 compared to 2015 is primarily due to the decrease in revenue recognition related to the Boehringer Ingelheim GmbH (Boehringer) and Takeda agreements. Revenue under the Boehringer agreement decreased because the development period, and therefore the related revenue recognition period, was completed in September 2015. Revenue under the Takeda MGD010 agreement decreased primarily due to a $3.0 million milestone being recognized during the year ended December&#160;31, 2015.  These decreases were partially offset by the $75.0 million in revenue recognized during the year ended December&#160;31, 2016 under the Janssen MGD015 agreement compared to $72.3 million recognized during the year ended December&#160;31, 2015 under the Janssen duvortuxizumab agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements increased for the year ended December&#160;31, 2016 compared to 2015 due to revenue from the NIAID contract which began in September 2015.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our research and development expense for the years ended December&#160;31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Margetuximab</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.4</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Enoblituzumab</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Flotetuzumab (a)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD007</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD009</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD010</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.8</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.6</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGA012</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MGD013</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immune checkpoint programs</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NA</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other preclinical and clinical programs, collectively</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8.2</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total research and development expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">122.1</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">98.3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">23.8</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">24</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) - Expenses are shown net of reimbursements from collaborator.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the year ended December&#160;31, 2016 our research and development expense increased by $23.8 million compared to 2015. This increase was primarily due to increased activity in our preclinical immune checkpoint programs, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">including MGD013, the initiation of two Phase 1 clinical trials combining enoblituzumab with other compounds, the initiation of a Phase 1 clinical trial of MGA012 and the addition of the NIAID MGD014 contract (which is included in Other preclinical and clinical studies, collectively above).  These increases were partially offset by decreased manufacturing costs for margetuximab. &#160;   </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expense</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following represents a comparison of our general and administrative expense for the years ended December&#160;31, 2016 and 2015:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Increase/(Decrease)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="14" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expense increased for the year ended December&#160;31, 2016 by $7.0 million compared to 2015 primarily due to increased staff, recruiting costs, stock-based compensation expense and patent expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other Income</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The increase in other income for the year ended December&#160;31, 2016 compared to 2015 is primarily due to an increase in interest income earned on marketable securities.</font></div><div><a name="s012E5CAAB0DB52A89556B610F127D04D"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have historically financed our operations primarily through public and private offerings of equity, upfront fees, milestone payments and license option fees from collaborators and reimbursement through government grants and contracts.&#160;&#160;&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had </font><font style="font-family:inherit;font-size:10pt;">$305.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, cash equivalents and marketable securities. In addition to our existing cash, cash equivalents and marketable securities, we are eligible to receive additional reimbursement from our collaborators, including under various government grants or contracts, for certain research and development services rendered, additional milestone and opt-in payments and grant revenue. However, our ability to receive these milestone payments is dependent upon our ability to successfully complete specified research and development activities and is therefore uncertain at this time.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Funding Requirements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not generated any revenue from product sales to date and do not expect to do so until such time as we obtain regulatory approval for and commercialize one or more of our product candidates. As we are currently in the clinical trial stage of development, it will be some time before we expect to generate revenue from product sales and it is uncertain that we ever will. We expect that we will continue to increase our operating expenses in connection with ongoing as well as additional clinical trials and preclinical development of product candidates in our pipeline. We expect to continue our collaboration arrangements and will look for additional collaboration opportunities. We also expect to continue our efforts to pursue additional grants and contracts from the U.S. government in order to further our research and development. Although it is difficult to predict our funding requirements, based upon our current operating plan, we anticipate that our existing cash, cash equivalents and marketable securities as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, as well as other collaboration payments we anticipate receiving, will enable us to fund our operations for approximately two years, assuming all of our programs and collaborations advance as currently contemplated.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash Flows</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents a summary of our cash flows for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(dollars in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net cash provided by (used in):</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating activities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14.4</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13.7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70.2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204.3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Net increase (decrease) in cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">127.6</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(112.0</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">38.5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Operating Activities</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by or used in operating activities reflects, among other things, the amounts used to run our clinical trials and preclinical activities. Net cash provided by operating activities during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to cash received under the Incyte agreement partially offset by an increase in the number of ongoing clinical trials and the expenses associated with increased enrollment in clinical trials.&#160; The increase in net cash used in operating activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to an increase in the number of ongoing clinical trials, the expenses associated with increased enrollment in clinical trials and an increase in the number of employees.  &#160; &#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Investing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to maturities of marketable securities, partially offset by purchases of marketable securities and making leasehold improvements to our facilities, including the build out of a manufacturing suite at our headquarters building in Rockville, Maryland.  Net cash used in investing activities during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily due to investing our cash in marketable securities and making leasehold improvements to our facilities.&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Financing Activities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;reflects net cash proceeds from our securities offerings of approximately $34.3 million, cash from stock option exercises and proceeds from the purchase of shares under our employee stock purchase plan.  Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes cash from stock option exercises.&#160; Net cash provided by financing activities for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;includes net proceeds from the Johnson &amp; Johnson Innovation &#8211; JJDC, Inc.  investment (described more fully in Note 9 to the financial statements), the follow-on equity offering, and cash from stock option exercises.&#160;</font></div><div><a name="sF3D5936D3C0B5A0791BF3F7386A06B63"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Obligations and Contingent Liabilities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table represents future minimum operating lease payments under non-cancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="20"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Less than 1 year</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">1 to 3 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">3 to 5 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">More than 5 years</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in millions)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Operating Leases</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">45.8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">9.6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our current obligations and contingent liabilities are limited to the operating leases at our facilities in Rockville, Maryland and Brisbane, California.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2008, we acquired Raven Biotechnologies (Raven). The Raven purchase agreement provides for certain contingent payments that are based on the achievement of development and commercialization activities for product candidates derived from the acquired Raven technology. We are required to make a one-time payment of $5.0 million to the former Raven stockholders upon the initiation of patient dosing in the first Phase 2 clinical trial of any product derived from the Raven cancer stem cell program. No payment shall be made if the Phase 2 trial start date has not occurred on or before July 15, 2018. Other consideration includes a percentage of revenue (excluding consideration for research and development, equity and certain cost reimbursements) we may recognize for each license of a product candidate derived from the Raven cancer stem cell program. The revenue percentage in each case is based upon the execution date of the subject license. No consideration is owed for licenses executed after July 16, 2018. There is additional contingent consideration of one-time payments of $8.0 million and $12.0 million, which depend upon the achievement of a specified level of sales of a product derived from the Raven cancer </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">stem cell program. At our sole discretion, each payment can be made in cash, common stock or a combination thereof.&#160; No additional amounts related to the Raven purchase agreement were recorded during the three years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The contractual obligations table does not include any potential future payments we may be required to make under the purchase agreement with Raven. Due to the uncertainty of the achievement and timing of the events requiring payment under that agreement, the amounts to be paid by us are not fixed or determinable at this time.&#160;</font></div><div><a name="s786EC6FB432F5EF1BB416793AAC6263C"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not have any off-balance sheet arrangements, as defined under the rules and regulations of the Securities and Exchange Commission.</font></div><div><a name="sB1470B487EAB5424A58B9F04010623FA"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 7A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our primary objective when considering our investment activities is to preserve capital in order to fund our operations.&#160;We also seek to maximize income from our investments without assuming significant risk.&#160;&#160;Our current investment policy is to invest principally in deposits and securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations, corporate debt obligations and money market instruments.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash, cash equivalents and marketable securities of </font><font style="font-family:inherit;font-size:10pt;">$305.1 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;Our primary exposure to market risk is related to changes in interest rates.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">Due to the short-term maturities of our cash equivalents and marketable securities and the low risk profile of our marketable securities, an immediate 100 basis point change in interest rates would not have a material effect on the fair market value of our cash equivalents and marketable securities. We have the ability to hold our marketable securities until maturity, and we therefore do not expect a change in market interest rates to affect our operating results or cash flows to any significant degree.</font></div><div><a name="sB0AA3C9392245881B47B5BA212F3F3F8"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information required by this item is set forth on pages F-1 - F-29.</font></div><div><a name="s0497764479FB59E082151BDB87E42D84"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CHANGES AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FINANCIAL DISCLOSURE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div><a name="sC5F5A12ABBF95689B0BE2842A573224C"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9A.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONTROLS AND PROCEDURES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Disclosure Controls and Procedures</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, including our principal executive and principal financial officers, has evaluated the effectiveness of our disclosure controls and procedures as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">. Our disclosure controls and procedures are designed to provide reasonable assurance that the information required to be disclosed in this annual report on Form 10-K has been appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms, and that such information is accumulated and communicated to our management, including our principal executive and principal financial officers, to allow timely decisions regarding required disclosure.&#160;&#160;Based on that evaluation, our principal executive and principal financial officers have concluded that our disclosure controls and procedures are effective at the reasonable assurance level.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our management, including our principal executive and principal financial officers, has evaluated any changes in our internal control over financial reporting that occurred during the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and has concluded that there was no change that occurred during the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Management's Report on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.&#160;&#160;Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company's principal executive and principal financial officers and effected by the Company's board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pertain to the management of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material effect on the financial statements.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.&#160;&#160;Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.&#160;&#160;All internal control systems, no matter how well designed, have inherent limitations.&#160;&#160;Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's management assessed the effectiveness of the Company's internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;In making this assessment, the Company's management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (COSO) in Internal Control-Integrated Framework.&#160; Based on our assessment, management believes that, as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company's internal control over financial reporting is effective based on those criteria.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The effectiveness of our internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;has been audited by Ernst &amp; Young, LLP, an independent registered public accounting firm, as stated in their report which is included herein.</font></div><div><a name="s25BE8DF7C4DE53CA840AEF2D4516088F"></a></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 9B.</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;font-size:10pt;text-indent:-96px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">OTHER INFORMATION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">None.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">56</font></div></div><hr style="page-break-after:always"><div><a name="sD3C0EDEB85E0593D982360F66EFEF0BD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of MacroGenics, Inc. </font></div><div style="line-height:174%;padding-bottom:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on Internal Control over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited MacroGenics, Inc.&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, MacroGenics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the COSO criteria.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the related notes and our report dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">, expressed an unqualified opinion thereon. </font></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</font></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Definition and Limitations of Internal Control Over Financial Reporting</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">57</font></div></div><hr style="page-break-after:always"><div><a name="sFC1BB2011CD852448087BDA3AE2FD417"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART III</font></div><div><a name="s19A814EAD55753199995AE423E03858D"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning directors, executive officers and corporate governance to be included in our definitive proxy statement for the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;annual meeting of stockholders (the "</font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement").</font></div><div><a name="sD6947B3F94A75F0B82EF972B5CF42729"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 11.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXECUTIVE COMPENSATION</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning executive compensation to be included in the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="s47CFF52B44275E4CBBA902ED9445B13E"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 12.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning security ownership of certain beneficial owners and management to be included in the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="s0F931FC496715003BE06FAC1A339838F"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 13.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning certain other relationships and related transactions to be included in the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><a name="sD577C939F9E8551D92A705E6AFEB7121"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 14.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PRINCIPAL ACCOUNTANT FEES AND SERVICES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We incorporate herein by reference the relevant information concerning principal accountant fees and services to be included in the </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;Proxy Statement.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">58</font></div></div><hr style="page-break-after:always"><div><a name="s3BD66A726B3952469F9D285AFAD1FB98"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART IV</font></div><div><a name="s1AB9B15FF1F75D6CA9260CF1C7F597A1"></a></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 15.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) The following documents are filed as part of this Annual Report on Form 10-K:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Financial Statements:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:74%;"></td><td style="width:26%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-2</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-3</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-4</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-5</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-6</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F-7</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial Statement Schedules:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:37px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:13px;"><font style="font-family:inherit;font-size:10pt;">(3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exhibits</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately following our consolidated financial statements. The Exhibit Index is incorporated herein by reference.</font></div><div><a name="sE104D8107D875334B4C5236128B87D0A"></a></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 16.&#160;&#160;&#160;&#160;FORM 10-K SUMMARY</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">59</font></div></div><hr style="page-break-after:always"><div><a name="sC0A27E47A81356B98E9056687DE9247B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:8px;text-align:center;text-indent:36px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.828125%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:8%;"></td><td style="width:43%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Koenig</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">President and CEO and Director</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Act of 1934, as amended, this Report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:37%;"></td><td style="width:1%;"></td><td style="width:31%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Signature</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Title</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Date</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Koenig</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and CEO and Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ James Karrels</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President, Chief Financial</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Karrels</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Officer and Secretary (Principal Financial Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Lynn Cilinski</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vice President, Controller and Treasurer</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lynn Cilinski</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Accounting Officer)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Paulo Costa</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Paulo Costa</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Karen Ferrante, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Karen Ferrante, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Matthew Fust</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Matthew Fust</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Kenneth Galbraith</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Kenneth Galbraith</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Edward Hurwitz</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Edward Hurwitz</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott Jackson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Jackson</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jay Siegel, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jay Siegel, M.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ David Stump, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Director</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">David Stump, M.D.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">60</font></div></div><hr style="page-break-after:always"><div><a name="sBE808ED3E783543994FA5A1FB5C8BD55"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:90%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Page</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Number</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF61CD5454F6D57B08FE8102C4B38015C"><font style="font-family:inherit;font-size:10pt;">Report of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm</font></a></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sF61CD5454F6D57B08FE8102C4B38015C">F - 2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D437E9F7E735A3399A2CD738683173A"><font style="font-family:inherit;font-size:10pt;">Consolidated Balance Sheets at December 31, 2017 and December 31, 2016</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s5D437E9F7E735A3399A2CD738683173A">F - 3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s501568E99EF6536EA1AC03718134E41E"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s501568E99EF6536EA1AC03718134E41E">F - 4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAB7DD30E3564539E88F8D2E5E97BC454"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Stockholders' Equity for the years ended December 31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAB7DD30E3564539E88F8D2E5E97BC454">F - 5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA0E544BFE28650788D5D562DDF7B733F"><font style="font-family:inherit;font-size:10pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2017, 2016 and 2015</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA0E544BFE28650788D5D562DDF7B733F">F - 6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72C8D8A485655BFFA7655286CBF67EB0"><font style="font-family:inherit;font-size:10pt;">Notes to Consolidated Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s72C8D8A485655BFFA7655286CBF67EB0">F - 7</a></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 1</font></div></div><hr style="page-break-after:always"><div><a name="sF61CD5454F6D57B08FE8102C4B38015C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the Shareholders and the Board of Directors of MacroGenics, Inc. </font></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Opinion on the Financial Statements</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have audited the accompanying consolidated balance sheets of MacroGenics, Inc. (the Company) as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial position of the Company at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, and the consolidated results of its operations and its cash flows for each of the three years in the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, in conformity with U.S. generally accepted accounting principles.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">, expressed an unqualified opinion thereon. </font></div><div style="line-height:174%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis for Opinion</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst &amp; Young LLP</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have served as the Company's auditor since 2006.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February 27, 2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 2</font></div></div><hr style="page-break-after:always"><div><a name="s5D437E9F7E735A3399A2CD738683173A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED BALANCE SHEETS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,394</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,151</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,483</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current assets</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">383</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">322,298</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">283,947</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,983</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Marketable securities, non-current</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,602</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,369</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities and stockholders' equity</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,451</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,134</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,202</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,048</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,319</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">175</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,755</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,302</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,637</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,045</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,867</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability, net of current portion</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74,645</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders' equity:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 36,859,077 and 34,870,607 shares outstanding at December 31, 2017 and 2016, respectively</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">611,270</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,198</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated other comprehensive loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312,340</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292,714</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders' equity</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,238</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities and stockholders' equity</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,883</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">311,263</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 3</font></div></div><hr style="page-break-after:always"><div><a name="s501568E99EF6536EA1AC03718134E41E"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share and per share data)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenues:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from collaborative agreements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,516</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">86,582</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">99,368</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from government agreements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,226</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,298</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,486</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenues</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,742</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">91,880</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">100,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Costs and expenses:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">147,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">122,091</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">98,271</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,653</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,831</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,765</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total costs and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">179,885</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">151,922</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,036</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(22,143</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(60,042</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,182</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,517</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,514</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other comprehensive loss:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,647</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,605</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,145</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted net loss per common share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted weighted average number of common shares</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 4</font></div></div><hr style="page-break-after:always"><div><a name="sAB7DD30E3564539E88F8D2E5E97BC454"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands, except share amounts)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="30"></td></tr><tr><td style="width:30%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Treasury Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Additional</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Paid-In</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Accumulated</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Other</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Comprehensive Loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Stockholders'</font></div><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Equity</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2014</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27,995,638</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">280</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">865</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">335,071</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(214,046</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">121,286</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock, net of offering costs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,976,827</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,407</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">373,289</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">925</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">908</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">882</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,790</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(48</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,345,754</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">547,185</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(234,186</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">313,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">524,853</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,887</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,854</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,862</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized loss on investments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(77</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,870,607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">349</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">561,198</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(292,714</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(82</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">268,751</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Issuance of common stock, net of offering costs</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,699,284</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,227</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,244</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock plan related activity</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">289,186</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,862</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,141</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,104</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Retirement of treasury stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,862</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unrealized gain on investments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance, December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,859,077</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">369</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">611,270</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(312,340</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">299,238</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 5</font></div></div><hr style="page-break-after:always"><div><a name="sA0E544BFE28650788D5D562DDF7B733F"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CONSOLIDATED STATEMENTS OF CASH FLOWS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(In thousands)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Operating activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,228</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,608</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,863</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10,878</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,540</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,711</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">332</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,677</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,405</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restricted cash</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">262</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(285</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,544</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,232</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued expenses</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,832</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,659</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,545</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lease exit liability</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,593</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,293</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,533</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,191</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(12,223</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,115</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,134</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,650</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(727</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(878</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) operating activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,405</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(43,679</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13,661</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(135,122</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(347,762</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(142,910</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from sales and maturities of marketable securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">242,401</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">288,894</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchases of property, equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29,403</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,381</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,197</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,876</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(70,249</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(152,107</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cash flows from financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from issuance of common stock, net of offering costs</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,244</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">203,467</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceeds from stock option exercises and ESPP purchases</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,144</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,893</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">911</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Purchase of treasury stock</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(39</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(29</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35,348</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,854</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,349</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net change in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">127,629</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,074</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,581</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,172</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">157,591</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">211,727</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84,098</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">196,172</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 6</font></div></div><hr style="page-break-after:always"><div><a name="s72C8D8A485655BFFA7655286CBF67EB0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</font></div><div><a name="s7A6AF83F42705AF9A9776BC51D5AEE5A"></a></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. Organization and Nature of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms, which have broad applicability across other therapeutic domains, including autoimmune disorders and infectious disease. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sCF5B47D5791F5E1A88AAC1B1EFAEA0A7"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#32;segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;that the Company determined to be other-than-temporary.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 7</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;includes approximately </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 8</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;">&#32;The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:68%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incyte Corporation (Incyte)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:75%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10% </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Equipment and Software</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;assets held-for-sale.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and DART&#174; technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.  The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license was to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:60%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the (FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, ASU 2016-10,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  The Company will adopt the new standard in the first quarter of 2018 using the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has substantially completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Due to the unique contract terms of certain agreements, the Company is still in the process of finalizing its analysis of those agreements.  Upon completion of the Company&#8217;s analysis, it will determine the cumulative effect of initially applying the new standard (if any).  The Company is also finalizing its accounting policy and designing and implementing the necessary changes to processes and controls to account for revenue under the new standard. Based on the Company's timeline and planned resources, the Company anticipates completing its implementation in connection with its first quarter 2018 interim financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">&#32;(ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company adopted ASU 2016-09 effective January 1, 2017 and has elected to continue to estimate the number of stock-based awards expected to vest, as permitted by ASU 2016-09, rather than electing to account for forfeitures as they occur.  </font><font style="font-family:inherit;font-size:10pt;">The adoption of this standard did not have a material impact on the Company's financial statements or related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018.  </font></div><div><a name="s3D6D2A90FD0E51AAB7BC182FDB84AC88"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;">3. Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;">&#32;were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,998</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,991</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company's available-for-sale securities held at December 31, 2017 had maturity dates of less than one year.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of December&#160;31, 2016 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All available-for-sale securities in an unrealized loss position as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;were in a loss position for less than twelve months.&#160; There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;that the Company determined to be other-than-temporary.  The Company recorded interest income of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the years ended December 31, 2017, 2016 and 2015, respectively, which is included in other income.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">&#160;&#160;&#160;&#160;</font></div><div><a name="sA589E3125D0652B7B5D1C44944C6DCDD"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. Property, Equipment and Software</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software consists of the following (in thousands):</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,111</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,549</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,919</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;consists of the costs incurred for the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which is expected to be completed in mid-2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in property, equipment and software at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;that was purchased in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;but was not paid for by year end.&#160; Property, equipment and software balance at December 31, 2016 includes approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in assets that were purchased in 2016 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s4909F2FF90FA5CFAB07010C9DCA25B6E"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. Stockholders' Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company's amended and restated certificate of incorporation authorizes </font><font style="font-family:inherit;font-size:10pt;">125,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock, and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of undesignated preferred stock, both with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of undesignated preferred stock issued or outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">450,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160;&#160;The Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$76.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from this offering, net of underwriting discounts and commissions and other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. (JJDC) became effective (see Note 9 for additional information).&#160; Under these agreements, JJDC purchased </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;">&#32;new shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, representing proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">3,525,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">528,750</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.&#160; The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$141.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase </font><font style="font-family:inherit;font-size:10pt;">1,100,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$21.50</font><font style="font-family:inherit;font-size:10pt;">&#32;per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were </font><font style="font-family:inherit;font-size:10pt;">$23.7 million</font><font style="font-family:inherit;font-size:10pt;">. The shares were offered pursuant to the Company&#8217;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">599,284</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to the ATM Offering.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s632495462D435BECB4931BD4D8085698"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. Stock-based Compensation</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 17</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved </font><font style="font-family:inherit;font-size:10pt;">800,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;">&#32;of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, employees purchased </font><font style="font-family:inherit;font-size:10pt;">38,012</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Option Plans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,051,644</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">4,336,730</font><font style="font-family:inherit;font-size:10pt;">. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, under the 2003 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">955,296</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.85</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company implemented the 2013  Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;">&#32;shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, (b) </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">6,769,888</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, under the 2013 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,549,346</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$24.62</font><font style="font-family:inherit;font-size:10pt;">&#32;per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,388</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:62%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:12%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67% - 68%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Term</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. The Company uses a simplified method to calculate the average expected term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:49%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246,225</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.05</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(253,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(326,607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,910,171</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.65</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,495</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,337,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company issued </font><font style="font-family:inherit;font-size:10pt;">253,036</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">526,715</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">374,214</font><font style="font-family:inherit;font-size:10pt;">&#32;net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of options granted during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$12.53</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$15.17</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$20.90</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, respectively. The total intrinsic value of options exercised during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total fair value of stock options which vested during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was </font><font style="font-family:inherit;font-size:10pt;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;">, which the Company expects to recognize over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.3 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="s571DB8EE4C4759D4A4A413577A23A598"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7.&#160;&#160;Income Taxes</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:75%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,346</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,284</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,385</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,847</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net decrease in the valuation allowance in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is primarily as a result of the legislation enacted in 2017, which lowers the statutory corporate tax rate from 35% to 21%,, which decreased the net deferred tax asset.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$239.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;that will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2025</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">2037</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Company has U.S. federal tax credits of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2025</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">2037</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Company's U.S. Federal NOLs are limited for use over the years </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;">&#32;&#8211; </font><font style="font-family:inherit;font-size:10pt;">2028</font><font style="font-family:inherit;font-size:10pt;">&#32;in which a range of such amounts could be utilized on an annual basis of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining </font><font style="font-family:inherit;font-size:10pt;">$226.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&#160;&#160;Further, despite the NOL and tax credit carryforwards, the Company may have a future tax liability due to recent changes in tax legislation or state tax requirements in which net operating losses do not exist.  The Company is still quantifying the impact of these changes.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred federal rate change reduction in corporate rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,447</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, of the total gross unrecognized tax benefits, approximately </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;">&#32;recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's U.S. Federal and state income tax returns from </font><font style="font-family:inherit;font-size:10pt;">2001</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;color:#252525;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740-10-25-47, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act is required in the interim and annual periods that include December 22, 2017.  As a result, the Company has revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.  The Company does not anticipate that other provisions of the Act would have a material impact on its financial statements. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div><a name="s9787AA433F8C5708ABDA9FE60AFF8BE2"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8.&#160;&#160;Lease Exit Liability</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&#160; During the year ended December&#160;31, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 21</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&#160; The Company will receive approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sublease payments over its term, which ends at the same time as the original lease in February 2018.&#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended December&#160;31, 2016 and recorded an offset to research and development expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in the same period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,593</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div><a name="sC663BDB9454851F5B367EB2EAA4BB3DD"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. Collaboration and Other Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incyte</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the collaboration and license agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in development and regulatory milestones, and up to </font><font style="font-family:inherit;font-size:10pt;">$330.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in commercial milestones. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; If commercialized, the Company would be eligible to receive tiered royalties of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;">&#32;on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012.  The Company and Incyte have agreed to initiate negotiations for a separate clinical supply agreement that will set forth terms and conditions. Finally, Incyte will fund the Company's activities related to the ongoing monotherapy clinical study until such time as the Company can transfer the Investigational New Drug application (IND) to Incyte. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration and license agreement with Incyte and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&#8217;s substantive performance obligations under the collaboration and license agreement include the delivery of the license and clinical activities through a brief technology transfer period.  The Company evaluated the collaboration and license agreement with Incyte and determined that the license and clinical trial activities each represented separate deliverables and were accounted for as separate units of accounting. The Company concluded that the license had standalone value to Incyte and was separable from the clinical trial activities because the license was sublicensable and Incyte has significant capabilities in performing clinical trials.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price (BESP) to each deliverable.  The BESP for the exclusive license was determined using information from other similar collaboration and license agreements.  The BESP for the clinical trial activities was determined using similar arrangements and is estimated at approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, which will be recognized over the technology transfer period as work is performed and the expenses are reimbursed by Incyte. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$151.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Incyte collaboration and license agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, including the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to clinical trial activities performed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Roche</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets.  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of this agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;which was received in January 2018. The Company will also be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in potential milestone payments and royalties on future sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration and license agreement with Roche and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&#8217;s substantive performance obligations under the research collaboration and license agreement include the delivery of the license and activities during the research period.  The Company evaluated the collaboration and license agreement with Roche and determined that the license and research activities do not have value on a standalone basis and therefore represented one unit of accounting.   The </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recognized over the expected research period, which is </font><font style="font-family:inherit;font-size:10pt;">30 months</font><font style="font-family:inherit;font-size:10pt;">. Each company will be responsible for their own expenses during the research period.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company determined that each potential future development and regulatory milestone is substantive.  Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Janssen</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;">&#32;new shares of the Company's common stock for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Upon closing the transaction in January 2015, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment from Janssen as well as the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;investment in the Company's common stock.&#160;&#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&#160;&#160; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the MGD011 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the collaboration and license agreement included the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative BESP method to each deliverable.&#160; The BESP for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The BESP for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;">&#32;per share exceeded the fair value of the common stock by </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">research and development activities.&#160; Of the total arrangement consideration of </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;">, the Company allocated </font><font style="font-family:inherit;font-size:10pt;">$62.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to equity (representing the fair value of common stock purchased), </font><font style="font-family:inherit;font-size:10pt;">$62.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone to the Company.&#160; </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue was recognized under the MGD011 Agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  During the years ended December&#160;31, 2016 and 2015, the Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$72.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD011 agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment from Janssen upon closing the transaction.&#160;In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the MGD015 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the MGD015 Agreement included the delivery of an exclusive license and research and development services during the preclinical research period. &#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the BESP method to each deliverable.&#160; The BESP for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The BESP for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$75.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD015 Agreement.  Revenue recognized in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;included the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront fee for the exclusive license.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Takeda</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&#160;&#160;MGD010 is being developed for the treatment of autoimmune disorders.&#160; Upon execution of the agreement, Takeda made a non-refundable payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company.&#160;&#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. </font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&#160;&#160;The Company concluded that the MGD010 option was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160;&#160;&#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&#160;&#160;The Company allocated </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the exclusivity clause to its technology and the research and development services and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the exclusive license for the initial research compound.&#160;&#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&#160;&#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&#160;&#160;During the first quarter of 2016, the Company determined that the development period would be extended by </font><font style="font-family:inherit;font-size:10pt;">eight months</font><font style="font-family:inherit;font-size:10pt;">, and prospectively adjusted the MGD010 option fee recognition period.&#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue under was recognized under this agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the MGD010 agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;included a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;milestone payment received upon initiation of a Phase 1a trial of MGD010.&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servier</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, Servier made a nonrefundable payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to the Company. In addition, the Company will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in license fees, </font><font style="font-family:inherit;font-size:10pt;">$63.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in clinical milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$188.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a </font><font style="font-family:inherit;font-size:10pt;">29</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&#160;&#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a </font><font style="font-family:inherit;font-size:10pt;">75</font><font style="font-family:inherit;font-size:10pt;">-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of Servier exercising its option in 2014, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&#160;&#160;Upon exercise of the option, the Company evaluated its </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;license fee was deferred and was being recognized ratably over a period of </font><font style="font-family:inherit;font-size:10pt;">82 months</font><font style="font-family:inherit;font-size:10pt;">, which represented the expected development period for flotetuzumab.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company and Servier determined that the expected development period should be extended to </font><font style="font-family:inherit;font-size:10pt;">124 months</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of this change in accounting estimate reduced revenue that would have been recognized in 2017 by </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">. In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&#160;&#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&#160;&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as an offset to research and development costs under this collaboration arrangement, respectively.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Boehringer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2010</font><font style="font-family:inherit;font-size:10pt;">&#32;the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in </font><font style="font-family:inherit;font-size:10pt;">October 2015</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company subsequently received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to preclinical and clinical development, </font><font style="font-family:inherit;font-size:10pt;">$88.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to regulatory milestones and </font><font style="font-family:inherit;font-size:10pt;">$82.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, </font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 26</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;under this agreement, including a payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the achievement of preclinical milestones.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Green Cross</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as well as clinical development and commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements (Revenue Recognition)</font><font style="font-family:inherit;font-size:10pt;">&#32;as the original agreement was accounted for prior to adopting ASU 2009-13</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;">&#32;The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through </font><font style="font-family:inherit;font-size:10pt;">June 2020</font><font style="font-family:inherit;font-size:10pt;">. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&#160;&#160;As a result, the Company recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue during 2014.  The Company has received a total of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenues of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;milestones were achieved under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was current and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of which was non-current.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NIAID Contract</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2015</font><font style="font-family:inherit;font-size:10pt;">,&#160;to perform product development and to advance up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to support development of MGD014 through IND application submission with the FDA, as well as up to </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">. The total potential period of performance under the award is from September 15, 2015 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2022</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended December&#160;31, 2017, NIAID exercised the first option in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in revenue under this contract during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><a name="s58E8D560BF44570B90D9902BDD9141E8"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;leases that have terms that expire between </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2027</font><font style="font-family:inherit;font-size:10pt;">&#32;unless renewed.&#160;&#160;During the year ended December&#160;31, 2017, the&#160;Company entered into an agreement to sublease a portion of the space it leases.  Under the terms of the sublease, the Company will receive a total of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">&#32;month term.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;The Rockville leases include a lease executed in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;">&#32;for space that the Company uses as its headquarters with office and laboratory space and manufacturing space currently under construction.&#160;&#160; Under the terms of the lease, which commenced on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160; In July 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was received during the third quarter.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also leases office and laboratory space in South San Francisco under a lease that expires on </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended December&#160;31, 2016, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8).  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, future payments to be received by the Company under this sublease total approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  In </font><font style="font-family:inherit;font-size:10pt;">April 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">72</font><font style="font-family:inherit;font-size:10pt;">-month lease commencing in </font><font style="font-family:inherit;font-size:10pt;">December 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;for office and laboratory space which will replace our current South San Francisco location.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had recorded a deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Rent expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:88%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,743</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,484</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</font></div><div><a name="sB8C8C5D15D625F94B1EA6445B0AE4005"></a></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. Employee Benefit Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;">&#32;years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;of their salary, subject to government maximums.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees are </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;">&#32;vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 28</font></div></div><hr style="page-break-after:always"><div><a name="s3B3D5D80F3F959D2A73A304F74F7CCF4"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12.&#160;&#160;Quarterly Financial Information (unaudited)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:49%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,055</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,663</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,359</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.87</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">F - 29</font></div></div><hr style="page-break-after:always"><div><a name="sD2E7A9DF6FB75A389F53F1A52872047A"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">EXHIBIT INDEX</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:4%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">No.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restated Certificate of Incorporation of the Company and Certificate of Correction to the Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibits </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex31.htm"><font style="font-family:inherit;font-size:10pt;">3.1</font></a><font style="font-family:inherit;font-size:10pt;">&#160;and </font><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513402831/d613759dex33.htm"><font style="font-family:inherit;font-size:10pt;">3.3</font></a><font style="font-family:inherit;font-size:10pt;">, respectively, to the Company's Current Report on Form 8-K filed on October 18, 2013)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex34.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated By-Laws of the Company (incorporated by reference to Exhibit 3.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513394786/d575431dex42.htm"><font style="font-family:inherit;font-size:10pt;">Specimen Stock Certificate (incorporated by reference to Exhibit 4.2 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 9, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312515075224/d838054dex43.htm"><font style="font-family:inherit;font-size:10pt;">Investor Agreement by and between Johnson and Johnson Innovation-JJDC, Inc. and the Company, dated December 19, 2014 (incorporated by reference to Exhibit 4.3 to the Company's Annual Report on Form 10-K filed on March 3, 2015)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex1014.htm"><font style="font-family:inherit;font-size:10pt;">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.14 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513391750/d575431dex1020.htm"><font style="font-family:inherit;font-size:10pt;">Option for a License Agreement by and between the Company and Les Laboratoires Servier and Institut de Recherches Servier, dated September 19, 2012 (incorporated by reference to Exhibit 10.20 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 4, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.3&#8224;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:10px;text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit10-3201710xkfinal.htm"><font style="font-family:inherit;font-size:10pt;">Global Collaboration and License Agreement by and between the Company and Incyte Corporation, dated October 24, 2017</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.4+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex103.htm"><font style="font-family:inherit;font-size:10pt;">Company 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.3 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.5+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513357191/d575431dex104.htm"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement under 2003 Equity Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on September 4, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.6+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex105.htm"><font style="font-family:inherit;font-size:10pt;">Company 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.7+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex106.htm"><font style="font-family:inherit;font-size:10pt;">Form of Incentive Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.8+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000119312513386872/d575431dex107.htm"><font style="font-family:inherit;font-size:10pt;">Form of Nonstatutory Stock Option Agreement under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.7 to the Registration Statement on Form S-1 (File No. 333-190994) filed by the Company on October 1, 2013)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.9+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534515000013/exhibit10-2.htm"><font style="font-family:inherit;font-size:10pt;">Form of Restricted Stock Units Grant Notice under 2013 Equity Incentive Plan (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 6, 2015)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.10+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000155278116002035/e00576_ex4-1.htm"><font style="font-family:inherit;font-size:10pt;">2016 Employee Stock Purchase Plan (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-8 (File No. 333-214386) filed by the Company on November 2, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.11+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1014.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Scott Koenig, M.D., Ph.D. (incorporated by reference to Exhibit 10.14 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.12+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000046/exhibit1015.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and James Karrels (incorporated by reference to Exhibit 10.15 to the Company's Annual Report on Form 10-K filed by the Company on February 29, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.13+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-1.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.14+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-2.htm"><font style="font-family:inherit;font-size:10pt;">Restricted Stock Units Grant Notice and Agreement between the Company and Jon Wigginton, M.D. (incorporated by reference to Exhibit 10.2 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.15+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534516000056/exhibit10-3.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Ezio Bonvini, M.D. (incorporated by reference to Exhibit 10.3 to the Company's Quarterly Report on Form 10-Q filed on May 4, 2016)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10.16+</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1125345/000112534517000041/exhibit1016.htm"><font style="font-family:inherit;font-size:10pt;">Employment Agreement between the Company and Eric Risser (incorporated by reference to Exhibit 10.16 to the Company's Annual Report on Form 10-K filed on February 28, 2017)</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:9%;"></td><td style="width:4%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit23-1201710xk.htm"><font style="font-family:inherit;font-size:10pt;">Consent of Ernst &amp; Young, LLP, Independent Registered Public Accounting Firm</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31-1201710xk.htm"><font style="font-family:inherit;font-size:10pt;">Rule 13a-14(a) Certification of Principal Executive Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit31-2201710xk.htm"><font style="font-family:inherit;font-size:10pt;">Rule 13a-14(a) Certification of Principal Financial Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32-1201710xk.htm"><font style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Principal Executive Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32.2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exhibit32-2201710xk.htm"><font style="font-family:inherit;font-size:10pt;">Section 1350 Certification of Principal Financial Officer</font></a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Schema Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Labels Linkbase Document</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Presentation Linkbase Document</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Portions of this exhibit (indicated by asterisks) have been omitted pursuant to a request for confidential treatment granted by the SEC.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:0px;"><font style="font-family:inherit;font-size:10pt;">+</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicates management contract or compensatory plan.</font></div></td></tr></table><div><br></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>2
<FILENAME>exhibit10-3201710xkfinal.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sd29e64e5aa434a9ebf834814f2acc929"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT MATERIAL</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIAL TREATMENT REQUESTED:  </font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Information for which confidential treatment has been requested is omitted and is noted with asterisks.  An unredacted version of this document has been filed separately with the Securities and Exchange Commission (the &#8220;Commission&#8221;).</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GLOBAL COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BY AND BETWEEN</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">AND</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INCYTE CORPORATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s4913d468d75c43f5894263512ea640cb"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:82%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TABLE OF CONTENTS</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Page</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 1</font><font style="font-family:inherit;font-size:12pt;">&#160;DEFINITIONS</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font><font style="font-family:inherit;font-size:12pt;">&#160;GOVERNANCE</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Steering Committee</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">25</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Development Committee</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">26</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Manufacturing Committee</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">27</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Intellectual Property Committee</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">28</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Commercialization Coordination Committee</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">29</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Committee Membership and Operations</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">30</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Subcommittees and Working Groups</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Authority</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Alliance Managers</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Decision-Making Limitations</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">32</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font><font style="font-family:inherit;font-size:12pt;">&#160;LICENSES</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">33</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">License to Incyte</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">33</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sublicensing</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">34</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Retained Rights</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">36</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Freedom to Operate Licenses</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">38</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Implied Licenses</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font><font style="font-family:inherit;font-size:12pt;">&#160;DEVELOPMENT</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transition of Ongoing Clinical Study</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">40</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Development Responsibilities</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">41</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Development Responsibilities</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">44</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Global Development Plans</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">49</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Delegation of Development Activities</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">50</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance with Law; Other Requirements</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">50</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font><font style="font-family:inherit;font-size:12pt;">&#160;REGULATORY RESPONSIBILITIES</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">51</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Data Sharing: Licensed Compound</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">51</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Data Sharing: Combination Regimens</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">53</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Data Sharing Limitations</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">55</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Right of Reference</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">56</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Regulatory Documentation; Regulatory Communications</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">57</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Adverse Event Reporting and Safety Data Exchange</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">59</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Recalls and Voluntary Withdrawals</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">61</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Labeling</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">61</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other Studies</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">62</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">i</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:82%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font><font style="font-family:inherit;font-size:12pt;">&#160;COMMERCIALIZATION</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">63</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Commercialization Activities</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">63</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pricing of Licensed Product</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">64</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pricing of Pipeline Assets</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">66</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transparency Reporting</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">66</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font><font style="font-family:inherit;font-size:12pt;">&#160;MANUFACTURING</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">67</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturing Technology Transfer</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">67</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General Clinical Supply Terms</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">68</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">General Commercial Supply Terms</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">72</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Records; Audit Rights</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">75</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Operation of MacroGenics Manufacturing Facilities</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">75</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quality Assurance</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">75</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Compliance with Law</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">76</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font><font style="font-family:inherit;font-size:12pt;">&#160;CONSIDERATION</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">76</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upfront Payment</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">76</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Milestone Payments</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">77</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Royalty Obligations</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">79</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Royalty Term</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">80</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Royalty Rate Adjustments; Licensed Product Pricing</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">80</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manner of Royalty Payment</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">81</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Monotherapy Development Sublicense Fees</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">81</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collaborator Sublicense Fees</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">82</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Currency</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">82</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party Financial Obligations</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">82</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.11</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Taxes</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">84</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.12</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Audit</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">84</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.13</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manner of Payment</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">85</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9 </font><font style="font-family:inherit;font-size:12pt;">INTELLECTUAL PROPERTY MATTERS</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">85</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Inventorship; Ownership and Disclosure of Inventions</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">85</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prosecution of Patents</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Infringement of Patents by Third Parties</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">91</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patent Term Extensions</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">94</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Infringement of Third Party Rights in the Territory.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">95</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patent Oppositions and Other Proceedings.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">95</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10</font><font style="font-family:inherit;font-size:12pt;">&#160;REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">96</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Mutual Representations, Warranties and Covenants</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">96</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Representations and Warranties of MacroGenics</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">97</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Representations and Warranties of Incyte</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">100</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">ii</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:82%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">No Other Representations or Warranties</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">101</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11</font><font style="font-family:inherit;font-size:12pt;">&#160;CONFIDENTIALITY</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">101</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Nondisclosure</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">101</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exceptions</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">101</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Authorized Disclosure</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">102</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terms of this Agreement</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">103</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Publicity</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">103</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Securities Filings</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">104</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Relationship to Confidentiality Agreement</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">104</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Equitable Relief</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">104</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Publications</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">105</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Additional Obligations Relating to Competing Antibodies</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">106</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 12</font><font style="font-family:inherit;font-size:12pt;">&#160;TERM AND TERMINATION</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Term</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Unilateral Termination by Incyte</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination for Material Breach</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination by Incyte for Safety Reasons</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination for Patent Challenge</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">107</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Termination for Bankruptcy.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">108</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">HSR Filing; Termination Upon HSR Denial</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">110</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effects of Termination</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">110</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Effect of Termination for MacroGenics Breach or Bankruptcy</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">115</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Remedies</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">117</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.11</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Survival</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">117</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 13</font><font style="font-family:inherit;font-size:12pt;">&#160;DISPUTE RESOLUTION</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dispute Resolution Mechanism</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Resolution by Executive Officers</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Provisional Remedies</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 14</font><font style="font-family:inherit;font-size:12pt;">&#160;INDEMNIFICATION</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indemnification by Incyte</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">118</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indemnification by MacroGenics</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">119</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indemnification Procedures.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">119</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insurance</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">120</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Limitation of Liability</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">121</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 15</font><font style="font-family:inherit;font-size:12pt;">&#160;MISCELLANEOUS</font></div></td><td style="vertical-align:middle;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">121</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notices</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">121</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.2</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Governing Law</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">122</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">iii</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:11%;"></td><td style="width:82%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.3</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Change of Control.</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">122</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.4</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Assignment</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">125</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.5</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Designation of Affiliates</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">125</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.6</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Relationship of the Parties</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">125</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.7</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Force Majeure</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">125</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.8</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Entire Agreement; Amendments</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">126</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.9</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Severability</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">126</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.1</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">English Language</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">126</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.11</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Waiver and Non-Exclusion of Remedies</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">126</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.12</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Further Assurance</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">126</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.13</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Headings</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">127</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.14</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Standstill</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">127</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.15</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Construction</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">129</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.16</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party Beneficiaries</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">129</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.17</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Counterparts</font></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">129</font></div></td><td style="vertical-align:bottom;background-color:;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">iv</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LIST OF EXHIBITS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:15%;"></td><td style="width:8%;"></td><td style="width:77%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensed Patents</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Global Development Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Global Development Plan</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Existing Third Party Licenses</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Form of Press Release</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit E</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ongoing Clinical Study Activities</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit F</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Shared Prosecution Expense Countries</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit G</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit H</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8210;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">v</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div><div style="line-height:120%;text-align:right;padding-left:48px;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><a name="s4fe50cf71a6d49fcae5da89a8171b034"></a></div><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GLOBAL COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;GLOBAL COLLABORATION AND LICENSE AGREEMENT </font><font style="font-family:inherit;font-size:12pt;">(&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is entered into as of October 24, 2017 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Execution Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INCYTE CORPORATION</font><font style="font-family:inherit;font-size:12pt;">, a Delaware corporation, having its principal place of business at 1801 Augustine Cut-Off, Wilmington, DE 19803 (hereinafter &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MACROGENICS, INC.</font><font style="font-family:inherit;font-size:12pt;">, a Delaware corporation, having its principal place of business at 9704 Medical Center Drive, Rockville, MD 20850 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Incyte and MacroGenics are sometimes referred to herein individually as a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; and collectively as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">&#8221;. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, MacroGenics has discovered and is developing the Licensed Compound (as defined below), coded by MacroGenics as &#8220;MGA012&#8221;, for various human therapeutic uses; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, Incyte desires to obtain certain rights to Develop, Manufacture, and Commercialize the Licensed Compound and products and treatment regimens incorporating the Licensed Compound, all in accordance with the terms and conditions of this Agreement; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, MacroGenics is willing to grant such rights, retaining certain rights for itself, all in accordance with the terms and conditions of this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW, THEREFORE</font><font style="font-family:inherit;font-size:12pt;">, in consideration of the foregoing and the premises and conditions set forth herein, the Parties agree as follows: </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEFINITIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acquirer</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Third Party that is a party to any Change of Control transaction and any of such Third Party&#8217;s Affiliates.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Affiliate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a particular Person, a person, corporation, partnership, or other entity that controls, is controlled by, or is under common control with such first Person. For the purposes of this definition, (a) the word &#8220;control&#8221; (including, with correlative meaning, the term &#8220;controlled by&#8221;) means the actual power, either directly or indirectly through one or more intermediaries, to direct or cause the direction of the management and policies of a Person, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, or by contract or otherwise; and (b) the term &#8220;common control&#8221; includes ownership, directly, or indirectly, beneficially or legally, of outstanding voting securities or capital stock by the same Person or Persons.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; has the meaning set forth in the Preamble, and means this Agreement as in effect from time-to-time, including all Schedules, Exhibits, and other attachments hereto. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Alliance Manager</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the person appointed by each Party from within their respective organization to coordinate and facilitate the communication, interaction and cooperation of the Parties pursuant to this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ancillary Therapy</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an approved (including a standard of care) therapy. For clarity, Ancillary Therapy excludes all therapies that have not received Regulatory Approval.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">1</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Applicable Law</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all applicable statutes, ordinances, regulations, directives, rules, or orders of any kind whatsoever of any Governmental Authority applicable to any activity hereunder, including the EU Data Protection Directive and the regulations issued under the U.S. Health Insurance Portability and Accountability Act of 1996 (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HIPAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the U.S. Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167;301 et seq.) (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FFDCA</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Prescription Drug Marketing Act of 1987 (21 U.S.C. &#167;&#167;331, 333, 353, 381), the Generic Drug Enforcement Act of 1992 (21 U.S.C. &#167;335(a) et seq.), U.S. Patent Act (35 U.S.C. &#167;1 et seq.), the Federal False Claims Act (31 U.S.C. &#167;3729 et seq.), and the Anti-Kickback Statute (42 U.S.C. &#167;1320a-7b et seq.), and the Foreign Corrupt Practices Act of 1977 (15 U.S.C. &#167;&#167; 78dd-1, et seq.), all as amended from time to time, together with any rules, regulations, and guidance documents, and regulatory standards (including GCP, GLP, and GMP) promulgated relating to any of the foregoing, all as amended from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved PD-1 Antibodies</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, all PD-1 Monoclonal Antibodies that have received Regulatory Approval (it being understood that this shall reflect on an ongoing basis any Regulatory Approvals that are received during the Term) in a given territory. As of the Execution Date, the Approved PD-1 Antibodies are pembrolizumab and nivolumab. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Biosimilar Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Licensed Product that has received Marketing Approval in a country in the Territory, (a) a biologic therapeutic containing the same amino acid polymer as any Licensed Product; (b) a biologic therapeutic containing an amino acid polymer that is highly similar, or similar enough to one contained in a reference Licensed Product, notwithstanding minor differences in clinically inactive components, to permit an applicant for Regulatory Approval for such biologic therapeutic to refer to and rely on clinical and other scientific Information regarding the safety, purity, potency and/or efficacy of the reference Licensed Product in order to allow such biologic therapeutic to receive Regulatory Approval in any jurisdiction within the Territory through an abbreviated regulatory pathway; or (c) a biologic therapeutic containing an amino acid polymer that is highly similar, or similar enough to one contained in a reference Product, notwithstanding minor differences in clinically inactive components, to permit such biologic therapeutic to be marketed in any jurisdiction within the Territory as generic-equivalent, functionally equivalent, biosimilar, biogeneric, biobetter, interchangeable, or by using any other description referring to the reference Product (and/or such Product&#8217;s clinical and other scientific Information) for support for safety, purity, potency and/or efficacy claims for such biologic therapeutic. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Breakthrough Designation</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Product, that such Product satisfies the requirements for a &#8220;breakthrough therapy&#8221;, as set forth in 21 U.S.C. &#167; 356, as amended by &#167; 902 of the Food and Drug Administration Safety and Innovation Act. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Business Day</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any day other than Saturday, Sunday or any other day on which banking institutions located in New York, New York are permitted or required by Applicable Law, executive order or governmental decree to remain closed. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Calendar Quarter</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31; provided, however, that the first Calendar Quarter and the last Calendar Quarter may be partial quarters as applicable under the relevant Calendar Year.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">2</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Calendar Year</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the twelve (12) month period ending on December 31; provided, however, that the first Calendar Year and the last Calendar Year of the applicable period (such as the Royalty Term) may be a partial year, as the case may be.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;[**]&#8221; means, with respect to the Licensed Compound, the [**] of (a) [**] or (b) the [**] of the [**] in [**]. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.14</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cancer Treatment Use</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following uses or methods of cancer treatment or therapy: (a) dosing regimens, schedules, sequencing or amounts; (b) incorporation of specific supportive care regimens; (c) treatment of patients according to a specific biomarker, genetic disposition, or genetic profile; (d) stratification of patients who are likely or unlikely to benefit from such claimed combination; or (e) data or uses of data to undertake or conduct any of foregoing (a) &#8211; (d). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Centralised Approval Procedure</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, to the extent compulsory or permitted for Regulatory Approval of the Licensed Compound or a Licensed Product in Iceland, Liechtenstein, Norway or any country in the European Union, the procedure administrated by the EMA which results in a single marketing authorization that is valid in Iceland, Liechtenstein, Norway and all countries in the European Union.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall occur if: (a) any Third Party acquires directly or indirectly the beneficial ownership of any voting security of a Party, or if the percentage ownership of such person or entity in the voting securities of a Party is increased through stock redemption, cancellation or other recapitalization, and immediately after such acquisition or increase such Third Party is, directly or indirectly, the beneficial owner of voting securities representing more than fifty percent (50%) of the total voting power of all of the then outstanding voting securities of a Party; (b) a merger, consolidation, recapitalization, or reorganization of a Party is consummated, other than any such transaction that would result in stockholders or equity holders of such Party immediately prior to such transaction, owning at least fifty percent (50%) of the outstanding securities of the surviving entity (or its parent entity) immediately following such transaction; (c) the stockholders or equity holders of a Party approve a plan of complete liquidation of such Party, or an agreement for the sale or disposition by such Party of all or substantially all of such Party&#8217;s assets, other than to an Affiliate; (d) individuals who, as of the Effective Date, constitute the Board of Directors of a Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incumbent Board</font><font style="font-family:inherit;font-size:12pt;">&#8221;) cease for any reason to constitute at least a majority of the Board of Directors of such Party (provided, however, that any individual becoming a director subsequent to the Effective Date whose election, or nomination for election by such Party&#8217;s shareholders, was recommended or approved by a vote of at least a majority of the directors then comprising the Incumbent Board shall be considered as though such individual were a member of the Incumbent Board, but excluding, for this purpose, any such individual whose initial assumption of office occurs as a result of an actual or threatened election contest with respect to the election or removal of directors or other actual or threatened solicitation of proxies or consents by or on behalf of any person other than the Board of Directors of such Party); or (e) the sale or transfer to a Third Party of (i) all or substantially all of such Party&#8217;s assets taken as a whole or (ii) a majority of such Party&#8217;s assets which relate to this Agreement, is effected.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means a Phase I Study, Phase II Study, Phase III Study, Phase IV Study or Pivotal Study, as applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.18</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply Shortage</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a failure by MacroGenics to Manufacture Committed Supply which has occurred or is reasonably likely to occur, and which results or is reasonably likely to result in the unavailability of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product when needed for use across: (a) Monotherapy Studies; (b) Incyte Combination Studies; (c) MacroGenics Combination Studies; or (d) Collaborator Combination Studies (in the case of (d), solely to the extent the request for such Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product is made at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after commencement of Manufacture at the MacroGenics Large-Scale Supply Plant). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.19</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborato</font><font style="font-family:inherit;font-size:12pt;">r&#8221; means a Third Party collaborator who conducts Collaborator Combination Study(ies) pursuant to an applicable Collaborator Contract. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.20</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Combination Regimen</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Combination comprising the Licensed Compound and at least one Collaborator Pipeline Asset (which Combination may also include any other compound that constitutes an Ancillary Therapy that is not a Collaborator Pipeline Asset (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.,</font><font style="font-family:inherit;font-size:12pt;">&#32;a triplet combination)). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.21</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Combination Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Clinical Study of a Collaborator Combination Regimen that is performed with, by, or on behalf of a Collaborator, pursuant to the terms of this Agreement and the applicable Collaborator Contract, but excluding any (a) Incyte investigator-sponsored Clinical Studies, (b) Clinical Studies conducted by Incyte with academic centers, or (c) Clinical Studies that include an Incyte Pipeline Asset. For clarity, any Clinical Study in which both an Incyte Pipeline Asset and a Collaborator Pipeline Asset are evaluated shall be considered an Incyte Combination Study.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.22</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a combination of the Licensed Compound and a Pipeline Asset in concurrent or sequential administration (which combination, for clarity, may include any other compound that constitutes an Ancillary Therapy and is not a Pipeline Asset (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.,</font><font style="font-family:inherit;font-size:12pt;">&#32;a triplet combination)). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.23</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a combination of the Licensed Compound and a Pipeline Asset sold in a single finished dosage form. For clarity, the term &#8220;Combination Product&#8221; shall not include any Combination Regimen(s), except that a single finished dosage Combination that is a component of such Combination Regimen may constitute a Combination Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.24</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination Regimen(s)</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, any MacroGenics Combination Regimen, Incyte Combination Regimen, or Collaborator Combination Regimen. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.25</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination Sponsor</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) with respect to any MacroGenics Combination Study, MacroGenics; (b) with respect to any Incyte Combination Study, Incyte; and (c) with respect to any Collaborator Combination Study, the applicable Collaborator or Incyte, as the case may be. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">4</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.26</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination Study(ies)</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, any MacroGenics Combination Study, Incyte Combination Study or Collaborator Combination Study.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.27</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialization</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all processes and activities directed to marketing, promoting, educating, pricing, payor contracting, market access, distributing, detailing, importing, exporting, offering for sale, having sold, or selling with respect to a Compound or Product, including the conduct of any Phase IV Studies with respect thereto, and Medical Affairs Activities, but shall not include any activities included within the Manufacture of such Compound or Product. When used as a verb, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercialize</font><font style="font-family:inherit;font-size:12pt;">&#8221; means to engage in Commercialization activities. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.28</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercially Reasonable Efforts</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to the efforts to be expended, or considerations to be undertaken, by a Party or its Affiliate with respect to any objective, activity or decision to be undertaken hereunder, reasonable, good faith efforts to accomplish such objective, activity or decision as such Party would normally use to accomplish a similar objective, activity or decision under similar circumstances, it being understood and agreed that, with respect to the Development, Manufacture, seeking and obtaining Regulatory Approval, or Commercialization of the Licensed Compound or any Licensed Product, such efforts and resources shall be consistent with those efforts and resources commonly used by such Party under similar circumstances for similar compounds or products to which it has similar rights, which compound or product, as applicable, is at a similar stage in its development or product life and is of similar market potential, taking into account: (a) issues of efficacy, safety, and expected and actual approved labeling; (b) the expected and actual competitiveness of alternative products sold by Third Parties in the marketplace; (c) the expected and actual product profile of the Licensed Compound or any Licensed Product; (d) the expected and actual patent and other proprietary position of the Licensed Compound or any Licensed Product; (e) the likelihood of Regulatory Approval of the Licensed Compound or any Licensed Product given the regulatory structure involved; and (f) the expected and actual profitability and return on investment of the Licensed Compound or any Licensed Product, taking into consideration expected and actual Third Party costs and expenses and pricing and reimbursement relating to the Licensed Compound or any Licensed Product. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.29</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Supply Commitment</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, (a) the MacroGenics Commercial Supply Commitment or (b) the Incyte Commercial Supply Commitment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.30</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Compound(s)</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, (a) the Licensed Compound or (b) any Pipeline Asset. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.31</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Confidential Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, subject to Article 11, all non-public or proprietary Information disclosed by a Party to the other Party under this Agreement, without regard as to whether any of the foregoing is marked &#8220;confidential&#8221; or &#8220;proprietary,&#8221; or disclosed in oral, written, graphic, or electronic form. Confidential Information shall include: (a) the terms and conditions of this Agreement; and (b) Confidential Information disclosed by either Party pursuant to the Mutual Confidential Disclosure Agreement dated [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Prior CDA</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">5</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.32</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Control</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Controlled</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, with respect to any Information, Know-How, Patent or other intellectual property right, (a) ownership by a Person or, subject to Section 15.3(d), any of its Affiliates, of such Information, Know-How, Patent or other intellectual property right, or (b) possession by a Person or, subject to Section 15.3(d), any of its Affiliates, of ownership of, or an exclusive license to, such Information, Know-How, Patent, or other intellectual property rights, in each case with the right (without taking into account any rights granted by one Party to the other Party under the terms of this Agreement) to grant access, a license or a sublicense to such Information, Patent or other intellectual property right without violating the terms of any agreement or other arrangement with, or necessitating the consent of, any Third Party, at such time that the Person would be first required under this Agreement to grant the other Person such access, license or sublicense; provided that, a Person or any of its Affiliates shall be deemed not to &#8220;Control&#8221; any Information, Know-How, Patent or other intellectual property right if such Person or its Affiliate is required to pay additional consideration to a Third Party licensor for the grant of any sublicense under such Information, Know-How, Patent or other intellectual property right (unless the other Person agrees in writing to pay such additional consideration).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.33</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Controlling Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) with respect to the conduct of any MacroGenics Combination Study or any related Development, regulatory (other than Licensed Compound Regulatory Discussions, for which Incyte shall be the Controlling Party), or other obligations, MacroGenics; (b) with respect to the conduct of any Incyte Combination Study or any related Development, regulatory or other obligations, Incyte; and (c) with respect to the conduct of any Collaborator Combination Study or any related Development, regulatory or other obligations, Incyte. For clarity, (i) except as set forth in subsection (a), MacroGenics shall be deemed to be the &#8220;Controlling Party&#8221; under subsection (a), and (ii) Incyte shall be deemed to be the &#8220;Controlling Party&#8221; under subsection (c), irrespective of which Party actually performs or causes to be performed the study or such other activity or obligation. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.34</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Core Regulatory Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, the FDA, EMA, MHLW, and Health Canada. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.35</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cover</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Covering</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a product, technology, process or method, that, in the absence of ownership of or a license granted under a Valid Claim, the practice or exploitation of such product, technology, process or method would infringe such Valid Claim (or, in the case of a Valid Claim that has not yet issued, would infringe such Valid Claim if it were to issue).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.36</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CPI Adjustment</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the percentage increase or decrease in the Consumer Price Index-Urban Wage Earners and Clerical Workers, U.S. City Average, All Items 1982-84=100, published by the United States Department of Labor, Bureau of Labor Statistics (or its successor equivalent index), in the United States, comparing the levels of such index on the last days of the two most recently completed Calendar Years. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.37</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all research and pre-clinical, non-clinical, and clinical drug development activities and processes, including toxicology, pharmacology, project management, regulatory affairs, statistical analysis, Manufacturing Development, formulation development, delivery system development, the performance of Clinical Studies, or other activities reasonably </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">6</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">necessary in order to obtain Regulatory Approval of Compounds or Products in the Field in the Territory. When used as a verb, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Develop</font><font style="font-family:inherit;font-size:12pt;">&#8221; means to engage in Development activities. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.38</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Partner</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Party, a Third Party with which such Party has entered into a Development Agreement pursuant to Section 4.5 to conduct Clinical Studies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.39</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means the first (1</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">) Business Day immediately following the date on which the Parties have actual knowledge that all applicable waiting periods under the HSR Act with respect to the transactions contemplated hereunder have expired or have been terminated.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.40</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EMA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the European Medicines Agency or any successor agency(ies) or authority having substantially the same function.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.41</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">European Major Markets</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, France, Germany, Italy, Spain, and the United Kingdom.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.42</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">European Union</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EU</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the European Union member states as then-currently constituted; provided, however, that the EU shall always be deemed to include the European Major Markets. As of the Execution Date, the European Union member states are Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, and United Kingdom.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.43</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;[**]&#8221; means, with respect to the Licensed Compound, the [**] of (a) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or (b) the [**] of [**] across all [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in which the Licensed Compound has received Regulatory Approval. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.44</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Executive Officers</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to each Party, the Chief Executive Officer of such Party (or his or her designee).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.45</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exploit</font><font style="font-family:inherit;font-size:12pt;">&#8221; means to use, have used, Develop, have Developed, Commercialize, have Commercialized, and Manufacture or have Manufactured. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.46</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the U.S. Food and Drug Administration and any successor agency(ies) or authority having substantially the same function. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.47</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Field</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means all uses, including the diagnosis, treatment or prevention of any disease in humans and animals. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.48</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">First Commercial Sale</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, with respect to a Licensed Product, on a country-by-country basis, the first sale for monetary value of such Licensed Product under this Agreement by Incyte, its Affiliates or its sublicensees to an end user for use, consumption or resale of such Licensed Product in such country in the Field after all Regulatory Approvals of such Licensed Product (i.e., when all applicable approvals, licenses, registrations or authorizations described in the definition of Regulatory Approval that are necessary to sell the applicable Licensed Product) have been obtained in such country in the Field, where such sale results in the recognition of Net Sales. The sale of a Licensed Product under this Agreement by Incyte to an Affiliate of Incyte or a sublicensee of Incyte shall not constitute a First Commercial Sale unless such Affiliate or such sublicensee is </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">7</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the end user of such Licensed Product. For the avoidance of doubt, the transfer or disposition by Incyte, its Affiliates or its sublicensees of reasonable and customary quantities of samples of the Licensed Product below cost for promotional or educational purposes, or the sale of Licensed Product for clinical study purposes, early access programs (such as to provide patients with a Licensed Product prior to Regulatory Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs), or any similar uses, shall not constitute a First Commercial Sale.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.49</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any event beyond the reasonable control of the affected Party, which may include embargoes; war or acts of war, including terrorism; insurrections, riots, or civil unrest; labor strikes or lockouts; epidemics, fire, floods, earthquakes or other severe acts of nature; widespread unavailability of raw materials or reagents affecting manufacturers generally, actions by a Regulatory Authority affecting the manufacture of Monoclonal Antibodies generally and the Licensed Compound specifically, and omissions or delays in acting by any Governmental Authority (other than delays incident to the ordinary course of drug development). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.50</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FTE</font><font style="font-family:inherit;font-size:12pt;">&#8221; means [**] hours of work devoted to or in direct support of specified Development, Manufacturing or other specified activities under this Agreement, conducted by one or more qualified employees, contractors, consultants or other personnel of a Party or its Affiliates. For clarity, any individual contributing less than [**] hours per Calendar Year (or equivalent pro-rata portion thereof for the period beginning on the Effective Date and ending on the last day of the first Calendar Year) shall be deemed a fraction of an FTE on a pro-rata basis.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.51</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FTE Cost</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any period and a Party or its Affiliate, the FTE Rate multiplied by the number of FTEs expended by such Party or its Affiliate during such period; provided that a Party shall not be charged twice for any FTE Cost if such FTE Cost is already included as a component of Manufacturing Expenses payable under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.52</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FTE Rate</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a rate of [**] per FTE per Calendar Year (pro-rated for the period beginning on the Effective Date and ending on the last day of the first Calendar Year); provided, however, that such rate shall be increased or decreased annually beginning on [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by the applicable CPI Adjustment. The FTE Rate is &#8220;fully burdened&#8221; and covers employee salaries, benefits, travel and other such costs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.53</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GAAP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means generally accepted accounting principles in the U.S., consistently applied.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.54</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Global Safety Database</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the global safety database for the Licensed Compound.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.55</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Clinical Practices</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GCP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in the guideline adopted by the International Conference on Harmonization (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ICH</font><font style="font-family:inherit;font-size:12pt;">&#8221;), titled &#8220;Guidance for Industry E6 Good Clinical Practice: Consolidated Guidance&#8221; (or any successor document), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA, PMDA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">8</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.56</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Laboratory Practices</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GLP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the then-current standards, practices and procedures promulgated or endorsed by the FDA as set forth in 21 C.F.R. Part 58 (or any successor statute or regulation), including related regulatory requirements imposed by the FDA and comparable regulatory standards, practices and procedures promulgated by the EMA, PMDA or other Regulatory Authority applicable to the Territory, as they may be updated from time to time, including applicable guidelines promulgated under the ICH.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.57</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Good Manufacturing Practices</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GMP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the then-current good manufacturing practices required by the FDA, as set forth in the FFDCA, as amended, and the regulations promulgated thereunder, for the manufacture and testing of pharmaceutical materials, and comparable Applicable Law related to the manufacture and testing of pharmaceutical materials in jurisdictions outside the U.S., including the quality guideline promulgated by the ICH designated ICH Q7A, titled &#8220;Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients&#8221; and the regulations promulgated thereunder, as they may be updated from time to time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.58</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Governmental Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any multi-national, federal, state, local, municipal or other government authority of any nature (including any governmental division, subdivision, department, agency, bureau, branch, office, commission, council, court or other tribunal). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.59</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Health Canada</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Health Canada, the department of the government of Canada with responsibility for national public health, and any successor agency(ies) or authority having substantially the same function.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.60</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HSR Act</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended from time to time, and any comparable Applicable Law in jurisdictions outside the U.S. related to the approval of transactions similar to those contemplated under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.61</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HSR Clearance Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means the expiration or termination of all applicable waiting periods and requests for information (and any extensions thereof) under the HSR Act.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.62</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">HSR Filing</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) filings by Incyte and MacroGenics with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice of a Notification and Report Form for Certain Mergers and Acquisitions (as that term is defined in the HSR Act) with respect to the matters set forth in this Agreement, together with all required documentary attachments thereto, or (b) equivalent filings with relevant foreign authorities.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.63</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Combination Regimen</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) a Combination comprising a Licensed Compound and at least one Incyte Pipeline Asset (which Combination may also include: (x) any other compound that constitutes an Ancillary Therapy that is not a MacroGenics Pipeline Asset (e.g., a triplet combination) or (y) a Collaborator Pipeline Asset (e.g., a triplet combination)); or (b) a Non-Proprietary Combination Regimen (which Combination may also include Ancillary Therapy(ies), provided that, such inclusion shall not preclude any inclusion of Ancillary Therapy(ies) in MacroGenics Combination Regimens). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.64</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Combination Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any (a) Clinical Study of an Incyte Combination Regimen or (b) other Clinical Study that is performed by or on behalf of Incyte that includes the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">9</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Licensed Compound and any other specific molecule or molecules (as monotherapies or combinations) other than a Monotherapy Study, Collaborator Combination Study, or a Clinical Study that includes a MacroGenics Pipeline Asset. For clarity, an Incyte Combination Study shall only be performed by Incyte, its Affiliates or its sublicensees.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.65</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Global Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the high-level, non-binding, written plan attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-1</font><font style="font-family:inherit;font-size:12pt;">&#32;covering Incyte&#8217;s (a) planned development of the Licensed Compound and any Licensed Products and (b) planned conduct of any Incyte Combination Studies, as updated by Incyte from time to time in accordance with Sections 2.2 and 4.4. For clarity, a PowerPoint presentation summarizing such planned studies would be sufficient as a written plan.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.66</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Pipeline Asset Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a molecule, that Incyte: (a) has previously conducted, or is conducting, a Clinical Study evaluating a combination of such molecule and the Licensed Compound and has entered into, or shall enter into, a bona fide license agreement with a Third Party with respect thereto (provided that, such Third Party licensee shall be contractually obligated to at least the same development obligations as Incyte, pursuant to Section 4.2 or otherwise in Article 4); or (b) has previously entered into, or enters into, a bona fide collaboration with a Third Party that governs the research, development and/or commercialization of such molecule, where Incyte retains development rights to sponsor and fund a Clinical Study and to provide input on the development of such molecule.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.67</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means (a) an Investigational New Drug application as defined in the FFDCA and applicable regulations promulgated thereunder by the FDA; (b) a clinical trial authorization application for a product filed with a Regulatory Authority in any other regulatory jurisdiction outside the U.S., the filing of which (in the case of (a) or (b)) is necessary to commence or conduct clinical testing of a pharmaceutical product in humans in such jurisdiction; or (c) documentation issued by a Regulatory Authority that permits the conduct of clinical testing of a product in humans in such jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.68</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indication</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) with respect to [**], any cancer with [**], even if they are, [**] or [**] or [**] (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, [**], [**], and [**]) or (b) with respect to [**], [**], [**] and [**] (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, [**], and [**]), but [**]. For the sake of clarity, treatment of [**] within [**] shall not be treated as [**] (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.,</font><font style="font-family:inherit;font-size:12pt;">&#32;[**] and [**] shall not be considered [**] shall not be considered different [**]). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.69</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Information</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means information, inventions, discoveries, ideas, developments, compounds, compositions, formulations, formulas, practices, procedures, processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, designs, drawings, correspondence, computer programs, skill, experience, documents, apparatus, results, strategies, Regulatory Documentation, information and submissions pertaining to, or made in association with, filings with any Governmental Authority or patent office, data, including pharmacological, toxicological, non-clinical and clinical data, analytical and quality control data, manufacturing data and descriptions, market data, patent and legal data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds, and the like, in written, electronic, oral or other tangible or intangible form, now known or hereafter developed, whether or not patentable. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">10</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.70</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Initiation</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a Clinical Study, the first dosing of the first subject enrolled in such Clinical Study.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.71</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Invention</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Information, whether or not patentable, generated, made, conceived, or reduced to practice in the course of performance of this Agreement, whether made, conceived or reduced to practice solely by, or on behalf of, MacroGenics, Incyte, the Parties jointly, or any Affiliate, subcontractor, or sublicensee of the same (including Collaborators or any development or commercialization partner or collaborator of either Party). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.72</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;[**]&#8221; means, with respect to the Licensed Compound, the [**] of (a) [**] or (b) the [**] of the [**] in [**]. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.73</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any Information; provided that, with respect to any Party, Know-How excludes any intangible Information contained within such Party&#8217;s published Patents. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.74</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Knowledge</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, as applied to a Party, that such Party has actual knowledge of a particular fact or other matter, or that a reasonably prudent person with primary responsibility for the applicable subject matter (whether an officer or employee of such Party) knew or should have known of such fact or other matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.75</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Label Combination Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Patents Controlled by MacroGenics or, subject to Section 15.3(d), any of its Affiliates (including, subject to Section 15.3(d), MacroGenics&#8217; or its Affiliate&#8217;s interest in the Joint Patents) to the extent (a) such Patents Cover a MacroGenics Combination Regimen that has received Regulatory Approval; and (b) Incyte has exercised its right under Section 5.8(c) to expand the label of the Licensed Compound to include such Regulatory Approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.76</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MGA012</font><font style="font-family:inherit;font-size:12pt;">&#8221; means: (a) the anti-PD-1 Monoclonal Antibody coded as &#8220;MGA012&#8221;, as further described in IND # 130952, or (b) any other anti-PD-1 Monoclonal Antibody (or any antigen-binding Fab fragment thereof) with at [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">sequence identity to each of the [**] in comparison to the anti-PD-1 Monoclonal Antibody coded as &#8220;MGA012&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.77</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound API</font><font style="font-family:inherit;font-size:12pt;">&#8221; means Licensed Compound active pharmaceutical ingredient of a Licensed Product. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.78</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Approval</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the first instance on which Regulatory Approval is received with respect to the Licensed Compound as either (a) the Monotherapy Regimen or (b) part of a Combination Regimen. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.79</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Bulk Drug Substance</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Licensed Compound API as produced in bulk, in accordance with the Clinical Supply Agreement or Commercial Supply Agreement (as applicable), as well as the applicable quality agreements and Quality Assurance processes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.80</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Drug Product</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Licensed Compound Bulk Drug Substance in its final finished form, which has been separated into unlabeled vials in accordance </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">11</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">with the Clinical Supply Agreement or Commercial Supply Agreement (as applicable), as well as the Clinical Quality Agreement and applicable Quality Assurance processes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.81</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Regulatory Discussion</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a material discussion with a Core Regulatory Authority related to the Licensed Compound in the context of any MacroGenics Combination Study. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.82</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all Know-How Controlled by MacroGenics or, subject to Section 15.3(d), any of its Affiliates as of the Execution Date or during the Term that is necessary or useful to (a) Develop (including seeking Regulatory Approval of) or Commercialize Licensed Products, as Monotherapy Regimens or as a component of Incyte Combination Regimens or Collaborator Combination Regimens, (b) seek Regulatory Approval of the Licensed Products as a component of MacroGenics Combination Regimens, or (c) Commercialize Licensed Products in accordance with any such Regulatory Approvals in (b) above in the Field in the Territory (for clarity, to Commercialize the Licensed Products to the extent it has an Indication in combination with any MacroGenics Pipeline Asset, but not to Develop or promote any MacroGenics Pipeline Asset), in each case (of (a)-(c)), excluding any such Know-How Controlled by MacroGenics to the extent such Know-How is solely related to any MacroGenics Pipeline Asset. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.83</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all Patents, other than Label Combination Patents, that (a) are Controlled by MacroGenics or, subject to Section 15.3(d), any of its Affiliates (including, subject to Section 15.3(d), MacroGenics&#8217; or its Affiliate&#8217;s interest in the Joint Patents), as of the Execution Date or during the Term; and (b) are necessary or useful to Develop, manufacture, use or Commercialize the Licensed Compound or Licensed Product, provided that Licensed Patents shall not include any Patents to the extent that the claims of such Patents Cover a MacroGenics</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Pipeline Asset. Notwithstanding the foregoing limitation, the Licensed Patents as of the Execution Date include (i) those set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">&#32;and (ii) those licensed under Existing Third Party Licenses.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.84</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Product</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means any pharmaceutical product, including all forms, presentations, strengths, doses and formulations (including any method of delivery), comprising the Licensed Compound. For clarity, in the case of a Combination Regimen, the Licensed Compound that is a component of such Combination Regimen shall constitute a Licensed Product, but neither the Combination Regimen as a whole, nor the applicable Pipeline Asset that is a component of such Combination Regimen, shall constitute a Licensed Product. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.85</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Technology</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, collectively, the Licensed Patents and the Licensed Know-How. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.86</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1,000L Supply Plant</font><font style="font-family:inherit;font-size:12pt;">&#8221; means MacroGenics&#8217; existing two by five hundred (2x500) liter GMP Manufacturing plant, located at 15235 Shady Grove Road, Rockville, Maryland.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.87</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Regimen</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Combination comprising a Licensed Compound and at least one MacroGenics Pipeline Asset (which Combination may also include any other compound that constitutes an Ancillary Therapy that is not an Incyte Pipeline Asset (e.g., a triplet combination)). </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">12</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.88</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Regimen</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Detailing</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an interactive face-to-face meeting between a sales representative acting on behalf of Incyte and a health care professional having prescribing authority within the target audience that occurs after Regulatory Approval of a Licensed Product, which shall be conducted in a manner consistent with Applicable Law and industry standards and with the quality of similar presentations made by Incyte&#8217;s sales representatives for Incyte&#8217;s other products, if applicable. During such meeting, the Incyte sales representative shall only discuss the MacroGenics Pipeline Asset as it relates to a component of MacroGenics Combination Regimen as it relates to the following provisions incorporated in the &#8220;highlights of prescribing information&#8221; section of the Licensed Compound label: (a) recent major changes, (b) indications and usage, (c) warnings and precautions, (d) adverse reactions and (e) dosage and administration. Unless otherwise mutually agreed by the Parties or required by a Regulatory Authority, the Incyte sales representative shall not discuss any other data that relates to the MacroGenics Pipeline Asset, including information contained in the &#8220;clinical studies&#8221; section of the Licensed Compound label such as clinical results from any MacroGenics Combination Study or information in the &#8220;pharmacology&#8221; section of the Licensed Compound label related to the MacroGenics Pipeline Asset. The Incyte sales representative shall refer the health care professional to a sales representative acting on behalf of MacroGenics for the purpose of such discussion, unless and until such time as the Parties execute a definitive Co-Promotion Agreement that includes requisite terms with respect to promotion of the MacroGenics Combination Regimen by the Incyte sales representative. For clarity, MacroGenics Combination Regimen Detailing shall not include (i) sample drops made by sales representatives, (ii) medical affairs activities or related activities conducted by medical support staff (such as medical science liaisons), (iii) activities conducted at conventions, (iv) electronic details or (v) activities performed by market development specialists, managed care account directors or other personnel not performing face-to-face sales calls or not specifically trained with respect to a Product. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.89</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Clinical Study of a MacroGenics Combination Regimen (which study (i) may include a MacroGenics PD-1 Control Arm solely subject to the terms and conditions of this Agreement, including Section 4.3(c), (ii) may evaluate the Licensed Compound as a monotherapy arm, and (iii) may include an Ancillary Therapy control arm, provided that such Ancillary Therapy is not an Incyte Pipeline Asset) that is performed by or on behalf of MacroGenics or its Affiliates or sublicensees in accordance with Section 1.94, but excluding any Required Monotherapy Study and excluding a Clinical Study that includes an Incyte Pipeline Asset.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.90</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Global Development Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the high-level, non-binding, written plan attached hereto as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2</font><font style="font-family:inherit;font-size:12pt;">&#32;covering MacroGenics&#8217; planned conduct of any MacroGenics Combination Studies, as updated by MacroGenics from time to time in accordance with Sections 2.2 and 4.4. For clarity, a PowerPoint presentation summarizing such planned studies would be sufficient as a written plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.91</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Large-Scale Supply Plant</font><font style="font-family:inherit;font-size:12pt;">&#8221; means MacroGenics&#8217; proposed five by two thousand (5x2000) liter GMP Manufacturing plant, to be located at 9704 Medical Center Drive, Rockville, Maryland. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">13</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.92</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Manufacturing Facilities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, individually or collectively, as the context requires, the MacroGenics 1,000L Supply Plant and the MacroGenics Large-Scale Supply Plant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.93</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics PD-1 Control Arm</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, in connection with a MacroGenics Combination Study, either: (a) both (i) a monotherapy arm of the Licensed Product and (ii) a separate monotherapy arm of a different PD-1/-L1 Monoclonal Antibody that is an Ancillary Therapy only (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, pembrolizumab), or (b) both (i) an arm that evaluates the Licensed Compound in combination with a given MacroGenics Pipeline Asset and (ii) a separate arm that evaluates a different PD-1/-L1 Monoclonal Antibody that is an Ancillary Therapy (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, pembrolizumab) in combination with the same MacroGenics Pipeline Asset. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.94</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Pipeline Asset Criteria</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a molecule, that MacroGenics: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:12pt;">&#32;&#160;&#160;&#160;&#160;(i) owned or Controlled such molecule for any period after the Effective Date, (ii) previously conducted, or is conducting, a Clinical Study with such molecule that evaluates a combination of such molecule and the Licensed Compound, and (iii) has entered into, or shall enter into, a bona fide collaboration with a Third Party that governs the research, development and commercialization of such molecule with respect thereto; or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:12pt;">&#32;&#160;&#160;&#160;&#160;has previously entered into, or enters into, a bona fide collaboration with a Third Party that governs the research, development and/or commercialization of such molecule, where MacroGenics retains development rights to sponsor and fund a Clinical Study and to provide input on the development of such molecule; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">provided that in each case (of (a) and (b)), such Third Party collaborator shall be contractually obligated to the same development obligations as MacroGenics, pursuant to Section 4.3 or otherwise in Article 4, except that in the case of (a), Incyte shall have the final decision-making authority pursuant to Section 4.3(b)(i)(3) and Section 4.3(b)(ii).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.95</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Pipeline Asset Information</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any commercially sensitive confidential information related to a MacroGenics Pipeline Asset, as reasonably determined by MacroGenics in its sole discretion. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.96</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacture</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any and all activities and processes related to the manufacturing of Licensed Compound or Licensed Product, or any ingredient thereof, including manufacturing of Licensed Compound Bulk Drug Substance, or Licensed Compound Drug Product for Development or Commercialization, labeling, packaging, in-process and testing of finished Licensed Compound or Licensed Product, release of the Licensed Compound or Licensed Product or any component or ingredient thereof, quality assurance activities related to manufacturing and release of Licensed Compound or Licensed Product, and ongoing stability tests and regulatory activities related to any of the foregoing. &#8220;Manufacture&#8221; shall exclude Manufacturing Development. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">14</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.97</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing Development</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any of the following with respect to Licensed Compound or Licensed Product: manufacturing process development and validation, process improvements, formulation development, associated analytical development and validation and the manufacture and testing of stability or consistency lots (including process development, qualification, QA, and test batches). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.98</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing Expenses</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to the Licensed Compound or any Licensed Product, the aggregate of fully burdened (excluding accounting expenses) internal costs (including actual direct labor based on internal FTE Costs) and Third Party Expenses (without mark-up) incurred by a Party and its Affiliates to Manufacture such Licensed Compound or Licensed Product, calculated as follows, in each case determined in accordance with GAAP, as consistently applied by such Party and its Affiliates: (a) to the extent that such Party or its Affiliates performs all or any part of the Manufacturing of the Licensed Compound or Licensed Product, (i) the direct material costs (including media and purification reagents) and direct FTE Costs for such Manufacturing of the Licensed Compound or Licensed Product, which may include, to the extent actually incurred in such Manufacture, cleaning costs of productions, Manufacturing administrative (including overhead costs allocable to the Manufacturing, but excluding all corporate general and administrative overhead costs), the costs of audits, and all directly incurred Manufacturing variances; (ii) a [**] of the costs of [**] of Licensed Compound (calculated by [**]) (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, [**]); and (iii) Manufacturing facilities costs (including depreciation, repairs and maintenance costs), scale-up directly allocable to the Manufacture of the Licensed Compound or Licensed Product (including API and drug product production), quality assurance and quality control and technical support, provided that, for commercial supply, each of (i) and (iii) may be included in Manufacturing Expenses only to the extent such costs and expenses are inventoriable under GAAP as consistently applied by such Party or its Affiliates; provided that, all costs of direct labor shall be calculated based on the FTE Rate; and (b) to the extent that a Third Party performs all or any part of the Manufacturing of the Licensed Compound or Licensed Product, the reasonable out-of-pocket</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">costs paid to such Third Party for such activities determined in accordance with GAAP. All invoices for Manufacturing Expenses submitted under this Agreement will include a detailed calculation and description of the relevant overhead allocations. For clarity, Manufacturing Expenses shall not include: (A) any [**]; (B) any costs, expenses or overhead associated [**] (e.g., if Manufacturing activities [**] Licensed Compound Bulk Drug Substance produced [**] ([**]) of the [**] of the plant if the plant were [**]); (C) any amounts [**]; and (D) any costs or expenses [**]. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.99</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing Process</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the manufacturing process for (including any associated Know-How owned or Controlled by MacroGenics relating to the then-current process, and necessary or useful for) the Manufacture of the Licensed Compound Bulk Drug Substance or the Licensed Compound Drug Product at the time of the Manufacturing Technology Transfer as more fully described in Section 7.1 and as further Developed under this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.100</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Marketing Approval</font><font style="font-family:inherit;font-size:12pt;">&#8221; means approval of a Regulatory Approval Application by the applicable Regulatory Authority. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.101</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Medical Affairs Activities</font><font style="font-family:inherit;font-size:12pt;">&#8221; means medical and scientific information and responses to external inquiries or complaints, medical education, Health Economics and Outcomes Research </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">15</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">(HECOR, HEMAR), advisory boards, educational grants and fellowships, opinion leader development activities, drug safety, local country government affairs, field-based medical science liaisons, medical doctors in field (separate from medical science liaisons), publications, medical communications and field medical education.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.102</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MHLW</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Japanese Ministry of Health, Labour and Welfare and any successor agency(ies) or authority having substantially the same function.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.103</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Monoclonal Antibodies</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any monospecific antibodies, but shall exclude any bi- or multi-specific antibody forms (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, Biclonics&#174;, DART&#174; and TRIDENT&#8482; constructs). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.104</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Monotherapy Regimen</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Licensed Compound administered as a single agent therapy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.105</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Monotherapy Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a non-clinical study (including Manufacturing Development), preclinical study, or Clinical Study of (a) solely the Monotherapy Regimen or (b) the Monotherapy Regimen that compares the Monotherapy Regimen to an Ancillary Therapy, in each case of (a) and (b), that is performed by or on behalf of Incyte (or by MacroGenics pursuant to Section 5.9(c)). For clarity, a monotherapy arm that is included as part of a Combination Study shall not be considered a Monotherapy Study. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.106</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Price</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any Licensed Product, the [**] (or its Affiliates or sublicensees) with payers. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.107</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Net Sales</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, with respect to any Licensed Product, the gross amounts invoiced by Incyte or any of its Affiliates or sublicensees for sales of such Licensed Product to unaffiliated Third Party purchasers in arms-length transactions, less the following deductions calculated in accordance with GAAP, to the extent actually taken, paid, accrued and allowed:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">cash, trade or quantity discounts, retroactive price reductions, coupons, charge-back payments, and rebates granted (in each case, whether in cash or in kind) to trade customers, hospitals, managed health care organizations, pharmaceutical benefit managers, group purchasing organizations, and national, state, or local governments;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">credits, rebates or allowances allowed upon prompt payment or on account of claims, damaged goods, rejections or returns of such Licensed Product, including in connection with recalls and withdrawals, and the amount of any write-offs for bad debt (provided, that an amount written off as bad debt but subsequently recovered will be treated as Net Sales);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">outbound freight, shipment and insurance costs, to the extent included in the price and separately itemized on the invoice price; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">taxes (other than income taxes), duties, tariffs, mandated contribution or other governmental charges levied on the sale of such Licensed Product, including Value-Added Taxes (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">VAT</font><font style="font-family:inherit;font-size:12pt;">&#8221;), customs duties, healthcare taxes, excise taxes, use taxes, and sales taxes; </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">16</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">compulsory payments and cash rebates related to sales of such Licensed Product payable to a Governmental Authority (or agent thereof) pursuant to Applicable Law by reason of any national or local health insurance program or similar program, including that portion of the annual fee on prescription drug manufacturers imposed by the Patient Protection and Affordable Care Act, Pub. L. No. 111-148 (as amended) that Incyte, its Affiliate or its or their sublicensee, as applicable, allocates to sales of the Licensed Products in accordance with Incyte&#8217;s, its Affiliate&#8217;s or its or their sublicensee&#8217;s standard policies and procedures consistently applied across its products, as applicable; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">any other similar and customary deductions (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g., </font><font style="font-family:inherit;font-size:12pt;">currently, co-pay cards) that are consistent with GAAP and Incyte&#8217;s actual practice (or its Affiliates&#8217; or licensees&#8217;) at the time in calculating and reporting its actual product net sales throughout its businesses (in the particular country, if applicable), provided that no item shall be deducted pursuant to this clause (f) if included in any another deduction provided for under this definition (for example, Incyte shall not deduct an allowance for bad debts pursuant to this clause (f), as actual bad debts are subject to deduction pursuant to clause (b)),</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All of the aforementioned deductions shall be determined, on a country-by-country basis, as incurred in the ordinary course of business in type and amount consistent with Incyte&#8217;s or its applicable Affiliate&#8217;s or sublicensee&#8217;s (as the case may be) business practices consistently applied across its product lines and accounting standards, as applicable. All such deductions shall be fairly and equitably allocated to such Licensed Product and other products of Incyte and its Affiliates and sublicensees. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event a Licensed Product is sold as part of a Combination Product, the Net Sales from the Combination Product shall be determined by multiplying the Net Sales of the Combination Product, as calculated above without regard for this paragraph, by the fraction A/(A+B), where A is the average sale price of the Licensed Product when sold separately in finished form, and B is the average sale price of the other therapeutic ingredient(s) included in the Combination Product when sold separately in finished form, in each case in the applicable country of sale or and during the applicable royalty reporting period, if sales of both the Licensed Product and the other therapeutic ingredient(s) did not occur in such period, then in the most recent royalty reporting period in which sales of both occurred. In the event that such average sale price cannot be determined for both the Licensed Product and all other therapeutic ingredient(s) included in the Combination Product, Net Sales shall be calculated by multiplying the Net Sales of the Combination Product, as calculated above without regard for this paragraph, by the fraction of C/(C+D) where C is the fair market value of the Licensed Product and D is the fair market value of all other therapeutic ingredient(s) included in the Combination Product. The Parties shall seek to determine such fair market values by mutual agreement and, in the absence of such mutual agreement, the Parties shall engage an independent valuation firm (and equally bear the costs of engaging such firm) to determine such fair market values.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the foregoing, amounts invoiced by Incyte, its Affiliates, or its sublicensees for the sale of a Licensed Product among Incyte, its Affiliates or its sublicensees for resale shall not be included in the computation of Net Sales hereunder unless such Affiliate or such sublicensee is the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">17</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">end user of such Licensed Product and as long as such Licensed Product is subsequently resold by Incyte, its Affiliates or its sublicensee and considered Net Sales. Net Sales shall exclude reasonable and customary quantities (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, samples) of the Licensed Product transferred, disposed of or sold at no cost or at or below cost for (i) promotional or educational purposes, (ii) Clinical Study purposes, (iii) early access programs (such as to provide patients with a Licensed Product prior to Regulatory Approval pursuant to treatment INDs or protocols, named patient programs or compassionate use programs) or (iv) any similar uses.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.108</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Proprietary Combination Regimen</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Combination that is evaluated in a Clinical Study comprising a Licensed Compound and at least one Ancillary Therapy that is not an Incyte Pipeline Asset, Collaborator Pipeline Asset, or MacroGenics Pipeline Asset (which Combination may also include any other compound that constitutes an Ancillary Therapy and is not an Incyte Pipeline Asset, Collaborator Pipeline Asset, or MacroGenics Pipeline Asset).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.109</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Registrational Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a Combination Study conducted by either Party that is not a Phase I Study, Phase II Study, Phase III Study, non-interventional Phase IV Study, Phase IV Study required by a Regulatory Authority for purposes of maintaining or changing the existing product label for the applicable Combination Regimen or Pivotal Study or otherwise in support of obtaining or maintaining Regulatory Approval (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, an early access, compassionate use, or special use program, or a Phase IV Study not required by a Regulatory Authority for purposes of maintaining or changing the existing product label for the applicable Combination Regimen). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.110</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; means all: (a) patents, including any utility or design patent; (b) patent applications, including provisionals, substitutions, divisionals, continuations, continuations in-part or renewals; (c) patents of addition, restorations, extensions, supplementary protection certificates, registration or confirmation patents, patents resulting from post-grant proceedings, re-issues and re-examinations; (d) other patents or patent applications claiming priority directly or indirectly to (i) any such specified patent or patent application specified in (a) through (c), or (ii) any patent or patent application from which a patent or patent application specified in (a) through (c) claim direct or indirect priority; (e) inventor&#8217;s certificates; and (f) other rights issued from a Governmental Authority similar to any of the foregoing; in each case of (a) through (f), irrespective of whether such patent, patent application or other right arises in the U.S. or any other jurisdiction in the Territory.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.111</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PD-1</font><font style="font-family:inherit;font-size:12pt;">&#8221; means programmed cell death receptor 1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.112</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PD-L1</font><font style="font-family:inherit;font-size:12pt;">&#8221; means programmed cell death ligand 1.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.113</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PD-1 IP</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any intellectual property that relates to anti-PD-1 Monoclonal Antibodies. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.114</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Person</font><font style="font-family:inherit;font-size:12pt;">&#8221; means an individual, sole proprietorship, partnership, limited partnership, limited liability partnership, corporation, limited liability company, business trust, joint stock company, trust, incorporated association, joint venture or similar entity or organization, including a government or political subdivision, department or agency of a government.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">18</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.115</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase I Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means a human clinical trial of a Product in any country that would satisfy the requirements of 21 C.F.R. &#167; 312.21(a) (FFDCA), as amended from time to time, or any foreign equivalent thereof. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.116</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase II Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a human clinical trial of a Product, or relevant portion of such trial (including expansion cohorts from a Phase I Study for which patients are treated at a defined dose or a set of defined doses), for which the primary endpoints include a preliminary determination of efficacy in patients being studied, as described in 21 C.F.R. &#167; 312.21(b) (FFDCA), as amended from time to time, or any foreign equivalent thereof. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.117</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase III Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a pivotal human clinical trial with a defined dose or a set of defined doses of a Product that is designed to ascertain efficacy and safety of such Product, as described in 21 C.F.R. &#167; 312.21(c) (FFDCA), as amended from time to time, or any foreign equivalent thereof, for the purpose of supporting the preparation and submission of a BLA or MAA. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.118</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Phase IV Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a clinical trial of a Product, possibly including pharmacokinetic studies, which trial (a) is not required to be completed prior to obtaining Marketing Approval of such Product; and (b) either (i) is required by the applicable Regulatory Authority as mandatory to be conducted on or after the Marketing Approval of such Product, or (ii) is conducted voluntarily to enhance scientific knowledge of the Product (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, providing additional drug profile, safety data or marketing support information, or supporting expansion of Product labeling). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.119</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any specific molecule (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">i.e.</font><font style="font-family:inherit;font-size:12pt;">, not a class of molecules), other than the Licensed Compound, that is: (a) Controlled (in accordance with Section 1.32(b)) by MacroGenics, or that otherwise satisfies the MacroGenics Pipeline Asset Criteria (either, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (b) Controlled (in accordance with Section 1.32(b)) by Incyte, or that otherwise satisfies the Incyte Pipeline Asset Criteria (either, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (c) Controlled (in accordance with Section 1.32(b)) by a Collaborator (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">&#8221;); or (d) solely for purposes of Sections 4.3(c) and 15.3(b), Controlled (in accordance with Section 1.32(b)) by an Acquirer in a Change of Control transaction with respect to MacroGenics (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acquirer Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as applicable.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.120</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pivotal Study</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) a Phase III Study or other human Clinical Study designed to be or that becomes a registration trial sufficient for filing a Regulatory Approval Application for a Licensed Product, as evidenced by (i) an agreement with or statement from the FDA or applicable Regulatory Authority, or (ii) other guidance of minutes issued by the FDA or such other Regulatory Authority for such registration trial, or (b) a Phase III Study or other human Clinical Study which Incyte intends to submit as the basis for Regulatory Approval of the Licensed Product. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.121</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">PMDA</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the Pharmaceuticals and Medical Devices Agency in Japan and any successor agency(ies) or authority having substantially the same function.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.122</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Product(s)</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, individually or collectively, as the context requires, (a) any Licensed Product or (b) any Combination Regimen.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">19</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.123</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proof of Concept</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to any [**] (but, for clarity, excluding the other [**]), the establishment of a [**] as established by the JDC on an [**], subject to an [**] (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g., </font><font style="font-family:inherit;font-size:12pt;">[**] or [**]).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.124</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Qualifying Termination</font><font style="font-family:inherit;font-size:12pt;">&#8221; means a termination of this Agreement in its entirety: (a) by MacroGenics pursuant to Section 12.3 (for Incyte&#8217;s material uncured breach); (b) by MacroGenics pursuant to Section 12.5 (for a patent challenge); (c) by MacroGenics pursuant to Section 12.6 (for Incyte bankruptcy); (d) by Incyte pursuant to Section 12.2 (for convenience); or (e) by Incyte pursuant to Section 12.4 (for safety reasons). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.125</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221; means that certain regulatory agreement to be entered into by the Parties to define the Parties&#8217; respective roles and responsibilities related to regulatory strategy, labeling strategy (including a delineation of any product label(s) of a Party that will be expanded to include the other Party&#8217;s Regulatory Approvals, in accordance with Section 5.8), dossier preparation, interactions with Regulatory Authorities, coordination of Regulatory Approval Application submission contents, timing and other matters, to enable each Party to comply with its respective obligations under Applicable Law, with regard to filings and interactions with any Regulatory Authority related to Incyte seeking Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen and MacroGenics seeking Regulatory Approval of the MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.126</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means any and all approvals (including supplements, amendments, pre- and post-approvals and pricing and reimbursement approvals, but excluding Manufacturing approvals), licenses, registrations or authorizations of any national, regional, state or local Regulatory Authority, department, bureau, commission, council or other governmental entity, that are necessary to Commercialize any Compounds or Products under this Agreement in any country or jurisdiction in the Territory, for one or more uses, including any pricing and reimbursement approvals that are necessary to conduct a launch of such Compound or Product in such country or jurisdiction (even if such approvals are not legally required to launch such Compound or Product in such country or jurisdiction). </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.127</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval Application</font><font style="font-family:inherit;font-size:12pt;">&#8221; means (a) a New Drug Approval Application (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NDA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or Biologics License Application (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BLA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (each, as defined in the FFDCA) in the U.S., or (b) any corresponding application for Regulatory Approval in any country or jurisdiction in the Territory outside the U.S., including, with respect to the European Union, a Marketing Authorization Application (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MAA</font><font style="font-family:inherit;font-size:12pt;">&#8221;) filed with the EMA pursuant to the Centralised Approval Procedure or with the applicable Regulatory Authority of a country in Europe with respect to the decentralised procedure, mutual recognition or any national approval procedure.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.128</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval in EU</font><font style="font-family:inherit;font-size:12pt;">&#8221; means receipt of Regulatory Approval in at least three (3) of five (5) European Major Markets.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.129</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Authority</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any applicable Governmental Authority involved in granting Regulatory Approval in a country or jurisdiction in the Territory, including (a) in the U.S., the FDA or any other applicable Governmental Authority having jurisdiction over any Compound or Product; (b) in the EU, the EMA or any other applicable Governmental Authority having </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">20</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">jurisdiction over any Compound or Product; (c) in Japan, the PMDA or MHLW; and (d) in any country or jurisdiction other than the U.S., EU or Japan, any applicable Governmental Authority having jurisdiction over any Compound or Product.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.130</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Documentation</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means, with respect to any Compound or Product under this Agreement, all regulatory filings, applications, notifications, registrations, licenses, regulatory drug lists, advertising and promotion documents, adverse event files, complaint files, Manufacturing records, Regulatory Approvals or other regulatory submissions or supporting documents, including any written correspondence or meeting minutes, made to, made with, or received from an applicable governmental agency or Regulatory Authority relating to such Compound or Product, and all data contained therein. &#8220;Regulatory Documentation&#8221; includes INDs, Regulatory Approval Applications, and amendments and supplements for any of the foregoing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.131</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Exclusivity</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, with respect to a particular country, either exclusive marketing rights or data protection or other exclusivity rights conferred by any Regulatory Authority with respect to such Licensed Product in such country or jurisdiction in the Territory, including orphan drug exclusivity, pediatric exclusivity, rights conferred in the U.S. under the Biologics Price Competition and Innovation Act of 2009 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">BPCI Act</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or in the European Union under Directive 2001/83/EC, as amended, and Regulation (EC) No. 1901/2006, as amended, or rights similar thereto in other countries or regulatory jurisdictions in the Territory. Regulatory Exclusivity shall not include exclusivity conferred by a Patent right. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.132</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Right of Reference</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the &#8220;right of reference&#8221; defined in 21 C.F.R. 314.3(b), or any analogous Applicable Law recognized outside of the U.S. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.133</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Royalty Term</font><font style="font-family:inherit;font-size:12pt;">&#8221; means, on a Licensed Product-by-Licensed Product and country-by-country basis, the time period commencing on the Effective Date and continuing until the later of: (a) the expiration of the last Valid Claim of a Licensed Patent Covering the composition of matter or method of use of such Licensed Product in such country; (b) [**] from the First Commercial Sale of such Licensed Product in such country; or (c) if Regulatory Exclusivity is granted with respect to such Licensed Product in such country, the expiration or termination of such Regulatory Exclusivity in such country.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.134</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Tax</font><font style="font-family:inherit;font-size:12pt;">&#8221; or &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Taxes</font><font style="font-family:inherit;font-size:12pt;">&#8221; means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including any interest thereon).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.135</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Territory</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means any country in the world.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.136</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means any Person other than (a) Incyte, (b) MacroGenics or (c) an Affiliate of either of Incyte or MacroGenics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.137</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Expenses</font><font style="font-family:inherit;font-size:12pt;">&#8221; means out-of-pocket expenses incurred by a Party or any of its Affiliates for services performed by a Third Party on behalf of Incyte or MacroGenics in the course of such Party&#8217;s performance of this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.138</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">U.S.</font><font style="font-family:inherit;font-size:12pt;">&#8221; means the United States of America, including its territories and possessions.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">21</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.139</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;[**]&#8221; means, with respect to the Licensed Compound, the [**] of (a) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or (b) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">([**]%) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">&#8220;[**]&#8221; (as such term is defined under applicable [**] ([**]), or if [**] ceases to be [**] in [**], its equivalent successor) of [**]. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.140</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Valid Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">means (a) a claim of an issued and unexpired Patent, to the extent such claim has not been revoked, held invalid or unenforceable by a patent office, court or other Governmental Authority of competent jurisdiction in a final order, from which no further appeal can be taken, and which claim has not been disclaimed, denied or admitted to be invalid or unenforceable through reissue, re-examination, disclaimer, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;review, post-grant review, other patent office administrative proceedings, or otherwise; or (b) a claim within a patent application that has not been pending for more than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">from the date of its first priority patent application filing anywhere in the Territory and which claim has not been revoked, cancelled, withdrawn, held invalid or abandoned.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1.141</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Additional Definitions</font><font style="font-family:inherit;font-size:12pt;">. Each of the following definitions is set forth in the Section of this Agreement indicated below: </font></div><div style="line-height:120%;padding-left:6px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.31623931623932%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:59%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13D Group</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.14(a)(iii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acquirer Combination Study</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.3(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ancillary Agreements</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Annual Global Commercial Supply Forecast</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Approval Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Approved CMO</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Bankruptcy Laws</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Binding Portion</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(e)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**] Conditions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">10.2(j)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Breaching Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.3</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CCC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.5(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Claim</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinical Quality Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Clinical Supply Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collaborator Contract</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collaborator Development IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Collaborator Sublicense Fees</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.8</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Commercial Supply Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Committed Supply</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cooperating Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.5(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Co-Promotion Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.1(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cure Period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.3</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Deadlocked Committee Matter</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6(d)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">22</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.31623931623932%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:59%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Development Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.5</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Development Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Disclosing Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Dispute(s)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">13.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**] Conditions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Existing Third Party Licenses</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Funded Collaborator Combination Studies</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte CDx IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Commercial Supply Commitment</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3(a)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Competing Product</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.3(b)(iii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Development IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Facility</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Indemnitee</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.2</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Know-How</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Method Claim</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(d)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Objection</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3(c)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Patents</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte PD-1 IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte [**] Objection</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3(b)(i)(1)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Technology</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IND Transition</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IND Transition Date</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IND Transition Plan</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indemnifying Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.3(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indemnitee</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.3(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Indication Population</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Information Transfer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Infringement Recovery</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.3(f)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insolvency Event</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Insolvent Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JDC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.2(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JIPC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.4(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JMC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.3(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Committee</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.6(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Inventions</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Joint Patents</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(e)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">JSC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">2.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Long Term Forecast</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(e)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics CDx IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(a)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Commercial Supply Commitment</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.3(a)(ii)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">23</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.31623931623932%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:59%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Competing Product</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.3(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Development IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Indemnitee</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">14.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Licensed Compound Data</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2(c)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics Method Claim</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(d)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics PD-1 IP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">3.4(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics-Responsible Joint Patents</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(e)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturing Technology Transfer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Manufacturing Transition Plan</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3(c)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.3(b)(i)(1)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MGA012 IND</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Monotherapy Sublicense Fees</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.7</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Non-Insolvent Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Ongoing Clinical Study</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Opt Out Notice</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(b)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Order</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(e)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patent Extension(s)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.4</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pharmacovigilance Agreement</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.6(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">POC Development Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prosecuting Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(f)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Quality Assurance Measures</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.6(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Receiving Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Regulatory Filing Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Representatives</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.1(e)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Requested Licensed Patent</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Requesting Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">11.5(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Required Monotherapy Study</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.9</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Required Regulatory Data</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.2(c)(iii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Responsible Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(e)(ii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rolling Forecast</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">7.2(e)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Royalty Floor</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.5(a)(iii)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Sales Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.2(e)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 365(n)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.6(b)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Standstill Period</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15.14(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Study Transition</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Study Transition Date</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Study Transition Plan</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">4.1(c)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subject Patents</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.2(c)(i)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Term</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.1</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Terminating Party</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.3</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party Infringement Claim</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.5(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party License</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party License Credit</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">8.10(a)</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Third Party Patent Challenge</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9.6(a)</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">24</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.31623931623932%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:59%;"></td><td style="width:41%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upstream License</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">12.8(d)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Transferred Documentation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">5.1(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2(a)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">6.2(a)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">GOVERNANCE </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Steering Committee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Formation and Purpose</font><font style="font-family:inherit;font-size:12pt;">. The Parties agree to establish and convene a joint steering committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JSC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Effective Date. The JSC shall consist of representatives from each Party as further described in Section 2.6(a) and operate in accordance with this Section 2.1 and Section 2.6. The purpose of the JSC shall be to provide a forum for overall coordination and communication with respect to the Parties&#8217; activities under this Agreement, including the resolution of Deadlocked Committee Matters properly referred to the JSC under this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibilities of the JSC</font><font style="font-family:inherit;font-size:12pt;">. The JSC&#8217;s overall responsibility shall be to:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss any issues arising with respect to the Development or Commercialization of the Licensed Compound or any Licensed Products or Combination Regimens;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss the clinical and/or commercial supply needs of MacroGenics, Incyte and any Collaborators with respect to the Licensed Compound and the Manufacturing plans with respect thereto;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss and oversee the Study Transition Plan, IND Transition Plan, and Manufacturing Transition Plan (provided that the selection of any Approved CMO(s) shall require mutual agreement, such agreement not to be unreasonably withheld), including discussing any amendments with respect to either of the foregoing;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">coordinate the wind-down of efforts under this Agreement following termination in accordance with Section 12.8;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">decide matters and resolve disputes referred to the JSC which the JSC has authority to decide or resolve under this Agreement and resolve Deadlocked Committee Matters referred to the JSC in accordance with Section 2.6(d); and</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">25</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">perform other obligations specifically delegated to the JSC under this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JSC Decisions and Actions</font><font style="font-family:inherit;font-size:12pt;">. Actions to be taken and decisions to be made by the JSC (including the resolution of Deadlocked Committee Matters referred to the JSC in accordance with Section 2.6(d)) shall be taken or made only following unanimous agreement, with each Party having one (1) vote. If the JSC fails to reach unanimous agreement on a matter before it for decision within [**] from the date that the matter is first presented to the JSC in writing, such matter shall be referred to the Executive Officers for discussion and resolution pursuant to Article 13 upon the request of either Party. Any resolution of such matter by the Executive Officers shall be final and binding on the Parties. If the Executive Officers are not able to resolve the matter within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">period specified in Article 13, then Incyte shall have the final decision-making authority with respect to such matter, and Incyte&#8217;s decision on such matter shall be final and binding on the Parties, subject to the limitations set forth in Section 2.10.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Development Committee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Formation and Purpose</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The Parties agree to establish and convene a joint development committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JDC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within [**] after the Effective Date. The JDC shall consist of representatives from each Party as further described in Section 2.6(a) and operate in accordance with this Section 2.2 and Section 2.6. The primary purpose of the JDC shall be to oversee, coordinate and facilitate Development of the Licensed Compound and Licensed Products under this Agreement. For clarity, notwithstanding the establishment of the JDC, Incyte shall have the sole and unrestricted right to conduct or have conducted any Clinical Study or other Development with respect to the Monotherapy Regimen, the Incyte Combination Regimens and the Collaborator Combination Regimens and to modify the Incyte Global Development Plan without restriction.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibilities of the JDC</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The JDC shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">oversee the Ongoing Clinical Study performed by or on behalf of MacroGenics with respect to the Licensed Compound; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee the transition of Development responsibilities from MacroGenics to Incyte as contemplated under this Agreement, including discussing the IND Transition Date and Study Transition Date, overseeing the Regulatory Transfer, and seeking approval of the IND Transition Plan and Study Transition Plan; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss Incyte&#8217;s plans with respect to the Development of the Licensed Compound and any Licensed Products in the Field in the Territory in accordance with the Incyte Global Development Plan;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">26</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss MacroGenics&#8217; plans with respect to the Development of the MacroGenics Combination Regimens in the Field in the Territory in accordance with the MacroGenics Global Development Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">annually review the then-current Incyte Global Development Plan and MacroGenics Global Development Plan;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss the protocol synopses for MacroGenics&#8217; proposed MacroGenics Combination Studies in accordance with Section 4.3; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">establish the [**] and [**] required for the achievement of Proof of Concept in a [**] or [**] of a [**]; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss any issues arising with respect to the Development of any Monotherapy Regimen or any Combination Regimen;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ix)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">coordinate, and encourage and facilitate, communication and information sharing regarding the Parties&#8217; performance of their respective regulatory responsibilities in accordance with Article 5;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(x)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">decide matters which the JDC has the express authority to decide under this Agreement; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(xi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">perform other obligations specifically delegated to the JDC under this Agreement. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Manufacturing Committee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Formation and Purpose</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The Parties agree to establish and convene a joint manufacturing committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JMC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within [**] after the Effective Date. The JMC shall consist of representatives from each Party as further described in Section 2.6(a) and operate in accordance with this Section 2.3 and Section 2.6. The primary purpose of the JMC shall be to oversee, coordinate and facilitate the Manufacture of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibilities of the JMC</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The JMC shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss manufacturing matters with respect to the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product, including the Manufacturing Process, and discuss and seek approval of the Approved CMO (as more fully set forth in Section 7.1); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">facilitate the sharing of the Rolling Forecasts and Long Term Forecasts pursuant to Section 7.2(e)(i), and review and seek approval of the Annual Global Supply Commitment pursuant to Section 7.3(a);</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">27</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee the Manufacturing Technology Transfer (as more fully set forth in Section 7.1), including discussing and seeking approval of the Manufacturing Transition Plan; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">perform other obligations specifically delegated to the JMC under this Agreement. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Intellectual Property Committee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Formation and Purpose</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The Parties agree to establish and convene a joint intellectual property committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">JIPC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within [**] after the Effective Date. The JIPC shall consist of representatives from each Party as further described in Section 2.6(a) and operate in accordance with this Section 2.4 and Section 2.6. The primary purpose of the JIPC shall be to coordinate, oversee, and provide a venue for discussion of intellectual property strategy, prosecution, maintenance, and enforcement matters relating to the Licensed Patents, Joint Patents, Incyte Patents and Patents within the Incyte Development IP. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibilities of the JIPC</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The JIPC shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee the preparation, filing, prosecution and maintenance of the Licensed Patents (as more fully set forth in Section 9.2);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee the litigation strategy with respect to any suits or other actions against any Third Party engaged in any existing, alleged or threatened infringement of any Licensed Patent or Joint Patent (as more fully set forth in Section 9.3); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee matters related to obtaining Patent Extensions (as more fully set forth in Section 9.4); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">discuss, coordinate and oversee the litigation strategy with respect to any Third Party Infringement Claim or Third Party Patent Challenge (as more fully set forth in Sections 9.5 and 9.6); and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;perform other obligations specifically delegated to the JIPC under this Agreement.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Commercialization Coordination Committee</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Formation and Purpose</font><font style="font-family:inherit;font-size:12pt;">. The Parties agree to establish and convene a commercialization coordination committee (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CCC</font><font style="font-family:inherit;font-size:12pt;">&#8221;) at least [**] prior to the earlier of the [**] of either [**] or [**]. The CCC shall consist of representatives from each Party as further described in Section 2.6(a) and operate in accordance with this Section 2.5 and Section 2.6. The primary purpose of the CCC shall be to oversee, discuss and coordinate commercial activities with respect to MacroGenics Combination Regimens and Monotherapy Regimens under this Agreement; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">28</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">provided that, except in connection with forecasting global commercial demand for Licensed Compound Drug Product in connection with Commercialization of the Combination Regimens, pursuant to Section 7.3(a), neither Party shall be obligated to share with the CCC any information, materials or strategy, or to coordinate on any strategy or commercialization content, with respect to its Combination Regimens or the Monotherapy Regimen. Notwithstanding anything to the contrary herein, (a) MacroGenics shall have final decision-making authority with respect to commercial matters related to MacroGenics Pipeline Assets and, subject to the remainder of this Section 2.5(a), MacroGenics Combination Regimens, and (b) Incyte shall have final decision-making authority with respect to any matters related to the Monotherapy Regimen and any commercial matters related to the Licensed Product being sold in accordance with its approved label. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsibilities of the CCC</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The CCC shall be advisory in nature and shall not have any decision-making authority, but shall:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">oversee, discuss and coordinate commercial matters with respect to MacroGenics Combination Regimens and Monotherapy Regimens, including market landscape, strategic positioning, communications and promotional strategy and medical strategy; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">oversee and coordinate procedures for sharing Information relating to the labeling of MacroGenics Combination Regimens; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;perform other obligations specifically delegated to the CCC under this Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CCC Membership and operations</font><font style="font-family:inherit;font-size:12pt;">. During the JSC&#8217;s first meeting, the JSC will use good faith efforts to mutually agree upon procedures regarding the membership and operations of the CCC, it being understood that the CCC shall be advisory in nature and shall not have any decision-making authority.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Joint Committee Membership and Operations</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Membership</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Promptly after the Effective Date, each Party shall designate three (3) representatives to the JSC, up to three (3) representatives to each of the JDC and JMC, and up to two (2) representatives to the JIPC (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Committee</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Each Joint Committee may elect to vary the number of representatives from time to time. Each representative designated by a Party shall be an employee of such Party or one of its Affiliates and shall have the appropriate level of experience in the subject area of the applicable Joint Committee, and at least one (1) representative shall have sufficient seniority within the applicable Party&#8217;s organization to have the necessary decision-making authority in order for such Joint Committee to fulfill its responsibilities. Either Party may designate employees as substitutes for any of its Joint Committee representatives if one (1) or more of such Party&#8217;s designated representatives is unable to be present at a meeting. From time to time, each Party may replace any of its Joint Committee representatives by written notice to the other </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">29</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Party specifying the prior representative(s) and their replacement(s). Each representative on a Joint Committee shall be bound by confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Committee Chairperson</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Each Joint Committee will have a chairperson, to be designated by MacroGenics initially with respect to the JDC and Incyte initially with respect to the JSC, JMC, and JIPC, and to be designated by the two Parties on an alternating basis annually thereafter. The chairperson shall be responsible for calling and convening meetings of its Joint Committee, but shall have no special authority over the other members of its Joint Committee, and shall have no additional voting rights. The chairperson of each Joint Committee (or its designate) shall: (i) prepare and circulate an agenda reasonably in advance of each upcoming meeting of such Joint Committee; and (ii) prepare and issue minutes of such Joint Committee meeting within [**] thereafter. Such minutes shall not be finalized until each representative on such Joint Committee reviews and approves such minutes, provided that any minutes shall be deemed approved unless a Joint Committee representative objects to the accuracy of such minutes within [**] after the circulation of the minutes. The minutes of each Joint Committee meeting shall be the Confidential Information of each Party.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Meetings</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Timing and Frequency</font><font style="font-family:inherit;font-size:12pt;">. Promptly following its formation, each Joint Committee will hold an in-person meeting to establish such Joint Committee&#8217;s operating procedures. After its initial meeting, the JSC shall meet at least once every Calendar Quarter during the Term (or such other frequency as agreed upon by the Parties), and each other Joint Committee shall meet as frequently as agreed by each such Joint Committee, but no less frequently than annually. Additionally, at least once annually, the Parties will hold an in-person meeting (as set forth in Section 2.6(c)(ii)(A)) with all Joint Committees in attendance. Additional meetings of a Joint Committee may be held with the consent of each Party (such consent not to be unreasonably withheld, delayed or conditioned), as required under this Agreement or to attempt to resolve any matter or Deadlocked Committee Matter in accordance with this Agreement. In the case of any matter or Deadlocked Committee Matter referred to a Joint Committee, such meeting shall be held within [**] following referral to such Joint Committee, or as soon as reasonably possible thereafter. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Meeting Procedures</font><font style="font-family:inherit;font-size:12pt;">. Meetings of each Joint Committee shall be effective only if a majority of representatives of each Party are present or participating. Other than the initial meeting, each Joint Committee may meet either (A) in person at either Party&#8217;s facilities or at such locations as the Parties may otherwise agree; or (B) by audio or video teleconference, provided that at least once annually, each Joint Committee shall meet in person as described in Section 2.6(c)(i). Each Party shall be responsible for all of its own expenses </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">30</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">incurred in connection with its representatives&#8217; participation in each Joint Committee meeting, including all travel and lodging. All other Third Party Expenses incurred by a Joint Committee in furtherance of a Joint Committee meeting, such as expenses associated with off-site meetings, shall be shared equally by the Parties.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Non-Member Participation</font><font style="font-family:inherit;font-size:12pt;">. Additional non-members of a Joint Committee having relevant experience may from time to time be invited to participate in a Joint Committee meeting, provided that such participants shall have no voting rights or powers. Non-member participants who are not employees of a Party or its Affiliates shall only be allowed to attend if: (A) the other Party&#8217;s representatives have consented to the attendance (such consent not to be unreasonably withheld, delayed or conditioned); (B) such non-member participants are subject to confidentiality and non-use obligations at least as restrictive as those set forth in this Agreement, including the provisions of Sections 11.10(a) and 11.10(b), and shall be deemed the &#8220;Representatives&#8221; of the Party inviting such participants to the meeting. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Committee Decisions and Actions</font><font style="font-family:inherit;font-size:12pt;">. Actions to be taken and decisions to be made by the JDC, JMC, or JIPC shall be taken or made only following unanimous agreement, with each Party having one (1) vote. If the JDC, JMC, or JIPC reaches unanimous agreement on a matter before it for decision, such decision by such Joint Committee shall be final and binding on the Parties. If the JDC, JMC, or JIPC fails to reach unanimous agreement on a matter before it for decision within [**] from the date that the matter is first presented to such Joint Committee in writing, such matter (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Deadlocked Committee Matter</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall be referred to the JSC for resolution upon the request of either Party pursuant to Section 2.1(c).</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Additional Subcommittees and Working Groups</font><font style="font-family:inherit;font-size:12pt;">. Each Joint Committee may establish other subcommittees or working groups as needed to further the purposes of this Agreement, including any responsibilities assigned to such Joint Committee under this Agreement; provided, however, that the JSC shall not delegate its authority to resolve Deadlocked Committee Matters to a subcommittee or working group. The purpose, scope and procedures of any such subcommittee or working group shall be mutually agreed in writing by the Joint Committee that formed such subcommittee or working group. Actions to be taken and decisions to be made by such subcommittee or working group shall be taken or made only following unanimous agreement, with each Party having one (1) vote. If a subcommittee or working group reaches unanimous agreement on a matter before it for decision, such decision by such subcommittee or working group shall be final and binding on the Parties. If a subcommittee or working group fails to reach unanimous agreement on a matter before it for decision within [**] from the date that the matter is first presented to such a subcommittee or working group in writing, such matter shall be referred to the Joint Committee that established such subcommittee or working group for resolution pursuant to Section 2.6(d) upon the request of either Party.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">31</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Authority</font><font style="font-family:inherit;font-size:12pt;">. The Parties agree that it shall be conclusively presumed that, unless otherwise explicitly stated, each voting member of each Joint Committee, or each subcommittee or working group established by a Joint Committee, has the authority and approval of such member&#8217;s respective senior management in casting his or her vote. Each Joint Committee, and each subcommittee or working group established by such Joint Committee, shall each have only the powers assigned expressly to such Joint Committee in this Article 2 and elsewhere in this Agreement, and shall not have any power to amend, modify or waive compliance with this Agreement. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Alliance Managers</font><font style="font-family:inherit;font-size:12pt;">. Promptly following the Effective Date, each Party shall designate in writing an Alliance Manager to serve as the primary point of contact for the Parties regarding all collaboration activities contemplated under this Agreement. Each Alliance Manager shall facilitate communication and coordination of the Parties&#8217; activities under this Agreement. The Alliance Managers shall not be a member of the CCC, or the JSC or any other Joint Committee. The Alliance Managers shall be allowed to attend, as a non-voting observer, meetings of the Joint Committees and the CCC, as well as any subcommittee or working group established by a Joint Committee of which the Alliance Manager is not a member.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Decision-Making Limitations</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary in this Agreement, to the extent that a Party has final decision-making authority with respect to any matter pursuant to Section 2.1(c), such Party shall not exercise such final decision-making authority to: (a) expand or reduce either Party&#8217;s rights or obligations in a manner inconsistent with the terms and conditions of this Agreement or any Ancillary Agreement; (b) determine that such Party has fulfilled its obligations, or the other Party has breached its obligations, under this Agreement or any Ancillary Agreement (including regarding MacroGenics&#8217; performance with respect to the Manufacture and supply of the Licensed Compound); (c) make any decision that is expressly stated to require the other Party&#8217;s approval or agreement or the approval or agreement of both Parties under this Agreement or any Ancillary Agreement; (d) make any decision for which the other Party has expressly been given final decision-making authority under this Agreement; (e) resolve any dispute regarding whether a Milestone has been achieved or the amount of any royalties or other payments owed by one Party to the other Party; (f) hold significantly more Joint Committee meetings at such Party&#8217;s facility than the other Party&#8217;s facility; (g) cause either Party to violate Applicable Law, regulatory requirements or guidance or industry codes; or (h) establish the [**] required for the achievement of Proof of Concept in a [**] or [**] of a [**]. If the Parties fail to mutually agree to the [**] described in (h), then such matter will be submitted to an independent Third-Party expert (mutually agreed upon by both Parties) to establish [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">based on an analysis of available or published data from all of the Approved PD-1 Antibodies, subject to the following parameters: (A) the [**] shall be consistent with the applicable [**] for which Approved PD-1 Antibodies have received Regulatory Approval as a Monotherapy Regimen, as derived from an assessment of monotherapy [**] of Approved PD-1 Antibodies (as of the date on which the applicable Clinical Study data is being assessed with respect to Proof of Concept) observed in comparable patient populations and Indications; and (B) the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall be based on the Licensed Product as a single agent based on the treatment of at least [**] in a specific Indication at a defined dose and schedule that does not exceed the maximum tolerated dose of the applicable Licensed Product. For clarity, the foregoing parameters apply only to the decision of the Third-Party expert, and the JDC may mutually agree to an [**] or [**] that falls outside of such parameters. Provided that the decision of such expert falls within the </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">32</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">foregoing parameters, such decision will be conclusive and binding on the Parties, except in the case of fraud or manifest error. The Parties shall equally share the costs and expenses of such expert. </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 3</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">LICENSES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">License to Incyte</font><font style="font-family:inherit;font-size:12pt;">. Subject to the terms and conditions of this Agreement, MacroGenics hereby grants to Incyte: (a) an exclusive (subject to Section 3.3(a)), non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses as provided in Section 3.2, under the Licensed Technology, to use, have used, Develop, have Developed, Manufacture or have Manufactured, the Licensed Compound and Licensed Products in the Field in the Territory, including as a Monotherapy Regimen or a component of an Incyte Combination Regimen, Collaborator Combination Regimen, or MacroGenics Combination Regimen (but for, clarity, not to use, have used, Develop, have Developed, Manufacture or have Manufactured, any MacroGenics Pipeline Asset, nor to conduct or have conducted any MacroGenics Combination Studies); (b) an exclusive, non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses as provided in Section 3.2, under the Licensed Technology, to Commercialize or have Commercialized the Licensed Compound and Licensed Products in the Field in the Territory, including as a Monotherapy Regimen or a component of an Incyte Combination Regimen or Collaborator Combination Regimen (but, for clarity, not as a component of any MacroGenics Combination Regimen); (c) an exclusive, non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses as provided in Section 3.2, under the (x) Licensed Technology and (y) Label Combination Patents, to Commercialize or have Commercialized the Licensed Compound and Licensed Products in the Field in the Territory as a component of a MacroGenics Combination Regimen in accordance with its approved label, provided that Incyte shall have no right to conduct any Medical Affairs Activities or activities directed to marketing, detailing, promoting, educating or any Phase IV Studies with respect to the Licensed Compound or Licensed Products as a component of a MacroGenics Combination Regimen other than MacroGenics Combination Regimen Detailing; (d) a co-exclusive (with MacroGenics), non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses as provided in Section 3.2, under the (x) Licensed Technology and (y) Label Combination Patents, to obtain Regulatory Approval of the Licensed Compound as a component of MacroGenics Combination Regimens and include such Regulatory Approval in the Licensed Compound label; and (e) a co-exclusive (with MacroGenics), non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses as provided in Section 3.2, under the Licensed Technology, to conduct or have conducted (by Third Party contractors, licensees or other research or Development Partners, as applicable) preclinical and nonclinical studies with the Licensed Compound and Licensed Product solely for research and development purposes. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Sublicensing</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte shall have the right to grant sublicenses of the rights granted to Incyte under Sections 3.1 and 3.4 to: (i) its Affiliates through multiple tiers; and (ii) Third Parties through multiple tiers, subject to the conditions in this subsection (a). Incyte may, in its discretion, grant any such sublicense to a Collaborator (pursuant to subsection </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">33</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">(b)) and to any bona fide Development Partners, commercial partners and distributors. Each sublicense shall refer to this Agreement and, except to the extent MacroGenics may otherwise agree in writing, be consistent in all material respects with the terms and conditions of this Agreement. Incyte shall remain responsible for the performance of its obligations under this Agreement and the performance of its sublicensees hereunder. Incyte shall provide to MacroGenics copies of all such sublicenses to Third Parties (whether granted directly by Incyte or by a Third Party which previously received a sublicense directly or indirectly from Incyte) within [**] after the execution date of each sublicense; provided that Incyte shall have the right to redact commercially sensitive information from such copies, and provided further that Incyte shall provide financial terms to the extent reasonably necessary for MacroGenics to calculate amounts due to MacroGenics hereunder (including Monotherapy Sublicense Fees and Collaborator Sublicense Fees). Information regarding the scope of the license grants, territory or term of each such sublicense shall not be considered commercially sensitive.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte shall require that each Collaborator agrees in writing to the all terms applicable to a Collaborator or Combination Sponsor under this Agreement, in addition to the following terms, all of which shall be set forth in a written agreement executed by Incyte and such Collaborator (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Contract</font><font style="font-family:inherit;font-size:12pt;">&#8221;): (i) Collaborator or Incyte shall bear all costs and expenses associated with the conduct of any Collaborator Combination Studies (other than any Funded Collaborator Combination Studies); (ii) Collaborator shall not have any input or decision-making authority with respect to any governance matters related to the Licensed Compound or any Licensed Products under this Agreement; (iii) Collaborator shall provide to Incyte all data Controlled by Collaborator, derived from the conduct of any Collaborator Combination Studies as set forth in Section 5.2(b); (iv) irrespective of inventorship, Collaborator and Incyte shall jointly own any Invention that relates specifically to the Licensed Compound or any Licensed Product and results from the conduct of any Collaborator Combination Studies, together with any intellectual property rights therein (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Development IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and, to the extent necessary to effectuate the foregoing, each of Incyte and the Collaborator, on behalf of itself and its Affiliates, shall agree to assign, and shall hereby assign, to the other party an undivided joint ownership interest in and to the Collaborator Development IP. Each party shall have the right to practice, Exploit and license, and assign or transfer its rights in, any Collaborator Development IP without a duty of accounting to the other party, and each party, on behalf of itself and its Affiliates, shall hereby waive any right it or its Affiliates may have under Applicable Laws of any jurisdiction to require any such approval or accounting; (v) Collaborator shall be subject to oversight and review and/or approval rights by Incyte with respect to the Development of Collaborator Combination Regimens, in each case, that are no less stringent than the oversight and, review and/or approval rights applicable to the Development of MacroGenics Combination Regimens under this Agreement; and (vi) Incyte shall require that each Collaborator Contract be assignable upon </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">34</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">termination of this Agreement at least in those instances where assignment is required pursuant to Section 12.8. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics shall have the right, in its sole discretion, to grant sublicenses of any of the rights granted to MacroGenics under Section 3.4 solely in accordance with Section 3.3(b) and subject to the remainder of this subsection (c). Each sublicense shall refer to and be subordinate to this Agreement and, except to the extent the Parties may otherwise agree in writing, any sublicense must be consistent in all material respects with the terms and conditions of this Agreement. MacroGenics shall remain fully responsible for the performance of its obligations under this Agreement and the performance of its sublicensees hereunder. MacroGenics shall provide to Incyte copies of all such sublicenses to Third Parties within [**] after the execution date of each sublicense; provided that MacroGenics shall have the right to redact commercially sensitive information from such copies. Information regarding the scope of the license grants, territory or term of each such sublicense shall not be considered commercially sensitive. MacroGenics shall not have the right, and shall not, without the prior written approval of Incyte ([**]) (which approval shall not be unreasonably withheld, conditioned or delayed), grant any sublicenses or allow any Third Party to exercise on behalf of MacroGenics any of the rights to be sublicensed to MacroGenics hereunder with respect to the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or [**]. </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Promptly after the Effective Date, the Parties will meet to discuss and agree upon the conditions under which MacroGenics may, without the need to obtain Incyte&#8217;s prior written approval,</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">grant sublicenses or otherwise allow Third Parties to exercise on behalf of MacroGenics any of the rights to be sublicensed to MacroGenics hereunder with respect to the [**] (the &#8220;[**]</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Conditions</font><font style="font-family:inherit;font-size:12pt;">&#8221;) or [**] (the &#8220;[**]</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Conditions</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided that, each of the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Conditions and the [**] Conditions shall not be [**] required under the [**]. (i) Promptly after execution of the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">as described in Section [**], Incyte shall provide a [**] of the [**] which Incyte [**] to MacroGenics, reasonably sufficient to [**] the [**]. Within [**] following MacroGenics&#8217; receipt of such [**], MacroGenics shall notify Incyte whether MacroGenics [**] to [**] under the [**] and/or the right to [**] or [**] under the [**] (the &#8220;[**]&#8221;). MacroGenics may [**] the [**] on a [**], subject to [**] Conditions or the prior written agreement of Incyte in each instance.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;(ii) </font><font style="font-family:inherit;font-size:12pt;">Promptly after execution of each [**] between Incyte and [**] as described in [**], Incyte shall provide a [**] of the [**] under which Incyte [**] to MacroGenics, reasonably sufficient to confirm the [**]. Within [**] following MacroGenics&#8217; receipt of such redacted [**], MacroGenics shall notify Incyte whether MacroGenics [**] under the [**] and/or the [**] or [**] under the [**] (the &#8220;[**]&#8221;). MacroGenics may [**] the [**] on a [**], subject to satisfaction of the [**] Conditions or the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of Incyte in each instance.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Retained Rights</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">General</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">35</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Retained Exclusive Rights</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary herein, MacroGenics shall retain the exclusive right: (A) to conduct or have conducted (by Third Party subcontractors or licensees in accordance with Section 1.94, as applicable) the MacroGenics Combination Studies; and (B) subject to Section 3.1(a), to Exploit any MacroGenics Pipeline Asset, including as a component of a MacroGenics Combination Regimen.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Other Retained Rights</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall retain, subject to the terms and conditions of this Agreement: (A) the co-exclusive (with Incyte) right to conduct or have conducted (by Third Party contractors, licensees or other research or Development Partners, as applicable) preclinical and nonclinical studies with the Licensed Compound and Licensed Product solely for research and development purposes; (B) the non-exclusive right to conduct or have conducted (by Third Party contractors, licensees in accordance with Section 1.94 or other research or Development Partners, as applicable) the Ongoing Clinical Study prior to completion of the Study Transition in accordance with the Study Transition Plan; and (C) the non-exclusive, non-transferable right to (x) Manufacture the Licensed Compound Bulk Drug Substance and (y) Manufacture or have Manufactured the Licensed Compound Drug Product. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sublicensing Rights</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall have the right to grant licenses or sublicenses (as applicable) of the rights retained by or granted to MacroGenics under Sections 3.3 and 3.4, subject only to the following (and, as applicable, Section 3.2(c)). In the case of Section 3.3(a)(i)(A), such license or sublicense (as applicable) shall be solely to those Third Parties referenced in 3.3(a)(i)(A), and shall be solely for the purposes of either (i) Developing a MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen or (ii) Commercializing a MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen in accordance with its approved label (but, for clarity, the retained rights and such licenses or sublicenses shall not include the right to Develop or Commercialize the Licensed Compound or any Monotherapy Regimen, Incyte Pipeline Asset or Collaborator Pipeline Asset). In the case of Section 3.3(a)(ii)(C)(x), individual elements of the Manufacturing Process may be performed by Third Parties on behalf of MacroGenics, provided that MacroGenics shall in any case continue to conduct the majority of Manufacturing-related activities in connection with the Manufacture of the Licensed Compound Bulk Drug Substance, and MacroGenics shall not engage in any Manufacturing Process technology transfer with any such Third Parties other than with respect to the specific Manufacturing Process to be conducted by such Third Parties and only to the extent reasonably required for such Third Parties to perform such Manufacturing Process</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary herein, MacroGenics shall not have any right to, and shall not, (i) Exploit any Combination Product, or (ii) sell, have sold, or distribute Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product other than (x) for use in those activities described in Section 3.3(a), or (y) </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">36</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">to Incyte for use in the Development activities or the Manufacture of the Licensed Product. Furthermore, notwithstanding anything to the contrary herein, MacroGenics shall not have any right to, and shall not, directly or indirectly, conduct or perform, nor contract with any Third Party to conduct or perform (A) any Clinical Study of an Incyte Combination Regimen or any Collaborator Combination Regimen, nor (B) any other Clinical Study that includes the Licensed Compound and any other specific molecule or molecules (as monotherapies or combinations) other than a MacroGenics Combination Study (or a Monotherapy Study pursuant to Section 5.9(c)). In the event that MacroGenics enters into any collaboration or analogous relationship with respect to the Licensed Compound involving a Third Party collaborator who owns or Controls an Ancillary Therapy that is being studied in connection with a MacroGenics Combination Regimen, (x) MacroGenics shall provide to Incyte all data Controlled by MacroGenics derived from any arm of the Clinical Study that solely comprises both the Licensed Compound and the Ancillary Therapy, and (y) MacroGenics shall grant and hereby grants to Incyte a non-exclusive, irrevocable, perpetual, transferable, fully paid-up, royalty-free, sublicenseable license under any Information or any intellectual property Controlled by MacroGenics arising out of any arm of the Clinical Study that solely comprises both the Licensed Compound and the Ancillary Therapy for any use consistent with the license granted pursuant to Section 3.4(a), in each case (of (x) and (y)) to the extent that MacroGenics has the contractual right to extend such rights, licenses, or sublicenses to Incyte, as applicable (and MacroGenics shall use Commercially Reasonable Efforts to obtain such contractual rights from the applicable Third Party collaborator). Any such Clinical Study shall otherwise be subject to all of the requirements and limitations set forth herein with respect to MacroGenics Combination Studies (e.g., the obligations and limitations set forth in Section 4.3 and Article 5). MacroGenics shall be responsible for any failure of the Third Party collaborator to comply with the obligations set forth in Section 3.3(b) and in this Section 3.3(c).</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Freedom to Operate Licenses</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement and without limiting the license granted pursuant to Section 3.1, MacroGenics hereby grants to Incyte a non-exclusive, worldwide, fully-paid, royalty-free, non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses to the extent provided in Section 3.2(a) and 3.2(b), under (i) any Patents Controlled by MacroGenics or, subject to Section 15.3(d), its Affiliates as of the Effective Date or during the Term, including MacroGenics&#8217; interest in any Joint Patents that Cover the Exploitation of PD-1 Monoclonal Antibodies (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics PD-1 IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) except that such license shall not extend to any claims in any Patents Controlled by MacroGenics that Cover a (x) MacroGenics Pipeline Asset, (y) Incyte Pipeline Asset or (z) MacroGenics Combination Regimen, unless such claims are necessary for Incyte to exercise the license granted pursuant to Section 3.1; and (ii) any other Patents or Know-How Controlled by MacroGenics or, subject to Section 15.3(d), its Affiliates, as of the Effective Date or during the Term, including MacroGenics&#8217; </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">37</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">interest in any such Joint Patents that Cover or are embodied in any </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:12pt;">&#32;device or other companion diagnostic used to detect, identify and/or diagnose the presence of PD-1 or PD-L1 for the Exploitation of the Licensed Compound or Licensed Products (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics CDx IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in each case (of (i)-(ii)) to Exploit the Licensed Compound and Licensed Products in the Field in the Territory, including as a Monotherapy Regimen or a component of an Incyte Combination Regimen, Collaborator Combination Regimen or, solely to the extent permitted under Section 3.1, MacroGenics Combination Regimens (but, for clarity, not to Exploit any MacroGenics Pipeline Asset). Notwithstanding anything to the contrary herein, to the extent of any overlap between the license grants under this Section 3.4(a) and the license grant under Section 3.1, any payment obligations of Incyte in connection with the license grant under Section 3.1 shall remain unaffected and shall continue in full force and effect. For clarity, this Section 3.4(a) shall not be construed to limit the rights granted to Incyte under Section 3.1 to Exploit the Licensed Compound as a component of an Incyte Combination Regimen.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement, Incyte hereby grants to MacroGenics a non-exclusive, worldwide, fully-paid, royalty-free, non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses to the extent provided in Section 3.2(c) and Section 3.3(b), under (i) any Patents Controlled by Incyte or its Affiliates, as of the Effective Date or, subject to Section 15.3(d), during the Term, that Cover the manufacture of the Licensed Compound, including Incyte&#8217;s interest in any such Joint Patents (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte PD-1 IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) except that such license shall not extend to any claims in any Patents Controlled by Incyte that claim an Incyte Pipeline Asset or Incyte Combination Regimen, (ii) Incyte Development IP Controlled by Incyte or its Affiliates that relates specifically to the Licensed Compound (and not, for clarity, to any Combination Regimen or Pipeline Asset), including Incyte&#8217;s interest in any such Joint Patents or Joint Inventions, (iii) any other Patents or Know-How Controlled by Incyte or its Affiliates, as of the Effective Date or, subject to Section 15.3(d), during the Term, that Cover or are embodied in any </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">in vitro</font><font style="font-family:inherit;font-size:12pt;">&#32;device or other companion diagnostic used to detect, identify and/or diagnose the presence of PD-1 or PD-L1 for the Development or Commercialization of the Licensed Compound or Licensed Products, including Incyte&#8217;s interest in any such Joint Patents or Joint Inventions (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte CDx IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and (iv) any other Patents or Know-How Controlled by Incyte or its Affiliates, as of the Effective Date or, subject to Section 15.3(d), during the Term, that relate specifically to the Licensed Compound (and not, for clarity, to any Combination Regimen), including Incyte&#8217;s interest in any such Joint Patents or Joint Inventions (such Patents, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221; and such Know-How, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Know-How</font><font style="font-family:inherit;font-size:12pt;">&#8221;; collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Technology</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in each case (of (i)-(iv)) solely to Develop and Commercialize any MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen in accordance with its approved label (but, for clarity, not to Develop or Commercialize the Licensed Compound or any Monotherapy Regimen, Incyte Pipeline Asset or Collaborator Pipeline Asset). </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">38</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics shall provide to Incyte reasonable access to MacroGenics CDx IP for the purpose of Incyte&#8217;s performance of the Incyte Global Development Plan. Incyte shall provide to MacroGenics reasonable access to Incyte CDx IP for the purpose of MacroGenics&#8217; performance of the MacroGenics Global Development Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement, Incyte hereby grants to MacroGenics a non-exclusive, worldwide, fully-paid, royalty-free license, non- transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses to the extent provided in Section 3.2(c) and Section 3.3(b), to any Incyte Method Claims under any Patent Controlled by Incyte or (subject to Section 15.3(d)) its Affiliates as of the Effective Date or during the Term, as necessary to Commercialize the MacroGenics Pipeline Asset in combination with the Licensed Compound or Licensed Product in accordance with the approved label of the applicable MacroGenics Combination Regimen. As used herein, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Method Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any claim that claims the method of using the Combination of the Licensed Compound or Licensed Product with a MacroGenics Pipeline Asset for the treatment of cancer in the Territory, excluding claims: (A) for which Incyte does not have the contractual right to grant the license under this Section 3.4(d)(i); (B) that arise from an Incyte Pipeline Asset disclosed in the Incyte Global Development Plan under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-1</font><font style="font-family:inherit;font-size:12pt;">, as of the Effective Date; or (C) that read on or include as an element a Cancer Treatment Use. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">Subject to the terms and conditions of this Agreement and without limiting the license granted pursuant to Section 3.1, MacroGenics hereby grants to Incyte a non-exclusive, worldwide, fully-paid, royalty-free, non-transferable (except in accordance with Section 15.4) license, with the right to grant sublicenses to the extent provided in Section 3.2(a) and 3.2(b), to any MacroGenics Method Claims under any Patent Controlled by MacroGenics or (subject to Section 15.3(d)) its Affiliates as of the Effective Date or during the Term, as necessary to Commercialize the Licensed Compound or Licensed Product in combination with the Incyte Pipeline Asset in accordance with the approved label of the applicable Incyte Combination Regimen. As used herein, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Method Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221; shall mean any claim that claims the method of using the Combination of the Licensed Compound or Licensed Product with an Incyte Pipeline Asset for the treatment of cancer in the Territory, excluding claims: (A) for which MacroGenics does not have the contractual right to grant the license under this Section 3.4(d)(ii); (B) that arise from a MacroGenics Pipeline Asset disclosed in the MacroGenics Global Development Plan under </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2</font><font style="font-family:inherit;font-size:12pt;">, as of the Effective Date; or (C) that read on or include as an element a Cancer Treatment Use. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Implied Licenses</font><font style="font-family:inherit;font-size:12pt;">. All licenses and rights are granted only as expressly provided in this Agreement and no license or other right is or shall be created or granted under this Agreement by implication, estoppel, or otherwise. All rights not expressly granted by a Party under this Agreement are reserved by such Party and may not be used by the other Party for any purpose. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">39</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 4</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DEVELOPMENT </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Transition of Ongoing Clinical Study</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ongoing Clinical Study</font><font style="font-family:inherit;font-size:12pt;">. During the period beginning on the Effective Date and ending on the Study Transition Date, MacroGenics shall use Commercially Reasonable Efforts to: (i) perform any Development activities assigned to MacroGenics in the Study Transition Plan; and (ii) subject to subsection (d) below, conduct (or have conducted by an Affiliate or Third-Party contract research organization) the ongoing Clinical Study of the Licensed Compound and all related Development activities that are identified (together with an estimate of the costs thereof through [**]) on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">&#32;(collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ongoing Clinical Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND Transition</font><font style="font-family:inherit;font-size:12pt;">. Within [**] after the Effective Date, or such other period defined by the JDC, but in any event no later than [**] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND Transition Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;), MacroGenics shall transfer to Incyte, and Incyte shall cooperate in good faith to support MacroGenics&#8217; transfer of, all INDs for the Licensed Compound (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MGA012 IND</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in accordance with a transition plan to be approved by the JDC promptly after the Effective Date (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transition</font><font style="font-family:inherit;font-size:12pt;">&#8221;; such transition plan, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IND</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transition Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Each Party shall bear all costs and expenses incurred by such Party in connection with the IND Transition. Upon the completion of the IND Transition, Incyte shall be solely responsible, at its sole cost and expense, for all filings, reports and communications with all Regulatory Authorities, with respect to the Licensed Products. Upon completion of the IND Transition, MacroGenics shall, and hereby does, assign to Incyte all such Regulatory Documentation and shall take all steps reasonably necessary to effectuate the assignment of all INDs, Regulatory Approval Applications and Regulatory Approvals included in such Regulatory Documentation to Incyte.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Transition</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics and Incyte shall jointly cooperate to complete the transfer to Incyte of the Ongoing Clinical Study, in accordance with a transition plan and budget to be approved by the JDC (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Transition</font><font style="font-family:inherit;font-size:12pt;">&#8221;; such transition plan, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Transition Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;), but in any event to be completed no later than [**] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Study Transition Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided that, MacroGenics may transfer certain responsibilities with respect to the Ongoing Clinical Study prior to the Study Transition Date, as determined by the JDC and set forth in the Study Transition Plan. At all times during the Term, Incyte shall cooperate in good faith to support MacroGenics&#8217; transfer of the Ongoing Clinical Study to Incyte. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">40</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Decision-Making; Costs</font><font style="font-family:inherit;font-size:12pt;">. At all times during the Term, whether prior to or after the IND Transition Date or the Study Transition Date: (i) Incyte shall have final decision-making authority with respect to matters related to the Ongoing Clinical Study (which Incyte shall exercise in good faith); and (ii) Incyte shall bear any and all FTE Costs and Third Party Expenses incurred by MacroGenics following the Effective Date directly related to the Ongoing Clinical Study in accordance with the Study Transition Plan, other than any costs specifically related and allocable to any MacroGenics Combination Regimen. Incyte shall reimburse MacroGenics within [**] after receipt of any undisputed invoice from MacroGenics setting forth such costs. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Incyte Development Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">General</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Following the Study Transition Date, subject to Sections 2.2, 3.3, and 4.1, Incyte shall, at its sole cost and expense, be solely responsible for and have sole authority over: (a) the Development of the Monotherapy Regimen in the Field in the Territory (other than pursuant to Section 5.9(c)); and (b) the Development of Incyte Combination Regimens and Collaborator Combination Regimens in the Field in the Territory, and will retain final decision-making authority with respect to each of the foregoing. Notwithstanding the foregoing, MacroGenics will continue to perform Manufacturing Development work as determined by the JMC with respect to the Licensed Compound following the Study Transition Date, and with respect to any such Manufacturing Development that relates [**] to the Licensed Compound, Incyte shall pay any and all such costs to the extent required pursuant to subsection (ii) below, and will retain final decision-making authority with respect to such Manufacturing Development. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte shall bear any and all costs and expenses incurred in connection with: (a) any Development activities that relate to the Monotherapy Regimen (other than any costs and expenses associated (i) with any monotherapy arms that are included in any MacroGenics Combination Study or (ii) Monotherapy Studies conducted pursuant to Section 5.9(c)) or any Incyte Combination Regimens and Collaborator Combination Regimens, including the Development activities set forth in this Section 4.2; and (b) any Development activities that are needed to pursue Regulatory Approval of the Monotherapy Regimen (other than pursuant to Section 5.9(c)) or any Incyte Combination Regimens. For clarity, except as set forth in Section 4.1 and in clause (i) above, (x) MacroGenics shall have no obligation to perform any Development activities that relate to the Monotherapy Regimen or any Incyte Combination Regimens and Collaborator Combination Regimens and (y) Incyte shall not be responsible for, and MacroGenics shall bear, any and all costs and expenses related to the conduct of (A) any MacroGenics Combination Studies or (B) other Development activities expressly required </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">41</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">to be conducted by MacroGenics with respect to the Licensed Compound for which the Agreement does not specify that Incyte shall reimburse MacroGenics for such Development expenses.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Study Registries</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall be responsible, in accordance with Applicable Law, for registering in the appropriate clinical trial registry and posting the results of all Clinical Studies of the Monotherapy Regimen (other than pursuant to Section 5.9(c)) and Incyte Combination Regimens in the Field in the Territory. With respect to Clinical Studies of Collaborator Combination Regimens in the Field in the Territory, either Incyte or Collaborator shall be responsible (as set forth in the applicable Collaborator Contract), in accordance with Applicable Law, for registering in the appropriate clinical trial registry and posting the results of such Clinical Studies. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Documentation</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records, accounts, notes, reports and data with respect to Development activities conducted by Incyte pursuant to this Agreement (including the Incyte Global Development Plan) in good scientific manner and in conformity with Applicable Law and Incyte&#8217;s standard practices, provided that, in no case shall such records be maintained for less than [**] following the Calendar Year to which such records pertain (or any longer period required by Applicable Law). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Progress Reports</font><font style="font-family:inherit;font-size:12pt;">. No later than [**] and [**] of each Calendar Year, Incyte shall provide to MacroGenics in writing (PowerPoint presentations are acceptable) a report summarizing Incyte&#8217;s efforts and progress during the [**] prior to such date, as applicable, to Develop and seek Regulatory Approval of the Licensed Compound and any Licensed Products. Each such report shall describe, among other matters: (a) material Development activities completed since the last report, including the object and parameters of the Development, when initiated and when completed; (b) a summary of all material results of any Monotherapy Studies or Monotherapy Regimens; (c) material Development activities planned to be undertaken before the next report, including the type and object of any Clinical Studies to be conducted and their projected starting and completion dates; (d) a summary of all material updates or developments with respect to the Manufacturing Process since the date of the last report; and (e) material changes in Incyte&#8217;s Development plans; provided, however, that (i) Incyte shall not be required to include in such reports any (A) information relating solely to the Incyte Pipeline Assets or (B) other confidential information related to the Incyte Pipeline Assets or Incyte Combination Regimens, in each case as reasonably determined by Incyte in its sole discretion; (ii) Incyte shall not be required to provide such a report for any Calendar Quarter in which it provided an update to the Incyte Global Development Plan pursuant to Section 4.4(a); and (iii) Incyte shall not be required to provide such a report for any Calendar Quarter in which it provided materially similar information to any Joint Committee.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">In addition, Incyte shall promptly respond to reasonable requests by MacroGenics for </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">42</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">information regarding Incyte&#8217;s Development and Commercialization activities for the Licensed Compound and Licensed Products, to the extent such information is necessary to assess Incyte&#8217;s compliance with its obligations hereunder. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Performance</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to the performance of any Incyte Combination Study or Collaborator Combination Study hereunder, Incyte shall (and shall require that Collaborator shall, with respect to any Collaborator Combination Studies): (a) perform the Combination Study in accordance with this Agreement and all Applicable Law, including GCP; (b) obtain all approvals and clearances necessary to conduct each Combination Study, including obtaining customs clearances and approvals from Regulatory Authorities, institutional review boards and ethics committees; (c) ensure that all consents required under Applicable Law in connection with such Combination Study have been obtained prior to commencing any Combination Study; and (d) not employ or subcontract with any Person or Third Party that has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and promptly remove any such Person or Third Party from performing any activities related to any Combination Study. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte shall require that Collaborators shall perform all Collaborator Combination Studies in accordance with the applicable Collaborator Contract and all applicable terms and conditions of this Agreement. For the avoidance of doubt, Incyte, as the Controlling Party, shall be responsible for the failure of a Collaborator to fulfill any obligation owed to MacroGenics pursuant to this Agreement in connection with any Collaborator Combination Studies, Collaborator Pipeline Assets or any Collaborator Combination Regimen, including any regulatory or other requirements related thereto, irrespective of which party performs the relevant obligation or to whom the relevant obligation is addressed.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Diligence</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall use Commercially Reasonable Efforts to: (i) complete the Ongoing Clinical Study as described in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit E</font><font style="font-family:inherit;font-size:12pt;">, subject to amendments to the protocol therefor and to corresponding portions of the Incyte Global Development Plan by Incyte in the exercise of its reasonable business judgment and (ii) Develop the Monotherapy Regimen and one (1) or more Incyte Combination Regimens.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">MacroGenics Development Responsibilities</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">General</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall, at its sole cost and expense, have the sole right to conduct, or have conducted, MacroGenics Combination Studies and shall retain final decision-making authority with respect thereto, subject to the remainder of this Section 4.3. Notwithstanding anything to the contrary in this Section 4.3, the protocol synopses for the MacroGenics Combination Studies in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2</font><font style="font-family:inherit;font-size:12pt;">&#32;have been </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">43</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">reviewed and pre-approved by Incyte prior to the Execution Date. Accordingly, Incyte will not have any further right to review, approve or object to the design or conduct of any such studies, unless the components outlined in the protocol synopsis reviewed by Incyte are materially different from the corresponding components in the protocol prior to its first submission to a Regulatory Authority, in which case Incyte shall be given a subsequent opportunity and right to review, comment on and object to the updated protocol synopsis before such submission. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Studies</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For a period of [**] following the Effective Date, MacroGenics shall provide to Incyte, through the JDC, a protocol synopsis (in a consistent format as included in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit B-2</font><font style="font-family:inherit;font-size:12pt;">) for each MacroGenics Combination Study (but for clarity, excluding any Phase IV Studies) proposed to be conducted by or on behalf of MacroGenics (which synopsis may be redacted by MacroGenics with respect to any MacroGenics Pipeline Asset Information), and: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(1) </font></div></td><td style="vertical-align:top;padding-left:192px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-192px;"><font style="font-family:inherit;font-size:12pt;">Without limiting Section 4.3(c), Incyte shall have the right to object to the design or conduct of such MacroGenics Combination Study in the event that Incyte [**] that [**] could [**] to its [**] ([**], a &#8220;[**]&#8221;; an objection pursuant to this Section 4.3(b)(i)(1), an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte </font><font style="font-family:inherit;font-size:12pt;">[**]</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;Objection</font><font style="font-family:inherit;font-size:12pt;">&#8221;), provided that, any such Incyte [**] Objection: (A) specifically identifies, in reasonable detail, the potential [**] such proposed MacroGenics Combination Study may pose; and (B) is provided in writing to MacroGenics within [**] following the provision of the protocol synopsis to the JDC. MacroGenics may proceed with any such MacroGenics Combination Study in the event that Incyte does not provide written notice of an Incyte [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Objection within such [**] period, unless the components outlined in the protocol synopsis reviewed by Incyte are materially different from the corresponding components in the full protocol prior to its first submission to a Regulatory Authority, in which case Incyte shall be given a subsequent opportunity and right to review and comment on an updated protocol synopsis within [**] of receipt of such updated protocol synopsis.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(2) </font></div></td><td style="vertical-align:top;padding-left:192px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-192px;"><font style="font-family:inherit;font-size:12pt;">In the event Incyte timely delivers notice of an Incyte [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Objection to MacroGenics: (A) the Parties shall, within [**] following the delivery of such notice, convene the JDC for the purpose of discussing the MacroGenics Combination Study, and MacroGenics shall consider in good faith any comments from Incyte related to the design and conduct of such study, with MacroGenics using Commercially Reasonable Efforts to resolve the Incyte [**] Objection, and (B) without the prior written approval of Incyte (not to be unreasonably withheld, conditioned or delayed; provided, however, that </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">44</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:192px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">withholding, conditioning or delaying such approval based on the continued existence of a [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall be deemed not unreasonable), MacroGenics shall not conduct or have conducted such MacroGenics Combination Study.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(3) </font></div></td><td style="vertical-align:top;padding-left:192px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-192px;"><font style="font-family:inherit;font-size:12pt;">In the event of any dispute relating to a matter set forth in this subsection (i), if such dispute remains unresolved after discussion through the JDC and escalation pursuant to Section 2.1(c), MacroGenics shall have final decision-making authority with respect thereto. Notwithstanding anything to the contrary herein, the time period for review of the protocol synopsis, from MacroGenics&#8217; first provision of the protocol synopsis to Incyte and any final casting vote in the JDC in the event of a dispute shall never exceed [**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(4) </font></div></td><td style="vertical-align:top;padding-left:192px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-192px;"><font style="font-family:inherit;font-size:12pt;">For a period ending on the earlier (x) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the Effective Date or (y) achievement of the first Licensed Compound Approval by either the FDA or EMA, after the first submission of any MacroGenics Combination Study protocol to a Regulatory Authority in accordance with Section 4.3(a) and Section 4.3(b), MacroGenics shall provide to Incyte an updated protocol synopsis to reflect any material amendments to the corresponding protocol as may be adopted from time to time, and Incyte shall have the right to review and comment on such amendments. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">With respect to any MacroGenics Combination Study, but without limiting the rights of Incyte pursuant to Section 4.3(c) with respect to Clinical Studies including a MacroGenics PD-1 Control Arm, MacroGenics shall employ a dosage or schedule of the Licensed Compound that (A) is consistent with a dosage or schedule of the Licensed Compound that has been previously tested in a Phase II Study or Phase III Study, (B) is consistent with a dosage or schedule previously recommended or required by a Regulatory Authority, or (C) has not been previously tested in any Clinical Study and is reasonably expected by the JDC not to pose any [**]. In the event of any dispute relating to a matter set forth in this subsection (ii), if such dispute remains unresolved after discussion through the JDC and escalation pursuant to Section 2.1(c), MacroGenics shall have final decision-making authority with respect thereto; provided that, the time period from the start of such dispute to its resolution shall never exceed [**]. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Studies that Include a MacroGenics PD-1 Control Arm</font><font style="font-family:inherit;font-size:12pt;">. Without limiting Incyte&#8217;s rights under Section 4.3(b), commencing on the Effective Date and lasting until achievement of the Licensed Compound Approval by either the FDA or EMA, MacroGenics shall provide to Incyte, through the JDC, (i) a copy of the detailed full protocol of each Clinical Study that includes a MacroGenics PD-1 Control Arm planned to be conducted by or on behalf of </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">45</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">MacroGenics (which protocol may be redacted by MacroGenics with respect to any MacroGenics Pipeline Asset Information), and (ii) a written statement explaining why such Clinical Study design is likely to be required or recommended by a Core Regulatory Authority in order to achieve Regulatory Approval of the applicable MacroGenics Combination Regimen:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte shall have the right to reasonably object to the conduct of such Clinical Study that includes a MacroGenics PD-1 Control Arm, in the event that Incyte provides notice of such objection in writing to MacroGenics within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the provision of the detailed full protocol to the JDC (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Objection</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Subject to the provisions of Section 4.3(b), MacroGenics may proceed with any such study in the event that Incyte does not provide written notice of an Incyte Objection within such [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">period.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event Incyte timely delivers notice of an Incyte Objection to MacroGenics, the Parties shall, within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the delivery of such notice, convene the JDC for the purpose of discussing the basis of the Incyte Objection. To the extent applicable, Incyte shall inform MacroGenics [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">that such MacroGenics PD-1 Control Arm is reasonably expected to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the [**] of the Licensed Compound (a &#8220;[**]&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If MacroGenics reasonably believes that the completion of the proposed MacroGenics PD-1 Control Arm will be required or recommended by a Core Regulatory Authority in order to achieve Regulatory Approval of a MacroGenics Combination Regimen, MacroGenics shall notify Incyte (via the JDC), and the Parties shall discuss in good faith whether reasonable modifications to the study protocol can be made or if alternative strategies can be employed (e.g., Incyte providing necessary components of care data to MacroGenics for submission to the applicable Regulatory Authority) in order to address the Incyte Objection or in order to avoid the necessity for the MacroGenics PD-1 Control Arm. MacroGenics shall reasonably incorporate into its protocol any modifications mutually agreed upon by the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If, following the procedures described in subsections (ii) and (iii) above, MacroGenics reasonably continues to believe that the completion of the proposed MacroGenics PD-1 Control Arm will be required in order to achieve Regulatory Approval of a MacroGenics Combination Regimen, MacroGenics shall have the right to proceed with the conduct of such proposed Clinical Study. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics shall not conduct any Clinical Study that includes both the Licensed Compound and an anti-PD-1/PD-L1 Monoclonal Antibody owned or Controlled by MacroGenics (or any Acquirer of MacroGenics or its or their Affiliates), and MacroGenics shall not enable any Third Party to conduct any such study.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">46</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Study Registries</font><font style="font-family:inherit;font-size:12pt;">. For all Clinical Studies of MacroGenics Combination Regimens in the Field in the Territory, MacroGenics shall be responsible, in accordance with Applicable Law, for registering in and maintaining the appropriate clinical trial registry and posting the results of such Clinical Studies. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Documentation</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall prepare and maintain, or shall cause to be prepared and maintained, complete and accurate written records, accounts, notes, reports, data and all related documentation pertaining to each MacroGenics Combination Study in good scientific manner and in compliance with Applicable Law and MacroGenics&#8217; standard practices; provided that in no case shall such records be maintained for less than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the Calendar Year to which such records pertain (or any longer period required by Applicable Law). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Progress Reports</font><font style="font-family:inherit;font-size:12pt;">. No later than [**] and [**] of each Calendar Year, MacroGenics shall provide to Incyte in writing a report (PowerPoint presentations are acceptable) detailing MacroGenics&#8217; efforts and progress during the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior to such date, as applicable, to Develop and seek Regulatory Approval of any MacroGenics Combination Regimen and to conduct other research and Development activities with respect to the Licensed Compound pursuant to Section 3.3(a). Each such report shall describe, among other matters: (i) material Development activities completed since the last report, including the object and parameters of the Development, when initiated, when completed and, for a period of [**] following the Effective Date, a summary of all material results (provided, however, that MacroGenics shall not be required to include in such summary of material results any MacroGenics Pipeline Asset Information, as reasonably determined by MacroGenics in its sole discretion); (ii) material Development activities planned to be undertaken before the next report, including the type and object of any MacroGenics Combination Studies to be conducted and their projected starting and completion dates; (iii) a summary of all material updates or developments with respect to the Manufacturing Process since the date of the last report; and (iv) material changes in MacroGenics&#8217; Development plans; provided however, that (x) MacroGenics shall not be required to provide such a report for any Calendar Quarter in which it provided an update to the MacroGenics Global Development Plan pursuant to Section 4.4(b); and (y) MacroGenics shall not be required to provide such a report for any Calendar Quarter in which it provided materially similar information to any Joint Committee. In addition, MacroGenics shall promptly respond to reasonable requests by Incyte for information regarding MacroGenics&#8217; Development activities for the MacroGenics Combination Regimen, to the extent such information is necessary to assess MacroGenics&#8217; compliance with its obligations hereunder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Performance</font><font style="font-family:inherit;font-size:12pt;">. With respect to the performance of any MacroGenics Combination Study, MacroGenics shall: (i) perform the Combination Study in accordance with this Agreement, the applicable protocol and all Applicable Law, including GCP; (ii) obtain all approvals and clearances necessary to conduct each Combination Study, including obtaining customs clearances and approvals from Regulatory Authorities, </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">47</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">institutional review boards and ethics committees; (iii) ensure that all consents required under Applicable Law in connection with such Combination Study have been obtained prior to commencing any Combination Study; and (iv) not employ or subcontract with any Person or Third Party that has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and promptly remove any such Person or Third Party from performing any activities related to any Combination Study.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Global Development Plans</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Global Development Plan</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The Incyte Global Development Plan shall include, among other things: (i) material Development activities reasonably anticipated to be undertaken by Incyte to advance the Development of the Licensed Compound and any Products, including high level summaries of the design for any Clinical Study (which will specify key endpoints, projected dosing and/or scheduling for the Licensed Product, and number of patients expected to be enrolled); (ii) activities to be undertaken by Incyte to further develop the Manufacturing Process; and (iii) estimated timelines regarding the foregoing activities, including estimated timelines associated with the preparation of any material Regulatory Documentation. Incyte shall submit any updates and/or amendments to the then-current Incyte Global Development Plan to the JDC, for the JDC&#8217;s review pursuant to Section 2.2. Incyte shall update the Incyte Global Development Plan no less frequently than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">during the Term; provided that, any amended Incyte Global Development Plan shall be consistent with Incyte&#8217;s diligence obligations set forth in Section 4.2(e), 4.2(f) and 6.1(d). In addition to the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">update of the Incyte Global Development Plan, the JDC shall review any Incyte updates to the then-current Incyte Global Development Plan. Upon reasonable advance notice, at the request of the JDC, Incyte agrees to make its employees and consultants reasonably available at their respective places of employment to consult with MacroGenics on issues arising in connection with the Incyte Global Development Plan and the MacroGenics Global Development Plan. Notwithstanding anything to the contrary herein, Incyte shall have final decision-making authority on all matters related to Monotherapy Studies or Incyte Combination Studies being conducted by or on behalf of Incyte pursuant to the Incyte Global Development Plan.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Global Development Plan</font><font style="font-family:inherit;font-size:12pt;">. The MacroGenics Global Development Plan shall include, among other things: (i) all material Development activities reasonably anticipated to be undertaken by MacroGenics to advance the Development of the MacroGenics Combination Regimens, including high level summaries of (x) the design for any Clinical Study (which will specify key endpoints, projected dosing and/or scheduling for the Licensed Product, and number of patients expected to be enrolled, and (y) other research and Development activities to be conducted by MacroGenics in connection with the Licensed Compound pursuant to Section 3.3(a)); and (ii) estimated timelines regarding the foregoing activities, </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">48</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">including estimated timelines associated with the preparation of any material Regulatory Documentation. MacroGenics shall submit any updates and/or amendments to the then-current MacroGenics Global Development Plan to the JDC, for the JDC&#8217;s review and approval (to the extent required) pursuant to Section 2.2 and Section 4.3, MacroGenics shall update the MacroGenics Global Development Plan no less frequently than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">during the Term; provided that, any amended MacroGenics Global Development Plan shall be consistent with MacroGenics&#8217; obligations set forth in Section 4.1(a) and 4.3(g). In addition to the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">update of the MacroGenics Global Development Plan, the JDC shall review any MacroGenics updates to the then-current MacroGenics Global Development Plan. Upon reasonable advance notice, at the request of the JDC, MacroGenics agrees to make its employees and consultants reasonably available at their respective places of employment to consult with Incyte on issues arising in connection with the Incyte Global Development Plan and the MacroGenics Global Development Plan. Notwithstanding anything to the contrary herein, but subject to Section 4.3, MacroGenics shall have final decision-making authority on all matters related to MacroGenics Combination Studies being conducted by or on behalf of MacroGenics pursuant to the MacroGenics Global Development Plan. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Delegation of Development Activities</font><font style="font-family:inherit;font-size:12pt;">. Each Party may delegate the performance of any Development activities conducted in accordance with this Article 4 to any bona fide licensee in accordance with Section 3.2 or Third Party subcontractor, provided that: (a) such licensee or subcontractor has entered or shall enter into, prior to performing activities under this Agreement, an appropriate written agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) that shall require, among other things, such licensee or subcontractor to be bound by obligations of confidentiality that are no less restrictive than the obligations set forth in Article 11; (b) such Party shall oversee the performance of any delegated activities in a manner that would be reasonably expected to result in their successful and timely completion; and (c) such Party shall at all times remain responsible for the performance of such delegated activities as if such activities were performed by such Party. In addition, if Incyte is the delegating Party, Incyte shall require that any Development Agreement executed between Incyte and any of its licensees or Third Party subcontractors shall permit the assignment of such agreement, in its entirety, to MacroGenics, upon the termination of this Agreement (other than in connection with Section 12.9), without any objection rights by the applicable licensee or subcontractor. For clarity: (i) MacroGenics may have funded or supported any MacroGenics Combination Studies and related activities pursuant to this Article 4 as investigator-sponsored Clinical Studies or conducted such Clinical Studies in collaboration with any academic institution; and (ii) Incyte may have funded or supported any Monotherapy Studies, Incyte Combination Studies, or related activities pursuant to this Article 4 as investigator-sponsored Clinical Studies or conducted such Clinical Studies in collaboration with any academic institution. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">4.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance with Law; Other Requirements</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Each Party shall (and Incyte shall require that each Collaborator shall) conduct all Development activities related to any Compounds or Products, in good scientific </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">49</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">manner and in compliance in all material respects with all Applicable Law, including applicable national and international (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, ICH, GCP, GLP, and GMP) guidelines. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">With respect to the conduct of a Non-Registrational Study in or including the same Indication subtype and line of therapy (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indication Population</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for which the Licensed Compound has received Regulatory Approval in a country in which the Non-Registrational Study is being conducted, if the Non-Registrational Study [**] (each of which meets the Indication Population criteria) in the Indication Population with the Licensed Product (on an Indication Population-by-Indication Population basis across all Clinical Studies and across all such country(ies) in which Regulatory Approval has been received) (the &#8220;[**]&#8221;), then, for clinical supply of the Licensed Compound to be administered to Indication Population patients [**] of the [**] in such country(ies):</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">where MacroGenics is the Combination Sponsor, MacroGenics shall either (x) obtain such clinical supply from Incyte at [**] of Incyte&#8217;s generally-applicable transfer price for commercial supply of the Licensed Compound in the applicable countries, or (y) continue to provide such clinical supply to such Non-Registrational Study and pay to Incyte an amount that results in Incyte receiving the same consideration that Incyte would receive pursuant to clause (x) above net of Incyte&#8217;s Manufacturing Expenses for such clinical supply; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to paying MacroGenics its Manufacturing Expenses for such clinical supply under Article 7, where Incyte is the Combination Sponsor, Incyte shall pay to MacroGenics an additional amount equal to [**] of Incyte&#8217;s generally-applicable transfer price for commercial supply of the Licensed Compound in the applicable countries.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For clarity, such use of the Licensed Compound under this Section 4.6(b) shall not give rise to any Net Sales.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Where MacroGenics is the Combination Sponsor, the restrictions in Section 4.6(b) above shall not apply to any Non-Registrational Study in an Indication Population to the extent MacroGenics achieved Regulatory Approval of a MacroGenics Combination Regimen in such Indication Population before Incyte, its Affiliates, or sublicensees (including Collaborators) achieved Regulatory Approval of a Licensed Product in such Indication Population. Where Incyte is the Combination Sponsor or conducting a Monotherapy Study, the restrictions in Section 4.6(b) above shall only apply to Non-Registrational Studies in an Indication Population to the extent MacroGenics achieved Regulatory Approval of a MacroGenics Combination Regimen in such Indication Population before Incyte, its Affiliates, or sublicensees (including Collaborators) achieved Regulatory Approval of a Licensed Product in such Indication Population (and, for clarity, only when such Non-Registrational Studies otherwise meet the criteria set forth in the introductory paragraph to Section 4.6(b)).</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">50</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 5</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REGULATORY RESPONSIBILITIES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Data Sharing: Licensed Compound</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Initial Information Transfer</font><font style="font-family:inherit;font-size:12pt;">. Upon Incyte&#8217;s written request (but in no event later than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Effective Date), MacroGenics shall deliver to Incyte electronic copies (unless otherwise required by Applicable Law) of all Regulatory Documentation relating [**] to the Licensed Compound or Licensed Products that is Controlled by MacroGenics or its Affiliates, but excluding any MacroGenics Pipeline Asset Information or any Regulatory Documentation or Information relating specifically to a MacroGenics Pipeline Asset (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Transferred Documentation</font><font style="font-family:inherit;font-size:12pt;">&#8221;;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">such transfer, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Information Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided that, to the extent that, during the Term, MacroGenics or its Affiliates Control any other Information relating to the Licensed Compound or Licensed Products that is (i) solely related to the Licensed Compound or Licensed Product, (ii) necessary for Incyte to perform its obligations or exercise its rights under this Agreement, or (iii) reasonably requested by Incyte for such purpose in (i) or (ii), MacroGenics shall promptly provide such Information. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Monotherapy Data</font><font style="font-family:inherit;font-size:12pt;">. During the Term, subject to Sections 5.2, 5.3 and 5.6, Incyte shall deliver to MacroGenics electronic copies (unless otherwise required by Applicable Law) of any then-current data Controlled by Incyte relating to the Licensed Compound and derived from Development of the Monotherapy Regimen, including any applicable preclinical safety data or clinical safety data in accordance with the Pharmacovigilance Agreement (including adverse event data), biocomparability data, biomarker data, response rate and other efficacy data, mechanistic data and other activity data, as reasonably requested by MacroGenics from time to time (subject to the Pharmacovigilance Agreement or as required by Applicable Law, such requests not to be made more frequently than [**] per Calendar Quarter following the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the Effective Date). MacroGenics shall be free to use such Incyte data for any purpose consistent with the rights expressly retained by or granted to MacroGenics pursuant to Section 3.3 and the license granted pursuant to Section 3.4(b).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Monotherapy Data and Ongoing Clinical Study Data</font><font style="font-family:inherit;font-size:12pt;">. During the Term, subject to Sections 5.2, 5.3 and 5.6, MacroGenics shall deliver to Incyte electronic copies (unless otherwise required by Applicable Law) of any then-current data Controlled by MacroGenics (i) relating to any anti-PD-1 Monoclonal Antibody being evaluated as a MacroGenics PD-1 Control Arm, or (ii) relating to the Licensed Compound and arising out of or in connection with the Ongoing Clinical Study or a Required Monotherapy Study conducted by MacroGenics, including in all cases (of (i) through (ii)) any applicable preclinical safety data or clinical safety data in accordance with the Pharmacovigilance Agreement (including adverse event data), biocomparability data, biomarker data, response rate and other efficacy data, mechanistic data and other activity data, as reasonably requested by Incyte from </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">51</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">time to time (but subject to the Pharmacovigilance Agreement or as required by Applicable Law, such request not to be made more frequently than [**] per Calendar Quarter following the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the Effective Date). Incyte shall be free to use such data for any purpose consistent with the license granted pursuant to Section 3.1. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Research and Development Activities</font><font style="font-family:inherit;font-size:12pt;">. In addition, as reasonably requested by Incyte in writing from time to time, MacroGenics shall deliver to Incyte electronic copies of all other material Information related to the Licensed Compound (but excluding Information related to the MacroGenics Combination Regimen or any MacroGenics Pipeline Asset, unless such Information is necessary for Incyte to receive Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen) arising out of MacroGenics&#8217; conduct of research and Development activities with respect to the Licensed Compound pursuant to Section 3.3. Subject to the Pharmacovigilance Agreement or as required by Applicable Law, such request shall not be made more frequently than [**] per Calendar Quarter. Incyte shall be limited to use such MacroGenics data solely for purposes consistent with the license granted pursuant to Section 3.1. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Data Sharing: Combination Regimens</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after Incyte&#8217;s receipt of a written request from MacroGenics, Incyte shall provide to MacroGenics, subject to Section 5.3, copies of and other access to any then-current data Controlled by Incyte or (to the extent Incyte is able to obtain permission to grant such right and access from the Collaborator in connection with a Collaborator Combination Study, through the use of Commercially Reasonable Efforts, in the case of such data that Collaborator is not required to provide pursuant to an applicable Collaborator Contract) any Collaborator, derived from the conduct of any Incyte Combination Studies and/or Collaborator Combination Studies, that is [**] related to the Licensed Compound or Licensed Products, including applicable safety data (including adverse event data), as necessary for MacroGenics to comply with applicable regulatory requirements or requests by Regulatory Authorities for the Development of, or seeking of Regulatory Approval of, any MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen or for the Commercialization of any MacroGenics Pipeline Asset in accordance with such Regulatory Approval. If Incyte conducts a Clinical Study with respect to the Licensed Compound involving a Third Party collaborator who owns or Controls an Ancillary Therapy that is being studied in connection with an Incyte Combination Regimen, (x) Incyte shall provide to MacroGenics all data Controlled by Incyte derived from any arm of the Clinical Study that solely comprises both the Licensed Compound and the Ancillary Therapy, and (y) Incyte shall grant and hereby grants to Incyte a non-exclusive, irrevocable, perpetual, transferable, fully paid-up, royalty-free, sublicenseable license under any Information or any intellectual property arising out of any arm of the Clinical Study that solely comprises both the Licensed Compound and the Ancillary Therapy for any use consistent with the license granted pursuant to Section 3.4(b), in each case </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">52</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">(of (x) and (y)) to the extent that Incyte has the contractual right to extend such rights, licenses, or sublicenses to MacroGenics, as applicable (and Incyte shall use Commercially Reasonable Efforts to obtain such contractual rights from the applicable Third Party collaborator).</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Without limiting the generality of the foregoing, Incyte shall require that each Collaborator Contract contains terms as least as protective of Incyte as the following terms set forth in this Section 5.2(b). Promptly, but in any event within [**] after Collaborator&#8217;s receipt of a written request from Incyte, Collaborator shall provide to Incyte copies of and other access to any then-current Information Controlled by Collaborator, derived from the Development of any Collaborator Combination Studies, including any applicable preclinical safety data or clinical safety data (including adverse event data on terms generally consistent with the Pharmacovigilance Agreement), biocomparability data, biomarker data, response rate and other efficacy data, mechanistic data and activity data, as reasonably requested by Incyte from time to time, as necessary for Incyte to seek Regulatory Approval of the Licensed Compound as a component of the Collaborator Combination Regimen or Commercialize the Licensed Compound as a component of a Collaborator Combination Regimen. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within [**] after MacroGenics&#8217; receipt of a written request from Incyte, MacroGenics shall provide to Incyte, subject to Section 5.3, copies (unless otherwise required by Applicable Law) of and access to any then-current Information Controlled by MacroGenics or its Affiliates or licensees derived from the conduct of the MacroGenics Combination Studies that relates [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to the Licensed Compound or Licensed Product, including any applicable preclinical safety data or clinical safety data (including adverse event data in accordance with the Pharmacovigilance Agreement), biocomparability data, biomarker data, mechanistic data and activity data as reasonably requested by Incyte from time to time (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Licensed Compound Data</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Incyte shall be free to use such MacroGenics Licensed Compound Data for any purpose consistent with the license granted pursuant to Section 3.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At least [**] prior to the anticipated database lock of any MacroGenics Combination Study that MacroGenics intends to submit for Regulatory Approval of a MacroGenics Combination Regimen, the Parties shall initiate discussions to negotiate and finalize a mutually agreeable Regulatory Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after database lock of any such MacroGenics Combination Study, MacroGenics shall provide to Incyte, subject to Section 5.3, copies (unless otherwise required by Applicable Law) of and access to any then-current Information Controlled by MacroGenics or its Affiliates or licensees derived </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">53</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">from the conduct of such MacroGenics Combination Study that relates to the Licensed Compound, a Licensed Product or any MacroGenics Combination Regimen, which may include applicable preclinical safety data or clinical safety data (including adverse event data in accordance with the Pharmacovigilance Agreement), biocomparability data, biomarker data, mechanistic data and activity data as reasonably requested by Incyte from time to time (but excluding, in all cases, Information that is solely related to any MacroGenics Pipeline Asset unless such Information is necessary for Incyte to seek Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen in accordance with Section 5.8) to the extent such Information is necessary for Incyte to (A) comply with any request or requirement by a Regulatory Authority, (B) seek Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen and expand the Licensed Compound label to include such Regulatory Approval in accordance with Section 5.8(c) or (C) to conduct MacroGenics Combination Regimen Detailing (and excluding in all cases, the right to Commercialize any MacroGenics Pipeline Asset) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Regulatory Data</font><font style="font-family:inherit;font-size:12pt;">&#8221;). For clarity, each Party will separately submit any non-clinical and any chemistry, manufacturing and controls (CMC) information specific to its Compound directly to any Regulatory Authorities. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Data Sharing Limitations</font><font style="font-family:inherit;font-size:12pt;">. Neither Party nor its Affiliates or sublicensees (including Collaborators) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">delivering Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall have the obligation to provide to any other Party or any Collaborator (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and the receiving Party shall have no right to access, any of the delivering Party&#8217;s data that is not [**] related to the Licensed Compound or Licensed Products (unless, and to the extent, such Information is necessary for the other Party to perform its obligations or exercise its rights under this Agreement). Notwithstanding the foregoing, MacroGenics will provide all data under its Control that is necessary for Incyte to Develop and/or Commercialize the Monotherapy Regimen and seek Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen in accordance with Section 5.8. Incyte and Collaborators will each provide to MacroGenics copies of all data under Incyte&#8217;s Control related specifically and solely to the Licensed Compound that is derived from any Monotherapy Regimen as necessary for MacroGenics to Develop any MacroGenics Combination Regimen or Commercialize the MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen. Notwithstanding the foregoing, any safety data that is related to the Licensed Compound or MacroGenics Combination Regimen shall not be excluded from the data sharing obligations under Sections 5.1, 5.2 and 5.3 but rather shall be shared to the extent set forth in the Pharmacovigilance Agreement. Additionally, notwithstanding anything to the contrary herein, any data or other information disclosed by the delivering Party pursuant to Sections 5.1 or 5.2 shall, to the extent permissible: (A) be subject to reasonable redaction with respect to any information that the delivering Party deems commercially sensitive, confidential or proprietary, including any data or information relating [**] to proprietary product(s) of the delivering Party, its Affiliates or any Third Party that is not a receiving Party hereunder (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g</font><font style="font-family:inherit;font-size:12pt;">., Pipeline Assets), to the extent the same would not unreasonably limit the receiving Party&#8217;s ability (i) to interpret any Clinical Study results, and (ii) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">54</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">where Incyte is the receiving Party, to seek Regulatory Approval of the Licensed Compound as a component of the MacroGenics Combination Regimen; and (B) to the extent disclosed, constitute Confidential Information of the delivering Party (provided that, as between the Parties, any information disclosed by Collaborator shall be deemed Incyte&#8217;s Confidential Information). Notwithstanding anything to the contrary herein, each Party shall provide the other Party with any Licensed Compound &#8220;components of care&#8221; data that is owned or Controlled by such Party, as required or requested by a Regulatory Authority to support Regulatory Approval by the other Party of any Monotherapy Regimen, Incyte Combination Regimen, Collaborator Combination Regimen, or MacroGenics Combination Regimen, as applicable. Nothing contained in this Section 5.3 shall limit the obligations of either Party or a Collaborator pursuant to Sections 5.1(a), 5.2 and 5.3 as applicable, except that in all cases, the delivering Party shall have no obligation pursuant to Section 5.2 to provide any data generated pursuant to a blinded Clinical Study until such time as the applicable Clinical Study has been unblinded. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Right of Reference</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after Incyte&#8217;s receipt of a written request from MacroGenics, Incyte shall grant, and hereby grants, and shall require its sublicensees to grant, to MacroGenics and/or the applicable Regulatory Authorities, subject to Section 5.3, a cross-reference letter or similar communication to grant MacroGenics a Right of Reference to any Regulatory Documentation related specifically to the Licensed Compound or any Licensed Product,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in connection with any Monotherapy Studies, Incyte Combination Studies or Collaborator Combination Studies, as necessary for MacroGenics to comply with applicable regulatory requirements or requests by Regulatory Authorities to Develop any MacroGenics Combination Regimen, seek Regulatory Approval of a MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen or Commercialize a MacroGenics Pipeline Asset in accordance with its approved label (but, for clarity, not to Commercialize any Incyte Pipeline Asset or Collaborator Pipeline Asset). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Without limiting the generality of the foregoing, Incyte shall require that each Collaborator Contract contain the following terms set forth in this subsection (b). Promptly, but in no event later than [**], following receipt of a written request from Incyte, Collaborator shall grant, and hereby grants to Incyte and/or all applicable Regulatory Authorities, subject to Section 5.3, a cross-reference letter or similar communication to grant Incyte a Right of Reference to any Regulatory Documentation (including INDs and NDAs) related to any Collaborator Combination Studies, to enable Incyte to comply with applicable regulatory requirements or requests by Regulatory Authorities, in connection with (i) the Development or Commercialization of the Monotherapy Regimen, and (ii) seeking Regulatory Approval of the Licensed Compound as a component of a Collaborator Combination Regimen, and Commercializing the Licensed Compound or any Licensed Product in accordance with such approved label (but, for clarity, not to Commercialize any Collaborator Pipeline Asset). </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">55</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Within [**] after MacroGenics&#8217; receipt of a written request from Incyte, MacroGenics shall grant, and hereby grants, and shall require its sublicensees to grant, to Incyte and/or all applicable Regulatory Authorities, subject to Section 5.3, a cross-reference letter or similar communication to grant Incyte a Right of Reference to any Regulatory Documentation related to any MacroGenics Combination Studies, as necessary for Incyte to comply with applicable regulatory requirements or requests by Regulatory Authorities, in connection with (i) the Development or Commercialization of the Monotherapy Regimen, (ii) seeking Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen and expanding the label of the Licensed Compound to include such Regulatory Approval as a component of a MacroGenics Combination Regimen or (iii) conducting MacroGenics Combination Regimen Detailing (but, for clarity, not to otherwise Commercialize any MacroGenics Pipeline Asset). </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Regulatory Documentation; Regulatory Communications</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Communications Relating to Ongoing Clinical Study</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Prior to the IND Transition Date, MacroGenics shall notify Incyte in advance of any material communications with Regulatory Authorities, including telephone conferences or discussions, in each case with respect to the Ongoing Clinical Study, to the extent permitted by the applicable Regulatory Authority; provided that, if MacroGenics is unable to provide Incyte with prior notice of any such communication, MacroGenics shall notify Incyte as soon as practicable after the occurrence of such communication. Incyte shall have the right to participate in all such material communications with Regulatory Authorities (it being understood that Incyte shall have the sole right to lead any discussion, or portion thereof, that relates [**] to the Monotherapy Regimen) and provide comments thereto, and MacroGenics shall consider such comments in good faith prior to responding to any Regulatory Authority. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At all times during the Term after the IND Transition Date, Incyte shall be solely responsible, at its sole cost and expense, for all filings, reports and communications with all Regulatory Authorities with respect to the Ongoing Clinical Study, in its own name. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Communications Relating to Monotherapy Studies</font><font style="font-family:inherit;font-size:12pt;">. As between the Parties, at all times during the Term after the IND Transition Date, Incyte shall be solely responsible, at its sole cost and expense, for all filings, reports and communications with all Regulatory Authorities with respect to any Monotherapy Studies, in its own name, provided however, with respect to Monotherapy Studies conducted by MacroGenics pursuant to Section 5.9(c), MacroGenics shall be solely responsible for all costs and expenses associated with the applicable Monotherapy Studies, and the Parties will discuss in good faith how to handle communications </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">56</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">with Regulatory Authorities in connection therewith. Without limiting the foregoing, each Combination Sponsor shall notify Incyte in advance of any material communications with Regulatory Authorities, including telephone conferences or discussions, in each case with respect to matters related to the Monotherapy Regimen, to the extent permitted by the applicable Regulatory Authority; provided that, if Combination Sponsor is not permitted by the applicable Regulatory Authority to provide Incyte with prior notice of any such communication, Combination Sponsor shall notify Incyte as soon as practicable after the occurrence of such communication. Incyte shall have the right to participate in such material communications and provide comments thereto, which comments the Combination Sponsor shall consider in good faith prior to responding to any Regulatory Authority.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Communications Relating to MacroGenics Combination Studies</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">At all times during the Term, without limitation of any other obligations of MacroGenics under this Agreement, MacroGenics shall keep Incyte reasonably informed of any material interactions and documentation related thereto with any Core Regulatory Authority that relate [**] to the Licensed Compound. Incyte will be given a reasonable opportunity to review and to provide input with respect to all such interactions and documentation related thereto, and MacroGenics will consider such input in good faith, to the extent reasonably practicable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition to the rights described in paragraph (i) above, on a region-by-region basis, until the earlier of (x) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Effective Date, or (y) achievement of the first Licensed Compound Approval by each of the applicable Core Regulatory Authorities, Incyte shall be entitled to either participate in or provide input on, at Incyte&#8217;s choosing, any Licensed Compound Regulatory Discussions (except that, in the event of any Change of Control of Incyte, Incyte shall be permitted to participate in only those parts of any Licensed Compound Regulatory Discussions that relate [**] to the Licensed Compound, as reasonably determined by MacroGenics in its sole discretion); provided that, Incyte shall not have the right to control or influence the timing or the agenda setting of any such regulatory discussion. MacroGenics shall notify Incyte in advance of each such Licensed Compound Regulatory Discussion and shall provide any such communications to Incyte, with respect to matters related to the Licensed Compound in connection with any MacroGenics Combination Studies (except that, in the event of any Change of Control of Incyte, MacroGenics shall provide to Incyte any such communications with respect to matters [**] related to the Licensed Compound in connection with any MacroGenics Combination Studies, as reasonably determined by MacroGenics in its sole discretion), to the extent permitted by the applicable Regulatory Authority; provided that, if MacroGenics is unable to provide Incyte with prior notice of any such Licensed Compound Regulatory Discussion, MacroGenics shall </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">57</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">notify Incyte as soon as practicable after the occurrence of such Licensed Compound Regulatory Discussion. MacroGenics shall provide to Incyte copies of all material regulatory-related communications in connection with any Licensed Compound Regulatory Discussions, subject to reasonable redaction by MacroGenics with respect to any MacroGenics Pipeline Asset Information. Incyte shall have the right to lead, in coordination with MacroGenics, any such discussion, or portion thereof, that relates [**] to the Licensed Compound as a monotherapy arm or as a component of a MacroGenics Combination Regimen, as reasonably determined by MacroGenics in its sole discretion, and provide comments thereto. MacroGenics shall consider such comments in good faith prior to responding to the applicable Regulatory Authority; provided, however, that Incyte shall not have the right to participate in any portion of any Licensed Compound Regulatory Discussion where any MacroGenics Pipeline Asset Information is discussed. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Documentation and Communications Relating to Combination Studies</font><font style="font-family:inherit;font-size:12pt;">. Without limitation of subsection (c) (in connection with MacroGenics Combination Studies), Combination Sponsor shall be solely responsible, at its sole cost and expense, for all filings, reports and communications with all Regulatory Authorities (including any INDs) with respect to its Pipeline Asset (including as a component of a Combination Regimen), as applicable, in its own name. Combination Sponsor shall sponsor its respective Combination Study under its existing IND for its Pipeline Asset or a separate IND for the Combination Regimen, with a Right of Reference to the IND of the Licensed Compound or Licensed Product solely if required by a Regulatory Authority and only as it relates specifically to the Licensed Compound or Licensed Product. Combination Sponsor shall be responsible for (i)&#160;drafting, and updating as necessary for its respective Combination Study, an investigator&#8217;s brochure for its Pipeline Asset and (ii)&#160;preparing, obtaining and maintaining, as applicable, all necessary Regulatory Documentation to its existing IND for its Pipeline Asset (including as a component of a Combination Regimen), including submitting to such IND any serious adverse event and adverse drug reaction cases emerging from its Combination Study, as applicable. Where Incyte is not the Combination Sponsor, Incyte shall have the right to provide boilerplate language that relates specifically to the Licensed Compound, and MacroGenics will reasonably include such language in its applicable Regulatory Documentation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Documentation and Communications Relating to Manufacturing Development</font><font style="font-family:inherit;font-size:12pt;">. Prior to the IND Transition Date,</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">MacroGenics shall be solely responsible for all filings and reports, and shall lead any discussions between the Parties, related to Manufacturing Development of the Licensed Compound. Following the IND Transition Date, both Incyte and MacroGenics shall prepare, and Incyte shall be solely responsible for making, all filings and reports, and shall lead any discussion between the Parties, related to Manufacturing Development for any Clinical Studies (including any Pivotal Studies) and commercial supply. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">58</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Adverse Event Reporting and Safety Data Exchange</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. On and after the IND Transition Date, Incyte shall assume sole responsibility, at its sole expense, for monitoring all clinical experiences, maintaining the Global Safety Database, safety monitoring, pharmacovigilance surveillance, compliance and filing all required safety reports, including annual safety reports, to all applicable Regulatory Authorities with respect to the Development or Commercialization of the Licensed Compound and any Licensed Products in the Field in the Territory, and shall be responsible for compliance with all Applicable Law pertaining to safety reporting and all other safety-related matters, including its responsibilities under the Pharmacovigilance Agreement, with respect to the Licensed Compound and Licensed Products. Incyte shall provide MacroGenics with, and MacroGenics shall have the right to access, any safety Information related to the Licensed Compound or any Licensed Products for which Incyte is responsible pursuant to this subsection (a), pursuant to the terms of the Pharmacovigilance Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Combination Sponsor Responsibilities</font><font style="font-family:inherit;font-size:12pt;">. Subject to subsection (a) above, each Combination Sponsor shall (and with respect to any Collaborator as the Combination Sponsor, Incyte shall require that Collaborator shall) be solely responsible for monitoring all clinical experiences, maintaining the global safety database, safety monitoring, pharmacovigilance surveillance, compliance and filing all required safety reports, including annual safety reports, to all applicable Regulatory Authorities with respect to the Development or Commercialization of its Pipeline Asset in the Territory (including as a component of a Combination Regimen), and shall be responsible for compliance with all Applicable Law pertaining to safety reporting and all other safety-related matters, including its responsibilities under the Pharmacovigilance Agreement, with respect to its Pipeline Asset, including as a component of a Combination Regimen. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Safety Information Exchange; Pharmacovigilance Agreement</font><font style="font-family:inherit;font-size:12pt;">. The Parties will initiate negotiations and use Commercially Reasonable Efforts to execute a pharmacovigilance agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pharmacovigilance Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) within [**] after the Effective Date. The executed Pharmacovigilance Agreement shall be in an appropriate format to enable the Parties to fulfill local and international regulatory reporting obligations and to facilitate appropriate safety reviews. The Pharmacovigilance Agreement will include safety data exchange procedures governing the coordination of collection, monitoring, investigation, reporting, and exchange of information, consistent with Applicable Law. Such guidelines and procedures shall be in accordance with, and enable the Parties and their Affiliates to fulfill, local and international regulatory reporting obligations to Governmental Authorities. Among other things, the Pharmacovigilance Agreement shall require MacroGenics and any Collaborators to submit safety data concerning any adverse experiences and any other safety information arising from or related to the use of the Licensed Compound as a single agent or as a component of any Combination </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">59</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Regimen in any MacroGenics Combination Study or Collaborator Combination Study, as applicable, as necessary for Incyte to maintain the Global Safety Database. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Recalls and Voluntary Withdrawals</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Product</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall use reasonable efforts to notify MacroGenics promptly, but in no event later than [**], following its determination that any event, incident, or circumstance related to safety issues or regulatory concerns has occurred that is reasonably likely to result in the need for a recall, market suspension or market withdrawal of the Licensed Compound or any Licensed Product in the Territory, provided that, prior to the implementation of such a recall, market suspension or market withdrawal, Incyte shall, to the extent practical, consult with MacroGenics and shall consider MacroGenics&#8217; comments in good faith, and shall include in such notice the reasoning behind such determination and any supporting facts. Incyte shall have the sole right to make the final determination of whether to voluntarily implement any such recall, market suspension or market withdrawal in the Territory. For all recalls, market suspensions or market withdrawals undertaken pursuant to this subsection (a), Incyte shall be solely responsible for the execution thereof, and MacroGenics shall reasonably cooperate in all such recall efforts. Subject to the provisions of Section 14.2 and except as may otherwise be set forth in the Clinical Supply Agreement or the Commercial Supply Agreement, Incyte shall be responsible for all costs of conducting any such recall, market suspension, or market withdrawal of the Licensed Product. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pipeline Asset</font><font style="font-family:inherit;font-size:12pt;">. The Controlling Party shall use reasonable efforts to notify the other Party promptly, but in no event later than [**], following its determination that any event, incident, or circumstance related to safety issues or regulatory concerns has occurred that may result in the need for a recall, market suspension or market withdrawal of its Pipeline Asset, in whole or in part, in the Territory, and shall include in such notice the reasoning behind such determination, and any supporting facts. The Controlling Party shall have sole authority to decide whether to implement any recall, market suspension or market withdrawal of its Pipeline Asset, and shall be solely responsible for, and control, the execution thereof. The non-recalling Party shall reasonably cooperate in all such efforts to implement a recall, market suspension or market withdrawal of the Controlling Party&#8217;s Pipeline Asset. The Controlling Party shall be responsible for all costs of any such recall, market suspension, or market withdrawal of its respective Pipeline Asset. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Labeling</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">If, at the time of submission of the Regulatory Approval Application for a MacroGenics Combination Regimen, there is no Monotherapy Regimen, Incyte Combination Regimen or Collaborator Combination Regimen that has received Regulatory Approval, Incyte shall use Commercially Reasonable Efforts to, contemporaneously and in coordination with MacroGenics, seek Regulatory Approval of a label for such Licensed Compound as a component of a MacroGenics </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">60</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Combination Regimen that, if such Licensed Compound label is approved, will sufficiently enable Commercialization by MacroGenics of the applicable MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen and Commercialization by Incyte of the Licensed Compound as a component of a MacroGenics Combination Regimen (provided that, Incyte shall have no right to conduct any Medical Affairs Activities or activities directed to marketing, detailing, promoting, educating or any Phase IV Studies with respect to the Licensed Compound as a component of a MacroGenics Combination Regimen other than MacroGenics Combination Regimen Detailing).</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">For each Regulatory Approval of a MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen, MacroGenics shall have the right to determine in its sole discretion, whether to include the Regulatory Approval for the MacroGenics Combination Regimen in its label for the applicable MacroGenics Pipeline Asset included in such MacroGenics Combination Regimen. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Without limiting Incyte&#8217;s obligations under Section 5.8(a), Incyte may, at its discretion, reference all Regulatory Documentation and other Information submitted by MacroGenics to the applicable Regulatory Authority as required by Incyte for the purposes of (i) seeking Regulatory Approval of the Licensed Compound as a component of a MacroGenics Combination Regimen and expanding the label of the Licensed Compound to include such Regulatory Approval as a component of a MacroGenics Combination Regimen or (ii) exercising its rights under Section 3.1(c). Notwithstanding anything to the contrary herein, the rights granted to Incyte in this Section 5.8(c) to include in the label for the Licensed Compound newly-generated Regulatory Documentation and other Information submitted by MacroGenics to the applicable Regulatory Authority shall immediately terminate on a going-forward basis (but, for clarity, the right of Incyte to continue to exercise its rights under Section 3.1(c) shall continue) upon the following: (A) after any Change of Control of Incyte, except that the right of Incyte to include in the label for the Licensed Compound newly-generated Regulatory Documentation and other Information submitted by MacroGenics to the applicable Regulatory Authority shall continue with respect to any Regulatory Documentation and other Information submitted by MacroGenics in connection with a Pivotal Study by MacroGenics (or an Acquirer of MacroGenics) that was Initiated prior to date upon which the Change of Control of Incyte was publicly announced; or (B) on a MacroGenics Combination Regimen-by-MacroGenics Combination Regimen basis, in the event that the then-current label of the Licensed Compound includes a Regulatory Approval for an Indication Population based on a Combination Study, other than a Combination Study conducted by MacroGenics, that is the same Indication Population for which MacroGenics seeks Regulatory Approval for the applicable MacroGenics Combination Regimen.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">61</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">5.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Other Studies</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary herein, in the event that an applicable Regulatory Authority requires or recommends, as a condition to the grant or maintenance of Regulatory Approval for a MacroGenics Combination Regimen, that a Monotherapy Study be conducted (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Required Monotherapy Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then MacroGenics shall notify Incyte in writing, and:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte shall provide reasonable assistance to MacroGenics, including provision of then-current Licensed Compound and Ancillary Therapy &#8220;components of care&#8221; data it Controls (subject to availability) and using Commercially Reasonable Efforts to continue the conduct of any then-current on-going Clinical Studies that include the Required Monotherapy Study that would provide relevant Licensed Compound and Ancillary Therapy &#8220;components of care&#8221; data it Controls, at Incyte&#8217;s sole cost and expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">In the event that Incyte does not have any Monotherapy Study on-going that includes the Required Monotherapy Study, but the then-current Incyte Global Development Plan includes such a Monotherapy Study planned to be Initiated within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">period following the date on which MacroGenics provides written notice pursuant to the first sentence in this Section 5.9, then Incyte shall use Commercially Reasonable Efforts to conduct such Monotherapy Study, and shall provide to MacroGenics relevant Licensed Compound and Ancillary Therapy &#8220;components of care&#8221; data derived from such Study and Controlled by Incyte (subject to availability) at Incyte&#8217;s sole cost and expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">In the event that Incyte does not have any Monotherapy Study on-going that includes the Required Monotherapy Study, and the then-current Incyte Global Development Plan does not contemplate the Initiation of such Monotherapy Study within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">period as described in subpart (b), then MacroGenics may design and conduct such Monotherapy Study solely to compare the Monotherapy Regimen to an Ancillary Therapy to produce the data required by the Regulatory Authority, at MacroGenics&#8217; sole cost and expense, subject to Incyte&#8217;s prior right of review and approval of such Monotherapy Study (not to be unreasonably withheld, conditioned, or delayed), and Incyte shall provide reasonable assistance and cooperation to MacroGenics in connection therewith, at MacroGenics&#8217; sole cost and expense. </font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 6</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">COMMERCIALIZATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Commercialization Activities</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Product</font><font style="font-family:inherit;font-size:12pt;">. Subject to Sections 2.5, 5.2, 5.4, 5.8, 6.1(b), 6.1(c) and 6.1(d), Incyte shall be solely responsible for and have sole authority with respect to, at its own expense, all aspects of the Commercialization of Licensed Products in the Field in the Territory, in accordance with its approved label, including as a component of a Collaborator Combination Regimen, and, subject to Section 3.1(c), as a component of a MacroGenics Combination Regimen, and will retain final decision-making </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">62</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">authority with respect thereto, including: (i) developing and executing a commercial launch and pre-launch plan; (ii) marketing, promotion, and branding; (iii) booking sales and distribution and performance of related services; (iv) handling all aspects of order processing, invoicing and collection, inventory and receivables; (v) providing customer support, including handling medical queries, and performing other related functions; (vi) the review and approval of all promotional materials for compliance with Applicable Law, including submission, where appropriate, to applicable Regulatory Authorities and (vii) conforming its practices and procedures in all material respects to Applicable Law relating to the marketing, detailing and promotion of Licensed Products in the Field in the Territory. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Pipeline Assets</font><font style="font-family:inherit;font-size:12pt;">. Subject to Sections 2.5, 6.1(a), and 6.1(c), each Combination Sponsor shall have sole authority over and control of the Commercialization of its respective Pipeline Asset in the Field in the Territory, in accordance with its approved label, and will retain final decision-making authority with respect thereto, including such activities set forth in Section 6.1(a)(i)-(vii) as applied to its Pipeline Asset.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Combination Regimens</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall have sole authority over and control of all promotional activities with respect to any MacroGenics Pipeline Asset as a component of a MacroGenics Combination Regimen in the Field in the Territory, in accordance with the MacroGenics Pipeline Asset approved label, and will retain final decision-making authority with respect thereto. In the event that a MacroGenics Pipeline Asset receives Regulatory Approval as a component of a MacroGenics Combination Regimen and is included in the Licensed Compound approved label, then without limiting Section 6.1, Incyte may conduct MacroGenics Combination Regimen Detailing with respect to the Licensed Product in accordance with Incyte&#8217;s approved label of the Licensed Product as component of a MacroGenics Combination Regimen; provided further, that to the extent Incyte elects to be involved in any additional promotional activities specific to the MacroGenics Combination Regimen, these activities shall be subject to MacroGenics&#8217; sole discretion and, if agreed by the Parties, a separate co-promotion agreement to be negotiated by the Parties (such agreement, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Co-Promotion Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Diligence</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall use Commercially Reasonable Efforts to seek Regulatory Approval for, and if the applicable Regulatory Approval is granted, Commercialize a Licensed Product in each of the U.S., [**] of the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">European Major Markets, and Japan. Incyte will, subject to MacroGenics satisfying its supply obligations hereunder to the extent necessary for Incyte to satisfy such obligation, use Commercially Reasonable Efforts to make the Licensed Product commercially available in quantities sufficient to fulfill global market demand at all times during the Term after the date of Licensed Compound Approval. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Pricing of Licensed Product</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall have sole and exclusive control over the pricing of Licensed Products on a worldwide basis and shall retain final decision-making authority with respect to obtaining and maintaining pricing and reimbursement approval, subject to Section 8.5(b) </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">63</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">and the following procedures and/or restrictions in subsections (a)-(e) below. Unless otherwise specified to the contrary, a reference price as it relates to the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">calculations shall be established using the following criteria: (1) [**] [**]; (2) for [**]; and (3) the dosage of the Licensed Product for [**]. By way of example, [**], which is calculated using the following [**]: (i) [**] [**],</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(ii) [**] [**]. To the extent permitted under Applicable Law:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">For Licensed Products sold in the U.S., Incyte shall not be permitted to [**] the [**] of the Licensed Compound [**] than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">([**]%) [**] (the &#8220;[**]&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Subsequent to receipt of Regulatory Approval for a Licensed Product [**], for a Licensed Product sold in [**] for which the Licensed Compound has received Regulatory Approval, the monthly Net Price of the Licensed Compound shall not be, on average across [**] in which the Licensed Compound has received Regulatory Approval, [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">than [**] ([**]%) [**] the [**] of [**] in which the Licensed Compound has received Regulatory Approval (the &#8220;[**]&#8221;). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">For Licensed Products sold in [**], Incyte shall not submit a Net Price to the MHLW that is [**] than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">([**]%) [**] the [**] of the [**] in [**] (the &#8220;[**]&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">For Licensed Products sold in [**], the monthly Net Price of the Licensed Compound shall not be [**] than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">([**]%) [**] the monthly [**] price of the [**] in [**] (the &#8220;[**]&#8221;).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte shall calculate any [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the Licensed Product (including any [**], [**], [**], and [**]) and any [**] of the Licensed Product (including any [**], [**], [**], and [**]) in accordance with this Section 6.2 upon launch of the Licensed Product, and shall thereafter update such [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">on an annual basis and at any time the Licensed Compound Net Price is changed in the relevant territory. Any disputes regarding such calculation(s) shall be resolved pursuant to Article 13. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">For Licensed Products sold in [**], [**], [**] or [**], Incyte shall not be restricted in setting the pricing of the Licensed Product through the use of a [**] or be required to pay royalties similar to Section 8.5(b) as if there were a [**], but rather, Incyte shall use Commercially Reasonable Efforts to achieve a Net Price that is at [**] the [**] of [**] in such market, assuming such [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">is ascertainable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte will have the sole right to establish all terms of commercial sale (including pricing, discounts and rebates) in all other countries of the world, and subject to Section 8.5(a), royalties will be calculated based on actual Net Sales in such country pursuant to Section 8.3.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">_____________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">1</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;For clarity, the [**]. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">2</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;[**] as of the Execution Date are [**] and [**]. [**]. </font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">3</sup></font><font style="font-family:inherit;font-size:10pt;">&#32;[**] as of the Execution Date is [**]. [**].  </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;padding-left:96px;text-indent:-48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">64</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(h)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">If at any time during the Royalty Term Incyte determines that it is not in compliance with the [**], [**], [**] or [**], Incyte shall initiate a process, and use Commercially Reasonable Efforts to complete such process, to bring Incyte into compliance with the applicable [**] (for example, initiating pricing negotiations with an applicable regulatory authority); provided that Incyte&#8217;s non-compliance with the [**], [**], [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or [**] shall not constitute a material breach of this Agreement so long as Incyte utilizes Commercially Reasonable Efforts to resolve such non-compliance. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Pricing of Pipeline Assets</font><font style="font-family:inherit;font-size:12pt;">. Each Controlling Party shall have sole and exclusive control over (a) the pricing of its Pipeline Asset and (b) any negotiation of the pricing, discounts and rebates applicable to its Pipeline Asset with any Regulatory Authorities or other Third Parties. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">6.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Transparency Reporting</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall be responsible for tracking and reporting transfers of value initiated and controlled by or on behalf of such Party&#8217;s or its Affiliates&#8217; employees, contractors, and agents pursuant to the requirements of the marketing reporting laws of any Governmental Authority in the Territory, including Section 6002 of ACA, commonly referred to as the &#8220;Sunshine Act.&#8221; </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 7</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MANUFACTURING </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Manufacturing Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Any time after the [**] anniversary of the Effective Date, Incyte may request, upon [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">written notice (which notice may be given prior to the [**] anniversary of the Effective Date) to MacroGenics (or immediately upon writing notice to MacroGenics, in the case of a Clinical Supply Shortage), that MacroGenics transfer or have transferred the Manufacturing Process to a manufacturing facility under the control of Incyte (or its designee, which designee may be an Affiliate) or, subject to subsection (d) below, to a facility of a Third Party contract manufacturer that is mutually agreed upon by the Parties. MacroGenics shall not withhold such agreement to a proposed contract manufacturer that has not experienced any material documented safety, compliance or quality issues in the preceding [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and has demonstrated the ability to manufacture products at the volumes and quality anticipated under this Agreement (such Incyte facility or Third Party facility, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Facility</font><font style="font-family:inherit;font-size:12pt;">&#8221; and such Third Party, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approved CMO</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Such transfer and implementation shall be sufficient to enable Incyte or such designee to perform the Manufacturing Process and Manufacture of Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product in accordance with Applicable Law, as more fully described in this Section 7.1 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing Technology Transfer</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and shall be subject to a written plan approved by the JSC with respect to the Manufacturing Technology Transfer (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Manufacturing Transition Plan</font><font style="font-family:inherit;font-size:12pt;">&#8221;), with Incyte having final decision-making authority on the Manufacturing Technology Transfer (provided that Incyte may not expand the scope of the Know-How and Information to be transferred pursuant to Section 7.1(b) beyond that which is required hereunder). The Parties shall use Commercially Reasonable Efforts to </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">65</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">effect the Manufacturing Technology Transfer to Incyte or its designee pursuant to this Section 7.1. The implementation of the Manufacturing Technology Transfer and Manufacturing Transition Plan shall be subject to the Incyte Facility being suitable for the Manufacture of the Licensed Compound Bulk Drug Substance as determined in accordance with this Section 7.1(a), as applicable, using the Manufacturing Process in compliance with Applicable Laws. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics shall provide all reasonable assistance requested by Incyte to enable Incyte to implement the Manufacturing Process at the Incyte Facility, including by transferring to Incyte or such designee all Know-How and Information necessary for the Manufacturing Technology Transfer. In connection with the Manufacturing Technology Transfer, MacroGenics shall cause appropriate employees and representatives of MacroGenics to meet with employees and/or representatives of Incyte and the Approved CMO (to the extent applicable) at reasonable times to assist with the working up and use of the Manufacturing Process and with the training of the personnel of the Incyte Facility to the extent reasonably necessary or useful to use and practice the Manufacturing Process. Incyte shall reimburse MacroGenics&#8217; FTE Costs and reimburse all reasonable Third Party Expenses incurred by MacroGenics in order to complete the Manufacturing Technology Transfer, within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after receipt of any undisputed invoice from MacroGenics setting forth such costs. Subsequent to the occurrence of the Manufacturing Technology Transfer, at any time during the Term, upon either Party&#8217;s reasonable request, the other Party will provide to the requesting Party updated manufacturing process (including associated Know-How) Controlled by such other Party necessary or useful for the Manufacture of the Licensed Compound Bulk Drug Substance or the Licensed Compound Drug Product, at the requesting Party&#8217;s cost and expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding the occurrence of the Manufacturing Technology Transfer pursuant to this Section 7.1, Incyte shall have the right to Manufacture or have Manufactured clinical and/or commercial supplies of Licensed Compound or Licensed Products, to the extent set forth in Sections 7.2(d), 7.3(a), 7.3(b), and 12.9.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Any time after the completion of the Manufacturing Technology Transfer during the Term, to the extent that either Party makes any material modifications, improvements or other alterations to the Manufacturing Process, such Party shall use Commercially Reasonable Efforts, at the other Party&#8217;s sole cost and expense, to provide access to such modifications, improvements or other alterations to such other Party, and to reasonably cooperate with the other Party in its efforts to ensure (including through the implementation of subsequent modifications to the Manufacturing Process, to the extent required) that the Incyte Facility and the MacroGenics Manufacturing Facilities (as applicable) Manufacture the Licensed Compound using such modified and/or improved Manufacturing Process and yielding comparable product. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">66</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte shall require that all agreements executed between Incyte and any Approved CMO with respect to such Approved CMO&#8217;s performance under this Agreement shall permit the assignment of such agreement, in its entirety in the event of termination of this Agreement (other than by Incyte pursuant to Section 12.3 or 12.6), to MacroGenics, without any consent rights by the Approved CMO (subject to MacroGenics agreeing to such assignment and the assumption of relevant obligations under such agreement). </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">General Clinical Supply Terms</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">. Except as otherwise provided herein, MacroGenics shall have the responsibility for Manufacturing clinical supplies of the Licensed Compound Bulk Drug Substance (and at any time prior to the completion of the Manufacturing Technology Transfer, MacroGenics shall also have the responsibility for Manufacturing clinical supplies of the Licensed Compound Drug Product) for (i) MacroGenics&#8217; use in connection with any MacroGenics Combination Studies, (ii) Incyte&#8217;s use in connection with any Monotherapy Studies or Incyte Combination Studies, and (iii) Collaborator&#8217;s or Incyte&#8217;s use in connection with any Collaborator Combination Studies. Within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Effective Date, the Parties shall initiate negotiations for a clinical supply agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) that will set forth the terms and conditions for MacroGenics&#8217; (or Incyte&#8217;s per Section 7.2(d)) provision of clinical supplies of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product, as applicable, to Incyte, MacroGenics, and any Collaborators and which will include all applicable provisions set forth in this Article 7 with respect to clinical supply and such other provisions as are customary and reasonable under the circumstances. The Parties shall also initiate negotiations to execute a quality agreement that shall further address and govern issues related to the quality of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product to be supplied by MacroGenics pursuant to the Clinical Supply Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Quality Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;). All negotiations for the Clinical Supply Agreement and Clinical Quality Agreement shall be undertaken by each Party in good faith. MacroGenics (or Incyte, per Section 7.2(d)) will use Commercially Reasonable Efforts to supply, or cause to be supplied, the Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product, as applicable, in accordance with the provisions of this Agreement, and once executed, the Parties shall comply with their respective obligations to supply, or cause to be supplied, the Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product, as applicable, in accordance with the provisions of the Clinical Supply Agreement and the Clinical Quality Agreement. MacroGenics shall supply all quantities of Licensed Compound Bulk Drug Substance from the MacroGenics Manufacturing Facilities, and shall not have the right to subcontract the Manufacture of the Licensed Compound Bulk Drug Substance. Further, MacroGenics shall supply all quantities of Licensed Compound Bulk Drug Substance that are required for any particular Incyte Monotherapy Study or Incyte Combination Study from the same MacroGenics Manufacturing Facility, provided </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">67</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">that such supply requirements do not exceed the reasonably available then-current planned capacity of the applicable Manufacturing Facility.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply Costs</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall provide clinical supplies of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product, in accordance with the Clinical Supply Agreement and Clinical Quality Agreement, (i) at a cost equal to [**] of the Manufacturing Expenses incurred by MacroGenics with respect to such quantities of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product, to (x) Incyte for Monotherapy Studies, Incyte Combination Studies and for any Combination Studies conducted by Incyte&#8217;s licensees and (y) any Collaborator for any Collaborator Combination Studies for which at least [**] of the costs are co-funded by Incyte (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Funded Collaborator Combination Studies</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and (ii) at a cost equal to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the Manufacturing Expenses incurred by MacroGenics with respect to such quantities of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product, to any Collaborator for Collaborator Combination Studies other than Funded Collaborator Combination Studies. Within [**] after the end of each month during which MacroGenics is conducting activities under the Clinical Supply Agreement, MacroGenics shall submit an invoice to Incyte for amounts owed by Incyte pursuant to the Clinical Supply Agreement. Incyte or Collaborator, as applicable, shall pay MacroGenics the full undisputed amount of such invoice within [**] after receipt of such invoice. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply Shortage</font><font style="font-family:inherit;font-size:12pt;">. In the event of a projected Clinical Supply Shortage of clinical supplies of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product, as determined by either Party in its reasonable discretion, the following shall occur: (i) MacroGenics shall provide to Incyte reasonable assurances that the projected Clinical Supply Shortage will not actually occur, or promptly alert Incyte as to the nature of the Clinical Supply Shortage and cause of such shortage; and (ii) the JMC shall convene and both Parties shall use Commercially Reasonable Efforts to remedy the situation giving rise to such Clinical Supply Shortage and to take action to minimize the impact of the Clinical Supply Shortage, including (1) the reallocation of any material from either Party&#8217;s safety stock to match actual projected usage in the applicable Clinical Study(ies) causing such Clinical Supply Shortage and (2) triaging any clinical supply allocation for ongoing Clinical Studies of either Party. If MacroGenics does not provide such assurances, or if the situation is not remedied through good faith efforts by both Parties within the [**] following such notification in a manner to avoid an actual Clinical Supply Shortage, then, without limiting any remedies available to Incyte under this Agreement or the Clinical Supply Agreement, during a period extending for [**] from the Effective Date, the clinical supplies would first be allocated to fulfill [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of Incyte&#8217;s clinical supply needs over the first [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the actual Clinical Supply Shortage period and thereafter the Parties will prorate subsequent supplies of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product based on the then-Binding Portion (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Committed Supply</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as of the date </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">68</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">of either Party&#8217;s notification to the other Party of such projected Clinical Supply Shortage, as further described in the Clinical Supply Agreement. In the event that an actual Clinical Supply Shortage occurs with respect to MacroGenics&#8217; supply of Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product for each of [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">calendar years, Incyte shall thereafter have the right to Manufacture or have Manufactured up to [**] percent ([**]%) of Incyte&#8217;s clinical supply requirements of Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product. A Clinical Supply Shortage due to the following causes shall not be deemed to be a breach of MacroGenics&#8217; clinical supply obligations pursuant to this Article 7 but shall still constitute a Clinical Supply Shortage for the purposes of this Section 7.2(c) and Section 7.2(d): (A) events of Force Majeure or (B) a mutually-agreed change in the specifications for Manufacture of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product which causes a Clinical Supply Shortage within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the implementation of such change in specifications. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Clinical Supply Rights</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary herein, Incyte shall have the right to Manufacture (or have Manufactured) clinical supplies of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product at the Incyte Facility, (i) in the event of a Clinical Supply Shortage, solely to the extent necessary to cover the projected shortfall of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product relative to committed Orders, or as otherwise set forth in subsection (c) above, or (ii) for the purpose of any Pivotal Studies of Licensed Product that are funded by Incyte. In the event that Incyte Manufactures, or has Manufactured, clinical supplies of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product for MacroGenics (it being understood that MacroGenics may request such Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product for MacroGenics Combination Studies and Acquirer Combination Studies), Incyte shall use Commercially Reasonable Efforts to provide to MacroGenics the quantities of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product requested by MacroGenics pursuant to committed Orders, and MacroGenics shall reimburse Incyte, with respect to a MacroGenics Combination Study, [**] ([**]%) of Incyte&#8217;s Manufacturing Expenses, irrespective of whether such Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product is used by MacroGenics. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Forecasts and Orders</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rolling Forecast</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">. </font><font style="font-family:inherit;font-size:12pt;">Commencing on the Effective Date, and on or before the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">day of each Calendar Quarter thereafter, each Party shall furnish the other Party via the JMC</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">with (A) a rolling forecast of the quantities of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product for which the other Party (for Incyte on behalf of itself and any Collaborators) reasonably expects to submit Orders in each calendar month </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">69</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">during the following [**] calendar months (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Rolling Forecast</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and (B) a rolling, non-binding forecast of the quantities of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product for which the other Party reasonably expects to submit Orders in each calendar quarter for months [**] through [**] (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Long Term Forecast</font><font style="font-family:inherit;font-size:12pt;">&#8221;), in each case of (A) and (B), for the purpose of conducting Monotherapy Studies, Incyte Combination Studies, Collaborator Combination Studies, or MacroGenics Combination Studies, as applicable. For the avoidance of doubt, the Long Term Forecast and months [**] through [**] of the Rolling Forecast will not be binding on the Party submitting such forecast, and months [**] through [**] of the Rolling Forecast will be binding on the Party submitting such forecast (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Binding Portion</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Orders</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;From time to time during the Term, Incyte and MacroGenics will enter into mutually-agreeable orders that reflect the Binding Portion of the Rolling Forecast (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Order</font><font style="font-family:inherit;font-size:12pt;">&#8221;) pursuant to which Incyte will order, and MacroGenics will agree to supply, (or, if Incyte is Manufacturing clinical supply for MacroGenics&#8217; use, pursuant to which MacroGenics will order, and Incyte will agree to supply) such quantities of clinical supplies of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product as specified in the Order, on the terms agreed upon by the Parties therein and the Clinical Supply Agreement. An Order shall be binding on the Parties in accordance with the terms and conditions of the Clinical Supply Agreement; provided that each Party shall submit and the other Party shall accept all orders consistent with the most recent Rolling Forecast and the provisions of this Section 7.2(e)(ii). Each Order will specify: (A) the quantities of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product to be supplied by MacroGenics, (B) the estimated cost of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product to be supplied, (C) the delivery date for such quantities of Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product and (D) the testing to be conducted and documentation to be provided for the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product supplied under such Order. For all units of Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product that MacroGenics Manufactures for its own use or use by its Development Partners in connection with a MacroGenics Combination Study, MacroGenics shall submit to Incyte in advance of such supply a confirmatory &#8220;Order&#8221; indicating the information set forth in (A) through (D) with respect to the quantities that it will supply. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">General Commercial Supply Terms</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Bulk Drug Substance</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">70</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Beginning [**] prior to the anticipated Initiation of the [**] Pivotal Study, and at least [**] prior to January 1</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;of each Calendar Year, Incyte, with input from MacroGenics, shall (x) determine the amounts of Licensed Compound Bulk Drug Substance to fulfill the annual projected global commercial supply of Licensed Compound Drug Product for such Calendar Year (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Global Commercial Supply Forecast</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and (y) provide a non-binding summary of the projected global commercial supply of Licensed Compound Drug Product for the following [**] Calendar Years. Each applicable forecast shall reasonably reflect MacroGenics&#8217; reasonably forecasted market demand for Licensed Compound Drug Product in connection with the Commercialization of MacroGenics Pipeline Assets as a component of a MacroGenics Combination Regimens in the applicable Calendar Year. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Except as otherwise provided herein, (x) MacroGenics shall have the right, but not the obligation, to Manufacture, at its expense, the lesser of (A) up to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the global commercial supply of the Licensed Compound Bulk Drug Substance corresponding to the Annual Global Commercial Supply Forecast, and (B) the annual then-current planned capacity of the MacroGenics Manufacturing Facilities (such amount that MacroGenics elects to Manufacture as set forth in this Section 7.3(a), the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Commercial Supply Commitment</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and (y) subject to successful Manufacturing Technology Transfer, FDA or EMA site validation, and Incyte&#8217;s notification that it is prepared to deliver the Incyte Commercial Supply Commitment, Incyte shall have the right and obligation to Manufacture, or have Manufactured, at the Incyte Facility, the percentage of the global commercial supply of the Licensed Compound Bulk Drug Substance other than the MacroGenics Commercial Supply Commitment, which shall be at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(such amount, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Commercial Supply Commitment</font><font style="font-family:inherit;font-size:12pt;">&#8221;). On an annual basis, the Parties will review and update, upon mutual agreement taking into consideration the prior year delivery, the Commercial Supply Commitments, including the percentage allocations for each Party to Manufacture (or in the case of Incyte, have Manufactured) its share of the global commercial supply of Licensed Compound Bulk Drug Substance. MacroGenics shall notify Incyte of its percent MacroGenics Commercial Supply Commitment within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after its receipt of the Annual Global Commercial Supply Forecast, and each Party shall be obligated to deliver the full quantity of its Commercial Supply Commitment. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event that MacroGenics delivers [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the MacroGenics Commercial Supply Commitment in [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">out of any [**] consecutive Calendar Year period (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Shortfall</font><font style="font-family:inherit;font-size:12pt;">&#8221;), Incyte shall have the right to limit MacroGenics&#8217; future annual commercial supply volume such that it does not exceed the [**] volume that MacroGenics delivered in either of such [**] in which the Commercial Shortfall occurred (i.e. Incyte may adjust MacroGenics&#8217; future right to manufacture [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by dividing the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">volume </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">71</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">that MacroGenics delivered in either of such [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">years in which the Commercial Shortfall occurred by the total projected volume demand for future years). </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In addition, in the event that (x) MacroGenics Manufactures [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the entirety of the MacroGenics Commercial Supply Commitment, or (y) Incyte Manufactures or has Manufactured [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the entirety of the Incyte Commercial Supply Commitment, then without limitation of any other rights or remedies available to the Parties, the other Party shall have the right (but not the obligation) to Manufacture, itself (in the case of MacroGenics) or through the Incyte Facility (in the case of Incyte), the remaining amount of the Licensed Compound Bulk Drug Substance, to fulfill demand for [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the Licensed Compound Bulk Drug Substance relative to the Annual Global Commercial Supply Forecast, in accordance with the terms of the Commercial Supply Agreement; provided that, at all times during the Term, MacroGenics shall use Commercially Reasonable Efforts to fulfill the MacroGenics Commercial Supply Commitment, and Incyte shall use Commercially Reasonable Efforts to fulfill the Incyte Commercial Supply Commitment; provided further, that, neither Party shall reallocate its then-current planned Manufacturing capacity to fulfill its respective Commercial Supply Commitment to any other compounds or products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In the event that Incyte Manufactures or has Manufactured [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the entirety of the Incyte Commercial Supply Commitment in a given Calendar Year, to the extent that MacroGenics has any Licensed Compound Bulk Drug Substance available at such time that is not committed for MacroGenics Clinical Studies, Incyte may purchase such Licensed Compound Bulk Drug Substance from MacroGenics in accordance with Section 7.3(c). MacroGenics shall supply all quantities of Licensed Compound Bulk Drug Substance from the MacroGenics Large-Scale Supply Plant or the MacroGenics 1,000L Supply Plant, and shall not have the right to subcontract the Manufacture of the Licensed Compound Bulk Drug Substance to any Third Party without Incyte&#8217;s prior written approval.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Compound Drug Product</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall be solely responsible, at its sole cost and expense, for Manufacturing from the Licensed Compound Bulk Drug Substance, itself or through an Approved CMO, [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the projected global commercial supply of the Licensed Compound Drug Product. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Supply Costs</font><font style="font-family:inherit;font-size:12pt;">. To the extent MacroGenics provides any commercial supply of the Licensed Compound Drug Product to Incyte pursuant to Section 7.3(a), the provisions of this Section 7.3(c) shall apply. MacroGenics shall provide such supply at a cost equal to [**] of the Manufacturing Expenses incurred by MacroGenics with respect to such quantities of the Licensed Compound Drug Product. MacroGenics shall thereafter provide Incyte with an invoice, and Incyte </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">72</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">would have up to [**] following its receipt of such invoice to request reasonable supporting documentation from MacroGenics to confirm the amount of Manufacturing Expenses set forth therein. MacroGenics shall provide any such reasonable supporting documentation within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following Incyte&#8217;s request. Incyte shall pay MacroGenics the full undisputed amount of any invoice with respect to commercial supply of the Licensed Compound Drug Product within the later of (i) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after Incyte&#8217;s receipt of such invoice from MacroGenics, or (ii) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after Incyte&#8217;s receipt of the supporting documentation in accordance with the procedure described above. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">. No later than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after Initiation of the first Pivotal Study, the Parties shall use Commercially Reasonable Efforts to execute a commercial supply agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Supply Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;) that will set forth the terms and conditions governing the provision of commercial supply of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product from MacroGenics to Incyte. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Commercial Supply Rights</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary herein, in the event that Incyte (as determined by Incyte in its reasonable discretion) is, or could reasonably be expected to be unable to Manufacture or have Manufactured the Incyte Commercial Supply Commitment, then Incyte shall promptly inform MacroGenics upon becoming aware of the events giving rise to such inability or expected inability, and (i) MacroGenics shall have the right to Manufacture such quantities of the Licensed Compound Bulk Drug Substance that Incyte is unable to Manufacture or have Manufactured until such time that Incyte is prepared to deliver the Incyte Commercial Supply Commitment, and (ii) Incyte shall Manufacture or have Manufactured quantities of the Licensed Compound Drug Product using the Licensed Compound Bulk Drug Substance provided by MacroGenics. In the event that Incyte notifies MacroGenics in writing that Incyte does not have an Incyte Facility that is equipped for commercial supply purposes (in Incyte&#8217;s reasonable discretion), MacroGenics shall have the right to Manufacture such quantities of the Licensed Compound Drug Product, in order to meet [**] of the global supply requirement for the MacroGenics Combination Regimen. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Records; Audit Rights</font><font style="font-family:inherit;font-size:12pt;">. Incyte and MacroGenics shall (and Incyte shall require that each Collaborator shall) keep complete and accurate records pertaining to its use and disposition of the Licensed Compound (including its storage, shipping and chain of custody activities) and, upon request of the other Party, shall make such records open to review by the other Party for the purpose of conducting investigations for the determination of the safety and/or efficacy of the Licensed Compound or a Party&#8217;s and the Collaborator&#8217;s compliance with this Agreement with respect to the Licensed Compound.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Operation of MacroGenics Manufacturing Facilities</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Subject to MacroGenics&#8217; compliance with its obligations under this Agreement and the Ancillary Agreements, MacroGenics shall have the sole discretion in the </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">73</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">operation and use of the MacroGenics Manufacturing Facilities to fulfill its obligations to supply the Licensed Compound Bulk Drug Substance under this Agreement and any Ancillary Agreements, including with respect to the following: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">scheduling of production runs to fulfill Orders and meet forecasts;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">scheduling of cleaning and maintenance and shut down to perform such activities; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">allocation of staff to activities and tasks to be performed in each MacroGenics Manufacturing Facility.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Quality Assurance</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Clinical Supply</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall use Commercially Reasonable Efforts to implement and perform operating procedures and controls for sampling, stability and other testing of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product, and for validation, documentation and release of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product and such other quality assurance and quality control procedures as are required by the specifications, GMP and the Clinical Quality Agreement (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Quality Assurance Measures</font><font style="font-family:inherit;font-size:12pt;">&#8221;), for clinical supply purposes. To the extent any clinical or commercial supplies of the Licensed Compound are Manufactured at the Incyte Facility pursuant to this Article 7, all parties in involved in such Manufacture shall adhere to the Quality Assurance Measures, subject to any modifications that may be mutually agreed upon by the Parties in writing from time to time. MacroGenics shall lead any discussions between the Parties related to Quality Assurance Measures for clinical supply of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product for Phase I Studies and Phase II Studies. Incyte shall lead any discussions between the Parties related to Quality Assurance Measures for clinical supply of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product for Phase III Studies and Pivotal Studies.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Commercial Supply</font><font style="font-family:inherit;font-size:12pt;">. Both Parties shall use Commercially Reasonable Efforts to implement and perform Quality Assurance Measures for commercial supply of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product. To the extent MacroGenics or an Approved CRO Manufactures any Phase III Study or Pivotal Study clinical supply or any commercial supplies of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product pursuant to this Article 7, such parties shall adhere to the Quality Assurance Measures implemented by Incyte in its production of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product, subject to any modifications that may be mutually agreed upon by the Parties in writing from time to time. Incyte shall lead any discussions between the Parties related to Quality Assurance Measures for commercial supply of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">74</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">7.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Compliance with Law</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall conduct all Manufacturing activities related to the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product in compliance with all Applicable Law, including applicable national and international (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">, ICH, GCP, GLP, and GMP) guidelines. </font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 8</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONSIDERATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Upfront Payment</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics shall invoice Incyte after the Effective Date and, within [**] after receipt of such invoice, Incyte shall pay to MacroGenics, One Hundred Fifty Million Dollars ($150,000,000) as a one-time, non-refundable, non-creditable upfront license payment. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Milestone Payments</font><font style="font-family:inherit;font-size:12pt;">. The applicable Party will notify the other Party within [**] following the achievement of each milestone set forth below (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Thereafter, MacroGenics shall submit an invoice to Incyte for the applicable Milestone payment, and within [**] after Incyte&#8217;s receipt of such invoice, Incyte shall remit the applicable Milestone payment to MacroGenics. In addition, except with respect to the Breakthrough Designation Milestone, if for any reason any other Development Milestone corresponding to a Milestone payment does not occur prior to the occurrence of Regulatory Approval, then such prior non-occurring Development Milestone shall be deemed to occur concurrently with Regulatory Approval, and the applicable Milestone payments for the applicable Development Milestones shall become due and payable in accordance with this Section 8.2. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proof of Concept Milestone</font><font style="font-family:inherit;font-size:12pt;">. The following payments shall be payable once as specified in the table below with respect to the first applicable Clinical Study (conducted by: (i) Incyte, its Affiliates, or sublicensees (excluding Collaborators); (ii) MacroGenics, in the case of the Ongoing Clinical Study, to the extent it meets the definition of a Phase II Study or Phase III Study; (iii) MacroGenics, if Incyte agrees in writing, in its sole discretion, that such study satisfies the POC Development Milestone; or (iv) MacroGenics, in the case of a MacroGenics Clinical Study in an Indication for which the then-current Incyte Global Development Plan also includes the Initiation of a Clinical Study in the same Indication within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">period following the date on which MacroGenics&#8217; Clinical Study achieved Proof of Concept) to achieve the corresponding Milestone:</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Proof of Concept Milestone</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**] or [**] Establishing Proof of Concept (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">POC Development Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;) </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">75</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Milestones</font><font style="font-family:inherit;font-size:12pt;">. The following payments shall be payable once as specified in the table below with respect to the first applicable Monotherapy Regimen, or Incyte Combination Regimen Developed by Incyte, its Affiliates, or sublicensees (excluding Collaborators) to achieve the corresponding Milestone (together with the POC Development Milestone, each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;): </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Development Milestone</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Treatment of [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#160;</font><font style="font-family:inherit;font-size:12pt;">cumulative subjects across all Incyte Clinical Studies (including Incyte Monotherapy Studies and Incyte Combination Studies) in a single Indication for greater than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#160;</font><font style="font-family:inherit;font-size:12pt;">continuously at a recommended Phase II or Phase III defined dose and schedule</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Initiation of a Pivotal Study</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Breakthrough Designation Granted</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">N/A</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">N/A</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Filing Milestones</font><font style="font-family:inherit;font-size:12pt;">. The following payments shall be payable once as specified in the table below, with respect to the first Monotherapy Regimen or Incyte Combination Regimen Developed by Incyte, its Affiliates, or sublicensees (excluding Collaborators) to achieve the corresponding Milestone (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Filing Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;): </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Filing Milestone</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">First filing of BLA in the U.S.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">First filing of MAA with EMA or in [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#160;</font><font style="font-family:inherit;font-size:12pt;">European Major Market countries </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Regulatory Approval Milestones</font><font style="font-family:inherit;font-size:12pt;">. The following payments shall be payable once as specified in the table below, with respect to the first Monotherapy Regimen or Incyte Combination Regimen Developed by Incyte, its Affiliates, or sublicensees (excluding Collaborators) to achieve the corresponding Milestone (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approval Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;): </font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:40%;"></td><td style="width:20%;"></td><td style="width:20%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approval Milestone</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">76</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:45%;"></td><td style="width:18%;"></td><td style="width:19%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Approval Milestone</font></div></td><td colspan="3" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">1</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">st</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">2</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">nd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">3</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">rd</sup></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#160;Indication</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Receipt of Regulatory Approval in U.S.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Receipt of Regulatory Approval in EU</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Receipt of Regulatory Approval in Japan</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Net Sales Milestones</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">The Milestone payments set forth in this Section 8.2(e) shall each be payable to MacroGenics one time only, upon the first time during the Term that the total aggregate Net Sales of Licensed Products in any Calendar Year in the Territory during the applicable Royalty Term for the Licensed Products in the applicable country exceed the amounts set forth in the following table (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sales Milestone</font><font style="font-family:inherit;font-size:12pt;">&#8221;).</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:76.92307692307693%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:70%;"></td><td style="width:30%;"></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;text-indent:56px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Aggregate Worldwide Net Sales Milestones</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sales Milestone</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Payment (USD)</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon the first occasion that aggregate annual Net Sales of Licensed Products exceeds [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon the first occasion that aggregate annual Net Sales of Licensed Products exceeds [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon the first occasion that aggregate annual Net Sales of Licensed Products exceeds [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Upon the first occasion that aggregate annual Net Sales of Licensed Products exceeds [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If more than one Sales Milestone described in this Section 8.2(e) is achieved during the same Calendar Year, then Incyte shall pay MacroGenics only the Sales Milestone payment that corresponds to the highest Sales Milestone that was achieved in such Calendar Year, and any Sales Milestone that was earned in such Calendar Year but not paid shall be paid with respect to the first Calendar Year in which no other Sales Milestone was achieved. For purposes of clarity, only one Sales Milestone payment shall be owed, on each of the first occasions that aggregate annual Net Sales of Licensed Products exceed [**], [**], [**] and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">under this Section 8.2(e). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Royalty Obligations</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall pay to MacroGenics royalties on the aggregate annual Net Sales of Licensed Products in the Territory, on a Licensed Product-by-Licensed Product basis, at the following rates set forth in this Section 8.3, in each case, subject to Sections 8.5 and 8.10:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">77</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:73.93162393162393%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:71%;"></td><td style="width:29%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Annual Net Sales</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Royalty Rate</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On the portion of worldwide annual Net Sales of Licensed Products less than or equal to [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">15%</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On the portion of worldwide annual Net Sales of Licensed Products greater than [**] and less than or equal to [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On the portion of worldwide annual Net Sales of Licensed Product greater than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#160;</font><font style="font-family:inherit;font-size:12pt;">and less than or equal to [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:6px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On the portion of worldwide annual Net Sales of Licensed Product greater than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#160;</font><font style="font-family:inherit;font-size:12pt;">and less than or equal to [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:left;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On the portion of worldwide annual Net Sales of Licensed Product greater than [**]</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:6px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:16px;text-align:center;padding-left:6px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">24%</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Royalty Term</font><font style="font-family:inherit;font-size:12pt;">. Royalties under Section 8.3 shall be payable on Net Sales on a Licensed Product-by-Licensed Product and country-by-country basis during the Royalty Term applicable to such Licensed Product in the applicable country. Following the expiration of the Royalty Term with respect to a Licensed Product in the applicable country (but not following an earlier termination of this Agreement), subject to the terms and conditions of this Agreement, Incyte shall have a perpetual, irrevocable, non-exclusive, fully-paid and royalty-free right and license, with the right to grant sublicenses, under the Licensed Technology and Label Combination Patents, to Exploit such Licensed Product in the Field in such country, and Net Sales of such Licensed Product in such country shall not count toward the milestones or royalty thresholds under Sections 8.2 or 8.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Royalty Rate Adjustments; Licensed Product Pricing</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The royalty rates set forth in Section 8.3 shall be subject to reduction as follows:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On a country-by-country basis, to the extent a Licensed Product is sold in a country in the Territory in which one (1) or more Third Parties is selling or has previously sold one or more Biosimilar Products, and such Biosimilar Products, collectively, have achieved a [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or more market share of the aggregate market share of such Licensed Product and such Biosimilar Products (based on data provided by IMS Health Incorporated, Fairfield, Connecticut) as measured on a units sold basis in any Calendar Quarter, or if such data is not available, such other methodology for estimating the percentage of unit sales based market share of such Biosimilar Products in such country as agreed upon by the Parties, then Incyte&#8217;s royalty obligations with respect to sales of such Licensed Product in such country during such Calendar Quarter and all future Calendar Quarters shall be reduced by [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the applicable rate set forth in Section 8.3 (as such rate may be adjusted pursuant to Section 8.5(b) below);</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">78</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">On a country-by-country basis and Licensed Product-by-Licensed Product basis, the royalty rates shall be reduced by [**], in each country in the Territory in which, at the time applicable Net Sales occur, no Valid Claim of Licensed Patents Covers the Commercialization of the applicable Licensed Product; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">In no event shall the reduction available to Incyte pursuant to Sections 8.5(a)(i) and 8.5(a)(ii) reduce the royalties payable to MacroGenics for a given Calendar Quarter to less than [**] of the royalty amount otherwise payable with respect to the applicable Licensed Product (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Royalty Floor</font><font style="font-family:inherit;font-size:12pt;">&#8221;) for such Calendar Quarter during the Royalty Term, provided that Incyte may credit against royalty obligations payable with respect to one or more future Calendar Quarter(s) any royalty reductions that Incyte was unable to take in any previous Calendar Quarter due to the Royalty Floor to the extent such credited royalty deductions do not cause the payments owed to MacroGenics in such future Calendar Quarter to be reduced below the Royalty Floor.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary herein, in the event that Incyte or its Affiliates or sublicensees sell the Licensed Compound [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in a Calendar Year such that the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">for such Calendar Year is [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the [**], [**], [**] or [**], as applicable, then, as Incyte&#8217;s [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and MacroGenics&#8217; [**] with respect to such sales, within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">following the end of such Calendar Year, Incyte shall pay MacroGenics a one-time payment in an amount equal to the shortfall of the royalty that would have been owed had the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the [**] been equal to the [**], [**], [**], or [**], as applicable. By way of example, if MacroGenics received $[**] in U.S. royalties over the course of a Calendar Year based on a [**], and the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in such Calendar Year was [**], then Incyte would owe MacroGenics a shortfall payment of $[**] ([**]). </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Manner of Royalty Payment</font><font style="font-family:inherit;font-size:12pt;">. Within [**] following the end of each Calendar Quarter ending during an applicable Royalty Term as to a Licensed Product in the Territory, Incyte shall provide MacroGenics with a report setting forth, on a Licensed Product-by-Licensed Product and country-by-country basis: (a) the Net Sales of such Licensed Product in such country, calculated in accordance with GAAP and (b) a calculation of the royalty payment due with respect to such Net Sales. Such report shall also include the exchange rates and other methodology used in converting Net Sales into U.S. Dollars from the currencies in which such sales were made for purposes of calculating the appropriate royalty rate and the royalty payment due, and the application of the adjustments, if any, made in accordance with the terms of Section 8.5 and Section 8.10. Following MacroGenics&#8217; receipt of an undisputed report, MacroGenics shall send an invoice to Incyte for the royalty payment due for such Calendar Quarter. Within [**] after Incyte&#8217;s receipt of such invoice, Incyte shall pay all undisputed amounts due to MacroGenics pursuant to Section 8.3 with respect to Net Sales by Incyte, its Affiliates and their respective sublicensees for such Calendar Quarter.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">79</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Monotherapy Development Sublicense Fees</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall pay to MacroGenics [**] of upfront fees and milestones received following the Effective Date but prior to the end of the Royalty Term by Incyte and its Affiliates from any Third Party with which Incyte enters into, during the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Effective Date, a bona fide collaboration (such collaboration being limited solely to Development of the Monotherapy Regimen in the U.S., EU or Japan), pursuant to which Incyte grants such Third Party a sublicense under this Agreement (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Monotherapy Sublicense Fees</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Collaborator Sublicense Fees</font><font style="font-family:inherit;font-size:12pt;">. With respect to each sublicense granted by Incyte under this Agreement with respect to a Collaborator Combination Regimen, throughout the Term, Incyte shall have the right, but not the obligation, to charge Collaborators an upfront fee, milestone or royalties on the net sales of the Collaborator&#8217;s Pipeline Asset in exchange for access to use the Licensed Compound in a Collaborator Combination Regimen, and shall pay to MacroGenics [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of any such upfront fee, milestones or royalties received during the Royalty Term by Incyte and its Affiliates from such Collaborator in connection with the applicable Collaborator Contract (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Sublicense Fees</font><font style="font-family:inherit;font-size:12pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Currency</font><font style="font-family:inherit;font-size:12pt;">. All payments under this Agreement shall be payable in U.S. Dollars. With respect to sales of a Licensed Product invoiced in a currency other than U.S. Dollars, such amounts and the amounts payable hereunder shall be expressed in their U.S. Dollars equivalents using the exchange rate Incyte uses for its public financial accounting purposes.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Third Party Financial Obligations</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Subject to Section 8.10(b) and 8.10(c) below, in the event that Incyte in its reasonable discretion</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">determines that it is necessary or useful to obtain a license under any Patents controlled by a Third Party in order to Exploit the Monotherapy Regimen (such license, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party License</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then Incyte may credit up to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">of the amount of [**], milestone payments, royalties, and other amounts actually paid by Incyte or its applicable Affiliate or, solely to the extent passed through to Incyte, its sublicensee, as the case may be, to such Third Party in connection with such Third Party License in a given Calendar Quarter, in each case to the extent allocable to rights to Exploit the Monotherapy Regimen, against future milestone payments and royalty payments owed to MacroGenics under Section 8.3 (as such royalties may be adjusted pursuant to Section 8.5(b)) in such Calendar Quarter (such credit, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party License Credit</font><font style="font-family:inherit;font-size:12pt;">&#8221;); provided, however, that in no event will such Third Party License Credit reduce any royalty or milestone payment payable to MacroGenics to less than [**] of the royalty or milestone amount otherwise payable with respect to the applicable Licensed Product. Any share of such Third Party obligations that [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">due to the [**]. For clarity, the Third Party License Credit shall not be [**]. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">As of the Execution Date, MacroGenics has the existing Third Party licenses set forth in </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit C</font><font style="font-family:inherit;font-size:12pt;">&#32;(such licenses, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Existing Third Party Licenses</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Incyte shall be solely responsible for paying to MacroGenics, with respect to the Existing Third Party Licenses, all license fees, milestone payments, and royalties (including royalty buyout payments) payable to the applicable Third Party licensor under such Existing </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">80</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Third Party License, to the extent resulting from Incyte&#8217;s Exploitation of the Licensed Compound and/or Licensed Product; provided that, [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall have [**] of the amount of such fees as a [**] in the manner provided in [**], subject to the [**] and [**] set forth in such [**]. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Notwithstanding anything to the contrary herein, Incyte shall be solely responsible for the payment of any and all costs and expenses, including upfront fees, milestone payments and royalty payments (without deduction pursuant to subsection (a)), and the assumption of any and all liabilities owed or incurred by Incyte or its Affiliates prior to the Effective Date or during the Term in connection with obtaining from [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">any Third Party License for the Exploitation of the Licensed Compound (including the promotion of the Licensed Compound as a component of a MacroGenics Combination Regimen) under those Patents identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit G</font><font style="font-family:inherit;font-size:12pt;">&#32;that are owned or Controlled by [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">as of the Effective Date (such [**], the &#8220;[**]&#8221;; such license, the &#8220;[**]&#8221;). During the Term, Incyte will use Commercially Reasonable Efforts to (x) [**] a [**] that [**] the [**] under the [**] by [**] to [**], [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">generally consistent with the license set forth in Section 3.4(b) (except that the [**] will be solely for the Exploitation of the Licensed Compound and any further sublicensing thereof shall be subject to the provisions to Section 3.2(c)); and (y) maintain the [**] for so long as it is commercially reasonable for Incyte to do so. For so long as Incyte maintains the [**] in effect, Incyte will not amend or modify the [**] in a manner that would have a material adverse effect on MacroGenics&#8217; rights under this Agreement without MacroGenics&#8217; prior written consent. For clarity, the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">hereunder with respect to the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall not include [**] to the Exploitation of any Pipeline Asset or the Combination of any Pipeline Asset with the Licensed Compound.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">[**]</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">. </font><font style="font-family:inherit;font-size:12pt;">Notwithstanding Section 8.10(a) and 8.10(c), during the Term and in the event&#160;that Incyte determines it is necessary to obtain from [**] any Third Party License for the Exploitation of the Licensed Compound (including the promotion of the Licensed Compound as a component of a MacroGenics Combination Regimen) under those Patents identified on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit H</font><font style="font-family:inherit;font-size:12pt;">&#32;that are owned or Controlled by [**] as of the Effective Date (such [**], the &#8220;[**]&#8221;; such license, the &#8220;[**]&#8221;), Incyte shall use Commercially Reasonable Efforts to [**] and [**] the [**], either as an extension of the [**] or a [**], and ensure that the terms of the [**] permit the [**] under the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by Incyte to MacroGenics, on terms generally consistent with the license set forth in Section 3.4(b) and the provisions of Section 8.10(c), except that the [**] will be solely for the Exploitation of the Licensed Compound, and any [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">thereof shall be subject to the provisions of Section 3.2(c). To the extent Incyte determines it is necessary to obtain the [**],&#160;Incyte shall be solely responsible for the payment of any and all costs and expenses, including upfront fees, milestone payments and royalty payments, without deduction pursuant to 8.10(a) or any other provision of this Agreement. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">81</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Taxes</font><font style="font-family:inherit;font-size:12pt;">. All payments due and payable under this Agreement will be made without any deduction or withholding of Taxes, unless such deduction or withholding Tax is required by Applicable Law in effect at the time of payout. If the paying Party is so required to deduct or withhold any Taxes, such Party shall (a) promptly notify the other Party of such requirement; (b) pay to the relevant authorities the full amount required to be deducted or withheld promptly upon the earlier of determining that such deduction or withholding is required or receiving notice that such amount has been assessed against the other Party; and (c) promptly forward to the other Party an official receipt (or certified copy), or other documentation reasonably acceptable to the other Party evidencing such payment to such authorities. Notwithstanding the foregoing, if as a result of (i) the assignment or transfer by operation of law or otherwise, of this Agreement by either Party to an Affiliate or Third Party outside of the U.S., or (ii) the exercise by either Party of its rights under this Agreement through an Affiliate or Third Party outside the U.S., withholding Tax in excess of the withholding Tax amount that would have been payable in the absence of such assignment or exercise of rights becomes payable with respect to any amount due to the other Party under this Agreement, then: (x) where the paying Party is the assigning or exercising Party described in (i) and (ii), the paying Party shall pay to the other Party such additional amounts as are necessary so that the other Party receives the amounts it would have received if such payments were not subject to such withholding Tax as a consequence of such assignment or exercise; and (y) where the receiving Party is the assigning or exercising Party described in (i) and (ii), the paying Party shall not be required to pay any amount in excess of the aggregate payment it would have been required to make based on the withholding Tax amount that would have been payable in the absence of such assignment or exercise of rights. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Audit</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall maintain complete and accurate records in the ordinary course of such Party&#8217;s operations in order to permit the other Party to confirm the accuracy of the calculation of royalties, milestones, FTE Costs, Third Party Expenses, Manufacturing Expenses and other payments under this Agreement. Upon reasonable prior notice, but not more than [**] per Calendar Year, such records shall be available during regular business hours for a period of [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">from the end of the Calendar Year to which they pertain for examination by a &#8220;Big Four&#8221; independent certified public accounting firm (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">i.e., </font><font style="font-family:inherit;font-size:12pt;">PriceWaterhouseCoopers, Deloitte &amp; Touche, Ernst &amp; Young or KPMG) selected by the requesting Party, having no prior engagement with the requesting Party, and reasonably acceptable to the other Party for the sole purpose of verifying the accuracy of the financial reports and correctness of the payments furnished by the other Party pursuant to this Agreement (it being agreed that if the Parties have collectively engaged with more than [**] of the foregoing Big Four firms at the time of selection for an audit hereunder, then at such time the Parties shall reasonably cooperate and determine additional acceptable certified public accounting firms who may conduct such audit pursuant to this Section 8.12). Any such auditor shall not disclose the other Party&#8217;s Confidential Information, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the other Party or the amount of payments due by the other Party under this Agreement. Any amounts shown to be owed but unpaid shall be paid within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">from the accountant&#8217;s report, plus interest, as set forth in Section 8.13, from the original due date. Any amounts shown to have been overpaid shall be refunded within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">from the accountant&#8217;s report. The requesting Party shall bear the full cost of such audit unless such audit discloses an underpayment by the other Party of more than [**] of the amount due, in which case the other Party shall bear the full cost of such audit.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">82</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">8.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Manner of Payment</font><font style="font-family:inherit;font-size:12pt;">. All payments due to a Party hereunder shall be made in U.S. Dollars by wire transfer of immediately available funds into an account designated by the receiving Party. If a Party does not receive payment of any sum due to it on or before the due date, such Party shall notify the other Party, and the paying Party shall have [**] following receipt of such notice to pay any undisputed amount. Thereafter, interest shall accrue on the undisputed sum due to such Party until the date of payment at the per annum rate of [**] over the then current prime rate quoted by Citibank in New York City of the maximum rate allowable by Applicable Law, whichever is lower.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 9</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INTELLECTUAL PROPERTY MATTERS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Inventorship; Ownership and Disclosure of Inventions</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Inventorship</font><font style="font-family:inherit;font-size:12pt;">. For purposes of this Section 9.1, inventorship with respect to any Inventions made by a Party&#8217;s (or its Affiliates&#8217;) own employees, agents, licensees or independent contractors in the course of conducting its activities under this Agreement, together with all intellectual property rights therein, shall be determined in accordance with U.S. patent laws. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ownership by Incyte</font><font style="font-family:inherit;font-size:12pt;">. As between the Parties, any Invention made solely by Incyte&#8217;s (or its Affiliates&#8217;) own employees, agents, licensees or independent contractors that arises in the course of performing any Monotherapy Study, Incyte Combination Study and/or any Collaborator Combination Study under this Agreement or performing any other activity under this Agreement, together with all intellectual property rights in each of the foregoing (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Development IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and Incyte&#8217;s interest in Collaborator Development IP shall, as between Incyte and MacroGenics, be solely owned by Incyte.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ownership by MacroGenics</font><font style="font-family:inherit;font-size:12pt;">. As between the Parties, any Invention made solely by MacroGenics&#8217; (or its Affiliates&#8217;) own employees, agents, licensees or independent contractors that arises in the course of performing any MacroGenics Combination Study under this Agreement or, performing any other activity under this Agreement, together with all intellectual property rights therein (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Development IP</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall, as between MacroGenics and Incyte, be solely owned by MacroGenics and, to the extent useful or necessary to Exploit the Licensed Compound or Licensed Product, shall, subject to Section 15.3(d), constitute Licensed Patents or Licensed Know-How (as applicable) for purposes of this Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Ownership</font><font style="font-family:inherit;font-size:12pt;">. The Parties shall jointly own any Inventions for which the inventors include at least one employee, agent, or independent contractor of each Party that arise in the course of performing activities under this Agreement, together with all intellectual property rights therein (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Inventions</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Subject to any licenses granted under this Agreement, each Party will have the right to practice and exploit any Joint Inventions without the duty of accounting to the other Party or seeking consent (for licensing, assigning or otherwise exploiting Joint Inventions) from the other Party by reason of the joint ownership thereof; and each Party hereby </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">83</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">waives any right such Party may have under the Applicable Law of any jurisdiction to require any such approval or accounting, and, to the extent Applicable Law prohibits such a waiver, each Party shall be deemed to so consent. In furtherance thereof, upon the reasonable written request of a Party, the other Party will in writing grant such consents and confirm that no such accounting is required to effect the foregoing regarding Joint Inventions. Each Party shall promptly disclose to the other Party any invention disclosures, or other similar documents, submitted to it by its employees, agents or independent contractors describing the Joint Inventions, and all Information relating to such Joint Inventions to the extent necessary for the use of such Joint Invention in the Development or commercialization of the Licensed Compounds or the Licensed Products in the Field and, to the extent patentable, for the preparation, filing and maintenance of any Patent with respect to such Joint Invention. Any such Information provided to the other Party pursuant to this Section 9.1(d) shall, to the extent it refers to or describes the Pipeline Asset of the Disclosing Party, be Confidential Information of the Disclosing Party, and the Disclosing Party shall have the right to require that any Confidential Information related to its Pipeline Assets be redacted from any Patent application(s) Covering Joint Inventions, provided that such Confidential Information shall not be redacted to the extent it is necessary to understand the Joint Invention, or is otherwise required for the patentability of the Joint Invention. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Assignment by Representatives</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall (and Incyte shall require that each Collaborator shall) bind its Affiliates, and its or their employees, agents, consultants and contractors (collectively, &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Representatives</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to disclose to such Party, and to assign to such Party or its Affiliate (or to Collaborator, as applicable) all right, title and interest in, any Invention that is made by such Representative in the course of conducting its activities under this Agreement, together with all intellectual property therein. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Prosecution of Patents</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Patents</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Subject to the oversight of the JIPC and in accordance with the remainder of this Section 9.2(a), MacroGenics shall have the primary right and authority to prepare, file, prosecute and maintain the Licensed Patents (other than the Joint Patents, which are the subject of Section 9.2(e)) on a worldwide basis, and shall prepare, file, prosecute or maintain the Licensed Patents in any jurisdiction requested by Incyte to the extent permitted under Applicable Law using independent outside counsel mutually agreed upon by the Parties.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Costs</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Such activities under Section 9.2(a) shall be conducted by MacroGenics (including through outside counsel selected in accordance with Section 9.2(a) above) at MacroGenics&#8217; own expense; provided that, Incyte shall reimburse MacroGenics for [**] of the reasonable, out-of-pocket costs incurred by MacroGenics in preparing, filing, prosecuting and maintaining the Licensed Patents in accordance with this Section 9.2, within [**] after receipt of any undisputed invoice from MacroGenics </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">84</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">setting forth such costs; provided, further, that if, pursuant to MacroGenics&#8217; agreement with any Third Party, MacroGenics is reimbursed by such Third Party for any such out-of-pocket costs in the preparing, filing, prosecution or maintenance of any such Licensed Patent, Incyte&#8217;s share of such out-of-pocket costs will be determined by [**]. Notwithstanding the foregoing, if Incyte wishes to seek Patent protection for a Licensed Patent in a jurisdiction other than those set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit F</font><font style="font-family:inherit;font-size:12pt;">&#32;(a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Requested Licensed Patent</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then Incyte shall so notify MacroGenics in writing and shall reimburse MacroGenics for [**] of the reasonable, out-of-pocket costs incurred by MacroGenics in preparing, filing, prosecuting and maintaining such Requested Licensed Patent in such jurisdiction in accordance with this Section 9.2, within [**] after receipt of any undisputed invoice from MacroGenics setting forth such costs; provided that, if the Requested Licensed Patent Covers a MacroGenics Pipeline Asset, then Incyte shall only be required to pay [**] of the reasonable, out-of-pocket costs incurred by MacroGenics in preparing, filing, prosecuting and maintaining the Requested Licensed Patents in accordance with this Section 9.2; provided, further, that if, pursuant to MacroGenics&#8217; agreement with any Third Party, MacroGenics is reimbursed by such Third Party for any such out-of-pocket costs in the preparing, filing, prosecution or maintenance of any such Requested Licensed Patent, Incyte&#8217;s share of such out-of-pocket costs will be determined by [**].</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Opt-Out Right</font><font style="font-family:inherit;font-size:12pt;">. Incyte may cease reimbursement of MacroGenics&#8217; costs associated with any Licensed Patent pursuant to Section 9.2(a) by providing MacroGenics with at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">written notice (an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Opt Out Notice</font><font style="font-family:inherit;font-size:12pt;">&#8221;). Upon receipt of an Opt Out Notice, MacroGenics may cease to pursue any efforts to prepare, file, prosecute or maintain the applicable Licensed Patent(s). Upon expiration of the notice period set forth in the Opt Out Notice, any Licensed Patent which is the subject of such Opt-Out Notice shall cease to be a Licensed Patent for all purposes under this Agreement, including for purposes of the licenses granted by MacroGenics to Incyte under Section 3.1.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Review and Comment Rights</font><font style="font-family:inherit;font-size:12pt;">. Subject to the oversight of the JIPC, MacroGenics shall provide Incyte with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain Licensed Patents, including by providing Incyte with a copy of material communications from any patent authority regarding any Licensed Patent, and by providing drafts of any material filings or responses to be made in advance of submitting such filings or responses. MacroGenics shall consider Incyte&#8217;s comments and cooperate with Incyte regarding such communications and drafts in good faith, and shall use Commercially Reasonable Efforts to address Incyte&#8217;s comments. If MacroGenics determines in its discretion to abandon or not maintain any Licensed Patent(s) in any country(ies) of the world, then MacroGenics shall provide Incyte with written notice of such determination within a period of time reasonably necessary to allow Incyte to determine its interest in such Licensed Patent(s) </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">85</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">(which notice from MacroGenics shall be given no later than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior to any final deadline for any pending action or response that may be due with respect to such Licensed Patent(s) with the applicable patent authority). If Incyte provides written notice indicating that it wishes to acquire such Licensed Patent(s), MacroGenics shall, free of charge, assign and transfer to Incyte the ownership of, and interest in, such Licensed Patent(s) in such country(ies), at Incyte&#8217;s own expense, and MacroGenics shall cooperate with Incyte for assignment and transfer of such Licensed Patent(s) in such country. Thereafter, all such assigned and transferred Patents will be deemed Incyte Patents and not Licensed Patents, and Incyte shall have the right to prepare, file, prosecute and maintain such Patents as set forth in Section 9.2(e), at its sole expense. Notwithstanding the foregoing, Incyte shall have no right to prepare, file, prosecute or maintain (a) any Licensed Patents, in connection with settlement proceedings, oppositions, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;proceedings and other similar circumstances; and (b) any Patents that are otherwise owned or Controlled by MacroGenics that are not Licensed Patents. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Patents; Incyte Development IP</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall have the sole right and authority to prepare, file, prosecute and maintain Incyte Patents and Patents within the Incyte Development IP on a worldwide basis at its own expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Review and Comment Rights</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall provide MacroGenics with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain Incyte Patents and Patents within the Incyte Development IP in each case that specifically relate to the Licensed Compound or Licensed Product (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Subject Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221;), including by providing MacroGenics with a copy of material communications from any patent authority regarding any Subject Patent, and by providing drafts of any material filings or responses to be made in advance of submitting such filings or responses. Incyte shall consider MacroGenics&#8217; comments regarding such communications and drafts in good faith, and shall use Commercially Reasonable Efforts to address MacroGenics&#8217; comments where practicable. If Incyte determines in its discretion to abandon or not maintain any Subject Patent(s) in any country(ies) of the world, then Incyte shall provide MacroGenics with written notice of such determination within a period of time reasonably necessary to allow MacroGenics to determine its interest in such Subject Patent(s) (which notice from Incyte shall be given no later than [**] prior to any final deadline for any pending action or response that may be due with respect to such Subject Patent(s) with the applicable patent authority). If MacroGenics provides written notice indicating that it wishes to acquire such Subject Patent(s), Incyte shall, in return for MacroGenics&#8217; payment to Incyte of [**] of Incyte&#8217;s accrued costs for filing, prosecution, and maintenance of such Subject Patent, assign and transfer to MacroGenics the ownership of, and interest in, such Subject Patent(s) in such country(ies), at MacroGenics&#8217; own expense, and Incyte shall cooperate with </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">86</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">MacroGenics for assignment and transfer of such Subject Patent(s) in such country. Thereafter, MacroGenics shall have the right to prepare, file, prosecute and maintain such Patents at its sole expense and Incyte shall have no further rights in or obligation to MacroGenics with respect to such Subject Patent(s). Notwithstanding the foregoing, MacroGenics shall have no right to prepare, file, prosecute or maintain (a) any Subject Patents, in connection with settlement proceedings, oppositions, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;proceedings and other similar circumstances; and (b) any Patents that are otherwise owned or Controlled by Incyte or its Affiliates that are not Subject Patents. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaborator Development IP</font><font style="font-family:inherit;font-size:12pt;">. As between the Parties, Incyte shall have the sole right and authority to prepare, file, prosecute and maintain Patents within the Collaborator Development IP on a worldwide basis at its own expense. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Patents</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">Subject to the governance of the JIPC and in accordance with the remainder of this Section 9.2(e), Incyte shall have the primary right and authority to prepare, file, prosecute and maintain</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the Patents included in the Joint Inventions (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Joint Patents</font><font style="font-family:inherit;font-size:12pt;">&#8221;)</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">at its own expense; provided, however, to the extent that claims of Joint Patents Cover MacroGenics Pipeline Assets, that</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">MacroGenics shall </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">have the right and authority to prepare, file, prosecute and maintain</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">the Patents included in the Joint Inventions </font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">that specifically relate to MacroGenics Combination Regimens or MacroGenics Pipeline Assets (but not to the Licensed Compound or Licensed Product) (&#8220;</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;font-weight:bold;">MacroGenics-Responsible Joint Patents</font><font style="font-family:inherit;font-size:12pt;background-color:#ffffff;">&#8221;).</font><font style="font-family:inherit;font-size:12pt;">&#32;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Costs</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">Such activities under Section 9.2(e)(i) shall be conducted by the responsible Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Responsible Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (including through outside counsel) at the Responsible Party&#8217;s own expense; provided that, the other Party shall reimburse the Responsible Party for fifty percent (50%) of the reasonable, out-of-pocket costs incurred by the Responsible Party in preparing, filing, prosecuting and maintaining the applicable Joint Patent(s) in accordance with this Section 9.2(e)(i), within [**] after receipt of any undisputed invoice from the Responsible Party setting forth such costs. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Review and Comment Rights</font><font style="font-family:inherit;font-size:12pt;">. Subject to the governance of the JIPC, the Responsible Party shall provide the other Party with a reasonable opportunity to review and comment on its efforts to prepare, file, prosecute and maintain the Joint Patents, including by providing such Party with a copy of material communications from any patent authority regarding any Joint Patent, and by providing drafts of any material filings or responses to be made in advance of submitting such filings or responses. The Responsible Party shall consider the other Party&#8217;s comments and cooperate with the other Party regarding such communications and drafts in good faith, and shall use Commercially Reasonable Efforts to address the other Party&#8217;s comments. If the Responsible </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">87</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Party determines in its discretion to abandon or not maintain any Joint Patent(s) for which it has prosecution and maintenance right pursuant to Section 9.2(e)(i) in any country(ies) of the world, then the Responsible Party shall provide the other Party with written notice of such determination within a period of time reasonably necessary to allow the other Party to determine its interest in acquiring the Responsible Party&#8217;s interest in such Joint Patent(s) (which notice from the Responsible Party shall be given no later than [**] prior to any final deadline for any pending action or response that may be due with respect to such Joint Patent(s) with the applicable patent authority). Upon written notice from such Party that it wishes to acquire the Responsible Party&#8217;s interest in such Joint Patent(s), the Responsible Party shall, free of charge, assign and transfer to the other Party the Responsible Party&#8217;s interest in such Joint Patent(s) in such country(ies), at the other Party&#8217; own expense, and the Responsible Party shall cooperate with the other Party for assignment and transfer of such Joint Patent(s) in such country. Thereafter, all such assigned and transferred Patents will be deemed Patents of the assignee party and not Joint Patents, and the other Party shall have the right to prepare, file, prosecute and maintain such Patents at its sole expense and the Responsible Party shall have no further rights (including any license rights hereunder) in or obligation to the other Party (including payment obligations hereunder) with respect to such Joint Patent(s). </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cooperation in Prosecution</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall provide the other Party all reasonable assistance and cooperation in the prosecution efforts with respect to Licensed Patents (including Joint Patents) provided above in Sections 9.2(a) through 9.2(e). The Parties will discuss and consider in good faith filing separate Patent Rights that include claims that Cover Licensed Compound, Licensed Product and Combinations thereof (e.g., methods of manufacturing and uses of such Licensed Compound and Licensed Product) specifically or generically and claims that Cover only other compounds and methods of making and using such other compounds. Each Party shall provide the other Party all reasonable assistance and cooperation in providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution, as well as further actions as set forth below. Such assistance and cooperation shall include making a Party&#8217;s inventors and other scientific advisors reasonably available to assist the other Party&#8217;s Patent prosecution efforts. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">All communications between the Parties relating to the prosecution efforts provided above in Sections 9.2(a) through 9.2(e), including copies of any draft or final documents or any communications received from or sent to patent offices or patenting authorities with respect to the applicable Patents, shall be considered Confidential Information of the Party controlling the </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">88</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">prosecution of the applicable Patents pursuant to Sections 9.2(a) through 9.2(e) (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Prosecuting Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), except that, other than as set forth in Section 9.1(d), such communications in connection with Joint Patents shall be considered the Confidential Information of both Parties. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Prosecuting Party shall keep the other Party reasonably informed of its prosecution activities with respect to the applicable Patents. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Infringement of Patents by Third Parties</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notification</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall promptly notify the other Party in writing of any existing, alleged or threatened infringement of any Licensed Patent, Joint Patent, or Subject Patent, of which it becomes aware, and shall provide all Information in such Party&#8217;s possession or control relating to such infringement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement of Licensed Patents</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Subject to Section 9.3(b)(ii) through 9.3(b)(vii), Incyte shall have the first right, but not the obligation, to bring an appropriate suit or other action against any Third Party engaged in any existing, alleged or threatened infringement of any Licensed Patent or Joint Patent, including the filing by a Third Party of any Biosimilar Application under the BPCI Act, and to compromise or settle such action by counsel of its choice.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte shall notify MacroGenics of its election to take any action in accordance with Section 9.3(b)(i) at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">before any time limit set forth in Applicable Law or regulation, including the time limits set forth under the BPCI Act. Notwithstanding the foregoing sentence, Incyte shall not initiate any such suit or take such other action with respect to any Licensed Patent or Joint Patent without first consulting with MacroGenics and giving good faith consideration to any reasonable objection from MacroGenics regarding Incyte&#8217;s proposed course of action. MacroGenics shall cooperate in the prosecution of any suit under this Section 9.3 as may be reasonably requested by Incyte. In the event that Incyte elects not to initiate a lawsuit or take other reasonable action with respect to an infringement described in Section 9.3(b)(i), MacroGenics shall have the right, but not the obligation, to initiate such suit or take such other action, after providing [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(or [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in the event there is a time limit) notice to Incyte and giving good-faith consideration to Incyte&#8217;s reason(s) for not initiating a suit or taking other action; provided, however, that if Incyte has notified MacroGenics that it is not proceeding with an action on the advice of competent outside counsel that has evaluated patent scope, validity, enforceability, and/or possible infringement defenses, then MacroGenics shall not commence an action as described in this Section 9.3(b)(ii) until such time that (A) the Parties have agreed that such action should be commenced or (B) a mutually-agreeable Third Party expert has mediated such disagreement and determined that such action is reasonably unlikely to </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">89</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">have a material adverse effect on the Licensed Patents, Joint Patents, or Subject Patents. If, prior to the outcome of such determination by such Third Party expert, a time limit will expire or deadline occur that will prevent or limit the ability to initiate or conduct such suit or action, MacroGenics shall have the right to proceed with such suit or action until the outcome of the determination, at which point MacroGenics may continue with such suit or action only in accordance with the determination.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Without limiting the obligations of the Parties under subsection (ii) above, if one Party elects to bring suit or take action under this Section 9.3(b) against an infringement, then the other Party shall have the right, prior to commencement of the suit or action, to join any such suit or action at its own cost and expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte will have sole decision-making authority with respect to the determination of which Incyte Patents, and primary decision-making authority with respect to the determination of which Licensed Patents or Joint Patents, to submit to a Third Party that files a Biosimilar Application, or any other act of patent information exchange or listing as required by the BPCI Act or other similar measure in any other country in the Territory; provided that (A) to the extent permitted by Applicable Law, Incyte shall confer in good faith with MacroGenics regarding which, if any, Licensed Patents or Joint Patents are listed pursuant to 42 U.S.C. &#167; 262(l)(3)(A) (or any successor legislation) or included in any litigation with the Third Party applicant and (B) prior to the submission of such list to the Third Party, MacroGenics shall have the right to review and comment on and (if agreed by the Parties) require Incyte to include additional Licensed Patents or Joint Patents therein. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall provide to the Party enforcing any such rights under this Section 9.3(b) reasonable assistance in such enforcement, at such enforcing Party&#8217;s reasonable request and expense, including joining such action as a party plaintiff if required by Applicable Law to pursue such action. The enforcing Party shall keep the other Party regularly informed of the status and progress of such enforcement efforts, shall reasonably consider the other Party&#8217;s comments on any such efforts, and shall consult with the other Party in any important aspects of such enforcement, including determination of material litigation strategy and filing of important papers to the competent court.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(vi)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Each Party shall bear all of its own internal costs incurred in connection with its activities under this Section 9.3(b). In the event that the Parties are joined in suit or action against the infringement or the non-enforcing Party elects to join such suit or action and, in either case, elects to be represented by the same outside counsel as the enforcing Party, then the enforcing Party shall be responsible for all expenses arising from such outside counsel, provided </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">90</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">that the enforcing Party consents to such joint representation by outside counsel, such consent not to be unreasonably withheld, delayed or conditioned.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(vii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The Party not bringing an action with respect to infringement in the Territory under this Section 9.3(b) shall be entitled to separate representation in such matter by counsel of its own choice and at its own expense, but such Party shall at all times cooperate fully with the Party bringing such action.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(viii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Neither Party shall settle any claim, suit or action that it brought under this Section 9.3 involving Licensed Patents or Joint Patents that would either (A) involve any admission of invalidity or unenforceability of a Licensed Patent or Joint Patent or (B) result in the imposition of any liability on the non-enforcing party for which the enforcing party is not indemnifying the non-enforcing party pursuant to Article 14, without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement of Patents Claiming MacroGenics Pipeline Assets / MacroGenics Combination Regimens</font><font style="font-family:inherit;font-size:12pt;">. With respect to any infringement of any Patent that (i) Covers any MacroGenics Pipeline Asset or MacroGenics Combination Regimen and (ii) either (A) does not Cover the Licensed Compound or any Licensed Product or (B) did not exist as of the Execution Date and is being enforced with respect to activity that does not infringe (x) any composition of matter or formulation Patent with respect to the Licensed Compound nor (y) any method Patent that Covers the Licensed Compound as a Monotherapy Regimen, MacroGenics shall have the sole and exclusive right, but not the obligation, to bring, at MacroGenics&#8217; expense and in its sole control, an appropriate suit or other action against any Person engaged in such infringement of such Patent. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement of Incyte Patents; Incyte Development IP</font><font style="font-family:inherit;font-size:12pt;">. With respect to any infringement of any Incyte Patent or any Patent within the Incyte Development IP, Incyte shall have the sole and exclusive right, but not the obligation, to bring, at Incyte&#8217;s expense and in its sole control, an appropriate suit or other action against any Person engaged in such infringement of such Patent. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement of Patents Claiming Incyte Pipeline Assets / Collaborator Pipeline Assets / Incyte Combination Regimens / Collaborator Combination Regimens</font><font style="font-family:inherit;font-size:12pt;">. With respect to any infringement of any Patent that Covers any Incyte Pipeline Asset, Collaborator Pipeline Asset, Incyte Combination Regimen or Collaborator Combination Regimen, as between the Parties, Incyte shall have the sole and exclusive right, but not the obligation, to bring, at Incyte&#8217;s expense and in its sole control, an appropriate suit or other action against any Person engaged in such infringement of such Patent. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">91</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Allocation of Proceeds</font><font style="font-family:inherit;font-size:12pt;">. If either Party recovers monetary damages or a monetary settlement from any Third Party in a suit or action brought under Section 9.3(b) or any royalties, milestones or other payments from a license agreement with a Third Party related to any alleged infringement as to which such Party had a right to bring a suit or other action pursuant to Section 9.3(b), then to the extent such damages or royalties result from the infringement of Licensed Patents, such recovery (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Infringement Recovery</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall first be allocated to the reimbursement of any expenses incurred by the Parties in such litigation, action or license negotiations; then, any remaining amounts shall be allocated to Incyte and treated as Net Sales for purposes of this Agreement; provided, however, that if MacroGenics is the party bringing the applicable suit or action, any amounts remaining amounts shall be allocated [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to MacroGenics and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to Incyte. For clarity, with respect to all other infringement suits or actions brought by a Party (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.,</font><font style="font-family:inherit;font-size:12pt;">&#32;with respect Incyte Patents or Patents within the Incyte Development IP or MacroGenics Development IP), the owning Party shall keep all recoveries. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Patent Term Extensions</font><font style="font-family:inherit;font-size:12pt;">. The Parties shall consult and cooperate with each other in obtaining patent term extensions, adjustments, or restorations or supplemental protection certificates or their equivalents (each a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patent Extension</font><font style="font-family:inherit;font-size:12pt;">&#8221; and collectively &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Patent Extensions</font><font style="font-family:inherit;font-size:12pt;">&#8221;) in the Territory for the Licensed Patents and Joint Patents to the extent they Cover Licensed Compounds, Licensed Products, or the Monotherapy Regimen; provided that, (a) Incyte shall have the primary right and authority to seek and apply for Patent Extensions with respect to Licensed Patents and Joint Patents that [**] claim Monoclonal Antibodies, subject to review and comment by MacroGenics, which Incyte shall consider in good faith; (b) MacroGenics shall have the primary right and authority to seek and apply for Patent Extensions with respect to Licensed Patents and Joint Patents that [**] claim bi- or multi-specific antibodies, subject to review and comment by Incyte, which MacroGenics shall consider in good faith; and (c) the Parties shall discuss in good faith and shall mutually agree upon whether to seek and apply for Patent Extensions with respect to any Patents [**] Monoclonal Antibodies and [**]. In the event that a Party does not intend to seek a Patent Extension that is or will become available for a Licensed Patent or Joint Patent, it shall so inform the other Party in writing in sufficient time to permit the other Party to seek such Patent Extension. The Party that does not apply for a Patent Extension hereunder will cooperate fully with the other Party in making such filings or actions, including making available all required regulatory data and Information and executing any required authorizations to apply for such Patent Extension. All out-of-pocket expenses incurred in connection with activities of each Party with respect to the Licensed Patent(s) or Joint Patent(s) for which such Party seeks a Patent Extension pursuant to this Section 9.4 shall be entirely borne by such Party. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Infringement of Third Party Rights in the Territory</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notice</font><font style="font-family:inherit;font-size:12pt;">. In the event that a Third Party makes any claim, gives notice, or brings any suit or other </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;proceeding against MacroGenics or Incyte, or any of their respective Affiliates or sublicensees (including Collaborators) for infringement or misappropriation of any intellectual property rights of a Third Party arising out of the Exploitation of any Licensed Product in the Field (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Infringement </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">92</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Party receiving notice of a Third Party Infringement Claim shall promptly notify the other Party.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Defense</font><font style="font-family:inherit;font-size:12pt;">. Subject to Article 14, the Party or its respective Affiliate or sublicensee against which such Third Party Infringement Claim is brought shall have the sole right to defend such Third Party Infringement Claim. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">9.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Patent Oppositions and Other Proceedings</font><font style="font-family:inherit;font-size:12pt;">. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Patents</font><font style="font-family:inherit;font-size:12pt;">. If any Licensed Patent or Joint Patent becomes the subject of any proceeding commenced by a Third Party within the Territory in connection with an opposition, reexamination request, action for declaratory judgment, nullity action, interference, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;review, post-grant review, other patent office administrative proceedings or other attack upon the validity, title or enforceability thereof (a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Patent Challenge</font><font style="font-family:inherit;font-size:12pt;">&#8221;) (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, an action for infringement against a Third Party under Section 9.5, in which case the provisions of Section 9.5 shall govern), the Prosecuting Party as to such Licensed Patent or Joint Patent shall have the discretion whether to defend and shall control any defense of such Licensed Patent or Joint Patent, at its own expense; provided, however, that if the Prosecuting Party, declines or fails to take any action to defend such Third Party Patent Challenge within [**] of the commencement thereof, then the other Party shall have the right to defend and shall control any defense of such Licensed Patent or Joint Patent, at its own expense.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Third Party Patent Rights</font><font style="font-family:inherit;font-size:12pt;">. Except with respect to any Patents within the [**] or [**] (in which case the provisions of Section 10.2(j) shall govern), if either Party desires to bring an opposition, reexamination request, action for declaratory judgment, nullity action, interference, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter partes</font><font style="font-family:inherit;font-size:12pt;">&#32;review, post grant review, or other patent office administrative proceedings or other attack upon the validity, title or enforceability of a Patent owned or Controlled by a Third Party and that claims the Licensed Compound or a Licensed Product (either specifically or generically), or the use, manufacture, sale, offer for sale or importation of the Licensed Compound or a Licensed Product (either specifically or generically) (except insofar as such action is a counterclaim to or defense of, or accompanies a defense of, a Third Party&#8217;s claim or assertion of infringement under Section 9.5, in which case the provisions of Section 9.5 shall govern), such Party shall so notify the other Party and the Parties shall promptly confer to determine whether to bring such action or the manner in which to settle such action. Each Party shall have the right, but not the obligation, to bring at its own expense such action in the Territory, provided that the Parties shall use reasonable efforts as practicable to coordinate and cooperate in bringing such action(s). The Party not bringing an action under this Section 9.6(b) shall be entitled to separate representation in such proceeding by counsel of its own choice and at its own expense, and shall cooperate fully with the Party bringing such action. Any awards or amounts received in bringing any such action shall be first allocated </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">93</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">to reimburse the initiating Party&#8217;s expenses in such action, and any remaining amounts shall be allocated between the Parties as provided in Section 9.3(f).</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 10</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">REPRESENTATIONS, WARRANTIES AND COVENANTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Mutual Representations, Warranties and Covenants</font><font style="font-family:inherit;font-size:12pt;">. Each of the Parties hereby represents and warrants to the other Party as of the Execution Date and, as applicable, hereinafter covenants that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Organization</font><font style="font-family:inherit;font-size:12pt;">. It is a corporation duly organized, validly existing, and in good standing under the laws of the jurisdiction of its organization, and has all requisite power and authority, corporate or otherwise, to execute, deliver, and perform this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Binding Agreement</font><font style="font-family:inherit;font-size:12pt;">. This Agreement is a legal and valid obligation binding upon such Party and enforceable in accordance with its terms, subject to the effects of bankruptcy, insolvency, or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance, and general principles of equity (whether enforceability is considered a proceeding at law or equity).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Authorization</font><font style="font-family:inherit;font-size:12pt;">. The execution, delivery, and performance of this Agreement by such Party have been duly authorized by all necessary corporate action and do not conflict with any agreement, obligation, instrument, or understanding, oral or written, to which it is a party or by which it is bound, nor violate any Applicable Law or any order, writ, judgment, injunction, decree, determination, or award of any Governmental Authority presently in effect applicable to such Party.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Further Approval</font><font style="font-family:inherit;font-size:12pt;">. It is not aware of any government authorization, consent, approval, license, exemption of or filing or registration with any Governmental Authority under any Applicable Law, currently in effect, necessary for, or in connection with, the transactions contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements (save for Regulatory Approvals and similar authorizations from Governmental Authorities necessary for the Exploitation of Licensed Compound and Licensed Products as contemplated hereunder), except as may be required to obtain clearance of this Agreement under the HSR Act. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">No Inconsistent Obligations</font><font style="font-family:inherit;font-size:12pt;">. It is not under any obligation, contractual or otherwise, to any Person that conflicts with or is inconsistent in any material respect with the terms of this Agreement, or that would impede the diligent and complete fulfillment of its obligations hereunder.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">94</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Certain Actions</font><font style="font-family:inherit;font-size:12pt;">. It shall not take any actions between the Execution Date and the Effective Date that would, or would be reasonably likely to, cause any representations or warranties made by such Party in this Article 10 to be untrue or inaccurate in any material respect as of the Effective Date.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Additional Representations and Warranties of MacroGenics</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics represents and warrants as of the Execution Date and covenants to Incyte that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">To MacroGenics&#8217; Knowledge, there is no actual or threatened infringement or misappropriation of the Licensed Technology or Label Combination Patents by any Person in the Territory. MacroGenics (or its Affiliates) is the sole and exclusive owner of, or otherwise Controls pursuant to an Existing Third Party License, the Licensed Technology, Label Combination Patents and the Transferred Documentation. MacroGenics has all rights necessary to grant the licenses under the Licensed Technology and Label Combination Patents, and Rights of Reference to Regulatory Documentation that it grants to Incyte hereunder. During the Term, MacroGenics shall not, and shall cause its Affiliates not to, grant to any Third Party any rights that encumber or conflict with the rights granted to Incyte hereunder with respect to the Licensed Technology, Label Combination Patents or Transferred Documentation.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The Licensed Patents set forth on </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit A</font><font style="font-family:inherit;font-size:12pt;">, together with the Label Combination Patents, represent all Patents Controlled by MacroGenics (or its Affiliates) that Cover or disclose the Licensed Compound or any Invention necessary or useful for the Exploitation of the Licensed Compound or Licensed Products in the Territory in the Field as of the Execution Date. The Licensed Patents and Label Combination Patents are free and clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and licenses granted to Incyte hereunder. To MacroGenics&#8217; Knowledge, no Third Party has challenged or threatened in writing to challenge the scope, validity or enforceability of any Licensed Patent or Label Combination Patents (including, by way of example, through opposition or the institution or written threat of institution of interference, nullity or similar invalidity proceedings before the U.S. Patent and Trademark Office or any analogous foreign Governmental Authorities). MacroGenics or its Affiliates have timely paid all filing and renewal fees payable with respect to any Licensed Patents for which MacroGenics controls prosecution and maintenance, and with respect to all Label Combination Patents. The development of the Licensed Patents and Label Combination Patents has not been funded, in whole or in part, by the U.S. government. To MacroGenics&#8217; Knowledge, as of the Execution Date, the Exploitation of the Licensed Compound as a Monotherapy Regimen does not infringe or misappropriate the intellectual property or proprietary rights of any Third Party in the Territory, [**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The Licensed Know-How is free and clear of liens, charges or encumbrances other than licenses granted to Third Parties that are not inconsistent with the rights and </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">95</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">licenses granted to Incyte hereunder. MacroGenics and its Affiliates have taken commercially reasonable measures consistent with industry practices to protect the secrecy, confidentiality and value of all Licensed Know-How that constitutes trade secrets under Applicable Law (including requiring all employees, consultants and independent contractors to execute binding and enforceable agreements requiring all such employees, consultants and independent contractors to maintain the confidentiality of such Licensed Know-How), and, to MacroGenics&#8217; Knowledge, there has not occurred any unauthorized access, use, or disclosure of the Licensed Know-How. The development of the Licensed Know-How has not been funded, in whole or in part, by the U.S. government. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics has not received any written notice or threat of any material suit, legal claim, action, proceeding or investigation against MacroGenics or any of its Affiliates that relates to the Licensed Technology or Label Combination Patents, and no judgment or settlement is owed by MacroGenics or any of its Affiliates in connection with the Licensed Technology or Label Combination Patents. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">All current and former officers, employees, agents, advisors, consultants, contractors or other representatives of MacroGenics or any of its Affiliates who are inventors of or have otherwise contributed or are otherwise expected to contribute to the creation or development of any Licensed Technology or Label Combination Patents have or will have executed and delivered to MacroGenics or any such Affiliate, prior to contributing to the creation or development of any Licensed Technology or Label Combination Patents, a valid and enforceable assignment or other agreement regarding the protection of proprietary Information and the assignment to MacroGenics or any such Affiliate of such person&#8217;s entire right, title and interest in and to any Licensed Technology and Label Combination Patents. To MacroGenics&#8217; Knowledge, no current officer, employee, agent, advisor, contractor, consultant or other representative of MacroGenics or any of its Affiliates is in violation of any term of any assignment or other agreement regarding the assignment, protection, or confidentiality of Licensed Patents, other Licensed Technology, or Label Combination Patents, or of any employment contract or any other contractual obligation relating to the relationship of any such Person with MacroGenics or any such Affiliate. Incyte has no obligation to contribute to any remuneration of any inventor employed or previously employed by MacroGenics or any of its Affiliates in respect of any such Inventions, Information and discoveries and intellectual property rights therein that are so assigned to MacroGenics or its Affiliate(s).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics has prepared, maintained and retained all Transferred Documentation for the Licensed Compound and the Licensed Products in the Territory pursuant to and in accordance with all Applicable Law, including, as applicable, GLP. All activities conducted by or on behalf of MacroGenics with respect to Licensed Compound have been conducted in accordance with Applicable Law (including GLP and GMP).</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">96</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">To MacroGenics&#8217; Knowledge, other than under the Existing Third Party Licenses and [**], no royalties, milestones, or other payments are owed to any Third Party for Patents controlled by such Third Party that are reasonably likely to be necessary or useful in order to Exploit the Licensed Compound or Licensed Products.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(h)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Neither MacroGenics nor any of its Affiliates has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and neither MacroGenics nor any of its Affiliates has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction. MacroGenics shall not engage, and shall ensure that its licensees and Representatives shall not engage</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction. MacroGenics shall inform Incyte in writing promptly if it or any Person engaged by MacroGenics or any of its Affiliates who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to MacroGenics&#8217; Knowledge, is threatened, relating to the debarment or conviction of MacroGenics, any of its Affiliates or any such Person performing services hereunder or thereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics is not subject to any agreement with any Third Party which would limit or restrict its ability to perform its obligations under this Agreement in any material respect.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(j)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">MacroGenics covenants and agrees, and shall cause its Affiliates and any sublicensees (subject to the remainder of this subsection (j)) to covenant and agree, not to directly or indirectly challenge the validity, enforceability, patentability, or inventorship of any claim of any Patent within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or the [**], except in response to a claim of infringement of the Patent within the [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or the [**], as applicable. MacroGenics further agrees not to provide assistance or support, financial or otherwise, to any Third Party in bringing any such challenge to the infringement, validity, enforceability, patentability, or inventorship of any claim of any Patent within the [**] or the [**]. The foregoing restrictions with respect to the [**] shall, subject to Section 10.3(e), apply until, upon inquiry by MacroGenics and confirmation by Incyte, the existence and continued effectiveness of the sublicense granted to MacroGenics with respect to the [**] and/or any [**] thereto have terminated, changed or been amended otherwise. For clarity, the foregoing restrictions shall apply only to those [**] that have received a [**] or [**], as applicable; provided further, that to the extent a Third Party who [**] other than [**] or [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">within the [**] or the [**], the [**] to such Third Party under such other intellectual property shall not be construed as an [**] under this Section 10.2(j). </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">97</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Additional Representations and Warranties of Incyte</font><font style="font-family:inherit;font-size:12pt;">. Incyte represents and warrants as of the Execution Date and covenants to MacroGenics that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte has all rights necessary to grant to MacroGenics the licenses under the Incyte Patents and Rights of Reference to Regulatory Documentation related to the Licensed Compound or Licensed Products that it grants to MacroGenics hereunder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Neither Incyte nor any of its Affiliates or any Collaborators, has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any similar sanction of other Governmental Authorities in the Territory, and neither Incyte nor any of its Affiliates or any Collaborators has used, in any capacity, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction. Incyte shall not engage, and shall ensure that its Affiliates, Representatives and Collaborators shall not engage, in any capacity in connection with this Agreement or any ancillary agreements, any Person who either has been debarred by the FDA, is the subject of a conviction described in Section 306 of the FFDCA or is subject to any such similar sanction. Incyte shall inform MacroGenics in writing promptly if it or any Person engaged by Incyte or any of its Affiliates or Collaborators who is performing services under this Agreement or any ancillary agreements is debarred or is the subject of a conviction described in Section 306 of the FFDCA, or if any action, suit, claim, investigation or legal or administrative proceeding is pending or, to Incyte&#8217;s Knowledge, is threatened, relating to the debarment or conviction of Incyte, any of its Affiliates or Collaborators performing services hereunder or thereunder.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte is not subject to any agreement with any Third Party which would limit or restrict its ability to perform its obligations under this Agreement in any material respect.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">To Incyte&#8217;s Knowledge, [**], no royalties, milestones, or other payments are owed to any Third Party for Patents controlled by such Third Party that are reasonably likely to be necessary or useful in order to Exploit the Licensed Compound or Licensed Products.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">10.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">No Other Representations or Warranties</font><font style="font-family:inherit;font-size:12pt;">. EXCEPT AS EXPRESSLY SET FORTH IN THIS ARTICLE 10, THE PARTIES MAKE NO REPRESENTATIONS OR WARRANTIES OF ANY KIND WHATSOEVER, EITHER EXPRESS OR IMPLIED, WRITTEN OR ORAL, IN FACT OR BY OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND EACH PARTY SPECIFICALLY DISCLAIMS ANY OTHER WARRANTIES, INCLUDING ANY EXPRESS OR IMPLIED WARRANTY OF QUALITY, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR WARRANTY OF NON-INFRINGEMENT OR AS TO THE VALIDITY OF ANY PATENTS. EACH PARTY HEREBY DISCLAIMS ANY REPRESENTATION OR WARRANTY THAT THE DEVELOPMENT, MANUFACTURE OR COMMERCIALIZATION OF ANY COMPOUND OR PRODUCT PURSUANT TO THIS AGREEMENT WILL BE SUCCESSFUL </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">98</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">OR THAT ANY PARTICULAR SALES LEVEL WITH RESPECT TO ANY COMPOUND OR PRODUCT WILL BE ACHIEVED.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 11</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">CONFIDENTIALITY</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Nondisclosure</font><font style="font-family:inherit;font-size:12pt;">. Each Party agrees that, during the Term and for a period of [**] thereafter, the Party receiving Confidential Information (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Receiving Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disclosing Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) shall (a) maintain in confidence such Confidential Information using not less than the efforts such Receiving Party uses to maintain in confidence its own confidential or proprietary Information of similar kind and value, (b) not disclose such Confidential Information to any Third Party without the prior written consent of the Disclosing Party, except for disclosures expressly permitted below, and (c) not use such Confidential Information for any purpose except those permitted by this Agreement (it being understood that this Section 11.1 shall not create or imply any rights or licenses not expressly granted under this Agreement). Notwithstanding anything to the contrary in the foregoing, the obligations of confidentiality and non-use with respect to any trade secret within such Confidential Information shall survive such [**] period for so long as such Confidential Information remains protected as a trade secret under Applicable Law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Exceptions</font><font style="font-family:inherit;font-size:12pt;">. The obligations in Section 11.1 shall not apply with respect to any portion of the Confidential Information that the Receiving Party can show by competent, written evidence:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is publicly disclosed by the Disclosing Party, either before or after it is disclosed to the Receiving Party hereunder;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is known to the Receiving Party or any of its Affiliates, without any obligation to keep it confidential or any restriction on its use, prior to disclosure to the Receiving Party or any of its Affiliates by the Disclosing Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is subsequently disclosed to the Receiving Party or any of its Affiliates on a non-confidential basis by a Third Party that to the Receiving Party&#8217;s Knowledge is not bound by a duty of confidentiality or restriction on its use;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is now, or hereafter becomes, through no act or failure to act on the part of the Receiving Party or any of its Affiliates, generally known or available, either before or after it is disclosed to the Receiving Party by the Disclosing Party;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is independently discovered or developed by or on behalf of the Receiving Party or any of its Affiliates without the use of or reference to the Confidential Information belonging to the Disclosing Party; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">is the subject of written permission to disclose provided by the Disclosing Party. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Authorized Disclosure</font><font style="font-family:inherit;font-size:12pt;">. The Receiving Party may disclose Confidential Information belonging to the Disclosing Party only to the extent such disclosure is reasonably necessary in the following instances:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">99</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">filing, prosecuting, maintaining, enforcing or defending Patents as permitted by this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">as reasonably required in generating Regulatory Documentation and obtaining Regulatory Approvals;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">prosecuting or defending litigation, including responding to a subpoena in a Third Party litigation;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">complying with Applicable Law or court or administrative orders;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">complying with any obligation under this Agreement;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">in communications with existing or bona fide prospective acquirers, merger partners, financing sources, investment bankers, lenders or investors, and consultants and advisors of the Receiving Party in connection with transactions or bona fide prospective transactions with the foregoing, in each case on a need to know basis and under appropriate confidentiality provisions substantially equivalent to those of this Agreement; provided</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:12pt;">however, that the Receiving Party shall remain responsible for any violation of such confidentiality provisions by any Person receiving such Confidential Information; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">to its Affiliates, sublicensees or prospective sublicensees, subcontractors or prospective subcontractors, consultants, agents and advisors on a &#8220;need-to-know&#8221; basis in order for the Receiving Party to exercise its rights or fulfill its obligations under this Agreement, each of whom prior to disclosure must be bound by written obligations of confidentiality and restrictions on use of such Confidential Information that are no less restrictive than those set forth in this Article 11; provided, however, that, in each of the above situations, the Receiving Party shall remain responsible for any failure by any Person who receives Confidential Information pursuant to this Section 11.3(g) to treat such Confidential Information as required under this Article 11. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If and whenever any Confidential Information is disclosed in accordance with this Section 11.3, such disclosure shall not cause any such information to cease to be Confidential Information except to the extent that such disclosure results in a public disclosure of such information (other than by breach of this Agreement). Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party&#8217;s Confidential Information pursuant to Section 11.3(a) through Section 11.3(e), it will, except where impracticable or not legally permitted, give reasonable advance notice to the other Party of such disclosure and use not less than the same efforts to secure confidential treatment of such information as it would to protect its own confidential information from disclosure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Terms of this Agreement</font><font style="font-family:inherit;font-size:12pt;">. The Parties acknowledge that this Agreement and all of the respective terms of this Agreement shall be treated as Confidential Information of both Parties, subject to the provisions of Section 11.3(f), 11.3(g) and 11.6.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">100</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Publicity</font><font style="font-family:inherit;font-size:12pt;">. Without limiting the Parties&#8217; rights and obligations pursuant to Section 11.9 with respect to publications:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Each Party shall make a public announcement of the execution of this Agreement in the form attached as </font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">Exhibit D</font><font style="font-family:inherit;font-size:12pt;">&#32;to this Agreement, which shall be issued at a time to be mutually agreed by the Parties, but no later than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the Execution Date. Except as required to comply with Applicable Law or as set forth in subsection (b), each Party agrees not to issue any other press release or other public statement disclosing other information relating to this Agreement or the transactions contemplated hereby without the prior written consent of the other Party, such consent not to be unreasonably withheld, delayed or conditioned.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The Parties acknowledge the importance of supporting each other&#8217;s efforts to publicly disclose results and significant developments regarding the Licensed Products and other activities in connection with this Agreement that may include information that is not otherwise permitted to be disclosed under this Article 11, and that may be beyond what is required by Applicable Law, but in each case consistent with the need to keep investors informed regarding such Party&#8217;s business in accordance with customary investor relations, and each Party may request to the right to make such disclosures from time to time. Such disclosures may include achievement of milestones, significant events in the Development and regulatory process, Commercialization activities and the like. Except for the initial press release(s) described in subsection (a), whenever a Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Requesting Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) desires to make any such public disclosure, it shall first notify the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cooperating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) of such planned press release or public announcement and provide a draft for review at least [**] in advance of issuing such press release or making such public announcement (or, with respect to press releases and public announcements that are required by Applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), with as much advance notice as possible under the circumstances if it is not possible to provide notice at least [**] in advance). The Requesting Party and Cooperating Party will discuss such proposed public disclosure in good faith. Unless otherwise permitted pursuant to Section 11.6 or required by Applicable Law, or by regulation or rule of any public stock exchange (including NASDAQ), the Requesting Party will not issue such press release or make such public announcement without the prior written consent of the Cooperating Party, not to be unreasonably withheld, conditioned or delayed, provided that the Requesting Party may issue such press release or make such public announcement if: (i) the contents of such press release or public announcement have previously been made public other than through a breach of this Agreement by the Requesting Party, (ii) such press release or public announcement does not materially differ from, or relies solely on facts publicly disclosed in, a previously-approved press release or other publicly available information, and (iii) the Requesting Party notifies the Cooperating Party reasonably in advance of issuance. The principles to be observed in disclosures pursuant to this Section 11.5(b) shall include accuracy, compliance with Applicable Law and regulatory guidance documents, reasonable sensitivity to </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">101</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">potential negative reactions of the FDA (and its foreign counterparts), and the need to protect competitively sensitive information regarding Licensed Products and the legal obligations and responsibility to keep investors informed regarding the Requesting Party&#8217;s business.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Securities Filings</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary in this Article 11, in the event either Party proposes to file with the Securities and Exchange Commission or the securities regulators of any state or other jurisdiction a registration statement or any other disclosure document that describes or refers to the terms and conditions of this Agreement or any related agreements between the Parties, or requires the filing of this Agreement as an exhibit to such registration, statement or disclosure document, such Party shall notify the other Party of such intention and shall provide the other Party with a copy of relevant portions of the proposed filing at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior to such filing (and any revisions to such portions of the proposed filing a reasonable time prior to the filing thereof), including any exhibits thereto that refer to the other Party or the terms and conditions of this Agreement or any related agreements between the Parties. The Party making such filing shall cooperate in good faith with the other Party to obtain confidential treatment of the terms and conditions of this Agreement or any related agreements between the Parties that the other Party reasonably requests be kept confidential or otherwise afforded confidential treatment, and shall only disclose Confidential Information that it is advised by outside counsel is legally required to be disclosed. Each Party acknowledges that the other Party may be required by securities regulators, including the Securities and Exchange Commission, or advised by such other Party&#8217;s outside counsel that the financial terms, including the milestone amounts and/or royalty rates must be included in such filings. No notice shall be required under this Section 11.6 if the description of or reference to this Agreement or a related agreement between the Parties contained in the proposed filing has been included in any previous filing made by either Party in accordance with this Section 11.6 or otherwise approved by the other Party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Relationship to Confidentiality Agreement</font><font style="font-family:inherit;font-size:12pt;">. This Agreement supersedes the Prior CDA; provided, however, that all &#8220;Confidential Information&#8221; disclosed or received by the Parties and their Affiliates thereunder shall be deemed Confidential Information hereunder and shall be subject to the terms and conditions of this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Equitable Relief</font><font style="font-family:inherit;font-size:12pt;">. Given the nature of the Confidential Information and the competitive damage that could result to a Party upon unauthorized disclosure, use or transfer of its Confidential Information to any Third Party, the Parties agree that monetary damages may not be a sufficient remedy for any breach of this Article 11. In addition to all other remedies, a Party shall be entitled to seek specific performance and injunctive and other equitable relief as a remedy for any breach or threatened breach of this Article 11. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Publications</font><font style="font-family:inherit;font-size:12pt;">. The publishing Party shall have the right to publish results of all Clinical Studies and Development activities conducted pursuant to this Agreement, (a) with respect to Incyte as the publishing Party, in connection with any Incyte Pipeline Asset, Collaborator Pipeline Asset, Incyte Combination Regimen, Collaborator Combination Regimen or Monotherapy Regimen and any other activity Incyte is permitted to conduct under this Agreement related to the Licensed Compound or a Licensed Product and (b) with respect to MacroGenics as the publishing Party, in </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">102</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">connection with any MacroGenics Pipeline Asset or MacroGenics Combination Regimen (and including, for clarity, any MacroGenics Combination Study (including translational data related thereto, pre-clinical data and other data related to Development activities conducted pursuant to this Agreement, but excluding pre-clinical data that is solely related to the Licensed Compound after the Study Transition Date), and the Ongoing Clinical Study (prior to the Study Transition Date)); provided, in each case ((a) and (b)) however, that the reviewing Party shall have the right to review all proposed publications with respect to the Licensed Compound or Licensed Products (including as a component of a Monotherapy Regimen or a MacroGenics Combination Regimen) prior to submission of such publication, for the purposes of identifying any relevant intellectual property or Confidential Information belonging in whole or in part to the reviewing Party and recommending any changes the reviewing Party reasonably believes are necessary to preserve any such intellectual property or Confidential Information. The publishing Party shall provide reviewing Party with a copy of the applicable proposed abstract, manuscript, or presentation no less than [**] ([**] in the case of abstracts) prior to its intended submission for publication. The reviewing Party shall respond in writing promptly and in no event later than [**] after receipt of the proposed material with one or more of the following: (i) comments on the proposed material, which the publishing Party will consider in good faith but is not obligated to accept ([**], for any such publications made or proposed to be made before the earlier of Licensed Compound Approval or [**] after the Effective Date, to the extent [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to the proposed material (x) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or [**] and (y) may be incorporated consistent with the [**], MacroGenics shall [**]); or (ii) any concerns regarding patentability or protection of its Confidential Information. In the event of concern over Patent protection, the publishing Party agrees not to submit such publication or to make such presentation that contains such information until the reviewing Party is given a reasonable period of time, and in no event less than [**], to seek Patent protection for any material in such publication or presentation which it believes is patentable. Subject to Section 11.3, any Confidential Information of the reviewing Party shall, absent the prior written consent of the reviewing Party, be removed by the publishing Party from such publication or presentation. In the case of conference abstracts and other rapid scientific communications, the Parties will use reasonable efforts to complete the review process in [**] or less. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">11.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Additional Obligations Relating to Competing Antibodies</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">In the event that MacroGenics or an Affiliate [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">(i) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">owned or Controlled by MacroGenics (or its Affiliates); or (ii) [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by MacroGenics or an Affiliate, in each case (of (i) and (ii)) other than Licensed Compound, MacroGenics shall and shall cause its Affiliates to: (x) adopt reasonable written procedures to prevent any of MacroGenics&#8217; Representatives (excluding any MacroGenics [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or [**], and [**] or [**], it being understood that such employees are otherwise subject to the applicable confidentiality obligations under this Agreement) involved in conducting such Clinical Studies or Commercialization from accessing or using any Confidential Information of Incyte or its Affiliates or sublicensees, or any of their commercially-sensitive information or pricing information relating to the Licensed Compound or Licensed Products and (y) require such Representatives to [**] and [**] between MacroGenics and Incyte under this Agreement (including Joint Committee meetings) and [**] to the Licensed Compound or any Licensed Product.</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">103</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">In the event that Incyte or an Affiliate directly or indirectly [**], in each case which [**] or [**] (</font><font style="font-family:inherit;font-size:12pt;font-style:italic;">e.g.</font><font style="font-family:inherit;font-size:12pt;">&#32;[**]), Incyte shall and shall cause its Affiliates to: (x) adopt reasonable written procedures to prevent any of Incyte&#8217;s Representatives ([**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">or [**], and [**], it being understood that such employees are otherwise subject to the applicable confidentiality obligations under this Agreement) involved in conducting such Clinical Studies or Commercialization from accessing or using any Confidential Information of MacroGenics or its Affiliates or sublicensees, or any of their commercially-sensitive information or pricing information relating to the MacroGenics Pipeline Asset and (y) require such Representatives to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">and [**] between MacroGenics and Incyte under this Agreement (including Joint Committee meetings) and [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to the MacroGenics Pipeline Asset.</font></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 12</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TERM AND TERMINATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Term</font><font style="font-family:inherit;font-size:12pt;">. This Agreement shall become effective as of the Execution Date and, unless earlier terminated pursuant to this Article 12, shall continue in full force and effect as long as Incyte continues to Exploit the Licensed Compound or Licensed Products in accordance with the terms and conditions of this Agreement (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Term</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The provisions of Article 1 (Definitions), Article 10 (Representations, Warranties and Covenants), Article 11 (Confidentiality), Article 13 (Dispute Resolution), Article 14 (Indemnification) and Article 15 (Miscellaneous), and Section 12.3 (Termination for Material Breach) and Section 12.7 (HSR Filing; Termination Upon HSR Denial),</font><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">shall become effective on the Execution Date; the other provisions of this Agreement shall not become effective until the Effective Date. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Unilateral Termination by Incyte</font><font style="font-family:inherit;font-size:12pt;">. Incyte shall have the right to terminate this Agreement in its entirety, or on a Licensed Product-by-Licensed Product basis, at any time after the Execution Date, for any or no reason, upon providing [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior written notice to MacroGenics. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination for Material Breach</font><font style="font-family:inherit;font-size:12pt;">. Either Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Terminating Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) may terminate this Agreement in its entirety, or on a country-by-country and Licensed Product-by-Licensed Product basis, in the event the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Breaching Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;) has materially breached this Agreement, and such material breach has not been cured within [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after receipt of written notice of such breach by the Breaching Party from the Terminating Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cure Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;). The written notice describing the alleged material breach shall provide sufficient detail to put the Breaching Party on notice of such material breach. Any termination of this Agreement pursuant to this Section 12.3 shall become effective at the end of the Cure Period, unless the Breaching Party has cured any such material breach prior to the expiration of such Cure Period (or, if such material breach is not reasonably able to be cured within the Cure Period, the Breaching Party has notified the Terminating Party of its plan for curing such material breach, has commenced and sustained its efforts to cure such material breach during the Cure Period and does cure such material breach within [**] after the end of the Cure Period). The right of either Party to terminate this Agreement as provided in this Section 12.3 shall not be affected in any way by such Party&#8217;s waiver of or failure to take action with respect to any previous breach under this Agreement.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">104</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination by Incyte for Safety Reasons</font><font style="font-family:inherit;font-size:12pt;text-decoration:underline;">.</font><font style="font-family:inherit;font-size:12pt;">&#32;Incyte shall have the right to terminate this Agreement, at any time after the Effective Date at any time upon providing [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior written notice to MacroGenics: (a) if [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">responsible for Incyte&#8217;s [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">in good faith that the [**] of the Licensed Product is such that the Licensed Product cannot continue to be Developed or administered to patients safely; or (b) upon the occurrence of [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">serious safety-related events related to the use of the Licensed Product that cause Incyte [**] safety [**] of the Licensed Product [**] of the Licensed Products.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination for Patent Challenge</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">MacroGenics may terminate this Agreement with respect to a Licensed Product (or this Agreement in its entirety if such Licensed Product is the only Product for which this Agreement is applicable), if Incyte or any of its Affiliates directly or indirectly disputes, or assists any Third Party to dispute, the validity of any granted Patent within the Licensed Patents in a litigation or other court proceeding with respect to such Licensed Product; provided, however, MacroGenics acknowledges and agrees that nothing in this Section 12.5 prevents Incyte from taking any of the actions referred to in this Section 12.5 and, provided further that MacroGenics shall not have the right to terminate if Incyte: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">opposes, or assists any Third Party to oppose, the grant of a Patent pursuant to any application in relation to the Licensed Patents in an administrative proceeding, such as a patent re-examination, </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">inter-partes</font><font style="font-family:inherit;font-size:12pt;">&#32;review, or other post grant proceeding or opposition;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">asserts invalidity as a defense in any court proceeding brought by MacroGenics, its Affiliates, sublicensees, successors or designees asserting infringement of a Licensed Patent; and/or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">either (i) acquires a Third Party that has an existing challenge, whether in a court or administrative proceeding, against a Licensed Patent or (ii) licenses a product for which the licensor has an existing challenge, whether in a court or administrative proceeding, against a Licensed Patent.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Termination for Bankruptcy</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Either Party may terminate this Agreement in its entirety upon providing written notice to the other Party on or after the time that such other Party makes a general assignment for the benefit of creditors, files an insolvency petition in bankruptcy, petitions for or acquiesces in the appointment of any receiver, trustee or similar officer to liquidate or conserve its business or any substantial part of its assets, commences under the laws of any jurisdiction any proceeding involving its insolvency, bankruptcy, reorganization, adjustment of debt, dissolution, liquidation or any other similar proceeding for the release of financially distressed debtors, or becomes a party to any proceeding or action of the type described above (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insolvency Event</font><font style="font-family:inherit;font-size:12pt;">&#8221;), and such proceeding or action remains un-dismissed or un-stayed for a period of more than [**].</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">105</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">All rights and licenses granted under or pursuant to this Agreement, including, for the avoidance of doubt, the licenses granted to Incyte pursuant to Section 3.1, are, and shall otherwise be deemed to be, for purposes of Section 365(n) of Title 11 of the U.S. Code (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Section</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">365(n)</font><font style="font-family:inherit;font-size:12pt;">&#8221;) and other similar laws in any jurisdiction outside the U.S. (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Bankruptcy Laws</font><font style="font-family:inherit;font-size:12pt;">&#8221;), licenses of rights to &#8220;intellectual property&#8221; as defined under the Bankruptcy Laws. Upon the occurrence of any Insolvency Event with respect to a Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the Insolvent Party agrees that the other Party (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Non-Insolvent Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;), as licensee of such rights under this Agreement, shall retain and may fully exercise all of its rights and elections under the Bankruptcy Laws. Further, each Party agrees and acknowledges that all payments hereunder, other than the upfront payment pursuant to Section 8.1, milestone payments pursuant to Section 8.2 the royalty payments pursuant to Section 8.3, and the payments pursuant to Section 8.10 do not constitute royalties within the meaning of Section 365(n) or relate to licenses of intellectual property hereunder. Each Party shall, during the term of this Agreement, create and maintain current copies or, if not amenable to copying, detailed descriptions or other appropriate embodiments, to the extent feasible, of all such intellectual property (Licensed Technology in the case of MacroGenics and Incyte Technology in the case of Incyte). Each Party agrees and acknowledges that &#8220;embodiments&#8221; of intellectual property within the meaning of Section 365(n) include laboratory notebooks, cell lines, product samples and inventory, research studies and data, Regulatory Approvals and Regulatory Documentation in each case to the extent related to the Licensed Compound and Licensed Products. If: (i) a case is commenced during the Term by or against a Party under the Bankruptcy Laws, (ii) this Agreement is rejected as provided for under the Bankruptcy Laws, and (iii) the Non-Insolvent Party elects to retain its rights hereunder as provided for under the Bankruptcy Laws, then the Insolvent Party (in any capacity, including debtor-in-possession) and its successors and assigns (including a Title 11 trustee), shall (x) provide to the Non-Insolvent Party immediately upon the Non-Insolvent Party&#8217;s written request copies of all such intellectual property (including embodiments thereof) held by the Insolvent Party and such successors and assigns, or otherwise available to them, and (y) not interfere with the Non-Insolvent Party&#8217;s rights under this Agreement, or any related agreements between the Parties, to such intellectual property (including such embodiments), including any right to obtain such intellectual property (or such embodiments) from another entity, to the extent provided in the Bankruptcy Laws. Whenever the Insolvent Party or any of its successors or assigns provides to the Non-Insolvent Party any of the intellectual property licensed hereunder (or any embodiment thereof) pursuant to this Section 12.6(b), the Non-Insolvent Party shall have the right to perform the Insolvent Party&#8217;s obligations hereunder with respect to such intellectual property, but neither such provision nor such performance by the Non-Insolvent Party shall release the Insolvent Party from liability resulting from rejection of the license or the failure to perform such obligations. All rights, powers and remedies of the Non-Insolvent Party as provided herein are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at law or in equity (including the Bankruptcy Laws) in the event of the </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">106</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">commencement of a case by or against a Party under the Bankruptcy Laws. In particular, it is the intention and understanding of the Parties to this Agreement that the rights granted to the Parties under this Section 12.6 are essential to the Parties&#8217; respective businesses and the Parties acknowledge that damages are not an adequate remedy. The Parties agree that they intend the following rights to extend to the maximum extent permitted by Applicable Law, and to be enforceable under Section 365(n): (A) the right of access to any intellectual property (including embodiments thereof) of the Insolvent Party, or any Third Party with whom the Insolvent Party contracts to perform an obligation of the Insolvent Party under this Agreement, and, in the case of the Third Party, which is necessary for the Exploitation of the Licensed Compound or Licensed Products; and (B) the right to contract directly with any Third Party to complete the contracted work upon failure of the Insolvent Party to comply with its applicable obligations.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">HSR Filing; Termination Upon HSR</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;"><sub style="vertical-align:bottom;line-height:120%;font-size:8pt"> </sub></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Denial</font><font style="font-family:inherit;font-size:12pt;">. If Incyte or MacroGenics determines that an HSR Filing is necessary, it shall so notify the other Party, and each Party shall, within [**] of the Execution Date (or such later time as may be agreed to in writing by the Parties), file with the U.S. Federal Trade Commission and the Antitrust Division of the U.S. Department of Justice, and/or with equivalent foreign authorities, any HSR Filing required of it under the HSR Act in the reasonable opinion of either Party with respect to the transactions contemplated hereby. Each Party will use reasonable efforts to do, or cause to be done, all things necessary, proper and advisable to, as promptly as practicable, take all actions necessary to make the filings required of such Party or its Affiliates under the HSR Act. The Parties shall cooperate with one another to the extent necessary in the preparation of any such HSR Filing. Each Party shall be responsible for its own costs, expenses, and filing fees associated with any HSR Filing; provided, however, that [**] shall be solely responsible for any [**] (other than [**] that may be incurred as a result of [**] on the part of [**]) required to be [**] in connection with [**]. If the Parties make an HSR Filing hereunder, then this Agreement shall terminate (a) at the election of either Party, immediately upon notice to the other Party, if the U.S. Federal Trade Commission or the U.S. Department of Justice, or an equivalent authority in the European Union, seeks a preliminary injunction under the Antitrust Laws against Incyte and MacroGenics to enjoin the transactions contemplated by this Agreement; or (b) at the election of either Party, immediately upon notice to the other Party, in the event that the HSR Clearance Date shall not have occurred on or prior to [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after the effective date of the HSR Filing. In the event of such termination, this Agreement shall be of no further force and effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Effects of Termination</font><font style="font-family:inherit;font-size:12pt;">.</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:12pt;">All of the following effects of termination are in addition to the other rights and remedies that may be available to either of the Parties under this Agreement and shall not be construed to limit any such rights or remedies. In the event of termination of this Agreement (other than in connection with Section 12.7 and except as otherwise noted below), the following provisions of this Section 12.8 shall apply from and after the effective date of termination:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, without limiting the effect that such termination shall have on any provisions of this Agreement, other than those provisions that this Agreement expressly provides shall survive such termination, all rights and licenses granted herein to Incyte shall </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">107</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">terminate, all such previously licensed rights shall revert to MacroGenics, and Incyte shall cease any and all Development, Manufacturing, and Commercialization activities with respect to the Licensed Compound and Licensed Products (to the extent such activities were being performed using such rights and licenses) as soon as is reasonably practicable under Applicable Law.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6 (in which events all payment obligations hereunder shall survive), all payment obligations hereunder shall terminate, other than those that are accrued and unpaid as of the effective date of such termination and royalties that become due under Section 8.3 with respect to Net Sales of the Licensed Compound and all Licensed Products made following the effective date of termination to the extent permitted under Section 12.8(f).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The Parties will enter into good-faith discussions with respect to any transition or conveyance of assets, rights, access to materials, or processes that are not otherwise transitioned pursuant to this Section 12.8 but may be necessary for the Parties&#8217; future development and commercialization activities with respect to the Licensed Compound and Licensed Products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Solely in the event of a Qualifying Termination, Incyte hereby grants to MacroGenics, effective as of the effective date of such termination, a non-exclusive, transferable, fully paid-up, royalty-free, sublicenseable license in the Field in the Territory, under the Incyte Technology that Covers the Exploitation of, or is incorporated into, the Licensed Compound or any Licensed Product at the time of termination, solely to Exploit the Licensed Compound or Monotherapy Regimen; provided, however, that MacroGenics shall reimburse Incyte for any amounts paid by Incyte to any Third Party in connection with MacroGenics&#8217; exercise of its right to obtain such license (it being understood that MacroGenics shall have the right to decline to accept such license as to some or all of the rights in this subsection (d) if MacroGenics does not wish to assume the related Third Party obligation); provided further, that MacroGenics shall have the right, on a license-by-license basis, to terminate its license with respect to any Incyte Technology licensed under such Third Party license at any time subject to any limitations on termination rights and any notice and ongoing payment obligations under the applicable Third Party license. Notwithstanding the foregoing, any rights, licenses, or sublicenses granted by Incyte under the Incyte Technology under this subsection (d) shall continue only to the extent and only for so long as Incyte continues to have the contractual right under the applicable Third Party license (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Upstream License</font><font style="font-family:inherit;font-size:12pt;">&#8221;) to extend such rights, licenses, or sublicenses to MacroGenics. Any assignee of Incyte&#8217;s rights under the applicable Upstream License will be required to take such assignment subject to the rights of MacroGenics under this subsection (d).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Wind-down</font><font style="font-family:inherit;font-size:12pt;">. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">108</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The JSC shall coordinate the wind-down of the Parties&#8217; activities under this Agreement. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Solely in the event of a Qualifying Termination: (A) Incyte, as soon as reasonably practicable after the effective date of such termination, upon MacroGenics&#8217; written request, shall provide to MacroGenics, as applicable and to the extent permitted under any applicable Third Party contract, any material Information, including copies of all Clinical Study data and results, arising out of the performance by or on behalf of Incyte of activities under this Agreement and Controlled by Incyte to the extent solely relating to the Licensed Compound and any Licensed Products, including control of, and all Information relating to, the Global Safety Database; and (B) Incyte will reasonably cooperate with MacroGenics to provide a transfer of such material Information. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, beginning on the date that notice of any termination of this Agreement is given by the terminating Party, (A) Incyte shall have no further right or obligation to commence or provide funding for any Clinical Study of the Licensed Compound, whether or not such Clinical Study had been Initiated on or before such date of notice of termination of this Agreement, except that: (x) if [**]; and (y) if [**] following the effective date of such termination or [**], whichever is earlier; and (B) if [**] as described in (y) above, [**] (except to the extent otherwise provided above, [**]).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Solely in the event of a Qualifying Termination, at MacroGenics&#8217; request, but without expanding the provisions of Section 12.8(d) with respect to any Upstream License, Incyte shall use reasonable efforts to (x) assign to MacroGenics any and all Third Party agreements to which Incyte or any of its Affiliates are a party that relate exclusively to any Development, Commercialization or Manufacturing activities conducted in connection with the Licensed Compound or any Licensed Products prior to such termination (including agreements relating to the sourcing and Manufacture of the Licensed Compound or any Licensed Products or, to the extent the First Commercial Sale of the Licensed Compound or any Licensed Product has occurred, for sale, promotion, distribution, or use of such Licensed Compound or Licensed Product), or (y) if such assignment is not permitted under the relevant Third Party agreement: (1) grant to MacroGenics other rights to provide to MacroGenics the benefit of such non-assignable agreement, at MacroGenics&#8217; expense, to the extent permitted under the terms of such non-assignable agreement; or (2) to the extent such grant is not permitted under the terms of such non-assignable agreement, discuss with MacroGenics in good faith an alternative solution to enable MacroGenics to receive, at MacroGenics&#8217; expense, the benefit of the terms of such non-assignable agreement. </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">109</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, in the event the Licensed Compound or Licensed Product are Manufactured by Incyte or its Affiliate or an Approved CMO, then, upon the written request of MacroGenics, Incyte shall supply MacroGenics with such Licensed Compound and Licensed Products and/or materials at a commercially reasonable price, until Incyte (or its Affiliate or Approved CMO) elects to cease Manufacturing of the Licensed Compound and Licensed Products, in which case: (x) Incyte will provide [**] prior notice to MacroGenics of the election to cease such Manufacture, and (y) if necessary and at MacroGenics&#8217; cost and expense, Incyte will provide reasonable amounts of technical assistance reasonably necessary to assist MacroGenics in the start-up of Manufacturing of such the Licensed Compound and Licensed Products and/or materials, and/or obtaining Regulatory Approval of the Licensed Compound and Licensed Products. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, at MacroGenics&#8217; request, Incyte shall transfer to MacroGenics, and [**], any Licensed Compound or Licensed Product held by Incyte that has not been sold or used by Incyte within [**] following such termination, [**], with respect to such Licensed Compound and Licensed Products.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(g)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, Incyte shall (i) transfer to MacroGenics any and all Regulatory Documentation and safety data Controlled by Incyte on the effective date of termination, to the extent such information relates solely to any Licensed Compound, Monotherapy Regimen, Licensed Products and, if applicable pursuant to Sections 5.8(a) or 5.8(c), MacroGenics Combination Regimens, (ii) transfer to MacroGenics any and all other related Know-How Controlled by Incyte on the effective date of termination, to the extent such Know-How relates solely to any Licensed Compound, Monotherapy Regimen or Licensed Products and (iii) upon MacroGenics&#8217; request, provide a Right of Reference to any Regulatory Documentation Controlled by Incyte on the effective date of termination, to the extent such Regulatory Documentation is necessary for MacroGenics or its licensees to Develop and/or Commercialize the Licensed Compound and, if applicable pursuant to Sections 5.8(a) or 5.8(c), MacroGenics Combination Regimens, and has not already been transferred to MacroGenics hereunder. MacroGenics shall [**] and [**] in order to complete the activities pursuant to this subsection (g), within [**] after [**] of any [**].</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(h)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, Incyte shall return to MacroGenics all Licensed Know-How, including Transferred Documentation and Regulatory Documentation, previously provided to Incyte by or on behalf of MacroGenics. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6 (in which case Incyte&#8217;s rights with respect to preparation, filing, prosecution, </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">110</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">maintenance and enforcement activities under Article 9 with respect to Licensed Patents shall survive termination), MacroGenics shall have the right to assume all preparation, filing, prosecution, maintenance and enforcement activities under Article 9 with respect to Licensed Patents as to which Incyte has assumed the right and authority to prepare, file, prosecute, maintain or enforce; provided that MacroGenics shall notify Incyte in writing at least [**] prior to the effective date of termination of this Agreement of those Licensed Patents for which MacroGenics wishes to assume such activities. During the period between delivery of such notice by MacroGenics and the effective date of termination, the Parties will discuss the list of Licensed Patents for which MacroGenics wishes to assume such activities, and following such discussion Incyte shall be free to continue, abandon or terminate without liability all preparation, filing, prosecution, maintenance and enforcement activities under Article 9 with respect to Licensed Patents (or the applicable activities) that are not included in such notice. Incyte will cooperate with MacroGenics and, if requested by MacroGenics, provide MacroGenics with reasonable assistance at MacroGenics&#8217; cost and expense, with the preparation, filing, prosecution, maintenance, and enforcement activities with respect to such Licensed Patents. In the event MacroGenics assumes any enforcement activities being conducted by Incyte prior to termination of this Agreement, then any amount received by MacroGenics in connection with a settlement, by award of a court, or pursuant to another dispute resolution with respect to such assumed activities shall first be used to reimburse the Parties for their respective costs incurred in connection with such action (whether before or after the effective date of termination), and any remaining amount shall be (i) allocated [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">to MacroGenics and [**] to Incyte to the extent the amount relates to infringing activity that occurred prior to the effective date of termination and (ii) retained [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">by MacroGenics to the extent the amount relates to infringing activity that occurred after the effective date of termination.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(j)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, for each Collaborator Contract that complies with the requirements of Section 3.2(b), Incyte shall assign such Collaborator Contract to MacroGenics, and MacroGenics shall assume such Collaborator Contract from Incyte; provided that MacroGenics shall not be obligated to participate in any cost-sharing arrangement in which Incyte had been participating under such Collaborator Contract; provided, however, that (i) in no event shall MacroGenics&#8217; obligations with respect to such Collaborator Contract be any greater than MacroGenics&#8217; obligations under this Agreement or its rights with respect to such Collaborator Contract be any less than MacroGenics&#8217; rights under this Agreement (it being understood that MacroGenics shall not be required to supply any Licensed Compound Bulk Drug Substance or Licensed Compound Drug Product beyond the planned capacity of the MacroGenics Manufacturing Facilities allocated to such products, as applicable, prior to such termination); (ii) MacroGenics shall have no obligation to assume any Collaborator Contract if doing so would put MacroGenics in breach of such contract; and (iii) Incyte hereby agrees to defend, indemnify and hold harmless the MacroGenics Indemnitees from and against any and all Losses to which any MacroGenics </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">111</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Indemnitee may become subject as a direct result of any Claim by any Third Party (including any Collaborator) to the extent such Losses result from Incyte&#8217;s breach of its obligations under the applicable Collaborator Contract prior to the date of assignment of such Collaborator Contract pursuant to this Section 12.8(j). </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(k)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Other than in the event of termination by Incyte pursuant to Section 12.3 or Section 12.6, for each Development Agreement entered into between Incyte and a licensee or Third Party subcontractor of Incyte pursuant to Section 4.5, at MacroGenics&#8217; option, Incyte will assign such Development Agreement to MacroGenics; provided that MacroGenics shall notify Incyte in writing at least [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">prior to the effective date of termination of this Agreement of those Development Agreement(s) which MacroGenics wishes to assume, and Incyte shall be free to terminate without liability any Development Agreement that is not included in such notice.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Effect of Termination for MacroGenics Breach or Bankruptcy</font><font style="font-family:inherit;font-size:12pt;">. All of the following effects of termination are in addition to the other rights and remedies that may be available to either of the Parties under this Agreement and shall not be construed to limit any such rights or remedies. In the event of termination of this Agreement by Incyte pursuant to Section 12.3 or Section 12.6, the following provisions of this Section 12.9 shall apply from and after the effective date of termination: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The rights and licenses granted herein to MacroGenics pursuant to Section 3.4(b) or Section 5.4(a) or retained by MacroGenics, in each case, related to the Exploitation of the MacroGenics Pipeline Assets and the right to conduct or have conducted the MacroGenics Combination Studies shall continue in full force and effect, in accordance with and subject to the terms and conditions of this Agreement (including for clarity, the retained rights by MacroGenics in Section 3.3 and as applicable, the licenses in Section 3.4(b)); provided, however, that: (i) any such rights, licenses, or sublicenses granted by Incyte shall continue only to the extent and only for so long as Incyte continues to have the contractual right under the applicable Upstream License to extend such rights, licenses, or sublicenses to MacroGenics; and (ii) if MacroGenics&#8217; breach of its obligations under this Agreement constitutes a breach under an Upstream License, then MacroGenics shall not receive any rights under this Section 12.9(a) with respect to any rights, licenses, or sublicenses that are subject to such Upstream License. Any assignee of Incyte&#8217;s rights under the applicable Upstream License will be required to take such assignment subject to the rights of MacroGenics under this Section 12.9(a). MacroGenics shall reimburse Incyte for any amounts paid by Incyte to any Third Party in connection with MacroGenics&#8217; exercise of such licenses (it being understood that MacroGenics shall have the right to decline such license as to some or all of the rights in this subsection (a) upon written notice to Incyte if MacroGenics does not wish to assume the related Third Party obligation); provided further, that MacroGenics shall have the right, on a license-by-license basis, to terminate its license pursuant to this subsection (a) under such Third Party license at any time upon written notice to Incyte, subject to any </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">112</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">limitations on termination rights and any notice and ongoing payment obligations under the applicable Third Party license. </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">All payment obligations hereunder shall survive, including those payment obligations that are accrued and unpaid as of the effective date of such termination; provided that Incyte may pursue remedies under Section&#160;12.10 and, pending resolution of any claim for remedies under Section&#160;12.10, Incyte may pay to a reputable Third Party escrow agent selected by Incyte and pursuant to a three-party agreement among Incyte, MacroGenics and the escrow agent up to [**] of any royalties or milestones otherwise owed to MacroGenics hereunder (but in no event more than the amount reasonably being asserted by Incyte pursuant to Section 12.10 as damages arising from the applicable breach or bankruptcy), and such escrow agent shall hold all such payments pending resolution of the dispute hereunder; provided that, following resolution of the claim, the escrow agent will be instructed to allocate the payments between the Parties as follows: %3. first, the escrow agent will pay to Incyte the amount of damages, costs and other amounts that MacroGenics is required (or agrees) to pay to Incyte in connection with the applicable claim pursuant to Section&#160;12.10, together with Incyte&#8217;s costs and expenses in connection with bringing such claim, and %3. any remaining amount will be paid to MacroGenics. The foregoing shall not be construed to limit Incyte&#8217;s ability to recover any amount asserted against MacroGenics under Section 12.10 [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">under this subsection (b). </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">All licenses granted to Incyte shall continue in full force and effect, in accordance with and subject to the terms and conditions of this Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">At Incyte&#8217;s option, in accordance with a commercially reasonable transition plan established by the JMC with the goal of allowing the Parties to continue to conduct their businesses following termination as contemplated under this Section 12.9, Incyte shall have the right, upon written notice to MacroGenics, to assume the Manufacture of one hundred percent (100%) of the global requirements of the Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product (other than quantities that MacroGenics may manufacture for its own use in MacroGenics Combination Studies thereafter), following which MacroGenics shall not have the right to supply any Licensed Compound Bulk Drug Substance and Licensed Compound Drug Product unless expressly authorized by Incyte in writing. Until such time that Incyte so notifies MacroGenics that it is prepared to Manufacture all such global requirements, MacroGenics shall Manufacture and supply to Incyte up to [**] ([**]%) of MacroGenics&#8217; then-committed supply of Incyte&#8217;s global requirements of the Licensed Compound Bulk Drug Substance and/or Licensed Compound Drug Product, in accordance with the provisions of Section 7.2 and Section 7.3. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(e)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte may at its sole discretion, in accordance with a commercially reasonable transition plan established by the JDC or JMC, as applicable, with the goal of allowing the Parties to continue to conduct their businesses following termination as </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">113</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">contemplated under this Section 12.9, commence the Study Transition, IND Transition, Manufacturing Technology Transfer, and/or Information Transfer upon written notice to MacroGenics, if and to the extent the same have not been commenced as of the effective date of termination, as to which transitions Incyte may specify shortened timeframes to the extent compliance therewith by MacroGenics is reasonably practicable, and the obligations of MacroGenics in connection with the Study Transition, IND Transition, Manufacturing Technology Transfer, and/or Information Transfer shall continue until their completion in accordance with the terms and conditions of this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(f)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte (or its Collaborators, as applicable) shall have the sole right and responsibility to conduct any and all Clinical Studies Initiated by Incyte or its sublicensees or Collaborators prior to the effective date of such termination, but shall have no obligations in connection with any Clinical Studies being conducted by MacroGenics as of the effective date of such termination. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For clarity, any termination pursuant to this Section 12.9 shall not affect MacroGenics&#8217; rights with respect to maintaining continued access to the Global Safety Database. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Remedies</font><font style="font-family:inherit;font-size:12pt;">. Except as otherwise explicitly set forth in this Agreement, termination or expiration of this Agreement shall not relieve the Parties of any liability or obligation which accrued hereunder prior to the effective date of such termination or expiration, nor prejudice either Party&#8217;s right to obtain performance of any obligation. Each Party shall be free, pursuant to Article 13, to seek, without restriction as to the number of times it may seek, damages, costs and remedies that may be available to it under Applicable Law or in equity and shall be entitled to offset the amount of any damages and costs obtained against the other Party in a final determination under Article 13, against any amounts otherwise due to such other Party under this Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">12.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Survival</font><font style="font-family:inherit;font-size:12pt;">. In the event of termination or expiration of this Agreement, in addition to the provisions of this Agreement that continue in effect in accordance with their terms, the following provisions of this Agreement shall survive: Article 1 (Definitions) (as applicable), Article 11 (Confidentiality), Article 12 (Term and Termination), Article 13 (Dispute Resolution), Article 14 (Indemnification) (solely as to activities arising during the Term or as to any activities conducted in the course of a Party&#8217;s exercise of a license surviving the Term), Article 15 (Miscellaneous); Sections 3.3 (Retained Rights), 3.5 (No Implied Licenses), 7.4 (Records; Audit Rights), 7.7 (Compliance with Law), 8.9 (Currency), 8.11 (Taxes), 8.12 (Audit), 8.13 (Manner of Payment), 9.1 (Inventorship; Ownership and Disclosure of Inventions) and 10.4 (No Other Representations of Warranties), and any other provisions of this Agreement that are necessary to interpret or effectuate the intent of the foregoing provisions. For clarity, the indemnity in Section 14.1(d) shall survive beyond the duration of the Term only with respect to any Losses arising from activities that occurred during the Term, irrespective of whether Incyte is continuing to extend [**] or [**] to MacroGenics at the time such Loss arises.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 13</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">DISPUTE RESOLUTION</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">114</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Dispute Resolution Mechanism</font><font style="font-family:inherit;font-size:12pt;">. The Parties agree that the procedures set forth in this Article 13 sets forth certain binding and non-binding mechanisms for resolving any dispute, controversy or claim between the Parties that may arise from time to time pursuant to this Agreement relating to either Party&#8217;s rights or obligations hereunder (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Dispute</font><font style="font-family:inherit;font-size:12pt;">&#8221;, and collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Disputes</font><font style="font-family:inherit;font-size:12pt;">&#8221;) that is not resolved through good faith negotiation between the Parties. For the avoidance of doubt, this Article 13 shall not apply to any decision with respect to which a Party has final decision-making authority hereunder. The Parties shall first attempt in good faith to resolve any Dispute, including Disputes that may involve the parent company, subsidiaries or other Affiliates of any Party or sublicensees (including Collaborators) of a Party, in accordance with Section 13.2.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Resolution by Executive Officers</font><font style="font-family:inherit;font-size:12pt;">. In the event of any Dispute regarding the construction or interpretation of this Agreement or the rights, duties or liabilities of either Party hereunder, the Parties shall first attempt in good faith to resolve such Dispute by negotiation and consultation between themselves. In the event that such Dispute is not resolved on such basis within [**] (unless otherwise agreed by the Parties), either Party may, by written notice to the other Party, refer the Dispute to the Executive Officers for attempted resolution by good faith negotiation within [**] after such notice is received (unless otherwise agreed by the Parties). Each Party may, in its discretion, seek resolution of any and all Disputes that are not resolved under this Article 13 in any court of competent jurisdiction.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Provisional Remedies</font><font style="font-family:inherit;font-size:12pt;">. In addition, each Party has the right to seek from the appropriate court provisional remedies such as attachment, preliminary injunction, replevin, etc. to avoid irreparable harm, maintain the </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">status quo</font><font style="font-family:inherit;font-size:12pt;">, or preserve the subject matter of the Dispute.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 14</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INDEMNIFICATION</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indemnification by Incyte</font><font style="font-family:inherit;font-size:12pt;">. Incyte hereby agrees to defend, indemnify and hold harmless MacroGenics and its Affiliates, and each of their respective directors, officers, employees, agents and representatives (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) from and against any and all claims, suits, actions, demands, liabilities, expenses and/or losses, including reasonable legal expenses and attorneys&#8217; fees (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Losses</font><font style="font-family:inherit;font-size:12pt;">&#8221;), to which any MacroGenics Indemnitee may become subject as a direct result of any claim, demand, action or other proceeding by any Third Party (each, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Claim</font><font style="font-family:inherit;font-size:12pt;">&#8221;), to the extent such Losses result from: (a)&#160;the Exploitation of any Compound or Product by Incyte or its Affiliate or Third Party sublicensee (including any Collaborator); (b) the breach by Incyte of any warranty, representation, covenant or agreement made by Incyte in this Agreement or in the Clinical Supply Agreement, the Clinical Quality Agreement, the Commercial Supply Agreement, or the Pharmacovigilance Agreement (collectively, the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ancillary Agreements</font><font style="font-family:inherit;font-size:12pt;">&#8221;); (c) the negligence, illegal conduct or willful misconduct of Incyte or its Affiliate or Third Party sublicensee (including any Collaborator), or any officer, director, employee, agent or representative thereof in connection with this Agreement or any Ancillary Agreement; or (d) any claims that the Exploitation of the Licensed Compound pursuant to and in accordance with the provisions of this Agreement infringes the [**] or the [**] (except that, to the extent (i) MacroGenics does not [**] as described in Section 3.2(c) in any instance and (ii) such sublicense to MacroGenics under the [**] would have prevented the occurrence of such Loss, then Incyte shall be relieved of its obligations </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">115</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">under this Section 14.1(d) in connection with any resulting claims of infringement); and except, with respect to each of clauses (a) through (d) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful misconduct of any MacroGenics Indemnitee or the breach by MacroGenics of any warranty, representation, covenant or agreement made by MacroGenics in this Agreement or any Ancillary Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indemnification by MacroGenics</font><font style="font-family:inherit;font-size:12pt;">. MacroGenics hereby agrees to defend, indemnify and hold harmless Incyte and its Affiliates and each of their respective directors, officers, employees, agents and representatives (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) from and against any and all Losses to which any Incyte Indemnitee may become subject as a direct result of any Claim to the extent such Losses result from: (a) the breach by MacroGenics of any warranty, representation, covenant or agreement made by MacroGenics in this Agreement or any Ancillary Agreement; (b) the negligence, illegal conduct, or willful misconduct of MacroGenics or its Affiliate or its licensee (other than Incyte or its Affiliate), or any officer, director, employee, agent or representative thereof in connection with this Agreement or any Ancillary Agreement; (c) the Exploitation of any Compound or Product by MacroGenics or its Affiliate or licensees, including in connection with the Ongoing Clinical Study, MacroGenics Combination Studies or any other activities conducted by MacroGenics or its Affiliate or licensees in connection with this Agreement or any Ancillary Agreement; except, with respect to each of clauses (a) through (c) above, to the extent such Losses arise directly or indirectly from the negligence, gross negligence, illegal conduct or willful misconduct of any Incyte Indemnitee or the breach by Incyte of any warranty, representation, covenant or agreement made by Incyte in this Agreement or any Ancillary Agreement. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Indemnification Procedures</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notice</font><font style="font-family:inherit;font-size:12pt;">. Promptly after a MacroGenics Indemnitee or an Incyte Indemnitee (each, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnitee</font><font style="font-family:inherit;font-size:12pt;">&#8221;) receives notice of a pending or threatened Claim, such Indemnitee shall give written notice of the Claim to the Party from whom the Indemnitee is entitled to receive indemnification pursuant to Sections 14.1 or 14.2, as applicable (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Indemnifying Party</font><font style="font-family:inherit;font-size:12pt;">&#8221;). However, an Indemnitee&#8217;s delay in providing or failure to provide such notice shall not relieve the Indemnifying Party of its indemnification obligations, except to the extent it can demonstrate prejudice due to the delay or lack of notice.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Defense</font><font style="font-family:inherit;font-size:12pt;">. Upon receipt of notice under this Section 14.3 from the Indemnitee, the Indemnifying Party will have the duty to either compromise or defend, at its own expense (and by counsel reasonably satisfactory to Indemnitee), such Claim. The Indemnifying Party will promptly (and in any event not more than [**]</font><font style="font-family:inherit;font-size:12pt;color:#ff0000;">&#32;</font><font style="font-family:inherit;font-size:12pt;">after receipt of the Indemnitee&#8217;s original notice) notify the Indemnitee in writing that it acknowledges its obligation (which acknowledgment shall not be deemed or construed as an admission of liability, either under this Article 14 or otherwise) to indemnify the Indemnitee with respect to the Claim pursuant to this Article 14 and of its intention to compromise or defend such Claim. Once the Indemnifying Party gives such notice to the Indemnitee, the Indemnifying Party is not liable to the Indemnitee for the fees of other counsel or any other expenses subsequently incurred by the Indemnitee in connection with such defense, other than the Indemnitee&#8217;s </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">116</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:12px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">reasonable Third Party expenses related to its cooperation provided pursuant to Section 14.3(c) below. As to all Claims as to which the Indemnifying Party has assumed control under this Section 14.3(b), the Indemnitee shall have the right to employ separate counsel and to participate in the defense of a Claim (as reasonably directed by the Indemnifying Party) at its own expense.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Cooperation</font><font style="font-family:inherit;font-size:12pt;">. The Indemnitee will cooperate fully with the Indemnifying Party and its legal representatives in the investigation and defense of any Claim. The Indemnifying Party shall keep the Indemnitee informed on a reasonable and timely basis as to the status of such Claim (to the extent the Indemnitee is not participating in the defense of such Claim) and conduct the defense of such Claim in a prudent manner.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Settlement</font><font style="font-family:inherit;font-size:12pt;">. If an Indemnifying Party assumes the defense of a Claim, no compromise or settlement of such Claim may be effected by the Indemnifying Party without the Indemnitee&#8217;s written consent (such consent not to be unreasonably withheld, delayed or conditioned), unless: (1)&#160;there is no finding or admission of any violation of law or any violation of the rights of any Person on the part of the Indemnitee and no effect on any other claims that may be made against the Indemnitee; (2)&#160;the sole relief provided is monetary damages that are paid in full by the Indemnifying Party; and (3)&#160;the Indemnitee&#8217;s rights under this Agreement are not adversely affected. If the Indemnifying Party fails to assume defense of a Claim within a reasonable time, the Indemnitee may settle such Claim on such terms as it deems appropriate with the consent of the Indemnifying Party (such consent not to be unreasonably withheld, delayed or conditioned), and the Indemnifying Party shall be obligated to indemnify the Indemnitee for such settlement as provided in this Article 14.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Insurance</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall, at its own expense, with respect to any Product, procure and maintain during the period commencing on the Execution Date through the period of Commercialization and for a period of not less than [**] following the termination or expiration of this Agreement, insurance policies, including product liability insurance, in amounts not less than [**] per claim and annual aggregate. All such insurance shall include worldwide coverage and shall include the other Party as an additional insured under its respective program(s). Prior to the Initiation of any Clinical Study, the Party responsible for such Clinical Study shall secure, and maintain in full force and effect, clinical trial insurance as required by Applicable Law in those territories where such Clinical Study shall be conducted. Upon request, each Party shall provide the other Party with a certificate of insurance evidencing the coverage required under this Section 14.4. Such insurance shall not be construed to create a limit of a Party&#8217;s liability with respect to its indemnification obligations under this Article 14. Each Party shall provide the other Party with prompt written notice of cancellation, non-renewal or material change in such insurance that could materially adversely affect the rights of such other Party hereunder, and shall provide such notice within [**] after any such cancellation, non&#8209;renewal or material change. The Parties acknowledge and agree that Incyte may meet its obligations under this Section 14.4 through self-insurance. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">14.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Limitation of Liability</font><font style="font-family:inherit;font-size:12pt;">. EXCEPT TO THE EXTENT INCLUDED IN LOSSES RESULTING FROM A THIRD PARTY CLAIM FOR WHICH ONE PARTY IS OBLIGATED TO </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">117</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">INDEMNIFY THE OTHER PARTY (OR AN INDEMNITEE OF SUCH OTHER PARTY) PURSUANT TO THIS ARTICLE 14 OR SECTION 12.8(J) AND ANY BREACH OF ARTICLE 11 (CONFIDENTIALITY)</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">,</font><font style="font-family:inherit;font-size:12pt;">&#32;IN NO EVENT WILL EITHER PARTY BE LIABLE TO THE OTHER PARTY (OR THE OTHER PARTY&#8217;S AFFILIATES OR SUBLICENSEES) IN CONNECTION WITH THIS AGREEMENT FOR LOST REVENUE, LOST PROFITS, LOST SAVINGS, LOSS OF USE, DAMAGE TO GOODWILL, OR ANY CONSEQUENTIAL, INCIDENTAL, SPECIAL, EXEMPLARY, PUNITIVE OR INDIRECT DAMAGES UNDER ANY THEORY, INCLUDING CONTRACT, NEGLIGENCE, OR STRICT LIABILITY, EVEN IF THAT PARTY HAS BEEN PLACED ON NOTICE OF THE POSSIBILITY OF SUCH DAMAGES. </font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">ARTICLE 15</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MISCELLANEOUS</font></div><div style="line-height:120%;padding-bottom:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.1</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Notices</font><font style="font-family:inherit;font-size:12pt;">. All notices and other communications given or made pursuant hereto shall be in writing and shall be deemed to have been duly given on the date delivered, if delivered personally, or on the next Business Day after being sent by reputable overnight courier (with delivery tracking provided, signature required and delivery prepaid), in each case, to the Parties at the following addresses, or on the date sent and confirmed by electronic transmission to the telecopier number specified below (or at such other address or telecopier number for a Party as shall be specified by notice given in accordance with this Section 15.1). </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">If to Incyte:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Corporation <br>1801 Augustine Cut Off <br>Wilmington, DE 19803 <br>Attention: &#160;&#160;&#160;&#160;CEO  <br>Fax: [**]</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:156px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">with a copy to:</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Incyte Corporation <br>1801 Augustine Cut Off <br>Wilmington, DE 19803 <br>Attention: &#160;&#160;&#160;&#160;EVP &amp; General Counsel <br>Fax: [**]</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">If to MacroGenics:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics, Inc.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">9704 Medical Center Drive</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rockville, MD 20850</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Attention: CEO <br>Fax: [**]</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;padding-left:156px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">with a copy to:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">118</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics, Inc. <br>9704 Medical Center Drive <br>Rockville, MD 20850 <br>Attention:&#160;&#160;&#160;&#160;General Counsel <br>Fax: [**]</font></div><div style="line-height:120%;text-align:left;padding-left:192px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.2</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Governing Law</font><font style="font-family:inherit;font-size:12pt;">. This Agreement and all disputes arising out of or related to this Agreement or any breach hereof shall be governed by and construed under the laws of the State of New York, without giving effect to any choice of law principles that would require the application of the laws of a different state.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.3</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Change of Control</font><font style="font-family:inherit;font-size:12pt;">.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Notice</font><font style="font-family:inherit;font-size:12pt;">. Each Party (or its successor) shall provide notice to the other Party of any Change of Control of the notifying Party within [**] after the date upon which the Change of Control closes or otherwise becomes effective. For purposes of this Section 15.3(a), a public announcement of the closing or effectiveness of a Change of Control shall be deemed notice to the other Party of such Change of Control. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics</font><font style="font-family:inherit;font-size:12pt;">. In the event of a Change of Control of MacroGenics, MacroGenics and the applicable Acquirer shall have the right to conduct Clinical Studies that evaluate the Combination of the Licensed Compound with any Acquirer Pipeline Asset or MacroGenics Pipeline Asset (such study, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acquirer Combination Study</font><font style="font-family:inherit;font-size:12pt;">&#8221;) only as set forth in the remainder of this Section 15.3(b). For clarity, in addition to the requirements and limitations of this Section 15.3(b), (x) any Acquirer Combination Study shall be subject to the requirements and limitations set forth herein with respect to MacroGenics Combination Studies (e.g., the limitations set forth in Section 4.3, and Article 5), (y) MacroGenics shall be responsible for any failure of the Acquirer to comply with the obligations set forth in this Section 15.3(b); and (z) except where this Agreement specifies terms and conditions that are specifically applicable to an Acquirer (e.g., Sections 5.5(c), 15.3(b), and 15.3(d)), all obligations of MacroGenics under this agreement shall apply to the Acquirer as if the Acquirer were MacroGenics hereunder. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">MacroGenics (or the Acquirer, as applicable) shall notify Incyte of each Acquirer Combination Study to be Initiated following the date of the Change of Control and until the earlier of [**] after the Effective Date, or (y) [**], shall provide Incyte with a copy of the protocol synopsis for the conduct of such proposed Acquirer Combination Study and, solely to the extent the components outlined in the protocol synopsis reviewed by Incyte are materially different from the corresponding components in the full protocol, such updated protocol synopsis, in each case, subject to reasonable redaction with respect to any MacroGenics Pipeline Asset Information (or commercially sensitive confidential information related to the Acquirer Pipeline Asset, as applicable). Incyte shall have the right to object to the </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">119</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:144px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">conduct of such Acquirer Combination Study if Incyte reasonably believes in its sole determination that: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the proposed Acquirer Combination Study poses a [**], following the procedures set forth in Section 4.3(b)(i)(3), but substituting &#8220;Acquirer Combination Study(ies)&#8221; for &#8220;MacroGenics Combination Study(ies)&#8221; and with Incyte (and not MacroGenics) holding the final decision-making authority with respect thereto pursuant to Section 4.3(b)(i)(3); provided that such veto right under this paragraph (A) shall expire [**] after the Effective Date; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">the design or conduct of any such Acquirer Combination Study (x) that does not satisfy the applicable dosage and schedule requirements of Section 4.3(b)(ii) (substituting for such purpose, &#8220;Acquirer Combination Study(ies)&#8221; for MacroGenics Combination Study(ies) in Section 4.3(b)(ii)), provided that Incyte (and not MacroGenics) shall have final decision-making authority with respect thereto pursuant to Section 4.3(b)(ii); or (y) for which the Acquirer Pipeline Asset, when combined with or compared to the Licensed Compound, is reasonably expected by Incyte, in its sole determination, to have a material negative impact on Incyte&#8217;s business (with Incyte&#8217;s objection rights under the foregoing clauses (B)(x) and (B)(y) expiring upon achievement of the first Licensed Compound Approval by either the FDA or EMA).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If Incyte so objects under subsection (i), MacroGenics (or the Acquirer, as applicable) shall not Initiate such Acquirer Combination Study without the prior written consent of Incyte, it being understood that such objection right shall apply with respect to the Initiation of each Acquirer Combination Study for each applicable Pipeline Asset until the expiration of such right as set forth in Sections 15.3(b)(i)(A) and 15.3(b)(i)(B), as applicable.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">If the Acquirer or its Affiliates owns or Controls, and has not discontinued the Development and Commercialization of, or divested, upon the consummation of the Change of Control, a clinical-stage or approved anti-PD-1 or anti-PD-L1 Monoclonal Antibody in the Field (such product, an &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Competing Product</font><font style="font-family:inherit;font-size:12pt;">&#8221;), then: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(A)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acquirer shall and shall cause its Affiliates, within [**]after such consummation, to: (x) adopt reasonable written procedures to prevent Acquirer&#8217;s employees or contractors ([**], and [**], it being understood that such employees are otherwise subject to the applicable confidentiality obligations under this Agreement) involved in the Development or Commercialization of such Incyte Competing Product from [**] or [**] to the Licensed Compound or any Licensed Product, for Development or Commercialization of the </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">120</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:192px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">Incyte Competing Product; and (y) if the Incyte Competing Product is undergoing a pivotal Clinical Study or has received Regulatory Approval, then require such employees and contractors of Acquirer to [**] and [**] between MacroGenics and Incyte under this Agreement (including Joint Committee meetings) and [**] to the Licensed Compound or any Licensed Product; and</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:144px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(B)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">on or before the date that is [**] after the date upon which a Change of Control of MacroGenics closes or otherwise becomes effective, the Parties shall dissolve the JSC and CCC and thereafter Incyte shall perform all activities assigned by this Agreement to the JSC; provided that, the JDC shall remain in place for the coordination of any MacroGenics Combination Studies, the JMC shall remain in place for the coordination of Manufacturing activities, and the JIPC shall remain in place for the coordination of the prosecution and maintenance of the Licensed Patents.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding anything to the contrary herein, in the event of a Change of Control of Incyte, if the Acquirer or its Affiliates owns or Controls, and has not discontinued the Development and Commercialization of, or divested, upon the consummation of the Change of Control, a clinical-stage or approved anti-PD-1 or anti-PD-L1 Monoclonal Antibody in the Field (such product, a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Competing Product</font><font style="font-family:inherit;font-size:12pt;">&#8221;), the following terms and conditions shall apply: </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:144px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Acquirer shall and shall cause its Affiliates, within [**] after such consummation to adopt the protections, and Acquirer shall have the rights and obligations, set forth in Sections 15.3(b)(iii)(A) and (B) </font><font style="font-family:inherit;font-size:12pt;font-style:italic;">mutatis mutandis</font><font style="font-family:inherit;font-size:12pt;">; and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;">Incyte&#8217;s right to object to the conduct of an Acquirer Combination Study pursuant to Section 15.3(b)(i)(B)(y) shall immediately terminate. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Acquirer IP</font><font style="font-family:inherit;font-size:12pt;">. Notwithstanding any provisions of this Agreement to the contrary, in the event of a Change of Control of either Party, such Change of Control shall not provide the other Party with any rights or access to the intellectual property or technology of the acquired Party&#8217;s Acquirer or successor which was a Third Party prior to such event. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.4</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Assignment</font><font style="font-family:inherit;font-size:12pt;">. Neither Party may assign or transfer this Agreement or any rights or obligations hereunder without the prior written consent of the other Party, except that a Party may make such an assignment or transfer without the other Party&#8217;s consent to (a) an Affiliate or (b) subject to Section 15.3 above, an Acquirer. Any successor or assignee of rights and/or obligations permitted hereunder shall, in writing to the other Party, expressly assume performance of such rights and/or obligations. Any permitted assignment shall be binding on the successors of the assigning Party. Any assignment </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">121</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">or attempted assignment by either Party in violation of the terms of this Section 15.4 shall be null, void and of no legal effect.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.5</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Designation of Affiliates</font><font style="font-family:inherit;font-size:12pt;">. Each Party may discharge any obligation and exercise any right hereunder through delegation of its obligations or rights to any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party&#8217;s obligations under this Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party&#8217;s Affiliate of any of such Party&#8217;s obligations under this Agreement shall be deemed a breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party&#8217;s Affiliate.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.6</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Relationship of the Parties</font><font style="font-family:inherit;font-size:12pt;">. It is expressly agreed that MacroGenics, on the one hand, and Incyte, on the other hand, are independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency. Neither MacroGenics nor Incyte shall have the authority to make any statements, representations or commitments of any kind, or to take any action which shall be binding on the other, without the prior written consent of the other Party to do so. All individuals employed by a Party shall be employees of that Party and not of the other Party and all costs and obligations incurred by reason of such employment shall be for the account and expense of such Party.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.7</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Force Majeure</font><font style="font-family:inherit;font-size:12pt;">. Both Parties shall be excused from the performance of their obligations under this Agreement to the extent that such performance is prevented by Force Majeure and the nonperforming Party promptly provides notice of such Force Majeure circumstances to the other Party. Such excuse shall be continued so long as the condition constituting Force Majeure continues and the nonperforming Party takes reasonable efforts to remove the condition. Notwithstanding the foregoing, a Party shall not be excused from making payments owed hereunder because of a Force Majeure affecting such Party. If a Force Majeure persists for more than [**], then the Parties shall discuss in good faith the modification of the Parties&#8217; obligations under this Agreement in order to mitigate the delays caused by such Force Majeure. In the event a Party is prevented from performing its obligations under this Agreement due to Force Majeure for more than [**] according to this Section 15.7, the other Party shall have the right to terminate this Agreement upon [**] notice after the expiration of such period. A termination under this Section 15.7 by either Party shall be treated as a termination under Section 12.3 above and the corresponding provisions for termination under Section 12.3 shall apply except to the extent the affected Party is prevented from performing due to the Force Majeure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.8</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Entire Agreement; Amendments</font><font style="font-family:inherit;font-size:12pt;">. This Agreement, including the Exhibits and Schedules hereto, and together with the Ancillary Agreements, sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties with respect to the subject matter hereof and supersedes, as of the Execution Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter hereof, including the Prior CDA. There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as are set forth herein and therein. No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties unless reduced </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">122</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to writing and signed by an authorized officer of each Party. In the event of any inconsistency between the body of this Agreement and either any Exhibits to this Agreement or any subsequent agreements ancillary to this Agreement, unless otherwise express stated to the contrary in such Exhibit or ancillary agreement, the terms contained in this Agreement shall control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.9</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Severability</font><font style="font-family:inherit;font-size:12pt;">. If any one or more of the provisions of this Agreement is held to be invalid or unenforceable by any court of competent jurisdiction from which no appeal can be or is timely taken, the provision shall be considered severed from this Agreement and shall not serve to invalidate any remaining provisions hereof. The Parties shall make good faith efforts to replace any such invalid or unenforceable provision with a valid and enforceable one such that the objectives contemplated by the Parties when entering this Agreement may be realized.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.10</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">English Language</font><font style="font-family:inherit;font-size:12pt;">. This Agreement shall be written in and executed in, and all other communications under or in connection with this Agreement shall be in, the English language. Any translation into any other language shall not be an official version hereof or thereof, and in the event of any conflict in interpretation between the English version and such translation, the English version shall control.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.11</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Waiver and Non-Exclusion of Remedies</font><font style="font-family:inherit;font-size:12pt;">. Any term or condition of this Agreement may be waived at any time by the Party that is entitled to the benefit thereof, but no such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the Party waiving such term or condition. The waiver by either Party of any right hereunder or of the failure to perform or of a breach by the other Party shall not be deemed a waiver of any other right hereunder or of any other breach or failure by such other Party whether of a similar nature or otherwise. The rights and remedies provided herein are cumulative and do not exclude any other right or remedy provided by Applicable Law or otherwise available except as expressly set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.12</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Further Assurance</font><font style="font-family:inherit;font-size:12pt;">. Each Party shall duly execute and deliver, or cause to be duly executed and delivered, such further assignments, agreements, documents, and instruments and do and cause to be done such further acts and things, including the filing of such assignments, agreements, documents, and instruments, as may be necessary including as the other Party may reasonably request in connection with this Agreement to carry out more effectively the provisions and purposes hereof.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.13</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Headings</font><font style="font-family:inherit;font-size:12pt;">. The headings of each Article and Section in this Agreement have been inserted for convenience of reference only and are not intended to limit or expand on the meaning of the language contained in the particular Article or Section.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.14</font></div></td><td style="vertical-align:top;padding-left:48px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Standstill</font><font style="font-family:inherit;font-size:12pt;">.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(a)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Incyte agrees that neither it nor any of its Affiliates (but excluding any Acquirer of Incyte or any Affiliates of such Acquirer following a Change of Control of Incyte), officers or directors acting at Incyte&#8217;s direction, alone or as part of any 13D Group, shall, directly or indirectly, for a period of twenty-four (24) months from the Execution Date (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Standstill Period</font><font style="font-family:inherit;font-size:12pt;">&#8221;), without the prior written approval of MacroGenics&#8217; Board of Directors (or any committee thereof):</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">123</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">acquire, offer or propose to acquire or agree to acquire or cause to be acquired ownership (including, but not limited to, beneficial ownership as defined in Rule 13d-3 under the Securities and Exchange Act of 1934) more than three percent (3%) of the voting securities of MacroGenics, or any rights or options to acquire any such ownership (including from a Third Party);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(ii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">make or participate, directly or indirectly, in any &#8220;solicitation&#8221; of &#8220;proxies&#8221; (as such terms are used in the proxy rules (Regulation 14A) of the Securities and Exchange Commission) to vote, or seek to advise or influence any person with respect to the voting of, any voting securities of MacroGenics;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iii)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">form or join a &#8220;group&#8221; (within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934) (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">13D Group</font><font style="font-family:inherit;font-size:12pt;">&#8221;) with respect to any voting securities of MacroGenics;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(iv)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">otherwise act, whether alone or in concert with others, to seek to propose to MacroGenics any merger, business combination, restructuring, recapitalization or similar transaction with respect to or with MacroGenics or otherwise act, whether alone or in concert with others, to seek to &#8220;control&#8221; (as such term is defined in Section 1.2), change the management or Board of Directors of MacroGenics, or nominate any person as a director of MacroGenics who is not nominated by a then incumbent director; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:102px;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(v)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">publicly announce its intentions to enter into any discussion, negotiations, arrangements or understandings with any Third Party with respect to, any of the foregoing.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(b)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">If at any time during the Standstill Period, Incyte or, to its actual knowledge, any of its officers or directors are approached by any Third Party concerning Incyte&#8217;s participation in a transaction of the type referred to in Sections 15.14(a)(i)-(v), Incyte shall, or shall use reasonable efforts to cause such officer or director (as applicable) to, promptly inform such Third Party that Incyte is bound by the provisions of this Section 15.14.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(c)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">The restrictions set forth in Section 15.14(a) shall terminate immediately if: (i) a Person or 13D Group (not including Incyte or its Affiliates) (A) commences or publicly announces its intent to commence a tender or exchange offer for voting securities of MacroGenics representing more than twenty percent (20%) of the then-outstanding voting power of the voting securities of MacroGenics or (B) publicly announces a bona fide proposal to enter into a transaction described in, or of a similar nature to those described in, clause (ii)(A) or (ii)(B) below and, prior to the termination, withdrawal or abandonment of such proposal by such Person or 13D Group (as evidenced by a subsequent public announcement or by communication to MacroGenics that is then either publicly announced or provided to Incyte), either (x) MacroGenics publicly announces its willingness to consider such proposal or alternative proposals for a transaction described in, or of a similar nature as those </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">124</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-left:96px;padding-bottom:16px;text-align:justify;"><font style="font-family:inherit;font-size:12pt;">described in, clause (ii)(A) or (ii)(B) below, (y) the Board of Directors of MacroGenics determines to engage in negotiations with such Person or 13D Group or any other party other than Incyte or its Affiliates with respect to a transaction described in clause (ii)(A) or (ii)(B) below, or (z) such offer or proposal is not publicly rejected or recommended against by MacroGenics within ten (10) Business Days after such offer or proposal becomes public, or (ii) MacroGenics or its Affiliates initiates a process to consider or enter into a transaction described in clause (A) or (B) below, or enters into a letter of intent or definitive agreement with any Third Party regarding (A) any merger, consolidation, sale, reorganization, recapitalization or other business combination pursuant to which the outstanding shares of MacroGenics would be converted into cash or securities of a Person or a 13D Group not including Incyte or its Affiliates and the stockholders or equity holders of MacroGenics immediately prior to such transaction would own, immediately after consummation of such a transaction, less than a controlling portion of the outstanding voting securities of MacroGenics or the entity surviving such transaction; or (B) any transaction or series of transactions that would result, directly or indirectly, in the sale or transfer to a Third Party of (1) all or substantially all of MacroGenics&#8217; assets; or (2) a majority of MacroGenics&#8217; assets which relate to this Agreement.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:0px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:48px;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">(d)</font></div></td><td style="vertical-align:top;padding-left:96px;"><div style="line-height:120%;text-align:justify;font-size:12pt;text-indent:-96px;"><font style="font-family:inherit;font-size:12pt;">Nothing in this Section 15.14 shall prohibit: (i) Incyte or its Affiliates or its or their Representatives from acquiring or offering to acquire any securities of MacroGenics in connection with any mutual fund, pension plan or employee benefit plan managed on behalf of employees or former employees of Incyte or its Affiliates; or (ii) an officer of Incyte from engaging in discussions with an officer of MacroGenics on a confidential, non-public basis regarding any of the transactions contemplated under this Section 15.14 that would not reasonably be expected to require Incyte or MacroGenics to make any public disclosure with respect thereto. </font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.15</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Construction</font><font style="font-family:inherit;font-size:12pt;">. Whenever this Agreement refers to a number of days without using a term otherwise defined herein, such number refers to calendar days. Except where the context otherwise requires, </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;wherever used, the singular shall include the plural, the plural shall include the singular; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;the use of any gender shall be applicable to all genders; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;the terms &#8220;including,&#8221; &#8220;include,&#8221; &#8220;includes&#8221; or &#8220;for example&#8221; shall not limit the generality of any description preceding such term and, as used herein, shall have the same meaning as &#8220;including, but not limited to,&#8221; or &#8220;including, without limitation&#8221;; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, refer to this Agreement in its entirety and not to any particular provision hereof; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;the word &#8220;or&#8221; has the inclusive meaning that is typically associated with the phrase &#8220;and/or&#8221;; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;the word &#8220;will&#8221; means &#8220;shall&#8221;; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;if a period of time is specified and dates from a given day or Business Day, or the day or Business Day of an act or event, it is to be calculated exclusive of that day or Business Day; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;Dollar&#8221;, &#8220;USD&#8221; or &#8220;$&#8221; means U.S. Dollars; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;references to a particular Person include such Person&#8217;s successors and assigns to the extent not prohibited by this Agreement; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;a capitalized term not defined herein but reflecting a different part of speech than a capitalized term which is defined herein shall be interpreted in a correlative manner; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;&#8220;written&#8221; includes communications sent and received by facsimile or electronic mail; </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;any definition of or reference to any agreement, instrument or other document herein shall be construed as referring </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">125</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:right;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">CONFIDENTIAL TREATMENT REQUESTED</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein) and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">%3.</font><font style="font-family:inherit;font-size:12pt;">&#32;references herein to pharmaceutical products, therapies, ingredients, and the like, shall include biologics and biopharmaceutical products, therapies, ingredients, and the like, as applicable. The language of this Agreement shall be deemed to be the language mutually chosen by the Parties and no rule of strict construction shall be applied for or against either Party. Whenever a provision of this Agreement requires an approval or consent by a Party to this Agreement within a specified time period and notification of such approval or consent is not delivered within such time period, then, unless otherwise specified, the Party whose approval or consent is required shall be conclusively deemed to have withheld its approval or consent. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.16</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Third Party Beneficiaries</font><font style="font-family:inherit;font-size:12pt;">. Except with respect to indemnification obligations pursuant to Article 14, for which MacroGenics Indemnitees and Incyte Indemnitees are third party beneficiaries, no other Persons, other than MacroGenics and Incyte (including their respective successors and permitted assigns), shall be entitled to enforce the performance of this Agreement. For the avoidance of doubt, Collaborators shall not constitute third party beneficiaries under this Agreement for any purpose whatsoever. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">15.17</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Counterparts</font><font style="font-family:inherit;font-size:12pt;">. This Agreement may be executed in two (2) or more counterparts, each of which shall be deemed an originafl, but all of which together shall constitute one and the same instrument. This Agreement may be executed by .pdf or other electronically transmitted signatures and such signatures shall be deemed to bind each Party as if they were the original signatures.</font></div><div style="line-height:120%;padding-bottom:48px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIGNATURE PAGE FOLLOWS</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">126</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request.  An unredacted version of this exhibit has been filed separately with the Commission.</font></div></div><hr style="page-break-after:always"><div><a name="s504786d65c9d41c994bf820bc8191966"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:48px;text-align:left;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">IN WITNESS WHEREOF</font><font style="font-family:inherit;font-size:12pt;">, the Parties have signed this Agreement as of the Execution Date.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">INCYTE CORPORATION</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:36px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MACROGENICS, INC.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title: </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;padding-bottom:36px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Date:</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:12pt;">____________________________</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">SIGNATURE PAGE TO GLOBAL COLLABORATION AND LICENSE AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s7b00cda6e22f4bd7bdfbd1a439f7e0a5"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT A</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Licensed Patents</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and applications claiming the benefit of U.S. Provisional Application Nos: [**], which cover the composition of matter, or the method of making or using, the sale or the importation of the Licensed Compound.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit A - 1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT B-1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Incyte Global Development Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;color:#ff0000;font-weight:bold;">CONFIDENTIAL</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-1 - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT B-2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">MacroGenics Global Development Plan</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.78632478632478%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2 - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;[**]</font></div><div style="padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**] </font></div><div style="padding-left:66px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2 - 2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit B-2 - 3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT C</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Existing Third Party Licenses</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit C - 1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="sb3d11c6e5e914a0ba9df4dee873b1b9a"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT D</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Form of Press Release</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-top:1px solid #ffffff;"><div><img src="exhibit103image2a02.gif" alt="exhibit103image2a02.gif" style="height:84px;width:118px;"></div></td><td style="vertical-align:top;border-bottom:1px solid #ffffff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #ffffff;border-right:1px solid #ffffff;border-top:1px solid #ffffff;"><div style="text-align:right;"><img src="exhibit103image1a02.jpg" alt="exhibit103image1a02.jpg" style="height:74px;width:134px;"></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">For Immediate Release</font></div><div style="line-height:138%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;font-weight:bold;">Incyte and MacroGenics Announce Global Collaboration and Licensing Agreement for Anti-PD-1 Monoclonal Antibody MGA012 </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;">Incyte gains exclusive, worldwide development and commercialization rights to MGA012 in all indications</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;">MacroGenics to receive an upfront cash payment of $150 million plus potential milestone payments</font><font style="font-family:Verdana,sans-serif;font-size:11pt;">&#32;</font><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;">and royalties, and retains right to develop its pipeline assets in combination with MGA012</font></div></td></tr></table><div style="line-height:138%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">WILMINGTON, DE AND ROCKVILLE, MD &#8211; October XX, 2017</font><font style="font-family:Verdana,sans-serif;font-size:10pt;">&#32;&#8211; Incyte Corporation (NASDAQ:INCY) and MacroGenics, Inc. (NASDAQ:MGNX) announced today that the companies have entered into an exclusive global collaboration and license agreement for MacroGenics&#8217; MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while MacroGenics retains the right to develop its pipeline assets in combination with MGA012.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">&#8220;Anti-PD-1 therapy is becoming a mainstay of cancer treatment across multiple tumor types, and we believe the addition of MGA012 to our clinical pipeline is important to fulfilling our long-term development strategy in immuno-oncology. This collaboration with MacroGenics will allow us to rapidly explore the potential clinical benefit of developing MGA012 as a monotherapy and also combining anti-PD-1 therapy with several of our existing portfolio assets,&#8221; said Steven Stein, M.D., Chief Medical Officer of Incyte.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">"We believe Incyte is the ideal partner for MGA012, given its immuno-oncology portfolio and dedication to researching and developing innovative and transformative cancer therapies and we hope that the combined resources of both companies will be able to significantly expand and accelerate the current development efforts for this promising molecule,&#8221; said Scott Koenig, M.D., Ph.D., President and Chief Executive Officer of MacroGenics.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - </font><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">&#32;&#8220;Furthermore, we look forward to exploring the combination of MGA012 with multiple molecules in our own portfolio, including DART molecules for redirected T-cell killing, antibodies with enhanced effector function and ADCs, potentially to provide improved patient benefit.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Enrollment in the dose escalation portion of the Phase 1 study of MGA012 has been completed and the molecule is currently being evaluated as monotherapy across four solid tumor types in the dose expansion portion of the study. Data from the dose escalation portion of the Phase 1 study have been accepted for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting in November 2017.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Terms of the Collaboration</font><font style="font-family:Verdana,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#32;</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Upon closing, Incyte will pay MacroGenics an upfront payment of $150 million. Incyte will receive worldwide rights to develop and commercialize MGA012 in all indications. </font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Per the terms of the collaboration, MacroGenics will also be eligible to receive up to $420 million in potential development and regulatory milestones, and up to $330 million in potential commercial milestones. If MGA012 is approved and commercialized, MacroGenics would be eligible to receive royalties, tiered from 15 percent to 24 percent, on future sales of MGA012 by Incyte.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Under the terms of the collaboration, Incyte will lead global development of MGA012. MacroGenics retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and MacroGenics commercializing its asset(s), if any such potential combinations are approved.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">In addition, MacroGenics retains the right to manufacture a portion of both companies&#8217; global clinical and commercial supply needs of MGA012. MacroGenics intends to utilize its commercial-scale GMP facility, which is expected to be fully operational in 2018. </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">The transaction is expected to close in the fourth quarter of 2017, subject to the early termination or expiration of any applicable waiting periods under the Hart-Scott Rodino Act and customary closing conditions.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">About Incyte Corporation</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit the Company&#8217;s website at </font><font style="font-family:Verdana,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">www.incyte.com</font><font style="font-family:Verdana,sans-serif;font-size:10pt;">.</font></div><div style="line-height:138%;padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Follow @Incyte on Twitter at </font><font style="font-family:Verdana,sans-serif;font-size:10pt;color:#0000ff;text-decoration:underline;">https://twitter.com/Incyte</font><font style="font-family:Verdana,sans-serif;font-size:10pt;">. </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - </font><font style="font-family:inherit;font-size:12pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">About MacroGenics, Inc.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. MacroGenics generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed MacroGenics to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see MacroGenics&#8217; website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Incyte Forward-Looking Statements </font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Except for the historical information set forth herein, the matters set forth in this press release contain predictions, estimates and other forward-looking statements, including without limitation statements regarding: whether the planned transaction will close within the expected timeframe or ever; whether MGA012 will successfully advance through clinical studies or will ever be approved for use in humans anywhere or will be commercialized anywhere successfully or at all; whether MGA012 will be effective in the treatment of cancer or other indications; and whether and when any of the milestone payments or royalties under this collaboration will ever be paid by Incyte. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: obtaining approval for this planned collaboration; research and development efforts related to the collaboration programs; the possibility that results of clinical trials may be unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; other market or economic factors; unanticipated delays; each company&#8217;s ability to compete against parties with greater financial or other resources; greater than expected expenses; and such other risks detailed from time to time in each company&#8217;s reports filed with the Securities and Exchange Commission, including the Form 10-Q for the quarter ended June 30, 2017 filed by each company. Each party disclaims any intent or obligation to update these forward-looking statements.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">MacroGenics&#8217; Cautionary Note on Forward-Looking Statements</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Any statements in this press release about future expectations, plans and prospects for MacroGenics, including statements about MacroGenics&#8217; strategy, future operations, clinical development of MacroGenics&#8217; therapeutic candidates, milestone or opt-in payments from MacroGenics&#8217; collaborators, MacroGenics&#8217; anticipated milestones and future expectations and plans and prospects for MacroGenics and other statements containing the words "subject to", "believe", "anticipate", "plan", "expect", "intend", "estimate", "project", "may", "will", "should", "would", "could", "can", the negatives thereof, variations thereon and similar expressions, or by discussions of strategy constitute forward-looking statements </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - </font><font style="font-family:inherit;font-size:12pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:8px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of MacroGenics&#8217; product candidates and other risks described in MacroGenics&#8217; filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent MacroGenics&#8217; views only as of the date hereof. MacroGenics anticipates that subsequent events and developments will cause MacroGenics&#8217; views to change. However, while MacroGenics may elect to update these forward-looking statements at some point in the future, MacroGenics specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing MacroGenics&#8217; views as of any date subsequent to the date hereof.</font></div><div style="line-height:138%;padding-bottom:8px;padding-top:6px;text-align:center;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"># # #</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Incyte Contacts:</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Investors</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Michael Booth, DPhil</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">+1 302 498 5914</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;color:#0000ff;text-decoration:underline;">mbooth@incyte.com</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Media</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Catalina Loveman</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">+1 302 498 6171</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;color:#0000ff;text-decoration:underline;">cloveman@incyte.com</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">MacroGenics Contacts: </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Investors</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Jim Karrels</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">1-301-251-5172</font></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;color:#0000ff;text-decoration:underline;">info@macrogenics.com </font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;font-weight:bold;">Media</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">Karen Sharma</font></div><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;">1-781-235-3060</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - </font><font style="font-family:inherit;font-size:12pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;text-align:left;font-size:12pt;"><font style="font-family:Verdana,sans-serif;font-size:12pt;color:#0000ff;text-decoration:underline;">ksharma@macbiocom.com </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:Verdana,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit D - </font><font style="font-family:inherit;font-size:12pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div></div><hr style="page-break-after:always"><div><a name="sfd40d202e6834b3ba8accc133be16b73"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT E</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Ongoing Clinical Study Activities</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:19%;"></td><td style="width:30%;"></td><td style="width:27%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit E - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT F</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Shared Prosecution Expense Countries </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.09401709401709%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:13%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit F - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:67.09401709401709%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:13%;"></td><td style="width:87%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[**]</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit F - 2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT G</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit G - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">EXHIBIT H</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#32;[**]</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Patents and patent applications claiming the benefit of [**].</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Exhibit H - 1</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">NG-6PHJ0AHM 4812-2013-0909v.1</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>exhibit23-1201710xk.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sD11F915482FA5153B603F9FA43F0EF3D"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 23.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We consent to the incorporation by reference in the following Registration Statements:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-192277) pertaining to the 2000 Stock Option Incentive Plan, the 2003 Equity Incentive Plan, and 2013 Equity Incentive Plan of MacroGenics, Inc.; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-8 No. 333-202470 and Form S-8 No. 333-209812) pertaining to the 2013 Equity Incentive Plan of MacroGenics, Inc.;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">3)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statement (Form S-8 No. 333-214386) pertaining to the 2016 Employee Stock Purchase Plan of MacroGenics, Inc.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">4)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registration Statements (Form S-3 No. 333-200092 and Form S-3 ASR No. 333-214385) of MacroGenics, Inc.</font></div></td></tr></table><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of our reports dated </font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">, with respect to the consolidated financial statements of MacroGenics, Inc. and the effectiveness of internal control over financial reporting of MacroGenics, Inc.&#160;included in this Annual Report (Form 10-K) of MacroGenics, Inc. for the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-top:24px;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Ernst&#160;&amp; Young LLP</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Baltimore, Maryland</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exhibit31-1201710xk.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3705EFF5CF2D5559BCCED6F52A3A6817"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Scott Koenig, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of MacroGenics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:168px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:120px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:168px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Scott&#160;Koenig</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Scott Koenig, M.D., Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:&#160;</font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exhibit31-2201710xk.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s70DE920A1C645E0C8D9EB8BC944C09BF"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, James Karrels, certify that:</font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I have reviewed this Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of MacroGenics, Inc.;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:96px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(c)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(d)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:96px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div></td></tr></table><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(a)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:192px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:192px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:144px;"><font style="font-family:inherit;font-size:10pt;">(b)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:48%;"></td><td style="width:3%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ James Karrels</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">James Karrels</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Senior Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Dated:&#160;</font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exhibit32-1201710xk.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3675F8E33BC058D09DB46553CD6AF1ED"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 32.1</font></div><div style="line-height:120%;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of Principal Executive Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Scott Koenig, President and Chief Executive Officer (principal executive officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Registrant (the &#8220;Report&#8221;), that:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Scott Koenig&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: Scott Koenig, M.D., Ph.D.</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date:  </font><font style="font-family:inherit;font-size:10pt;text-transform:default;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>exhibit32-2201710xk.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s29677E463D3E589E91E7979607309F6C"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">EXHIBIT 32.2</font></div><div style="line-height:120%;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. 1350 (Section 906 of the Sarbanes-Oxley Act of 2002)</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, James Karrels, Senior Vice President and Chief Financial Officer (principal financial officer) of MacroGenics, Inc. (the &#8220;Registrant&#8221;), certify, to the best of my knowledge, based upon a review of the Annual Report on Form 10-K for the period ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;of the Registrant (the &#8220;Report&#8221;), that:</font></div><div style="line-height:120%;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Report fully complies with the requirements of Section&#160;13(a) or 15(d)&#160;of the Securities Exchange Act of 1934, as amended; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:26px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:2px;"><font style="font-family:inherit;font-size:10pt;">(2)</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.</font></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ James Karrels&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name: James Karrels</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:inherit;font-size:10pt;">February&#160;27, 2018</font><font style="font-family:inherit;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>8
<FILENAME>mgnx-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:54AD223573085039B2D50F570E98E40C,x:4c4b540f491c425990458fab501f6fc5-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20171231" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="mgnx-20171231.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2018Q1Feb23">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-02-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMGA271Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:USGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:ServierMGA271Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_IncyteCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_LaboratoryAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:LaboratoryAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">mgnx:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Jul1-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-07-01</xbrli:startDate>
			<xbrli:endDate>2015-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2Apr26_us-gaap_SubsidiarySaleOfStockAxis_mgnx_RegisteredDirectOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-04-26</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JohnsonAndJohnsonDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2014Q1Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr26toApr26_us-gaap_SubsidiarySaleOfStockAxis_mgnx_RegisteredDirectOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-26</xbrli:startDate>
			<xbrli:endDate>2017-04-26</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q1Feb1-Feb28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-02-01</xbrli:startDate>
			<xbrli:endDate>2014-02-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_mgnx_AtTheMarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JohnsonAndJohnsonDevelopmentCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May03toMay03_us-gaap_SubsidiarySaleOfStockAxis_mgnx_AtTheMarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgnx:AtTheMarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-03</xbrli:startDate>
			<xbrli:endDate>2017-05-03</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgnx:UndesignatedPreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2003Q1Feb28_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2003-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2013Q4Oct31_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:StockIncentivePlan2013Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2013-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4SD_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:EquityIncentivePlan2003Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2006-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q2_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-05-18</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2May01toMay31_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgnx:TwoThousandSixteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">mgnx:DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2016Q2May31_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgnx:RavenBiotechnologiesIncMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:ContractTerminationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2010-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-05-01</xbrli:startDate>
			<xbrli:endDate>2014-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2014Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ResearchCollaborationAndLicenseOptionAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-05-01</xbrli:startDate>
			<xbrli:endDate>2014-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-12-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q3Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2018Q1Jan01toJan31_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-15</xbrli:startDate>
			<xbrli:endDate>2015-09-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Dec01toDec31_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-09-01</xbrli:startDate>
			<xbrli:endDate>2012-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q2Jun1-Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-06-01</xbrli:startDate>
			<xbrli:endDate>2010-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Oct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD011AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-01-01</xbrli:startDate>
			<xbrli:endDate>2015-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:NationalInstituteOfAllergyAndInfectiousDiseasesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-09-15</xbrli:startDate>
			<xbrli:endDate>2015-09-15</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:GreenCrossCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:ServierMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:ServierDARTMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q3Jul01-Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:JanssenBiotechIncMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:JanssenMGD015AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:IncyteCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">mgnx:IncyteMGA012AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:TakedaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">mgnx:TakedaMGD010AgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgnx:BoehringerIngelheimMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul21toJul21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-21</xbrli:startDate>
			<xbrli:endDate>2017-07-21</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3Jul06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-07-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3Jul06toJul06">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-06</xbrli:startDate>
			<xbrli:endDate>2017-07-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q2Apr01toApr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2012Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2012-01-01</xbrli:startDate>
			<xbrli:endDate>2012-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q4QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q1QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001125345</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="U011">
		<xbrli:measure>mgnx:Segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U010">
		<xbrli:measure>mgnx:Lease</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U004">
		<xbrli:measure>mgnx:Molecule</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="U008">
		<xbrli:measure>mgnx:Payment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q4YTD" id="Fact-74E806DC77C4FA31E43C9625EFC11501">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q4YTD" id="Fact-442E53BFD35F84C2C3389625EFD1EB2E">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q4YTD" id="Fact-FED93635689D1E50D1FE9625EFD15FBD">FY</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q4YTD" id="Fact-305ED8BC05FBDD6C61BC9625EFD24380">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q4YTD" id="Fact-35E1D81BF55FD35A7A349625EFC002FC">2017-12-31</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q4YTD" id="Fact-A9B76B72410DF52906089625EFD19B40">10-K</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q4YTD" id="Fact-07D17B372ABF0F4FBF729625EFD12A6F">0001125345</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2018Q1Feb23" decimals="INF" id="Fact-D8FF171DD5A55B9CB3079625EFD1969F" unitRef="shares">36918852</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityCurrentReportingStatus contextRef="FD2017Q4YTD" id="Fact-C4486B5BDC6365422CB19625EFE27FDF">Yes</dei:EntityCurrentReportingStatus>
	<dei:EntityFilerCategory contextRef="FD2017Q4YTD" id="Fact-42FDE815738BF0BD29039625EFC10CEC">Large Accelerated Filer</dei:EntityFilerCategory>
	<dei:EntityPublicFloat contextRef="FI2017Q2" decimals="-6" id="Fact-84E7ED682B9E210321899625EFC97B4D" unitRef="usd">936000000</dei:EntityPublicFloat>
	<dei:EntityRegistrantName contextRef="FD2017Q4YTD" id="Fact-8B3DB0C9820BDCE9997D9625EFC98D1A">MACROGENICS INC</dei:EntityRegistrantName>
	<dei:EntityVoluntaryFilers contextRef="FD2017Q4YTD" id="Fact-1C054E30C4568161F7BB9625EFC8DF80">No</dei:EntityVoluntaryFilers>
	<dei:EntityWellKnownSeasonedIssuer contextRef="FD2017Q4YTD" id="Fact-4F2D42BD3F91385866909625EFC1E732">Yes</dei:EntityWellKnownSeasonedIssuer>
	<mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-B7D7C85EF0180345A6799625EFD1652D" unitRef="usd">17000000.0</mgnx:AdditionalDevelopmentFundingOptionsUnderAgreement>
	<mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement contextRef="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-F08944B2E435A8FE16239625EFD02F26" unitRef="usd">2500000.0</mgnx:AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-53C140C836D11307E3D89625EFD12334" unitRef="usd">34000000</mgnx:AdditionalPotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-77CF0BC24B2139F76F709625EFD00C35" unitRef="usd">88500000</mgnx:AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement contextRef="I2010Q3Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-8F1459D7D17EC66A5F5B9625EFD8E848" unitRef="usd">82500000</mgnx:AdditionalPotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-4590F316B3E18EF467DC9625EFC8822F" unitRef="usd">1300000</mgnx:AdjustmentToRevenueUnderAccountingStandardsCodification>
	<mgnx:AggregatePotentialFutureCostReimbursement contextRef="I2010Q2Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-9231A396AC0F41ECEC169625EFCAF8F9" unitRef="usd">5500000.0</mgnx:AggregatePotentialFutureCostReimbursement>
	<mgnx:AmountAllocatedToEquity contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-55261350106DE2D887F69625EFD0FF4F" unitRef="usd">62700000</mgnx:AmountAllocatedToEquity>
	<mgnx:AmountAllocatedToLicenseAndRD contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-3874BFC2374E968BC95F9625EFD0E2CC" unitRef="usd">62300000</mgnx:AmountAllocatedToLicenseAndRD>
	<mgnx:AmountOfImmaterialErrorCorrection contextRef="FD2015Q4YTD" decimals="-5" id="Fact-17047CD0532B015749B19625EFD035A2" unitRef="usd">1900000</mgnx:AmountOfImmaterialErrorCorrection>
	<mgnx:ChangeInAccountingEstimateCurrentYearImpact contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-BD8812DF010DC20152079625EFD1BDA2" unitRef="usd">3700000</mgnx:ChangeInAccountingEstimateCurrentYearImpact>
	<mgnx:ChangeInAccountingEstimateCurrentYearImpact contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-4E8DEE921E70254B7C97B0F1FACF5F03" unitRef="usd">800000</mgnx:ChangeInAccountingEstimateCurrentYearImpact>
	<mgnx:ClinicalMilestoneEarnedDuringPeriod contextRef="I2015Q3Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-1F727606085C6AE5D0079625EFC9E864" unitRef="usd">10000000</mgnx:ClinicalMilestoneEarnedDuringPeriod>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-BDA2EE98B715F7668B6C9625EFCA1982" unitRef="usd">500000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-5A2C858E8F7CFA45098D9625EFD10EB5" unitRef="usd">2600000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-CB9FE059A30996EC5A30B0EC3B2A3670" unitRef="usd">3200000</mgnx:CollaborationArrangementOffsetToResearchAndDevelopmentCosts>
	<mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance contextRef="FI2017Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-0245346CC8754C7C94319625EFDB12B4" unitRef="shares">1960168</mgnx:CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance>
	<mgnx:CommonStockMaximumAmountAvailableForIssuance contextRef="D2017Q2May03toMay03_us-gaap_SubsidiarySaleOfStockAxis_mgnx_AtTheMarketOfferingMember" decimals="-5" id="Fact-385D3CB43AEF13DD260B970C4C6A6B2B" unitRef="usd">75000000</mgnx:CommonStockMaximumAmountAvailableForIssuance>
	<mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage contextRef="FD2017Q4YTD" decimals="INF" id="Fact-20DA2C58B2865716E6F39625EFD206C3" unitRef="number">1</mgnx:DefinedContributionPlanEmployeesContributionVestedPercentage>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C26A45CC8D5B835647549625EFC73D54" unitRef="usd">661000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E709D0EF78EC394A603F9625EFD1471B" unitRef="usd">173000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F8CA1069AD22571EC2DE9625EFC86FB7" unitRef="usd">607000</mgnx:EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-E319F0E8A199C7E8C7AD9625EFDBA04C" unitRef="usd">18600000</mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount>
	<mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-4C520F0DBC029A064ECAD85C0B71E0BF" unitRef="usd">6500000</mgnx:EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-141E75A17888630C5B859625EFC857D0" unitRef="usd">493000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-67DA29377EE12D725ED89625EFC1D857" unitRef="usd">32000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-AABA3771A89A16291B069625EFCA673F" unitRef="usd">485000</mgnx:EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount>
	<mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent contextRef="D2017Q2May01toMay31_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-2B2D86C368AA184ABCB6B0AE5C4F4CF1" unitRef="number">0.1</mgnx:EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent>
	<mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan contextRef="FD2012Q4YTD" id="Fact-EEA5AD6A1D9C1A8A18BE9625EFDAFE21">P21Y</mgnx:EmployeesEligibleAgeToParticipateInBenefitPlan>
	<mgnx:FundedValueOfBasePeriod contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-065BD343F56F52C583D79625EFD8F658" unitRef="usd">7500000</mgnx:FundedValueOfBasePeriod>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A094FBA8E4FB8547759D9625EFD9F551" unitRef="usd">4650000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7296AC9CDF72E5A0CE939625EFE12682" unitRef="usd">-1134000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:IncreaseDecreaseInDeferredRent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-85EDEB11299F9305A3C69625EFD829F1" unitRef="usd">6115000</mgnx:IncreaseDecreaseInDeferredRent>
	<mgnx:NonRefundableUpfrontFees contextRef="D2010Q2Jun1-Jun30_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-3041F5228A1A8FF8B3499625EFC867B7" unitRef="usd">1000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-E0CCADA2DAA76E8EAFEE9625EFD18BB5" unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-819BB19734613D3516839625EFC8FAB3" unitRef="usd">20000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-261DC0C440730114C6A99625EFCFFFF1" unitRef="usd">15000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2016Q3Jul01-Jul31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-7C95CEC9B89DC0A1D5249625EFD02539" unitRef="usd">75000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="D2018Q1Jan01toJan31_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" decimals="-5" id="Fact-5D021DE4777CAF7CDF80B1278C3043B0" unitRef="usd">10000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-8FFC593284DEE8EF7A2E9625EFD18824" unitRef="usd">50000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-11947A28FAE6D61576859625EFC9230E" unitRef="usd">75000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2017Q4QTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-3795895D76B3C064DE5BB0F748F0E36A" unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NonRefundableUpfrontFees contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-80BF0B3315C9C4FA3980B11E3BF62FDC" unitRef="usd">150000000</mgnx:NonRefundableUpfrontFees>
	<mgnx:NumberOfAnnualMaintenancePaymentReceived contextRef="D2010Q4Oct1-Oct31_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-4DBD0EF87643535D2E359625EFD89A40" unitRef="U008">3</mgnx:NumberOfAnnualMaintenancePaymentReceived>
	<mgnx:NumberOfLease contextRef="FD2017Q4YTD" decimals="INF" id="Fact-69C38454C2A5ED9DF61CB0E1D628A754" unitRef="U010">5</mgnx:NumberOfLease>
	<mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="INF" id="Fact-61E1679203D488AD95029625EFD11D9E" unitRef="U004">2</mgnx:NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement>
	<mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="-5" id="Fact-5619DA073A2CFD5795FE9625EFC88384" unitRef="usd">1400000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
	<mgnx:OperatingLossCarryforwardsAnnualLimitationAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="-5" id="Fact-00E0DBB2949A358ED94F9625EFCA01A2" unitRef="usd">200000</mgnx:OperatingLossCarryforwardsAnnualLimitationAmount>
	<mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount contextRef="FD2017Q4YTD_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-DF009192B5397A634BB29625EFC9760D" unitRef="usd">13500000</mgnx:OperatingLossCarryforwardsLimitationsOnUseAmount>
	<mgnx:OperatingLossCarryforwardsNotSubjectToLimitation contextRef="FI2017Q4" decimals="-5" id="Fact-F8F8A6DC3937CBB832709625EFC8C79C" unitRef="usd">226200000</mgnx:OperatingLossCarryforwardsNotSubjectToLimitation>
	<mgnx:OptionExerciseFee contextRef="FI2014Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-9BA201058F03F57BDE489625EFD198F8" unitRef="usd">15000000</mgnx:OptionExerciseFee>
	<mgnx:OptionExerciseFeeRecognitionPeriod contextRef="FD2014Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-7CE53763735D344D00169625EFC9A977">P82M</mgnx:OptionExerciseFeeRecognitionPeriod>
	<mgnx:OptionExerciseFeeRecognitionPeriod contextRef="FD2016Q1QTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" id="Fact-56A1BECEF828CF7E6407B0F3B6EF0308">P8M</mgnx:OptionExerciseFeeRecognitionPeriod>
	<mgnx:OptionExerciseFeeRecognitionPeriod contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-9C7C3D311C250115FCB3B0F1CD963689">P124M</mgnx:OptionExerciseFeeRecognitionPeriod>
	<mgnx:OriginalPeriodOfDevelopment contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-219D02BAA9B9D5229DDC9625EFD13A17">P29M</mgnx:OriginalPeriodOfDevelopment>
	<mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="3" id="Fact-C9FA9EA503E042898B5F9625EFC0C81C" unitRef="number">0.040</mgnx:PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan>
	<mgnx:PotentialClinicalMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-35DB7218DA38CC182B179625EFCA9657" unitRef="usd">63000000</mgnx:PotentialClinicalMilestonePaymentsUnderAgreement>
	<mgnx:PotentialCommercialMilestonePaymentsUnderAgreement contextRef="I2017Q4Oct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-5197D6FD997674DD9321B100AF97843E" unitRef="usd">330000000</mgnx:PotentialCommercialMilestonePaymentsUnderAgreement>
	<mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement contextRef="I2017Q4Oct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-395CD50E8361BBA8776BB0FC91D83ABD" unitRef="usd">420000000</mgnx:PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:PotentialLicenseFee contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-5AD3EEFDB5EC5CAF20699625EFC806F8" unitRef="usd">40000000</mgnx:PotentialLicenseFee>
	<mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" decimals="-5" id="Fact-E8EBFD877DD9946851EEB12753EEC492" unitRef="usd">370000000</mgnx:PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement>
	<mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-807719CDBD502F44AC2B9625EFD788BB" unitRef="usd">188000000</mgnx:PotentialRegulatoryMilestonePaymentsUnderAgreement>
	<mgnx:PotentialSalesMilestonePaymentsUnderAgreement contextRef="I2012Q3Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="INF" id="Fact-82FF8083D207B5AD6C589625EFCADE0C" unitRef="usd">420000000</mgnx:PotentialSalesMilestonePaymentsUnderAgreement>
	<mgnx:PremiumReceivedOnStockPurchase contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-AA22BB04294486C6697C9625EFD1750A" unitRef="usd">12300000</mgnx:PremiumReceivedOnStockPurchase>
	<mgnx:ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-9AC761C85D517BAC45A3B0EF2F010EC8" unitRef="usd">10800000</mgnx:ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement>
	<mgnx:ProceedsFromResearchAndDevelopmentServices contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-61A78F2CCFB986A110249625EFCFF2A5" unitRef="usd">5500000</mgnx:ProceedsFromResearchAndDevelopmentServices>
	<mgnx:ProceedsfromRoyaltiesPercent contextRef="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="2" id="Fact-C131EC1BFA187F692A47B1064AD47F31" unitRef="number">0.24</mgnx:ProceedsfromRoyaltiesPercent>
	<mgnx:ProceedsfromRoyaltiesPercent contextRef="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="2" id="Fact-94D1D1D5C2A0C916F95BB1052DAD0A2D" unitRef="number">0.15</mgnx:ProceedsfromRoyaltiesPercent>
	<mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="FD2015Q4YTD" decimals="-3" id="Fact-ED9D79C9E51E06BE758A9625EFD7BF99" unitRef="usd">911000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
	<mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="FD2016Q4YTD" decimals="-3" id="Fact-DD49037CFDFC807CCCA59625EFDAE7EC" unitRef="usd">1893000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
	<mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases contextRef="FD2017Q4YTD" decimals="-3" id="Fact-50E90F151513BC3B26C69625EFD83DAD" unitRef="usd">1144000</mgnx:ProceedsfromStockOptionsExercisedAndESPPPurchases>
	<mgnx:PropertyPlantAndEquipmentNonCashAdditions contextRef="FI2016Q4" decimals="-5" id="Fact-F06D3692A53C17E9363E9705B4E2E816" unitRef="usd">300000</mgnx:PropertyPlantAndEquipmentNonCashAdditions>
	<mgnx:PropertyPlantAndEquipmentNonCashAdditions contextRef="FI2017Q4" decimals="INF" id="Fact-D542D99D23D4A2349A5D9625EFC23262" unitRef="usd">9615000</mgnx:PropertyPlantAndEquipmentNonCashAdditions>
	<mgnx:ReductionInResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-5" id="Fact-47F639FFE82813F876789625EFD16824" unitRef="usd">1300000</mgnx:ReductionInResearchAndDevelopmentExpense>
	<mgnx:RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-1CCD63FA5B3DD827CB65B10FDBF3AA97" unitRef="usd">1100000</mgnx:RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount>
	<mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="D2016Q4SD_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-FC8827436DD58EFA82F29625EFE29390" unitRef="shares">4336730</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
	<mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-E1E282EFD00E23F020439625EFE24E50" unitRef="shares">6769888</mgnx:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-5276550A623169EC64949625EFDAD5C4" unitRef="shares">373289</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-C2D66932AD0C07D107EB9625EFC815CE" unitRef="shares">925</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A9B76F0C30E002238A949625EFC11366" unitRef="shares">524853</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-489D4919FD889F4B06379625EFCA32CC" unitRef="shares">1862</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-ABCBF865BA7F577B9E9C9625EFD2D69E" unitRef="shares">289186</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesStockPlanActivity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-37D89A73F57781E8F621D7CF5DDB0BC1" unitRef="shares">1862</mgnx:StockIssuedDuringPeriodSharesStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="D2014Q1Feb1-Feb28" decimals="INF" id="Fact-D46E977FB7056DA352E59625EFC1C725" unitRef="shares">450000</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
	<mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption contextRef="D2015Q3Jul1-Jul31" decimals="INF" id="Fact-362A9EF857209C2385989625EFCFBE69" unitRef="shares">528750</mgnx:StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F612405405039AAAA7419625EFC74FE4" unitRef="usd">882000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3D45E203E25FBCCB7F339625EFD9998B" unitRef="usd">908000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-6196F96FD16EB21202AF9625EFD953ED" unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-C2D6125D5247175557549625EFD13323" unitRef="usd">-29000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6AD627664BA6E089B55D9625EFDAA4F3" unitRef="usd">1854000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-A9CCC010A1CBE3AA04899625EFD0A414" unitRef="usd">1887000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-A789970614DB7E075C579625EFCFCC5E" unitRef="usd">6000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-7FDA154F2F926DB0B9A59625EFC86936" unitRef="usd">-39000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A1F57E926D2C268D5B2A9625EFC8EC83" unitRef="usd">1104000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-F6935F13CAA85E2E84159625EFC20843" unitRef="usd">1141000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-DD15C8B73F0E2051F9F39625EFD00CA6" unitRef="usd">3000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:StockIssuedDuringPeriodValueStockPlanActivity contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-8CD6804C7F07BB87740A9625EFE2C7F8" unitRef="usd">-40000</mgnx:StockIssuedDuringPeriodValueStockPlanActivity>
	<mgnx:TotalConsideration contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-3277D29BD963D951E8449625EFCAC9D9" unitRef="usd">125000000</mgnx:TotalConsideration>
	<mgnx:TotalPotentialValueUnderAgreement contextRef="D2015Q3Sep15-Sep15_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="INF" id="Fact-E697D90355A509F4C8919625EFD73D57" unitRef="usd">24500000.0</mgnx:TotalPotentialValueUnderAgreement>
	<mgnx:UpfrontFeeAllocatedToAgreement contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" decimals="-5" id="Fact-C73FB8FFC36D42812CD69625EFD10991" unitRef="usd">5000000</mgnx:UpfrontFeeAllocatedToAgreement>
	<mgnx:UpfrontFeeAllocatedToAgreement contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-76671D46359AC184C0379625EFC94BEA" unitRef="usd">10000000</mgnx:UpfrontFeeAllocatedToAgreement>
	<mgnx:UpfrontPaymentRecognitionPeriod contextRef="D2012Q3Sep1-Sep30_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" id="Fact-5D73033A704014EC6AAF9625EFD18037">P75M</mgnx:UpfrontPaymentRecognitionPeriod>
	<mgnx:UpfrontPaymentRecognitionPeriod contextRef="D2014Q2May1-May31_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" id="Fact-ABC6A81134067D9B80E49625EFD2C38D">P24M</mgnx:UpfrontPaymentRecognitionPeriod>
	<mgnx:UpfrontPaymentRecognitionPeriod contextRef="D2017Q4Dec01toDec31_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" id="Fact-F21ECAF85D31A16E368EB128F1000032">P30M</mgnx:UpfrontPaymentRecognitionPeriod>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B6353482C8326EC7DA599625EFD8A96D" unitRef="usd">3995000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-377CAF559DA10FD02B249625EFCF7ED3" unitRef="usd">2451000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-66C923D13B7D92E499BB9625EFD94E9B" unitRef="usd">2764000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-EA61487A4C4466AF22B49625EFD89117" unitRef="usd">13643000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-5E29C26D3C81773447169625EFD14D82" unitRef="usd">16134000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-04550E8CA6146EFBF6559625EFC1AC30" unitRef="usd">38581000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-A4E8DF5477B6C0E28BD79625EFC8A169" unitRef="usd">25823000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-0B5AE18EF6B071A475799625EFC1D97F" unitRef="usd">28919000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FI2016Q4" decimals="-3" id="Fact-A9F4F9A4E69526F86B709625EFD17532" unitRef="usd">-82000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FI2017Q4" decimals="-3" id="Fact-82904FB4D5A448E76B559625EFD1757E" unitRef="usd">-61000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2016Q4" decimals="-3" id="Fact-0BA04FED1852934DFBFE9625EFCF7C66" unitRef="usd">561198000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="FI2017Q4" decimals="-3" id="Fact-16268CF2D4A910457F659625EFC9076C" unitRef="usd">611270000</us-gaap:AdditionalPaidInCapitalCommonStock>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5BAB163AE30C3FD49A649625EFD105C8" unitRef="usd">7847000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D6E013778B8F0163EC569625EFE26A6E" unitRef="usd">7847000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3131B9B3C0D05C771F839625EFC1D6B6" unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-7D89C3B3367696D5AB319625EFC259A9" unitRef="usd">12165000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-98D024D2CF9D377850129625EFD2C76D" unitRef="usd">14744000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-BD4C44790E291A9E28C89625EFC8711D" unitRef="usd">14744000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1B1F46B1A822908277409625EFDA9F1D" unitRef="usd">7847000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-37B44E98B2864F3273139625EFC1326D" unitRef="usd">4224000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2015Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-8CFEFE040CF32E09E9C39625EFD93516" unitRef="usd">3623000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B0070AFD7CDDBB74BB659625EFDB82B4" unitRef="usd">12165000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-32EBCC6866F6C9843A869625EFDA8E77" unitRef="usd">6387000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-53D2561F819C02F9F37D9625EFDA20BB" unitRef="usd">5778000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CC1F36D4415B9D7F27199625EFC13A0A" unitRef="usd">14744000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-B5994A51873BBACF908A9625EFDA11F3" unitRef="usd">7356000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-CB00CDF60BF7135AD5F49625EFE29419" unitRef="usd">7388000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2016Q4" decimals="INF" id="Fact-A7880ABC061FC431A07A9625EFC7A182" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AllowanceForDoubtfulAccountsReceivable contextRef="FI2017Q4" decimals="INF" id="Fact-4E5618C9A48F72355CA29625EFC1F6AE" unitRef="usd">0</us-gaap:AllowanceForDoubtfulAccountsReceivable>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2015Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-39D42461134FE71CC6449625EFCAD6DB" unitRef="shares">4146064</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-55D703A81C43A0FEAE479625EFC9CB45" unitRef="shares">3838060</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" decimals="0" id="Fact-B1178F3BA7E1BDBFE7019625EFC989DD" unitRef="shares">4504642</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-1E74F260EC80CAD66F279625EFE17E85" unitRef="usd">311263000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q4" decimals="-3" id="Fact-5D561423A98A677C2A459625EFD1D9EF" unitRef="usd">373883000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-335B22369DB763217EBE9625EFD9044D" unitRef="usd">283947000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-ACE50BB442C97EB04DB29625EFD29668" unitRef="usd">322298000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4" decimals="-3" id="Fact-E822DACF90FA91C211E09625EFC917CB" unitRef="usd">251666000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-EFE7FDEC2124239E68699625EFCA75B0" unitRef="usd">46781000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-49170AE94F2DA8C121E19625EFD06862" unitRef="usd">204885000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-542B235F1B0B53BC77A39625EFD08338" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4" decimals="-3" id="Fact-7B7D6E13C3BB13130DAC9625EFC9AEC4" unitRef="usd">155910000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-32453B1A4777DA5888979625EFC96AD2" unitRef="usd">61512000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-9B60C5914653C1BCE4D29625EFD079E2" unitRef="usd">94398000</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-18C94F8AB528D50FACAE9625EFC97DCE" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="FI2016Q4" decimals="INF" id="Fact-0E2A92FFB4CA27FA994D9625EFC8DFC0" unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
	<us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup contextRef="FI2017Q4" decimals="INF" id="Fact-1054AF984F7BDCF0C0549625EFC79375" unitRef="usd">0</us-gaap:AssetsHeldForSaleNotPartOfDisposalGroup>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-A0422A49C2E207FDE39C9625EFD04CA1" unitRef="usd">56000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-D6ADFDE11D77075907F896F21C5FAC5A" unitRef="usd">51000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-F55E191AC80D9A84BD7D96F21C44767F" unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-6EBEA37BE6D79FD5C6EE96F21C6DB420" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-D090078418A060014DF39625EFDA882D" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-665FA632C5237772780E9625EFE1A006" unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-D9336B34D0F4BAF561909625EFDA71D5" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-BF6BF9E22AFA099F0F4A9625EFDA7BA2" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4" decimals="-3" id="Fact-5D589C3BEA0403892CF99625EFD8C4AD" unitRef="usd">138000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-9B478DC2703A4B6E4EFC96F21C58B32F" unitRef="usd">127000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-CADDE4C71603FEA4B1B096F21C515BC1" unitRef="usd">10000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-10F1902268CA91168F0C96F21C741DEE" unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4" decimals="-3" id="Fact-9B576D5FB06322E19D189625EFDA19CC" unitRef="usd">63000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-B4A9725CAB242D9BCB239625EFDAC9B2" unitRef="usd">50000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-5D588CE91E78906865A59625EFD98EA9" unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-6236D29956CADC78AFFA9625EFD92524" unitRef="usd">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4" decimals="-3" id="Fact-3E19E3C8C9F960403D909625EFD9A9B1" unitRef="usd">200966000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-E2B7EFFF0C15DF34BC5996F21C669A26" unitRef="usd">166376000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-DF26399D3EB3E45BC51996F21C828A73" unitRef="usd">29764000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-3F591C4611CDCA00E2E696F21C7B7FB6" unitRef="usd">4826000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4" decimals="-3" id="Fact-C79604ED1CA374DE93969625EFDA7EB2" unitRef="usd">93455000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-403411020055E3AD63709625EFD959EE" unitRef="usd">77462000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-B8152CFA7DBB175437939625EFD2FA21" unitRef="usd">11998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-8110B111BC9D9F03AAA09625EFDA13EC" unitRef="usd">3995000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-846E6A8A5DC2502D22DB9625EFCA865C" unitRef="usd">166300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-0FDB4F9E772DACCC80C49625EFC8C6E4" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-F7CF78CAFC010E524C949625EFCA929B" unitRef="usd">166300000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-02944928DCECE57B3C2C9625EFCAF88B" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-36E6D71EDFE7FF471ED69625EFD19872" unitRef="usd">29759000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-96315E6155D3BE2A3EC39625EFD08C01" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-ABED7067C1CFE6FF12229625EFCA192C" unitRef="usd">29759000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-2E1D14E5B6BD1F53AAF09625EFC8064F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-CCD547C143C1DF77F2729625EFD0962B" unitRef="usd">8826000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-C2FAB9258108B5D09DCE9625EFCAC727" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-7D1A29912516CA00855A9625EFD00720" unitRef="usd">8826000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-31F060E2DDF870B1DED89625EFD0580E" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-9298CA7F03F30AC3F7649625EFCF3FB5" unitRef="usd">78418000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-4CF18800C0B5B1E13ADE9625EFDADB51" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-01C9E70C2E7B36D823779625EFC9CE16" unitRef="usd">78418000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-CD005154428FDC7A6A409625EFC88EF8" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-514C10CF223F493768B79625EFC8FC05" unitRef="usd">11990000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-7533B70863422734392B9625EFC9A908" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-B8324522CBE7DEA5C0739625EFC90E32" unitRef="usd">11990000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-C855593903E97ABD71B09625EFD221FD" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-7D37CE7D44E3B8F7A48F9625EFC912CC" unitRef="usd">3990000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-D0D4F082ADB60B8A310E9625EFC9661F" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-B441F9E772EF613A442D9625EFD072D3" unitRef="usd">3990000</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecurities contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-3A442292C92A869CF3879625EFD0731A" unitRef="usd">0</us-gaap:AvailableForSaleSecurities>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0BFCDE80EAA2E31F80FC9625EFE0F45E" unitRef="usd">192898000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-9D2CC4D687D64978DA859625EFC97CE2" unitRef="usd">93394000</us-gaap:AvailableForSaleSecuritiesCurrent>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost contextRef="FI2016Q4" decimals="-3" id="Fact-0487760596987CF152849625EFD9172F" unitRef="usd">7981000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="FI2016Q4" decimals="-3" id="Fact-23EFA964DE70A6638DE59625EFD9C13D" unitRef="usd">7986000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="FI2016Q4" decimals="-3" id="Fact-6B8DA4ACF2C70C113A139625EFD977D2" unitRef="usd">192985000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
	<us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="FI2016Q4" decimals="-3" id="Fact-2C1872391CF5A68835E09625EFD834AE" unitRef="usd">192898000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4" decimals="-3" id="Fact-1C2188B7B6309F540A799625EFD9A97D" unitRef="usd">200884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-9E44D4C0268617312D2C9625EFD9C0DB" unitRef="usd">166300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-54CA389D1B74EC60C0F29625EFD12DA3" unitRef="usd">29759000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2016Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-06232F032C432E5AC7089625EFD810BE" unitRef="usd">4825000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4" decimals="-3" id="Fact-4D97C8F1EED0E72189FC9625EFD81202" unitRef="usd">93394000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_CorporateDebtSecuritiesMember" decimals="-3" id="Fact-3C39AC6CB8EE76029DB19625EFDA5410" unitRef="usd">77414000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" decimals="-3" id="Fact-43D87050972AE2830CC49625EFDA15E8" unitRef="usd">11991000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="FI2017Q4_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_us-gaap_USTreasurySecuritiesMember" decimals="-3" id="Fact-DB16B1B57B045853039E9625EFDAB360" unitRef="usd">3989000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-56081C74F9C072C665D89625EFDA4EF8" unitRef="usd">7986000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:AvailableForSaleSecuritiesNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-0FADA53B871A3D1331F79625EFD93DC5" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesNoncurrent>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2014Q4" decimals="-3" id="Fact-E4E3719EAF36D0E790FE9625EFD81916" unitRef="usd">157591000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-B43F758B00D256C5B8F99625EFD2FD29" unitRef="usd">196172000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-7014B6E3C42E3206C6AC9625EFC89B1E" unitRef="usd">84098000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q4" decimals="-3" id="Fact-60170DB3E2031F6C02749625EFE0BA9E" unitRef="usd">211727000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4" decimals="-5" id="Fact-3D91D4C81E3F7102CE109625EFC2028B" unitRef="usd">50800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-7A21996B7A262949A0D89625EFD0AF31" unitRef="usd">46781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-3B6B2927DCC95E9502BF9625EFD185DD" unitRef="usd">46781000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-120BACEC48000CFD90B29625EFD1F1A7" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-3C58C5A9713C9B4D1F909625EFC88D51" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4" decimals="-5" id="Fact-6A270D7A4B52905803359625EFC1D290" unitRef="usd">62500000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember" decimals="-3" id="Fact-0900D9AE4D95CBEA000F9625EFE1D09E" unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-4B881ABB81A9725783799625EFC98A0B" unitRef="usd">61512000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" decimals="-3" id="Fact-ECB5B4D0190F72EF5DA79625EFD139BA" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q4_us-gaap_FairValueByAssetClassAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-5B41739C54BCD52205389625EFCA4F1B" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1662DDCCEC6588222B3E9625EFD945AD" unitRef="usd">38581000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2016Q4YTD" decimals="-3" id="Fact-67843EFA2739704672219625EFD2AC50" unitRef="usd">-112074000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="FD2017Q4YTD" decimals="-3" id="Fact-13DA707BC7E81FA5B58B9625EFD26A56" unitRef="usd">127629000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-98B2A4FB251043AE7C129625EFD85DB6" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q4" decimals="INF" id="Fact-4160F49F52227CA3278E9625EFD85CA2" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-F3257C7B1B96C383537D9625EFD94B23" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q4" decimals="INF" id="Fact-8AE4308571F9E2AA69C19625EFD84707" unitRef="shares">125000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-E3400D7B52BAAB2774399625EFD8B2B9" unitRef="shares">34870607</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q4" decimals="INF" id="Fact-CBAA689B178F4F5D973F9625EFD93D89" unitRef="shares">36859077</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-D8D686DED4BD5E80789E9625EFE18383" unitRef="usd">349000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q4" decimals="-3" id="Fact-5C3D71D02D6B091181269625EFD1B502" unitRef="usd">369000</us-gaap:CommonStockValue>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_BoehringerIngelheimMember" decimals="2" id="Fact-42B27691CE45C8DA663F9625EFDA6F75" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2015Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-28187283A471C45928F0BB35D83CBA46" unitRef="number">0.72</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-BA4F70AC017C67651CA39625EFD105CB" unitRef="number">0.40</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member" decimals="2" id="Fact-83692482C348A03EF7A09625EFD18108" unitRef="number">0.31</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_USGovernmentMember" decimals="2" id="Fact-D986459E4AA85B006C7BAF61B38CB76E" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2016Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_JanssenBiotechIncMember" decimals="2" id="Fact-37FE3A745122670142A19625EFD9742C" unitRef="number">0.85</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" decimals="2" id="Fact-E2FCCBBAFECCB44ED70BAF6175422CAF" unitRef="number">0.73</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_ServierMGA271Member" decimals="2" id="Fact-9349AC03E20603D13C6EAF6176169CD0" unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConcentrationRiskPercentage1 contextRef="FD2017Q4YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueNetMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_us-gaap_MajorCustomersAxis_mgnx_IncyteCorporationMember" decimals="2" id="Fact-9D5F07EFD9F6B34E4DBA96E36E22E9E4" unitRef="number">0.96</us-gaap:ConcentrationRiskPercentage1>
	<us-gaap:ConstructionInProgressGross contextRef="FI2016Q4" decimals="-3" id="Fact-C52CA81EC296646057A19700BACDE7F0" unitRef="usd">0</us-gaap:ConstructionInProgressGross>
	<us-gaap:ConstructionInProgressGross contextRef="FI2017Q4" decimals="-3" id="Fact-71ED2BBE75E87DF539D99700BAE4409C" unitRef="usd">32800000</us-gaap:ConstructionInProgressGross>
	<us-gaap:CostsAndExpenses contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7A1895DF89995B0ACE4F9625EFCF9E6B" unitRef="usd">121036000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2016Q4YTD" decimals="-3" id="Fact-73133B83FE98AB59CD919625EFD1301D" unitRef="usd">151922000</us-gaap:CostsAndExpenses>
	<us-gaap:CostsAndExpenses contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C7DFA8A1FE12A7A814EC9625EFC80621" unitRef="usd">179885000</us-gaap:CostsAndExpenses>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="INF" id="Fact-AE9EFF0225D1943DD61DB0D0C46FED99" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="INF" id="Fact-0D3456849BE6AC1F8D2AB0D0C118C23B" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="INF" id="Fact-304CC3E394B96376C4C09625EFD0BA5C" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2016Q4" decimals="-3" id="Fact-D5A61208B6581D3382469625EFC79F86" unitRef="usd">1406000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredIncomeTaxLiabilities contextRef="FI2017Q4" decimals="-3" id="Fact-22CB651669D6EB6CE12D9625EFC14174" unitRef="usd">805000</us-gaap:DeferredIncomeTaxLiabilities>
	<us-gaap:DeferredRentCredit contextRef="FI2016Q4" decimals="-5" id="Fact-024A7B535983BEEFAD8A9625EFD8D281" unitRef="usd">6200000</us-gaap:DeferredRentCredit>
	<us-gaap:DeferredRentCredit contextRef="FI2017Q4" decimals="-5" id="Fact-51FC348E2AA978DCC7249625EFD85510" unitRef="usd">12300000</us-gaap:DeferredRentCredit>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8DD8629C074A9F9D28F2BB367196DE14" unitRef="usd">1319000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-C2DE65AAE5BDAB9ED4B99666604C0B2B" unitRef="usd">1048000</us-gaap:DeferredRentCreditCurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-FD403E6F7F6455A507D49625EFCA489E" unitRef="usd">4867000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRentCreditNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-F77FBC7F50D77DAAA47F9625EFD995EE" unitRef="usd">11253000</us-gaap:DeferredRentCreditNoncurrent>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-B96653644DD0AB8694F1B3FB83AB539E" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-294AC8C220C79AD7A63F9625EFD06B1C" unitRef="usd">3200000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-D2292697763752CBCE0A9625EFCF3D14" unitRef="usd">11100000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="INF" id="Fact-C7A372FCBB5C6152A269B3F79CDD9C14" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-909176399F2506113AB39625EFD1151D" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" decimals="-5" id="Fact-EE943E7A3D802083D4A5B122640A9A1D" unitRef="usd">10000000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-401AB2C8AB3432CAEDAEB0EDD914F64D" unitRef="usd">2300000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-A39AF2FFCFC91B7C8D48B0F0C37C15C6" unitRef="usd">8500000</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenue contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="INF" id="Fact-363E1E18A541E455BD509625EFD20EB4" unitRef="usd">0</us-gaap:DeferredRevenue>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-0E77D891CFCDE0ECAFF39625EFC1D9C8" unitRef="usd">4261000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-E2572FC7FEC20A25F9099625EFD0E6A3" unitRef="usd">900000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-B7BA4D599678933091149625EFC22BF1" unitRef="usd">3300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AD14F4FF058AD4C42A149625EFD95668" unitRef="usd">7202000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" decimals="-5" id="Fact-13314807951F29B48EC2B1220C62CE39" unitRef="usd">4000000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-D2C88EEE24C312330F9AB0EE1DCCF138" unitRef="usd">900000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueCurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-9400D1E995F3CA7E0699B0F1024E81E9" unitRef="usd">2300000</us-gaap:DeferredRevenueCurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8DF5786813D995AFA0009625EFDA88C4" unitRef="usd">10045000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-419E6EAED5CC6A1487919625EFD2247C" unitRef="usd">2300000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2016Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-A0BF25756671A30B24A09625EFD10CEB" unitRef="usd">7800000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-D398D887ABF2F4A8B4629625EFC8C379" unitRef="usd">13637000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" decimals="-5" id="Fact-48437F4081A242EBAF36B121B9C1BCB4" unitRef="usd">6000000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-F43E948DADF684E2F7C7B0EE4EF3B4F0" unitRef="usd">1400000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredRevenueNoncurrent contextRef="FI2017Q4_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-135EB639799476EE7EBAB0F139EC155A" unitRef="usd">6200000</us-gaap:DeferredRevenueNoncurrent>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2016Q4" decimals="-3" id="Fact-35301C3AAD7C6164F27D9625EFC1B9A7" unitRef="usd">5098000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsDeferredIncome contextRef="FI2017Q4" decimals="-3" id="Fact-282420115B452958D83F9625EFC88C0F" unitRef="usd">2982000</us-gaap:DeferredTaxAssetsDeferredIncome>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2016Q4" decimals="-3" id="Fact-D31609A195FB76746F1C9625EFC90CCA" unitRef="usd">130250000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsGross contextRef="FI2017Q4" decimals="-3" id="Fact-FD44F80C09C8602248F09625EFC81101" unitRef="usd">113258000</us-gaap:DeferredTaxAssetsGross>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2016Q4" decimals="-3" id="Fact-08ACD722E661E0B53DBD9625EFC79DD0" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="FI2017Q4" decimals="-3" id="Fact-729EC4EDFCB06F3DD4299625EFC18E8F" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2016Q4" decimals="-3" id="Fact-E0F706D582FE2207E83A9625EFD04579" unitRef="usd">1406000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsNet contextRef="FI2017Q4" decimals="-3" id="Fact-2CE7783FA09EC0C46F329625EFC84D35" unitRef="usd">805000</us-gaap:DeferredTaxAssetsNet>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2016Q4" decimals="-3" id="Fact-5983BE9BC99CF84F776A9625EFC1F0E6" unitRef="usd">75377000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="FI2017Q4" decimals="-3" id="Fact-D66B23E7D3670DAB34379625EFC87E9A" unitRef="usd">50346000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2016Q4" decimals="-3" id="Fact-4DEED8E135FD081E549C9625EFD05A86" unitRef="usd">6583000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="FI2017Q4" decimals="-3" id="Fact-137F12E5360409CD12BE9625EFD1B9EA" unitRef="usd">7551000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
	<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" decimals="-5" id="Fact-CD599F469C8A542B38969625EFC808EB" unitRef="usd">239700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2016Q4" decimals="-3" id="Fact-BE73EF878DF994E5A9489625EFC87F15" unitRef="usd">5085000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsOther contextRef="FI2017Q4" decimals="-3" id="Fact-DEB9215C01E084820EF39625EFC87E4E" unitRef="usd">5847000</us-gaap:DeferredTaxAssetsOther>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-63F60B7383DEF63323219625EFC981E2" unitRef="usd">2926000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment contextRef="FI2017Q4" decimals="-3" id="Fact-5E13A0C17618DF9D95B99625EFD06DE8" unitRef="usd">155000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="FI2016Q4" decimals="-3" id="Fact-26A6FFD5FB864062EADA9625EFCF2849" unitRef="usd">19855000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther contextRef="FI2017Q4" decimals="-3" id="Fact-5F224EE6CAB9ED3A961E9625EFC83C61" unitRef="usd">21708000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsOther>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2016Q4" decimals="-3" id="Fact-3FA771F9220AED1B05BD9625EFC8A9E9" unitRef="usd">12829000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="FI2017Q4" decimals="-3" id="Fact-9EFFA94297BE6CB34B829625EFC09F81" unitRef="usd">21284000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2016Q4" decimals="-3" id="Fact-3308D3A4EFE3A93292649625EFCA1A0E" unitRef="usd">2497000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent contextRef="FI2017Q4" decimals="-3" id="Fact-A7DC3256ED94A35F30DC9625EFC9A7DF" unitRef="usd">3385000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2016Q4" decimals="-3" id="Fact-B6CF2A8657B3141D94B79625EFC19FDC" unitRef="usd">128844000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="FI2017Q4" decimals="-3" id="Fact-0BFACAEE904995E4FF479625EFC2460B" unitRef="usd">112453000</us-gaap:DeferredTaxAssetsValuationAllowance>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2016Q4" decimals="-3" id="Fact-C0337E43772C44DB5DC99625EFC81351" unitRef="usd">1406000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="FI2017Q4" decimals="-3" id="Fact-C2F7D8D1BC283CAC8C479625EFCA7357" unitRef="usd">805000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2015Q4YTD" decimals="-5" id="Fact-01D8CB8CD25E1594100D9625EFD83026" unitRef="usd">400000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2016Q4YTD" decimals="-5" id="Fact-E827ADDC7D6800966B059625EFD9F26D" unitRef="usd">1000000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="FD2017Q4YTD" decimals="-5" id="Fact-B554F0D9BAA9D70A93B49625EFDBC12B" unitRef="usd">1100000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
	<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="FD2012Q4YTD" decimals="INF" id="Fact-71AB3B9AE540F69742D39625EFC9F5DE" unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
	<us-gaap:Depreciation contextRef="FD2015Q4YTD" decimals="-5" id="Fact-2AED3C6D991DCA947A4F9625EFC07F6A" unitRef="usd">3200000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2016Q4YTD" decimals="-5" id="Fact-24CD40BB9D036416C5479625EFE25E27" unitRef="usd">6800000</us-gaap:Depreciation>
	<us-gaap:Depreciation contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D740E68886A39AC8F4299625EFC1AD4F" unitRef="usd">7000000</us-gaap:Depreciation>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2015Q4YTD" decimals="-3" id="Fact-51B29A5984F663C870419625EFD95923" unitRef="usd">2863000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B2473E341ABA499F77D59625EFD91B82" unitRef="usd">7608000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EAB756B0F813A206550B9625EFDAF63B" unitRef="usd">7228000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q1QTD" decimals="2" id="Fact-A1767754E8A1133E62A19625EFDA8B0D" unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q2QTD" decimals="2" id="Fact-0F32DCADFDFB4D9C43879625EFC94A90" unitRef="usdPerShare">1.17</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q3QTD" decimals="2" id="Fact-787F41BC645D06F872C69625EFD2918C" unitRef="usdPerShare">-0.97</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2016Q4QTD" decimals="2" id="Fact-E28083C7E7FB6D5A3E5C9625EFD11611" unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q1QTD" decimals="2" id="Fact-32E94DB67614823526FA9625EFD92E38" unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q2QTD" decimals="2" id="Fact-A9739092FF372162CF089625EFC1844F" unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q3QTD" decimals="2" id="Fact-C7EFCB0496FF54B7380E9625EFD8173E" unitRef="usdPerShare">-1.28</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasic contextRef="FD2017Q4QTD" decimals="2" id="Fact-05C2F94F3D9BEB0D75739625EFD96134" unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareBasic>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2015Q4YTD" decimals="2" id="Fact-1E60A8787826DB553E2E9625EFE16E57" unitRef="usdPerShare">-0.63</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q4YTD" decimals="2" id="Fact-E62672170DBBFA6B69249625EFE20FAE" unitRef="usdPerShare">-1.69</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q4YTD" decimals="2" id="Fact-F4DA949220B54511BD539625EFC0FE13" unitRef="usdPerShare">-0.54</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q1QTD" decimals="2" id="Fact-302F11CD8D4C1AFEA3E7CFCE6955FFB5" unitRef="usdPerShare">-0.88</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q2QTD" decimals="2" id="Fact-DDB791AAE3B6824B7757CFCE69676661" unitRef="usdPerShare">1.12</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-39A665B9C086A1B798D8CFCE696E02D7" unitRef="usdPerShare">-0.97</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2016Q4QTD" decimals="2" id="Fact-DB812B1E1A457437E916CFCE6967A93B" unitRef="usdPerShare">-1.00</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q1QTD" decimals="2" id="Fact-D8F23E66FB90E56799739625EFD9AE78" unitRef="usdPerShare">-1.08</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q2QTD" decimals="2" id="Fact-41CBA0A88DB0650D20BB9625EFD23F3B" unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-2184720D5FCD1B5AEC1F9625EFDA3F14" unitRef="usdPerShare">-1.28</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EarningsPerShareDiluted contextRef="FD2017Q4QTD" decimals="2" id="Fact-1CE20F7B0745CAE7BCB99625EFD9C662" unitRef="usdPerShare">2.80</us-gaap:EarningsPerShareDiluted>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q4" decimals="-5" id="Fact-2F8C0785766B2851B3209625EFDA9270" unitRef="usd">20300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q4YTD" id="Fact-B368E1A2A463165F2DE79625EFC11C79">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-228DE5C18B59500D1FB69625EFE239DD" unitRef="usd">22765000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB3CA034DD0E68C73F8A9625EFCA6921" unitRef="usd">29831000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-552EE1CBCBDCF1A105709625EFC7ADB0" unitRef="usd">32653000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset contextRef="FI2016Q4" decimals="INF" id="Fact-D812046403DFF6B946F09625EFC10793" unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
	<us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset contextRef="FI2017Q4" decimals="INF" id="Fact-DD423EA519D0FB9806F29625EFC799C7" unitRef="usd">0</us-gaap:ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2015Q4YTD" decimals="2" id="Fact-85DEC3A9E5DD7272808D9625EFCAA792" unitRef="usdPerShare">-0.63</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2016Q4YTD" decimals="2" id="Fact-D1DC44D6C8FDD6FA9FD09625EFE19FDD" unitRef="usdPerShare">-1.69</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare contextRef="FD2017Q4YTD" decimals="2" id="Fact-2403EE474BFE64AAE7809625EFC78E1D" unitRef="usdPerShare">-0.54</us-gaap:IncomeLossFromContinuingOperationsPerBasicAndDilutedShare>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1442680139C71CBC82389625EFD0D635" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2016Q4YTD" decimals="-3" id="Fact-366DCA17E6DF8CEA46069625EFC103C7" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxExpenseBenefit contextRef="FD2017Q4YTD" decimals="-3" id="Fact-38F81BFA3B7D1204C7A89625EFC8C8E9" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2015Q4YTD" decimals="-3" id="Fact-26EE287E7B0F1A0224319625EFC13ED6" unitRef="usd">10103000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4B4455CFED275EB1905C9625EFC8E1D4" unitRef="usd">24444000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="FD2017Q4YTD" decimals="-3" id="Fact-5CC807C1FC16E5E553B99625EFD11C6D" unitRef="usd">-24000000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-35A47E9603EF70E871BDD83948D91C5A" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-0D6E8368D15B1545421FD83948D7F49C" unitRef="usd">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-12F710287EF216708A44D83948DC94A7" unitRef="usd">39447000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2015Q4YTD" decimals="-3" id="Fact-E2E3A6E9DC05E023D4BD9625EFC80724" unitRef="usd">-7049000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D3C3D8900B6884EC1FA79625EFCA9823" unitRef="usd">-20489000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="FD2017Q4YTD" decimals="-3" id="Fact-39F648E1DE356FE1E58C9625EFC2AC05" unitRef="usd">-6869000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2015Q4YTD" decimals="-3" id="Fact-141ADB638E915CC92B719625EFD2928B" unitRef="usd">1102000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C654A8E0919745668F659625EFC1650F" unitRef="usd">1997000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1E3F1740E901899608B79625EFD15552" unitRef="usd">2067000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9260E4F47544EA3482339625EFD02C8B" unitRef="usd">-25000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2016Q4YTD" decimals="-3" id="Fact-046078895D364897515E9625EFC881EE" unitRef="usd">145000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="FD2017Q4YTD" decimals="-3" id="Fact-58F4F632E623E5631C639625EFC981DF" unitRef="usd">276000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F756F9328760CE3C95059625EFD0B47F" unitRef="usd">-897000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D4C006249768C1479F429625EFD18BB9" unitRef="usd">-3116000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B9C7D4DEFC86C4CC00679625EFDAB418" unitRef="usd">-735000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7BE8B0D23CAD0F90BD0E9625EFC830CE" unitRef="usd">106000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1B561FEB04DE5DF4DF309625EFC813BD" unitRef="usd">571000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsOther contextRef="FD2017Q4YTD" decimals="-3" id="Fact-9BE3C95BB30A0F5B9BD29625EFD11EB7" unitRef="usd">1853000</us-gaap:IncomeTaxReconciliationTaxCreditsOther>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A823412368C7CBA39F3E9625EFCAC1F4" unitRef="usd">3296000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A6997DDB697FE2E95B319625EFC85EA6" unitRef="usd">2551000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8C7D53879C54AF9C8AD39625EFD106CC" unitRef="usd">8455000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-A93A950F4C53DBDFCEE69625EFD98A2A" unitRef="usd">-163000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E18D54E157D80278D5E19625EFDA719B" unitRef="usd">2232000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-31DAE04FAAEA8B0F4A089625EFD2BA4E" unitRef="usd">-1544000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2015Q4YTD" decimals="-3" id="Fact-6BCF9491B94ED06DD4389625EFE29074" unitRef="usd">-1711000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2FA933208FB0B65367569625EFD272DD" unitRef="usd">1540000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4AE5617472FCC71AFF1A9625EFD94727" unitRef="usd">10878000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-FA76C56875B52ED4D4F79625EFD2934E" unitRef="usd">3545000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-B30150C5626079BA8D919625EFE0FF2F" unitRef="usd">4659000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EE5443FA1D6D6BCEB34F9625EFE220EC" unitRef="usd">12832000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-85EA5F6D2663DE65C1599625EFD95DF3" unitRef="usd">-12223000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-95BEFEECF7601621B92A9625EFD8FBC3" unitRef="usd">-4191000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1D210A900CEC398A436E9625EFD15CF7" unitRef="usd">6533000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-00DA593DE42507D0BE809625EFD92670" unitRef="usd">-878000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-331D7D21748A3074AEB29625EFD991D8" unitRef="usd">-727000</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-C961D6C126E5CFDE00AF9625EFE1D739" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2015Q4YTD" decimals="-3" id="Fact-728C33321668AA26803E9625EFD2795A" unitRef="usd">285000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F0622C77CAA13A05AB909625EFD975EB" unitRef="usd">-276000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInOtherOperatingAssets contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1A5FBB2F1F500B0CBDDA9625EFDB9B98" unitRef="usd">-262000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-9258ACD669F05EFC88069625EFE2AD3A" unitRef="usd">-2405000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-3380FA554A94FAF57AD29625EFD297F6" unitRef="usd">1677000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-872CB2429DA7D9AED2B29625EFD93D38" unitRef="usd">-332000</us-gaap:IncreaseDecreaseInPrepaidExpense>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-F98918B76BE37634ABB99625EFD986D3" unitRef="usd">-300000</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-E84B47AD17E390AD2ADE9625EFE28500" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-8826AA366CE146FABCE49625EFE210D5" unitRef="usd">0</us-gaap:IncreaseDecreaseInRestrictedCashForOperatingActivities>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2015Q4YTD" decimals="-3" id="Fact-4197333407262E8053CF9625EFDA5714" unitRef="usd">-3293000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2016Q4YTD" decimals="-3" id="Fact-4908B8724FD0B97D37439625EFD97D9A" unitRef="usd">-2822000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncreaseDecreaseInRestructuringReserve contextRef="FD2017Q4YTD" decimals="-3" id="Fact-CD121C279249F7A6E9539625EFE22E5C" unitRef="usd">-1593000</us-gaap:IncreaseDecreaseInRestructuringReserve>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2015Q4YTD" decimals="0" id="Fact-FA5A9C9CFBC649FFD5419625EFD29C81" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2016Q4YTD" decimals="0" id="Fact-287C9FBB91932728707B9625EFE21778" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements contextRef="FD2017Q4YTD" decimals="0" id="Fact-544CB4D8B3CF38B59C599625EFE21FCE" unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
	<us-gaap:InterestIncomeOther contextRef="FD2015Q4YTD" decimals="-5" id="Fact-24E69C0772490F80C5EBD8147FF2E2A1" unitRef="usd">200000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="FD2016Q4YTD" decimals="-5" id="Fact-20D66DCAC9CB7544E943D81462794961" unitRef="usd">2300000</us-gaap:InterestIncomeOther>
	<us-gaap:InterestIncomeOther contextRef="FD2017Q4YTD" decimals="-5" id="Fact-DF33955C41431CD7E849D8140FE33AD2" unitRef="usd">2400000</us-gaap:InterestIncomeOther>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="D2017Q2Apr01toApr30" id="Fact-9188513F14F1C923E5ABB0E287F4882C">P72M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="D2017Q3Jul06toJul06" id="Fact-81030615DEA9859703C7B0E21AFF7347">P30M</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-686DAC3379600CA39CAC9625EFD16A53" unitRef="usd">42512000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q4" decimals="-3" id="Fact-95A4CE74475BFA20B3E89625EFD2CC90" unitRef="usd">74645000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-36C97BB77291012C30789625EFD08461" unitRef="usd">311263000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-96A5991206128F12827E9625EFD29C24" unitRef="usd">373883000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-B1B530EFE6052C0F0C9A9625EFD1339E" unitRef="usd">27302000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-2638A6171132BB1B0F039625EFE2A8E7" unitRef="usd">49755000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2015Q4YTD" decimals="-3" id="Fact-5D9719BE2FFC60F316629625EFE29B32" unitRef="usd">99368000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CB2EE1CD97297FC3A5DD9625EFE2F574" unitRef="usd">86582000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q4YTD" decimals="-3" id="Fact-96BA130F4B4FF4D68B1A9625EFE148B1" unitRef="usd">155516000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-BBE3B60D926807FF53659625EFC82AA5" unitRef="usd">12500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-70BBA3C1F6779D7E88D59625EFC9DA55" unitRef="usd">500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-254F28BE6A754CCCF2599625EFD177DF" unitRef="usd">72300000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-8A32A3EE6D26ADEEFE289625EFD1C68D" unitRef="usd">200000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-FCF831B7D84B2F423C309625EFC76014" unitRef="usd">3500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-BE0A4907038D0E6999709625EFD10899" unitRef="usd">8000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-892D4D6D981F4B532ADCB3FAB43C876E" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-69622277AC5176476C059625EFCAE3B5" unitRef="usd">800000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-C3E166E6AC78D3BDBD459625EFD20444" unitRef="usd">2000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-B8455F2543298ECA8D159625EFC9FC61" unitRef="usd">75800000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-7BD1BC87FFE2DB1F64189625EFCA6E0B" unitRef="usd">5100000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-D8566DB6E9254E8CC3179625EFD03898" unitRef="usd">3300000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-7AAF5ACAB1A5BD20A35F9625EFC9E91A" unitRef="usd">2100000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="INF" id="Fact-62B45FA55452B56E0C7F9625EFD8BC81" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="-5" id="Fact-F0FC942545E146A6555BB0EFAD8F950C" unitRef="usd">900000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-BAA4FB23C02C7FFC6EC6B10F1FC0F197" unitRef="usd">151100000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-9EBA2F52B18AE01718B8B0F5F05CDE91" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD015AgreementMember" decimals="-5" id="Fact-A0D54796142566FAC082B0F4D2901F3F" unitRef="usd">600000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" decimals="-5" id="Fact-0ECCDCB5BB2A48F70829B0EE951A389C" unitRef="usd">1700000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_ServierMember_us-gaap_TypeOfArrangementAxis_mgnx_ServierDARTMember" decimals="-5" id="Fact-2AAC5AF99C3AAF499311B0ECF8993E97" unitRef="usd">2500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-3FBD08AE72BBEC1984CAB16325EEFB4C" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-065FA9F6A19CAB55F9AD9625EFD933C8" unitRef="usd">204349000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-AEC5021DE8B1F4AF47C59625EFE2370A" unitRef="usd">1854000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EBA7E7D8D78CA4DD065D9625EFD2C4AA" unitRef="usd">35348000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C2B09C527E9E331704239625EFD907AF" unitRef="usd">-152107000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-81B699738441C3981E099625EFE23EB2" unitRef="usd">-70249000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-50E3629CF55C76AA24E69625EFD8885C" unitRef="usd">77876000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1A30FF5F41C3CF09409B9625EFD9D984" unitRef="usd">-13661000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2016Q4YTD" decimals="-3" id="Fact-FFA2F7556D6AD19E2C779625EFD24F14" unitRef="usd">-43679000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4D932813C30FDA765E3A9625EFD2BAE1" unitRef="usd">14405000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-0D474AB859D6E192F8A99625EFD08897" unitRef="usd">-20140000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-26BA0CFB0226A96F908C9625EFC86D06" unitRef="usd">-20140000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q1QTD" decimals="-3" id="Fact-8631D2634927269F3D269625EFD069A9" unitRef="usd">-30363000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q2QTD" decimals="-3" id="Fact-E3A8BA8D81E2877851309625EFD2A690" unitRef="usd">40464000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-ECD158635B2F4693A6439625EFD958AF" unitRef="usd">-33846000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4QTD" decimals="-3" id="Fact-E2C5977AEB527724EA989625EFD9C12C" unitRef="usd">-34783000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-740DA4AD225BC6FD10EB9625EFE2F125" unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-72AD9E896656C7E183909625EFD0FEEB" unitRef="usd">-58528000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q1QTD" decimals="-3" id="Fact-8BD504CC84133205B9069625EFD2DBBE" unitRef="usd">-37655000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q2QTD" decimals="-3" id="Fact-02D7F9628E7BC9FE5C9D9625EFD87DDB" unitRef="usd">-40654000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-19ACA450E8DACA6D802C9625EFE25143" unitRef="usd">-47043000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4QTD" decimals="-3" id="Fact-DC7D32442200DB78200C9625EFD82149" unitRef="usd">105727000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-59AB2C159A452221BF0E9625EFD29580" unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-BE8338F286243AD3A3219625EFC81DC6" unitRef="usd">-19626000</us-gaap:NetIncomeLoss>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2017Q4YTD" decimals="INF" id="Fact-68D66DC54858387089C69625EFC10BA9" unitRef="U011">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingIncomeLoss contextRef="FD2015Q4YTD" decimals="-3" id="Fact-37F9AA13851EE8AFA08E9625EFDA8049" unitRef="usd">-20182000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q4YTD" decimals="-3" id="Fact-510328CE2875D0653E2B9625EFD1AD2C" unitRef="usd">-60042000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4C0DCA6CB8569A8AD01C9625EFE2AEF7" unitRef="usd">-22143000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q4" decimals="-3" id="Fact-C2493EB440EFF0F13D809625EFD2713F" unitRef="usd">45803000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-AE233A2B32282169DA6B9625EFD94088" unitRef="usd">6574000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="FI2017Q4" decimals="-5" id="Fact-B93B5329E6428214E47BB0E2630CB727" unitRef="usd">100000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="I2016Q2May31_us-gaap_BusinessAcquisitionAxis_mgnx_RavenBiotechnologiesIncMember" decimals="-5" id="Fact-6AA6ED94A6AECCF1CFBE9625EFD09C61" unitRef="usd">1300000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals contextRef="I2017Q3Jul06" decimals="-5" id="Fact-C9F1AA83090C1556CE9CB0E1F3C56249" unitRef="usd">2400000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="FI2017Q4" decimals="-3" id="Fact-70987D6BD499F5D3E1629625EFD95B47" unitRef="usd">4885000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q4" decimals="-3" id="Fact-F7DC2C2673AC4FF9E6039625EFD921F4" unitRef="usd">4743000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q4" decimals="-3" id="Fact-35A32102DCC27D0C83499625EFD2E3B9" unitRef="usd">4775000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q4" decimals="-3" id="Fact-996E9DBCB7C5859C630B9625EFC99333" unitRef="usd">6342000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="FI2017Q4" decimals="-3" id="Fact-1D34876A4D3F46D246769625EFD94582" unitRef="usd">18484000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2015Q4YTD" decimals="-5" id="Fact-A9C3FC7327C2A3B9761B9625EFD8C0C2" unitRef="usd">900000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2016Q4YTD" decimals="-5" id="Fact-4B7DD1C6EA23BBBE09899625EFD259CB" unitRef="usd">3000000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OperatingLeasesRentExpenseNet contextRef="FD2017Q4YTD" decimals="-5" id="Fact-033996E5BDD864959F2E9625EFDA343E" unitRef="usd">3100000</us-gaap:OperatingLeasesRentExpenseNet>
	<us-gaap:OtherAssets contextRef="FI2016Q4" decimals="-3" id="Fact-8922B503368073E73CD49625EFD80082" unitRef="usd">704000</us-gaap:OtherAssets>
	<us-gaap:OtherAssets contextRef="FI2017Q4" decimals="-3" id="Fact-AEC62CBA71D5CEAE50909625EFD86A54" unitRef="usd">383000</us-gaap:OtherAssets>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6BD083352AA9F4467E0F9625EFE2F902" unitRef="usd">1369000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-44E61DEDA9F07B67760E9625EFD88121" unitRef="usd">1602000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CAC3B0EC12FF01C28C719625EFD25228" unitRef="usd">-5000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2016Q4YTD" decimals="-3" id="Fact-09900F4704CC99644BEB9625EFDA5CA6" unitRef="usd">-77000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EB8035926A05501095C09625EFD12769" unitRef="usd">-21000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C6E1EA7D21AFF61F9C009625EFD07E03" unitRef="usd">-20145000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2016Q4YTD" decimals="-3" id="Fact-7837B67023510E78531A9625EFD1FF81" unitRef="usd">-58605000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B927D9FFA683AD268E219625EFDA295D" unitRef="usd">-19647000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-C7999C27984920349B929625EFD1E99A" unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherLiabilitiesCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-91A9D12F7BB8C7A800439625EFC2E0DD" unitRef="usd">175000</us-gaap:OtherLiabilitiesCurrent>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-EB5141AAB3BABC1469569625EFD9D81B" unitRef="usd">42000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-6C9CFAB69FCF7B7D8D979625EFD27AFB" unitRef="usd">1514000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherNonoperatingIncomeExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-50DF8AE13F5601541F7F9625EFDAFC7A" unitRef="usd">2517000</us-gaap:OtherNonoperatingIncomeExpense>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2016Q4YTD" decimals="INF" id="Fact-D7E68D21A8EF9DAA74239625EFC78B48" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities contextRef="FD2017Q4YTD" decimals="INF" id="Fact-C6AF80EE6F5923420AA29625EFC1F74C" unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities>
	<us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="D2015Q3Jul1-Jul31" decimals="-5" id="Fact-96832137B74FCAE5F366B0E233800D3F" unitRef="usd">5100000</us-gaap:PaymentsForProceedsFromTenantAllowance>
	<us-gaap:PaymentsForProceedsFromTenantAllowance contextRef="D2017Q3Jul21toJul21" decimals="-5" id="Fact-877F1E7F0902D650B5AFB0E249F039FD" unitRef="usd">7500000</us-gaap:PaymentsForProceedsFromTenantAllowance>
	<us-gaap:PaymentsForRestructuring contextRef="FD2016Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-48A5E08FA2B550998B579625EFC8AD7E" unitRef="usd">2822000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsForRestructuring contextRef="FD2017Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-05AF66FFE4021E4C0FA89625EFCA3AF6" unitRef="usd">1593000</us-gaap:PaymentsForRestructuring>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-434FBB3FA29600FA8FFF9625EFD9D181" unitRef="usd">29000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-A7D2872AFF838D40361A9625EFD27D1B" unitRef="usd">39000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-6F243AA6F4490D410C879625EFDAB046" unitRef="usd">40000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2015Q4YTD" decimals="-3" id="Fact-60E96EBA05FF024EE12E9625EFDA44EC" unitRef="usd">142910000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2016Q4YTD" decimals="-3" id="Fact-C07CA9FA23D31AAEC1C99625EFE1D9F1" unitRef="usd">347762000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="FD2017Q4YTD" decimals="-3" id="Fact-116D173A3B8EC789E6CF9625EFD2E749" unitRef="usd">135122000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2015Q4YTD" decimals="-3" id="Fact-C4A0F92FDB1A79EBC5069625EFE2E491" unitRef="usd">9197000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q4YTD" decimals="-3" id="Fact-CFC83045C2C9A5F3DBCC9625EFD87D8C" unitRef="usd">11381000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q4YTD" decimals="-3" id="Fact-DDB414ECDD7C35F1A7019625EFE1B928" unitRef="usd">29403000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-EBE461EA8F0A8F8892ED9625EFC1D5E6" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-81E3A259A15CF3279BF69625EFC7CCDA" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-A3CD7B4B4FEE48E3A9CB9625EFE20E45" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesIssued contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-71520A2749521229B04E9625EFD06F13" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-EB67833CD4137712A4AB9625EFCA699C" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PreferredStockSharesOutstanding contextRef="FI2017Q4_us-gaap_StatementClassOfStockAxis_mgnx_UndesignatedPreferredStockMember" decimals="INF" id="Fact-E3E22A696CAD92E513F79625EFDA78CE" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-F35AD9D7FD0492FD39EC9625EFD1238D" unitRef="usd">3483000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:PrepaidExpenseCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-9356E7BDBCEA8EA5B01B9625EFD944E8" unitRef="usd">3151000</us-gaap:PrepaidExpenseCurrent>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2017Q2Apr26toApr26_us-gaap_SubsidiarySaleOfStockAxis_mgnx_RegisteredDirectOfferingMember" decimals="-5" id="Fact-2F1DCA41C1DB00E4D713970A8F78EF96" unitRef="usd">23700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2015Q4YTD" decimals="-3" id="Fact-49F72E744AC0DE3069C09625EFD2CFEB" unitRef="usd">203467000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q4YTD" decimals="-3" id="Fact-770FA6E45CD82ACE53969625EFD255C7" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD" decimals="-3" id="Fact-221FD9757534C5A8BE489625EFD9DA92" unitRef="usd">34244000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" decimals="-5" id="Fact-5319B7D2E9E96E80561CB0AEAE304F36" unitRef="usd">600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2014Q1Feb1-Feb28" decimals="-5" id="Fact-35FC65FF3DBC675A8E149625EFD08627" unitRef="usd">76700000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="D2015Q3Jul1-Jul31" decimals="-5" id="Fact-7FF76AAA5F929EC54E5E9625EFC8D0D2" unitRef="usd">141000000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2015Q4YTD" decimals="-3" id="Fact-BF1BDDE11928085D958A9625EFE237D2" unitRef="usd">0</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8D0C3FA524B790DD37F59625EFE1C5C5" unitRef="usd">288894000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="FD2017Q4YTD" decimals="-3" id="Fact-F88814543BA76D68ADE49625EFD8E986" unitRef="usd">242401000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2015Q4YTD" decimals="-5" id="Fact-1A8F76305DDD1A6E21EE9625EFC0E10E" unitRef="usd">900000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q4YTD" decimals="-5" id="Fact-5C6473BAB88DA5567BF59625EFDA6BEE" unitRef="usd">1900000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q4YTD" decimals="-5" id="Fact-2B8CAF16B15269FCDB579625EFE2C98B" unitRef="usd">500000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" id="Fact-6CBF47746F76EF60A9009625EFD8E593">Shorter of lease term or useful life</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-0AFFAFE5453D0B0715AB9625EFC8C5D2" unitRef="usd">43784000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember" decimals="-3" id="Fact-8F2CA59665DB2C5C212C9625EFCAF8F4" unitRef="usd">897000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-CBC05E51CFE4BEBFC48B9625EFC8466B" unitRef="usd">2520000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-CCF13AF3ECF8EDEB88BD9625EFCA1636" unitRef="usd">20208000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-2E5408062B8D569BB8689625EFCF53F9" unitRef="usd">17807000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" decimals="-3" id="Fact-4680580F371495510EB09625EFC82589" unitRef="usd">2352000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4" decimals="-3" id="Fact-AD33DF594D1DC9B425E19625EFC8DF4B" unitRef="usd">78902000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_FurnitureAndOfficeEquipmentMember" decimals="-3" id="Fact-10BFDBCD5449CD9EF8369625EFCA5625" unitRef="usd">656000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-B14FBECF25EEE5FE33249625EFC79465" unitRef="usd">2261000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-A0263FC2D1F25C13A9129625EFC9D186" unitRef="usd">20549000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-F4BE105BF5DA1321E19B9625EFCA49CE" unitRef="usd">17525000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" decimals="-3" id="Fact-72548BECC97C148190EA9625EFC76FFD" unitRef="usd">5111000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-EC9B1812F02CFD8ABB7A9625EFD2E84E" unitRef="usd">17961000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q4" decimals="-3" id="Fact-1D8B940CB02E20685A0E9625EFC9A44C" unitRef="usd">49983000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_mgnx_LaboratoryAndOfficeEquipmentMember" id="Fact-08976782E348B9973B879625EFD11D25">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" id="Fact-88016E66505FEF09C4419625EFD91650">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" id="Fact-DA37AD836E9E4D662E3A9625EFD00622">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q4YTD_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" id="Fact-81732E51306047A021EF9625EFD067F0">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2015Q4YTD" decimals="-3" id="Fact-CB8F76BF8C7706196E7A9625EFCA127A" unitRef="usd">98271000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q4YTD" decimals="-3" id="Fact-8EE7C2B06CB330A7B9B69625EFE24C54" unitRef="usd">122091000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q4YTD" decimals="-3" id="Fact-1D21F86A0B5AE1B918059625EFDADEEB" unitRef="usd">147232000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RestructuringReserve contextRef="FI2015Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-BBD02C7CD4C1E0FAD71E9625EFC82777" unitRef="usd">4713000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2016Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-CBF5A6264F048F5AA86B9625EFC1C53A" unitRef="usd">1891000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserve contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_ContractTerminationMember" decimals="-3" id="Fact-3BE4E53F8577529B01A19625EFC8FCE5" unitRef="usd">298000</us-gaap:RestructuringReserve>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-27B2BBE4D757139C1E1C9625EFD2B2F4" unitRef="usd">1593000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RestructuringReserveCurrent contextRef="FI2017Q4" decimals="-3" id="Fact-3D55BAFDCC24215A234C9625EFD1EBE9" unitRef="usd">298000</us-gaap:RestructuringReserveCurrent>
	<us-gaap:RestructuringReserveNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-46193B0CCD01BC2358139625EFDA0386" unitRef="usd">298000</us-gaap:RestructuringReserveNoncurrent>
	<us-gaap:RestructuringReserveNoncurrent contextRef="FI2017Q4" decimals="-3" id="Fact-E4BF0783D7595F493DD79625EFD859D2" unitRef="usd">0</us-gaap:RestructuringReserveNoncurrent>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-E211D197C3FA79B827809625EFD98F61" unitRef="usd">-292714000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q4" decimals="-3" id="Fact-CA84F1123F52647C1D7E9625EFD2F6D3" unitRef="usd">-312340000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2015Q4YTD" decimals="-3" id="Fact-77EE76C6D36D2E8DC7549625EFDAC0AF" unitRef="usd">1486000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q4YTD" decimals="-3" id="Fact-706FC5A19178B3FE13899625EFDA4D73" unitRef="usd">5298000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q4YTD" decimals="-3" id="Fact-4FFBB68E9EAB58AD4D499625EFD05A80" unitRef="usd">2226000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_BoehringerIngelheimMember" decimals="-5" id="Fact-E0AA3DBB021B25E121DE9625EFC98EC0" unitRef="usd">5000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-D630DE6A38A3EB1D0C92B3FE8BC8D3C6" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2015Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_TakedaMember_us-gaap_TypeOfArrangementAxis_mgnx_TakedaMGD010AgreementMember" decimals="-5" id="Fact-777B63DAA80A0D08430F9625EFD10A79" unitRef="usd">3000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2016Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-CBBCE3AEC84045FFFB2CB3FE6DD0EA72" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="FD2017Q4YTD_us-gaap_CounterpartyNameAxis_mgnx_GreenCrossCorporationMember" decimals="INF" id="Fact-F0A57A7908549C72E48F9625EFD134DA" unitRef="usd">0</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
	<us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount contextRef="D2017Q4Oct01toOct31_us-gaap_CounterpartyNameAxis_mgnx_IncyteCorporationMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_IncyteMGA012AgreementMember" decimals="-5" id="Fact-009AC524E5D03F217A7AB10E703C201D" unitRef="usd">4000000</us-gaap:RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount>
	<us-gaap:Revenues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-32222F93BE9DC6DFFCA99625EFD02B48" unitRef="usd">100854000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q1QTD" decimals="-3" id="Fact-8268374B4E3C412475839625EFDAB285" unitRef="usd">2846000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q2QTD" decimals="-3" id="Fact-1EE57DE2105BC85D79879625EFDA7F12" unitRef="usd">80673000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q3QTD" decimals="-3" id="Fact-9D1750B354BADD56B5679625EFE169D2" unitRef="usd">3255000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4QTD" decimals="-3" id="Fact-2B3919A931C9984AFEC59625EFD1473F" unitRef="usd">5106000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2016Q4YTD" decimals="-3" id="Fact-F36B97B2363DDC43AE699625EFD0E933" unitRef="usd">91880000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q1QTD" decimals="-3" id="Fact-92CE0E077240A2D10E3C9625EFE116DA" unitRef="usd">2055000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q2QTD" decimals="-3" id="Fact-429A9D2BC243A3AC9F1F9625EFDAE2F5" unitRef="usd">1666000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q3QTD" decimals="-3" id="Fact-D75F5668E0499ED1C04A9625EFDAF6BB" unitRef="usd">1663000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4QTD" decimals="-3" id="Fact-97656AC7BEA8E97E985B9625EFD9CC32" unitRef="usd">152359000</us-gaap:Revenues>
	<us-gaap:Revenues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-0D480AF618114CADF1CF9625EFD9B630" unitRef="usd">157742000</us-gaap:Revenues>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-36AF97B991F74C0496A49625EFD282D9" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="-5" id="Fact-7006EA171651F9C225989625EFD2B170" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="-5" id="Fact-6B66B7EE6935E42AACD99625EFC75116" unitRef="usd">75000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2017Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_mgnx_AtTheMarketOfferingMember" decimals="-5" id="Fact-B18307445212A0C40C39970E30AA7CB8" unitRef="usd">10800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2014Q4Dec01-Dec31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-DB95F48B8BCC0CFF4E4E9625EFD1B914" unitRef="shares">1923077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2015Q1SD_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="INF" id="Fact-8365A923C26FD0DFA2659625EFCF3BBC" unitRef="shares">1923077</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JanssenBiotechIncMember_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_mgnx_JanssenMGD011AgreementMember" decimals="INF" id="Fact-64B9795B09187042A67E9625EFD03FDA" unitRef="usdPerShare">39.00</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2015Q1Jan31_us-gaap_CounterpartyNameAxis_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" decimals="INF" id="Fact-F774F48F87C604DC70859625EFCF32F8" unitRef="usdPerShare">39</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:ShareBasedCompensation contextRef="FD2015Q4YTD" decimals="-3" id="Fact-1D00871DE4E1573D092F9625EFE25685" unitRef="usd">7847000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q4YTD" decimals="-3" id="Fact-527D90484A2451F378EF9625EFE2B576" unitRef="usd">12165000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EFE6C68E3E1CD003B3F19625EFD75F02" unitRef="usd">14744000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2015Q4YTD" decimals="INF" id="Fact-C674285D41A08FDCF7639625EFDAB23A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q4YTD" decimals="INF" id="Fact-C2F9B1A612C083C704B19625EFD957F8" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q4YTD" decimals="INF" id="Fact-523572BA701C3930037C9625EFD9775B" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-B2E89E5CC7D99112710BB0B22B1B20E3" unitRef="number">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-CD3CF85C8F04B29DDF78B0B229B1667D" unitRef="number">0.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-E1347E38EC2F3215820B9625EFC1EB7B" unitRef="number">0.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-93EB7A63E49C4222C9219625EFC12595" unitRef="number">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="2" id="Fact-C0191F004718F92018019625EFC22E75" unitRef="number">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="2" id="Fact-F1925F90B9E0E40094B19625EFC1F7D1" unitRef="number">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-2CA7440D919F66E2ABAA9625EFC8A798" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2015Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-60D8C43D348C629876AE9625EFC10218" unitRef="number">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-ACB53AA47F519D9CA6EA9625EFC1FAE3" unitRef="number">0.024</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-52CD7266045AAF8D98949625EFC1E682" unitRef="number">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" decimals="3" id="Fact-5D8909A721B22BA433AD9625EFC15EB1" unitRef="number">0.023</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" decimals="3" id="Fact-07EEAA8977B9365166CB9625EFC2AAB6" unitRef="number">0.019</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2003Q1Feb28_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-AF0154399D29DACF84009625EFE20E4B" unitRef="shares">2051644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2013Q4Oct31_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-82B0691309C6D81F0D9A9625EFD06AF6" unitRef="shares">1960168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="I2017Q2_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-DFF44A91032E2D8C7E8EB0AE40D11A4A" unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="FI2017Q4" decimals="INF" id="Fact-C432B0CECB6E7028FFD29625EFDB6B97" unitRef="shares">2910171</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-A46CE1300B528EF134AF9625EFC84902" unitRef="usdPerShare">17.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2015Q4YTD" decimals="-5" id="Fact-CCDB20BEC297374848B99625EFCF81AF" unitRef="usd">10900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2016Q4YTD" decimals="-5" id="Fact-AF5E994A373C2A5F26729625EFC1552F" unitRef="usd">10800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="FD2017Q4YTD" decimals="-5" id="Fact-D8D5C1C06AB9A03BEFB99625EFC0B1C1" unitRef="usd">4200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-042D3A7C14B7015C10049625EFD017ED" unitRef="shares">326607</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="FD2017Q4YTD" decimals="INF" id="Fact-32D0150BA3E8CC3C13279625EFC17C53" unitRef="shares">1246225</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2015Q4YTD" decimals="2" id="Fact-BFD7820E51E6D1E9DAEE9625EFDA8660" unitRef="usdPerShare">20.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q4YTD" decimals="2" id="Fact-870828EEAAD755CB07599625EFE2295C" unitRef="usdPerShare">15.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q4YTD" decimals="2" id="Fact-5F229AD2BBA869614BAD9625EFDA871F" unitRef="usdPerShare">12.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-62D4D59FC8F0F27AF99B9625EFC12A45" unitRef="usd">18343000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4" decimals="INF" id="Fact-A28964DC5EB9D194049D9625EFE2EDA5" unitRef="shares">3838060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-51CA1D070F6E88EE642C9625EFC864E8" unitRef="shares">4504642</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="INF" id="Fact-A699533EAFD3343A01A49625EFE288F5" unitRef="shares">955296</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="INF" id="Fact-B35D68A5FE47A7CA1B259625EFE1B26F" unitRef="shares">3549346</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4" decimals="2" id="Fact-896302CDC7BB9CE530079625EFC14FF1" unitRef="usdPerShare">18.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-B8ED4B9F23A88E2E244E9625EFC142C4" unitRef="usdPerShare">19.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_PlanNameAxis_mgnx_EquityIncentivePlan2003Member" decimals="2" id="Fact-CC46FE403928FFBFEE4B9625EFD8BB5B" unitRef="usdPerShare">1.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4_us-gaap_PlanNameAxis_mgnx_StockIncentivePlan2013Member" decimals="2" id="Fact-983F0729AB28F46C2B9E9625EFC1734C" unitRef="usdPerShare">24.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="FI2017Q4" decimals="-3" id="Fact-70DECF23582ED2D4B8B89625EFC22B65" unitRef="usd">18275000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber contextRef="FI2017Q4" decimals="INF" id="Fact-89C96E4CE8B7F38CDF199625EFC19974" unitRef="shares">4337015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice contextRef="FI2017Q4" decimals="2" id="Fact-ECA8F74E89A36E933C859625EFC825E0" unitRef="usdPerShare">19.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" decimals="0" id="Fact-ED9D41BA8DA2B531E139B0AE96F90A15" unitRef="shares">38012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-FDF22A26813A1D951A669625EFDA7FB3" unitRef="usdPerShare">2.16</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-29A03A7CC531DAAA62E39625EFE18A5C" unitRef="usdPerShare">24.26</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q4YTD" decimals="2" id="Fact-85BA0CEF2D3AAD3AA2E29625EFC195A4" unitRef="usdPerShare">20.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharePrice contextRef="I2014Q1Feb28" decimals="INF" id="Fact-F0EB323B158403565A549625EFD14690" unitRef="usdPerShare">36.50</us-gaap:SharePrice>
	<us-gaap:SharePrice contextRef="I2015Q3Jul31" decimals="INF" id="Fact-68220240BB076F1B5E459625EFD1041B" unitRef="usdPerShare">37.00</us-gaap:SharePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q4YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-C0C1036FDB72C20BCE879625EFC07804">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2015Q4YTD" id="Fact-159F828E6E750B68BC0C9625EFD9B3AF">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q4YTD" id="Fact-FA8985B76D0B5F7017339625EFD9A869">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q4YTD" id="Fact-62E2EE1BC8DF97A5AC619625EFDA0F55">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="FI2017Q4" decimals="-3" id="Fact-964888310F5FB96D29529625EFC9A820" unitRef="usd">17495000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD" id="Fact-033A6712B81E2E6292519625EFDB4CA7">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2016Q4YTD" id="Fact-DD73E1B97DB1FB4E285C9625EFDA0FE3">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="FD2017Q4YTD" id="Fact-F41A3692647D89B3A7139625EFE29407">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="FD2017Q4YTD" id="Fact-0C11D68EDD478782FC4F9625EFDA76FD">P6Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2015Q4YTD" decimals="-5" id="Fact-D88931BFAF6A4E64473D9625EFE05357" unitRef="usd">7300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2016Q4YTD" decimals="-5" id="Fact-1FF685927724DDCDB4E99625EFC0BF78" unitRef="usd">11600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 contextRef="FD2017Q4YTD" decimals="-5" id="Fact-32A4D34302FA31BBD8E89625EFC825C4" unitRef="usd">14600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent contextRef="D2017Q2May01toMay31_us-gaap_PlanNameAxis_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" decimals="INF" id="Fact-8B1764895E29DB0D65A0B0AE7B2F18BA" unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-D4B377E509B720B286219625EFC1704B" unitRef="shares">27995638</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-E44D0890183E7B04E1699625EFCAFC8C" unitRef="shares">865</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-55C7C0BB69C71D4EBD029625EFE23766" unitRef="shares">34345754</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-BA83E2340455C8C0887D9625EFD9497D" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-880431DB8D65BC11D59B9625EFD1BDC2" unitRef="shares">34870607</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-86E4B5803345A7FABE889625EFE22BF3" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BB4C45C107840AEAFA859625EFD971F2" unitRef="shares">36859077</us-gaap:SharesIssued>
	<us-gaap:SharesIssued contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-2456F73A3A23683EF2489625EFC883DF" unitRef="shares">0</us-gaap:SharesIssued>
	<us-gaap:SharesIssuedPricePerShare contextRef="I2017Q2Apr26_us-gaap_SubsidiarySaleOfStockAxis_mgnx_RegisteredDirectOfferingMember" decimals="2" id="Fact-B4E349846B90F36A80EC9709B105CF74" unitRef="usdPerShare">21.50</us-gaap:SharesIssuedPricePerShare>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2014Q1Feb1-Feb28" decimals="INF" id="Fact-D2D07204C7D1BEE346569625EFCAF634" unitRef="shares">1800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2015Q3Jul1-Jul31" decimals="INF" id="Fact-C7A3B1AD7B8DC53B01BD9625EFC99CE4" unitRef="shares">3525000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q2Apr26toApr26_us-gaap_SubsidiarySaleOfStockAxis_mgnx_RegisteredDirectOfferingMember" decimals="INF" id="Fact-A507B7FEFD4C8FC54D7C9707873661F4" unitRef="shares">1100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F5F383FB769B398160AB9625EFC8FF59" unitRef="shares">5976827</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-BB5CE40AC00D1E1605FD967E03602B62" unitRef="shares">1699284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q4YTD_us-gaap_SubsidiarySaleOfStockAxis_mgnx_AtTheMarketOfferingMember" decimals="INF" id="Fact-790962CDE5F158FCAC65970DBAB15D3D" unitRef="shares">599284</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2015Q4YTD" decimals="INF" id="Fact-3717014CE1CDA3015BBE9625EFDA685C" unitRef="shares">374214</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2016Q4YTD" decimals="INF" id="Fact-3AFD5F9767259423CF779625EFC1638B" unitRef="shares">526715</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q4YTD" decimals="INF" id="Fact-B7E5F362E30782BA33F79625EFE1F88E" unitRef="shares">253036</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD" decimals="-3" id="Fact-24F200DD01AFB80191059625EFE214F3" unitRef="usd">203467000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-067422638C94F3AFD1699625EFD9B26B" unitRef="usd">203407000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-9DD1C33D33783D3989549625EFE148EA" unitRef="usd">60000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD" decimals="-3" id="Fact-EF4CD4153CAB7316DDE2967E11BBDAB0" unitRef="usd">34244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-9F8D77AFFBC38A128659967E0CAA23EC" unitRef="usd">34227000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-07AB653B56F80B5D06CAD7FF67E12DC0" unitRef="usd">17000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4" decimals="-3" id="Fact-081E2A017AB73B245EC29625EFC90945" unitRef="usd">121286000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-1338E9AA0249FE7BFBE49625EFD26C3E" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-34EDA9ECE489867C7BD89625EFC1B700" unitRef="usd">335071000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7ED621A9E3D6C0A6B5259625EFDB5155" unitRef="usd">280000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-B288163A0F880A03A47C9625EFD2757B" unitRef="usd">-214046000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2014Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-499FD9066A8A96C21A0D9625EFC1656E" unitRef="usd">-19000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4" decimals="-3" id="Fact-38E108962F90A99719EE9625EFE2986D" unitRef="usd">313337000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-21940338863B7FC453CA9625EFD8DCF6" unitRef="usd">-5000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-C914BDF716CBA26973B79625EFE23642" unitRef="usd">547185000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2439CE402D80EBF769539625EFC974C0" unitRef="usd">343000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1F429A1003C1831491239625EFC8B1D7" unitRef="usd">-234186000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2015Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-1C264EA80968972604BE9625EFC9FBF9" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-733C17BEF5C0858A2C809625EFD80A1C" unitRef="usd">268751000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-09E4DCCC7AE3D60052619625EFD8EC4C" unitRef="usd">-82000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-23774B388578A5D3BD439625EFDA0DE2" unitRef="usd">561198000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-7680AC1C4B57BC7BEBF19625EFE2878A" unitRef="usd">349000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-CEB4AD8BEEE0A6915A169625EFC7BD71" unitRef="usd">-292714000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-96051CB70F91133F8FE29625EFD00F1D" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4" decimals="-3" id="Fact-7A97E05EAAA565A144BA9625EFC9D715" unitRef="usd">299238000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-22FB947ADB54059A0A439625EFCA1CD2" unitRef="usd">-61000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-3AF541142620C10991BA9625EFE1C7F6" unitRef="usd">611270000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-EC832A173FBF0BE384429625EFD20899" unitRef="usd">369000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-FECB7A54B42DA2914E5E9625EFCA91D9" unitRef="usd">-312340000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-474D6817A0AD45FA4CB39625EFD0E304" unitRef="usd">0</us-gaap:StockholdersEquity>
	<us-gaap:TaxCreditCarryforwardAmount contextRef="FI2017Q4_us-gaap_IncomeTaxAuthorityAxis_us-gaap_DomesticCountryMember" decimals="-5" id="Fact-907CB1B1B44DA9A612E89625EFD08B92" unitRef="usd">42800000</us-gaap:TaxCreditCarryforwardAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD" decimals="-3" id="Fact-7AAC06D9C7B97875C26C9625EFC29485" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-5E9BAF564A7CEF6FE16E9625EFDA4278" unitRef="usd">48000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-EB63ABD7D71FAD2AC3E49625EFD02AD2" unitRef="usd">-48000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD" decimals="-3" id="Fact-1BF1434EA04A74E946E89625EFC89DBC" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D358135FA7740D6EC9D19625EFD8B976" unitRef="usd">39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-67123C4C5B48FA0FBAB69625EFC0160B" unitRef="usd">-39000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2017Q4YTD" decimals="-3" id="Fact-54B3A80464764EBF442A9625EFD85573" unitRef="usd">0</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-4455C8A840D5B67939359625EFD9FC85" unitRef="usd">40000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockRetiredParValueMethodAmount contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="-3" id="Fact-EB8708E5DA5DA4B771C29625EFD893BD" unitRef="usd">-40000</us-gaap:TreasuryStockRetiredParValueMethodAmount>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-90C4643D7A77C63A2D449625EFD2EF1A" unitRef="shares">1790</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-A3BECDEEC592BA0ED8DC9625EFD05290" unitRef="shares">1862</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:TreasuryStockSharesRetired contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" decimals="INF" id="Fact-BCE5F13E98D80A1CDB8ED7CEF4AF0726" unitRef="shares">1862</us-gaap:TreasuryStockSharesRetired>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD" decimals="-3" id="Fact-55C2EC8298325F3BA23DD81B1A46C69C" unitRef="usd">-5000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2015Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-C0D898E5A2585D71A052D7CF98A3F0A4" unitRef="usd">-5000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD" decimals="-3" id="Fact-2CCFA8A0EB95084978AA9625EFD03FAF" unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2016Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-E7BA16B58A54324275409625EFD968D5" unitRef="usd">-77000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2017Q4YTD" decimals="-3" id="Fact-B610FCD66E17049AF29D9625EFDA141B" unitRef="usd">21000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrealizedGainLossOnInvestments contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" decimals="-3" id="Fact-FE7E413877CCF2D369129625EFD14407" unitRef="usd">21000</us-gaap:UnrealizedGainLossOnInvestments>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2014Q4" decimals="-3" id="Fact-211421E7166B0AEAEC969625EFE23F52" unitRef="usd">2047000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2015Q4" decimals="-3" id="Fact-010769260D83689FBF819625EFC16568" unitRef="usd">2425000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2016Q4" decimals="-3" id="Fact-8585D0CEFFC577EC454A9625EFDA7A33" unitRef="usd">2465000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefits contextRef="FI2017Q4" decimals="-3" id="Fact-73D56BA9374075866B959625EFDA6679" unitRef="usd">3395000</us-gaap:UnrecognizedTaxBenefits>
	<us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-D424F8EB62CD8FC632449625EFC1E8A8" unitRef="usd">268000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2015Q4YTD" decimals="INF" id="Fact-0C353B7CC381C45B193EB0D47C55CDE7" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2016Q4YTD" decimals="INF" id="Fact-64A5C14A860003456A26B0D47BAE046A" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="FD2017Q4YTD" decimals="INF" id="Fact-454D268887C06F5E07A79625EFC9BE0C" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-80B097CA155431C6947C9625EFC8042D" unitRef="usd">357000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2016Q4YTD" decimals="-3" id="Fact-918DFEC728702487DDB99625EFDAE7CC" unitRef="usd">308000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-D23A15F83BF825B441BB9625EFC10F8B" unitRef="usd">569000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2015Q4YTD" decimals="-3" id="Fact-479D0A6255F8034D45E09625EFC0F1D9" unitRef="usd">21000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="FD2017Q4YTD" decimals="-3" id="Fact-A77F9EC0CF970C1483379625EFDAF2FB" unitRef="usd">361000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2016Q4" decimals="-5" id="Fact-C6745298E28B44D334FB9625EFCAA2B8" unitRef="usd">2400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="FI2017Q4" decimals="-5" id="Fact-D859B9793F541D687D639625EFCA2660" unitRef="usd">3400000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2015Q4YTD" decimals="0" id="Fact-FD4219A2B6953F48811A9625EFE2618C" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2016Q4YTD" decimals="0" id="Fact-0CE096CCD50D5334EE9F9625EFE12606" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="FD2017Q4YTD" decimals="0" id="Fact-B401E74535865BB3E9C99625EFD2301C" unitRef="shares">36095080</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2015Q4YTD" decimals="0" id="Fact-E8FB7E5D01D49DFC85B79625EFD28505" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q4YTD" decimals="0" id="Fact-F79BCFC9BD452CE9DD479625EFCAE5E4" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q4YTD" decimals="0" id="Fact-3219ADFB2522E5A2ECD39625EFD1FC6B" unitRef="shares">36095080</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2015Q4YTD" decimals="0" id="Fact-1733D0AD1B7B8E1974479625EFE1A6E4" unitRef="shares">31801645</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2016Q4YTD" decimals="0" id="Fact-766A70E761D65672EC869625EFE1CA16" unitRef="shares">34685274</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="FD2017Q4YTD" decimals="0" id="Fact-9DAFEC9356A5B02476639625EFD8CF99" unitRef="shares">36095080</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
	<mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-7B2AE734DD4FC27E1AC79625EFCA2F57">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Collaboration and Other Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Incyte&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the collaboration and license agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$420.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in development and regulatory milestones, and up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$330.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in commercial milestones. The Company determined that each potential future clinical and regulatory milestone is substantive.&amp;#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&amp;#160; If commercialized, the Company would be eligible to receive tiered royalties of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012.  The Company and Incyte have agreed to initiate negotiations for a separate clinical supply agreement that will set forth terms and conditions. Finally, Incyte will fund the Company's activities related to the ongoing monotherapy clinical study until such time as the Company can transfer the Investigational New Drug application (IND) to Incyte. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the collaboration and license agreement with Incyte and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&amp;#8217;s substantive performance obligations under the collaboration and license agreement include the delivery of the license and clinical activities through a brief technology transfer period.  The Company evaluated the collaboration and license agreement with Incyte and determined that the license and clinical trial activities each represented separate deliverables and were accounted for as separate units of accounting. The Company concluded that the license had standalone value to Incyte and was separable from the clinical trial activities because the license was sublicensable and Incyte has significant capabilities in performing clinical trials.&amp;#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price (BESP) to each deliverable.  The BESP for the exclusive license was determined using information from other similar collaboration and license agreements.  The BESP for the clinical trial activities was determined using similar arrangements and is estimated at approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which will be recognized over the technology transfer period as work is performed and the expenses are reimbursed by Incyte. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$151.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Incyte collaboration and license agreement during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$150.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to clinical trial activities performed. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Roche&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets.  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of this agreement, Roche received rights to use certain of the Company&amp;#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which was received in January 2018. The Company will also be eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$370.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in potential milestone payments and royalties on future sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the research collaboration and license agreement with Roche and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&amp;#8217;s substantive performance obligations under the research collaboration and license agreement include the delivery of the license and activities during the research period.  The Company evaluated the collaboration and license agreement with Roche and determined that the license and research activities do not have value on a standalone basis and therefore represented one unit of accounting.   The &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recognized over the expected research period, which is &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Each company will be responsible for their own expenses during the research period.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition, the Company determined that each potential future development and regulatory milestone is substantive.  Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,923,077&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new shares of the Company's common stock for proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;Upon closing the transaction in January 2015, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Janssen as well as the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; investment in the Company's common stock.&amp;#160;&amp;#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&amp;#160;&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of the MGD011 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&amp;#160; The Company's substantive performance obligations under the collaboration and license agreement included the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &amp;#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&amp;#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&amp;#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative BESP method to each deliverable.&amp;#160; The BESP for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The BESP for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share exceeded the fair value of the common stock by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical research and development activities.&amp;#160; Of the total arrangement consideration of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$125.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company allocated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to equity (representing the fair value of common stock purchased), &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&amp;#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&amp;#160;31, 2015.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone to the Company.&amp;#160; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue was recognized under the MGD011 Agreement during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  During the years ended December&amp;#160;31, 2016 and 2015, the Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$72.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under the MGD011 agreement. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment from Janssen upon closing the transaction.&amp;#160;In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of the MGD015 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&amp;#160; The Company's substantive performance obligations under the MGD015 Agreement included the delivery of an exclusive license and research and development services during the preclinical research period. &amp;#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&amp;#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&amp;#160; Thus, the total arrangement consideration for these two deliverables was allocated using the BESP method to each deliverable.&amp;#160; The BESP for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The BESP for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under the MGD015 Agreement.  Revenue recognized in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront fee for the exclusive license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Takeda&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;May 2014&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&amp;#160;&amp;#160;MGD010 is being developed for the treatment of autoimmune disorders.&amp;#160; Upon execution of the agreement, Takeda made a non-refundable payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company.&amp;#160;&amp;#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&amp;#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&amp;#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&amp;#160;&amp;#160;The Company concluded that the MGD010 option was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&amp;#160;&amp;#160;&amp;#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&amp;#160;&amp;#160;The Company allocated &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the exclusivity clause to its technology and the research and development services and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the exclusive license for the initial research compound.&amp;#160;&amp;#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&amp;#160;&amp;#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&amp;#160;&amp;#160;During the first quarter of 2016, the Company determined that the development period would be extended by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;eight months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and prospectively adjusted the MGD010 option fee recognition period.&amp;#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&amp;#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue under was recognized under this agreement during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the MGD010 agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160; Revenue recognized during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; included a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestone payment received upon initiation of a Phase 1a trial of MGD010.&amp;#160;&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue was deferred under this agreement at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Servier&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September 2012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the agreement, Servier made a nonrefundable payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to the Company. In addition, the Company will be eligible to receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in license fees, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$63.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in clinical milestone payments, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$188.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in regulatory milestone payments and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$420.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&amp;#160;&amp;#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As a result of Servier exercising its option in 2014, the Company received a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&amp;#160;&amp;#160;Upon exercise of the option, the Company evaluated its performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; license fee was deferred and was being recognized ratably over a period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which represented the expected development period for flotetuzumab.&amp;#160;&amp;#160;During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company and Servier determined that the expected development period should be extended to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;The impact of this change in accounting estimate reduced revenue that would have been recognized in 2017 by &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&amp;#160;&amp;#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&amp;#160;&amp;#160;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company recorded approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as an offset to research and development costs under this collaboration arrangement, respectively.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, under this agreement.&amp;#160;&amp;#160;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Boehringer&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 2010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;October 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the agreement, the Company received an upfront payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company subsequently received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$34.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to preclinical and clinical development, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$88.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to regulatory milestones and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$82.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  The Company recognized revenue of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under this agreement, including a payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the achievement of preclinical milestones.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; revenue was deferred under this agreement at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Green Cross&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2010&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as well as clinical development and commercial milestone payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Multiple Element Arrangements (Revenue Recognition)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as the original agreement was accounted for prior to adopting ASU 2009-13&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The initial &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;June 2020&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&amp;#160;&amp;#160;As a result, the Company recorded an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue during 2014.  The Company has received a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognized revenues of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; milestones were achieved under this agreement during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&amp;#160; At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of revenue was deferred under this agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was current and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of which was non-current.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;NIAID Contract&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;15, 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;,&amp;#160;to perform product development and to advance up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to support development of MGD014 through IND application submission with the FDA, as well as up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$17.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The total potential period of performance under the award is from September 15, 2015 through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;14, 2022&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  During the year ended December&amp;#160;31, 2017, NIAID exercised the first option in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company recognized revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in revenue under this contract during the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:CollaborationAndLicenseAgreementsDisclosureTextBlock>
	<mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock contextRef="FD2017Q4YTD" id="Fact-567AAC9A41A7174EEDBC9625EFC19014">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock>
	<mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock contextRef="FD2017Q4YTD" id="Fact-EE32F896E5CAAF6DE0099625EFE1696C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,246,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised or RSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(253,036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(326,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,504,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,910,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,337,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</mgnx:ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock>
	<us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="FD2017Q4YTD" id="Fact-4DBF49E92331A25BC5E79625EFDABEFE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company's available-for-sale securities held at December 31, 2017 had maturity dates of less than one year.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The contractual maturities of the available-for-sale marketable securities as of December&amp;#160;31, 2016 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature between one and five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-29DE68A6E65AE6B1E0729625EFC0F482">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&amp;#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-B36D7EC84700DB1E7D9D9625EFC226FB">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&amp;#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; that the Company determined to be other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-572FABD77D0826CBB59F9625EFD8A01B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Commitments and Contingencies&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Operating Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company leases manufacturing, office and laboratory space in Rockville, Maryland under &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; leases that have terms that expire between &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2027&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unless renewed.&amp;#160;&amp;#160;During the year ended December&amp;#160;31, 2017, the&amp;#160;Company entered into an agreement to sublease a portion of the space it leases.  Under the terms of the sublease, the Company will receive a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; over the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; month term.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Rockville leases include a lease executed in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;July 2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for space that the Company uses as its headquarters with office and laboratory space and manufacturing space currently under construction.&amp;#160;&amp;#160; Under the terms of the lease, which commenced on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;January&amp;#160;1, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160; In July 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which was received during the third quarter.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company also leases office and laboratory space in South San Francisco under a lease that expires on &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;February&amp;#160;28, 2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  During the year ended December&amp;#160;31, 2016, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8).  As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, future payments to be received by the Company under this sublease total approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  In &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;April 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company entered into a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month lease commencing in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for office and laboratory space which will replace our current South San Francisco location.&amp;#160;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the leases contain rent escalation clauses and certain leases contain rent abatements.&amp;#160;&amp;#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had recorded a deferred rent liability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Rent expense for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under noncancelable operating leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Contingencies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-431458202F5F4E3D09969625EFC193B2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-CF7864192B7FD226936C9625EFE2197C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q4YTD" id="Fact-024DF4B706A3FDB9D7859625EFE2D46A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q4YTD" id="Fact-0691970EBE1C667D0FBE9625EFCFF0A1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2017, the Company&amp;#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&amp;#8217;s common stock at a discount through payroll deductions of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the fair market value of the Company&amp;#8217;s common stock on the last day of the offering period.  During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, employees purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;38,012&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Option Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,051,644&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,336,730&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&amp;#160; As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, under the 2003 Plan, there were options to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;955,296&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.85&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2013, the Company implemented the 2013  Plan.&amp;#160;&amp;#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,960,168&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares.&amp;#160;&amp;#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,960,168&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, (b) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,769,888&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;&amp;#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, under the 2013 Plan, there were options to purchase an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,549,346&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$24.62&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Employee Stock Options&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67% - 68%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64% - 69%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73% - 75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2% - 2.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Dividend Yield&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Volatility&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&amp;#160;&amp;#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Risk-Free Interest Rate&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Expected Term&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company uses a simplified method to calculate the average expected term.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&amp;#160;&amp;#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes stock option and restricted stock unit (RSU) activity for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Weighted-Average&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Remaining&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Contractual Term&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(Years)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Aggregate Intrinsic Value&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18.93&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,246,225&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options exercised or RSUs vested&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(253,036&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.16&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited or expired&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(326,607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24.26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding, December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,504,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.79&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,343&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercisable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,910,171&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17.65&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,495&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Vested and expected to vest&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,337,015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19.60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.9&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,275&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; the Company issued &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;253,036&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;526,715&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;374,214&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&amp;#160;&amp;#160;The Company received cash proceeds from the exercise of stock options of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average grant-date fair value of options granted during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.53&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$15.17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.90&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, respectively. The total intrinsic value of options exercised during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;The total fair value of stock options which vested during &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$14.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&amp;#160;&amp;#160;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which the Company expects to recognize over a weighted-average period of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.3 years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-42A6405AE523928C881E9625EFC1B3F2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock contextRef="FD2017Q4YTD" id="Fact-C1708B3625CD122082FF9625EFC19DF7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q4YTD" id="Fact-DD1CA2C10234A642E4989625EFC20664">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &amp;#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of Level 2 securities is determined from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  &lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-FF0DD4A409117F082BBC9625EFC76E17">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company determined that there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impaired assets and had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; assets held-for-sale.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-DF757DBC990EEA257DCB9625EFC81FBD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; there was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal U.S. net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(112,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(128,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenditures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax asset/(liability)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net decrease in the valuation allowance in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is primarily as a result of the legislation enacted in 2017, which lowers the statutory corporate tax rate from 35% to 21%,, which decreased the net deferred tax asset.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has U.S. federal and state NOL carryforwards of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$239.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that will expire in various years beginning in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. In addition, the Company has U.S. federal tax credits of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$42.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; which will expire in various years beginning in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2037&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$13.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the Company's U.S. Federal NOLs are limited for use over the years &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#8211; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2028&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in which a range of such amounts could be utilized on an annual basis of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$226.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$18.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&amp;#160;&amp;#160;Further, despite the NOL and tax credit carryforwards, the Company may have a future tax liability due to recent changes in tax legislation or state tax requirements in which net operating losses do not exist.  The Company is still quantifying the impact of these changes.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;United States federal tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,049&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred state blended rate adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred federal rate change reduction in corporate rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases for current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, of the total gross unrecognized tax benefits, approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;not&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's U.S. Federal and state income tax returns from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;forward remain open to examination due to the carryover of unused net operating losses and tax credits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740-10-25-47, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act is required in the interim and annual periods that include December 22, 2017.  As a result, the Company has revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.  The Company does not anticipate that other provisions of the Act would have a material impact on its financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-1A9EF4867ECD410421479625EFC8B7B1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-767E8A8272C6A71ACDF59625EFDA539B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;"&gt;Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Available-for-sale marketable securities as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,995&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,989&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,998&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,991&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77,462&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(50&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77,414&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;93,394&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gains&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Gross&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unrealized&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Losses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,825&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,764&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(10&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,376&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(127&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;56&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(138&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All of the Company's available-for-sale securities held at December 31, 2017 had maturity dates of less than one year.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The contractual maturities of the available-for-sale marketable securities as of December&amp;#160;31, 2016 were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:4%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Amortized Cost&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature in one year or less&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,985&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;192,898&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Mature between one and five years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,986&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,966&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;200,884&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All available-for-sale securities in an unrealized loss position as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were in a loss position for less than twelve months.&amp;#160; There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that the Company determined to be other-than-temporary.  The Company recorded interest income of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; during the years ended December 31, 2017, 2016 and 2015, respectively, which is included in other income.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-39BC77A7639C302D23329625EFC1D9ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the (FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&amp;#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&amp;#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&amp;#160;earnings at the effective date for existing contracts with remaining performance obligations.  In 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, ASU 2016-10,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  The Company will adopt the new standard in the first quarter of 2018 using the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has substantially completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Due to the unique contract terms of certain agreements, the Company is still in the process of finalizing its analysis of those agreements.  Upon completion of the Company&amp;#8217;s analysis, it will determine the cumulative effect of initially applying the new standard (if any).  The Company is also finalizing its accounting policy and designing and implementing the necessary changes to processes and controls to account for revenue under the new standard. Based on the Company's timeline and planned resources, the Company anticipates completing its implementation in connection with its first quarter 2018 interim financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&amp;#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company adopted ASU 2016-09 effective January 1, 2017 and has elected to continue to estimate the number of stock-based awards expected to vest, as permitted by ASU 2016-09, rather than electing to account for forfeitures as they occur.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The adoption of this standard did not have a material impact on the Company's financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-7657324FFF002161FA009625EFDA577E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future minimum lease payments under noncancelable operating leases as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are as follows (in thousands):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,574&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,342&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,775&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2021&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,743&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2022&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Thereafter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18,484&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45,803&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OperatingLeasesOfLesseeDisclosureTextBlock>
	<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-7FBBBC2E557275BBA0C29625EFC96E9B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Organization and Nature of Operations&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms, which have broad applicability across other therapeutic domains, including autoimmune disorders and infectious disease. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
	<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-53B368782D190848ED479625EFDAC4EE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Employee Benefit Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of their salary, subject to government maximums.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Employees are &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-C4CB42A3266A286208169625EFC1AAF8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Property, Equipment and Software&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,261&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; consists of the costs incurred for the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which is expected to be completed in mid-2018.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;We had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in property, equipment and software at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; that was purchased in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; but was not paid for by year end.&amp;#160; Property, equipment and software balance at December 31, 2016 includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in assets that were purchased in 2016 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2015&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-6AA38CA213AFA97C7CEE9625EFC15C7B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property, Equipment and Software&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q4YTD" id="Fact-02467C68D4A7E62509F29625EFC1658E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software consists of the following (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,261&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,520&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,111&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,352&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;656&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,549&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;20,208&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,525&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,807&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Construction in progress&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;32,800&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,902&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;43,784&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(28,919&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,823&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;49,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;17,961&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:QuarterlyFinancialInformationTextBlock contextRef="FD2017Q4YTD" id="Fact-40BBB3361719BB43979B9625EFD1935E">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quarterly Financial Information (unaudited)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(47,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q4YTD" id="Fact-6B5AFCD9A97481B8F3C29625EFC7AA00">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&amp;#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-8362EAC9BF6B683FE3D19625EFD17AFA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Lease Exit Liability&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&amp;#160; During the year ended December&amp;#160;31, 2016, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&amp;#160; The Company will receive approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in sublease payments over its term, which ends at the same time as the original lease in February 2018.&amp;#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended December&amp;#160;31, 2016 and recorded an offset to research and development expense of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in the same period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Changes in the lease exit liability are as follows (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments (net of sublease receipts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q4YTD" id="Fact-2CDF82ACFBD7FC7F85099625EFC18994">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and DART&amp;#174; technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &amp;#8211; Multiple-Element Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and FASB ASC Topic 605-28, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&amp;#8211;Milestone Method&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Exclusive Licenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, the Company may have an option to participate in the co-development of product candidates that result from such agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.  The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&amp;#160;&amp;#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&amp;#160;&amp;#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license was to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-to-Develop Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&amp;#160;&amp;#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&amp;#160;&amp;#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q4YTD" id="Fact-001553987DF279B1245F9625EFC7327C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,504,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="FD2017Q4YTD" id="Fact-B6C3DE00D249364852999625EFC87D96">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Federal U.S. net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;50,346&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75,377&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State net operating loss carryforward&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,583&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,284&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,829&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,708&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19,855&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred rent&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,385&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,497&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,982&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,098&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Depreciation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,926&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,085&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;113,258&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;130,250&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(112,453&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(128,844&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid expenditures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Gross deferred income tax liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(805&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,406&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net deferred income tax asset/(liability)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="FD2017Q4YTD" id="Fact-1B0DA2BF1E9EB75C7BFF9625EFC79620">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss used for calculation of basic and diluted EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,095,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,095,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
	<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-FB21D95F310FDC7D6AFB9625EFD05FA8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;United States federal tax at statutory rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6,869&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,489&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(7,049&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;State taxes (net of federal benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(735&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,116&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(897&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred income tax adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;173&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;661&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred state blended rate adjustments&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(485&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(32&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(493&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred federal rate change reduction in corporate rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;39,447&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(8,455&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,551&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(3,296&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Orphan drug credit, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,853&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(571&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other permanent items&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;276&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;145&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Equity-based compensation&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,997&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,102&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Change in valuation allowance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(24,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;24,444&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10,103&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Income tax expense/(benefit)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q4YTD" id="Fact-FB7F679B95B5C19968B99625EFDA5996">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following stock-based compensation amounts were recognized for the periods indicated (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,388&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,778&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,623&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,356&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,387&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,224&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total stock-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;14,744&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12,165&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,847&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock contextRef="FD2017Q4YTD" id="Fact-7E23D8485B3E1B419B6C9625EFD84359">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:49%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;1st Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2nd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;3rd Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;4th Quarter&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(in thousands, except per share data)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,055&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,663&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;152,359&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(37,655&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(40,654&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(47,043&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,727&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.87&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.08&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.28&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Revenue&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80,673&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,255&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,106&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(30,363&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40,464&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(33,846&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34,783&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.17&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net income (loss) per share, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.88&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.12&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.97&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
	<us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="FD2017Q4YTD" id="Fact-F5F401C9D62357E02AE99625EFD0D293">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Changes in the lease exit liability are as follows (in thousands): &lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:88%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,713&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,822&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,891&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal payments and other adjustments (net of sublease receipts)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,593&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrual balance at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;298&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q4YTD" id="Fact-EDC9EF156F3C6BA5C4A49625EFCA0825">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;67% - 68%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;64% - 69%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73% - 75%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.9% - 2.3%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.2% - 2.4%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.6% - 2.1%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.25 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="FD2017Q4YTD" id="Fact-55E03B7D5CA59D6975D49625EFCF5DD9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Beginning balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,047&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases for current year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;569&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;308&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;357&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Increases/(decreases) for prior year tax positions&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(268&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Ending balance&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,395&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,465&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,425&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
	<us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock contextRef="FD2017Q4YTD" id="Fact-F5B589D5D5C9868C39009625EFC122A6">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Incyte Corporation (Incyte)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen Biotech, Inc. (Janssen)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Boehringer Ingelheim GmbH (Boehringer)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Government&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;* Balance is less than 10%&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q4YTD" id="Fact-775A5873AFA052FB7C519625EFC1965F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Summary of Significant Accounting Policies&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation and Principles of Consolidation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&amp;#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash, Cash Equivalents and Marketable Securities&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&amp;#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; unrealized losses at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt; that the Company determined to be other-than-temporary.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allowance was recorded as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as the Company has a history of collecting on all outstanding accounts.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Fair Value Measurements and Disclosures&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:&lt;/font&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 1 &amp;#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 2 &amp;#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:72px;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;font-size:10pt;padding-left:48px;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8226;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;" rowspan="1" colspan="1"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Level 3 &amp;#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &amp;#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial assets measured at fair value on a recurring basis were as follows (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,990&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;78,418&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;155,910&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;61,512&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;94,398&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$62.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:38%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:2%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Fair Value Measurement at December&amp;#160;31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Quoted Prices in&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Active Markets for&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Identical Assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant Other&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Observable Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Significant&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Unobservable&lt;/font&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Inputs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 2&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S Treasury securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;8,826&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Government-sponsored enterprises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;29,759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Corporate debt securities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;166,300&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total assets measured at fair value &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;(a)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;251,666&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;46,781&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204,885&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(a) Total assets measured at fair value at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; includes approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; reported in cash and cash equivalents on the balance sheet.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value of Level 2 securities is determined from &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentration of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; The counterparties are various corporations, financial institutions and government agencies of high credit standing.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's revenue relates to agreements with various collaborators and&amp;#160;contracts and research grants received from U.S. government agencies.&amp;#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Incyte Corporation (Incyte)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;96%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen Biotech, Inc. (Janssen)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;85%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;72%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Boehringer Ingelheim GmbH (Boehringer)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;73%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Les Laboratoires Servier and Institut de Recherches Servier (Servier)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;12%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Janssen&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;U.S. Government&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;*&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;19%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;* Balance is less than 10% &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property, Equipment and Software&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:50%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;10 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Laboratory and office equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5 years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Shorter of lease term or useful life&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Property, Plant and Equipment&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company determined that there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impaired assets and had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; assets held-for-sale.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenues&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and DART&amp;#174; technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition &amp;#8211; Multiple-Element Arrangements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and FASB ASC Topic 605-28, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&amp;#8211;Milestone Method&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Exclusive Licenses&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, the Company may have an option to participate in the co-development of product candidates that result from such agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.  The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&amp;#160;&amp;#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&amp;#160;&amp;#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license was to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Right-to-Develop Agreements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&amp;#160;&amp;#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&amp;#160;&amp;#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development Costs&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&amp;#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock-based payments are accounted for in accordance with the provisions of ASC 718, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Compensation &amp;#8211; Stock Compensation&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss Per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:59%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Numerator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss used for calculation of basic and diluted EPS&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(19,626&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(58,528&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(20,140&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Denominator:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, basic&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,095,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Effect of dilutive securities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options and restricted stock units&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;height:18px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average shares outstanding, diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36,095,080&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;34,685,274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;31,801,645&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net loss per share, basic and diluted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.54&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1.69&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.63&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:60%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:12%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;2015&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock options&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,504,642&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,838,060&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,146,064&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recently Issued Accounting Standards &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the (FASB issued Accounting Standards Update (ASU) No. 2014-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers (Topic 606) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&amp;#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&amp;#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&amp;#160;earnings at the effective date for existing contracts with remaining performance obligations.  In 2016, the FASB issued ASU 2016-08, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, ASU 2016-10,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and ASU 2016-12, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; &amp;#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  The Company will adopt the new standard in the first quarter of 2018 using the modified retrospective method.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has substantially completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Due to the unique contract terms of certain agreements, the Company is still in the process of finalizing its analysis of those agreements.  Upon completion of the Company&amp;#8217;s analysis, it will determine the cumulative effect of initially applying the new standard (if any).  The Company is also finalizing its accounting policy and designing and implementing the necessary changes to processes and controls to account for revenue under the new standard. Based on the Company's timeline and planned resources, the Company anticipates completing its implementation in connection with its first quarter 2018 interim financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&amp;#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&amp;#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March&amp;#160;2016, the FASB issued ASU 2016-09, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Improvements&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;color:#252525;"&gt;The Company adopted ASU 2016-09 effective January 1, 2017 and has elected to continue to estimate the number of stock-based awards expected to vest, as permitted by ASU 2016-09, rather than electing to account for forfeitures as they occur.  &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The adoption of this standard did not have a material impact on the Company's financial statements or related disclosures.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q4YTD" id="Fact-2863FAB0A47C0BE8A5E39625EFC83574">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;Stockholders' Equity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;The Company's amended and restated certificate of incorporation authorizes &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;125,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock, and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of undesignated preferred stock, both with a par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;There were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of undesignated preferred stock issued or outstanding as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2014, the Company completed an equity offering, in which the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,800,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;450,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$36.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160;&amp;#160;The Company received proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$76.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from this offering, net of underwriting discounts and commissions and other offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp;amp; Johnson Innovation &amp;#8211; JJDC, Inc. (JJDC) became effective (see Note 9 for additional information).&amp;#160; Under these agreements, JJDC purchased &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,923,077&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; new shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$39.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, representing proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In July 2015, the Company completed an equity offering, in which the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,525,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;528,750&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company's common stock at a price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$37.00&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share.&amp;#160; The Company received net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$141.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; from this offering, net of underwriting discounts and commissions and other estimated offering expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,100,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its common stock at a purchase price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$21.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$23.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The shares were offered pursuant to the Company&amp;#8217;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$75.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through an &amp;#8220;at the market offering&amp;#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;599,284&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock resulting in net proceeds of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; related to the ATM Offering.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="FD2017Q4YTD" id="Fact-E18DB046582F67F5F55B9625EFC1261F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Accounts Receivable&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; allowance was recorded as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, as the Company has a history of collecting on all outstanding accounts.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
	<us-gaap:UseOfEstimates contextRef="FD2017Q4YTD" id="Fact-7BFBB1163BC5F675ED5B9625EFC77EB4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>mgnx-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://macrogenics.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgnx="http://macrogenics.com/20171231" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgnx-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CollaborationAndOtherAgreements" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements">
        <link:definition>2112100 - Disclosure - Collaboration and Other Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsBoehringerDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails">
        <link:definition>2412406 - Disclosure - Collaboration and Other Agreements, Boehringer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails">
        <link:definition>2412401 - Disclosure - Collaboration and Other Agreements Collaboration and Other Agreements,  Incyte Corporation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails">
        <link:definition>2412402 - Disclosure - Collaboration and Other Agreements, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsGreenCrossDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails">
        <link:definition>2412407 - Disclosure - Collaboration and Other Agreements, Green Cross (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsJanssenBiotechIncDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails">
        <link:definition>2412403 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsNiaidContractDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails">
        <link:definition>2412408 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsServierDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails">
        <link:definition>2412405 - Disclosure - Collaboration and Other Agreements, Servier (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAndOtherAgreementsTakedaDetails" roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails">
        <link:definition>2412404 - Disclosure - Collaboration and Other Agreements, Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://macrogenics.com/role/CommitmentsAndContingencies">
        <link:definition>2113100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesDetails" roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails">
        <link:definition>2413402 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2313301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfStockholdersEquity" roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://macrogenics.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://macrogenics.com/role/EmployeeBenefitPlan">
        <link:definition>2114100 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlanDetails" roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails">
        <link:definition>2414401 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://macrogenics.com/role/IncomeTaxes">
        <link:definition>2110100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails">
        <link:definition>2410402 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2410404 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails">
        <link:definition>2410403 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://macrogenics.com/role/IncomeTaxesTables">
        <link:definition>2310301 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiability" roleURI="http://macrogenics.com/role/LeaseExitLiability">
        <link:definition>2111100 - Disclosure - Lease Exit Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails">
        <link:definition>2411403 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails">
        <link:definition>2411402 - Disclosure - Lease Exit Liability Lease Exit Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeaseExitLiabilityTables" roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables">
        <link:definition>2311301 - Disclosure - Lease Exit Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://macrogenics.com/role/MarketableSecurities">
        <link:definition>2103100 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesAvailableForSaleSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails">
        <link:definition>2403403 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetails" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesDetailsCalc2" roleURI="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2">
        <link:definition>2403402 - Disclosure - Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://macrogenics.com/role/MarketableSecuritiesTables">
        <link:definition>2303301 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndNatureOfOperations" roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations">
        <link:definition>2101100 - Disclosure - Organization and Nature of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentAndSoftware" roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftware">
        <link:definition>2104100 - Disclosure - Property, Equipment and Software</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentAndSoftwareDetails" roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails">
        <link:definition>2404402 - Disclosure - Property, Equipment and Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentAndSoftwareTables" roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables">
        <link:definition>2304301 - Disclosure - Property, Equipment and Software (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnaudited" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited">
        <link:definition>2115100 - Disclosure - Quarterly Financial Information (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedDetails" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails">
        <link:definition>2415402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="QuarterlyFinancialInformationUnauditedTables" roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables">
        <link:definition>2315301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://macrogenics.com/role/StockBasedCompensation">
        <link:definition>2106100 - Disclosure - Stock-based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEmployeeStockPurchasePlanDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails">
        <link:definition>2406402 - Disclosure - Stock- based Compensation - Employee Stock Purchase Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationOptionPricingAssumptionsDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails">
        <link:definition>2406404 - Disclosure - Stock- based Compensation - Option Pricing Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>2406403 - Disclosure - Stock- based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails">
        <link:definition>2406405 - Disclosure - Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://macrogenics.com/role/StockBasedCompensationTables">
        <link:definition>2306301 - Disclosure - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://macrogenics.com/role/StockholdersEquity">
        <link:definition>2105100 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://macrogenics.com/role/StockholdersEquityDetails">
        <link:definition>2405401 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails">
        <link:definition>2402408 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails">
        <link:definition>2402407 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails">
        <link:definition>2402409 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails">
        <link:definition>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" name="AdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" name="AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" name="AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" name="AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" name="AdditionalPotentialSalesMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" name="AdjustmentToRevenueUnderAccountingStandardsCodification" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AggregatePotentialFutureCostReimbursement" name="AggregatePotentialFutureCostReimbursement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_AmountAllocatedToEquity" name="AmountAllocatedToEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AmountAllocatedToLicenseAndRD" name="AmountAllocatedToLicenseAndRD" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_AmountOfImmaterialErrorCorrection" name="AmountOfImmaterialErrorCorrection" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_BoehringerIngelheimMember" name="BoehringerIngelheimMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ChangeInAccountingEstimateCurrentYearImpact" name="ChangeInAccountingEstimateCurrentYearImpact" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ClinicalMilestoneEarnedDuringPeriod" name="ClinicalMilestoneEarnedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgnx_CollaborationAndLicenseAgreementsAbstract" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" name="CollaborationAndLicenseAgreementsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" name="CollaborationArrangementOffsetToResearchAndDevelopmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" name="CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mgnx_CommonStockMaximumAmountAvailableForIssuance" name="CommonStockMaximumAmountAvailableForIssuance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" name="DefinedContributionPlanEmployeesContributionVestedPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" name="DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" name="EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" name="EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" name="EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" name="EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" name="EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" name="EmployeesEligibleAgeToParticipateInBenefitPlan" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_EquityIncentivePlan2003Member" name="EquityIncentivePlan2003Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" name="F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_FundedValueOfBasePeriod" name="FundedValueOfBasePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_FurnitureAndOfficeEquipmentMember" name="FurnitureAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_GreenCrossCorporationMember" name="GreenCrossCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_IncyteCorporationMember" name="IncyteCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_IncyteMGA012AgreementMember" name="IncyteMGA012AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenBiotechIncMember" name="JanssenBiotechIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenMGD011AgreementMember" name="JanssenMGD011AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JanssenMGD015AgreementMember" name="JanssenMGD015AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" name="JohnsonAndJohnsonDevelopmentCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_LaboratoryAndOfficeEquipmentMember" name="LaboratoryAndOfficeEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" name="NationalInstituteOfAllergyAndInfectiousDiseasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NonRefundableUpfrontFees" name="NonRefundableUpfrontFees" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfAnnualMaintenancePaymentReceived" name="NumberOfAnnualMaintenancePaymentReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfLease" name="NumberOfLease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" name="NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" name="OperatingLossCarryforwardsAnnualLimitationAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" name="OperatingLossCarryforwardsLimitationsOnUseAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" name="OperatingLossCarryforwardsNotSubjectToLimitation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OptionExerciseFee" name="OptionExerciseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_OptionExerciseFeeRecognitionPeriod" name="OptionExerciseFeeRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_OriginalPeriodOfDevelopment" name="OriginalPeriodOfDevelopment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" name="PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" name="PotentialClinicalMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" name="PotentialCommercialMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" name="PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialLicenseFee" name="PotentialLicenseFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" name="PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" name="PotentialRegulatoryMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PotentialSalesMilestonePaymentsUnderAgreement" name="PotentialSalesMilestonePaymentsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgnx_PremiumReceivedOnStockPurchase" name="PremiumReceivedOnStockPurchase" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement" name="ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ProceedsFromResearchAndDevelopmentServices" name="ProceedsFromResearchAndDevelopmentServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ProceedsfromRoyaltiesPercent" name="ProceedsfromRoyaltiesPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" name="ProceedsfromStockOptionsExercisedAndESPPPurchases" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_PropertyPlantAndEquipmentNonCashAdditions" name="PropertyPlantAndEquipmentNonCashAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgnx_RavenBiotechnologiesIncMember" name="RavenBiotechnologiesIncMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ReductionInResearchAndDevelopmentExpense" name="ReductionInResearchAndDevelopmentExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" name="ResearchCollaborationAndLicenseOptionAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount" name="RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" name="ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierDARTMember" name="ServierDARTMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierMGA271Member" name="ServierMGA271Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_ServierMember" name="ServierMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_StockIncentivePlan2013Member" name="StockIncentivePlan2013Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" name="StockIssuedDuringPeriodSharesStockPlanActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" name="StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_StockIssuedDuringPeriodValueStockPlanActivity" name="StockIssuedDuringPeriodValueStockPlanActivity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TakedaMGD010AgreementMember" name="TakedaMGD010AgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TakedaMember" name="TakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_TotalConsideration" name="TotalConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_TotalPotentialValueUnderAgreement" name="TotalPotentialValueUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" name="TwoThousandSixteenEmployeeStockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_USGovernmentMember" name="USGovernmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgnx_UndesignatedPreferredStockMember" name="UndesignatedPreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgnx_UpfrontFeeAllocatedToAgreement" name="UpfrontFeeAllocatedToAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgnx_UpfrontPaymentRecognitionPeriod" name="UpfrontPaymentRecognitionPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>mgnx-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20171231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20171231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20171231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftware" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_5046b63b-148e-eb12-dd52-2a1e8f1e69c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_56f89e4f-d247-3cf0-a749-00554ab475a6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_fb0efb32-4bb1-57d0-236e-d8af81dc125f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_5021b8a7-49e1-51a4-4dec-1be505fea6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_cb56b01f-b9c5-ca9e-8988-e23b27fc7a20" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_OtherAssets_cb56b01f-b9c5-ca9e-8988-e23b27fc7a20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_e844b255-713b-0357-7991-a8c78d02cb50" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_e844b255-713b-0357-7991-a8c78d02cb50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_0ab9456b-855b-4b5f-17aa-958b2bf5fece" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRevenueCurrent_98f473f8-2d19-99d7-6142-37f86ccd14ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_19647a29-cf9d-afd8-c508-550f1bbe8b53" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_19647a29-cf9d-afd8-c508-550f1bbe8b53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_43c6e378-ecf6-909b-c479-f69075aa8f69" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_RestructuringReserveCurrent_43c6e378-ecf6-909b-c479-f69075aa8f69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_b4e6cca3-6c62-3e0a-6782-510b974f1199" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_11e98ceb-5737-f44d-6a16-2d8b64b1228d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_9f03ff53-e1b7-c80d-4f89-ca1750146781" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_9f03ff53-e1b7-c80d-4f89-ca1750146781" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_1b45ee5e-adac-35f8-12cc-16e67b074fc4" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_1b45ee5e-adac-35f8-12cc-16e67b074fc4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_41895068-9590-2880-73df-521995865843" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e38d562c-e1dd-d525-b8c6-f86d8a100397" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_e38d562c-e1dd-d525-b8c6-f86d8a100397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_041c459c-7014-17e7-2bb4-75218378e2d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_1804f16e-dffd-8294-fdf5-c9d0d6ade974" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_1804f16e-dffd-8294-fdf5-c9d0d6ade974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_ac9066b4-6e40-13ed-8628-1a20304926d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_922bda36-1ccf-4fe5-b328-6ba4949143b3" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_922bda36-1ccf-4fe5-b328-6ba4949143b3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_ffd27c4c-26d9-b562-4f31-9625fc68e31a" xlink:type="locator" />
    <link:calculationArc order="12" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_ffd27c4c-26d9-b562-4f31-9625fc68e31a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_cc375194-a38e-33da-b1f1-b2b16c2222e2" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_9ead1b94-5c78-ce9f-379f-74649d16d2bc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_cc375194-a38e-33da-b1f1-b2b16c2222e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_15394837-f38b-15ac-34b9-3c880d46492b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_4beb4a13-125c-79a5-e70a-88872f47be70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_2be04cf9-8ceb-0f9e-f8fc-88519ffff574" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_dd2e9db6-10f9-d78a-ba84-b18268245a83" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_135ba02e-a122-f9a5-7f87-b0a88a3e8138" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_135ba02e-a122-f9a5-7f87-b0a88a3e8138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_ef560d3a-690c-ef17-1fe6-55654352e2f7" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_6d67f644-e190-e5ce-9449-e00a27ad7771" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_33f76b65-31cf-be04-0849-25af345446d5" xlink:to="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_0d9ff7d0-e871-5bdf-adbd-21d7dbf57556" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_250c3b2f-7db5-7088-68cc-1dd831a2c2d7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_72d12753-e25c-cdc0-88b6-98db8d7b7fae" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_548688b8-2d34-462c-5a92-aa79f1c44c1a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_95b2e317-3338-2d68-dd44-b4b78f4246b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_95b2e317-3338-2d68-dd44-b4b78f4246b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a9e69e90-362c-096d-424d-dfd51b492a2e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_a9e69e90-362c-096d-424d-dfd51b492a2e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_d2622f64-9e39-fc5b-64b5-c22437d85e64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_a2fa314f-f573-50b1-a27d-33b9e8bcf3e7" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_a2fa314f-f573-50b1-a27d-33b9e8bcf3e7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_a555e786-b508-abe7-94ba-dbe8a1e0ca9e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_a555e786-b508-abe7-94ba-dbe8a1e0ca9e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_d5bdadc0-cf22-f4bf-e68b-7f9b7b17d502" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_282bf2b0-848d-b911-5d17-5d4663ae6cab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_40f9cbe3-f1cd-d4d3-e7be-f62e64714b00" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_91623f44-5f42-408a-f7b7-7a4698afab83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d74724c2-178d-7f3f-8e86-5f5ba690672c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_46929883-d93f-69b0-5ded-4c800feeb57f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b361a033-37cf-a2bc-6e1f-0297b90aa5a9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_9fb66626-9640-44ad-4417-4000d4376288" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_bbf9fd06-b461-3f65-8882-6e322d99a60b" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_9fb66626-9640-44ad-4417-4000d4376288" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_16f0a3f7-750c-3f06-7b05-d8ae2aae120b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_bdbdc685-443d-bab4-6ccc-ce6a14aaa242" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_48dcf869-f8e3-a2cc-77be-9625fd56b03e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_48dcf869-f8e3-a2cc-77be-9625fd56b03e" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_fee47c42-edce-f639-ebee-9625fc28f21a" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_fee47c42-edce-f639-ebee-9625fc28f21a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0241d40c-718a-28d6-e497-9e09edfdc0b5" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_0241d40c-718a-28d6-e497-9e09edfdc0b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dae4c6cc-5e4f-e8ac-846e-00b9cc00facc" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dae4c6cc-5e4f-e8ac-846e-00b9cc00facc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_365bf91b-f3ba-1347-a6a6-0b0659e96d1d" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_365bf91b-f3ba-1347-a6a6-0b0659e96d1d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_78c00b87-b340-b6bf-c92a-52d121d458e4" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_78c00b87-b340-b6bf-c92a-52d121d458e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_553df36e-9753-8848-960f-086f1d52da7b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_553df36e-9753-8848-960f-086f1d52da7b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_78b7d85e-8366-fe6d-cb1f-faac5a041b79" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_5a4be234-601b-ead6-df60-5106285cb5b9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bb34ca49-0ca6-d513-414f-31e205fa11cc" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_bb34ca49-0ca6-d513-414f-31e205fa11cc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa6902f3-9ec3-0632-57ef-52a27e57695e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_fa6902f3-9ec3-0632-57ef-52a27e57695e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c867d9b-5594-18ef-c82a-679b606d1bd3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_302B97EACDD2776005B2D840F1DB5CA9_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_302B97EACDD2776005B2D840F1DB5CA9_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_302B97EACDD2776005B2D840F1DB5CA9_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_302B97EACDD2776005B2D840F1DB5CA9_065ac417-143a-3361-82a5-1e59ffd9749a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_302B97EACDD2776005B2D840F1DB5CA9_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_302B97EACDD2776005B2D840F1DB5CA9_fc961581-2899-aa00-cc82-b67bd4267bb3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_302B97EACDD2776005B2D840F1DB5CA9_6806c6da-7794-6cc2-dea6-0fe1f4c6a026" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_223fd9c8-68e8-e433-7c40-f98b238e79de" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_86e61cf2-b7b2-e230-65f1-5a2b152f3a30" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_91fe4b11-d4f7-61c5-b8e1-4b77ba5422d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_b86af6cd-ef38-8a02-5297-9329a99c960d" xlink:to="loc_us-gaap_AvailableForSaleSecurities_d444402b-921b-e0fa-119c-908ab66850af" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>mgnx-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20171231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20171231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20171231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftware" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:to="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_6582EACFFA5B675FA15FD840F016F914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:to="loc_mgnx_BoehringerIngelheimMember_6582EACFFA5B675FA15FD840F016F914" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_34ED33C28D4192A188A3D840F017FE5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_34ED33C28D4192A188A3D840F017FE5D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_BBAF57367F4AA9A6E824D840F017B924" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_LicensesRevenue_BBAF57367F4AA9A6E824D840F017B924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FED7A5509306159EE69AD840F017CB0E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_DeferredRevenue_FED7A5509306159EE69AD840F017CB0E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:to="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:to="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3830D45354E9935DACA4D840F08838A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:to="loc_us-gaap_MaximumMember_3830D45354E9935DACA4D840F08838A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_3BF172071DFD5B2EA30AD840F0884E70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:to="loc_us-gaap_MinimumMember_3BF172071DFD5B2EA30AD840F0884E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteMGA012AgreementMember" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteCorporationMember" xlink:label="loc_mgnx_IncyteCorporationMember_5BC9280E28C5AAF5B944D840F0894282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:to="loc_mgnx_IncyteCorporationMember_5BC9280E28C5AAF5B944D840F0894282" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_85DC6C0973066FE9877AD840F089353F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_NonRefundableUpfrontFees_85DC6C0973066FE9877AD840F089353F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromRoyaltiesPercent" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_320D85409DAE5645EDD5D840F08FEBA7" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_us-gaap_LicensesRevenue_320D85409DAE5645EDD5D840F08FEBA7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount" xlink:label="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:to="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_4FD6F059A871695CB442D840F0768998" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_4FD6F059A871695CB442D840F0768998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:to="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_56F42E133981971496C0D840F07842AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_56F42E133981971496C0D840F07842AC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_60ADBAE2BF26A705D4DED840F0787397" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_60ADBAE2BF26A705D4DED840F0787397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_88A1DD5947A438078F24D840F0780DC9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenue_88A1DD5947A438078F24D840F0780DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:to="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:to="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:to="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:to="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:to="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:to="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_12FD50A4C467E69681E1D840F00E1E3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_NonRefundableUpfrontFees_12FD50A4C467E69681E1D840F00E1E3D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_DD6D2515C466435C5F3BD840F00E4CE4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_LicensesRevenue_DD6D2515C466435C5F3BD840F00E4CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_A42762DFD903471598A5D840F00F3028" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenue_A42762DFD903471598A5D840F00F3028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_437156EE173B1852A469D840F00F8F45" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenueCurrent_437156EE173B1852A469D840F00F8F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_96BD621EECA20C5F54CBD840F00F9EBF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_96BD621EECA20C5F54CBD840F00F9EBF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:to="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:to="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_B96259AD5FE062E5B9ECD840F05E7B3E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_NonRefundableUpfrontFees_B96259AD5FE062E5B9ECD840F05E7B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_389222FA3703F53B20D9D840F0655FCD" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_LicensesRevenue_389222FA3703F53B20D9D840F0655FCD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:to="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:to="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:to="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:to="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5457EC82404FCA6FFE9DD840F008C876" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:to="loc_us-gaap_MaximumMember_5457EC82404FCA6FFE9DD840F008C876" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_1A265B93371A00885535D840F00986FB" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_us-gaap_LicensesRevenue_1A265B93371A00885535D840F00986FB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:to="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:to="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:to="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A1DAA20697D274622074D840F031EC5E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:to="loc_us-gaap_MaximumMember_A1DAA20697D274622074D840F031EC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:to="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_002B52FC9FF3C03C24BCD840F03208A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_NonRefundableUpfrontFees_002B52FC9FF3C03C24BCD840F03208A9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_3167BFB4BC7FCD2882CDD840F0325498" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_3167BFB4BC7FCD2882CDD840F0325498" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4AC7B8B2CE725BF0F317D840F033C548" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4AC7B8B2CE725BF0F317D840F033C548" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_BF0D2B9246D33982DA26D840F033B892" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_LicensesRevenue_BF0D2B9246D33982DA26D840F033B892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_5B4D27CF74434CB95E2AD840F033FCF6" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenue_5B4D27CF74434CB95E2AD840F033FCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_EDF551E70A0460D71BB7D840F0339694" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenueCurrent_EDF551E70A0460D71BB7D840F0339694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_47DFB62E37C2F12B01ACD840F0342AB1" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_47DFB62E37C2F12B01ACD840F0342AB1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:to="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:to="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:to="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:to="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:to="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E2D6DF4B36EAE598C2E5D7F3E49E1268" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_NetIncomeLoss_E2D6DF4B36EAE598C2E5D7F3E49E1268" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:to="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:to="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:to="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_43B8F33DE6CD4AF3E9B7D85A44DEF073" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:to="loc_us-gaap_MinimumMember_43B8F33DE6CD4AF3E9B7D85A44DEF073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1CCD91C8F3DD268C13F5D85A44DEA8DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:to="loc_us-gaap_MaximumMember_1CCD91C8F3DD268C13F5D85A44DEA8DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:to="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:to="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:to="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:to="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:to="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:to="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_1E34445D1EE648ABE65FD840F0AA4B00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_1E34445D1EE648ABE65FD840F0AA4B00" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountOfImmaterialErrorCorrection" xlink:label="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_13E93A5BA482DB4E8346D840F1B27081" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_ComputerEquipmentMember_13E93A5BA482DB4E8346D840F1B27081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3E1D815E0A327D566EFBD840F1B32D47" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3E1D815E0A327D566EFBD840F1B32D47" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_EAE59521C3A3F3107E29D840F1B3D33B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_EAE59521C3A3F3107E29D840F1B3D33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:to="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:to="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:to="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:to="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:to="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:to="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1BFD527FD0D3B6B4379AD840F142DF08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:to="loc_us-gaap_MinimumMember_1BFD527FD0D3B6B4379AD840F142DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2326628147CE61D2A6E6D840F1425086" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:to="loc_us-gaap_MaximumMember_2326628147CE61D2A6E6D840F1425086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:to="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:to="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:to="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:to="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62CA07B9F572C0703C14D840F159995E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62CA07B9F572C0703C14D840F159995E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RegisteredDirectOfferingMember" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AtTheMarketOfferingMember" xlink:label="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:to="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:to="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:to="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:to="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0C1E2E17DD216FAFEB85D840F197C77F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0C1E2E17DD216FAFEB85D840F197C77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9C835BE1C112466A8D41D840F1971A19" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9C835BE1C112466A8D41D840F1971A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657DC082C24FB1FBE8E4D840F198C3ED" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657DC082C24FB1FBE8E4D840F198C3ED" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:to="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:to="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_09F218532C572E96A42ED840F22BBCC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_09F218532C572E96A42ED840F22BBCC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:to="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_82CC0E7B2D3B2F53C4FAD840F22BCDC2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_JanssenBiotechIncMember_82CC0E7B2D3B2F53C4FAD840F22BCDC2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:to="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteCorporationMember" xlink:label="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:to="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>mgnx-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in Lease Exit Liability</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="lab_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:to="lab_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from collaborative agreements</link:label>
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0_label_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Services Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:to="lab_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from government agreements</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:to="lab_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F_label_en-US" xlink:label="lab_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:to="lab_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs and expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:to="lab_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:to="lab_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:to="lab_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized loss on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per common share</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic and Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted weighted average number of common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:type="arc" />
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5_terseLabel_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eligible age to participate in plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5_label_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employees Eligible Age To Participate In Benefit Plan</link:label>
    <link:label id="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5_documentation_en-US" xlink:label="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to minimum eligible age of employee to participate in benefit plan.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:to="lab_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee contribution to salary</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:type="arc" />
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C_terseLabel_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of employee vested contribution</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C_label_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employees Contribution, Vested Percentage</link:label>
    <link:label id="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C_documentation_en-US" xlink:label="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage vested of employee's contributions to defined contribution plan</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:to="lab_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, employer discretionary contribution amount</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:to="lab_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="lab_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:to="lab_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="arc" />
    <link:label id="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712_terseLabel_en-US" xlink:label="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte Corporation (Incyte)</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712_label_en-US" xlink:label="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:label id="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712_documentation_en-US" xlink:label="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte Corporation [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteCorporationMember" xlink:label="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:to="lab_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50_verboseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Janssen Biotech, Inc. (Janssen)</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50_label_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc [Member]</link:label>
    <link:label id="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50_documentation_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:to="lab_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="arc" />
    <link:label id="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE_terseLabel_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Boehringer Ingelheim GmbH (Boehringer)</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE_label_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Boehringer Ingelheim [Member]</link:label>
    <link:label id="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE_documentation_en-US" xlink:label="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:to="lab_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales revenue, net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Revenue, Net [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:to="lab_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of all significant revenue earned</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Stock Options Award Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:type="arc" />
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564_terseLabel_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option and Restricted Stock Unit Activity</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564_label_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label id="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564_documentation_en-US" xlink:label="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:to="lab_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3_label_en-US" xlink:label="lab_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:to="lab_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range</link:label>
    <link:label id="lab_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE_label_en-US" xlink:label="lab_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:to="lab_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3_label_en-US" xlink:label="lab_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:to="lab_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases/(decreases) for current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Decreases for prior year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized interest or penalties</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of leases</link:label>
    <link:label id="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D_label_en-US" xlink:label="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Lease</link:label>
    <link:label id="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D_documentation_en-US" xlink:label="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of lease during the period.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfLease" xlink:label="loc_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:to="lab_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Future sublease payments to be received</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Future Minimum Sublease Rentals</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee leasing arrangements, term of operating leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58_label_en-US" xlink:label="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:to="lab_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease incentives</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Tenant Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:to="lab_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent liability</link:label>
    <link:label id="lab_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66_label_en-US" xlink:label="lab_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:to="lab_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum rental payments required under all non-cancelable operating leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Exit Liability</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:to="lab_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="arc" />
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB_terseLabel_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB_label_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:label id="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB_documentation_en-US" xlink:label="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:to="lab_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996_terseLabel_en-US" xlink:label="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</link:label>
    <link:label id="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996_label_en-US" xlink:label="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier MGA271 [Member]</link:label>
    <link:label id="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996_documentation_en-US" xlink:label="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Servier for enoblituzumab</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:to="lab_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="arc" />
    <link:label id="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1_terseLabel_en-US" xlink:label="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1_label_en-US" xlink:label="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">USGovernment [Member]</link:label>
    <link:label id="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1_documentation_en-US" xlink:label="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents counterparty in contractual arrangement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:to="lab_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Percentage of significant accounts receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">December 31, 2016</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Options exercised or RSUs vested</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">December 31, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">December 31, 2016</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options exercised or RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited or expired</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">December 31, 2017</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining contractual term, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value, Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:to="lab_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive stock options</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:to="lab_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:type="arc" />
    <link:label id="lab_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:to="lab_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:to="lab_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:to="lab_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss) per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:to="lab_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Fair Value Measurement Financial Assets</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Percentage of Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:type="arc" />
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Useful Lives</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment Estimated Useful Life Table [Text Block]</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property plant and equipment estimated useful life.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:to="lab_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8_label_en-US" xlink:label="lab_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:to="lab_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="lab_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:to="lab_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:to="lab_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:to="lab_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="lab_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:to="lab_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0_label_en-US" xlink:label="lab_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:to="lab_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Value Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:to="lab_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock plan related activity (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares Stock Plan Activity</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares issued due to stock plan related activity.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Retired, Par Value Method, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:to="lab_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Retirement of treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Retired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:to="lab_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:to="lab_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:to="lab_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements [Abstract]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:to="lab_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="arc" />
    <link:label id="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F_terseLabel_en-US" xlink:label="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceutical Company Limited (Takeda)</link:label>
    <link:label id="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F_label_en-US" xlink:label="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F_documentation_en-US" xlink:label="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:to="lab_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:to="lab_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="arc" />
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E_terseLabel_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda MGD010 Agreement</link:label>
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E_label_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda MGD010 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E_documentation_en-US" xlink:label="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Takeda for MGD010</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:to="lab_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="arc" />
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07_terseLabel_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Option Agreement</link:label>
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07_label_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Option Agreement [Member]</link:label>
    <link:label id="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07_documentation_en-US" xlink:label="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Takeda for research</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:to="lab_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:type="arc" />
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4_terseLabel_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4_label_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-refundable upfront payment</link:label>
    <link:label id="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4_documentation_en-US" xlink:label="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial fee received from collaboration or license agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:to="lab_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="arc" />
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to agreement</link:label>
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9_label_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Fee Allocated To Agreement</link:label>
    <link:label id="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9_documentation_en-US" xlink:label="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of upfront fee allocated to agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:to="lab_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="arc" />
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B_terseLabel_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected period of development</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B_label_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment Recognition Period</link:label>
    <link:label id="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B_documentation_en-US" xlink:label="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to upfront payment recognition period.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:to="lab_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="arc" />
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee recognition period</link:label>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3_label_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Fee Recognition Period</link:label>
    <link:label id="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to option exercise fee recognition period.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:to="lab_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recognized revenue under agreement</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:to="lab_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099_netLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Milestone received</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:to="lab_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of annual maintenance payments received</link:label>
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D_label_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Annual Maintenance Payment Received</link:label>
    <link:label id="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D_documentation_en-US" xlink:label="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of annual maintenance payment received.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:to="lab_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical milestone payments</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Clinical Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:to="lab_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:to="lab_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Sales Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential sales milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:to="lab_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="arc" />
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE_terseLabel_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies Inc.</link:label>
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE_label_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies Inc [Member]</link:label>
    <link:label id="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE_documentation_en-US" xlink:label="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Raven Biotechnologies, Inc.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:to="lab_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:type="arc" />
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F_terseLabel_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in research and development expense</link:label>
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F_label_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction In Research And Development Expense</link:label>
    <link:label id="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F_documentation_en-US" xlink:label="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction In Research And Development Expense</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:to="lab_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58_terseLabel_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of research and development expense</link:label>
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58_label_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount of immaterial error correction</link:label>
    <link:label id="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58_documentation_en-US" xlink:label="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of immaterial error correction made during period</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountOfImmaterialErrorCorrection" xlink:label="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:to="lab_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:to="lab_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:to="lab_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="arc" />
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80_terseLabel_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80_label_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80_documentation_en-US" xlink:label="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Sixteen Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:to="lab_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation, number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="arc" />
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C_terseLabel_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock discount percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C_label_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:label id="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C_documentation_en-US" xlink:label="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:to="lab_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of fair market value to purchase shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchased by employees (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:to="lab_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F_terseLabel_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments and royalties on future sales</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F_label_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F_documentation_en-US" xlink:label="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Milestone Payments and Royalties on Future Sales under Agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:to="lab_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue included in current liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:to="lab_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue included in long-term liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876_label_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss used for calculation of basic and diluted EPS</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:to="lab_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic, Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:to="lab_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options and restricted stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Securities [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:to="lab_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC_terseLabel_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:label id="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC_label_en-US" xlink:label="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Major Types of Debt and Equity Securities [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="lab_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC_label_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government-sponsored Enterprises Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Debt Securities, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:to="lab_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restricted Cash for Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:to="lab_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:to="lab_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:type="arc" />
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3_terseLabel_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3_label_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Rent</link:label>
    <link:label id="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3_documentation_en-US" xlink:label="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in deferred rent.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:to="lab_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Available-for-sale Securities, Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:type="arc" />
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises and ESPP purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595_label_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:label id="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised And ESPP Purchases</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:to="lab_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Related to Tax Withholding for Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:to="lab_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:type="arc" />
    <link:label id="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97_terseLabel_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Green Cross</link:label>
    <link:label id="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97_label_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Green Cross Corporation [Member]</link:label>
    <link:label id="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97_documentation_en-US" xlink:label="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:to="lab_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48_label_en-US" xlink:label="lab_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:to="lab_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="arc" />
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E_terseLabel_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate potential future cost reimbursement</link:label>
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E_label_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Potential Future Cost Reimbursement</link:label>
    <link:label id="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E_documentation_en-US" xlink:label="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential future cost reimbursement from collaborator</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:to="lab_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical and commercial milestone payments</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC_label_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Potential Clinical And Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC_documentation_en-US" xlink:label="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:to="lab_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="arc" />
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1_terseLabel_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to revenue from contract material modification</link:label>
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1_label_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To Revenue Under Accounting Standards Codification</link:label>
    <link:label id="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1_documentation_en-US" xlink:label="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the adjustment to revenue under the accounting standards codification.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:to="lab_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="arc" />
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from research and development services</link:label>
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437_label_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Research And Development Services</link:label>
    <link:label id="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437_documentation_en-US" xlink:label="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Research And Development Services</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:to="lab_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone achieved</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:to="lab_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="arc" />
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316_terseLabel_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316_label_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003 [Member]</link:label>
    <link:label id="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316_documentation_en-US" xlink:label="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2003</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:to="lab_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C_terseLabel_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C_label_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:label id="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C_documentation_en-US" xlink:label="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Incentive Plan 2013 [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:to="lab_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="arc" />
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA_terseLabel_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increased number of shares authorized (in shares)</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA_label_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized After Increase</link:label>
    <link:label id="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA_documentation_en-US" xlink:label="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award number of shares authorized after increase.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:to="lab_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average exercise price (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="arc" />
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6_label_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6_documentation_en-US" xlink:label="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:to="lab_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="arc" />
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692_terseLabel_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of common stock share outstanding</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692_label_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Shares Of Companys Common Stock Outstanding For Increase In Shares Reserved For Issuance Under Stock Plan</link:label>
    <link:label id="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692_documentation_en-US" xlink:label="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:to="lab_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's Consolidated Quarterly Results of Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:to="lab_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D_label_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen MGD011 Agreement [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:to="lab_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657_terseLabel_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657_label_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657_documentation_en-US" xlink:label="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen MGD015 Agreement [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:to="lab_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="arc" />
    <link:label id="lab_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784_terseLabel_en-US" xlink:label="lab_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen Biotech Inc.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:to="lab_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="arc" />
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906_terseLabel_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906_label_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premium received on stock purchase</link:label>
    <link:label id="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906_documentation_en-US" xlink:label="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:to="lab_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="arc" />
    <link:label id="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0_terseLabel_en-US" xlink:label="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0_label_en-US" xlink:label="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0_documentation_en-US" xlink:label="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total consideration received under agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:to="lab_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256_terseLabel_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to equity</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256_label_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount allocated to equity</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256_documentation_en-US" xlink:label="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of consideration allocated to equity.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:to="lab_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="arc" />
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1_terseLabel_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount allocated to license and R&amp;D</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1_label_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount allocated to license and R&amp;D</link:label>
    <link:label id="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1_documentation_en-US" xlink:label="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portion of consideration allocated to license and pre-clinical research and development.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:to="lab_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="arc" />
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE_terseLabel_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during period</link:label>
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE_label_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during period</link:label>
    <link:label id="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE_documentation_en-US" xlink:label="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical milestone earned during the period</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:to="lab_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States federal tax at statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State taxes (net of federal benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deferred Tax Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA_negatedLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deferred state blended rate adjustments</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Reconciliation State Deferred Taxes Adjustments, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:to="lab_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred federal rate change reduction in corporate rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Research credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other permanent items</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Compensation Cost, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense/(benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Nature of Operations</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="arc" />
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3_terseLabel_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3_label_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3_documentation_en-US" xlink:label="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RegisteredDirectOfferingMember" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:to="lab_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="arc" />
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E_terseLabel_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Offering</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E_label_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E_documentation_en-US" xlink:label="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AtTheMarketOfferingMember" xlink:label="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:to="lab_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:to="lab_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:to="lab_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="arc" />
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E_terseLabel_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E_label_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:label id="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E_documentation_en-US" xlink:label="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Undesignated Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:to="lab_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="arc" />
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA_terseLabel_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Johnson &amp; Johnson Innovation JJDC, Inc,</link:label>
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA_label_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Johnson And Johnson Development Corporation [Member]</link:label>
    <link:label id="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA_documentation_en-US" xlink:label="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents counter party in stock purchase arrangement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:to="lab_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="lab_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:to="lab_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Undesignated preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued or sold (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017_label_en-US" xlink:label="lab_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:to="lab_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="arc" />
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852_terseLabel_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional shares sold under over-allotments option to underwriter (in shares)</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852_label_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period Shares To Underwriters For Exercise Of Over Allotment Option</link:label>
    <link:label id="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852_documentation_en-US" xlink:label="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock issued during period, shares to underwriters for exercise of over allotment option.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:to="lab_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of shares</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:to="lab_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds of stock sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock purchase price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:to="lab_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="arc" />
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE_terseLabel_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock maximum amount available for issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE_label_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:label id="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE_documentation_en-US" xlink:label="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock, Maximum Amount Available For Issuance</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:to="lab_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495_terseLabel_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information (Unaudited)</link:label>
    <link:label id="lab_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495_label_en-US" xlink:label="lab_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Quarterly Financial Information [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:to="lab_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="lab_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="lab_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:to="lab_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F_label_en-US" xlink:label="lab_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:to="lab_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:to="lab_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities, non-current</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_57299814810345BF9E38B14F588A38CC_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_57299814810345BF9E38B14F588A38CC_label_en-US" xlink:label="lab_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:to="lab_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:to="lab_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:to="lab_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:to="lab_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:to="lab_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:to="lab_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:to="lab_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent, net of current portion</link:label>
    <link:label id="lab_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A_label_en-US" xlink:label="lab_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Rent Credit, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:to="lab_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease exit liability, net of current portion</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:to="lab_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37_label_en-US" xlink:label="lab_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:to="lab_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="lab_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 36,859,077 and 34,870,607 shares outstanding at December 31, 2017 and 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:to="lab_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:to="lab_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD_terseLabel_en-US" xlink:label="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier</link:label>
    <link:label id="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD_label_en-US" xlink:label="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier [Member]</link:label>
    <link:label id="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD_documentation_en-US" xlink:label="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Counterparty in collaboration agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:to="lab_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="arc" />
    <link:label id="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4_terseLabel_en-US" xlink:label="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier DART</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4_label_en-US" xlink:label="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Servier DART [Member]</link:label>
    <link:label id="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4_documentation_en-US" xlink:label="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents agreement with Servier for DARTs</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:to="lab_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential License Fee</link:label>
    <link:label id="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141_label_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential License Fee</link:label>
    <link:label id="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141_documentation_en-US" xlink:label="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential license fee company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:to="lab_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7_terseLabel_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential clinical milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7_label_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Clinical Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7_documentation_en-US" xlink:label="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential clinical milestone payments company could earn under agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:to="lab_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE_terseLabel_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential regulatory milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE_label_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE_documentation_en-US" xlink:label="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential regulatory milestones company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:to="lab_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259_verboseLabel_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential sales milestone payments under agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259_label_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Sales Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259_documentation_en-US" xlink:label="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total potential sales milestones company could earn under agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:to="lab_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="arc" />
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73_terseLabel_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Original period of development</link:label>
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73_label_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Original period of development</link:label>
    <link:label id="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73_documentation_en-US" xlink:label="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Original recognition period for development.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:to="lab_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="arc" />
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75_terseLabel_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in accounting estimate, current year impact</link:label>
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75_label_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change In Accounting Estimate Current Year Impact</link:label>
    <link:label id="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75_documentation_en-US" xlink:label="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of the effect of a change in accounting estimate on current year operations.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:to="lab_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="arc" />
    <link:label id="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4_terseLabel_en-US" xlink:label="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4_label_en-US" xlink:label="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Exercise Fee</link:label>
    <link:label id="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4_documentation_en-US" xlink:label="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment from collaborator upon exercise of option to develop and commercialize product.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:to="lab_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offset to research and development costs under collaboration arrangement</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72_label_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement Offset to Research and Development Costs</link:label>
    <link:label id="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72_documentation_en-US" xlink:label="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to collaboration arrangement offset to research and development costs.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:to="lab_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-For-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets for Identical Assets, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:to="lab_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:to="lab_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S Treasury securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37_verboseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Government-sponsored enterprises</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:to="lab_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:to="lab_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets measured at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="arc" />
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4_label_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4_documentation_en-US" xlink:label="lab_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document and entity information.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="lab_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3_terseLabel_en-US" xlink:label="lab_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3_label_en-US" xlink:label="lab_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:to="lab_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D_label_en-US" xlink:label="lab_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:to="lab_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:to="lab_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:to="lab_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:to="lab_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA_label_en-US" xlink:label="lab_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:to="lab_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:to="lab_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:to="lab_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:to="lab_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:to="lab_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155_label_en-US" xlink:label="lab_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:to="lab_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868_label_en-US" xlink:label="lab_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:to="lab_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:to="lab_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718_terseLabel_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718_label_en-US" xlink:label="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:to="lab_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Costs</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based Compensation</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:to="lab_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:to="lab_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, other than temporary impairment losses</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other than Temporary Impairment Losses, Investments, Available-for-sale Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allowance recorded</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance for Doubtful Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impaired assets</link:label>
    <link:label id="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0_label_en-US" xlink:label="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impaired Assets to be Disposed of by Method Other than Sale, Carrying Value of Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:to="lab_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held-for-sale</link:label>
    <link:label id="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05_label_en-US" xlink:label="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets Held-for-sale, Not Part of Disposal Group</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:to="lab_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Minimum Future Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Disclosure [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:to="lab_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract termination</link:label>
    <link:label id="lab_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9_label_en-US" xlink:label="lab_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:to="lab_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="lab_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Accrual beginning balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:to="lab_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments and other adjustments (net of sublease receipts)</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:to="lab_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Accrual ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:to="lab_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options granted, maximum term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision for federal or state income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal U.S. net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State net operating loss carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred rent</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenditures</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax asset/(liability)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="arc" />
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB_terseLabel_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal and State</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB_label_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:label id="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB_documentation_en-US" xlink:label="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority and State and Local Jurisdiction [Member] [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:to="lab_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal Government</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:to="lab_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Federal tax credits carry forward</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss for limited use</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Limitations On Use Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net operating loss carryforward, which are limited for use over the range of years.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:to="lab_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating losses limited for use utilized on an annual basis</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Annual Limitation Amount</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of net operating loss which are limited for use, utilized on a annual basis.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:to="lab_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="arc" />
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147_terseLabel_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining portion of net operating losses</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147_label_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards Not Subject To Limitation</link:label>
    <link:label id="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147_documentation_en-US" xlink:label="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards not subject to limitation.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:to="lab_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously unrecognized excess tax benefits</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="arc" />
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E_terseLabel_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously unrecognized excess tax benefits, tax effected portion</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E_label_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</link:label>
    <link:label id="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E_documentation_en-US" xlink:label="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:to="lab_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:to="lab_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="arc" />
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20_terseLabel_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and office equipment</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20_label_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory and Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20_documentation_en-US" xlink:label="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">A facility that provides controlled conditions in which scientific or technological research, experiments, and measurement may be performed. and tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:to="lab_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:type="arc" />
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05_terseLabel_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05_label_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05_documentation_en-US" xlink:label="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Furniture and office equipment are movable furniture, fixtures, or other equipment that have no permanent connection to the structure of a building or utilities. These items depreciate substantially but definitely are important costs to consider when valuing a company, especially in liquidation.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:to="lab_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:to="lab_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:to="lab_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and software, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="arc" />
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A_terseLabel_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment purchased but not yet paid</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A_label_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Non-cash Additions</link:label>
    <link:label id="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A_documentation_en-US" xlink:label="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:to="lab_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_694F974967046075B557D840F1B9393C_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_694F974967046075B557D840F1B9393C_label_en-US" xlink:label="lab_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:to="lab_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Single Maturity Date, Amortized Cost Basis [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mature in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mature between one and five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Amortized Cost Basis</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mature in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mature between one and five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:to="lab_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:type="arc" />
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146_terseLabel_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146_label_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:label id="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146_documentation_en-US" xlink:label="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Incyte MGA012 Agreement [Member]</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteMGA012AgreementMember" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:to="lab_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862_terseLabel_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development and regulatory milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862_label_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862_documentation_en-US" xlink:label="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Development and Regulatory Milestone Payments Under Agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:to="lab_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="arc" />
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D_terseLabel_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential commercial milestone payments</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D_label_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:label id="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D_documentation_en-US" xlink:label="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential Commercial Milestone Payments Under Agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:to="lab_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="arc" />
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential proceeds from royalties percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47_label_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:label id="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47_documentation_en-US" xlink:label="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Royalties, Percent</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromRoyaltiesPercent" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:to="lab_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial activities selling price amount</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Determination of Selling Price, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:to="lab_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="arc" />
    <link:label id="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C_terseLabel_en-US" xlink:label="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical trial activities performed, revenue recognized</link:label>
    <link:label id="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C_label_en-US" xlink:label="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Services Performed, Amount</link:label>
    <link:label id="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C_documentation_en-US" xlink:label="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Multiple-deliverable Arrangements, Services Performed, Amount</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount" xlink:label="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:to="lab_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of the Company's Deferred Income Tax Assets (Liabilities)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Reported Estimated Income Tax Benefit</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:type="arc" />
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9_terseLabel_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NIAID</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9_label_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">National Institute of Allergy and Infectious Diseases [Member]</link:label>
    <link:label id="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9_documentation_en-US" xlink:label="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents a collaborators with which entity has an agreement related to contracts and research grants received from U.S. government agencies.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:to="lab_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="arc" />
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B_terseLabel_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercialization of molecules</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B_label_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Molecules To Be Developed And Commercialized Under Agreement</link:label>
    <link:label id="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B_documentation_en-US" xlink:label="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of molecules to be developed and commercialized as per collaboration.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:to="lab_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="arc" />
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D_verboseLabel_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Base period value</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D_label_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Funded Value of Base Period</link:label>
    <link:label id="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D_documentation_en-US" xlink:label="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Funded value of base period</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:to="lab_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="arc" />
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97_terseLabel_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional development funding options</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97_label_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97_documentation_en-US" xlink:label="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional funding available under agreement at counterparty's option</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:to="lab_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="arc" />
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8_terseLabel_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total potential value</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8_label_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total potential value of agreement</link:label>
    <link:label id="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8_documentation_en-US" xlink:label="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Refers to total potential value under agreement.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:to="lab_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="arc" />
    <link:label id="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1_terseLabel_en-US" xlink:label="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from additional development funding options under agreement</link:label>
    <link:label id="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1_label_en-US" xlink:label="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Additional Development Funding Options Under Agreement</link:label>
    <link:label id="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1_documentation_en-US" xlink:label="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Additional Development Funding Options Under Agreement</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:to="lab_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="arc" />
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36_terseLabel_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and Other Agreements</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36_label_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements Disclosure [Text Block]</link:label>
    <link:label id="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36_documentation_en-US" xlink:label="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for collaboration and license agreements.</link:label>
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:to="lab_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>mgnx-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsServierDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:href="mgnx-20171231.xsd#CollaborationAndOtherAgreementsTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgnx-20171231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="mgnx-20171231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:href="mgnx-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:href="mgnx-20171231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlan" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:href="mgnx-20171231.xsd#EmployeeBenefitPlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxes" xlink:href="mgnx-20171231.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:href="mgnx-20171231.xsd#IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/IncomeTaxesTables" xlink:href="mgnx-20171231.xsd#IncomeTaxesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiability" xlink:href="mgnx-20171231.xsd#LeaseExitLiability" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:href="mgnx-20171231.xsd#LeaseExitLiabilityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecurities" xlink:href="mgnx-20171231.xsd#MarketableSecurities" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:href="mgnx-20171231.xsd#MarketableSecuritiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:href="mgnx-20171231.xsd#OrganizationAndNatureOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftware" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:href="mgnx-20171231.xsd#PropertyEquipmentAndSoftwareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnaudited" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:href="mgnx-20171231.xsd#QuarterlyFinancialInformationUnauditedTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensation" xlink:href="mgnx-20171231.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:href="mgnx-20171231.xsd#StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockBasedCompensationTables" xlink:href="mgnx-20171231.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquity" xlink:href="mgnx-20171231.xsd#StockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/StockholdersEquityDetails" xlink:href="mgnx-20171231.xsd#StockholdersEquityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgnx-20171231.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreements" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0F408780D79E10D4358AD840F091F367" xlink:type="locator" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_0F408780D79E10D4358AD840F091F367" xlink:to="loc_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock_5387AE64D2699A8EA91FD840F0927D36" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_D6F38406BBF3DFBFA21ED840F016BB38" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_D6F38406BBF3DFBFA21ED840F016BB38" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:to="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_95562412B1C0DB8A97A1D840F0165663" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_6582EACFFA5B675FA15FD840F016F914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_902190D1C52648BA7E7CD840F016734F" xlink:to="loc_mgnx_BoehringerIngelheimMember_6582EACFFA5B675FA15FD840F016F914" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_EDABB1D7C9C234B66F4ED840F016BF5D" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_34ED33C28D4192A188A3D840F017FE5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_34ED33C28D4192A188A3D840F017FE5D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfAnnualMaintenancePaymentReceived" xlink:label="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_NumberOfAnnualMaintenancePaymentReceived_A09D56EB7C85C33E9008D840F017020D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement_C22613FA92D341FC1E28D840F017F016" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement_170074F8F703B1B59463D840F0175928" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement_7ECAE5E4363287113E82D840F017B24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_BBAF57367F4AA9A6E824D840F017B924" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_LicensesRevenue_BBAF57367F4AA9A6E824D840F017B924" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_F17ECC831A9EF9BC2E80D840F017B409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_FED7A5509306159EE69AD840F017CB0E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E2F676BBCBBF1FBDC94FD840F016E95A" xlink:to="loc_us-gaap_DeferredRevenue_FED7A5509306159EE69AD840F017CB0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_1AC86D7CCE24AE0100F9D840F088417F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_1AC86D7CCE24AE0100F9D840F088417F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E360318D5965923C1166D840F088CCA9" xlink:to="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_3830D45354E9935DACA4D840F08838A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:to="loc_us-gaap_MaximumMember_3830D45354E9935DACA4D840F08838A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_3BF172071DFD5B2EA30AD840F0884E70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_403FD10E8DAB7707EEF6D840F088231F" xlink:to="loc_us-gaap_MinimumMember_3BF172071DFD5B2EA30AD840F0884E70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_346D99F9ACC21C10A810D840F0889848" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteMGA012AgreementMember" xlink:label="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_6DDC1436339AA6CDC1D4D840F08825FE" xlink:to="loc_mgnx_IncyteMGA012AgreementMember_6C28ED44229FF4A02EBED840F088F146" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_68CF970DADB7377D104CD840F089627A" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteCorporationMember" xlink:label="loc_mgnx_IncyteCorporationMember_5BC9280E28C5AAF5B944D840F0894282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_C7C4C29915C592287456D840F0894B85" xlink:to="loc_mgnx_IncyteCorporationMember_5BC9280E28C5AAF5B944D840F0894282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FEE06E4928FA092B1AC9D840F088BCF3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_85DC6C0973066FE9877AD840F089353F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_NonRefundableUpfrontFees_85DC6C0973066FE9877AD840F089353F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement_980F7AFC1E511BC29B68D840F0894862" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement_30CF53F2FE1C3E3EC2CDD840F089CA8D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromRoyaltiesPercent" xlink:label="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_ProceedsfromRoyaltiesPercent_C61536E8AA7417B945B5D840F08EEA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount" xlink:label="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount_2EC49CB8A0C56A189894D840F08FF406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_320D85409DAE5645EDD5D840F08FEBA7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_us-gaap_LicensesRevenue_320D85409DAE5645EDD5D840F08FEBA7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount" xlink:label="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B644FD6BC3E33CD524A9D840F0890391" xlink:to="loc_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount_4AE400A93D74F148B570D840F08FB32C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4A9D3E18619E1F357934D840F070FF82" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_4A9D3E18619E1F357934D840F070FF82" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:to="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_1B00ED5E3200714399AAD840F07565D5" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_4FD6F059A871695CB442D840F0768998" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_CC2786584DB5097289D7D840F0769246" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_4FD6F059A871695CB442D840F0768998" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_E4026E69484DE38A071DD840F0772E4B" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_922D7B9EB0D9510CBC57D840F077BC82" xlink:to="loc_us-gaap_SubsequentEventMember_AFE234581904B8325E88D840F077FEB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_218259DDEC32452935B1D840F070420F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_56F42E133981971496C0D840F07842AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_NonRefundableUpfrontFees_56F42E133981971496C0D840F07842AC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement" xlink:label="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement_B6E58D6CA5CFBD2CE5A2D840F078797F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_60ADBAE2BF26A705D4DED840F0787397" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_60ADBAE2BF26A705D4DED840F0787397" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_88A1DD5947A438078F24D840F0780DC9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenue_88A1DD5947A438078F24D840F0780DC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenueCurrent_0EA530D2B230B64F6088D840F0785438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9CC553A1D3A662DDB05CD840F077621A" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_49B0B81453446F0334BDD840F078B876" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_7EBB9A675F57B406F4C6D840F00D8AA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_7EBB9A675F57B406F4C6D840F00D8AA0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:to="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_374B125A56201CFDE320D840F00ED86C" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_GreenCrossCorporationMember" xlink:label="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FFD5D3DEE30A849A67C3D840F00E17B7" xlink:to="loc_mgnx_GreenCrossCorporationMember_8859B85496CC3498837BD840F00E3F97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:to="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5E9ED74A4191AE90789BD840F00E3F9E" xlink:to="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BC89620A82B6F5361433D840F00E6EAE" xlink:to="loc_us-gaap_MaximumMember_C03AE47A1481106E5FDED840F00EAD48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3A9CC3369A8D16CEE548D840F00E7903" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AggregatePotentialFutureCostReimbursement" xlink:label="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AggregatePotentialFutureCostReimbursement_482511E8C21CBC440340D840F00E7A7E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement_2659D79CBD23E3DCDD1CD840F00E02AC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_12FD50A4C467E69681E1D840F00E1E3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_NonRefundableUpfrontFees_12FD50A4C467E69681E1D840F00E1E3D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification" xlink:label="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification_A1FB012298A639670E55D840F00E7BC1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromResearchAndDevelopmentServices" xlink:label="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_mgnx_ProceedsFromResearchAndDevelopmentServices_ED7651496C044DB54664D840F00E5437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_DD6D2515C466435C5F3BD840F00E4CE4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_LicensesRevenue_DD6D2515C466435C5F3BD840F00E4CE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5E949B58E0735D986F99D840F00F0BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_A42762DFD903471598A5D840F00F3028" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenue_A42762DFD903471598A5D840F00F3028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_437156EE173B1852A469D840F00F8F45" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenueCurrent_437156EE173B1852A469D840F00F8F45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_96BD621EECA20C5F54CBD840F00F9EBF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_09234BB720731FD30F12D840F00E203C" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_96BD621EECA20C5F54CBD840F00F9EBF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_46F69B8BB6DB710023DBD840F05D9534" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_46F69B8BB6DB710023DBD840F05D9534" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_E1B730BD4DBE22FA43E9D840F05D1353" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD011AgreementMember" xlink:label="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:to="loc_mgnx_JanssenMGD011AgreementMember_06F4EB088679DEF8637AD840F05D6A9D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenMGD015AgreementMember" xlink:label="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_204F503BF0AD600EECB1D840F05DF479" xlink:to="loc_mgnx_JanssenMGD015AgreementMember_05A4D81BD6921BD7648ED840F05EF657" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:to="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_2F382AD3C84094CBFEB2D840F05E0580" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_FF3F4C7C22DC0F4240DAD840F05E549E" xlink:to="loc_mgnx_JanssenBiotechIncMember_046BE7E8D7AA4D85A037D840F05E6784" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7BD63D6C8122629BC2A7D840F05D7E6F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_CD849324D9ABD7DEA20DD840F05E5F26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_87722B698F91649EC286D840F05E33E2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_B96259AD5FE062E5B9ECD840F05E7B3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_NonRefundableUpfrontFees_B96259AD5FE062E5B9ECD840F05E7B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_FC71526BF4D44E647139D840F05EC8DF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PremiumReceivedOnStockPurchase" xlink:label="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_PremiumReceivedOnStockPurchase_CD99A4084EEB8D45F328D840F05E5906" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalConsideration" xlink:label="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_TotalConsideration_91C13B23A771F343058BD840F05ED9F0" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToEquity" xlink:label="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_AmountAllocatedToEquity_F9544B74FFDA7F8D520DD840F064F256" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountAllocatedToLicenseAndRD" xlink:label="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_AmountAllocatedToLicenseAndRD_9BDF7960287C5397018CD840F065D1D1" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ClinicalMilestoneEarnedDuringPeriod" xlink:label="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_mgnx_ClinicalMilestoneEarnedDuringPeriod_D4D8D19F5AAB72555472D840F065BFCE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_389222FA3703F53B20D9D840F0655FCD" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C598BEDDD71F69EC15C3D840F05E8ED7" xlink:to="loc_us-gaap_LicensesRevenue_389222FA3703F53B20D9D840F0655FCD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_75D4C500C413B9D579E3D840F0072DC4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_75D4C500C413B9D579E3D840F0072DC4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:to="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_99A7BE5F3BBF82C9C8AFD840F0085E66" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember" xlink:label="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_F350A721491735F09724D840F008E231" xlink:to="loc_mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember_7A992E850ED0324BE367D840F00821E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:to="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_E322FF4E68E82BFDFD8AD840F008A449" xlink:to="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_5457EC82404FCA6FFE9DD840F008C876" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A669A68EDA564CF12F88D840F00808E6" xlink:to="loc_us-gaap_MaximumMember_5457EC82404FCA6FFE9DD840F008C876" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_FF5CCFEFDBECEE09EB8AD840F008BB95" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement" xlink:label="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement_FC1BD430CD6A927E0B22D840F0087B7B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FundedValueOfBasePeriod" xlink:label="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_FundedValueOfBasePeriod_FA1F2F124F6258993F9FD840F008A53D" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement_24EA6694C9B728ECFFDED840F0085E97" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TotalPotentialValueUnderAgreement" xlink:label="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_TotalPotentialValueUnderAgreement_42CC34073F76995B65FAD840F00854F8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement" xlink:label="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement_B93372A170EED4F16366D840F00971E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_1A265B93371A00885535D840F00986FB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7FD29301EC93CA417518D840F00891EC" xlink:to="loc_us-gaap_LicensesRevenue_1A265B93371A00885535D840F00986FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_693657B12051648EA19FD840F030FD2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_693657B12051648EA19FD840F030FD2F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_88F1912E66EB6B49D180D840F030A0C7" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMember" xlink:label="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_56EDB2CC0E0F43A38957D840F0310407" xlink:to="loc_mgnx_ServierMember_8C22AA1693C9F1E7E398D840F03135DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3E94C3CF69EBF3F3382DD840F031E13A" xlink:to="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_A1DAA20697D274622074D840F031EC5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_CD30AC9B8FC352522770D840F0311D43" xlink:to="loc_us-gaap_MaximumMember_A1DAA20697D274622074D840F031EC5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9D3D8AD6594827BCB3A1D840F031BEFC" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierDARTMember" xlink:label="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_16849983EABCCFBDDF1CD840F0328BC8" xlink:to="loc_mgnx_ServierDARTMember_26EA2E6938A60DF8D889D840F032C4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9278965C1ADC514F3710D840F0302F77" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_002B52FC9FF3C03C24BCD840F03208A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_NonRefundableUpfrontFees_002B52FC9FF3C03C24BCD840F03208A9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialLicenseFee" xlink:label="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialLicenseFee_AB9D4DE5DB0369A41A58D840F0324141" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialClinicalMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement_21D6B703FD7A2997F554D840F032AFD7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement_19CA6410D79B1327F3EED840F032FFDE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PotentialSalesMilestonePaymentsUnderAgreement" xlink:label="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_PotentialSalesMilestonePaymentsUnderAgreement_768FB77BD057F3B977D6D840F032F259" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OriginalPeriodOfDevelopment" xlink:label="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OriginalPeriodOfDevelopment_1D0F3AF3D236D54837A2D840F0324D73" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_3167BFB4BC7FCD2882CDD840F0325498" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_3167BFB4BC7FCD2882CDD840F0325498" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ChangeInAccountingEstimateCurrentYearImpact" xlink:label="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_ChangeInAccountingEstimateCurrentYearImpact_6145B23BA42EBB0D1667D840F033EC75" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFee" xlink:label="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OptionExerciseFee_4F1DADE08E8723E0A289D840F0334EE4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4AC7B8B2CE725BF0F317D840F033C548" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_4AC7B8B2CE725BF0F317D840F033C548" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts" xlink:label="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts_23C417735531F5533675D840F0337C72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_BF0D2B9246D33982DA26D840F033B892" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_LicensesRevenue_BF0D2B9246D33982DA26D840F033B892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_5B4D27CF74434CB95E2AD840F033FCF6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenue_5B4D27CF74434CB95E2AD840F033FCF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_EDF551E70A0460D71BB7D840F0339694" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenueCurrent_EDF551E70A0460D71BB7D840F0339694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_47DFB62E37C2F12B01ACD840F0342AB1" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_66F6728BA5C88BCA78D7D840F032D1CF" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_47DFB62E37C2F12B01ACD840F0342AB1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CollaborationAndLicenseAgreementsAbstract" xlink:label="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_CollaborationAndLicenseAgreementsAbstract_9D4ED7E0285B4F6E5656D840F044DCA1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_28E5C6A08328FEBEF94ED840F044EF30" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMember" xlink:label="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_A1E1A335549740EBA347D840F049F174" xlink:to="loc_mgnx_TakedaMember_BFFB7C38BF95FA4A2212D840F04AAE7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_B0265C14FC917E906A03D840F04AD5CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TakedaMGD010AgreementMember" xlink:label="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:to="loc_mgnx_TakedaMGD010AgreementMember_FDC56DD2F4AF38CC214FD840F04AC74E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ResearchCollaborationAndLicenseOptionAgreementMember" xlink:label="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0D983A4F461A2ABF5B50D840F04AD784" xlink:to="loc_mgnx_ResearchCollaborationAndLicenseOptionAgreementMember_71F8042F58C8ED1249F7D840F04A9D07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_355C427D427A42FD6A8ED840F0449883" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NonRefundableUpfrontFees" xlink:label="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_NonRefundableUpfrontFees_CEC6728AFA49896AFF42D840F04A7BF4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontFeeAllocatedToAgreement" xlink:label="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_UpfrontFeeAllocatedToAgreement_AE4D603395AD39F233E2D840F04A22C9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UpfrontPaymentRecognitionPeriod" xlink:label="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_UpfrontPaymentRecognitionPeriod_AA607BCD9E2F00CF7252D840F04AAA2B" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OptionExerciseFeeRecognitionPeriod" xlink:label="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_mgnx_OptionExerciseFeeRecognitionPeriod_6004383784030610D70ED840F04A4AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_LicensesRevenue_54842EF6D974863E76F5D840F04AFB89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_5528AB37943C215CF3A9D840F04A5099" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9C73C4EE1AEE860E0486D840F04AA8EF" xlink:to="loc_us-gaap_DeferredRevenue_E3FA619E456C69918EACD840F04A512E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5A88E4420446C391362DD840F003AF7D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5A88E4420446C391362DD840F003AF7D" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_991BA771B090B3656B7FD840F0045EEC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:type="locator" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_NumberOfLease" xlink:label="loc_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_mgnx_NumberOfLease_683EF04006577466E9E7D840EFFEDE8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_749BA14082D738977411D840EFFE3775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_FD1928804DF89F346742D840EFFEBF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForProceedsFromTenantAllowance" xlink:label="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_PaymentsForProceedsFromTenantAllowance_77A05601EB28CD7F7BA0D840EFFED7FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCredit" xlink:label="loc_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_DeferredRentCredit_3BF8C29BBAF0DA0ACAF0D840EFFE4B66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_50DAD908FDEF1EC82031D840EFFE0834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_E23E1B01393EBF212BFFD840EFFEB107" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_8071367FCFD82A4D0276D840EFFF265A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_8EC1E91AC954A7C88B6FD840EFFF63A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B57E2C33DEC175789C6D840EFFFBC3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5A22789CA410519A8724D840EFFF4B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_93DCFAC5A1634E821281D840F000540E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_611320B1ACBCE01E6E79D840F000071E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_432AD05637F66C3C9104D840EFFFD4CD" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_E06355E2F849C6BC3DDCD840F000280D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9D76B570B9A12ACCDD64D840F00201DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock" xlink:label="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9D76B570B9A12ACCDD64D840F00201DF" xlink:to="loc_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock_ED931B339AE0C73B38FAD840F002B6E3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_C122417F43F6F9445EB7B14F58894E33" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C122417F43F6F9445EB7B14F58894E33" xlink:to="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_C78EDB194E3CDA708ED1B14F5889A49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesCurrent_7237ACF087D2DAC951FAB14F58896B69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_AA2C3BA506D7B1F5B6E3B14F5889435B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_1A2964F65F6363CA8CC7B14F58898D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_OtherAssets_14DA2FE8E7FE718F43B1B14F5889EA9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_0E9886BE63FC7ECD61B5B14F5889F462" xlink:to="loc_us-gaap_AssetsCurrent_2126FCB5F105EF401CE4B14F5889FD52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C42218D48144BC2662D0B14F58899F96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesNoncurrent_CF4D4AEB8D03B476F6B9B14F58893C73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_420758870A37DD0807F7B14F5889596E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_E9BFA761252C9A012332B14F58894479" xlink:to="loc_us-gaap_Assets_57299814810345BF9E38B14F588A38CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_C122417F43F6F9445EB7B14F58894E33" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_AccountsPayableCurrent_2642A4988077B581DF14B14F588A85A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_AA143CD3B5004B27345FB14F588ADBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_DeferredRevenueCurrent_B5A45E0256D3076EFE1CB14F588A7EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_DeferredRentCreditCurrent_3B501DA7A62DAC0B2B5BB14F588A27A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveCurrent" xlink:label="loc_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_RestructuringReserveCurrent_200EEB6C96475F0A52E4B14F588A06EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_0B479FC53251D3EDBDEAB14F588AC30E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_7F797077CB02F5E30BCCB14F588AF27B" xlink:to="loc_us-gaap_LiabilitiesCurrent_FF8BC3A853CFD6E735F1B14F588AAAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="loc_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_DeferredRevenueNoncurrent_523488C40B65F4046D5FB14F588A08ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_DeferredRentCreditNoncurrent_5DFD85C75777D37E5810B14F588AA05A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveNoncurrent" xlink:label="loc_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_RestructuringReserveNoncurrent_237CB5AC52EC3FFEDA22B14F588AC656" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_Liabilities_BB27FCFC460909E2E0CBB14F588A3B37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="loc_us-gaap_CommonStockValue_B1BB5CC431D2F8D8A27FB14F588B03EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_8551E604CD3BA6C07803B14F588BEC3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9367878B17CCB08ACE62B14F588B30D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_74EF9EF3C992632AFF4BB14F588B29A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_F38E5BFBFD8C0B0ACED7B14F588BC171" xlink:to="loc_us-gaap_StockholdersEquity_2BB9BAF502ACB80C5428B14F588B37A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6CAB2DFC6B2DD6607C84B14F588A3F59" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_D5C6FC3821388E51E6D8B14F588B9EDA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_22E0186BA7926333D0D9962627B4E856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_F8936BBDB90338D6AEB8962627B410F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_BA42AC3AF69797B404FA962627B47FA0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_62F624B7ABEB1EA4E00F962627B49FF3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_774E40CE57A754967B7ED85A454EED40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:to="loc_us-gaap_NetIncomeLoss_774E40CE57A754967B7ED85A454EED40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_34FA4FE4BE78B26AB1AFD85A454E9E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:to="loc_us-gaap_ShareBasedCompensation_7B0A9F969778FE4F1646D85A454FDAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_B7A05F6CCFB9CC2FEBA6D85A454EF31D" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_36B98258F2AA7E945120D85A454FB847" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_83D6AAF705AA4AA5C4ECD85A454F5E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities" xlink:label="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities_F19BC15B0D6E115AA691D85A454F3DEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_92551CB775D242D6B140D85A454F05C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_C279CD723A6EDFE375A8D85A454F436E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_9A7EE53197409F2990C1D85A454F2BF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInRestructuringReserve" xlink:label="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInRestructuringReserve_190ADFF3F637ADCA9569D85A454FA7A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C2C1D07FB7801EDA70C3D85A454F21B8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncreaseDecreaseInDeferredRent" xlink:label="loc_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_mgnx_IncreaseDecreaseInDeferredRent_D89107FC6DE1F0806250D85A454F6DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5D62AF70DBBEB3711A8FD85A454FE688" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities_191E7C72D2374D4A5705D85A454F7DA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_B286336D332874E26FECD85A454ECE1C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_4A08A9784A402C0E25BAD85A455025EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2A4922F44DA516F89601D85A45502822" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_9000B7C82BABC15BA145D85A4550C164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2D508CBC60A39AB89AF1D85A45503A8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_8F623B795AF61C6B5585D85A455023C0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_91DCEC43366429689013D85A4550645F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F494AEF0539C4D716E3BD85A455061BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_F494AEF0539C4D716E3BD85A455061BE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases" xlink:label="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:to="loc_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases_78081C1BC7E9DB8E59ADD85A45501595" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_7F950A70FABD7FDB1F7ED85A4550B907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_8B76D0523032686115F8D85A45508ADE" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_0FC5399960CDA5BD91F5D85A455091C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_B688A3545A3C6D41F2CCD85A45507E71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_BC20C05627484725AA57D85A45506467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_66B8A99B16BE9DF13B2DD85A454E288D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AC27A141919BC48FFAA8D85A45500ABC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_947D5ED78AAA6A14D051967A9C656FD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:to="loc_us-gaap_RevenueFromGrants_3F1810B7F6326C841C0D967A9C65C202" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_371C5F06087D788509B8967A9C646CA7" xlink:to="loc_us-gaap_Revenues_D034B6331E97935765FB967A9C653B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_EE2E6B8A71BBE8E54C1C967A9C653B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_C06975F9693D765AA1BB967A9C65402F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_1FFF3D0F6D2E1E02EFDE967A9C65113C" xlink:to="loc_us-gaap_CostsAndExpenses_AF7985493B63FD2BCE38967A9C654AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_OperatingIncomeLoss_EDF73BE8B550812C0CD4967A9C65A452" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_FAD53A41F897058577D7967A9C66FA53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_NetIncomeLoss_0D9FF4E3815A44EC9893967A9C66D050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_D7EB2AEFC0281A62A959967A9C667A39" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_8FF7B0EC3CA56EDFCB38967A9C66698E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ED3AB0E30523CE3C6DCD967A9C66C8BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare_C248EB097984DB0E3092967A9C663183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_6109AA6814E1AD770ECC967A9C64A30D" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_DFC52F9724C9506DD47C967A9C66B271" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_37AE405E487C21AA0230D7F3E49DA0B0" xlink:to="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9F27D3032178E38A9334D7F3E49DA796" xlink:to="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_CommonStockMember_FD6906B60750D7BB334ED7F3E49DA6F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_TreasuryStockMember_F02AA4DD0D04945BF938D7F3E49D3B3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6DB74CD5723F91E89148D7F3E49D0EE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_RetainedEarningsMember_9018DFB1819D24172175D7F3E49D4010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0B39B6AE0CD42F3386CDD7F3E49D7768" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9A125A7BC3C8E163ABB7D7F3E49DDF23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_634A85331AB4A87D60F6D7F3E49D2AA8" xlink:to="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockholdersEquity_AA6474F67C5C8D2968B9D7F3E49D4F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_SharesIssued_6A0DCAA2D6981CBCD8DDD7F3E49D07A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_FA0EFDFD6B0DF074BF03D7F3E49D23E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_5D02BB176773150214B1D7F3E49D2ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_5DA8738C0CE28E25608BD7F3E49E8811" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodValueStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_mgnx_StockIssuedDuringPeriodValueStockPlanActivity_E544953835C699248315D7F3E49E2D45" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesStockPlanActivity" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity_52B2E8502E1BD95D190DD7F3E49E9F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockRetiredParValueMethodAmount" xlink:label="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_TreasuryStockRetiredParValueMethodAmount_DC7A83AE58F5E2BAE03DD7F3E49E0B2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TreasuryStockSharesRetired" xlink:label="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_TreasuryStockSharesRetired_C5DCD2A148A5A8590591D7F3E49ED1E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestments" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestments_964D6EFF829145A610FDD7F3E49E88E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_E2D6DF4B36EAE598C2E5D7F3E49E1268" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_NetIncomeLoss_E2D6DF4B36EAE598C2E5D7F3E49E1268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_StockholdersEquity_81480B76A38720CBC000D7F3E49EC4F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_60A5E867F704987450AFD7F3E49D519E" xlink:to="loc_us-gaap_SharesIssued_26B88A8E83C344F0B535D7F3E49EDD97" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DocumentAndEntityInformationAbstract" xlink:label="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_DocumentType_4CB42202C5D7E40CE8FB9626283BBCC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_AmendmentFlag_90E695C43F4D3926C45A9626283C940D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_DocumentPeriodEndDate_727E5F02E5460A9792FA9626283C520E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_DocumentFiscalYearFocus_02B690BCA1BDBBB029D19626283C2614" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_DocumentFiscalPeriodFocus_80D0002307E4E93602F79626283C065E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityRegistrantName_566997E9507C9DD67AAD9626283CF2FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityCentralIndexKey_7F2D6F2DD31C9816E4B29626283C2857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_CurrentFiscalYearEndDate_BE3F00B2E54A7CFA1DFC9626283C07AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_CC37AB99B4BA7E66FD1E9626283D3E93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityCurrentReportingStatus_61B23E4199F3A898FF3F9626283DE91F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityVoluntaryFilers_EC1F856036311F196A8E9626283D24CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityFilerCategory_2FAC5CEB9696F7A2D7B79626283D3155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_BAB7F5E2D7BDBD9D419B9626283DB863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DocumentAndEntityInformationAbstract_CA80E39E286926601F8C9626283AD8C4" xlink:to="loc_dei_EntityPublicFloat_65E887D2456E327BC0D69626283DC868" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_177C798E8950C88D0735D83BD482D642" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_177C798E8950C88D0735D83BD482D642" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_96FFCEA1AA870182746DD83BD4823E61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/EmployeeBenefitPlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:type="locator" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan" xlink:label="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:to="loc_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan_22A2DD56AD56EF5FCDFAD83BD480BBB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8FFE6CB7B86FCA56C34FD83BD480BCF8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage" xlink:label="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:to="loc_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage_CB418E9EDFA56ADCD006D83BD480267C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_190FA96C193E0F5622A4D83BD480A2E8" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_3712A5FA86A0DE8AB0FCD83BD48052AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_CF5AD79E6058763B79F6D840F1133BC8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_CF5AD79E6058763B79F6D840F1133BC8" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_077D7DBA50D06FEA8B62D840F113938F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0C321F590CBB1A7B592ED85A44DDCE54" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0C321F590CBB1A7B592ED85A44DDCE54" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_072DC174F07D5A65CE61D85A44DDAE77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0C321F590CBB1A7B592ED85A44DDCE54" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_6BC5D86F55572CE26F00D85A44DDC4BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_0F2F82ED29DFA6B6D112D85A44DD6BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_60226FD2A1EC5EB118DFD85A44DD00DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther_4E636CE7E65D58268B64D85A44DD66DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_DF08BA98762FC6621D1ED85A44DDC46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_0C9A7E441517ECF9E781D85A44DDF979" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_88CD49BAA7DF5809B069D85A44DD90C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_83B9771329073C4444D1D85A44DD2A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_2570140471E956FC5D7ED85A44DD3934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_E2FFC970474B1E3CF2D1D85A44DDB2DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_A5909AE212B969BBC61AD85A44DDB346" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_36A1A5B4EBCDDE9D0F76D85A44DD75A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0C321F590CBB1A7B592ED85A44DDCE54" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_73DF43FAF330B3E7D481D85A44DEC135" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_C3043A4E228CADA2202BD85A44DE96BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_006032E54001D9073C4BD85A44DE9F59" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_8B8313039FE90A25E1ECD85A44DE8CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0C321F590CBB1A7B592ED85A44DDCE54" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_3129118A723025827713D85A44DED432" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember" xlink:label="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_92EC500765DFF948E894D85A44DE94C9" xlink:to="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember_F9021E8E1E9799ADD77BD85A44DEB6CB" xlink:to="loc_us-gaap_DomesticCountryMember_B2A1B741E83EFF0D8778D85A44DEDE89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_104288E8F82174AB12B1D85A44DE7C78" xlink:to="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_43B8F33DE6CD4AF3E9B7D85A44DEF073" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:to="loc_us-gaap_MinimumMember_43B8F33DE6CD4AF3E9B7D85A44DEF073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_1CCD91C8F3DD268C13F5D85A44DEA8DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_D1B52305A7379520D175D85A44DE1D1B" xlink:to="loc_us-gaap_MaximumMember_1CCD91C8F3DD268C13F5D85A44DEA8DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_8AD939436B31F81447B7D85A44DE39C7" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_D042E30C1E6B427855CFD85A44DE6416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_B140AC9FC61217D88EB2D85A44DE92AE" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount_276248E71BC7502B14D2D85A44DF3107" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsAnnualLimitationAmount" xlink:label="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount_8AB84B7AF6A610EE9A08D85A44DF9A54" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_OperatingLossCarryforwardsNotSubjectToLimitation" xlink:label="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation_41B7A1965CE487776F3BD85A44DF3147" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount_8C15603E3D1887B8F207D85A44DF8125" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2BFC1707AFAAC9E26B55D85A44DE227E" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount_C8FBC897A101D229ACF1D85C0B3D175E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_076B2F3332CB930B9EFCD840F0C9CEBC" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:to="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_3D6AE8DDFA65D8B19BD1D840F0CA6AD3" xlink:to="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_35BFE650FD31B874553AD840F0CA0FEE" xlink:to="loc_us-gaap_MinimumMember_2D7FCD194B1756AC6546D840F0CA6FC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_74C59946240412A927D8D840F0CACAA6" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_A2F1A3BACF307AE0626BD840F0CAA9CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_23895D93D7E83E273D7ED840F0CAE289" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_3DD99A9F9C7BF0984CA2D840F0CA3AE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_E3E6FC91E4B7DB079D30D840F0CAF183" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_0EB9DB82147A7FA88D67D840F0CAD0A5" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_917D9188F54F113596DFD840F0CBA0DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_ECC523D2DE4264CDCEE4D840F0CBE472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_D6BAAB30A2FDC9FF6BCBD840F0CA34C9" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_B7E768C29772346D64DCD840F0CBE576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_F606FF92267291E06A3DD840F0DA6299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_F3700DBEB7D7360B3BFED840F0DA97AC" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount_89760AECE145F7D35E36D840F0DA3A35" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount" xlink:label="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount_4AB8535321C86A976980D840F0DAE0AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_849E98C36A53E0734754D840F0DB614D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_8A1EFE10D2D447CA6104D840F0DB7D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsOther_A0B815B95954953C3567D840F0DB8E16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_5F5C14CDB81AD85630F1D840F0DBBA32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_CFA61BB937CCF2E40492D840F0DBC78C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_4A4C11550DD8B0E4E80AD840F0DB941B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_E2AF0514174CAB21DC37D840F0DA7D6D" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_96EB1D46417030BB6149D840F0DB6148" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A064567F8407283410ABD840F10A83AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A064567F8407283410ABD840F10A83AC" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_B748B80BC137147721CED840F10A4DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A064567F8407283410ABD840F10A83AC" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3A35317B99E66F867CABD840F10B12AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A064567F8407283410ABD840F10A83AC" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_9F2C675750A20F7EBAACD840F10B4E09" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiability" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_82452B066DE0D881196BD840F0BBEE87" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_82452B066DE0D881196BD840F0BBEE87" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_A6C2FBEB262B120C229AD840F0BBEDDB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_16499FCF7D83B8DF151AD840F0A171D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_16499FCF7D83B8DF151AD840F0A171D3" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_E2820EA7AADC1F618D44D840F0A10CC9" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractTerminationMember" xlink:label="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_C94F5339999830A1DC7CD840F0A18A87" xlink:to="loc_us-gaap_ContractTerminationMember_D1983F01B99FB6BC8C93D840F0A1D8A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_36B615B8C66055A8F0C5D840F0A1F465" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_5350B57E5F7B2CBDE19CD840F0A19972" xlink:to="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="loc_us-gaap_RestructuringReserve_4D14DEE8704F2BA67ED0D840F0A1BD0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForRestructuring" xlink:label="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="loc_us-gaap_PaymentsForRestructuring_6E65B3DBD7BFF0E9A115D840F0A1AD46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_A484D6DCCF31B199F7A4D840F0A157BB" xlink:to="loc_us-gaap_RestructuringReserve_CB1DD2595F82AFB7F5EBD840F0A293B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_61A2DD69313B9CAE30A3D840F0AAD2B0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_61A2DD69313B9CAE30A3D840F0AAD2B0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DCC70F721F00B27B384CD840F0AA18E7" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RavenBiotechnologiesIncMember" xlink:label="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5CD6E87D9CE3B82FE37ED840F0AA0111" xlink:to="loc_mgnx_RavenBiotechnologiesIncMember_D7192254130A6AB871BCD840F0AA3BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_E034C62A8AE66442CF16D840F0AA04B9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_1E34445D1EE648ABE65FD840F0AA4B00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals_1E34445D1EE648ABE65FD840F0AA4B00" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ReductionInResearchAndDevelopmentExpense" xlink:label="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_mgnx_ReductionInResearchAndDevelopmentExpense_4087820E9E0641773227D840F0AA260F" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AmountOfImmaterialErrorCorrection" xlink:label="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_8483F5F1A0889D030E9DD840F0AA6D70" xlink:to="loc_mgnx_AmountOfImmaterialErrorCorrection_7682D7820B499165EC29D840F0B0EF58" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/LeaseExitLiabilityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7BCAF563D277901AF90FD840F0B26CC3" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_52F6E9FF00E9E4704E0ED840F0B20F7A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6366F9EAD91A024B8731D840F1F12418" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_6366F9EAD91A024B8731D840F1F12418" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_6E5D284893777D558260D840F1F1EA9C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF4CC6F7BF4A850DCF21D840F1CEBB85" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_A69BC5B1C1A4F7D27BF7D840F1CE24DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF4CC6F7BF4A850DCF21D840F1CEBB85" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_A69BC5B1C1A4F7D27BF7D840F1CE24DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF4CC6F7BF4A850DCF21D840F1CEBB85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_B1840DB2A5CA870FE620D840F1D3A4B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_32E6D57C9AF5691484A2D840F1D44287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FE51ECFD6BA022D1F086D840F1D4217D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_886319E632310203A3A2D840F1D3ADDB" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_FE51ECFD6BA022D1F086D840F1D4217D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF4CC6F7BF4A850DCF21D840F1CEBB85" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_B11E6105AD59938BFF8CD840F1D42038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_747C5E5684F0626D5ECBD840F1D46B89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E101FF8F861DA1F204A7D840F1D45503" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_E1DC328541761941525AD840F1D49C10" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E101FF8F861DA1F204A7D840F1D45503" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_AF4CC6F7BF4A850DCF21D840F1CEBB85" xlink:to="loc_us-gaap_InterestIncomeOther_98E939116D23E665AB60D840F1D42CFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable" xlink:label="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_45B5A2F1B0D1FD42B041D840F1E31E64" xlink:to="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:label="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_D1EDFF04DBA9272DB179D840F1E312D2" xlink:to="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_7E7327B46A6E7A179A00D840F1E40892" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_709176EDD72A354C5D67D840F1E4AFDC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_1F6F04CEC1D785D29155D840F1E3BACC" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_9D07430CA986FF937BB3D840F1E5891E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfTradingSecuritiesAndOtherTradingAssetsTable_217BCAE39F80F30136D6D840F1E30975" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_724720E2CCED95D16A95D840F1E504DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_A003EE8096F9AC4EF201D840F1E59819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C693BD885C2E2B4109E2D840F1E672D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_42875DC38C595F517078D840F1E5F01F" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1C9D0A0B72E4DFCD47DFD840F1E6D314" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E2E4818677F4F71C958AD840F1EEC098" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_E2E4818677F4F71C958AD840F1EEC098" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesTextBlock_13DDE863B642FCB8F51AD840F1EE032E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/OrganizationAndNatureOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_75F9516968D510BEE8AFD840F283040C" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_D3CE8C56C0D28CE2BB69D840F283BEA3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftware" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_FFABA7840BD947950738D840F1C5B752" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_FFABA7840BD947950738D840F1C5B752" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2EE12F0C9E98EBC17EEBD840F1C56210" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6124DE568189075BFF88D840F1B207C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6124DE568189075BFF88D840F1B207C8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_A82FC0D23BB7FAE6E08BD840F1B2071D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_13E93A5BA482DB4E8346D840F1B27081" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_ComputerEquipmentMember_13E93A5BA482DB4E8346D840F1B27081" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3E1D815E0A327D566EFBD840F1B32D47" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_3E1D815E0A327D566EFBD840F1B32D47" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_FurnitureAndOfficeEquipmentMember" xlink:label="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_mgnx_FurnitureAndOfficeEquipmentMember_41A1595AF27E8E8D0704D840F1B32E05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_EquipmentMember_105F5048A20EBCC16CE1D840F1B38655" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_EAE59521C3A3F3107E29D840F1B3D33B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_2F53BDE140A343993E92D840F1B2CD38" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_EAE59521C3A3F3107E29D840F1B3D33B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_152888103E0C9B805F45D840F1B23B80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_237E8493AA6BBC1F2764D840F1B3FA72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_ConstructionInProgressGross_91B3D73FDE0F3BC53830D840F1B3D46F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0AE7BE53BD5859D30ECBD840F1B31491" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0616ABB851494882F4DAD840F1B370B9" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PropertyPlantAndEquipmentNonCashAdditions" xlink:label="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_mgnx_PropertyPlantAndEquipmentNonCashAdditions_F765E64C9CE9B0E27BCCD840F1B9E19A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_AF0A50CC75AD44A2534CD840F1B343F1" xlink:to="loc_us-gaap_Depreciation_694F974967046075B557D840F1B9393C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_28FBD1183559958DC340D840F1BC679C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_7BAF4D95F6388E80F207D840F1BC7E01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_47894F01770DFBF64491D840EFF155ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:label="loc_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_47894F01770DFBF64491D840EFF155ED" xlink:to="loc_us-gaap_QuarterlyFinancialInformationTextBlock_A110ED27E40E9A018007D840EFF2C495" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:to="loc_us-gaap_Revenues_F87EC3EE2CE85392D9F6D840EFEB33FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:to="loc_us-gaap_NetIncomeLoss_EC79928099A5069C35E8D840EFEB5573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:to="loc_us-gaap_EarningsPerShareBasic_FEF32D08D469C7A2F07BD840EFEBC5EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_60D15A1A3D74B96FEC93D840EFEBD904" xlink:to="loc_us-gaap_EarningsPerShareDiluted_6F6F39BF2958F69CFA41D840EFEBE6C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:label="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_05B4C098F0A5DF7D6791D840EFED9AB7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_QuarterlyFinancialInformationDisclosureAbstract_05B4C098F0A5DF7D6791D840EFED9AB7" xlink:to="loc_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_945FA19B480BC8EA4851D840EFED2D5E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5F4A715C30C051D856EFD840F17A23FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5F4A715C30C051D856EFD840F17A23FC" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B00956A2B825C8930A66D840F17A4A29" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B7D0AE3BAC7CAF4B223D840F16A100F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7B7D0AE3BAC7CAF4B223D840F16A100F" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:to="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_87FE167A6DAF45B4991DD840F16ADD67" xlink:to="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember" xlink:label="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_EE5660E5A4A25C44B526D840F16AD95C" xlink:to="loc_mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember_2A923862480068E12E2ED840F16ADB80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_59E0AFED09BF83C6F028D840F16A125B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_5417E4DB3BF96F619401D840F16AE5A7" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent_A50C04E7891CDD8364A3D840F16A050C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_BF43EC9EC18DD60915DDD840F16A68DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_13B145889C04B31D1A2BD840F16AD311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E3FE44EEB2E5F2A523A6D840F16ACA84" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_32F13CFE6FA6313ED701D840F16AF8C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6C99908F0CDEEA2630D9D840F14248DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6C99908F0CDEEA2630D9D840F14248DF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:to="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5085F27F43E55796F350D840F1426045" xlink:to="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_1BFD527FD0D3B6B4379AD840F142DF08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:to="loc_us-gaap_MinimumMember_1BFD527FD0D3B6B4379AD840F142DF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2326628147CE61D2A6E6D840F1425086" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_BFA84496A7D597341D67D840F142FBD0" xlink:to="loc_us-gaap_MaximumMember_2326628147CE61D2A6E6D840F1425086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_49A12C71F49696AD4EFED840F14280EF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_951E9DC4CC9899F848A1D840F1431031" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_8BB85CCAED15AC55552BD840F1483525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_7AA7BA22D8AF6F083997D840F148D188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_ECF806350B8C2FCDA3FED840F148BBF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_C1C63B3F7FC304E22E4BD840F142A156" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_A395387548764BF5974FD840F1483986" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92338D6E3CA6186BDE7CD840F159EE7E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92338D6E3CA6186BDE7CD840F159EE7E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:to="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7F9CEE3AAD83A7AF6BC8D840F1591957" xlink:to="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_EquityIncentivePlan2003Member" xlink:label="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:to="loc_mgnx_EquityIncentivePlan2003Member_AAEA9637C3538C1E5838D840F159B316" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIncentivePlan2013Member" xlink:label="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_E62EB36B89AD4A65BDD1D840F1598E2A" xlink:to="loc_mgnx_StockIncentivePlan2013Member_552EBBC668EB8A6BA367D840F159CA0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_C6E91FCA87AB754EDA50D840F159D0E2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62CA07B9F572C0703C14D840F159995E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_62CA07B9F572C0703C14D840F159995E" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease" xlink:label="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease_C6826667BB9047E966BAD840F159CCFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7578F94C09B7BF59F0A2D840F15A99B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_BFF683EA8AC5C5B777F7D840F15AB1E4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance" xlink:label="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance_7C7589D541729E7C91B0D840F15AB4C6" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan" xlink:label="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F0812BF65E644CDE9E2AD840F159957C" xlink:to="loc_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan_6E1DCBDBCEED20E925A6D840F15A1692" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_92338D6E3CA6186BDE7CD840F159EE7E" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_9CB5D780704E48246E55D840F15A8F84" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_92EF749B98622585FB1BD840F15A3DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_5FA95EB3894E7DBD32A7D840F15A6B39" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_6378A396379C6519B06DD840F15A96EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_E05A87C72047D04F58FED840F15A3ADB" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_45A61B678AFC6CC8CC53D840F15A1E75" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1DA5F9EA457EB2C446A7D840F15AF890" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4CF6AA7CED8F75FCD1B1D840F12FFF8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_FE2B02811DF3D4AE3800D840F12F1688" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_CF4B12C6461840C67812D840F13001F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_B227D6DF319E48171E95D840F130D986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_E97323383B6AE5CA6594D840F130ED0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_78D8BCFD350C75EB1AFFD840F1309625" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B7719C50B191EE82C117D840F12FC2D2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_4C864188742B29492F9ED840F1303604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_1C1B2A89F02F08BCD2AFD840F130DBB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4B7D118659DE1FD08F0ED840F130C438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_C25B32742AF72A4F6767D840F130F14F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_B9324D87419DB0989044D840F1306B6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_28EDF0AAA1CEF7B4FFC8D840F130849B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7931F9539A033CBBB6D5D840F1305D21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract_043E9965D194493641B6D840F1305F4B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_D02BD40C1F829E670564D840F130EFD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_DAD76C23C447179C70BCD840F1313D5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_4A9BA1FDD2DCBB40155AD840F1317FBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_4272E9F25C138E8C34EED840F1313AD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_57C588A315D8E7357290D840F131B9D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_F41923B8F854BF456496D840F131946E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_D09AA0DDD5D1E30B0FAED840F13140C2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2A2F13F5FBD49378769AD840F1314123" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_E121F94C9F80036D7935D840F13170BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_63637FD3EFB688C72339D840F131177E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E4798F3A84F7BCBD2387D840F1312E60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_C96A66A37DA6832A966ED840F1313521" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_9800DB19A09BAD754ABBD840F1310733" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_021BF3DB39EB90F78536D840F131CA31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_631DBFCE537AE832CE05D840F12FC64D" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_C0C9FDFAEE5336A3FA4BD840F131CDCB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_885792D9A60FBAF73DD3D840F172390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_671C021879D69531230AD840F172B865" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CB6ADAAE07B29BB9BD7FD840F1723EB5" xlink:to="loc_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock_DB91B244A4922AAB7B1ED840F172B564" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4A593115F6A85797173BD840F1A16D45" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_CEBF60472E08DD5773B0D840F1A1DBEF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D3B117EA981076BFE952D840F1934014" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D3B117EA981076BFE952D840F1934014" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_BC8812382F9E99E97A4AD840F19422A0" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_RegisteredDirectOfferingMember" xlink:label="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:to="loc_mgnx_RegisteredDirectOfferingMember_532F1C2E3A02DDB0F0ACD840F1956DA3" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_AtTheMarketOfferingMember" xlink:label="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_E8820B0AF7F388E72245D840F194C9AF" xlink:to="loc_mgnx_AtTheMarketOfferingMember_0C0C409B0580F79F57A5D840F195204E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_161EB295A1C9D3A53318D840F196AF32" xlink:to="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_UndesignatedPreferredStockMember" xlink:label="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_8A4D9856DA4483F5466AD840F196A77C" xlink:to="loc_mgnx_UndesignatedPreferredStockMember_0DCC77EE114914F05B9AD840F1965E7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_01BDB77C65C93C97D418D840F1967E1B" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JohnsonAndJohnsonDevelopmentCorporationMember" xlink:label="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_55111B65ABA25A82F20FD840F196797A" xlink:to="loc_mgnx_JohnsonAndJohnsonDevelopmentCorporationMember_1057B92636816B6AF02FD840F1968BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_D89F6FFCE335F2E47F6CD840F193D338" xlink:to="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_0C1E2E17DD216FAFEB85D840F197C77F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_0C1E2E17DD216FAFEB85D840F197C77F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_E86A9119504551A6347DD840F197FA37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_A6C007B83813698901C3D840F1976498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_A57D5E607B69AF65736ED840F197D7F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesIssued_56C58CFE9DE5EA016517D840F197BF9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_400D735715A5681A045ED840F197DCEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_237375B983E4C07B3AD6D840F1978AAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SharePrice_18E9A484F0EDDA8FF654D840F197E017" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption" xlink:label="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption_CB411B78937BEA4D245DD840F197A852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOrSaleOfEquity_B5A9F43551CC3527F331D840F1979470" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3F7C00FC4674BA738B74D840F1972689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_9C835BE1C112466A8D41D840F1971A19" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_9C835BE1C112466A8D41D840F1971A19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_908CADD824D6046B0E1ED840F1988FF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_446077DEE6FD5F455A31D840F1984920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657DC082C24FB1FBE8E4D840F198C3ED" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_657DC082C24FB1FBE8E4D840F198C3ED" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_CommonStockMaximumAmountAvailableForIssuance" xlink:label="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_8A60CD64F24F1DD8C126D840F196537B" xlink:to="loc_mgnx_CommonStockMaximumAmountAvailableForIssuance_473523E8F81480234D24D840F1982FFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3B12B410B25D402E3154D840F27C6F4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3B12B410B25D402E3154D840F27C6F4D" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_454EEA6671D4DD610F7DD840F27CEA3A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_CC47303BF9CB2F9C0502D840F20A7A83" xlink:to="loc_us-gaap_NetIncomeLoss_843A9BB45CBC5124FE3DD840F20AF51C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:to="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract_42C61C5AEC9A97372496D840F20A26ED" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6F214C5C01486EFD8310D840F20AB2EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_1349F67D2D15CF3332C4D840F20BB6E7" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_9B00E9D7B02D8AD2E6C2D840F20B28FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_074C7DDFAABBB4ED27C2D840F20BB79B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_35D19B8314FA0C4F704BD840F20A3099" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_A800FB8A59FC025B047DD840F20B0769" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:to="loc_us-gaap_NumberOfOperatingSegments_B9106BF5BF8EF2A27712D840F25A4A32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities_F2690EFEF90E86B6D6C1D840F25AE22C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_91FD316FC5178F193D7CD840F25BCED4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset" xlink:label="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:to="loc_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset_809FF0E8322CF0559893D840F25BEAC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup" xlink:label="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6182D1772CCBF1F5E04CD840F25A1F1F" xlink:to="loc_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup_4E31F654A7B59B4B7631D840F25B8F05" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8396C5ADEF72687FEDE3D840F21A7A3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8396C5ADEF72687FEDE3D840F21A7A3C" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_53A94ED4753714586504D840F21AE53D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_ComputerEquipmentMember_83066AFB61A56DA52422D840F21A4FA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_445C0FCF2D9BDB8EFAA5D840F21A9B1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_3670EBC74BFBD7C2077FD840F21B27CA" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_LaboratoryAndOfficeEquipmentMember" xlink:label="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_mgnx_LaboratoryAndOfficeEquipmentMember_DCE611E2377D22E62CFAD840F21B8C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CD75A77E8F183A7D5249D840F21AC694" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_D650171C2F6BFB716C23D840F21BA244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_44B53DCAB054E70C9EDCD840F21AC490" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_BA6384799D2051B2BF6AD840F21BFC22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_243CC357C4C202D0BDDFD840F21B5D84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_AFD34C5697B9BEC1142DD840F21BC6D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_A69C28A9828FB6D6FF80D840F273B078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_UseOfEstimates_AD7136298EFB56763FB6D840F273605B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_B32D09ECE7796350D21DD840F2748DC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_59DE45C080C99655F35DD840F274D718" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_2EC3FDC7D38CAD19935FD840F2740BDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_3D4DEF2E95AAEBFF6D9FD840F274D0E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_BD2221EA36EB6989506FD840F274DB96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0D649FCBECB59BCF7D63D840F2746A8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_633FAF8A96AB329D9728D840F27427AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_689B2CE03E2EA61DC662D840F274A0B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_280C3B5AB7922297F764D840F2744DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_AD100F2121137C5A8CD3D840F274131A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:label="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_CompensationRelatedCostsPolicyTextBlock_522B164D4EA79BC2CE50D840F274EF22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_E7F1A0C2437CAEDEF674D840F274A920" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C6D23F1B3A58461B3D45D840F27384CF" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_34372F2B04EB8C756575D840F2747AA0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_087F5D3EF4FE463AEE7BD840F1FBA32F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_087F5D3EF4FE463AEE7BD840F1FBA32F" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_73A52284E755A2F1E9C0D840F1FB48C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_774F78F4C3A4CD21F35AD840F1FB733D" xlink:to="loc_us-gaap_StockOptionMember_B37F8CFE4AAA5CD8271BD840F200BC4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3DDB7ABABBD88A99F092D840F1FB6FB2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C991A0D03BCCE9B39E7ED840F20137F1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_46D4F2157BD46462A420D840F2017B4A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62A8E36BA882636B6DA6D840F22A0315" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62A8E36BA882636B6DA6D840F22A0315" xlink:to="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_EC9542ECDA8338BE4CDAD840F22B232D" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_09F218532C572E96A42ED840F22BBCC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_E8554A62EC57503BD3F6D840F22B810E" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_09F218532C572E96A42ED840F22BBCC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_73A00EAEEC9AA534B591D840F22B031C" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_D01746429BC1396AA004D840F22BC20A" xlink:to="loc_us-gaap_AccountsReceivableMember_875FE58629745D86C955D840F22B22D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_BF71A1B0C79AADD184FFD840F22B7A99" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member" xlink:label="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member_DEC10BCF50096A5D91AED840F22BA8DB" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_ServierMGA271Member" xlink:label="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_ServierMGA271Member_D3CBBFC080A3ECF2ED0AD840F22B5996" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_82CC0E7B2D3B2F53C4FAD840F22BCDC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_JanssenBiotechIncMember_82CC0E7B2D3B2F53C4FAD840F22BCDC2" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_USGovernmentMember" xlink:label="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_E386AE0BE5949FEE68CFD840F22B29A8" xlink:to="loc_mgnx_USGovernmentMember_92300B0D4500CC16D6D6D840F22B2CE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_623C3068850406B929FAD840F22B38B6" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_9D5E420F3B9091635368D840F22B6233" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_A17E626CF1DFECF06C39D840F22C0480" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2B9201DD99BE2A9FEEB3D840F23B5C86" xlink:to="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_45F535B7C173C0E36669D840F23BAFE2" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_IncyteCorporationMember" xlink:label="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_IncyteCorporationMember_35E76DB91413F6899118D840F23BA712" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_JanssenBiotechIncMember" xlink:label="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_JanssenBiotechIncMember_461B93346062F7B4351DD840F23B9A50" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_BoehringerIngelheimMember" xlink:label="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_640229E520B84F76BE5DD840F23B4781" xlink:to="loc_mgnx_BoehringerIngelheimMember_D33E57EF40C7A6BFD6A1D840F23B13CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_155B2336B26AD0E65DCFD840F23B1524" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_C9387E97D758A2E19888D840F23C216F" xlink:to="loc_us-gaap_SalesRevenueNetMember_785476F990D198ED92E8D840F23C378F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_0490F7E1F64AA56AE922D840F23CB728" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_F51A51F8831018A09CFBD840F23C2B50" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_7E7DFBC6D40DFE0B4FE1D840F23C4D7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_A66BEFDE46DB961EF605D840F23BFE1E" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_7002F0DB12A8E31D4144D840F23C96E3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_58FF2E0E56846B4A0B19D840F23C2DA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_C1523C00B23A66382E51D840F24B04CA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_C1523C00B23A66382E51D840F24B04CA" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_28B7808942F61A066E60D840F2519389" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4CF70F2EF375C97F8CEAD840F251CB8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_5B83D3A94F84C28F948CD840F2518D60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0514B2F3253ED027CFAED840F251795D" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_15383CAC89FFE6FB786FD840F25127B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_E1AEA51D5DB9184F7F44D840F251846B" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_MoneyMarketFundsMember_92BB1AEDF1E946A0FB3DD840F251C1FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_0E624163CD8C56EF0B64D840F252B3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_C9C8A2540C99F77568E8D840F2529A37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_D3EDC99C310512C60A83D840F2510464" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_B1777BD2CA71D6D67230D840F252B104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0895063E038C6B6ED45AD840F24B2C5D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_DC6D921AF0B23B4CCFD0D840F252DADE" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_CA86132F0392F86D3125D840F2521282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_AvailableForSaleSecurities_9CE788D8C52626932DB1D840F252BBB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_15EE964624BF28A35D68D840F2521D75" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_DCFA2A9CA81281C6CEEBD840F252E338" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_1768255F7BC6D740F507D840F26278A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_A7AEB330E969800ADF50D840F26228D4" xlink:type="arc" />
    <link:loc xlink:href="mgnx-20171231.xsd#mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock" xlink:label="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:to="loc_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock_45DCE49C4DAD5C21F206D840F262FBB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_55A871EEFA21F2DA6900D840F263C5A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_BED90A7B753F9AECB3EAD840F262430D" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2BDF170A1142EF8975E4D840F2639B3F" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit103image1a02.jpg
<TEXT>
begin 644 exhibit103image1a02.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" "\ 5$# 2(  A$! Q$!_\0
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MBB@ HHHH **** $;E:P/'_CKP[\-?"%]XT\5ZFEK8V,)DDD=L;NF%7U9B0H
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MW7@CP=H?@#POI_@WPU9BWL=-MUAMX]O8=STRQ.23W))K8HHJ "BBB@ HHHH
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MT7ZFOJFJ]K!!:0I;P0"-(U"JJC@ =JL9QUI2?, 4444@"BBB@ HHHH ****
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M ))CKQ_ZCO\ [1CKZ(EF2&%II6PJKEJ^=_\ @G%_R337A_U'O_:,==Q^U_\
M$'_A7_P/U:XMY=MUJB_V=:_*>6E!#<CH1&'8'IE17[UP)F=')O"?"XVJ]*=%
MR^YRM^)^9<3X.KF''%;#4_BG42^^VIXCXL_X*)?$&'Q)?1>#_#&BOI<=TZV$
MEY!,97C!^5FVR#DCG&!C..>I]9_9._:9U/X\IJFF^*K'3[74M/97CCLV*K+$
M<@D*S,QVD<G./G4<=_EOX"_!"Z^,.E^*[J&-F.BZ"TEBL,@5GO"=T*#( (81
MR*<GC(I_[*7Q%/PW^-FDZI+<>79WS_8;[+A%\N0[023T"OM8\_PU^*\,>(G&
MV&XAP.-S>O)X/%2DE%V44N;E[=':VNQ^BYUPEPU7RG%8?+Z:6(H1BVTVV]+]
M[:J]^Q^A#%E&*\?^/W[6O@_X)S'0+:Q;5-:*JWV&.38D:G^)WP<?0 D^W6O2
M/'/BNT\(^#M2\57DJK#8V<DS.5+=%ST'6OSBGN?$7Q3\?&XNWDN=2UK4/FQN
MD;<[=!DEB #P,\ 8K]<\6./L?PKA:&"RRWUG$/W6^BNE=+JVW9'P? _"^%SV
MM5Q&-O[&DKNVEWVOV2U9Z]>_\%#/C1-<++;Z'H,,:L2(UM92&7T.9/Y8KU']
MFS]M*]^+'BJ/P'XU\.6MG?7"LUK=6+,(W(_@*L6(..^X].@KN/AU^RO\&?!W
MA:UT6]\!:7JERD?^D7VI6,<TLK]SEE.!GHHX%3Z1^R[\)O#_ ,1K?XF>'- _
ML^\MHV5;6SQ';ECQOV <$#^[@'N#7#D/#7BS@L9A\;BLSC5BW'GI-;1>^MK-
MI=CIS3..!<5AZM"C@G3DDU":>[6UU?9];W.(_:J_:J\9_ WQA8^&O"6@Z;<?
M:+'SYYM021OXB H"NOIGOUKRW_AXM\92,?\ "*^&S_VZS_\ QZC_ (*(\?%K
M31C_ )@R_P#HQJ]*_8\^%_PI\3? 73M9\6> M$OKN2XN5DN;[38Y)& F< $L
MI)P/>OD<9FG'?$/B/C<GR_,WAX4TY*Z322LK;=;WW/=PV#X8RG@["YCC,&JT
MINSU:=W=WWMT.:\ ?\%&)IKR&R^)'@F..&1L37VDS-^['KY3DD\XS\^<<\]#
M]-Z)KNF^(M'M_$.C7*W%G>6Z36LRGY71AD,/P-?G[^TWH_@WP[\<M=T?P$EO
M'IT5S'B&S8>7%*8U,B+@G&'W?+P%.5 &,5]0?LY^)9OA]^Q?:>+[ZQ9SI^FW
M]TL/W6=1/,ZC)SUZ@^_XU[/AKQWQ%6S['9/G%95HX:,Y>T77DDHO5;I[H\_C
M+AO**>587,<NINFZSBN1O^:-U:^S5K/H7OC_ /M?^#/@S=MX7TZS;5M<5 SV
ML4VV.W!Z>8_.#CD* 3C&< @UX7?_ /!0OXT74@:VT?0[902<1VKG(SWW.?S&
M*\E\.Z7K/Q5^(UKI=U>[KW7=4"S7,B\!Y7RSX'N3T&*^^/!7[/'P@\$Z%%HF
MF> =-FV0".:ZNK-))K@=S(Y7+$GMT'8 <5Y63YQXC>*688BOEV,6$PM.5E97
MOV3ZM]6]NAZ&88#A'@G#4:6,P_UBO-7=W9+_ ('1=[7/G_P1_P %&/$RZJL7
MQ"\&64EF6 DFTG>DD:]VVNQ#?3*U]0>!?&_AKXB^&K?Q9X3U%;BTNDW(R]5]
M58=B.XKY2_;D^ ?A7X?/I_CKP/I,=A;WDS0WEC;Q;8D?&0ZC.%STV@<GFMG_
M ()S>-=3^UZWX#N+C=:K&EU;H[DE&)VL%&=H'<X YZUZO"'%W%V1\</ACB"J
MJW-\$[:[77;1[6Z,X,^R+(,SX96=Y33=.WQ0Z+6S^:?WH?\ MN_%>#]DCP7K
M7CW13')XL\87LEKH+R1L?L<>W,LP(!Y&00,KDLO7:17P%^S]\ OBC^UY\6?^
M$8\/32S32O\ :-<UV^W/':1%N9'/\3GD*F06([ ,P]^_X+/:\+WXX^'-#@O6
M:.S\.YD@W?*KM*QSCU*X_"O9O^"./P_L=!^ >J>/9;6$W>N:W(%NE4>9Y,0\
MM8RV/NAP[ = 7)[UZ.<4:G&7B'_9M>3]A1WBNMDG^+T/9RFI'A#P_694(KV]
M9Z2?2[:7W)7L;G@+_@D;^RQX<T=;/QE8ZMXBO#AI+RZU26#!P,A4@**%R,C.
MXC.,FN5^,/\ P1K^$^OVEQ?_  ;\9:EH%ZVWR;*^D^U6G"\CYOWH+''S;V Y
M^4UZ1^U/_P %$OAQ^RM\1;?X=>(?!>L:M=S::EVTVGM$J1!G<!3O8$MA-WI@
MCOG'FC_\%J?@Z[!3\(/$W7/^NMS_ .SU]%F5/POPW-@,4J<)1T=D[KY]SYS+
MY>)F)<<?AG4DIZIW33^3=K?(][_8N^#'B[X ?L[Z+\+O&][:S:EISW/G?89F
MDA7?<2.H0L%.-K ]!R3Q7R?\;O\ @KE\</ 'Q=\1>"?"'P]\,'3](U6:S@;4
MH;B29O+;:68I,@Y()P%X''/4_:WP ^,_A_\ :$^$^E_%[POI=Y9V6K1R&.UO
MU02QLDKQ,#L9A]Y"1SR,9P<@?CU^TV ?VB/'&X?\S5??^CVKCX]SC%</\/X/
M^R*SC"3LFM;Q45;5H[> \IPN?Y_BUFU%3DE=IZ6DY:Z(^A6_X+/_ +2;C!^'
MW@O_ , [O_Y(KZ+_ .">W[=?Q$_:W\1^(/#7Q \(Z/8OI-G'<P7&CK+&KAFV
ME&61W^N<CZ5/\)-,_P""<#?"OPR?$UI\'?[2.@VAO_MPTSSO.\E=^_=\V_=G
M.><YS7MOP8\-? /2]#GUGX :+X5@TZ\EVSW7A.&W$,SKQ@M -K$?4XKTN&\O
MXH^O4JV(S6-:%KN"LVTU^ET>;Q#F'#3P-2AALLE1J7LIMO2S_5)GS%^V_P#\
M%)OBK^S=\;IOA1X"\$Z#<0V=C#-/=:NLTC2-(N[Y1'(@4 <?Q9Z\=*K?L;_\
M%2O&/QN^,%G\*OBWX1T73QJRLFEWVDK+&HG"EMCB61^&4'!!&",<[N/GK_@K
M!D_MD:OD_P#,)L?_ $2*\J^,'PY\1?LX_%:WLM+O9(FMUM=4T&^#;F*,%EB?
M=L4%U. < J&7'-? YEQEQ/E_$]>HJKEAZ57E<=+6;>FU]D^NY]UEG!_#.8<,
MX>FZ26(K4N92N[\UEKO;=K2VUS]C?C#XVOOAW\)?$GQ TVVCFN-%T&[OX89@
M=CM%"\BJ<$'!*XX-?*O[#7_!1SXP_M,?'./X7>.O!GARTLY-)N+I9])AG219
M$*XSYDK@J02,8SR.< @^I3?&K3OV@O\ @GOXB^)U@FV2^\ ZFMY#N)\JX2UE
M25,D#.'# -CGK7Q7_P $D&S^V#:E3_S+M[S_ -\5]UGW$6.7$>5PP=5JE6LV
ME:TDVM[^I\/D>0X.7#^:3Q=).K0T3=[Q:3OMYH^SO^"@G[6OCW]DSP%H?B3P
M%H6E7UUJFK&UE&K1R-&L8B=N!&Z'<2!SG&,\<C%'_@G;^V/\1?VN-+\477Q
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MACZ69ISYES4G;1)ZKYK8]SBB/#60UIX"IEC45'W:J;NY-:/L[/S^1Z%Y[_\
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M(W'GL.W_ ."?VLV7A[X->*=;U*?R[>SU.2>>3!.U%MT8GCV%?-^H3ZW\;_C
MSH^+SQ%K06/S&9UA$CX';.U0?P Z<5YG$&=5J/A#E&3X?^)B4E9?RJ3_ #=D
M>AE.7PJ>(&.S"M\%!MW\VOT5V>Y_LE?'CX"_!SX5OI'BGQ-)#JVH:A+<7\?]
MFS/L_@10R1D$;$#=3@NU> ?$>;PR?B'JU[X#OEFTJ34&FT^2.U,(6-CO5 C
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M&[Y37,_%KX4^"?C5X&O?AU\0M'6^TO4(PLT>XJR,#E75ARK \@_@<@D5^?\
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MI9%PF<X^5AGDUM^"O OAKX?>'H?"WA'3%L[&%F,,"LS!222>6))Y/K6P00W
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MQ+XFNE:9LK8V*M^\N9,?= ]!QD]!7YU_$GXC^/?V@/B*VNZJ)KR_OIA#I]C
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit103image2a02.gif
<TEXT>
begin 644 exhibit103image2a02.gif
M1TE&.#EA*@'3 /<           $! 2<IE"8IE28IE"8IE2@JE2@JE"HLE"HL
ME2HME2HME2HNE"PNEBTNF"TOF"TOF"TOF"TOER\PF# PF2\PFC$PG#$PG#$P
MG#$PG#$PG#$PG#$PG#$PG#$PG# QES QES$QG# QF"TQDS REC$SFC$SF3$S
MF#(TG#(TG#,UF30VFC4WFS8XG#<YG3@ZG3D[G3H\G3T^GSX_H#4_D#(_BC]
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M@-L23 "#'^<,="I!=@]T3R[G&73/&B&88/2O#"#13$+/"*$ WVH@%,4 -FO
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MH !*V)54&?(/;?BT'&!%1SW;PHD?_  (9D5*#G(@@QQ4X1A;G58XMD!#%%A
M#$Z-ZT*Z&M9UP,,<Q--0-;#0 @H@+6DBV%3A5E"&:ZQ3KVTYAQY8@((1@*
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MR*>&J-8 *V &M?!8R1 )6] ""5  .5!)#C$**V!H=M0""]00S2 $)D  I:,
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ML8^?>(4PJL&.>=0Q.!"1H3\<> YIX"(3B;C&;O*1"T)L008H"$$(1G "BX0
M<9P!92A!*0(35,!1*%C!"DJP@AK4P AQR(0TNFC'M."C'<EXA24JP<<^A@(8
MW$@DW>+^\PY>[&$(?A)EXB9  A(T@$ ,R!T"I#E-:$*S 228@+(LQZP0H,";
MWT2!#<0Y3G'RH =AZ 0WJD7+E-R#'<1(Q28LL0EY?L(78=H?.6JQ!A@@($TE
M<$ R1XE)RY4 E3>"@0RN% ,8L& %*# H"% P LN!H)O@1$$-R#E.'IBS!Q_M
M01""T(,K0.(9HF-G0N[!C5U\XA/RM,0G<%$-0^KO&I&@PGB2HK@0@"!53RO
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%+1(0 #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>form10k2017adcc.jpg
<TEXT>
begin 644 form10k2017adcc.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#R17AI9@  34T *@    @ ! $[  (
M   -   (2H=I  0    !   (6)R=  $    :   0T.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $IO:&XN4V-A
M;&QO;@    60 P "    %   $*:0!  "    %   $+J2D0 "     S(V  "2
MD@ "     S(V  #J'  '   (#   ")H     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_P"%U>(O^?+2_P#OU)_\<KSRDS1[6?</['R__GTCT3_A=7B+_GRTO_OU)_\
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M$2[41>BBNVE1Y'S7N?GN<9S];I>P47%IZ_(GHHHKI/E@HHHH **** "C%%%
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MQ'Q9\27GACP3]JT^\ALI9[J&W:XEB\WRD=L.P3^(@9.#[T >>Z=8^"];\9:
M-.U.:Z;74:2]TW3[O=:HR S$,A&X(7SQD<]J]Y'2O+/A78P'6+V]L]6\,ZS;
MB(*+K3+%8+@,3SO"\ ''XUZG0 4444 %%%% !1110 4444 %%%%  1D8/2O)
MM1MO^%8>+3.OR>$]:F"[5^[I]TQZ^T;_ *&O6:I:QI%EKND7.F:G L]K<QF.
M1&&<@]_J.H-14IJI'ED5&3B[H\]\9:#>/-;^)O#2J-<TX<*3\MW!_'"WJ",X
M]ZXK2[FVTK4[&?1U;_A&O$A:33XR.;*X7)EA([#()'XUUMII7Q%\.Z?)HEG8
M6.LQ1$QV.ISWIC98_P"'S4VDE@/0\XK&\1^&#X0TGX?:/)/]HFAU&=YI0,!I
M'C=FQ[9)Q7DU\,Y82I3JZI)M?([:56U:,H!*TFA>/M US3W,4EY>)IU[&O2X
MB<';N]U(R#2+,_B+XB^(-8U!B[:;>/IME$3\L")C<1[L><TNO_\ (2\,_P#8
M=M?_ &:H_#W_ "'?%W_8P77\Q7@^VJ?V)OUM\CTO9Q^O[=+E#5Y[?6-0O?[3
M++X:\.JMQJH'6[EZQVZCN"<9_ 5V/@W1+R:[F\5>)8D35KY0L%N/NV%L/N0K
MZ''+>]<_X:\-?\)?8_$/1TF\B6>[@,,O4)(L892?;(&:V[O3_B/KNE1Z)/IM
MEI#2XBO-5BO=X\OHQB0#(8C/7I7NX;#.&#ITZ*LFDV>;6J\U>4I]-AMO;'XG
M>+#"/F\)Z/,1<9^[J-PO11ZHAZ^IKUA5"J%4  #  [50T+1+'P[HEMI6E0B&
MUMD"(H_4GU)/)-:%>M3IJG'E1Q2DY.["O&M \4>.?%/BS78K/7M'L++2]6>S
M%O<6^9)$5NQSZ<?6O9:\L\!_#6&W\0>*-1\4Z':R37&M27-A/*JNWEDY!![<
M\UH2=#-\4/#T/BI] 5KN>YBG2WFF@MF>&&1N%5G' .>*T_&_BJ#P7X-U#7KF
M,RK:QY6,?QN3A1^9%</X0TCQ3X,\0Z[IG]@#4+75M6-[%J(G542-V&[?GYMR
MCH .?:K'B?X.Q:CX2UNQT[6-4GNK^(>4M_>-+$CAPXX/3D8S0!B:EXB^*'AO
MPM'XWU6ZTJYT_:DUSH\<!4Q1.1]U^I89'7CZUUVI_&#PQI-Q;V]R;R2YN+&*
M_BAM[8R,\;\C&.X )/M7(ZW:_$3Q;X!B\%3^&8]/F=([>]U.2Z4PF-2/F0#D
MDXZ=JJ7(O?#'Q\BM]"T=M8-EX4C@\A9%1PBOM##=P>0H(]": .A\1?'/2=.L
M?#]]HMM-J-IJTX5W$+9C0$A@,=7!'W:-%^)4&I^-=;O/[4NTTC3]*^TOIEQI
MYBDCV\M(">3QGBN9M_AQXHT?X?\ AYQIZW6H6.OG5KFQ@E&41C]Q">"16_J_
MA/7]6\8>*=673&ABU3PS]C@5Y5SYY!^0X/7GKTH T8OCUX'EEC3[5=HLL/F1
M2-:-ME.!\BG^)LG&!WXJ'Q!\3=.UWX8ZEK7AG6;C27LKE()Y9;/=+ VX J8S
MZYK/LO .KQ6WPN2338_^)$&.HC<O[HF,<^_S>G>LW7_AYXCO-!^(=O:Z>&DU
MC58;BR7S%'FHI!)Z\?C0!V^I_%?0/#NI6^EZO_:!N)#%&)ULF\N1W4$8;IDY
MZ"IM5^*_AO2-4NK.Y:[D6QD6*\NX;9G@M7;HKN. >?PKF=3T3Q/>_$S3=0U+
MP_+J&AZ-;(MC!%<Q -<$#=,RLPY7D#Z USO_  K#4+;6?$EGK6DZUJEGJM\]
MS;OIVHK%#(K\[9E+#!!QS@_I0!Z'XM^*OAWPW=/IDMQ<2WK6AN,VL!E6%"/E
M=R/NCH<U)\(=9O\ Q!\,-+U+5[EKJ[G#EY6 RV'('3VKD6\*^)/"WCK7;K1M
M!&K6.N:;%:P,UPH^RLB!-KEOX<<Y&<UV/PFT'4/#7PUTS2M9@$%Y '$D88'&
M7)'(]C0!V=%%% !1110 5POQ/N=>73["S\-R10374DI>:6V$X CA>0+M/&6*
MXS7=5R7C1O$-GJ.C:KX?LY=3M[.27[9IT$PB>8,FU6!;@[3DX/KGM0!RWP.U
M2XU>TUB>YDL;G;)"JW-G8+;!B8]S*< ;BK'!_P#KUZM7&?#RUUU!K5[KUDVF
M17][Y]GI[RB1K9-B@@D<#+ G ]:[.@ HHHH **** "BBB@ HHHH **** "BB
MB@ KS#XO?\ASP9_V$I/_ $2U>GUYA\7O^0YX+_["4G_HEJYL7_N\_1_D;4/X
ML?5&!K:&35_#*+U.NVWZ;C4/A[_D.>+O^Q@NOYBK6J_\A[PM_P!ARW_D]5?#
MW_(=\7?]C!=?S%?&?\R3_MX][_F/^1T?P?\ ^0YXT_["4?\ Z*%>HUY=\'_^
M0YXT_P"PE'_Z*%>HU]GA/]WI^B_(\&O_ !9>K"BBBNDQ"N#\9?%G1_!7BS3M
M"U"VN)I;T(S318V0*S[06S[UWA. 2>@KYHU&RU[XB2>.-7T[P^NI6E[+]CLK
MPW2QFW6W.054C)R>?>@#Z3>XAC*B25$+ E0S 9QUK)\0^+-'\,^'Y-:U2Z L
M8V53)$-^22 , =>37AUSJ5O\1)?A*VJ%I1<M=6]ZH<J79$57!(YYV\^H-9&M
MZ)9V_@#XDZ;;6N;+1M=B>SAR6%LI(#;?08S0!] S^*L>(-*T^PL'O;>_1G>[
MBE7;;X&1N&<\UC^ _$>B^,_.\3#3;>PU/SI=-$CNK2R1HPX!P#@GG%>>V.F^
M%;3XJ?#^]\%P6L=M>07/FR6V=LC*F#GZ'->;V[>&Q\-[_P AF'C3^WLZ=L+>
M: 91C9_L\-G'?\* /KV:[MK8J+B>*(M]T.X7/YTZ6XA@CWSRQQIG 9V 'YU\
M]W\GAV7XA>,$^++Q^?':1?V6ET256/R^3%VW;L=.<UD6DN;7X;Q_$Z27_A'V
MM;EG^V,VQGW-Y7F?\!VXSVH ]U\+>-[?Q)J>O6A@%I_9&HM8!WE!$Y SD=.O
MIS73^;$9O*\Q/,QNV9&<>N*^9=&T"WUSX?>/I?#&_&F:Z-1TMFSNVQKN7&>>
M4SC//2N_^#EW)XU\2:_X_N(V1;H16%HK]51%!?'L6- 'KU%%% !1110 4444
M %%%% !7F?B/Q5\0-#\2&&U\-1:CIK7I\JXCF"*8#&<!R>4(<9+$8QQWKTRN
M0^)FA7_B#PD+73(OM+1W<,\UIYOEBZB5LO%N]QZ\4 6_!^N:QKMO<SZO::=;
M(K 0_8;X7.>N0Q  !''YUTE><_#_ $"^LO%FHZI%X<C\,:1-:QPQV"R*6ED5
MB3*57Y5.#CWKT:@ HHHH **** "BBB@ HHHH **** "BBB@ KR3XYW-S9W'A
M*>RA2>=-1D*1R/M5OW3=3@XKUNO)/CCDW_A!>WVZ8_E":SJI.G)/L1.I*G%S
MCNM3C+;7-9U'Q=X7AU+3;6VA_MF!M\5P7;.&P,;159-;UG3_ !3XJBTW3K6Y
MB.MW+%Y;@H<[NF-IJW;_ /(V^&/^PS!_)JK1?\C1XI_[#EUV_P!JO&]A1^I<
MG*N6^VIP?VMBOJ_UJ_O7M\CN/@5<W-W<^+I[V%()WU&/?'&^Y5_=#H<#->NU
MY'\"_P#CZ\7?]A%/_10KURO8HI*G%+L=\*DJD5.6[U"BBBM2P(SUJ*WM;>UA
M\JUACACR3LC4*,GV%2T4 5(M*T^$QF&RMXS$Q:/;$!L)ZD>A-/\ L%IMG7[+
M#MN#F8;!^\/^UZ_C5BB@"I!I=A;+"+>RMXA "(MD8'EYZX]*:-%TM9HYETZU
M$D1)C<0KE"3DX...:NT4 5+O2=.OY$DOK&WN'C^XTL08K],TZZTZROH%AO;2
M&XB4@JDL88 _0U9HH SK[2(Y](OK.P*6,EW"T?G11C*DKM#8[D?TJGX+\*VW
M@OPE9:%9R&5+93NE9<&1B<EB/<FMVB@ HHHH **** "BBB@ HHHH *BNVE2S
MF:V"M,L;&,-T+8XS[9J6B@#P'5/B[J6LZ-I]K->)HMS<20RS-I+F>=(\LKH4
M*_*X8 XY^7/ISZ_X&U6\UKP/I>H:G&\=W-#^]WIL+$$C=M[9QG'O7DOCBY@T
M;XEW]MJ^I7'AS3IHXY[6+1;-3<:FQR')< D,#QCCBO9?#>HC5= M;H6=Y9!E
MP(;Y=LR@< L,GDCG\: -2BBB@ HHHH **** "BBB@ HHHH **Q-4\10VF8K;
M$LPX)_A6L :]J2L6%R3ST(&* .ZKS[XM^%[KQ!HUA=Z7-"E]I=SY\4<S;5F!
M4JR9[$@\5HKXIOA&0R1,<?>P:RKBZGNY/,N9&D;W/2AJZLR9)25F>?>&]+O[
MOQ1IFJ>)(X]!TS2KG[0XN90TEQ(%.T*%SP">34FJ^'=57Q%J^J>$K:/Q!I6I
M71N@;>=5DMI'^\KAL<9!(-:WBW2[G4+.*2UR_DDEHA_$#W'N*S_">FW\<=RY
MEN+.*0+C;C#D9Z@^G]:R]A#DY+:&'U6E[+V5M#K/AMIS>"=)U"7698YM2U2Z
M^TRP6QW+ -H"INZ$@#D^]=Q;>)K&=L.6A/\ MCC\Q7GXBU&(86>";_?0J3^(
M_P *7[1>(/WUGO\ >&0']#BM4DE9&\4HI)'JD4T4Z[H9%=?53FGUYII?B4:5
M=!Y([B*,\.KQG!_$9%=W8Z[I>HQJUG?029[!QD?A04:%%&110 4444 %%%%
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MVE)#M=I=8U+:5LEXR%7J6/Y<5Z+5/5=)L-;T]['5[2*\M7(+0S+N5L'(X^M
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MO"R7>HWNI6D[PW-W:K;2IG"2A6R">^<9'T-8&G>"CILS7,]M:Q1D%72-5_>
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@!&&88_E6I110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>form10k2017dart.jpg
<TEXT>
begin 644 form10k2017dart.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X )D%D
M;V)E &3      0, %00#!@H-   U%@  TOL  0WC  %*(O_; (0  0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0(" @(" @("
M @(" P,# P,# P,# P$! 0$! 0$" 0$" @(! @(# P,# P,# P,# P,# P,#
M P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#_\( $0@!.@*\ P$1
M  (1 0,1 ?_$ 3\  0 # 0 # 0$!           '" D&! 4* P(! 0$  @,!
M 0$!            !@<$!0@) P(!$   !@$" @D"!@$$ P$    " P0%!@<!
M  A -1 @,!(3%#0V-Q$54#$S%A<X(6" H#)P(B,8$0 !! $"! ,#" 8$"08(
M#P$" 0,$!081$@ A$P<Q(A1!(Q40,%$R0K46=B! 83,D=5*RM AQ@6)R0S1T
M)1>14W.&ML9@L8+31#4FEE!P@*'ADJ)C@Y.S5-4G-Q@2  $! P8'"PD' P4!
M 0    $" !$#$"$Q01($0%%A<;$R$S"!D:'!T7*R,W,44/#A(D)28B-T(/&"
M)#0%%<+2)8"@DD-CHE03 0 ! P(#" ,!  ,! 0    $1 "$Q05$087$@,$#P
M@9&AL5#!T>%@@/&@</_:  P# 0 "$0,1   !W\
M
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M?(=[^:;HTD_/Z   \(^5*:QKU/2--<WI]CIWR[>'"_G]1!M\'3F/[31G^?T
M>D/7G2E#2^)_A^AQ!V! )_A8H  X$[4B4X M">*?V<2?F0@263,  5B*.4U.
M;^1?;8TVW#+MR_256X&Z2M954QSG[!H_Z%>D*K[\  &#4;VL[>=?4/0:_)I'
MZ$\RV(FL?ME1U@31KLK,>_*YW!V&,  (7,.Y?HKV[C SFBNZTOT6QP-Z,I^3
M9Y%8^I>R/JVI^PY9  !@_L,3//J2C?<['#[7FBZ=$HION?G,<FS+^%4H')=[
M<3[@"A92,T0,_2/SJ"!CMS2\K"2X:7@ &3)4<UJ,_B.R*COBP9YIPQIT3^
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M>L=:41I3Q;?5YZ LJ@?2E4[9]>TC84_@^<FN)3>_S\Z7X_;X4/\ HIR]'O\
M&P]*SSA\GY9^7E7VZ&?C@   "M)C!*=-?;?:RANFV%WHCO,.+RK"3+6@<7UE
M-OIVH2U;4 ^9N0Z>"NH*1\?X_2W7+EX^/B9-V)Q'/7?G]5A@TC^@;%^P
M&4!J^ 0&?.?\OU](_P!?S[H^?$V6/-,4SZ3#VP,X"[Y(      !D/\?W,M'S
M^QVIS<9[=A4U;[7^V\[NGY>B6ZSN[RYR^D*W83C_ *[)]=YW=03#$=UG5W=S
MK9:UX9=2CK E[ R<:KD@WT&2?4^T     ,J_U_((F\=L9G8V<D4W=LM3F92=
M/TCVDBU'A<\VY]8-?2[*S[?+&GIZDNVDFF]9SW;FEU?RSS9S')FROCG)#]]]
M'&HSNC     ,H#5\ ^<:F)Y>KA[H.F_?O-<N3F/0+%MO>B<Q_$2SH3[2XJ[T
M)YDNS>O69HS@+OD@      '^'S]:;.UBI&?>K_?\S*O&OXNA$@OOY_=+17)]
M1,OI)RKFKRE<NDG+=OT%Z2JJVG7U(?M3LXOQ%=OD]8D9UPLF+3J      ?/M
ME?&T<YC?F?U3:#R*-]OKH2Z>I+P<;[:Z\C] 8U6W .XNVLXPK.:[/4':U9Y?
MHKL;C H1H=GM!%MS98     &4!J^ ?/72%@W8X=Z#RNZQIC4J9:"W^@V/RT7
MW7/@].TK+<]BMSN3K[^@#4; 9P%WR0       <,84P??[%U5,,N9IHK 6S#8
M?\X^II"C^R\GT\Y'H)QO>FCW.UH55]$N8/UV^!J[34YI))-7(5SP71W]?P
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MS2-"R7@         #. @KS8ZLZS59GJ/3SD>G7%E]Z$4#9-9?1?ES=:=1X
M        4@/G7ZBH[L9!J=4>/>A\4KPK&9+8@5DN8[L^CR)[\
M5))X(>)P.O           !G 05YL=6=9JLSU'IYR/3KBR^]"*!LFM?HYRSNA
M-="          *0'SK]14=U^_P!5JSQ]T-B9>%8S);$"LES'=GT>1/?@
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M"$"%M@           0X<V6'..*ZEN3^@          1R>B)+(9)F/\/[/;
M                                      &?1PI48\LC8YPF(WW
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ME3IC] >.>0         97%.C0D_4Y [$C(S)-6B/3PR="S1G>>W-6#V
M !E<58+NGNB,B6B'C.\T*/0GYEA"Q1GD>V-03I0     97%2"^IYYP!(Q%!F
MX:7'+GH3V!,9[,G0IV=D:3@      RH/'*R$T$7DVDV$&'KSNSVI2P^@<Q^(
MR-L3I0     #*@Z0H\6:*W%J21CCR&"63WQ30WW,JR"S9 D@     &5!YQ4(
ML 0<6,)8(N(_)3/:D?'"G\FM)DD2*:\       CLD0CLD0   $9DF
M $=DB$=DB    C,DP       $=DB$=DB               RC.I)X../<GJ"
M*"_ACL2Z20:4@        S3.8+.'$GDGX$7&AIB*6)(\-FSR      0J92EX
MS^STYV1"Q*A9 SI.J)&)P.#.+.G(L/2'/'.DQ&BX      ,\R'RH9/1Z8J,7
M^+K&<Q_)WQL2        "EY4,@,DLYXJF:!FAYCL>Q)@-:#J      #%HJX:
M*&1Q:HZ$[HN*9NFAA7<D@H03^>$6&*W'7'4'L#5L        @$CTN   5^+
M@         $(D.ET  "OQ8$       'XF<QH,>Y      /6$2$W
M
M                      __V@ ( 0$  04"_P!AN<X#A9=U2(%C:Z-KRB[1
MYLZNH\M:7EH?D7:N-U5.TK&AZ9Y A[1\L> 1E6RR!BDB+\*W.RU_?)0@HRN$
M:%E<W3;3.T2Q*XH^RW(V\YL>H_0,,2-Z@MUVXRL@XI23V>[>Q7EM FAK$03
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M"4:Y$=^CLJ^+(IZC6U7YSXAXJ^N9 N4;<:V.DR>G*H2G8Q@..(W8?"4"]C2
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M8:HXHH!)8QX!C"G_ #^#(A8$1I8G\,6,YQEF<L."?4B:_"'UT20U<H3)RTI
MQ@+ Z. W%2  C!$E!)!H[.!&]=1C/?T09]>AT1>5-TSKOKV!YP$Y2@\:DW&,
MBRW(\)"<YQC!@\C%HO&< _!2#LDC"+ PB#@83BLDC1+#$*A.H+5$F%@- YH!
MMZGJXQG.69LPWI]2)T\06DB?P0Z6J/IV(P8&'.,ASC/TT6/OA/) H*4$#3&X
MSD.6]9A83UG1=YHW3.AZ#S.]G1!?U_"$:CP\Z4$X/!G&0Y87/R9VG1O XIC
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M!G>P,(1A6I!)#M-2WS)6AB" *Y6)8=IJ0^7+SG <#'D8M$E]S' 1]$4L69
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M1K0H:TFAK*J"UDT,+Q"JI&,8F3'@SH4&,*('H4'%C"/9F=)QCT5_:<*6>O\
M4KULF3SKD\! /RTZV4XMZO+FDM*[0R;%%->XN+.+/#/K8PHFJ6,)=(:TFD,\
M]J*?/+]O9H[!/&<?-)XN+^'GYI+(U9+9H\D;->H9'>U4UDTMX>,?RRSP''SR
M&$>U$Z3EYC6QAQ Y8+C]G^0CB8:G]W-)8A_JET9!CYLN9GEMLNBJ2;7+/-.Y
M/&M(]GBAK2.W31ER2"*FBO*&$1$Z#]GPL+M#3D'IT23]BFGF9PH:P*9,C.'D
MG9JUQ)M4:PID\)&/ST";*GG$GCX ^8G6RC'O:,WV+![!,ZCR9RP0B9(#*O$7
M5''D95XBZQXLC? *6<*&MJH:VK=+8HDLG5D\5#U#3GQ[^F3P\3LE49#Z?L;0
MZ]0RL5KG46$*'K%A"1]Y9];/+.%+.& OJPFTFEK0IDMI[,LF-"+HB2PCHIK&
M(LXM;A_IET9,G-DD$&$'Q%%A 136<9DV<+]*BC*<?-DSM832UA,CAV8W5Q;)
M)9-+%"YTEMF=2HY)-E$[9/&/.F0K7,D-;]BH9)-M$[97$&>:&?(\ZV DQ@^&
M@/=C-3;-0!1BJ8PX?9$6AO\ I:RAGI+S((,*9:J\C6T+4]DQO>&!VO9K:TFA
MK"J"U@M:/8*F5S[S!29TEHD*)19)S$4&2)>CVC[(R5GAD\! /S%:V08M_1GD
MM*[0R;%&_P V[N9QI9XI9];6/;JSL4+F4&$5&L)$01JJIWI/$1.R31E/HDLC
M5DMFC K'OH(Y>22"L:[B-#N5G>V:9"ZLL1B '+RR(AXDC!-DO5,CS2^2#W89
M?0.B2)WG()(W38/DF[0X#:&M]B)GY!+#S'DDA[_6+%TF1G8%"BU!8X*^)C%B
M%R$AY95^BZGLC1YXY+(URSV\0CM44YO.=D0\:A@UE0M-ZU$D'NPR^@=$D3O.
M021NFUI-+3I]9K:Z<">)FFIDB9^02PQD,D/?ZQ9Q:8S,X8)"N4 TI2I>=U&]
M7E8(30&M*H#%7FZ3X6MI[!Q4-#N/"8/=AE] Z)(G><@DC=/"(F?D$J.C)#W^
ML<'MJUS)L4T"F1XH,EDTC"8/=AE] Z)(G><@DC=/"(F?DE1T9(>_UC@SSJ"1
M_M5,C;:ZT6N%_')X0]I9>SBSPSQA$'NPR^@=$BS_ .IZJ9(W3PB)TI4=&2'O
M]8X+9326L!GEO$Q/TL+C-7.>!H4?$2GAG&@R*C0Z4'0PO,.NF2R:#A$'NPR^
M@=$B^^/53)&Z>$1.E*CHR0]_K'!=L=Z38)I-+)N\.@<9K++QI<KCYFM&@,5F
MDEO#&>&O2SJI,N#P>[#+Z!T2+[X]5,D;IX1$Z4J.C)#S<IP79+F+/?.UI5):
M%%QH'#7QM%VFILU:&B%--F0Q*DIT^9;*SJVGIP>!W2>J&7T#HD7WQZJ9(W3P
MB)TI4=&2'FY3A%B&Y4+$>1MDIR(.(5YV<:&?"791B<_E:Q#WSCPJ!W*.J&7T
M#HD7WQZJ9(W>'"(G289Y$=&2'FY3Y6@=RCJAE] Z)%]\>JF2-WATX1$Z3#/(
MCHR0\W*?*T#N4=4-$/P'1(OOCU4R1N\.G"(G289Y$=&2'FY3Y6%UOALJ1,#4
M1R.95WNAMQ5ASZ@*]^14"\=@HO?B/I:VA=M=0'G,RHR]=1)X<(\1=YWTA@N.
M+,('AD"H?:IXVLE-D8RR82:$C_:I_P#_V@ ( 0$!!C\"_P#D&JJJB(B:JJ\D
M1$\55?8B<.0)/<'&1DM.=%T0L ?;;<0MI 4B.CL=% N1>;R^WABRJ+"%:5\D
M=\:=72F)L-\/#<S)CFXRXFOT+\Z===YOB]98-*J/09=W ;EL*GV9$?K]5@OV
M&B<-V5':5]Q7O:HU.K)D>=$-4TW"+\9QQI2'7FFNJ?/.5\[/\:;ELKM=;;L
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MKANO(W&:0?Z;\A41/V(O&,XZIHXM#C]-2JX.JBXM771H.]%71="Z&OZ)HV2
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MWD2>847>R>[<TZ.K3C2HJ+IIK\.I.K9VD_2)%:ALNO%U9"]($;$0W/ODI:
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MN%-RB-71IA&=$#.,NU[]:L>JG(Z\V!R3E.,@8DO2Y[N.X62779<<PKK*XO\
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MZJ3;&N06E@@"(NY#+=RUTV\^(.=8)T;M^ZE^EJEL:NR=K8SL27&:M8]X,:1
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M.C?=<KGA:4+!.G7N;=O(N6GCQ@K%2W,%[-LWH&:F+.B/0IZ([$M6]ST)\1<
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MA'VZ7#SM+1?3@ 3C)%%!B"@BY&@B4N+@BE[E>8-Z\0_JH$;2"VOL8(R-%0*
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M\"=?_8:BU('&U!_S]O"5QZ)I4_P^S;*8D48TO1JLQ4J]@6)&$,BH0 $-I B
M!J62BHPI2M=QYUOCLY/"FHB%8<JI%#X('Q!010SA$!(C58R((AK3 -,FX*H@
MB((D(W$<B:C5_LKKV;"RY5%%12IBF&[S#%[1O(310D%$$)D"H<!MY4)*Z$;)
M19NN]-*L5@[F4N#!XS.J-2 E2U'FN$S<78*$4AM 11BGR KNBF0'\ !M7@!*
MN*(8WFV^L0VB!T@*7<+94"X(L2#ZXIPIA0Z04*C\-YOF94@ EH3U$W#'"BC-
MH:]/F:GR8!1K0.\*H"(S2D!6%FA4FF*U@G#D3CF\!5$?KC+))M*E IP>C,)1
MTUOIC418*Q;> ;P7KV8F5PCK/]<AFZ:65[9O=4'5%))!)A!I\+F2YR&" E!*
MMNWW983N':M:8"N!2D+P<1$:%0I9T(-I(/-)]Z1 <QH>DS'S\3*J($ *$ NJ
MM@"KZ#KRCI/:!D,FN_J^+H%NHU%=2O?S;X G/+X3G*+DL-6YH6&(SH2?^\^%
M&]+$$0U0H$HMO@J\-E2 O;H8Y@N\(!14%#?"X+%1D8,'=K8Q)X>$U$SI,;*1
MS?T+6;6I3*@ _P"@/,B=YO @^* 0$1$21&R(Y&H*:*R1U=Y%,$HPZQ @8 0P
M(28(0#LN0*"#J(+N4[T7Y)B)K'EBL7)S_0V01A*(.GOUAEVD8+(U82BQ>1*&
MR"26&;C7-R.E3 0/@ (U+1I@W-O\7Q4IN,N@,9*!%1DDE)Z%:W=LB#46K %U
M&J9*7!+;> ##Q49 <J#5 TL!3+K*D''*%F[[&?*(9N.+EF%Q3K3[&[N4+=3E
M;E"^F:49@C/B$$ -;7CEO(V-1Q"*J;PU0-^!R! 4I+6K D,;6X]2@=,JDOI(
M0YQ4KAH4U 6$;Y98*5XDB]!S>9N7 H(X10R(FY0VF*(#<8I <>3XUGI5C.32
MV'\2;7 +VP91"?+'&R"J%\"-WB;"7MD9?@5-Q@A,?P"ZSD79X'Y-VPS0RO!Y
M2AXYB(X9QA&2Q3AE>,NT(F44;\U E%+%XHQ.PW!X,E21N(RO)_$Q<O! ^,%G
MM+#M@-EL*FH:L#>(6)6CA27 K!2R-%<HD@CF3(=ZU#L2=EOP-Q&U)Y>\SM J
M,%*6,:[4*'K'7^$]7,9]6,G4 TL%/J4IBTB4HD9]L=8%42H026V[';:7&9#8
ML4P1#)(,\?J8PZ: :C(B",C<3";E#.C&+B.._N0HM0T9UOH<,Q<@*QV9CH^L
MO7R6=*V2T,J'S4AVAZ,#+S;P;FT3LH/:NAYM21Q:A*$QL2.)=P99/^GLGB2,
MD*(\4FM\U3A'(P]N:H%  55@ NJN H;WZ"CVZ,9)<J)P@LC(0WW>TU@I=?2A
M TS!@W "H4G#1[&ULGFB['!71(\@HO9*%;09]6PX=L1<;492?!9<OUD#5F48
M(8%DV,VD<V*F0(P9W+(:]S,,"E(."/(>K(L1*\&#XE],*,<F<DC/8#\\\3\2
M0.3>*7>\-,42MW%5"&<\"($ "QVV_ W$USREA",%%EW58?!&#2-8^^ ;4P(X
M# 1F=>8 ? S%WN@MYH\V(B(H?+L8(A-D%#(BL5"=W''X&D;V$76'H.!$Q 1V
M)CHA)P+,2V(BC,&.'G^U(HN!;VB?K-]%W::R-4U0*)< T0#@_->[JEBCW*<-
M96WAB"FFRJ)<A$I36F% 2T3R0S^M-DE",=J; B>&2NB3,:46W:$'</S#"L4(
ME%D6E ;!$3T[-7 P*6O)PE=P/V^ZB#C$'%O=K:3A9R],M NXHW=K#LS8%NVW
M@\3$8DJ8Y- *;(0N\O"$,3FR00@)4E#W)3%D6>I;%0Z0%0<U792R(_# ^/;?
M@;B:T:[:I YB-32I7ST=/.@8T "6IZ*D2K6$ C8\ MF.M_G^W=-7&1PFV<PX
M,..*)$E!S#,+&2H"-1O"_LQT),F(#.P5;)AL-6]>"UF0IH;8R6T!+C>J+4L_
M/N)+C_Y=4VF(C&\1F(P05:5*R93A<H "()WC7*KAA%_89.$*=E)2J7(D$DK4
M%<T$G$M] KU5<2[(PB:9&UI.$9R;N1-Y-P &L?KJNDC.(83"#3OIE!BI:,N-
M$TL8&ER9I8.&^K?O3?B<1FJ$UHAT.BV0L 2V/PO;?@;B:WJ)R#./QN61D.Z-
M$WP/0 AS:0(1SMD'1)[+K?Y_MWB<M!U#;W4-/G0+GO?V:X"9D"@      @ L
M & [4 FBU,(K0R4%2C?.HA4\J" ('QX[FH +1%0NJYB5!.%F&UM1!H>(6P(!
M'YD*C4$ O\0Q4H$+IBH$HC1IF"$*120*77THP-,R9-B@(E0&DBSI:*TB 3:B
MPAR@@(0(%C,:4!F&^E'JYCF'XEVWX(\I0%97'([T(I-8X?Y-GCVNDX=;_/\
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M;_>FA-<X"$=+%Z\&WK("%>@(D0PP)0)!-HTJ7J/'BPR\&E 8!T# 8DF;SE=
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MAA\1Q-"Q5NX1QQF' A1+:3<L'R"D5X(CL<0QZYV91616CXCK",M6%<I6&(X
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MVW6+8X0IWX'0Z3OMIF:D5DNA!\W])K2+G7GZY_\ E3__V@ , P$  A$#$0
M$
M
M                (      (      !      !
MJ@    !E@     .L     %2    (!(  () ( (     !LZ    (?P     .L
M@   !,?     )   (( !  )    H+QP   "T:2   &9B>    FC^@     !(
M   )  !(  (OJ.(   !ASD  !)@X=    ;,O@ !! (!   ()!!)(  !I^R@
M +ONNH   #*JXP !P4!C    !(      )      -RYP0!#\EVP   !&DA6
M2.\B    !  ! !         !/9?H K)E"    !!I 1 /6I=     ! !/)!(
M       !?3*4'FD8@     ),#<P202\     ! !$PD4         )8,<!VYU
M      !.F]Y"A<(     !  /CVR          _I/+X^\       !X 829N
M !  ! !+?&M          "1/+XK    (   )] 92:8   !( !!)#+L+
M      !/+X    !)    ! 8B0     ! !( !R!D((         !/+X
M    !(8B0        ! N8#KP          !/'X           *8B0
M  "_0!-H          !/-X           *8C          #\7+W<
M  !/-X           *8C0        !$1ABE6           ?-X
M *8C0         ( P_)(          !O-^           *XC0
M)(            !O-V           +HC0           ((            !C
M-V           +HC0          ( )(           )M-           !*PI
M@          ! (!           !(!            )             )!
M                                        !
M                         !        !  !  ((!( (  !(  ( !! ) !
M    !   ! ())    !!)))!)) !)(   ! )) ))!!!)(    !!!  )))
M !( !  )!! !!(    !! ((((( )        (!
M                                (  !!()(      ! !!()!)
M!    !(!(       !)!!((!       ! ( !  ((     !(((! ())
M((   !        !!    (       !!               (( !)
M)   )      !( (  !(!!(        )!)!(         )))(!        ! (
M) )))!        !   (          (  !                !
M
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M7=4/QV.[YRXNU:>$2%,F\\6_<(Z;@&HQM0B$ H%M^C9*;-J84:@)@   @ @
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MU>'P,C2V19-8,UJW^-Z,C(E$+A!TR)-B[0@T.(50OCKTD2CB5R+%'= S#%K
M&8I&0QD,L,'J<U"6%[P3_P!%W WP7KB2HZ4(B"U=LE[KXW[!X8DPSX[Z (!S
M!I$$ ! 4$B$B(V:1_J@I-$F\K%**$T^%+*:2 !VC\+0I]26MOL4MS(BP'"MV
M) D46FX!BFD)+"068( ITM61 'I-C$6$CN)5&::I2.&>,B;0HZZR-[J,"]I2
M=!SPY0  2K8*-F:)@S-T&@,R3*"@>0L<E8.3*T$F&&D+FV<800W9 /\ X8B\
MHE!I;([S@3*.I%*X"MO(6HI.SM20+5L,FC4A1.?U%VBT*!W:6L^:)M!#[ (
M#+B?[4\+DK4)X-FWZ*K\!30U]J9O.64AM9BT@*4AS/,(6GQA45">X$KM$0
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M,5&'WC5@  2_\\&VH(G!\<,T@-AY)U$[)G7_  T2,H;E>6+Z?V/](AP&H=&
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M)!31*VJHZ]"+-$!5F8X3QCA$\$>@MW.H!J;*"%F 4?Q2(14)0F IFY%U0GZ
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MIS$%D:1(@X /@ML2&@4!P+6@4A1"C6IJX+;LHE[B_L-ZG4"8/%X$"B5R$-:
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MF1HH6C)9QGOA',1M *RZ0&PD <R1\BP.W92J+,*[28,IF" 5!U" 0%:?5]!
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MU$N-%A'Q("@Q()V1A"*)G* Z=B-)HHM9E([9!(V4&BJ314\'=216WAUTV]H
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M:40%< R<H][S!NI4Y$]: ^$GPP!8()(-)0(;P+JK>AT7(HG+?*[^P<//=O9
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&_P"5/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>form10k2017image1.jpg
<TEXT>
begin 644 form10k2017image1.jpg
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M  (1 0,1 ?_$ /<  0 " P$!               $!0$#!@(' 0$  P$! 0
M             0(#! 4&$  !! $"!0,# P,% 0$    # 0($!0 1$A @,$ 3
M%!4&(3$B,B,T4#,D<)!!-19%)A$  @$# @(&!@@$ @D$ P   0(# !$$(1(Q
M$T%182(R!1 @,'&!%)&AL<%"4B,S0&)R)-$T4/#Q@I*R0W,5X:)3=&.#LQ(
M 0,# P,%            $4 !(0 082 P4( Q<7"0H$&1$P$  @(! @4$ P$!
M 0$! 0 ! !$A,4%181 P<8&1($"AP?"QT>'Q4'"08/_:  P# 0 "$0,1   !
M^J     &DP0B620  :#<8()8         ^<&#26QY+<HCV3CJ#ABR(A1GU4
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MD9B=?5YVGTOGVN&R8DVC?6)54[Y_UI7%U:?0Y*_V_+LZ6O\ .]YEIMB0
M.,Y?;X;+TO*<PR$Y,F35U>;X]'P9&_-F7F$_FUOO ]2R[^23U8>*ST$6V@
M  'F)^3\/U50G*<F2YORY/1[129]OCJ\[/K_ #&ZT1*3ZEW_  [V-)]$.5O$
MV0    !4Y]GRSD^AC(&3*94Y[IK,G./&E?3<:_<^/D[\_;<>]E2<9SI-Y$E=
M1-@     <OS^M\WQ]769"<PR#*<F0EKRSMN3Z8X;33DUG,3$N$25[$S@
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MRO.A   -)SR/9X.G2   !R!4$(MC24)>G8D H"*3#OP   5Y5(C2Z6)D@
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MZ*4LB 61Z.>+8M#CSZ <J9-A5'0G3@  'D] P#)@R 124#!D \GH&#(!$)8
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M@R*T0"9XMJ[MCA$0C.FYR-;,,KUY*QPU/&1LF4>)K.L@B1,=]FKP^RHN1=[
M(N.77'Y _L=.T)LA2%_/DC'\!@RWA"RT*C5G&>#@GT5,@UD25 BTD&.^6)6$
M:[@_(/\ 'Z=Z_P# BZOZ86(J5B:0L(QKV.:X3_\ @F0OXW3O7?Y&O4!_;A-V
MQ.$N/Y6?\$R"_P#9Z=XO^7U M71K=K>+L)@7*C6/1[>E=_S.FQ-SJL/DE\BX
M3!K] DVNZ5ZG^9TX[-$J8WBC\5^SL)C5TQKL!_:Z/R >%30G1$/>M9"]07D7
M[/33'(JJ>%O1K%:H2C>G1GQO413C5>B,2NR%"?(>$(PCY9"#V,T15,JC=@7*
MDCI6U8YRD#KBM<WE:-[L9'1,A4Y2X(0Q,YIJ*H6NQ,=@?Y'3F5,>1AZ::/"1
M=N>G'C8S%4-9*=@:$RY&KXL?I2!>$C%QV1_Y70EG< +/D:O(KD3AJF?1R>,&
MOJ([)&?^@0BL(CA6$OTL+W5WJN<PD*P;7->[(W\KHU7_ '=AZ:<<[BE^/7%?
M'AP8<'QRXL*=)@2*Z)(^2V+7>V_'GB=3W?F-<NBS(]1_]/H26IJ_!_W0DW)T
M PP!.2CKR2/:87IKT!396PW-LO\ S]=OFU4261$T0GQRK>655PY+&5,-L;V^
M+Y>A*Q^,_N,>J*UR.3DMI;XL TUT984P<L);[:U-=+&6D.%$BV2Y(M'QREMW
M)*6Z"X);-PVOO@,CQSO(&%[E8@D6OB-ZU36T*;*'6<TK'YK^379&?^7)="*2
MNL*Y)LB*"5'&TJ,;(EV 13HC9<.(ZX;BT4YZ1(916<>IGQ16%9(F+[250*FJ
M1 6T 4RE<M@RL*V;Z0X8'-*^[\"#S8FK5B,55Y_0PD+V9!H]KHALC1T"U6M7
M^ES;")"'#GQ)H^$^<"#&:[<W'O8QK7(Y)UU6PGQ90)0.$F0..!EK'=DR6*)&
M"5I0O>QC6N1R=7Y$\Q+20"=75TP=A"&*6:NFEC',%)Y4GL/.?%OH2@A0HB10
M?%6L,.<XDFX9.F,H!>JB7LITJ34>H("WDCDR:R20DJ?)66:BL7FB']-?I35@
MQ3*D(_&'I>@C^NF0(\Q)]?&G"CTT$$>)\?KXQ3?'JTQI5-"DC-10BQA#08C?
M&JPIIE-"ER?9('I4KXR3!?&JP3F5D1A8_P <K@$DT%?(D2:6%(CRJ2')1])%
M<#V"N0',]=&5<N[F!KK%718UQ72<K;N+.R/;UT@T2]B29:6<)8,FW@1G#L(A
M'K80TQ+ZH5\.RA3,#<UIBMO @G"*,HVVOTC%OY#73;<ME"M%,&KL9<J7.G74
M,<SW?R54QTVO]U@>%2L0,>5>S12)EHMI#L9)G+,MXTN),(^7A?[7QVL8V$L8
M[JIL@=A=055];!:,RUQV MTD;/CEK+&\TR2$-DBO,&5'_P <BR17;3%E/',!
M"M/CH2AJ8T5\FC@W<7Q-FCA7=, _F@-<EVZTCRYMI*I#+1^K]LEB(:?(8DJ#
M6W (D.1*'$^00O*LQ7PB6(?S^1<ZN:WCJF*J)P147D9%",_!51.3<W7@BHO(
M"*$"\OQDGIG4ZN==0A09-?/]OD5LF*.JFI"#8)&7W243R#AUQ(0[NP_?M)3(
M+KNHA FTU1%@CGWTH!(5G8+))>1:]N56OMJW$]#6<A\:N@45>^)[=#FW]</4
M\,<1MW4_M2N@7X^1]8ROV6 JVSA+[');6BK)1)9ZF<A"U)1.BP9<2+#@G;*G
MC(.R?76;+"+6EB5T*"*-!G5;#!L8+I>20W;G0(;84+V(RX8+3@C0KN,TM=9)
M81ZP\6.ROL#3:H9'2.<Q6B%76(+"- MHLTGOK'Y,M1Q4AVL>25_R"*TDRV''
M.ZW%Z>#:CF'+,&.3P^V5MK&L&FO1A659*$D*8&9&X+?#<Z5;CCGB6D:2UEX/
MS F#,7GL/X I#ZZ."&X*19!O8"27'-*(,_R$;V-^'UG[5Q2'9&HZ..1D0/U^
M1,@I-8Z%"/?LEE'1PW2(=K\@:7T9_/(C_'",?5VRH&>0*) ^.%![,5S4^2A*
M(OR2T\P9:?3Y+SO8U[%A1%QH!-*6CJ2E-6P##C0XL9JU5<Z3+K8,Q20XQ 9(
M@N=,6CDOCK2L-9-@0VH:.$^)15"%E4];**(0Q#;"BM:(;!#-251BR:R!)<R)
M%&"/35<<L:$HY?+:&(&N'+LXY$)8R;'7QA]?:L@3+/=.GV#@,C(0\.,ZS2Y'
M,M/>B%LIDQEK+GC]PLA1*V89]A:2C#21< #(A303 3+4$8Q+#:%+J%Z)MH21
M<X2YB"<(OD##=:6@IQ+'UT:5.!8G-81C#DF9;\;41"UM7408H@TX#V9*QCS^
MGL"5CAF@V JR7"%5C.TU+%,(!XYEO7>L@315TJN82%8GC0P*MI;?MS2221_D
M-?5')%(R1 M)SYI9*5D_VUKI4NVB'(9EE7S9\P+U,"O),J@V'JDL !G2+&<A
M9RO_ '?D7/Z@'F+( '#2  8";#.T5A *XQP 8(PC,&8)%>8(UPA()Q>"(*<L
MR(F%*(3.#GM8T%A!.H[&O*\\F/':V9$<'BP(F.Y[=',N;MR2Y"#9*^0@FQR8
M"OA$^, >Z9*@1VK-I&QXA9$V/)F7IW#I[=BQG2#SBVXXGJWK*]T9/;*=%I[*
M39FO$\LU8L8;8%?!-\9A*^13UD<9VTAWGJ>DZO$^4*B".NFU?FD1JEPR,^/?
MLS*QI\@0&Q&QZ\822:6"9UE"277I$?+9)@M/)B0&1Y$*G!$F3HJRHPJL()=A
M7BFBC0IC'#^.Z D0CN:E>6'%@14B0OZ+_]H " $"  $% O\ 5#3FT[C3I*G:
MHG'3-.33-.*IV:=/3^@JG!>Q3@G47L-<UQ.P7K*F)C<3AKP5Z)B+KT5Q>HK^
M&G!,3B]VB+@G[5Z"XO2<[&8Y,;]]<<N,=B+BOTQ9#L\^J< /U3BG(N+TE3&\
M$3'XJXBZ8F.&CL,';R!?M=Q3K[OKC\:N.^[> G<'MW(X:IR-*Y,;)3$7D7%Z
M3EX:XY>*8T:KB"5.*XX*+A![>2,[Z];;FW-/IR#^W*1NJ<$;K@!:<->JJ\["
M:8UZ+R:<#-T7(R_77-<UZKUZ+2KC7:\A![L4:X)FF:]HF)FF+P$[Z\B]@[GU
MS7->+5U3'.^N[L7]1KU3%,N-[)_63LG_ - =]^HWLW]5J=F_J-3M%3IHFO;.
M;T4;W"MS;R:+FS$3_<4__]H " $#  $% O\ 5#7FU[C7I:]JO'7HIV:_TY.Q
M7OD:JXYNF+V"=5&JN"?JCW:J1J)B\FU<TZ2=/;@X^.T1K7Z<%Q>+$U5,>W5.
MBG2$'7). )KAE_%&*N"9N4XM."-USPIGBTXE;HO%>5.D,B.PRZN;A"[FQV_B
M,:-QS-R8UVF,)KR$;JG8HFN>+:W(Z?D<6 3\2_IR2/:[&KHJ/1>1PT7'!7F3
MI!'IP:/\@,TQ4Q,(FJ.DM1'R$>G%I53&/UY#)].LDAV>H7/)^7)(_7RL=HO#
M7"DUZXV[ETS:G*8&['B5O,-VJ89/IPTZL9OTZ#XK5P@U;R-=IF],([7-.NB:
M)R%^SOQ1K_Q$[A)9JWD3L )J[E<FJ*S5?%FQ->!&;5S3-.QBIU""1V-BM3#?
MJ[&+]NJ3]78QOT]5>RC?HZAW:-[*+^GJ2'ZKV41<7IF)M3LQ/VN<G11,(1&H
MYVJ]I'/BMYM,VX20B8KM>W'(5N-D-7/HN;,VIBE8F.EICS.=WFY?]OC_V@ (
M 0("!C\"Z[38.OQP U3P(X O\*O_V@ ( 0,"!C\"ZJC4+)7%^U,U#[T1HA1%
M9L]'\59N5AL-0=3VHZ7X#-2H.S$+#;Q0>WA;BBUQZ:#<SRH?9A='N*__V@ (
M 0$!!C\"]G9W53VFU&3>O+7Q/?0?&GG7(0Q1^-[Z"N; XDCX;AZXYLBQWX;B
M!]M7!N#TT6.@&I-12<T;)VV0M^9CT#^#Q^?C/E1\@_I1KN;B=;:5*<3'.'!N
M'-BE4J_B4::U@HY@VMD1@!4(UMW;CJJ#!,L$,SH9)LAA9 +Z;5ZS:LZ279,^
M%MM)%X'YGA^OC0DEEA[ZWY6P]UCPUOKVU-F9$BMC(97=;'?<:FQZJ7S5^4<<
MV8XP!W;";>+KJ/#PPEIL<2AWOW>\=?H'"EYQWR@=]EZ3V"G\PS4$\^0[>/4*
MH-@!6-B8H2'G,0C2>!%&K'ZZRL.26/(VP&5)X>%N!!&NM>0__:3_ )S_  <6
M;A&&\<9CM-NZ3_+4V-.81DR$;2F[98,#TW/16(D94&":.5]U^" WM46;C<MI
MHUY;Q3>%EX_ UD8V4D,!FMMY%]+:C=POK4<>4(.4@LSH6W-III]M38,O+;!D
MYG?!/,L_1:UJ'ECO#\H+*9QNYA0&]MO"]1YBE>0F/R-NNZ^Z_HD3R]H9,1VW
M+'-<%">JW16+*6B^>QCNL03$V[Q#KJ83PX\.Y"J<J][GK-N%>6P;DWX<RRRF
MYL0&)[NG\))._AC4L?A4$N:0LTPTCC#$W.M@-3H.-<V!MR<.JQ'00=13ABQY
M9VR,J,RACT%@+7H-J+B]CH?HIN05$OX2]ROQM:IHW..$QI DEE>YZ=.]4,,*
M<S*R6VQ*=!IJ2>P5(^>T B47WQ[A;KONO4H@<\U8RZAE*W'YAN N*\G#-_FU
ME,^@UV+<5*LH G@D:.3;PTX$>\?PN4B:L8S8>[6L'/AYK0",AACFSC>.(^^M
M\./D.9Y_U!-;?KH7/9I6;=)V\L>8R2"%5*-MMO.YK-XAK:I9FA?Y:.-94FZ'
MW= [:!(L3T5Y@[J5667=&>L6K#S8$YK8C-NB'$K(+&W:*R<>*"6%RHV\T!+F
M][#7LK>T>9STB<#Y@@H"PMM'77DFZ,CY=9A-_+N72]>83C]MYMJ]O+4*3]/\
M-LC4(H_"HL/0VC\MR6:$2.(R3Q[E[5L*C9^6VFG#T:L*\8K1@?2$C4(@X*HL
M/XCO'X5W>[7>-_4T:N^/B*NIO_#[8_\ BK7V%U-C6UM&_A=B\.D^G3O&NKW5
MJQKC6CFN]WJMX6ZCZ=K>+^#L/$WHN:[.KV&U^]']8H,INIJXXU?IZ?X(M]%7
M-7/LM=8SXA]] C4'A5NAO8:FWJ<K>.;;=LOWK==O5/;IZ-O0OM# W1JGWCT!
MNOUX/_L1_?4TN, TR+N56U!MQX6Z*P&Q0IGSF4!6U 'X^!'AJ?'A?'A:&0HD
M$V[<X'XOCV4\/*2XQ=_- [Y[_AOU4KB3&5=WZN+WN:J@_;Z/U'"UNC-UX7I1
M1/M5D'X35QP->[UT3'V\Q)5D[V@[M?WD<"Q6XQEB;_&LEU;?BX9:/&Z@9#N:
MWNX4T+8T [WZ67N.Y5OII:][4<RX,?RW)!/'=NOK6/--!#CO#('?(C8[F _#
MPZ>VKR-MKI,<FJ?X4D72HU]_31$B[632K=9]'57BK07K73V,1[+?1I3>_P!@
MT,R[XW\2T(H$$<8X*/1R[]ZU[=E;8-3^?_"H]YON87K9(.!N#VCT*>REK<?A
MZG;T>Q3X_;1]_LN7'K-]E2SN;EC:]?,1#NGQ#JI.RYI48]Y^%77QDV%6E-R.
M!KW=-*!775T/PK7T7Z&J-Y4,CRZ[;[;"C,T6Z\I4#=:PM>HV5&DCF6Z1WUOP
MM4=EY;L+O%QMU?3ZD0[+_3K0[=?8D7MVT9">8I_'40Z6&X_&FYG@_%>I)5UB
M9>[07J45"GXE&O;5OR^(TQ;A5U ZJL=&]3M'"ECG5OT_"R6X'H-Z,+J^WF%U
ML1U6UH<Q2L2+MC5.CZ>-111@[(KV+<3?TJ@XL;4J+[A5NKV)=C91Q-<M_P!A
MNYLJPX#A5OS'[-:$+'4>#_"I>PV^BKGH'V#T+UHW>^[T!O5U&O6*[G>JQT/J
M'(;@-$^^N8>CA[+Y>,]P>(]9I6ZC29"ZJ;%AV&DV'NV^L_[*O3,=23QH7X<#
M5C1!\+"S5;T>[UMW2/3M'A_$U+$@L!04<![+P;?Z3159>\/PZ7I\8$MH;7_U
MZZVGH]:_H]_J:5WM*V+PZ3Z.I.EJ$40_U[:MT])]FTG3^'WUUL=35KM]-$]?
MJZ^IKK6G'JKM'H!'$5X;>^KOWS]5?E7KJR_3[01?ACU;WU?V'5ZMB=R]M!@I
MVMP-<-:LW&K@4&'3[0L> U-,QXN;^JL+Q(X:^K7OPK>8E6.-2[HE[';]/$TD
M<8VK/M9!U!N/T4DT*;(R60CM4\?B/71'XJ+6ZO1?T?'VC];=WZ:MU>JLMK[>
MCX6ITC[KR6O(#8V'12[AOF0,$F)U&_\ PIX929=Q!5F).TCU4,J=_7OC0\:#
M@%V'#?T?96_\+?;Z@]Y]I$G62?H_VT?:7-1_'[?05;@:*-T>E?C]OM(UZEO]
M)_\ 3VT0_E'U^FX\:\/2%ZO:>Y![55'$_?07JT]9:O[-OZ1[0"EZD[Q^[UQ7
M9T^S]Z#VF[KK>?')K\.CU#ZH]E%+[U/VBC[+LJY'Z2>+_#UK&K#B:!4V8"QZ
MM*[W#LJR]'1[)X_Q<4]XK^9>CV/4*V)H@\3=5"-!91ZVYQ5QQHJ>/H2W2;>S
M.1 +G_J)]XJXT-:CU>%:ZF@TOZ<?5^(T$C&U1T>O<=!N?43W^TW#].3\P^\5
MHO,7^7_"N_&4/;IZ- 37<@([3I]M?JN%'4-35T6[?G;4^R_D/A]*?Z]'L3(L
M3S$?]./5J>-,#):2*W,4*+B_"^M:FWHX\.-=8JVU=WN%+B\)64N%'Y1IZ&.)
MASY,*&QF0:?[O72R$% P!LVA%^NI<D#?RUW6ZZ\OAY?^=0N3?PV3=[ J?A3*
MW$>A/C]GLO-_?#_RFLPQX'S!@!CER'DV %1^$:\*\I)D.\Y$:\SI'C J)8(_
MT#D(<B$,=THX6UXD]59GF$.)\O&D7]NCK9MX&I UM4<\&'?+8\Q?,.>-^Z_5
M]5J6.>/<'Q>8XN?'NM>LE8O%R7"?\-8W*M8+9K?FZ?KK'Q>1\S"(C(,<ORPS
M7(U/3:U>:++#\OCL V/#OYFW\VM>0_\ 8?\ _E[$-T\/38\1[&:=!:3(MS3U
M[>%/.RF\AO(@8A&/\R\#4&/L_2QW$D0N=&'^VL8&%I\(,3E11^/AW+<#QXVI
M9<7'EQ<,(1*LS'OMT64EN%$J'1";M$KL$)]PI)9-RRH+*Z,5-NK2K4TFQH]^
MKJC%5/P%1K(O[/[3J2&7W&I<?ONDW[I=V8GXUCR[>_BJ5A-^ (V_9[%?3<5<
M>K)+'^[HL?\ 4QVC[:AQ51\O+*;K"PT&A8DV UKFH"NI5T;BK+H0:,D>,TF.
M).3SMR@;KVX<;7K70]539-MW+6X';T5%//FG<;-)"%39;\HTO\;U^KBR+C[Q
M'\Q=;7.@-KWM61C0XLD\F-M+[=H%F7=TD?16,\$;S29=S%"+ Z<;DZ"U0J<9
MSESWVXUUOW>)+7VVI9FB<'G?+R1?B5[7^-<R6(P'7N-8FWPKYSYLXR2$\B%%
M4V4&W>O>]/#%!)DM H;(*;1MOKTD7-N@5$T,C?+R8;2*MS:]^-NNO+,EI"ZR
M/RLC=K?>Q :YUT/KCU+=!]63E"\D9655Z]C!ONJ#S"*),I#%L,,AVZ'O @ZZ
MZU D&/#"C.3D1AB;#HVG36I/,N2DN,9C-'&9BG3I^EJNZII.4C=Y%Q%%[G?8
M'?[JEQF-A(MK]1Z#4<,\,15='R _$#^3;QHJ\<33"7F?.,Q+L-U[6MW=*S\E
MK<O)Y7+Z^XMC>L&6,))D8JNDD1:P8.;Z-;H]U8V5)!$\T>X2XK,=I4\+/;B/
M=6*(\>/%,>6D[QJQ;NKVVXU8U\I#%'D0*3R9&?80";V86-ZFR1BQ9B3[>[(Q
M0HP%M-#H:AF54CB3%,)13P8F^G97EWEC:S<T-)MU 2-MY/V>N/0X'$"XJQT-
M;^@>PYOR\?-X\S8N[Z?X2WT>CK8\36HO_HL294G+1CM!L3K\+T9,:02*-#T?
M4=?2V1-?8MN''72@W7KZ"[D*BZLQT H,IN#J"*V9$UI/R %C]5+/ V^)O"W#
M[?3)/)X(U+-\*Q;*_P#>"\7=Z/YNJGR)?VX^-OHI)5\,BAA?CKK1=R%1=68Z
M 4&4W!U!'MO+\>"+GR1WGY5PM[<-3_2:S\R2T.5FN@2.(^'7LZ>-00?-R-E^
M8R)&\I.B <=G5XJ\RA65\C'QX.8.:=UI-+"_;>O+>=DR2R>82!I8V/=V]@Z+
M UYQDF1N1B1[(X[G;OMU<+W6O*\#YB19,V\DT^X[]G$ $]E8^'%D3/\ ,SA;
M.^ZX/^!H0B224#\4K;FK)SI!?)EF8,3Q ZOKJ/RR.5L?&CCYTW*.TGLO69D?
M,2/)),(L=]QO86U'O%ZAC?)DF_MS+EAC=;V/ =&M-YA)D/S<N7E1X]_T]M_#
MM^%21J[?*^6X=VB!.TD#2X]QK&GERG>?S*<(8;]S;?H7L(%9J?,/C8OEL7=$
M9VW:W$U@K)/(TV;/8C=Q#'[K"PK&\JADR98R#+,RG=,5X!5.EAW:R AD$C2[
MH8R]Y1%U;NNIEQ\K(3F-L)E:[QL.('#C21[B^Q0N]N)MTGV?SNO/V<L=5O=4
M8FN1$XD4#K'70CG![IW(RFS ]8-2P*I99_WF8W9O>:BF3>TD-^67:_'2II7#
M7G\:AN[?KMUU C;D^7%H70V8#W_"H8&,GZ!+1R!N_<FYU]])&+D( H)U.G73
MR]].9K(B-93\*7(EW"0#:=K;=R]1J#%L>3COS$%_Q=O7QJ3,L3-*G+:_#;U6
M^%(P#GEOS(U+$@$=0K)EL6;+TFN>CA:HW7>S0MNCW->WN%23N'W2BTBJUE/;
M:H(&W*,:W)9#9A;M^%0[RZR8Z[8Y5:SV]]1PAY4Y=R'5SN[W&YJ&$*P2&3FC
M7B_6WKL>H5#DM\L,>35E ??:]NNU94^7( D,\B;CI95X4_)FW<L;F%B#;KL1
M<TX6Z,I;B&MM7IO8#X5R8I@SF^W0B]N.TG0_"I,==P*MMC.UN]I<]'=^-?/<
MS^U_^2S=>WA:_&K3.RZ;O Y%O> 142(]VG3F1"QU7KK(O)_E?W]#W=+_ !^%
M;/F5N 3T@:=O"F^6DWE/$+$$? VI8HYKN_@N& /N) !K-BS)@L<3*(1:YMMN
M?"":62-@R,+JPK.R' &'B$HI_$S+XOKT%1Y']O%%)9N2VXML/;UVK+QL3Y?9
MB\O]T/<[UOT&I^;"5R<72:%>]K_+UWK,AR(A#R.7M0:M^H">\>%-F2K!\NC
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M%MTGEM]M02X$D:\B+]8.+ZJNHTX&]>19$M@TF]FZ!JE8"X[!G@64Y!76RD6
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M,%444Q1%EC,!L=BZT]!=1H(L,[5%)[T5@>EL&0[PUGL.MD$"&P6S@5>\U+4
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M';Z>"RMMOG4I"<0+40]7/)E3F-AX4GWXPO REE=<=M%T&WQ*J=O .JL'D-D
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MM^SV\QE1]F8>4RU^TN(>3?@@K[7D(/UW+]P*^W!BR9ERY="!/O*__GQ__]H
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M222222220"0   22222222222022"0"2222222220200" "22222222200
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M "0"2222022 2" "220""222 "20"2"02"0  22  "002 "2" 200"222 2
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M= P.#OYW]BH%6@RK&5NT>AQ"KT>N5X#UBP]N,=",8_6L!$ JS7'HOS#2A-6
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M!6'$ >()V:NEJ5[!E@W7#M04/@@ST0NPH\D$36H A.6^5FZ 8HCD$PP)1A=
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M5V\EM'B2PP[.BCJ4GLG(S409.1Y'Z:+2R"S#M<>DQX'.I/-4!O (+:E,ZJE
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M1Z60 *-?_*# )<B]:ZYJODEE,8:M874-7EXJ+3+&8,AY.=# 0)'0"-#-)>?
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MMW7]$J$8^%&\:82IB4$(WG+X%IP$H\M0X\^G,( 8"*-Y/0A@\+EQ6[^A]?\
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M=2OT_P!:F?:]'_)ZL06_F;CVL_U<+AEWP?[_ %,11T&#_OO]V-0+_1BY+?\
$_/?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>form10k2017image2.jpg
<TEXT>
begin 644 form10k2017image2.jpg
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M  (1 0,1 ?_$ /4  0 " P$!               $!0(#!@$' 0$  P$! 0
M             0(#! 4&$  !! $!!@4"!0,% 0     "  $#! 41$" P0!(&
M,3(3%!4A-% B,S46<)!!8",D)39&$0 ! @0"!@<%!@,&!04    ! @, $1($
M(3$005%A(A,@<8&1,A0%,$"Q4B.AP4)B<C/1@K)0X<)3<W3P\4,D%6"2LX0&
M$@ ! @4%               14"$0($"0 6!P@*!A$P$  @(! P(%!0 " P$
M   ! !$A,4$046%Q@2 P0)&A\+'!T>%0\6!PD(#_V@ , P$  A$#$0   ?J@
M     !$,"<0R0;"("6           "A.?.N.1+HK@#M0           12@+P
MX8DE.=$#LP                           #!&BT:P9DBLYI
M \177K7WK&M7 TR&V&PD5M84M8TMDD        "#:M-KG#F*'2*N\:)C9#89
MHE1-C2;2MI=9N,[SZ7        I],ZO2G-Z1S6E<C:;(;#8C,SAF9%G2UO2U
MGG>ZST       I=,ZW2G$[137KMAN-ALAL,T9PS,S(R-\+W+2UI>[RT
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M7)K<9W          $4J4192H= D            #PI41")+I8F8
M    5Y6(ARVE[$S0            8%$B)**3X6R;             &LYU$:7
MA(+>)L0            0RJ1<)@H@E^G<            #G$"4:3TOD@
M       <V@;C0#I4@            <\CP$.70Q,T             IT1R+*5
M#H$@            >%*B(19=;$Y@            %>5B(<I$.F3Z
M    #24J(LHY8PODY@            KBJ1!ED3X7J=P            (Y2(G
ME#*=#H4Y@             $,])8
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M@(96G1'/%B;B@.J/2M!B69RA?F1S9;FXLBO*PZ,                __]H
M" $!  $% N+);JQ$-ZD1*:Y4@<)(Y!7NZ_NH;=>:3F,CC*$X=M8R@>+R%GVU
M'!8>I/2M2T\)CCRF7IE_]=@OW'F+7VO;#.V#NU_<U,9FH\;6S75EL+$':D[Z
M/_+,$SMD?QES 4]J!E[R%>\A36H'0F!<P[LS2719'8E+8Y@*]S77N($Q@6P+
M$HH+HIB8FY.:T((Y#-Y9XHFERZ.U8DW0FE%!>)1S1R(#('AM"7)6+6NRWEF9
M.1&3)DV_%;)D),35[3CR%FQU)WT5_(O,[)DR9-P(I2C>.03&M8Z>-;FZ666O
M:NR9,FX<<C@0DQ#4FU;AF; !$Y%?M>WKIDR9-Q*\O23.[/&;&'"NR?59:?U+
M3)DRCC.0Y:5J$0H7#!Q=GBBDD+@USZPI2:%PC+J.0V"-W<B9,F6+^_FEA@&V
M1#7N0^L6-.2.X7FX%8M)!+I)GU;@62Z85DRZ:3)DR902E#*1.9AD91CDEDE.
M"4H9?%U#5GF;V\S2R4[48KT9/3V,^CLJI:P\"\_Y%F/M&0B[OZ4,*]RFEB)2
M1=.]4$"QX31G;HN7OR@'H*4Y,=MA?6*B_P"7@7O%9%@.#IHH(/3C'&3.TM>6
M)58/5-P!AGB87W!F-HHI"C,[TY"O5/TMM?\ 1H^;@7O'S/?#JIB"K&TEIG1"
M)#!!Z+$I_P!/=9G=-&2](EH[;E?]&CY^!?\ */A8?2!U')Z<D<C$S/L)E-Y-
MP!U<64H:@F/5$/2^P&T"BW!RTP0U/DK"]Z,L#HE4F<$))G7BIVT'< =&9E+^
MFU>1T4$@KQC4(]4BIMI%P.Y1+T&=,Z=$H_+!-T(23.C!C$P<"V1#]1!TP[-5
MJOR+H9U5CT91CTQ\"S7CL07*<U.9G3HE%Y559WC%TSJ6)I!:M*[C4%,(BM5J
MNI=2GM!&P6I%"+F3?1ZP=4O"R-..U7G@D@D1*'P5'RDR%TRU6JZEU)S9/*K4
MY,(LF5(.FN?A5CZ(]VED&M397*#CX9LA5BHPY#)R$3Z".7M#/D:0&SMHB4:%
M]51\I+P75].I=287=3: *=V9B)S-F4$7J2"X+H<FWL7?I5KTYV[N9=K/PV3R
MP$W7D8Y[$U=LB8,8SCTS$A3.J,S$B4GE8B9!U.S,F4A]9*U(A9,M5U+!SE.^
M\]:N[B "N@>IJE5C4=:O$ZO-I<)?Y9U6-VF](G15F=BI.F!Q3,K)=(/,+([!
M:-J[LB?1M5JL!2.&'BYRD0RNH<0XU#Q,[/5H%&0)VU9@4D8NK=GT41N3ZIWU
M=FV15;=EX.V[!*KA:-=^.-:L)*6F)*>*2-!L=$2R0DTVJU0LF6%QXR;,1?DN
MP9C+RTBR&2"K5KOG?5F>5HHKV3BR'&OM_L1["=,!R$=$Y!_CT;ODZ@UK3,JE
M<K$\<8QQK"9&"G$%6_?N#'=:A/<KVLDPVZBI^U?+<:ZW_&B'07=&2J0>E'LS
M&,.RH\5?(L=C@J!RU@F]-T9*E#UGS;OHTA]1$Z^I%59FBYNQ(B=&2A'15?+S
M1OH+NC)>+@JO-R-J!.F$Y#EC].8%5\>:L3^FG_.\'I]%Z%B44<A**/H'FK):
MV102.*=U!(XS<W;^Z'83JLSG8YN]]P#?1W1NJD'I1\W<CUE=$2I0]9\V[Z-(
M?41.OJ1 # /-V)$[HR4(Z,WAS4I] NZ(D/U(4'DYJTZ)T3J-"H?T^:GB]07K
M6'>*DPQLSB0H&Z0YV6K'(\58 _TOW'=DJ8J&WF*.0L]SX^O+=[AJ598,O1FH
M9GN(+>/#(05[=?+5I[D?<U26Q+W,7RIF(!6/,YLO=EB,?4[BJ6;,_<U&(PS%
M(L;E\XV0KS%6DSUONFD*P]Z+'=OU>Y*=B?\ DQEE;V<K59V[BQWQM+,!96,R
M4.1K[W=>MB:CV]0HR]I1M*J.1K8Z_+5LU^TK%FGD,F]Z"MW50"<\%V[D\9[/
MM^Y7^9R44DV/P6?QM/%Y^:(<UCK$5ON'&EZ?;]^%X>VBLULEW%4]2Q?'(4X^
MU\O''5L8^:/(=T=LW*[Y&'I'*6*W;PXC"9J2&A7ECE@WGCC<D  #'7@,R$2$
M8(03PPO(  #1UZ\9-7@:1/6K/))#%*S1QLO1AZ"CC(!AB%#'&":M692112L,
M<8NU>!I)*U>0I(()6>"%X]WN'*7*+>_A^/P&6MVPKWLSDF>7(U\95M=R34S[
MAB^&:]EJ=G.9JW3&P5UZOO<O3OF8@'RUWX23*9NG5R%_(_*!D\A4MK*YNW!,
M@M5SG@M5YWR-^>OD%)G9QS&5R(8^J(]SD(]73<'-'/C\AD;-?%WFO4MF:9GR
M0.;C4A*67"&-O!U)[,F-Q%NM7P3Q2_ 9^0)B[L_9-0]O9@^+RF:ZOB+W3_$*
MV$L6ZMMV;NG/31V[+_-^\[J^U7<G7[SM_P!G\5FW9LQ=O15J88_,GA<C<]SB
MLT4I48Y,W)2MU6N1]N2=,G;?Z>R6K!+)[.K[J*K!%):P6)M20XRC!7#M_# 1
M1QG'4PV,J2V:L%J&S2JVH:F%Q=20Q$QHXMXZ  (!<Q6/N'4Q]*ILLU*]D5'3
MK1V(*=:N5S&TKJ;M[#,W@H:-2"+^-83K  C"WA,7<E]FU:GC:(T:2L2^C7PF
M8^2BM9[TLOD,M[>>K8S+SS9>_P#)4,OZ]@\W>,GS%-L=A\F=\/F[\RIVXK=6
M3(/\D^8R,EQL^)8OYG*1P5[$5B"_D(:4>'R+Y"F1@*(P%Y) CCBR^5MC;R.7
MABQF1R=Q8;(OD*62NC2I8G(^^K++9P*,UG(/7NK(?88Z0<>01EK7=@[LGMY:
MKE:/_J+CC)W3VT0!B^UA_P"C[904LKCHNUXR#"8O\V<J?*?,7<:]'MZ&2*+#
MX*3(5\%7*62'M#]FS%:M/CNWY#OWNX!,L-ASC/%9;]KP'[-VA^S=PSG+=QUJ
M2//?)Y0([-R#V7<$X3X92QC+%-A*4V/FQU>5[^*J7E#@*T=BS@:L]NCC*=)K
M/;]*>:&*.&*E0@IJ? UIYA$1%ZEB'-5J$%>Q<J16ZP]M8],S"RQ]""C7OT(;
ML4V-KR6G9G;^-U!)ZD;TZM:.K7C[9IQ#5Q=>M8MX^"T:NT8;D>2J6+EO\!__
MV@ ( 0(  04"_H?HM%HM.:T6F_HM.5TVZ;^FW3DF;8S</38[<@S;&;CNW&;8
MS<B_&;D7XK;&W=5KQ7Y$MC)D7"?AML;?TW=5JM=]^"VP=S1:)GWG\4_@O\[C
M\%MC.OJG)>Z9!(Q*:3I;K=0RZ[^F\Z?@ML;98\J9]%+)U;(?-NN3,NI:[KI^
M"VQMD@=3.VFY#YMR:3IV0%H2T3;C\$5TK3;+%U)VVQ>;<,M747F>P*&<77^=
MK\$-Z:+7:):.):MLL'O [Z:I^(S[UEOKLCDZ7><45ET[Z[L<3DNE/L?AL^]:
MX @[H:R&(6VNG3\1GW;6_ &K[S\E:'9$WYG!G4K,S[(PZ6WC;C-X;2'5GA=1
M!TK52^95@6F^;\8'V=2U1%MU1AU(*R9M-UW76G+D-=FJ?='=,N;U76AV._/"
M2ZF1%K_>+__:  @! P !!0+^A^JU6JUYK7@Z\KKPM=NO):\?7D'Y%N,_)M^&
M/P-.*W(MM=-PFX;\'7=TV:;[<%][7@-L;?;@ON:+T71 [*,-5TLI TW]=]N"
M^Y%XIV0!ILD\-UF=:+3>;@ON"^CL^Y)X;D8:[)1^BUW6X+[H'IN2>&X(Z,I/
M!H711.VZW!?>C/3:3:HATVPCO%XZ)N2A\-AAJO2=- F;3=(]%KM;AOO0<!RT
M3S)S=]UN(^[!OREHV\W)0/L/P8G91N[ML,M7WFY)GT7J(RU6B#P4Q<!N,[;-
M-C;=$):)YM_1:<EIO/NLW-Z+3\!=EHF;^\7_ /_:  @! @(&/P+G2\&B,Z<]
M0?8F038J61'I\(!D9"->]^__V@ ( 0,"!C\"LY': = [_]H " $! 08_ O:T
MN/(0K8I0!@)3<-E1P "TZ)/OMM$Y5J"?C%2%!:=HQ&CRM?UZ:Z/R[8=;:74M
MDTNC8?>77W6$K="#QG/ 81:W2V$FXFI7,US2LR^$/OC-M!4.O5";R\0+BYN9
MK4IS&%*9:DFK@:'XEJ[X9<]19:%L\H():*JD$_-/[H_^K_BCU?\ U_X^\O?H
M5\(M@<#Q_P#R*AZWRYJ"F?6(38^I(6PZQ@E5)(4-4I0';5M9Y;M="A)2@F8,
MN^$-A+Q>60.3]68._5A$Y8>5S_FCU:8S>P^W^VL2!'BC7&N/%&!!]XF<!' )
M[X\7=HXE =<?N)[X_<3WQ@H'1@KOCC$MXB8,Q[I).*HFHSB;BI1)I':K^$<2
MSU##HX*,<8GU1PG'9$TF425@KW*E&6LZ*+?$ZU_PBI1F3K/LI+Q&W7$QB(I7
MX=ON%"?#K,3.4%MK!K;M]KAVB)B*%>'X>VH&9ST>7;. _</W>WF.T1,1RSF,
MO:%1U05',P5#QG!'7[C(^$Q,9B H>S".TZ*!X6\.W7T A FHY"*G&E)3M@+2
MTHI.1B1$B,Q%+:2I6P>RWB"C;E[,JVPI9R2)P5',XGH,?JB[3SN:MXD!L R3
MCOBSI)'T]77#!4M"'5- N%9IG"6 H4E7$4ZY#;L@]?L9;8"MD3]BKNT.;Y#[
M>BEU/B3B)PI9S49GMA"*&SRQ)"BF9$%;AJ4=<)<3XDY3TDMHJ S@-%!#AR$5
M+;(&W1S:>#*K3/0-V'L4C?H_F&B0Q)CZO&OY!]YCA;0.R.-L#>G" 0:D'(])
M\+70FI/%*<6J$$J#>%9UP0/"2JL:I;X+@<1+4B?%"BLSDX .[H)A0]BCMT24
MJE(,RK./&OKE!4QQN*\.H@1,J$XXQAMU1CX1G%,L-D3&714T/ K$]D!:?$G*
M"G!(5XJ1*>CE?@)J[>@F%>Q1$M4.#9CW:"K*29)&BE6(,*&<SAH/3V=<82/1
M3"NKV*3UZ%]1T!7? (R/0/3ZM$EY;8EI V0L]7L:E9SDD;XU=4+2KA7+#9I_
M+T#TSM.$;(V]4?IT :)[3[%E7X0H@]O_ "Z4CX=-,4G3/I+^V.$SW05'7H2G
M9[%3+GA5'+<_E5J(Z1W:9:]1C*.(SC =':K9!GC/.!+OB7= V#'V92H8C%)B
ME?8=O15$_881*>*M*3K,=43UJZ5TV$4^6<Y<YY[X2OEEU:S)+8P. F3V 1YU
M:OH4A8.V>4()].4AA9'&7$U '6403*J0\(S,,MW=D;=NX50TNM*^+4"!E$B.
M%61V'HKZ?YCHF<H*M 3JUG=%*2,-4=9 Z?J8N'D-%5P9!1E"G+-#;S5FCE_4
M)":G1Q2E/5A#MFM,WO3'TJ6V,9M>(?&&;BQ]0'$I"?+"F9F<20>(0MQ]3 L4
M5*F OF!(VZHLW;:[\^XMZ7(*@L(2K-2:92EOBDPM.Q1'V] I/CV[=!C QCIG
MW:.6/YNB0X9EGP]O3F6D$G,TB.%(3/.4%4A4<SKBL,H"_FI$^_14VTA!.92D
M#0_^M7QZ");8PB2HX5=\2.8T2RG&&.B9SZ*GG!)3N0W#^/MO,H$T*\>XZ/KI
MQ<QWIV1P$*'= <=.(R2-.,;XI3XS$SB>C]%I2AMU=^43?<#8V#B,!036L9*7
MC_=[A4EI"5?,$B>B:.$_9 J';T:M2AAT2^\F:,D _'0XXM(24.J;$MB8;0RW
MS52+CPV-)S,(=0GG+>(1;H'XE*RA'F!;<D^,(KJ'?@8464A3LN!*C(3ZX8M;
MU+)\R%%"F:N&@3XJO;]1'0I2)Q2IN8WQE+=..4D2 2-"6DZ\SL$);1@E(D-#
MS+Z7 LOK4/IJ.!WRB\NFW$LMJG;)#B*IMISEE@3%O]-3KWI-Q)2 ,5MC6GLB
MT<LW'RX74\]OZ@2$#:,H<N+FZ5<, ?M!I,QCGPXF46ZO20X6R%"\4L+IIU";
MF,Y[/;K_ .-<3TX^-7BTI=:_=2)%.T13RB-YP$?,ZKQ*^X>[TG\6GF*\*<NO
MWR<3T2$2V>^4CMTSUF#[V3T5>]D:*4YP4;-!][D/$8FK&. 4[8"P>,:HP3$M
M>OWM6[09:] &I6!]\5OE\.@G=B??!O3T,?&KQ>^(.J6GF*\*<NOWR9B>BF E
M.0]\I';IGK/OD]>KHIZO>QT4^]X9C*)4PJ>*U"4]D$',: /?JLE;1$\S_P"E
MW'&E4.DI2A76?X18-W%SYA%Y34T1BFK#[)P\R4N*=9532D#B.['5K@,<MQU^
M52VFQ,IU\4&^2N3"?'/,2U'?'*MDNM..K2$%0IJ3M21O$6_I4EJ?+8XAX9 :
MS.?X8N+5(4%6W[JS*COG ;89>=05!'.2GAF8Y+3#J[=H'FI2B;A5U82$%:\$
MI$U'<(<?:N396:54M!(Q/P^,5>I7!N'*B$2&)V#5]L-VP;=0^Y.:%)E3(3QQ
MUP^W0ZMQA5*DI .69SR&^/\ R%12Q+7G.<I=\,6UJEUAQUU,JN&:3@)2WQ;6
MP<>#MNBJA,N7_-C.+A#0<5RTJ ? X*Y8"?7"+J\6H\U1(&:CJ $]R8:MPTZA
M]TD<M292D)S..4H+3;#J[9 DI*4<=>W&4A'EPARXN)3+3(J(&^//S5RJJ*)<
M5?R[(<G;O,<M-9YB98;H+[25)2%%/'NZ=A8 _O.35N_#/[3'FBI;KJ1@XZ9R
MB[]04/J/ND [O$?C'JSEY,714>4D@\0F3(=>$)J!'.N XH?DID)]J1'I5K:<
M5NQC5*0X9&78$Q=O7)/"V$L( )),DR ZX]6NP/JW"C/J&*OZC%I9-+_[A0,V
MY'Q8J5CE%^7E4W#[E+2)'(%1,7+3?C6VH)ZY0BVN5%MYHJJ12<9J)U=<>FN7
M.%HD5SU3G_RB\OY288:X21+^;M ,>I^H+_=N2I,^O#XJCTU*I\I2ZW9?FFH?
M88L$VV-O;)*@J4AALW @"/7+QO%:&UM,D;92$O\ V0;-O&Z=5]42RXLY]0 C
MT9NXPM60*]DQ*<.W2!])AJ3:B)3GK[9F+WF*E=73IH;D<A4HQZCYJ^58K4LS
MPQ4F9R.K5#-DI\M-/?68>5.95\QPWY1<NWKA=MF%A#+TL53U?"&W6_VW$A2=
M6!QZ844@J&2I8Z)(2$C8,("UMI4L9*(!,%*A4DY@P*6TIIP3(#" X4)+@R7+
M'OB2$A(V#""IMI*%',I $<T-IYGSR$^_1S"T@N?/2)]\2<0E8&I0G"I)'%XL
M,^N**$T?++#NBA204?*1AW0"E"4R$A(:MD&A(3/.6$&32.(S/",3MBEQ 6G8
MH3@E*0"<R(+@;2'#FN0GWQ4XTA:AD5)!B3C:5@9!0!CE%M/*^20I[NDQY4))
M<KJJ$_")QY[_ *7+YOV3E%RJ\"4<FDX"4@1/&"]9<NVM)R;6X"I2Y:XN7;HM
MJN&D+4@M@T\*9B<X1>(\NXE8JY/$%2^$X/J#:/J3Y?)/^9L^^+9/J'+6S=*H
MFV""A9R&\0X+9F?*I+CRQP<1P VF ;0(+YE^Y.G'/*+5F\4T\W=FD<L%)2?X
M8PI:C)*1-1W"'_4J4IQG;HE^"J0JWPU?7(8=M5TE8;J"P%=>$6]E9%L<YNNI
MP'5/9U0S;>IH;HN#2U<-3E5L4#H2BW9DT'4M./.# E6I ZM>A=NE8+S>*V]8
M$+#*POEFE<M1V1Z?;HE1<J4')Y\,LN_1R0E/D$N)MUN:^8H'7N,<XIK432VV
M/Q*.J.;7;(4<>00KN)@5>+7**;13+3$O&L%2I]647K)"!>VJB@+'@4?^!#=Q
M*E1P6G8H9C3Z4#B"XN?<('_YXSF+F1_VX^I'KS+?B7P)[4$"&[9I\V]PUPN4
M^-,E;#MCUIMYXO\ (YK:%JV!)BV6\XE"4MXS,.791)M=X+@)_)E'IC31"UN7
M*'$R^4:^K&'>M']4)"ET5)I!G(XC5OBS6A]5TX^OE%#YK<"3K2<Q%W3GRE=T
ML?L@4Y>7:_PQ;>=O5/6P2A2;<("!E@"1G%E/ <A7^*+&QMR''^>'%TXT)3M[
MXP\MY.K\_,I^$XM/]TW\%:&/(5?^3H7.C_*EK^Z&?*^"7'MK_%/?'H\_G<_P
MP]<5 \M),M^K[84UY=!#Q\P7:OJ5'BG+;*/3/4O$EEY"K@=6!^T0J_M+U2$(
M1-*42I5%FY:FW56PA3A?KJ*B/RPEM5RMAQO%SRZZ<QKW1>622EQJV6*'TB55
M6<Y9G"+Z7[?FW:.K#2TXXBI;)FV=A@W?+'F"FDN;H=<;12MXS<.TP77K<%PY
MJ!*9]=)$+MVF0EIT2<3MGAUQ4+5$QMF?L,X+:D@H(D4ZI1S;=@(<^;$]TYR@
MLOHK;.:>J.0^W6U\O5',M[<)7J49J/95."A0FE0D1NA=A=4O6P4>5G.B<P%9
M8B$H2))2))&X0%W+(<4D2!QR[(/EF4MSS(S[\]"4OHK"%!:?U#7H7<)1]=S!
M:]<H<4RB@NFIR6L[90CS30<HG1.>$\\NJ"!;"2A)6*NO;NB0A;+;0#3A)6C,
M&>><5^5$_P!2I=TY0E"!2A(DE(U 1S;ABMSYIJ'P(A;/IZ$-+EP3P%6TYF&[
M=)G3XE;5',Z'793Y:2J74)PX5-\IQLB:)SX5":3VPWZ>AJL**$N.3\)7_=#=
MJPR;F\=Q2T#( ;5'5"47-HA#2LW4.3I[(?LK6T2]R DE173X@#]\*M+ADVMX
MD5<M1F"-J5:XN%65H'K:U44N.%4BHISI$(OR3RG/ G\15\LML/*4UR2TX6Z9
MS.&V'7K*S#MHP2DK*Y*53G2(;N6O X)C[Q#=BTBM127'E?(G5VDQ=6]K9I>%
MJ0%'F4YY9]47%XEHAVV-+K"CDJ<LX%R_Z=_VI%16VX%$).,Z80^T:FW!-)@*
M6"I:S2TTG%2E;!'F"CEFHIIG/*!4H)GE. %* *O"#KA3BS2A FI6X1SK*Q!M
MOP*=72I74(+PL4\M+?,<FZ)IPFH=D-.+M$MVK@GS>9,[N'K@7)1RYJ(IG/*'
M;E6- P3M.0$%:D<IUM9;=;SDH:&6$HYKKA%0RI23*9BW9<1]&YX4N['-22-^
MBY_TE_TQZ?=K--O=6Y;>/YD8I/W1Z;=N?NWMYSCU'PCNB[#F"G64\B>P2F!V
MB+1EUUM;%TM0 "9$)3O[8]3_ $-?TIBQ2UBXRA9>(U)(,IQ<5_\ 3=<YL,5#
M6HB?ZC'J'^Z7%PVRZR+&:G.<N=: <\,C#%6%52AU%1CU92O&"TD?II_NCU7R
M!9'&CF%ZK?*FF+ZMSFOO'F/.9345"&W'OVDL)KGLIBW+%KYDK4HTUAN29YXP
MA;[/)=UMS"Z=68W0G]:H>3<&A"15S/E(R,<^^5.YMVTBW;(EPD?N;YQ=!&='
MV X_9%H6_#RDCM D?MB\_P!!S^@Q:?HA/ZU1:63;2GZ#YA]I&9"<A#J76%6R
M+]-24+_S$9]\.N7'IQ:0V@J!#J7)JU"0A*G X;UZX0[<+4@@8?A3U:H;N6Y@
MAU"V@H2,P9=FA;2O"L%)[8;L%U<EJ5!GQ8;^V+:<QY504T!NA)>!#B/ Z@TK
M';#=PX^_<.-8M\YRJ7PARZYKS;KLJ^6NG(2^Z%<A$E+\:SBH]9,..5NM<[]]
MMI=*%_J$):;%+:!)(W"'>5/ZRRXN>TPI;[S[K:E5>74Y]/N@)2))&  CS;*:
MF;A%%SB,"GPJW[(N+A$Z[D@N3RX=G?"[=V?+<SEGMA/,4Z^A/A;<62GNP@ "
M0&0T>79G1,GBQ.,!IXJY8(44I,JI:C#-UBAYC!)1AP_*=T2.4*Y#]Q;(49EI
MIRE/=!M#/E%OE3UTRISA%NW.AL23/.*6[BY0G8ER0^$*N$J6MU2$ME2S/A2)
M?=##CDPNW56VI.&.A+;LY(6'!+:F+5JF5FTKG.KF,5)\*99]?]A?_]H " $!
M P$_(?F\\_Q,^%(L#185= 7T.: %G[B$''3B>YTX5VMO*LJK?F%@JR)NQD.W
M'U-=HJS8_"#@0%>Q_:D3,CUU0_E.&,AHM #C1+,YE7P;;:/L3ATW&+D1\]"_
M&?O]3S_19PV$,QQ 5' ^QH'V9?3#,%M*W]0B9(M)4N^\BGN#4YK[K+<Y]J[+
M\HLH V><_P#-?S&-3N#T&/\ U)^H3L#U&?A,?J+\G<9@+/=@_N;>AVPZ?G!!
M/^@0?^A/QD(]-F)VR(S%CU"51=P^DM/XHGH )5X>#E]#<9TC]6']SAEZ#[%0
M@0(33[Q=GV8? CO@S\L&&98$I?7N'Z%0+=1+O7WOI% MU&6K0N0_E'B][(P0
M00(0A"&,DJ?TY]X$>SF4#7PY$$2S(Z?GW%</<_R %*&58^5.'1_S!!!!! A"
M$(=++K[#/N+.TNVYZ?TU\[*_>=C_ 'HS]I'+_3F""""! A"$(0Z_[:(>ULSS
MW/<[>WS-0 FX MA-..\N?;<+6W*[8(((($"$(0Z'P?\ 5RPVU9"<Z&SL_+L#
MQ]SCH[)AKZMOX]H(((PA]'M9P1*YC[PB[6!=D3NPDPCY(+8N"Y2-.R$(?%2W
MVV6#K/U'^?*4"W1N.URN;E _8N+#;J>7,$$$_6>)LBH 7RN%GB/*HFTD.:-R
MLT/K'8&8"7*[F/SW[PA\?CF/OQ&$VK@ -.3Y-BY?W=,:W5]Q?X@@@@E<MO()
MO!E7=7-$*"]$L9KMJ4Q[-AJHJB[<PC0D4A/YCO !Q?I%0#O8/6KZ4W(;1:OJ
MP#8V1"":<SR?]C_/D^I+?8_WI>OG]I@A(] "<IY>@@ TGN?O,']LWM/T6/A\
MPA"$)LB593V,S6R.4^SM.#6<S.!96.1A=&*_F60'8@&H?!8?%?;$]!H_?_KY
M+P?IKICYFAY8QZPU6^A7]R]5')R/(,H#O-9?NQ7D:.5+SR_XDI GBQ.5?CLP
MA"$IZM,.;TFQ\NT#3QC]Y,] GADN]"O@_>?NQ8?!\G\1_B/H._,K0T#[K_8C
MI;@E(:>-!1TT0:23.U+%XKGH%_HYA"$.FF%B\U3OA.X]!BBDI^ 5[G[S]!Y^
M2:[']/VAH_> E+*J]2NA^-,#PQ*[R#TMRKIR$.F^T= %><SH0W<.1$L>SU\-
M@GXA^_R7F:CN$.(78J>$2G8_)U!0<O9V\PT$;'720%,<KVA"$"Y0'2L %X >
M8=D/5_EPBTIRP^^OP].RUV^ATO>Z_&/DL#^4!C]WPD:HRYGXZ@S6+TQ8.3\P
MZ6_@G+*@$N,,H44U^F)4OUC<;:L#TZ>.&?7GY)J8:LV.Q/1B$\;/W1_),QU/
MW(1MN[X/'5+,P(-#"N74)GTA@A%$$89894%]D_S,%4>]+'XWX$]%8]_+V_WY
M=[3&-CXE#O/&.Y'H61YA-?R2MI[]'3H989-MZ:EZ8L<'/0$*@PVOOB<G.4SK
MO/IQ\31&S5L?05&JDHV":SC(G"IAE%:!W;AO1/1VEE<EW'/:1*,'!=%LS.(&
M6+##;U8^YT6_%+B=L="J_6:G/$_(/YZ%M?$"AC*G4\%,:9Y>QT18!E8Z.='8
MZ2:C;M<I4* 4!X(B!Q/JP**^)!I!:3.KE, ZT7$A;F@+-G7,P.+ 7L3-I7;#
M"!2FHE>R4 **5QYQ*C99[.MDG63&NEF8KS7IT%2],4E4M[!W\]#KT)O CM+?
M2H%NC<1>/[.EZ>I_ Z C-AL:>\J3._/FO=*^-OG$B*^M2_S"Z M[M0$)81"U
M:MG)]:C;V7$$1+'9&NTR+ZH'2D56H\*KHNN@1UE)[+3'@I?%ON3@CXP_N>\1
MTMH.14,=,"),=I89%E89ZHQEG%:]^SF?=\Y8BGAP8M\,"M!:Z)JOLG_09X.]
M<O<AL'N3/=8I_$S'?V3+:[HU:T+5X(M>S:QGT(Z6 MU+#H0"ON5^4K_T)F@_
M,;KG(P?!C\/GH)3D=D\;Y#[@Z?8@_3$T@+HX10U%T@;UK>F$C+T@@XA8:Q3=
M/&H  !0:('J$O6"G-YS"=H\O- *K.<11R<ZW<^"LQS&VNG5F>1B%X2R%P&C4
M(^Y:U8I:QT)S\^Z_=?Q_,RJ:.CF:;?2)#=M']S*6/L_RPK:1RW=YSTN63Z!M
M^T+"F#P=!J/@*T!HCB6WC=1,LJJ6"+<^+/!\Z!Z0CQ]8Y3:&YF(NRHRTT$XG
M]Q-9 D5O5^ 7S[/!3^$S#;UCW ?P/;KC6VICF*>XL]1+^Z/\1$K[ #]CZ<JR
M:5%T,99/?_CZP$6C<5G['CHM+FE0Z5?67/$?EU"A:"P^?J_#I.=Z Q4>1Z?5
MJ=M,2K#N&CM?8\LY(PSWQ%"W\5]6),FOP=XBG%SQ^U0Z'L'>4Y&!MLF 1\UC
M[SO997U;6>P/MT!CW)WH8ME'U@KP%^SI7HUAK\;_ 'ZPTG8_=E%WGK/N _I[
M?67;HK^\72QED]_^/K 30;B,_8\=.ACGF%50T?67/$?EUC.?\(K#W/J[7DQU
M4,SHZ';>'U;6>*>FZT1='X7U?84E8>^RH>NV[%NT(.DI)G.^89^NN[]X]8CM
MQ+_XNFT9MC8U[&59K2-+U9;<TXAVD-BP5\5-JF-!P(:[A37:5/.V-+L!?(UN
M:MP@-50>(?6)=)!"%[A;T30*%CV6/?9Q.7+U^HRHUGF8*-=C!$\'<7Z^9P%K
M[1TK+!7WI;YTO4+9)DJ^ \"U7OJ//*K<MOH-5<.K=:S.MTKRTA9V9:XC1+SI
MB8U!S:XB38J9TNC:59;957C, RZ+F[<O(H:_&8BAO]:N0>3=2@Y8".S[-*O4
MW3WVTX0O=SU_VR5ZUB(M#@G>PO*L[U%2]K^\=K5])67Z@%:-E*5GXQ0[6<,#
M[)64N0::R@!QWN"Y\1LX'J_C$*L8#0D"@MOBJE6+6>1?<$?:6/IO;@;8=SZP
MA1=$=!.<J]8CS'S+9]BI&[DJJ"&G8UF)M+KLH"PK &^TSD'QRG1[ZA8?;-7
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M%14L +ZP3!SVA:531NM80=85!@ T!T%JR&V3;($PKE,;#"J0-5M\67#3?A$
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<+],_ RR6ERHRY4"BOK=@@W$]]_\ A5_^.W__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>form10k2017image3.jpg
<TEXT>
begin 644 form10k2017image3.jpg
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M  (1 0,1 ?_$ /8  0 " P$!               $!0$" P8' 0$  P$! 0
M             0(#! 4&$  !! $# P,# P0# 0     !  (#! 40$1(@,!-
M,10A(A4R,P9P030U8( C)!$  0($ P0'!04$!PD      0(# !$2!"$Q$T%1
M(C(0(#!A<10%@9%"4B- H<%R,['18B3A@K)#4W,58/#QDJ+"8[,T$@ ! @4"
M! <            A !$0,$ !,5!A8'" 02"049'! B(3 0 " @$"!@$% 0$
M P$   $ $2$Q05%A$" P<8&1H4#PL<'1X?%0<(!@_]H # ,!  (1 Q$   'Z
MH     #D=#(  !@R<#<Z         P?,CV!7 KRQ*H]@>9+8IS):GI0
M   #S)%(Q<'B"\)1?%,=RF+4L"Z         .!T-SD41>%*7A3%Z4!:DH
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M@,A%/U8^3]'DJ>K'O,=[1-Y]/3>;UQ_,[=<[W-\Y^V1&T21F&;1([,I/3D
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M_C]KV79XG2:@    " 5R))$-3TB0    !49]MMIQY0     !4HKB0<S4]*D
M 5Y3'$G&H)!Q-BE+DYDHV* ](68 !@\O,=H8!Z1(  @E$1C0P79P/+GHRM)Y
M#+LY%.>Z   (I1HR9/2) %:0B6;'0YE269W-#SQ?'(@%Z:G FD,FG8  K"L1
MQEZ2)D %6>%-R22"&1BP(1[ \R22H/0GGCF3P=#U1;@ %:52(\K*%VG8 %*3
M2: "F)9.   *@MP  "K*N8ADV%HFS             *HJYCF<R[A;)
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MBU#C*D<G9DCCD;/BGL3BUXC;%=K3T9V&#*?=T.?LN#RG_8T6RHY \)T43CT
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MJS.VH+#\C-F:EJ^ZQ9_,06_DY6T^SE;$T6-M7)+N(MRV*O1\/(P8NMCG5\G
MQU.F*=MG\<M_,RSGNL8[)X.K-6Q];&V9?XGSMY&W_(1M7O1V*^5FM/NX[S9"
M;$S_ !ZL%1^0IT,/)QECK[5*$<\-!M6Z+UZM\JE2R5F"O8DGK9S'5[<F0H03
M2Y')UZSI[F/-:+%UY/RF!^YO=G\/A@\7A[\O#Q5O!\?3_]H " $"  $% OZ=
M[KEZ+=<ER7)<ER7);K?1TP"-E#FY"+MS_01S[]')<ENMUR7)<ER7)<US7);I
MS04^/91S;)KM^R6KF6ISPYK1NFR%JYK=;K?N$$H1!"%J:T=M\"+2T[[KCMU
M+=<D7('K#NX3V7:'0: +BMEQ7%<4T]H]C;9 I^F^H7]@$?;?;0Z-*'8>>MND
M#-)X^)U!0/6.R[WZO[* _13,W;MT\NL=@];4V$!",#61NQ1Z&]00ZW>_4T_7
MHG9OH==NL=AX[#92$V4'H=&"G0%$:-TVZ AV#VFR$)IW&LC.0$2,>R:-M"-6
MIO9>-6H'1J!7]G>\#M=TYVW2_P!]!VW-VUW6ZY+DN6C3L043LN2W3';]#O=
M(#N$;=D/(1<3J"@=3[@(#ND(MV[K#JYJ#?0.:N6_;;Z-[PU<C(1&-BWL;:-;
MZ)VZ=&]?<%&QSD!LBU>-<2MM-EQ*X+;TCG;(,+R!Z[CR]>1_WX__V@ ( 0,
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M/E D(X$!/@)=F>N?#H#NQP?>.A(5RJP,</$(D<#U,<8F.V/7U/ES\(-!H1L
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MP>26>D![M2JGIX/9V12G2KT;>;*\*#QPNSV=D/;C>7V;Q0%=&69G6GL<$&:
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MJJ7ZCH(O=H[BPPQ="/U3?Y+]7'FEXYBZ + +Z@*$$@"@# !ZU(5H/C&WV5+
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M(X%Z>MGT^;9W8V7.'_%A[5C5\?H/_7<?RG5/IZ.EKXKQ_]H " $" P$_$/\
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M?I&,- .!^_W_ '0M/6'US%L>+>C]_O\ H H]4\CZJ9M(%>L>1_\ @'_X!_\
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2/ZY17C5^PQ$JVOK/_P"Z?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>form10k2017image4.jpg
<TEXT>
begin 644 form10k2017image4.jpg
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M  (1 0,1 ?_$ /H  0 " P$!               $!0$#!@(' 0$  P$! 0
M             0(#! 4&$  ! P,# @0$!0,% 0     ! @,$ !$%$# 2(!-
M(10&,2(R%4$C,S0U4!8V8'" 0R0E$0 ! @0"!0@(! ('" ,    ! @, $1($
M(3$005%Q$R P88&1(C(%0*&Q0E(C,Q3!T6)RLB10\.'Q@D-38)*BPG.#LW0T
M%242   & @(" @,            00!$A,0%A(#!0@*!1<0(B$P$  @$"! 4%
M 0$  P$    ! !$A,4$046%Q(#"!D:% \+'!T>'Q4'" 8/_:  P# 0 "$0,1
M   !^J         \D<WF34;R*"4           #0?.#Z&<0=04)%)IVH
M       !QYV!P1<G G0EB=@                          >40[1%M75,>
M3T;HF76TNML@         'A%3I2OO6):*ZT1YC!NA)B9U9DQ-E2]IG;TD
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M]%MYH    Y28E0A2VEY$S0"DS[OFO)]+4VY=<U&09B<@EQI:QIW?3X/0[>:
M   !S2-A9)CHMDY !SV7I<%R_05\UCSGK4RG9%I"\N+='IP=ET>)-O@
M-9J)(   -,7Y[+TJ?/MB5V](GWY[6_'>:<$BV8         %&<D=0;S20"T/
M!2'8'$'2&DK@=F        #BBN*L^@'SDN"P-1U1S9#/9+!VH        -)&
M-Q$./.L)()Y7$LADP&X
M%8<\=:#<<H=0#60C8<X=< #DCHBH.@(9/!Z/8   ."/13E>8+0CD0ZL]$(^A
M'Q<WEF4I*+0JRN.A(Y>'7$T   %66!$*(LC!6EH:#>;R"0"X-A1EP1205I(-
MIX+\]        %(0"&69%.L,@            BG/G*&3LR86H
M /!$.>+<@G3        $,I#V=&9/)Z,$0F '+FTC%H:B]!%.=-Q+*TL2\
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M!1D(<-M64P<AAF?DXZI./P68@C'>Y' _%3#;?EXO_(/:'\-X)EAEE!Q\$O\
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M*-@_\0 H &F83Q:W/WX9IHK?QWE",OR"N7=ZW_".HT(#HXC:ME\+XCB9J%6
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MI8]W1'NP8!T#6_,W/7SN5^H),(D-YQ(W9CYSN2FWURJ8^82*@H.A_P"$_]H
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M*N-&'IW\-O=&G\\E^ XE<0\;U$+IF!&M(>)2U'V5_LK_ ,3'EF.J</',J+Q
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M!?&AWY0VF:(UX!"MBVAY06%+8Z%.96X,9TS+:2-J0-I# +7#9%&T&&ELFPN
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M$F:C;"O88.-#\S\C]3[QSXIPSJV2*O>(Q$:?I1-5J8U7<0A"912V72@!G*"
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M(_:_(BH7\4UO8)U!DK0'UE;(5V(#6I:\7,\_L-0V/,LG0(#0YC'0I-66.NT
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2<H_LTC\K\X^(I:?;EI_]Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>perfchart201710k.jpg
<TEXT>
begin 644 perfchart201710k.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %N J$# 2(  A$! Q$!_\0
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MR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH
M_+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*O
MU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#
M_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_
M9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_
M $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/
M^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(
M5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P
M?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L
M@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D
M?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9
M_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /
MRY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D
M*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX
M/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_
M ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_T
MCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,
M_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\
MA4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?
M!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^
MR#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^
MD='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_A
MR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH
M_+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*O
MU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#
M_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_
M9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_
M $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/
M^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(
M5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P
M?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L
M@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D
M?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9
M_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /
MRY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,_P""2/\ TCH_9!_\,CX/_P#D
M*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\A4?\.3/^"2/_ $CH_9!_\,CX
M/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?!_\ \A4?\.3/^"2/_2.C]D'_
M ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^R#_X9'P?_P#(5'_#DS_@DC_T
MCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^D='[(/\ X9'P?_\ (5'_  Y,
M_P""2/\ TCH_9!_\,CX/_P#D*OU&HH _+G_AR9_P21_Z1T?L@_\ AD?!_P#\
MA4?\.3/^"2/_ $CH_9!_\,CX/_\ D*OU&HH _+G_ (<F?\$D?^D='[(/_AD?
M!_\ \A4?\.3/^"2/_2.C]D'_ ,,CX/\ _D*OU&HH _+G_AR9_P $D?\ I'1^
MR#_X9'P?_P#(5'_#DS_@DC_TCH_9!_\ #(^#_P#Y"K]1J* /RY_X<F?\$D?^
MD='[(/\ X9'P?_\ (5<+\3_^"+O_  2>TCX;?$#5--_X)X_LC66H:?X&\87E
MC>6_P4\'I<6EY;>&M4GM;J"3["3'/;SI'/#*F)(I8TDC9)%5E_8"O./C#_R2
MCXF?]D^\;?\ J+:M0!_@G4444 ?[67_!$S_E$C_P3H_[-!^"/_J'V5?J-7Y<
M_P#!$S_E$C_P3H_[-!^"/_J'V5?J-0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5PWQ,^)?@#X-?#_QC\5?BGXOT
M'P%\.?A]X=U7Q9XT\9>*-0@TK0/#?AW1;62\U/5M4O[AA'!:VMO&S' >6:0Q
MV]O%-<310OW-?E'_ ,%M_P!C/XM_M]_\$S?VE_V8?@7K,&F_%7QIH_@_7O!V
MFWVK0:'I/C+4_AWX^\,_$ > M5U:Z>&RT^#QC#X<DT:RO=2N;32+769M*GUF
M[MM(COIT /J3X:_ME_#?XGVWP3U72O!OQJT'PU^T9?7=K\%O%/C'X1^*?#6C
M>+[6#P1K_P 1K+5=42\B?6/AM8Z_X-\-ZIK/AB+XM:1X"U7Q$([>QTK2[G4K
MRVLY/K;>I!/S<?[+9^H&,D>X!%?!OAKXB?%GXJ_LH0Z-\-OA/\2/@Q^T+=_
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MU%%% '^UE_P1,_Y1(_\ !.C_ +-!^"/_ *A]E7ZC5^7/_!$S_E$C_P $Z/\
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M_L:_\$Q=*^+/ASX\>)(/A[^P=^U]\._VAOAY;7^N:K\5K3]KJ_\ @]I_A/\
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MC^#_ (=D333=^!O$GIGP2_9[_:>_88_:T_X+*>/K?P=XW\=VG[;=WX9_:/\
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M$X?%GPXTKP81X'DOO@5X9^&'A#0_BKXI^)'PTU2Z3Q;XN^ '@^]TR[T+XF?
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M)O'WAJR^/.F?!F:_@^)NG_#N^GT>YL[_ ,7>%7TVZ>;P+JD^D>,]5M%2_P!
MT+5K":&Y?YA_X)6^)/B!\5O^""7P#\0>)=5\;_%+XD^._P!D7XCK>ZIJM[KO
MCCQYXT\4Z_+\2=,M6N[^_FU'7->UK5=0N;6!KN]N9I79Q-<W"6\<DL?X^?\
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M;3[%M"N)XM5EM[@:A;P2V2/,O\SO_!.C]FC_ (*7?"[QG\!-=U[1?VB/"?Q
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M8F=VQ<Y)SM&<GJ<XSD]SUIU% "%5)!(!(S@D D9X.,],CKBD"(N"J*I (&%
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MGOZUY;J?P0^$6L>+KKQWJ7PZ\)77B[4;G2K[5M=?1K1;S7+_ $&&PMM U#Q
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M70!T%%<_L\4?\]M!_P"_&I?_ "71L\4?\]M!_P"_&I?_ "70!T%%<_L\4?\
M/;0?^_&I?_)=&SQ1_P ]M!_[\:E_\ET =!17/[/%'_/;0?\ OQJ7_P ET;/%
M'_/;0?\ OQJ7_P ET =!17/[/%'_ #VT'_OQJ7_R71L\4?\ /;0?^_&I?_)=
M '045S^SQ1_SVT'_ +\:E_\ )=&SQ1_SVT'_ +\:E_\ )= '045S^SQ1_P ]
MM!_[\:E_\ET;/%'_ #VT'_OQJ7_R70!T%%<_L\4?\]M!_P"_&I?_ "71L\4?
M\]M!_P"_&I?_ "70!T%%<_L\4?\ /;0?^_&I?_)=&SQ1_P ]M!_[\:E_\ET
M=!17/[/%'_/;0?\ OQJ7_P ET;/%'_/;0?\ OQJ7_P ET =!17/[/%'_ #VT
M'_OQJ7_R71L\4?\ /;0?^_&I?_)= '045S^SQ1_SVT'_ +\:E_\ )=&SQ1_S
MVT'_ +\:E_\ )= '045S^SQ1_P ]M!_[\:E_\ET;/%'_ #VT'_OQJ7_R70!T
M%%<_L\4?\]M!_P"_&I?_ "71L\4?\]M!_P"_&I?_ "70!T%%<_L\4?\ /;0?
M^_&I?_)=&SQ1_P ]M!_[\:E_\ET =!17/[/%'_/;0?\ OQJ7_P ET;/%'_/;
M0?\ OQJ7_P ET =!17/[/%'_ #VT'_OQJ7_R71L\4?\ /;0?^_&I?_)= '04
M5S^SQ1_SVT'_ +\:E_\ )=&SQ1_SVT'_ +\:E_\ )= '045S^SQ1_P ]M!_[
M\:E_\ET;/%'_ #VT'_OQJ7_R70!T%%<_L\4?\]M!_P"_&I?_ "71L\4?\]M!
M_P"_&I?_ "70!T%%<_L\4?\ /;0?^_&I?_)=&SQ1_P ]M!_[\:E_\ET =!17
M/[/%'_/;0?\ OQJ7_P ET;/%'_/;0?\ OQJ7_P ET =!17/[/%'_ #VT'_OQ
MJ7_R71L\4?\ /;0?^_&I?_)= '045S^SQ1_SVT'_ +\:E_\ )=&SQ1_SVT'_
M +\:E_\ )= '045S^SQ1_P ]M!_[\:E_\ET;/%'_ #VT'_OQJ7_R70!T%%<_
ML\4?\]M!_P"_&I?_ "71L\4?\]M!_P"_&I?_ "70!T%%<_L\4?\ /;0?^_&I
M?_)=&SQ1_P ]M!_[\:E_\ET =!17/[/%'_/;0?\ OQJ7_P ET;/%'_/;0?\
MOQJ7_P ET =!17/[/%'_ #VT'_OQJ7_R71L\4?\ /;0?^_&I?_)= '045S^S
MQ1_SVT'_ +\:E_\ )=&SQ1_SVT'_ +\:E_\ )= '045S^SQ1_P ]M!_[\:E_
M\ET;/%'_ #VT'_OQJ7_R70!T%%<_L\4?\]M!_P"_&I?_ "71L\4?\]M!_P"_
M&I?_ "70!T%%<_L\4?\ /;0?^_&I?_)=&SQ1_P ]M!_[\:E_\ET =!17/[/%
M'_/;0?\ OQJ7_P EU+ GB(31&XET4P!U\X0PWZS&//S"(R7+('Q]TNI7U!H
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M /I)-7XJ_P#!N!_RA0_8)_[)QXX_]79\4:_:K6O^01JG_8.O_P#TDFK\5?\
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HI"0.N>?0$_G@'
M]S@51M-5TV_FOK:RU"RN[C3)DM]1@M;NVN9K"XDB6=(+R*"622UF>%EE2*X6
M.1HR)%4H0Q3:32;2<KI)M)MI7:2ZV2;=NBN7&G.49RC"4HTTI5)1BW&"E*,$
MY-*T4YRC%-VO*22U:1?HK\W/VBO^"KG[&W[-'C?Q'\+_ !KXR\5^(/BCX3EB
MM]=^'G@+X?\ BCQ'XBL[JYTNTUFSM//GL]*\/RSWNG7]E<VPBUN2-TN8@SJ2
MP7[!\4?$3Q1>_ G5?BK\'_!4WCOQ5??#)O'GP\\ ZU>?\(K=^*M2OO#L>O\
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M/&YAEN/P&*J87$1HU\/B9>]2J4ZD:=2$X16B@$'D'(]117IGQ(4444 %%%%
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M\0_]!C3O_!'+_P#+NC[+XA_Z#&G?^".7_P"7= &[16%]E\0_]!C3O_!'+_\
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M/<\9/4@ 'A1AU%% &9K7_((U3_L'7_\ Z235^*O_  ;@?\H4/V"?^R<>./\
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MS"X3"8;!8NK5J5<5%S>'G0H0K8F5.A/[N) &20 ,DDG  ').?8<FOS\\5?\
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M-0NH+.RL;"S@>YO;R\N[J2*WM+.UMXI+BZN9Y8K>W@CDGGDCC1W'XU_LL?\
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MA7Q6&PJ@\3B*&'56:ITW7K4Z2J5'M3@ZDH\\WTC&\GT1X^<<1</\/0PE3/\
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MC_LT'X(_^H?95^HU?ES_ ,$3/^42/_!.C_LT'X(_^H?95^HU !1110 4444
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MG.,TG9V>L7ORRC\4)+K&24EU2%HHHKQC0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KSCXP_\ )*/B9_V3[QM_ZBVK5Z/7
MG'QA_P"24?$S_LGWC;_U%M6H _P3J*** /\ :R_X(F?\HD?^"='_ &:#\$?_
M %#[*OU&K\N?^")G_*)'_@G1_P!F@_!'_P!0^RK]1J "O$?BQ^T?\$O@AJ'A
M[1_B?\0M$\,:YXJS)X?\/NFI:OXBU*R35=*T*XUB'P]X?L-7UN/P]8ZUKNB:
M5J?B6XT^'P_I5_K&F6NHZG;3WUM'+[=7X#?\%>/A(=2^*7PD_: ^!?C7XK?
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MJ?\ T,FH?^ .B?\ RLH_LK4_^ADU#_P!T3_Y65P%&]16#_96I_\ 0R:A_P"
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M<[/5_C?^RC<FV"F#2_!>FW^L6OQ;^ %O='S("?A=XZN_!&EI*+B/X5:@UO%
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M34/_  !T3_Y64 ;U%8/]E:G_ -#)J'_@#HG_ ,K*/[*U/_H9-0_\ =$_^5E
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M_!'_ -0^RK]1J_+G_@B9_P HD?\ @G1_V:#\$?\ U#[*OU&H **** "BBB@
MHHHH S-:_P"01JG_ &#K_P#]))J_%7_@W _Y0H?L$_\ 9./''_J[/BC7[5:U
M_P @C5/^P=?_ /I)-7XJ_P#!N!_RA0_8)_[)QXX_]79\4: /V]HHHH ****
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M_E"A^P3_ -DX\<?^KL^*-?M5K7_((U3_ +!U_P#^DDU?BK_P;@?\H4/V"?\
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MU_=WETMLLUQ,\@!_2UN'HW_?#_\ Q-&X>C?]\/\ _$U^-W_#E#X&_P#1W/\
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M'<_\%2__ !9=^U9_\VU '[([AZ-_WP__ ,31N'HW_?#_ /Q-?C=_PY0^!O\
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M>C?]\/\ _$U^-W_#E#X&_P#1W/\ P5+_ /%EW[5G_P VU'_#E#X&_P#1W/\
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M ,31N'HW_?#_ /Q-?C=_PY0^!O\ T=S_ ,%2_P#Q9=^U9_\ -M1_PY0^!O\
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M?$=U9:CK^GZ=+X<\,P66A:5?:G)-X@U;3YKNWMI5TJUU*:.6., ^C@ .@ X
MX ' Z#CL,G'IFEKXB\8?\%"_V7_ WQFU+X)>(?&MW:^(?#WQ8^#'P$\8Z^FD
M3R>#?!/QQ_:)T"Z\3_!+X4^)]<,J3VGBSXA:-#97&FM9:9J&@:1<:_X5TWQ5
MKN@:IXIT*SO:OQ>_X*'?LY_ K1OBMXF^)=_XST7PM\)?CW\,/V9M5\2Z=X+U
M3Q3I.O\ QG^+&B> M:\.>$_#LGA4ZQ-'%9/\2?"VA^(=?\4P^&/#VC^)+F[T
M6;5)+NS=& /N?_/Y=*J6-A8Z9:06&FV=K86-J@BMK.RMX;2UMXP2PC@MK=(X
M84#,QV1HJY).,DU\8?M#?\%!_P!F/]F#Q=XA\&?%GQE>Z5J/@+X7Z!\;_BQ=
MZ?HUSJ>F?"#X,^*?B/;_  F\._$WXAW4<D4NG^&=6\=RW>EV\6AVWB#7X]/T
M;Q%XGN]#M_"OA[5]:M:'[0__  4!^$7[.>K^/M UGP+\?/BEK7PY\"_#[QYK
MNC_L^_!KQ1\<=9>P^)&I>/+?1-/MM#\ C4M6M[W3]!^&_BGQKXDU#6[31_#&
MA>$X]&O+KQ =2\1Z%I6H 'W317YY/_P5$_9 O/A5\!/B]X1\=:O\0/#G[2OP
MI^)7QR^$NF>#_"^I7/BO7?A'\%_"R>+_ (P^.;WPYK)T.[T6Q^&NF36UEXCT
MG4W@\3W'B6\LO"'AS0]>\3WEOI3^DO\ MY_LP2^._P!CSX=Z1\0+CQ'KO[>7
MAGQ%XW_9?O/#WA7Q5J7A?XB^"O"OPSE^+FM>*(_&(TB'POHUA;>"/L&IQV&L
M:K:>(KIM8TR.WT21);B:U /L2BOC;3_VX/A1/^U;H_['^M>%_C'X.^)GC'P=
MXW\<?#+7O&'PJ\1Z+\-OBMH?PSN-&M_B*_@3QN1<VMS<>#G\0:')J<>OV7AV
M*]M]8TNXT*XU>'4+)[G[)H **** "BBB@ HHKYN_:N_:P^"W[%OP=U+XZ_'S
M7-9\._#W3/$/A'PG+J.A^$O$OC"\D\2>//$>G>$?"&EFP\-:;J$EDNM^)-6T
MW2(M5UB33-!M+J\@&HZM9K+&6 /I&BO@C]J7_@H]^SM^QU\0OAWX%^-UG\8]
M)TKQ]XC\(>$[[XM^'_@C\1_%GP*^&?B#XA:[!X8\ :5\6OC!HFB7'@OP)?\
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MR ?;%><?&'_DE'Q,_P"R?>-O_46U:OF\_M__ +.EQJ_[:?AW1-3\<^)?$W[
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M.T3QUX@_9RDT[2M?TG2=5TCQ$_[(;5.,JIQTX''THP.>!SUXZ\8Y_  ?08H
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MDB-R;6QA-S>W @(E,-K;@J9KB0(5BB# R.54$$U=HH _G9_8@\/?MV?L&?\
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M&/PP\!>+/AO+X9O3;^*=)USQWHB:EHT5M+-+'_1U2;5'10,'(X'7IGZX)&:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ KSCXP_P#)*/B9_P!D^\;?^HMJU>CUYQ\8?^24?$S_ +)]XV_]
M1;5J /\ !.HHHH _VLO^")G_ "B1_P""='_9H/P1_P#4/LJ_4:ORY_X(F?\
M*)'_ ()T?]F@_!'_ -0^RK]1J "BBB@ HHHH 0L!QS^"L?U (I-P]&_[X?\
M^)KXA_:$_8$^$/[2?CV/XB>-_B#^U)X8UJ+P_IGAQ=-^#W[6G[0?P4\)FRTJ
MXU"XM[E_!WPR\>>&_#DFKS/J4ZWVLOIYU*_ABLX;JXECLK98_#/^'0G[./\
MT6/]OG_Q8E^V-_\ /<K[S+LH\.JV!PM7,^-N)<!F%2E"6+P>%X#P>88?#5W;
MGI4<=4XVP$\53BW[M:6#PSG9OV43FE/%*34,/1E%/W9/$RBVNC<?J\K/?3F=
MN[Z?8?[4/[7/[._[&7PV'Q;_ &E?B?H7PM\"2Z_HWA>SU;6DOKJYU/7M=NEM
M[+3-'T72;2_UO6;F&$7&K:FNF:?=#1] T_5=?U0VFD:9>W</O.A>(-#\4:)H
M_B7PUJ^F^(?#OB#2[#6]!U_0[VVU;1=;T;5;6*^TO5](U2PDN+'4M,U*RG@O
M+"_LYYK:[MIHIX)7C=6/\R?_  4Q_P"#=O3?VD_ASX+O/V9?CI\8+;XM^ _$
M#_8M,_:G_:(^-OQW\ :QX8\37.F6?B86.H_$+7?'/B#X?Z_I-O:0ZU9W7A.&
M*R\51V$GAOQ!9^9<Z1KNA?:GP%_X(:_L[?!?X-_#KX67'QV_;8UJ\\%>&K32
M-1U?PE^V7^TA\(?"^I:J9)KW5KWP]\,/AQ\2-&\$^!M%N-3N[N33/#F@V"PV
M%FT2WMYJFIM?:K>_I&9<%_1]H>'W#.=X'Q>XJQ/&./SS.L)GF0_Z@X><\!EF
M%IX9Y?B)8&7$N&HX2,G)5%C%Q!F<,T^NO#T,%@:N2X^5;FA7S)XFK3E@J*H1
MITY4ZGUE^].5^=<WLFY6U7+[*'+RW<I*I%+]K=P]&_[X?_XFE!STS^((_F!7
MY6_\.A/V<?\ HL?[?/\ XL2_;&_^>Y7VK^SG^SEX*_9C\$:CX"\">)?BYXIT
MC4_$U[XJGU#XS?&7XD_'#Q1%J%_IVE:9-:6?BSXH^(O$OB"QT2.#2+:6UT&U
MOXM)M+R:_OK>U2ZU&]EF_+<[RS@;"X%UL@XLS_.,Q]K3C'!9CP=A<DPSHR_B
MU'CJ/%N<3C.FK<M+ZDU4=TZE.USKISQ$I6JT*5.-G[T:[J.^EERNA3T>NO-I
MV=].9_:Z_;'^!/[#GPL@^-?[1OB+6/!WPN/BO0?"&I>+M-\*>(?%MEX?U'Q&
M\\>FWOB*U\,6.IZGI'A\&UN'U'Q'<6)T;1H86N-6N[* I(Q>?MC_  &M?VK?
M"_[%L7B;4M1^/WBWX0:I\=M+\.:7X:UR_P!"C^&&C:M;:'?^(;_QK#:?\(G9
MS1ZEJ.D11Z&VJOKL\&MZ/?0Z<]AJ$%R</]LO]G&T_:I\!>&/@YXF\-:1XJ^%
MOBCQ+XCT;XRZ3JNLG2)I?AGXQ^#OQ5^&6MR:$%TS4Q?^(K.[\?Z=JFDVTATZ
M."33'OTU.&[M;2"Y_&C2O^"4?[9WP\UWX3>(K3QK\%?VA?%GPU_X)#_M$_L.
M^(_%OQ?\4^._"B?%3X_?%";PK)X'U?Q38>#- _X26/X.:3X:\"^'? .O:OI?
MC30_B/'H]M9SZ9&=16[U^OC3<_I(&J::T4$XO[(P7-T;&WF%U;F*>]6:2W-G
M#*)#'+=">*6'[/&S3>;%)%L\R-U4EU338$DDFO[.)(H9;F5Y+JW1([:!Q%-<
M2,T@5((9&"2S.1'$Y"R,K$ _S=?"3_@EM^U[X3_:)OOB/\6+;X+_ !H^!_CC
M]H3]IGQ+XT^!'B;XG>(H-(TKP1^TA\./V--4T+XE:"+#X966@M\1?A#\:?V:
M_$\4GANTTG1[6^\,>-+CQ/X/\0:9KMUK.G:MZWX-_P""5'Q8T"[^*/CZZU7X
M::1\3==_X+"Z[^V_I^O>'9[N_P!?\=_L<ZO\:/!7Q8O/V;/%/BF_T'2-1T27
M4]<\,VGCZ]\"P7&H_#NY^(WA/PK<7VLSQ75[K6G@'ZU_$+]J;X5_#_XO>!OV
M?_M.O>-/CC\0O!VO_$K0?A9X T.?Q+XIM?A?X5U/3-#U_P")OB9UFLM"\'>!
MK37M9TOP_I^M^*-:TH>*/$-W_8'A"W\0:Q;7EE;>C?#;XK>#_BKX+\.^._#$
M^K6NB^*(]6DTNU\6>'M<\$>) VAZIJ&CZO;ZCX3\6V.D>(](O=.OM,O([VPU
M33;6\LUC62Z@A1U)_#']F_\ X)A_M7?LF?$_P'^T!HWQ3T/XQ_$?4?V$_B!^
MQO\ $"QOO$U[H6I?#S4W_:.\>?M!? CQ?\+_ !'XI\/:_I7B3PG\.+3QZ_PI
M\1>&O$^D:1/_ &#X4\/>*_#MKK$DFI>#KCL/AC^P'^VM=?'?X$?%;]LCX@^#
M?VIM1TW]F;X%:7\1_$NA?%/Q1\(8OAQ^U_\  /Q[\9_&C?$;P#X#\!_#+P1X
M6\<?#+XF:1\7_P#A&=?\/:G8>$X-4D\*6=GXW\)ZYX5U&&TT< _:GQQ\1=#\
M"Z!=>(+JR\2>)([/6?!^AW&C^ O#>K^._$R7'C7Q)HWAK3+O_A&O#-OJ&L'2
MK&36H=;\0:I]E^Q:!X4LM7\4ZG+!HNDWUW#UKZKIL:7<DE_9QQV$JP7TDEU!
M&EG,XC9(KIWD"VTDBS0M&DYC9UFB9 RRH6_DZ^'7_!$7]L;P%\!O#'PJM-1_
M9[M=6M/V3_\ @F1\)?%TVE^/?%D.D^(_C/\ L2_\%"/$?[4/Q \?7<[?"M+O
M4H-9^"VN#X?> O$&I6;>()]7\SPWK.G^'_"44&HU]<VG_!+W]I6]_9+\9?!3
M4_$?ACPK^T[HOQG\7^)/ _[:G@OXB76L>)_BIH6@?$7]ISXO_ #Q)\>/AKXQ
M^'\VA^,M#MKW]H/5_A9\</@KXEU'Q#H^O>%?&7Q U?PIXHE72/!VES@'[T_$
M/QYH'PR\ >,OB5XG>\7POX#\*:_XT\13Z;9R:G>P^'_#.E76N:S=V>GVQ^TZ
MC-:Z7975U'968EO+SR3!9PSW,D4,G$_ GX__  S_ &C/@U\+_CW\,M8N;WX:
M_&3PKX>\;?#O5M=TR[\+W^O^%_%L N_"^J#0=<6TUC3_ .WK)H[O3K'4;2UU
M.2&1!)913;HE^>]6\*_M*_$CX*_MA_ [QCX)^$^@177@W7OA1^SCX@\(Z_XC
ML-#\8^&_%GP#TC09-1\:Z7K6C377@R?0?B3JOB2PDCT"/Q'I7_")VVE)ITFJ
M:O9:C]J_!3Q;_P $1?VS==^$/P;\*Z?KGP"M/'GP?_X)=_L4?L<:'K$_C[QA
M]BTGX]_LO?MM> OVA?$'Q!\-ZK%\-#J.F>%=5^''A75-(\)^*(=.M/&<'B+5
M!HE[X?TO1KJ_UN@#^M".[MII[BVBN(9+FT\K[5 DL;36WGJ7A\^)6,D(F16>
M$RJHE0%X]R@FO%/B_P#M%?"[X)1:JOC/6+Z75M%^&?C_ .,>H>&/#.C:CXI\
M5Q?#+X80Z;)XV\81^'=&BN-2N--TF;6-)TV".")[[6M:U&ST30;34]6F%F/@
M3]FC]F/]IO\ 9SU?]H/Q')\.O@-\4?BIXB_:<^)FO_#?XW^)?BGXOT/Q3XO_
M &7/VA?VH[WX[^(_!7CVUL?AIJ\_A_Q;\"M#\9>*](\%>'K&?7?"/B*]\.^%
M=/T;5?"6@ZMJ4.EL_:&_9M^-'B']M7XW?%#PA8QZQX<^/7_!,^?]E[P--J.H
MS6'AOPC\8/!'QC^('C=D\2ZE9Z/JUQH-GXV\,?%BVU6PU5M+U&*[E^&NLZ5)
M)'J#:#9:B >Q3_\ !4S]B\?!S]DOX[:=\2M6U[X>_MO_ !,\,?![]F^]T'P#
MXUU/5?&WQ'\7:OJ'AW2O"^HZ%%HR:GX+NX?$NEWGAG6;CQG#H=CH/B&)=(U>
MZM+R2.-O0[7]N[X#:QJWQ.M?"D_CKQSX;^#/Q6L_@5\3_B%X&^'OB;Q5X!\)
M?&.?6_#_ (>U+X?SZ[I5K-/K&H^$-7\4:-8_$76O#>FZUX.^&EY)J%CX]\2^
M';[0]=M=-_(KQ_\ \$;OC'H5Y\.X?@QXS\&:MX$\%?\ !9;X0?\ !1WP=\-_
M&>N7WAK2?@M\"/#VJR?%3XM? WX?76E>%/$)U#Q#XO\ COXN\?>*="MY_P"R
M_"EOH_\ PCME-J>FM9.C^N?"W]@W]N[]F#X?ZO\ LZ?LP_&3P9X.\&:Q_P %
M#/$_[3$_QNU2^T_5/$>K_LJ_&/XE2?$;XU?!#Q=X(\8?#KQZ6^,-L=3UCPMX
M,\=>&[R'2-;M8M,\5WNO^ M7DOM&H _0/1/^"A_[,/B3QW\?OA7H7BS7-1^*
M7[,GQ!^'GPZ^,/PY7PAKMKXO\/ZC\5?$>G>$_ /B#3=,U""S3Q7X%\0:]JME
MIT?CCPM<ZMX<L+EIXM5O;"6SNXX;'PT_;]^ 7Q>UGQYX6\ #XDZUXU^%_P"T
M6O[+?Q!\#2_"_P 6Z/XR\)?%?_A'Y/%CKK/A[6K33[ZV\!KX7C_X2.+XJ!6^
M'%]H3#5],\2WVGI-<1?&_P 8O^"9GBGXM_%SX7_M+:'K^F?"/X^_!W]L2\\7
MMKWA_5'U'3_CE^Q9XN^-?@#XC_$3X _%00Z/8O,=0_X1"S\<^"K*[CUN#P'\
M3?#]E<Z)K<%MXBUK4HK'B+]CW]J71_V\?AC_ ,%#/@_I?P>\&^/O'#Z]\!/V
MV/A7JWCO4E\&_$G]DS0KR2?X+^,_#7B+3/AE<ZAJ7[2'PUOH+/Q E[K6DZ1I
M>HZ%JNO?"JX\4KX7T/PSJMT ?K+\//B'X/\ BIX2TWQQX$UJVU_PUJL^KV=O
M?VRS1-#J?A[6M1\->(]&O[6YCAN]-UOPYXDT?5_#OB#1[Z"#4-&US2]0TK4+
M>"\M)HE[6OSZ_P""<_P9^('PB^&GQVU7X@_VI8S_ !U_;4_;"_:1\(>%];0P
M:MX/^&_QJ^-WB3Q1X T?4K'+'2M1U/PW]C\9ZEHTTCWFC:AXKN=+U!;?4;6\
MM+?]!",@@]P1^= ##-$I(:6,$<$%U!!]""<B@30D@"6,DD  2*22>   <DD]
M!7Y1_&'_ () _L__ !J^*7CSXL>(_B5\<]*U[X@^([SQ-JVG>'_$OA.TT2SO
M;V.".6#3+>[\%7UU#:*MNGEI<7ES*N2#,R[0M'X7_P#!'']GKX4?$CP%\3]"
M^)OQXU'6OA[XO\/^,])L-:\3^$KG1[W4?#NHP:G9VNJ6]KX(L[F?3YYK=([J
M*WN[:9X2RQSQ,0P\5XS._;."R7#NC[5Q5;^UXJ3H\]E5]E]2NI.'O^RY]'>'
M/]I_CD^+?&=9S/"0\'LBGDJS.6&AG#\4\)#$3RM8OV4<S>5_ZI.<:LL)_M3P
M'UMRC/\ V?ZPY+VC^]_B)^T_^SM\)/$/_")_$[XV?##P%XF&GVFJG0?%OC+1
M="U7^S;YITL[[[%?W,4_V6Z:UN%@FV[)##*%)V&O<4N;>2**=)XFAGC26&42
M*4EC=5='C;.&5D965@2"K ]"*_$S]OK_ ()9_$G]KWX]-\6_"WQ2\#^$-*/@
M;POX4&D>(-&\17^H?:M!GUN6>[,^F$6OD3C5(A"G,JF*3?P5S]H?M5_L#_#+
M]L"U^&,7Q(\8_$;PU-\+]*UG3=+;X?:OHVDQ:A_;\6@)?R:DNL^']=:;RF\/
M6QLO)-MY2SW(E$Q=#'G2QN=RJYK&64TG##5J<,M<L3&@L=2E5G&I4G5_VCV3
MITE"HDZ,>9OD25VX\V"XO\8ZN9>)E"IX99;6PG#^8Y50\/'5XCI9+#C+ 8G'
M8JCFF*Q>8SIYQ'+99?@:>'QM.$LM@\3.K]748N:J4ON3SX/^>T7_ '\3_&I
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M0\6?MBVGQL\2>'O$&D_![X]^%?&_ACXB_L=_'72M4EO-;T*_;X+:5\)?BQX
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MCQ#^SU_P4\U']L#6/'WB;PUX2\'Z]X>N_'WQX^"NH^'[;XI>)/"B6ZZU\<_
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MNFAFN%MDN(7N&M[>9+>>=8%<RM#%/(D$L@0I',Z1.RR.JG^;#]MK_@DQ\?\
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MF-:F^%_9FS$WV<W7VJ#[,+CSQ:^0UQYGDK,+DBV,1<2"X(@V^:0A_G,^(?\
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M_:[\/5\'V?A?QC\(OB)=>"M2\9>&/$NN+?6EFOC#4O$]_P"!M,^(VBV.H:F
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M#^T2BOXN_P#B-F_8,_Z-2_:^_P"_?P6_^>11_P 1LW[!G_1J7[7W_?OX+?\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>pipelinechart201710k.jpg
<TEXT>
begin 644 pipelinechart201710k.jpg
M_]C_X17K17AI9@  34T *@    @ # $   ,    !!]    $!  ,    !"AP
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   =    M $R  (    4    T8=I  0    !    Z    2  "  (  @ "OR
M   G$  *_(   "<0061O8F4@4&AO=&]S:&]P($-#("A7:6YD;W=S*0 R,#$X
M.C R.C$V(#$R.C Q.C,Q       $D   !P    0P,C(QH $  P    '__P
MH ( !     $   D*H , !     $   42          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M<9N[W^Y)OU*^M4GUKS8"VL-->??66[6AMGM-%C7[W?O+0_YS?6#]_#_SZ_\
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M[B1NW%N*/S4;&^IWUAIS<2X76!E-]%MI?G6V L8]EF0ST?0;O]@<RO\ 2?\
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MW_\ ?$#'J:,ACQ3AM,N/J4D&S@C=7^C_ +-GO5O*HLL#!6RJP!TN%X+M(/\
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MY^VRL-V[7-9[-]C_ &VK-J?]8C4UIRW.N@ D9>/M+CQ[=N[_ *2['\W_  ?
M^'YJE^</H<CXIT.#V_\ P3\TOFX./Y8?\S]S_#7CBXC_ +GVCWK]/^4WCA9U
MV)=E6>V-Q&7C:3I^Y^<JO5S];'8.)]ASPR[U;S:[[30TFLAGV7<\G99_-W_0
M_EKM:N7?S'?Z'Q'TD0<G^;X;Q\3S_P!\4N+AO_+[?I\/_<K<G%7^0W_1M\\;
MA_XP;V!V+=DNXWN&;C/;Q^9LJ'_3_,5G$Z=_C#;U/$?99DMPFWU');;DT6$U
MBQIO_FFU[F^C^8N]K_.^CV^C\!])34XJQ\^_]5A-U_DW_]G_[1WJ4&AO=&]S
M:&]P(#,N,  X0DE-! 0       << @   @   #A"24T$)0      $.CQ7/,O
MP1BAHGMGK<5DU;HX0DE-!#H      34    0     0      "W!R:6YT3W5T
M<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#
M;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$58
M5    "D 7 !< $T 1P Y #< ,  T $D 3@!4 %  4@!4 #  ,0!< #D -P P
M #0 +0 T #4 ,  P "T 4 !R &D ;@!T &4 <@ M $, ;P!L &\ <@
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!2            "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 $@    !  $ 2     $  3A"24T$)@      #@
M           _@   .$))300-       $____Q#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          3A"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #:P    8
M        !1(   D*    &P!0 &D < !E &P :0!N &4 +0!F &\ <@ M #(
M,  Q #< +0!& &\ <@!M "T ,0 P "T 2P    $
M     0             )"@  !1(                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P  !1(     4F=H=&QO;F<   D*    !G-L:6-E
M<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO
M;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53
M;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53
M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   42     %)G:'1L;VYG   )"@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     3A"24T$#      4@0    $   "@
M6@   >   *C    490 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 6@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M_P#FSSHSZ7T%7YS-+'@G,'6-?C+A9>6A&>6,9"P;T_P6M_SYQ/\ N)=][/\
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MH_ ?24U.*L?/O_583=?Y-__9 #A"24T$(0      4P    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !( 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# $,    ! #A"24T$!@      !P ( 0$  0$
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M 1$  A$! Q$!_\0!:@ !  $#!0$!              D'" H! @,%!@0+ 0$
M 00# 0$             !@($!0<! P@)"A    ,' @0#!0<$ 0(% P,%  <(
M 0(#! 4&"1(8$1,6%Q49"A! (10W(&!P(C8X&C!0-#4Y@#&0,B-&.J!'*"4G
M*DI!)"9)$0  !0($  8,!P@,"P0# ",! @,$!08' !$2""$Q,I(3"4&1T2+3
M%-35-Y<XF%'A0M(5EM808:$C-946.2! <;(SDY0VMA=WMS!0@5)B)'6G&'@*
M8'"B=K%R4[69\,'Q@D-S-"6X&6.T@)!$)B<H.J#"*8G)@T96QTA8:,AY$@
M P,$"0T*"0@( P8% P4  0(1 P0A,1(%05&1H3*2TA,U87&!T>$BHC.3TS24
M!A"QP5+B(Q2TU#8@0&!P0H)T%77P8G*R\I75!S#"0U/C)(2D4/$6@&-S1,0E
MD(-DA0B@HU3%L\,W%__:  P# 0$"$0,1    S^    #XZEE.>QX
M               ]C;]O75\>?[>L                      56LNRE-[U@
M          >ZM>WSG;U]1V\           57L^RE%YU@          5:M.VD
MMWU           58L^VD]YU              "J]GV4HO.L
M           "\7 7_>\<@   #QM;\I7W!I0                        2
MR0"06\9FRLBDV,                      &1]IR78X.XXB          !,
M?KB06027'VGR+'@          9(&H)=C?[?B(          &2#J&6XWVWHD
M         !D@Z@EN-]M^)              #) U!+L;_ &_$0
M             /U"_%6X[D;&X    'CJGY3?M[2P
M    E@@F=MURUC93);                       9'6H99CB[>B8
M   $Q.N\[9!)K*U7/8\          #(ZU%+,<7;L3           R/-22K'#
MVW%0          ,CS4DJQP]MQ4              9'6HI9CB[=B8
M                'Z@_B[<=QUAW    #QU3\IOV]I8
M       2P03.VZY:QLIDM@                      ,CK4,LQQ=O1,
M      "8G7>=L@DUE:KGL>          !D=:BEF.+MV)@          9'FI)
M5CA[;BH          &1YJ258X>VXJ              ,CK44LQQ=NQ,
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M>-O#=RX^.:@6%<Z&O)'3#LZH/]G1[B['(;NIP\]?)7V<E/ 'Z@_B[<=QUAW
M   #HN6'IOB"    ;3CHHWUU[P       ;#2BC=77N         +PX_?TTO.
MB@^4MP                     !)_#<O&!,L0          !>[&K^W[*=-(
M\C;           2?0[+Q@S'$           2?P[+1@3'$@          2@0_
M+1?S#$@             "3Z'9>,&8X@                   ;:6SFCEYK
M   RTM&SBJW16    -#B                        !J:<\..0
M              H*P          "AIV<:\<@          *"L          !
MK0TK           :T-*P              4%8
M #4Y0
M
M                                    46O.B).=X._B+Y2]B.W\/4_P
M$M<%SMH>=L[EL/=4VN^J+B9X>3Z'9;Z::HL9KAY*(=E;E,7<V#2BPD9BN2^6
MA%O-<-2R[HF!@>9[I5%],,50G(6<A<5R_0U+A,?VVH9VVO\ XS?@
M
M
M ;3\\/U+JW)8U'+\:G;,4S@/.>P_SF_6>KLJG1\SMVS=C/GJ^187'H&#906H
M);=C@+_"V] :_P I?4,QQ;-OQ+.H\V[#PX=_P+/<\U;(@)V-&8?Y[B+Y(U?6
MO9BSOOCF2CFEN(EU@F?EB@^7P8_2>NY-X7F)8X+FIB(;G
M
M                                                       /.GYZ
M?J;5_P"B1Y9VABA;FA\B$9O\?;9\=IC>]5VF"N9HH)GH(-A1_.3\\[!M5O;/
M#=]#0//,\V;(PM]^P*<#7<BQJ]NQ+/<\T[(PYM\02;_6LCDSAV8_/7]6:LNS
MPU[D?Z:E^+[NN'9=.B)O$?.<)#!L/!9_WF/9//R
M
M                                                 V'Y]'IS6\[.
MM<_CZ;5C.=9YLV)AU;\@N3EIN6_GN>IM:_HL>4]FX4_H6#Y)>I)/(%$\EA@[
M\@N1;K&2XY.V(WG;^:-A8"OJ76>29J"7>[Q_="YL6/WD1V^^'BBZ3%W\>,JQ
M5"+_ *,I33<OX7,(^RX[F :(FX
M
M                                    %.[CJC)F6'O?C&3N6QEU9AFK
M&\_ WT><GQM[&"OO W/7'M+<=(U#<E]CF-J88B06*96L%AVQM2G'\EUUR#P[
M+6;2&PIC=V\G<1R_+QQ'%*,7XFZHDQB&6Z+M4=O;>ZS%W8
M
M
M
M
M
M         X::=>           &VNC17OH           :=G&O7R
M  [.'7R          !I5QS<U@
M                                                           "
MA,*D^*1\M?J"          !?#NG3= 8+,J.1"9           2B^F_-<77F3
MTH          !*/Z9\VQ<>9O20          $KOJ3S!.A[;\;
M                                     <//.M/.BCFYY   'ST/HK #
MY^L/H[  'S=;Z>P            !9D5<*XFTT-YL-YQFTYCP!YTK"4Q+<RII
M1PN[+>RNQ[TYBF!4HH4?&=*59+:2\TL1+XCQH!4THN=@;2K8 +>X%-,)KXQ?
M80          "1OT/HBV;6VPK?8#-0          )F/8/D^&?Q]ZP
M    F6]?>4(:?(/J\          ";3V=Y R-?H9X& X@<H   !Q Y0
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M)&2B'UG<$'Q-,1UGGR5P]>1SEZ1CR&3"6PE\ +6CU9]P+:R*@R5P8VI>03!
M@.-"48[\W'PE"2^@L )(CD          !^<QZIUA+M!,KVW%S7S%]\6LVQ->
M\5W35ZYD6.+M>'W^QG)QU2_&2&1/+T!O[3WW%4G<&S7J^></G?$)RW]#32TV
M06=*+WIM>S%G5"V[;Q8_D(M9MB;AL1<[.>G+%T?.(6K;MC\.\/;DSQC!F1Z6
M5GH3(*       !B GQ%U)6<H"?2><*[E$2H)D?F-@>>+_"P,MD,E<Q$23LN%
M)%C'C)OB-0R6 6P&.B5',C4QX"/(RT3%Y!?R>-*!D^)?L<X +>X%-,)KXQ?8
M0          "1OT/HBV;6VPK?8#-0          )F/8/D^&?Q]ZP
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MI:]%WT6\Y.S]!TU^\H[;<LM;96FE9C 33S=2;RTLOY*)%J)X@J29%
M (/3W!>&72$#!( 6/EUI0 N*+LR&0D^+W"S@CC+T2I9Y4C!+W24LYS'6,BD$
M)I<$=X6,DZ);J79EG -3YR\@LS+T@ "WN!33":^,7V$           D;]#Z(
MMFUML*WV S4          "9CV#Y/AG\?>L           )EO7WE"&GR#ZO
M         FT]G>0,C7Z&>!APF, 4U)/24XQO25(B^))2MQ:@2]&+R2GE.S[R
M/4E&(Z2[0Z(G&     ,8(F[(]RCYSEQY5LH,6KE_I864K)%2WHMH)#RG!Z\F
MU,<DOC+;3UY907-%T)*D0Q%MQ? 2G$-92XI2>H*_EPI'*>S+.3)>*O
M     X')PXJ4\;:N-RJV'+6<0,^P\DD.R=_,;R.WFEQ5KQ2KJW<4Z4\:5MRO
M;13NKYVBAMJXU<[N>>932LJ:#>#8:'.4M*I@            'SF\Y0    <)
MS          M[@4TPFOC%]A           )&_0^B+9M;;"M]@,U
M  F8]@^3X9_'WK           "9;U]Y0AI\@^KP          )M/9WD#(U^A
MG@8#B!H<QQFT&TY#:<QQFAH;S0T- #F     .(U-#:;3D-IN- ;CC-QH#D-I
MX4]^<1H#0WFTT.<X#<<1]1P@&X T-AO-#F              -AO
M          !PG,                      "C\7D&.7\[_?X          %
MV^V-7T;B,NI9%9$          !(-O_1,?.@-[           2#[^T7'QH'>@
M          $CGH704O'K/RZ
M                                  !1H^8
M 'SX+)Q?^4/5H          %<9I"J=Q[.>2QF9           NHV5K2U?6NR
MP          ),/1WG.X*>0T          #933S]@
M                                                     <)Y\[\Y
MP#@.<^(^ [P' ;@<H . Z,]&<)L-X-#G. &A]      !;Q )IA0?&+[#
M       2*^B]"VT:VV'0'7LW           F2]C^28;?''K8          #+
M$^J/S"DB]%Z"
M                                     &*(7>$MI#@26EL)&J2TGB3V
M!9V9 YC<F146@G5EO9W)3 M)*R&028XA\19F7#GW&4"1J$91]1DL&\     %
MO<"FF$U\8OL(          !(WZ'T1;-K;85OL!FH          $S'L'R?#/X
M^]8           99GU2^8<COHC08
M                                                     Q;BYLIV
M66$H)3T\44Y,@0PSC,R*_&-47ID8I(.19EUAV1]0)!R(0N./?DD)!<7YDSIC
MC'7&1^=B     "WN!33":^,7V$           D;]#Z(MFUML*WV S4
M    "9CV#Y/AG\?>L           ,LSZI?,.1WT1H,
M
M       1 EI)<N6JDAA;.>J*G$CA9(1T&0Z8UQDN'6D*ATQ>>:E,2F9-*1Z$
MAY:41 DD1(8<I'>16&2\<H     +>X%-,)KXQ?80          "1OT/HBV;6
MVPK?8#-0          )F/8/D^&?Q]ZP           RS/JE\PY'?1&@P
M
M                          !TAW8       !TAW8     !;W IIA-?&+[
M"           2-^A]$6S:VV%;[ 9J          !,Q[!\GPS^/O6
M   &69]4OF'([Z(T&
M               .$W@
M      %%(?)L7OYE_24          "\W<^GZ'06:4CB4L           DK]'
M^=HU/.'HD          #(4]_>#+V]S:G
M                       &PY@     "S\\\
M                         >5CUW9_Y ]#@          >[G42\W'<OU&'
MRP          %\_N#S7NYJ           V]?&^OD
M                               =B7H        X34T<\S@        <
M9MYXYN.0            !P&H.8X34Y3@-30&\VFIPG*<P             *.
MZJF>-S^<WZ^           7>>L= 48TWL2E6LIV          !E4?J'^*
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M)^N0          %X'K+1E%-03ZE6K)J          !E4_J)^+
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M!+N76@ '&8;AV1?J1UGG21<R.S' *AE%R*LE^)NS'V)!"T@R/P
M   4?U9-<;;\Y/UR           O ]9:,HIJ"?4JU9-0          ,JG]1/
MQ8                         \"8M)*"8PI(X58*R&I9X1TDCA5PRE0
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M;\Y/UR           O ]9:,HIJ"?4JU9-0          ,JG]1/Q8
M                 X#<;0:&H-P-IH:G.         #C.,'T' ;SC-YM-QM-
M#4%K!:"7;%UQ&V7&%RA:\73FIM-AJ:F\T-#C.8M6+KCA-0<9N-P.,^D
M                            '&;@                      4DUK*X
M!_@A]20          +H?36DJ2:MGE.=;S$          #)5_1S\BP
M                                        !Q'*#B-IS@
M                                  %&CY0
M =WB^^G'GW:H          '>RS =/@<CQ6-\          !<WZ6U&
M
M                              !Q&AM/H/E-YS@X#G!\Q])P@W&PU.8^
M<WFIJ<9J#F        !1O54SQN_SE_78          "[OUGHFB^GI[2S5LY
M          RJ/U$_%8
M                                                       "%P]8
M0U&6H8?Y+F3B@@I)*"ZDPR#,H,.DE%/&DQAC.F6<8LI( 18&7Z8^)4([TFZ
M       !1_5DUQMOSD_7(          "\#UEHRBFH)]2K5DU  H=.HQ:QM6$
MUG@\FNRU3/-.KIT[J=U%>XX^.S=5U[E5HNUX/=OJB;  #*I_43\6
M
M                             !Q&&R=T7J%M)9V2L&1V<AC1%K)-N01E
M3CW)Z,EE+8C'@)?"II3@[(R.2*L[PCA,EX        %']637&V_.3]<@
M      +P/66C**:@GU*M634 "&/V9Y_I5*L3<;K>5>7R^*[ZWOZ,RF.W P*3
MV[;'C-38UE+=I[$KR=1;!M)VW L@7Y\^J  !E4_J)^+
M
M                     \81>'FSU9':7W%,SB)Y#&8)Y2OQ$X1S%]QXDI<6
M5F6(1 EF)?"<A*68C!D+$5ADT@        H_JR:XVWYR?KD          !>!
MZRT9134$^I5JR:@ 1.>KM'RM>6=W1,>JM'VO;:A755TR.>;ML1Y>A-5W^Z(V
MA9=NK7=R&MY=;WL"*>VP^4FI\5>@@ !E4_J)^+
M
M                XC4VF\V@U!R%M9<H#@-34W&T'*<)J;#D-IRGFRE!7P
M      %']637&V_.3]<@          +P/66C**:@GU*M634 #2IK2W5<;:2G
MA75KQ4YXU-M'&M-6O;QMXX  &53^HGXL
M                                      #@ZVO8   4-U;<
M                                        4>UE+L<_\ZWUK
M    NW]5Z1HQJ>=4OU9-           ,I'].WQF
M                                           VG( #']V7&XV9=B
M )/H=EY)M;R3HP
M #H;6XH[#Y6          !W.0QW46=WMZ^X          "X"=0P
M                                                      #[B](
M&#SZ*@./AM:*   9'6HI9FK^?)[N!P4\[JN-KC=37JH5<[%6^BG;7QIQSK0T
MK:\5;>*?HK                  <1L/H!Q&P^@XS0Y#:;P
M  "W> 3+"B^,GV.           D4]#>?+:=9['H#!9X          !GR_=KX
M?@                             <9L-I](
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M9*HIDZ-7_1R4TRF0K,]#<<7B1[(QCS/"W":KE5L!3T]@3-D;Y)N1='PF02
M           #&P+NB)XJH5D+$RZ4^$RC3'&+^CWI&.1U'2EZ)X<U*=EZQ1$R
ML0          "WN!33":^,7V$           D;]#Z(MFUML*WV S4
M   #/I^[7Q'                         &,<4()%BTL]:2+F.\33%D1+\
M5]*"DC(        .$Y0#B.8                       P>?14!Q\-K10
M#(ZU%+,UOSY/0,9/;,3HID^FZ#"W/PEE,@Q]X.#R5W6 O+$)7C/*4]=S&.N9
M)(CF**9*UQV=K1>:O7F>J;KF2T*,@8@/*3DPQ<B10E!#(0             !
M (?(6J%TQ40M^*4ES)D"D')(N0'EUQZPU-"V<T+ER^LQ_C+=           +
M>X%-,)KXQ?80          "1OT/HBV;6VPK?8#-0          ,^G[M?$<
M                       8OY7L\(6RD]IB8$J)YDMC,H,NJ         !3
MDA* )Q3VP                      !@\^BH#CX;6B@  &1UJ*69K?GR>@?
M/3QJJW<-*FO7QLKYW\\\7#6JE0W5->>=32AMKXH.7 '$;3G!P% RX,
M       ' ;C8<AQFXT!SG$:G";S4T-38;C4T-#Z           "WN!33":^,
M7V$           D;]#Z(MFUML*WV S4          #/I^[7Q'
M              %*C[#A*1EII::3>'0EMQ?:=J
M             #!Y]%0''PVM%-7/J;>L<'//G._J&1UJ*69J_GR>Z@
M                                         %O, F>%%\8?L8
M    !(GZ&\^6U:ZV10'7T[           SX_N[\0
M       !\QH?4                                   :'( #!Y]%0''
MPVM%*PV'?G.^:=CQ.SG!T[N^K&GW#$AD=:BEF4KY\GO3
M                                '06?=3K 2,          #[[C'];T
M=V_BZ           K)*XL
M                        !]9>H #!Y]%0''PVM%-A6W'W'H[:NW+,V@&1
MUJ*69JOGR>\@.&ANK.MO[''QQNIYVUN4XN&BKFYIX>*M::=*JN;FD
M          #C-QN!PFIRG :G(;#E     .$WFPY@   <1RG$<H/G/H  */:L
ME^-Q^<OZ^           7=^L]#45TQ/:7:SG@          &51^H?XJ
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MN#)%-A#&32  %']637&V_.3]<@          +P/66C**:@GU*M634
M   #*I_43\6                                        !2P[$HL=^
M7$FTU+5BO!XPZ@KT:%L!="64EZ9O.0                &#SZ*@./AM:*<-
M;*%TC,*VXV^C"F^%A0V-&QD=:BEF:WY\GH'YKGK+5.1/JJ4T!RUOXBOJDNB&
M7K?9]E'+SKC(F.&]E;=BKLGXU=(X+=F1^;/7&<@1V;',I+1LX@M+<"V\R[B)
M<F2,?LR7" ,O^(_B?XQ520LIN74$FI Z>*+SR5,       &+.2O$&1=">H+:
M#Z3W1E&F.$2)GN"-DB>/M+YSP1]A3@N/*=EV13P[LL]+;BIYZDHB7 FXLZ,[
M@PAR7PC%)DR#XDF,CX  H_JR:XVWYR?KD          !>!ZRT9134$^I5JR:
M@          95/ZB?BP                        !P'. ;#>
M   "E!CS$0!,65V/H/#%!R^@C</8E]![THR?60VD^Q:*9%H
M   ,'GT5 <?#:T4NEP-_(C$;^$'9<?R;]+3+&8W5#QD=:BEF:WY\GH&(WNR&
M4:OK6[C"9'IZEJN?Q\O$$S<.6P,%?;%+_P IW*<Y#IRO='S7&9W!$[D\1WQV
MRC'9-NCIM$677EOA\)[8D!(]2= Q=27TCJ*\%CYZ\I^>U+_"@)YTK83/
M    @$*-%M!<\5.+3C4K@9)9CZ$G1 N7!GIS>;"V$^HN5)1S%');SWA,D09%
MDQ)F4C-YJ4$*W&0T05$+I+21_'L2](O&)1@ 4?U9-<;;\Y/UR
MO ]9:,HIJ"?4JU9-0          ,JG]1/Q8
MHV0T $\QVH            !^>^9#A;X?4<1[(N.(RB9XC.+>B.8GI*8GT%L9
M>&9+P                ,'GT5 <?#:T4N8PM]D[:4F-,K_I]M;5XA&_X&,C
MK44LS6_/D] X*2OAUMW-3BG7DY;..=O#3ES\MO'&SAN<[ZUH1=V:@'(<9R'S
MFXW'":FX&XT-2TPNI/O       !P&IM-X-IN.,^DX@<1O-P-AO. YS8;3<;S
M<<1L.4U-AO!H<QPFPY#:;3D-IS@ H_JR:XVWYR?KD          !>!ZRT913
M4$^I5JR:@          95/ZB?BP
M       !:*7*%#2AQ]16@]$<9&<2HE!34]^4K+?R]LC=)K@
M   8//HJ X^&UHIV/5SE:Z2FD:<PQ$,&PX_R\5#(ZU%+,UOSY/0
M                                      !1O5DQQO/SD_7P
M  "[GUCH2BVH-ATOU;.           ,J?]1/Q2
M                                            &#SZ*@./AM:*7EQR
M^E*A>;NYCM[C[;8C%G4AL!D=:BEF3_Y\GOG
M                       #H<5W46TUL,          #O9+BOBPN0^:SN0
M         +@-]ZR
M                   [4OJ !@\^BH#CX;6BE1K.XF@UYG'-7D+GKA(V+'1D
M=:BEF:KY\GO,                            <!O.0X#G
M     !2#64LQ]OS_ 'U8           NI]/Z0F_^U_SJ
M
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MUEHR>G[K_,L                                    #@.< V&\
M       %!B#HA-)BRZX^H\J6ADFI%T?.2=%2RTDJ(09&1<6<$_P
M       ,'GT5 <?#:T4   R.M12S-;\^3T#"[WW!J2WEO>5@LCU7;1:YE;&7
M^!9Z';86"O.CN0Z'OZ:=WM.7SH2<8K&ZHA?S%+RQN2V&0'IN915'QFAZDWDF
M)&(9 !B-DZI8@5!*\%?C&A+ACYR_TI66>EVID%@      $$Y924;*_E4BRLJ
MH5!,H QOR5 @V*HGJ ;2V0Y"Y<EC,1PSP@          "C^K)KC;?G)^N0
M        %X'K+1D]/W7^98                                    %%
M2&H GH.W            !Q'Y\9/04\.U/D.R+FB-8GY,?HY"-0GA/$':%J)<
MN9/8                ,'GT5 <?#:T4   R.M12S-;\^3T#YZ:..KC=PW4=
MO3=]'=]7"FK;6^>EIV\?;15PJ.H[.>YZNSEJIL0+[30T!SG$<IP'&<QYX]";
M #4'.<!8N7W@      'EST9TQW!J;3J3MSF.$'3G;FIO-AUYO/O/E.N._
M        */ZLFN-M^<GZY           7@>LM&3T_=?YE@
M                      <9N -34             CL+V"V H6<Q<&>H.N(
MNR60MF/C*UE%2V\OO+"R<<                &#OZ)@6/;M:*@  9(&HI3F
MM>?9\                                                *.ZIFF-
MU^<KZ[           7>>M-!SU_=?YH@
M                                                "%*?8"P64V
M $AT3R%[$$SW0
M 'F,'<VR>8=V@          >OF\<N/\ 0^JMW5P          !L[F_I
M      ;:JN3CD
M    =D7G  QV?4VK8OMUPP  "5S0LXR!_-&S=P
M                         !0N%2?%(^6OU!           O@W3IJ@D%F=
M&HA,@          )0_3?FN+SS)Z4           R0/H?\_;Z]X:9
M                                           '$<X ,4;VSIB&+T-K
M\  ";WS+L7*9\=;B X:.-G-/TU5@"@]_;5XL+FB]YU?1134.T[.WJKY@
M 4)O[>NUA<#A-QM-YM!J:FT'*      "&8N )%#0CF*FEY9'&5O(@23 O[!N
M-IH;P;0;CE+,B\8W&T 'B"VXO/+%B.$DV(P"7TN3+<#PQ\Q>B 6]P*:837QB
M^P@          $C?H?1%LVMMA6^P&:@          3,>P?)\,_C[U@
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M.,94RJ2S\B&//&2^ 6]P*:837QB^P@          $C?H?1%LVMMA6^P&:@
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MIA-?&+["           2-^A]$6S:VV%;[ 9J          !,Q[!\GPS^/O6
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M3BFQ;$7MGU@IB16DT !;W IIA-?&+["           2-^A]$6S:VV%;[ 9J
M         !,Q[!\GPS^/O6           &69]4OF'([Z(T&            .
M,U -#D             (=B2<LS*'G,7$'O"F1'D2]ECQT)=(4'+:"_DM:)R0
M                8HWMG3$,7H;7X  $WOF78N4SXZW$              /F
M/I   !\I]0                 . YP       #@.< MU@$SPH_C)]A@
M      )%O1&B+9=:; H' IN          !,C[!\EPW>/O6@          &6)
M]5?E_)%Z%T,
M    !BC>V=,0Q>AM?@  3>^9=BSM>.MQ>=
M                      *?X?(16>5O4(          %:9;#*?8S/\ E\+E
M           +G-G:WMCUKLH          "1WT)Y_KM.88
M                                    .R+SP 8HWMG3$,7H;7XV]O.M
MOUZ=G?NXZQ-[YEV+E*>.MQ;P
M           "F\!D4.?Q^]_@          7 ;ZU?3+7LJ\9!Y,
M!.I]O_F\
M           !QG, #%&]LZ8AB]#:_P#28_LR!O)VT*3R2UW<4P5^GM;B;WS+
ML7*9\=;B X*>->>=.OC2IR<-E;<;::M*N-30U-.&ZFKF[*>$W@U-AM-QH#F
M-AH#4U-AO-P       !%45<+]30L8/8EVI8T>V(MR_LO[!H#<#4T!J<H
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M*:@GU*M634          #*I_43\6
M        !:J1_D%)*<2&'VG:$.A-,0L%TI) 5*(RR[4QT3*&+.R6T
M         &*-[9TQ#%Z&U_VUE7=C"\Y2"26-Q<+REAFT8T)O?,NQ<IGQUN(#
M\\WU'K"_V+9&LEA>TGNK6XS%7]V&*[OEH[HQI;@_:T=CCL<];CLN;P/?&/-,
M1EB>>-B1L%C)) 4V+Z2',^4FF(13+!,*8RV"&0R&2 DZ,EX(*RN1D$@
M  %LAC;%=SS15,CA)S"PTR@S' )#SPA'H>P-3D*=GRE0"8TQUS+J
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M$M[*\D-!):?$:&I10^XJV="6B$KH          !1_5DUQMOSD_7(
M  "\#UEHRBFH)]2K5DU           RJ?U$_%@
M  #B.0 V'(             0#$NA864<.0N+*EE%BQ8EN(^SQI>D4"+9B_DH
MT3F                 Q1O;.F(8O0VO_0V??=;",O,+H"=0S>A(#:+/L*)O
M?,NQ<IGQUN(#BXJ&ANYITXXW4\[*^.9SQCBIS2XJVJ=W+D.G.T-YQ',<!N!J
M :&IH:FAN-A\!VH                             !1_5DUQMOSD_7(
M        "\#UEHRBFH)]2K5DU           RJ?U$_%@
M                        #@.0T-QH;#D-IM-30W&PW&AJ:G(
M       #%&]LZ8AB]#:_]MBN^2'4LO\ ;X;MI-G[:,K=,-$WOF78N4SXZW$
M                       !38X                       ?/%\U'[\X/
M7(          %7-M0/Q,-D/F8OFP          )6OJ/XL
M                                                   &*-[9TQ#%
MZ&U_KPTIHF@\\; A?]%0(";WS+L7*9\=;B                         \
M\;@                      >0A>>BU^5_M\          "MNZM;T_@\C\E
M#9*          !,Q]A/ 0
M                           Q1O;.F(8O0VOZ[1'*3@^=-CPL>A]=VW3+
M$ZN!-[YEV+E,^.MQ                          "U0]B5X-Q:P>\*SEKA
M4HM=*^EP0-IH: U-YL-#D*7%2S0H45\*#%<BP(NY.@*REN!4DY3TA;05V/C*
MG@ H_JR:XVWYR?KD          !>!ZRT9134$^I5JR:@          95/ZB?
MBP
M        ,4;VSIB&+T-K^ZJ"9RZ&"9NI>*NJWQS)8_7J[5@F]\R[%RF?'6X@
M                         !AG&401-EVA8R7'%KQXLR*3%H)T"Z0M@(H#
MMR]8\R?4>'/3G 3BF,^3CGE3#W,T@P42<4E++CC&C)K")T],4_)^BD)$T>I,
ME\ %']637&V_.3]<@          +P/66C**:@GU*M634          #*I_43
M\6
M        !BC>V=,0Q>AM?U"PU]<+$\E0^36?UT=5'9%8";WS+L7*9\=;B
M                       %BI"45).B/9D8YD<D;!DS&-^2!'IR+@[L^0^L
M\V?(=H2^$*YE%&-$5?/#GHB!LE>/D)RB!HM^+@RN1\!>R7>$;)(L0[&2^ "C
M^K)KC;?G)^N0          %X'K+1E%-03ZE6K)J          !E4_J)^+
M
M    Q1O;.F(8O0VOZOQO*9#_ )*V?VUNIUFK;&P]CZE$WOF78N4SXZW$
M                      (#"_\ +4RZT]4<)&82+%]A9T72$!9*$?6:FXMV
M.8N!/E+%";PQT#(H-Q:F4O/<E4R%TKL2]%J);85M*['O2!@O=+*#(I !1_5D
MUQMOSD_7(          "\#UEHRBFH)]2K5DU           RJ?U$_%@
M
M 8HWMG3$,7H;7]U$)S<_OEG9-4<)?^*R-MB?>YM*B;WS+L7*9\=;B
M                              ' <X       .$Y@ 4?U9-<;;\Y/UR
M          O ]9:,HIJ"?4JU9-0          ,JG]1/Q8
M                                                   &*-[9TQ#%
MZ&U^ZFO-(T[.3D3>^9=BY2?CK<7(
M                4\A6>B6^3WND          "N6[M;4^U_)_'1&1
M     36?9;Y\
M                <1S@ Q1O;.F(8O0VOP  )O?,NQ9V?'6XO/
M                                      %'+"\QGM-[@
MN_S\9R =KZXUZNP          #?50
M                                !V1>> #%&]LZ8AB]#:_   F]\R[%
MRF?'6X@/,U=?==?9U/=U=MT]OB[KK]W;=GE.^GN>OCHN[GU70^+GGZNJKR5Q
MU^QZ:N3GG0&H.4X#4&TW%-BIX           !X8[D] "B)[@]L41*I'ESOCT
MP               !9S'\O\ EQ^,O9           $T4]U]^B!ZP\P@
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M!EORX_&'LH          ":2?:^_0^]8>8
M                         !:T42(=B^XEQ-AV)"^2K%LQ1TE%.T+"B]8@
M6,@HIX5;                !BC>V=,0Q>AM?@  3>^9=BY3/CK<0& )Z:UO
M<?A[NYG%75&+SHK#:]]9,=W718"^OYC&0A^G6&MQD%G<O@[N02(9''\VQ&Y.
MH9D^PUG*:9ELYDR$:I6L@S/9D\A&N>@)^3Z@           "*XCL/O.D/8D7
M9DDD;1DOF-^7]GN2+P'6'>'GSX#@)<"+8R50          "SG 9;\N/QA[*
M          FDGVOOT/O6'F                                     "
MC9#& 3V':             X#!S*O%[Y00^,\>7BE!"O)%<7H%NA>H4[*'';%
MAY^@B                #%&]LZ8AB]#:_   F]\R[%RF?'6X@(PI;B*?W?5
M[_I[O9679$K.,)/_ *PD\(^Q8W(!%<M8Q*<5+%!L[3"]Z;A,-=PI[,CDIT!S
MED^$OJIEO9?T7O'U%D +5BH128FC            ! 47D%IY=2>T.K(X"_\
M)-"P O#,?TDG.Z-H+<CG+A3UA'$3X@          %G. RWY<?C#V4
M   !-)/M??H?>L/,                                     ' <P!L.
M0             Q%2?LCC*=G1ETA64MI*%%Z!8&4*)22WTMJ+]3O2<H
M           &*-[9TQ#%Z&U^  !-[YEV+E,^.MQ        ?,:GT   ' :G,
M                                  "SG 9;\N/QA[*           FD
MGVOOT/O6'F
M   #YCF.(U!J:&T'*; ;0;C4',                #%"]KZ5AE]"0(  ";[
MS5L3*5\<[CW                                                %
MM>'O\%;S3Z0           DLF$.S$=_:1
M                                                 V'* "V"4XJD
M\CLP  *OQJ^\O&,GY\
M      \E',E99XN]&           5!V'$?-1W,]''LL          !(![T\P
M
M    =B7G@       X7&YSLX;^6RGKUY[->.=:N%#3AKRTX:5U...:K@
M            #YC><P/"'NP  #YCZ0>$/=@             HYJJ:8W7YS/K
MF          !=[ZPT71;3FP:5ZRF8          &51^HCXL
M            #C-3>  <1R@   '"<P     . WFAH<P!Q@V@Y@<)S'$<H
M                    ,4C<D,R)]52N%?8<>O#P60C6EN(FJU_(X)MC1F4Z
M&YJFES;^/[^OV'1V>/[^OPO>H+F+/*JTU,: E?3:;BF!M(\2[0L!)HS>:GP$
M,)<X4M+V2SLO2+@P       #%5+PR^LH:68$F)3 K =>6&$TA"F4K)?B.(IL
M9(0             */ZLFN-M^<GZY           7@>LM&44U!/J5:LFH
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MC&8]?@[N&<C%+P2H)Z,^0NM+8CK294C+*YG;%O!2@^XNO(Z"YLR#0
M"$,^,]Z4++R2CA20N^+Y" <E#(R2[8HX6]%^Q+R             "C^K)KC;
M?G)^N0          %X'K+1E%-03ZE6K)J          !E4_J)^+
M                %+R#@MW/'$A!>Z0]$G)#L=>2$%[I?68FQ6(LY*UE1CNR
MHQ9N79$B1[4OJ   !A8D_!:.6['(7,%;2S\I>7?EEI9\2ZEO1;@7MGL3(%
M                    !P&M/.Q3KS5OHIVU"O3FG:XUXKTYHUXKW5T;J>=W
M*&(\<>R)DSD-34VFIJ;3<;#<: WFXM1+L0       #8#0&AJ:FTY3C-YL!H:
MFIO             !1_5DUQMOSD_7(          "\#UEHRBFH)]2K5DU
M        RJ?U$_%@                        #@-QL-X.,'(:&H.,^DX#
M0AC)F3D-IJ#<:&T^D   '$#8:&IO!P'(;S0&T&@-QS@
M            '$#8?0              #C.0                      %)
M=:RJ!GX2?3P          "YWTSIFDNKIK3S6\Q           R0/T2_)D
M                             ?.?0
M                                    4:/D
M  !VV'NZ3^;MO           >FEL?Z/!W_RX[(@          79>J=+
M
M                                 <9M.8'$<H  !\I]0. YS@.<'"<Q
MP&\XS4U-QQ&XVF\T-IN.<    H[J>:8W/YS?KP          !=WZRT+1?3^P
M:6:MG(  &YV[74   -7.C@  95'ZBOBF
M
M         !C2E;R5XH^1?$R!3PK(4F*"DG1%&6_DJ9: 68&1:0)DYA0$Q>#+
MC,.DG8+623(BH)7B'XJ<;21HM,*!E2R>P    H_JR:XVWYR?KD
M!>!ZRT9134$^I5JR:@ 4"V!%;6-K0NM$'DUWNHIOIU]ZKI._3GHTI<G/9MII
MM W' ;O]/SP  95/ZB?BP
M                                                          !B
MZF4"8O!T96\I2=2>/)(R&<HH9;I#V2JF,Z7AF548T9>J1B%QY:,6RD@Q.(1N
MD.1<R7$G 2E'@BKI926O&2Z    4?U9-<;;\Y/UR           O ]9:,HIJ
M"?4JU9-0 (6?9N@:<R7 7$:ZF/B9'B^[L+JD$SC]==?2.@>PHW[[ Y*W6?1"
M]/3VP;5MEPS('\ >I@ !E4_J)^+
M
M     &/.5,.O*%EZ)18I.7?E_1!62%%AY6XHZ4(+V2=,QES)4*7%AQ'R7NE2
MRP(I\3$EK);V5"))#RACTDNA8:9-@   !1_5DUQMOSD_7(          "\#U
MEHRBFH)]2K5DU  BO]4Z1E.\K[OB@]6:3M>VG!NK[.J1CSKMZ/?T-J6_?1&T
M+/-Q:]N5UC,K;=CQ#V6-R$SOBWT(  ,JG]1/Q8
M
M                XC8;C4&@-3E.,V@T!O-#E+?RX '&:&IJ;0:&IH: W&AJ
M4%*_@   %']637&V_.3]<@          +P/66C**:@GU*M634 !QV.>O2EK7
MR-:"JK3EK3QIU<:]U&O/.WCD  95/ZB?BP
M                                            !QG(
M                                    4?UC+,>/\]/UC
MNL]6:*H]J.?4TU?-P          ,GS],GQP
M                                       XCE      +0#S0
M                                        !K05           -E#7K
MIW=]0          &G(
M                     #M2\\
M
M
M
M
M
M
M
M
M
M             'ST-U/'-V\\%+7DJXTZW)SP.-5KPTJ:\<;>.=U?&E/.E?/T
M<<<'5SKV<:.=7&G-6O71KV-.&VGG=7PHJX^:=_#54KIWT\;.>>;GGYJ&]U[*
M^WZ7 X*6O+1SHXUI:U-'/)Q1LYJW\4[.OG2OG;V\[^BG7ENJXVT\[:N=>6G'
M)QKPWU./JJY^ZGY^JIV4ZT\#GKYX.*N3CKV45Z]O&WFEUU.>5%.G9SR\4\5/
M9]'93\]#<;JFRGAR<<\G-.SBOFKX
M
M       BKEV%PB?14%_22\F;0Q?MR1*9+7N>LSS]A0R\Z(H=A8.US-6>3SI>
M7PMS_"='VVOLNONRI-+S+'-VK%:HVMQ1"]MLQ'1$Z_-A]=ZGSCO-FQ<)+T=
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M[OB1GV)GPU;GYZ-=R0
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M,MT0S(
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M6ZUD54.OL
M                                               %H68LXQ)-AI\M
M>R?%EW'$<@364BQ2MV1"HMG7EH:3F5*[RB*>9X.>37,C@!V/'8=Y['IIM?2.
M5.'9B(J;8+V_37>[',K#U/(_>['+^]7 Y2(J<8"O>,N+A,5=QT2O%Y%FK95B
M8;LAE&LA;95.F)=&1+L5,; 9!#E/(ZJJZ&JF*>;8J>#6TAE^A>9B/F>'QZ-H
MQ6[G#923"$Y*9Z%9R##8,=D*B^8B*G& R*M6RG$,W=",C[5<MA6V!'<F[4TL
MLZS-KBT;IAUS\;OLD;5\EQ,=X0WWUEVY@^CIKC(;7B>3?JB608;!CLA47S%E
M<AQL">R8O)I$LWDD:HE./CLR-Q'SF/Y .L)1L58_NSXK//K:43203.6/9RSQ
MA=QQ2ZO#=V35J"6P3;&C\AL7RF,SM^'7LQS*S20#.8SVW8K>A%LAT=SU94.H
M)A"[.X_0')6D3LWPLN\$S]>,;WP>;'P<NT"S4\^OI
M
M                    .'BK13S\OG<<CG15MXIY^7'0V=CGX<?#;QQNXY&W
ML;3?PV<-U)6VT\;N.5513S<N'@Y<QP<MW#2AIV-3DHYX^..:MQ&VGC=S7M4<
M_//S\MW#;3Q]%7/SN-SG9P^GEPG)3SLY<O/'&J<<<G/'!QQS\\_/RW<-3;3Q
MNYKY>:>+BK9Q1R5<C;QQNIYY*W%2WN=O//)S3\W#6EK7QN5:<<\G''#53NX<
MW//#0&VKC>KTIIY.>>*OCGX
M
M
M
M
M              #S&/N+2]4;:           ]OF,#YNPO^LMK\
M"ITFB-,8S+@          +E-E:TJ/G<0
M                                  !PT5;ZZ=X   !Q@Y
M     #@.8XSE   /G/H.,&TV'T@X#G .$U.4    X3<<@    +=H#-L*#XR_
M84          "17T)H*VO76Q;?H!.           )DO7WDB&WR#ZW
M    RROJ7\P9'O1N@@                              !M-AJ:'* #A.
M8                       MER-M"ALJ/7JQB_EN@^<V\T[>*M:Z8:IYA*@
MVEQ*O"\KK4W.-KCB->6ZCG7D<V\9&VMJS'1(Q&;[E<^?*8GJCXRIA14J>>D
M         !X8Q&B6,F4*3E*"[DM7+JCH3%N,LHBJ+!BO1=D5V*K&/&9 Q6P&
M(^7>$Q![DH^5P-AYP[,\^=*1^%4R1PMU*_EK!? <P !;W IIA-?&+["
M      2-^A]$6S:VV%;[ 9J          !,Q[!\GPS^/O6           &69
M]4OF'([Z(T&            !$$7)&AY C_)H"',K07:ES!;T=.6W%XQ2\Y20
M4L2+[0     6QGMBP,K(7[@W$?Y=>4X//EVQN+,B\HB[)1CC/J
M            .LXZ\2;>$/R?-0RK$CW;$9,(?D(QI=B[I\1>>9N.JN&-N*LX
MSMHSDNKJ.^GT%NIO=]=I^9M/7]/=D+:ND..YM6.RA1')P_S'#2HQ++RLZNE$
M)I><6;E[Y1 C$)1B?@^L          &."3YF.Z6>$C98P1XDVQDF&.09'Y"
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MVPK?8#-0          )F/8/D^&?Q]ZP           RS/JE\PY'?1&@P
M        ,?4QH#(K/.%RI1TL:.S*[EWI'X9)1$$0)$MQO,GPQP#)!      ,
M 0R/RV4H";"Y$N&(\"MQPEMY'<3CEO)1P[ ]&9>X
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MXJR><. XSD/5GECU(     !Y([XZ@Z4Y#LSZCZ2DQ54Z4U/M.L/.%22BI7T
M                    XCD  !PT<<U?(       V&\  V&\           '
M$ :G(                   6[0*8X4'QD^Q@          $C'H70%M&N-B6
M_0&=@          3*>OO),-?D'UL          !ED?53Y>20>A-"@
M                                           #8<@     !9 >=
M                                             .JM>SR$+D
M     'T9"RX.BXTMNT          #WT\C/+QR          !MKYW@
M                                            [0OM      .,W
M                       &PT.0  V'&<X     !Q&IH:',  #B.4     H
M[JR9XW_YROKR          !=MZMT+1C4FPJ8:MG           &5%^HCXI@
M
M  ;3D       !%'-<3)'#\I8;)\9=1A;N+&;X>4."YB-.;8F3J%9>CMWT^9O
M*+P(Y>VQYVUZ_MHX.%_<:R7$<9O-3YSF-AJ;C0^@ ^8WFTT-YM-#4Y#@.4Y@
M     1:GJ"1PU+."\0ZLHH>J*@FT[0ZT^@'8FAQ'3G<G5G>&..>5)BBY(]*=
ML?&?<=6:D*1-4=N=4<I])]X  */ZLFN-M^<GZY           7@>LM&44U!/
MJ5:LFH          &53^HGXL
M    "B9]Q:Z>]+O38<I9:7+'GRDY=F;BS O+(]R0<U.<
M      'YFGK;4V6EI&:QB3#$]8IF&@,@JM;51Y2>QLMDF*][9]_%QUROP[/Q
MLRO#^*[^G7AF&Z0G, !:&2B$1Q?,4G*Q%BI4XHD9?I&27'D3A5LL*/D)>B&H
MXRJQ9Z76$QQ((     ##T.\+KS86=ETQ[ L\/&E83:5Y(]3QQ?N54. M2.A.
ME(^#]#$QOR<@PXR[PJ8=&46/6%X92 I 0I$UY0X[ GB)70  4?U9-<;;\Y/U
MR           O ]9:,HIJ"?4JU9-0          ,JG]1/Q8
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MFH          &53^HGXL                         48(9P">L[0
M        _/O,D0M /.G 5L+A".,DO+%RW8C_ ">,H:>5*5E>S*T
M             !0[(6WR'T<<^XMZ[1LU878X7(6U96RNYP]_3VYZ>C[*:Y6%
MU16]M_OXX^"OBNV.NHMBX(^\H22%D;!>06@EQ9UI=\4O. ]61]%9BJ!Z@JN6
M %[)'B>T+I2L     !Q&AM-30VG(<AQFTW&IJ;#0WFPU-IJ: ^DXS8;C8#>;
M34T-0;C:;SC-A]0  */ZLFN-M^<GZY           7@>LM&44U!/J5:LFH
M        &53^HGXL                                         40*
MME-2GI]1[D[([@LG+R3PAM/0'E"EY<L63DC@                    !QFX
M        X#G          .$Y@                           "CNK)GC?
M_G*^O(          %VWJW0M&-2;"IAJV<           947ZB/BF
M                                                       !M.0
M     L@/.@                                               '46
M/?Y2)Y\          #FO+#Y;:YY*.X          "H4ZC(
M                                                 ':%]H     !
MQ'(                          <1J <AQG(                  "CNK
M)?C=?G+^O@          %W?K/0U%],3VEFLYX          !E3_J'^*@
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MC))$;3WY N>L/3E5BQ8NC)U#T8         ,,,]$7-%4#S!+B7S
M          H_JR:XVWYR?KD          !>!ZRT9134$^I5JR:@
M 95/ZB?BP                         /SDS(/.\)O##',GHC!),2(,O2+
M5RKQRFI;\5P)B2\8      M (9"+LDZ*Z'JRE9:B2K$/!=(5[*[E/3R)#R3S
MEKID)@                      P1_1NN_24]EX$8NZ(9+KUYXDAC>2H/?6
MMJ.8Z*A6M?2]M&7+HR<8L>Y8;Y/OM[+Y)9YZ7F[8^/L1KE<"[\C7,C@M1+42
M2(Y2V0E6(0CPQ<(7WE]X         ,> NS+$2=8PJ#/7.0
M    %']637&V_.3]<@          +P/66C**:@GU*M634          #*I_4
M3\6                         !C?F. 9(!T92@],?437$!I<&5!/6$<!=
ML4!*VDQ1>,      <9^=^9#)TIY4^0](54+0R3\B^.L(W";4IZ?66IEZQDG
M                      LYSEGYSLH[GCFH5C7'-+L3)!$<S'S+L=)5#,G1
M^]M_)]]%[^ R5G^<L+R<#?V;Y_'WGX&_AW+]C8;#Q9>06QFA<Z0[%<"UXDP(
MSSW!+B=J         #B!L-P.8                   H_JR:XVWYR?KD
M       !>!ZRT9134$^I5JR:@          95/ZB?BP
M        +;BCY4PX"Z8L *F$6A,J>(.Q+D"Q,J6:'N#V![\      %DY<,>'
M+5SUA5\[,Y2+XE?*1'FBII1(HR7AEA9-4
M   <!S@     'SGT                                %&]53/&[_.7]
M=@          +N_6>B:+Z>GM+-6SD          #*H_43\5@
M                                                          +/
MSSX                                               !T.,[Z#^?]
ML           >AE<?ZG#9'Y,;?@          7+>D]0
M                                               =B7G@     '&;
M@
M
M                 #8<H
M                                                   /EXXYG(
M             '!QQ]=7(^;IIY:^                -E7;S\TCY...3LJ
M               &O1QS=@
M                                                   12?+[VA%E
M\N?;8               %0)W%<FC])GQ^$(OC#V#CH_/;WX
M  !Z2\QV>)]S/BF,;_4NS<%WS-Z/                'ZUWNKQ+[2YI
M
M                         $5'R\]L16_+GV>               !4.?1G
M)F_27\?A"3XS]AXYGSQ]Z@               >AR5CGD?<CXJC'!U'L[!;\V
M^D@               !^MC[E\1^QN>L    #B-X               -34
M
M    BH^7GMB*WY<^SP *9R?$==W4TVDF&K_ )-2B68;X;OHHW+([4V.9KS60
MM:YP:1^*S^.N*UO+ *1RW#6K;2@U_>A-J4(G\7JW#\]:3MF!U=B6?MLV/$/2
M8ZZONT5LH "H<^C.3-^DOX_"$GQG[#QS/GC[U&]Q7R>0K;0H%!IK7F?0RDL2
MDUXNW-46;Z@VU6&81*ET4E%4)9'*!P"9@"OT^@] 8#.]>RC=15V%W:UJF40^
M[LZK==?S[?V<;.KE5U7$[#@MN^NI_MYH4\CT.2L<\C[D?%48X.H]G8+?FWTD
M  /OYZKH<UB/J<VB87-W;YK!T8L;N_Z5QJ+V$S23*80^@.*R=/;2\H%C<F!I
M1UW>Y[!T'QF5OOE,9CFB<HKKD+&M.1QM@\9E(  'ZV/N7Q'[&YZP    (6#J
M                34G:@
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M9MSV5Q97O2' 5#O;?'-U1M.B&-R8  'ZV/N7Q'[&YZP    .,W@
M      V'(
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M<,EDYFQM?]QWVM:KVQMPQ.9V\4W.9S%P4:QV+8M').  !^MC[E\1^QN>L
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MXFV;#Y:XO-XJ@>%R?7N\ >UN;/Q-O>56N++T/=U4'Q^0]UWV_L;FVHM89,
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MQE%CYRNAN-AJ4&.Q/!%7B@1ZLJ24^+D2Q\K84]+M"-DNT)(0   #YZ*-:^
M              '5V<_:'#QUN0               &US]"L<3G52
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MY$J=0>F*F%@I;&2%%0"IA9@7GE[9!0>T+C"HA80<QZ NU,?HR,"-HZ R82(
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M*D%FA&>2!%C9*R>Y+CBR$L:.,K^4Z.M+;R28Z\D2/3$9A.80M':EBI>F> /
MF4V8ZQU1M,B,Q[3:1.DU9#83!EJ)WI6D\Z4G*G%X93XI&1HF6<8@9EV$*)28
MRG3&*.^.V*6EU93XYSH"EI<P=*>>+B2/$RN3&7+VB$4G2,7PR-2*,N&*[&12
M8VIZ(XCKS[CQ!5HI^4N*\$SY",1JDUA F2Q$[9!(2D%L)CI$S)]1;^5K/M+1
MR8PL>.M+QB)HJP5D,B,QBP?*=L=X="=X>V(6C-]($#[RQ(D++$2O1TI)0;2S
M@K26A&4>8^1#D2I'D"W(Y3TA<T#M"9$B )LRM@                 !M+0S
MF/4E@I(06GETQ1T]$=66QESAT!<<4#+@BP,I431%"BJY%R5@/4GV%6S0I&6]
MDMQ;D=.8=Q)D9"QX,M#.U)42.(\V7EE6R)\D$(^2YHO1(;"1<HH=40B&2@>O
M*8EK)YXE',30R22$8ND)<2+(O\/@/2'6$=!,H6-GV%FY<N>_+6BZLMW*UETY
M;P5)*^EKI2TMN+Y#T!H?(6B%XQH"TTNB*!%QI'D7^'IBKI:J=@>V.C+8B[$K
MV4".M/M.C(_"0\^\\6?"5"*@D*)+,>T(Z"^P%)C@+[B.0YBNQ60IF:G6EAY>
M\=T>*+8"PPEN. \^=J<I;27QETQ#J2REK1X OT,30R3"S0N^*S%D!<@65%WQ
M[0[(Y2-LL(,G0P3B1PR'B-8D5++2YPI*7%ER!%85P*L&TV&I'F74&\K"7"D3
M)<.5P.@+1R4LLG-2SHD./H.$Y <92D^8N%+6CJBNA0HN7*Y$-9?(4M(AB:,@
MK,@HM/+2#(F+<S86X%?"/PO-/,%#"1$^4CN+$#)K+>#J#[BW$\@7?@L_)"2F
MQ28CY))"\D                                  XSHCN#Z0       #
MX#4^X  X#Y#LCJ#MC4                                      'R'S
MG9@     X#Y#L@    #YSKSN#SIW1]                       .K.T.J.
MU.C.S/I     /D/A.Y
M
M
M
M
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M[>4Q7S%G(-/O*<O<P)=Z3NMZI6W:E;N.'5[AO6;H%$A7,9LNWVUS_=?TH/\
MD^VU:#/UVO4@L9&3J9R<6P84O A0*.UWO 8SC7+'DJ%,ULIK>O&X(UJE_;54
MMRB%S#A3-ZW3<;MLTNC3AH5V4*9QYRL6?!=>-,Y&L; GX;LK3"8<<=H%R<SI
M0I-'2];_ -&3?^COJ[G+8E)Z 9;UN$\[#9;)30HC]5,6BQJ[:]-O.X9^UK=M
M:=MFRB^A7Q$DH-H7S'NDPHC[A@OS0BZN[_\ 6,?]%69^E_9_]Z#3<AQ:W4FO
MPZ66+\=RV289RY V77G*\;_Z7,1YYA?VK%EW+=N^XX=L4VFSAGURFD_">AS=
MN<R(<)F\URRW.=V@*YQURQKL?=<-DPH,.<OJZWHSUJE(QQZV/>##_6?V#<=:
MVI=KY^89*T>2I-$)Z7@<LZ(CT2W*7)F2[0[+LRYK7;(136U&C^IC7_2DS0I:
MYK$CW!,3-E__ &R)ICT:V38G($&UB_DXLG9_M-/]%6I^E_;>?Z7LRTJQ6:/:
ME@4>V8MSPX$R;5\OQF6?8]2EJ&7=$K!E7-#L]DQ*F9<5C5AE1MB]ZWXR_!N6
MH&96[?,*XI:BRT>2HCKT6'',MG"ZOLDW_H_L25'GZS?],+"3A3QP,=9;%O,9
M*6Z6<.'U8]>=VW1<%[2U?EJU>5ENW:ZY=5[69'-YO.F(U(-*<DR]MV=M:F\'
MWFWA=<S4YRUK3<M63^Q!^K/V#0@/3%SO%?.3<:=ILC3+5)F'\M;]W..0S3N^
M[INF5&]Z9>DK;=LTF6KQ;QI._; %TW' N8M+2@&%&M:UK-N*F76+@MFCW**]
M(1"UJKGY_L&W_B>Q^'K!2SLM*SL3BX#HTO2<BR-X86_+ZULWZH3'UHNV[ZO#
MK5]REX0Z%'8\\494NQH5J5-V&X<LDY"CF_?['FV?;[[[Y0E-+RT.UK[NV/;[
M;BD#$=MDL>+ME$S\P[)&7R>MIYD;PPFFNN2I30HC]5>>U-]AR?Z/VE+&EJ97
M'G8D&#;D1VLFE+1'6G(:;K[+/H7T\)V7EV4;6\UIO2L6+;%D34M-VGRYAUE'
M:[W@,9QKECT]LW&)\JG'&6A1&OQC@.)UUVE7PUYA>6&X\RU"S@0>LS><>?GS
MA=?9#<III1I,NK7GK9@D[+R[&G/$8VW*&V!X*9/-Z+MVKP*$6](K1GW%)V,S
MD&-+_6@&; ;.7-==IQK6?DVR'3Q/?XMOSL_8];MBC7/.W??LO!F3 NE^,VT"
ME8QML%#S(=1O"S8MU,<NJ]K,CPW^?!]E<_W7]*#_ )/MLRT:O;]6%^6E5[L@
MB[+-FZE49FS+[NAZ]8]%H=L4RV#,ILE9EQ7&Y<EG6C6*!6[IMZ#=%*D+;,5R
M7L:SIRVZM;EHU>0O>_+2J]V09N#\U L*UJK:4C%ALC02WF7:)7*C+MF9&PK6
MJMI2-^6D]=$C L^^:Y!+^WIVW*785IUBW)@R*G3Y.BR%L&739*QZ_<$W6)\O
M;CH=5MVDF#%JU\VG.5Z%;D.])*%93K]R7M_6,?\ 15F?I?V='UKN+>=H5FX*
MA-P?FH%B6I4[4IL:PKLMJKSA<W?4)N_[6JUR4J8MZ6J=NRUK&G1).I6A/5>S
MY.VS&^6L.U)VUH]P6/<\&X:A;EU56Q[<HL20M9VRKVM2):5E3<I6;GM*LU6\
M+AE(DY2; H<[;U)]X,/]9_8ORSJS<4UJ8'X>N#8=IU:U(-<HLE7Z7*6J95&D
M[6I=8DG7F.M%YV?6;AJU\T2=N.CVW)O2-'O(MYVOU7PF<Z'IUCWU285++/G3
M[CD.%!]II_HJU/TO[;EE(D_2+#HDY0:0*K:-7G+_ +II\U5Z11;3C0;'I%J&
M317;9LB?MJ[:C1C$EZC:]DUM^X;ML:-5*PVG&W/!R'H@B\;1K%?K?V2;_P!'
M]BW+2J]-O87_ &M5KDI5.EVRTC9UHUB@5N/8UVV]6YPO+RJ46[:3=K\_-V;>
MUT1KCM23N&ERE$-63@V[*U>4D;BA56;IU.LB_J0V@T$PY:L_8@_5G[%W6A6:
MW=&I@J,NV9D; M:K6W2KCM&KS][WG:4]4:Q.6/>=>I4M;=P2=CSE ,^?I])L
M^G4VWI6S[^MJ';%+O.!'#]',VDORA?7'<4\Y^3[!M_XGMN:P8\W5(5"-V9>K
MUM2=PTJ':QER,G:=IREJ25N6C5Y"]XMIUA\Q+MLJNQ;AJ%EWQ<]-B4&=?L&F
MV3?-L4VS[,G9"?O"S)FK5"=LZ_+JAU*BR\"V[&HD[;E'OJTIFY&=&WS7(5ET
M&=H%"D;*O6V:I<MG2]RR,Q:YFS=-MFW).V*985IUBW)CVG)_H_;=MA/U.LQ+
M3,ZJ0[4M23M:7O*QJQ-7!4;*OFYJ93Z1-R5G6!:U6MNE"=DX%0EXE@WI;4S:
MU"OZ'/W99LW4JC,V9?=T/5NB18MMV51IRWK;I5HU>3O^_;6JMVR-T4&<JUGV
MM3YJD4BSK1K% K=^VG6+CF+GMN4N>0@T TZ3!MJ3K4E(6':57M.#7:%*7!2X
M%M&I1Y*IVW<4[8TE:KT6QZ7:IE4EEJV3/VO=D*TZPX8@NNSZS6+HK5)EZ[2K
M-MJYZ'3K2H$]85*H-%NNJ3<>KW[:%4N>TJS5;PN&4B3E)L"ASMO4F'8UWVS7
M:I1K]?I\W9M[71&AN<B#[*Y_NOZ4'_)]KT*!$]D6' C>QCT6&'60VBZ[5@7/
M).4HUW(%KV9)VW%>A0(GL><AQ&/1(C8#T* UD6' C>R% A0?9-6]3)JJ/O,?
M$*!"@AUZ+#CQ''8H=B/M#(4!HNRU8%T0?"S7Y%L6=)VV[#=Y;8CCL4/1'V3$
MY(0:A+TFE2%"EOZQC_HJS/TO[.7!#L*!#]D*!"@B&X["&E@>AP6!QYC@=UL&
MJ+Q><AQ&/1(D0.0F0QI^+ST6)'AN.P@[$?:'84"&QUYC [$?;[R8?ZS^PV%
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M .5 '*@#E0 EYK73G-72TS^5 '*@#E0!RH Y4 <J .5 '*@#E0!RH Y4 <J
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MF D*/,!(4>8"0H\P$A1Y@)"CS 2%'F D*/,!(4>8"0H\P$A1Y@)"CS 2%'F
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M;/3<%ES6%27*/7+QCOS1;19F:I!24$M_':;1*4]1S -9CL*[*9,3M1*&I/\
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M0N6_/UK4IF9D+"ZWNL6'^M3;FIYQV8967I8G)YR))F!1IF2N&'+3T=@*S]%
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M0AR(0Y$(<B$.1"'(A#D0AR(0Y$(<B$.1"'(A#D0AR(0Y$(<B$.1"'(A#D0A
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MXK(#Q60'BL@/%9 >*R F)^4E(OBL@/%9 >*R \5D!XK(#Q60'BL@/%9 >*R
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M!C:X =U#FP_;+4Z:F8$M*/34><DXDA'EI1Z:C_+O<U^V:M#@3=*J4I]FW/\
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MO\SVR4A-SS>EJP)F#$EAI:-3PU/#7 $3C##S'A*46?G&3EOU.5A!V(XWV:X
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M+3*>[/U28AT20C74\[\E4WGW;8L]D-D> UK)ZZV.MG*9R_G;JU_/27^==/\
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M91)29GZI,56@34:L2,L[ JM2EYR2IT[X?/19ZB,CU:I.52#-5*7F:7;U3EI
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M60V#4T-APX@TPN1$<:^'H;C0ZUY@T0!Q#K7F>\T+_2_8>=A-]KKL)GL<B1W
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M&< _29%\.PW7(4:5@S,'I^D"6E9:3@Q9>#,P>G*0)64EY-C[FMCE&I;@\!I
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MK)D#:R9 VLF0-K)D#:R9 VLF0-K)D#:R9 VLF0-K)D#:R9 VLF0-K)D#:R9
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MS@&?&(\Q\:G0\UUT:G0QUK!^9@9\1^9@9\0WX!CO'[I%K]0O=U)_24L_I_\
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MDD],2<G#D(%5I[*G AP'7(,2UH3&R=/EI)GW1MK]3>[FC^C/P>,;_<_;+?\
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MO#L";P[ F\.P)O#L";P[ F\.P)O#L";P[ F\.P)O#L";P[ F\.P)O#L";P[
MF\.P)O#L";PM@NKWO*3[ F\.P)O#L";P[ F\.P)O#L";P[ F\.P)O#L";P[
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MV<+F+])!NI10IA#Q]**0B^F/'4I0JLN%^8XLCJ9,A-GXL%ULR(9',6RHU=9
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MC(+<4:Y;^IBG,7V6DTZ,N!4N3+.$41L&&M+U$Q:&,::8%%6#?E4P,IL2^?\
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M]7,]4..)75H)P2(G"KW^4>(6PY281SC$O6S[E(? VNJ;@)LQF+G3!5[/0&C
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MJ;,(OTZI?9!<XDI8*!S?4^='J6U6+#2 N/*5BW5>G\B<O14)<NS(MF%CH2-
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M +B/:A):2EBE4CE449,)A0I@P,E2E1R!94,AZH+K59!P8KJDJ,MR 8Q*8JT
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M#RSWAY9[P\L]X>6>\/+/>'EGO#RSWOP'SF_NS#6?!YCSK<-5TVW;5V>W!/\
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M R%P9RVAD-C [#:Z&0F!L+B&0N#S(36,Y#&#D\!RQRN#7H3'G2&2X0Z8J?\
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M&!D;B&S+K [&U#FC6X.:P,CL:WG.\>=\.>S@[&=>#'VM#(_%@^8^#(_$<YC
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MXL'%@XL'%@XL'%@XL'%@XL'%@XL!5,;$-'V9K(;(98? ? ? ? ? ? ? ? ?
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ME^5.IZ_L,ZA"]5*J:^,[BH81"V9DGI5ZY&3.R%].Y$[MS1*1-FGY>UP2:F\
M:G5L%=C$+Q/&5LTZNK=3N9"4(C("B[):=9LK)!(JEM(WSBP)K0R0J7LXH,N&
M0Q7MCT:?J,]2%IYA+92$MU,.3M0-PKG+TZR.4/F*L/-<;:GS(QSY*J6M8F;U
MSJJ:K)*9ZS<IZF,8RF#83]5LD=\9E[BF5SX[<CAF*G.6]LLJDSC-7'BMJRLB
M2.<@^1$KL?)9'1FQ5XC:B'_DW4/-+/./**9J24()B4SE*NXXSMRD'9="G[OS
M;FU<^)E%F1]7*#,3J>%897KS-8(W4<G-0"GB%S<*[7$E?'LMBR\AR-ES+B)K
M'Z0";%9Y5#1-8P,NAP& >^/[(J6B^"9(C.:JA;B7++S9'LL @(F4JT#NPDX[
MEUJ>0SANR(Y#R'L/$RMG(,1>'BSG<LZLRJ5*NW)K,II.<M<PQP;T]_N6LV<R
M]9.DDCMS'W/E^.PV3?0#D0*9?R?TW9NU5Y TXXWEWV=D?1VK5?$!*JGU)Y@;
M1(3);=>0-Z!DO(Y<%L7"3^")6>0^^TRX8EK+#I""L>ZUK*R&HWRE'U#3%CD]
M+X5%22K5/4;&3=61>]\HYH'/.FK8?I^\0=BEM9ED)>QQ)'2A4#VN;,+F\.8W
M+QJ^6] "/\;Q#Y!4Y*44_8'I5R8L^S,?YL8P4&J"41@8LVQ[46J8YDV.4-A6
MAFF5$8):PLU%ONX=STS:JG+@@UH9+201HF;,3DL7Q;N.D@RDHY#$:O)<>3"K
M9CU*Y3[J3L\D_*1?1G*N$/,R9QPJ>(W-J>2DZ+C4R03BWK%MG,LI]1,FG+,@
M7BCD'Q<W"NS11TJ/+L79 XK5VK-E$'H;]0HKA5=2QA;^X^-U )_9O5>H=+A>
M62V01_=% 6+E*M$IL RM<D"@RKQ?KUCY)TEIBRKV^H9(Z-<O*MLA$L;&4T_S
M#4?C77K0<C26EW+K)3'JG8^<X2M4.$A8U;KMQ64M/,);*0ENIAR=J!N%<ZEL
MJMV6DJ! .2>467>%NYQ3U4@9B]EU93*]DI/91]JFHJM2V56[+25 @')/*++O
M O<TIO*C,3&'D*J"_"L/H]RP3,3E>SFJ>M$G<[*\3!)3$[ACL91!-(H7]D0B
MI#N,I\LF2:XETH]CO'SGZD,T:AU -M_*"39UXL<6ZX57H_PUF1E22F5N/4W,
MVRN4@$KG*OBZ%,(B=@.0W%9Y0+VL-3BFEFJZ+7$_4ZH6../!(L_* 5>-D_":
MRE*AIZ]+B.8B3JS*7[E54"<"A3OR>5)'*+C^S>J]0Z7&8QV=/):^O@VX,LJA
MST/;'+EGM?(K>:;LW:J\@:<4IY7D_*)QKRF:E7U-)STX!:5ZRL2^07(666/L
MM4GJ)R<F.:_G+J /BY"%R@D.HK'M*9TE8FDBPT,V1]W@GA466LL4^8GSNS8G
MP1=O*.SC'\GZQ\@F0NS4(6DE[)DI2OK;O_-B85<6"H;*.829[+3"H]==7",\
M@B.B@Q2F!FN5PF<E,VQPWBJ+$Q3:/3Z/3+TRF*W-U3:L<FACHGQE+M6;*(/0
MVN/+);"!DLWIF&5 1AH9$LM)?8\#U+C*BJ*TULJ<?GS_ /42XS<@E-R%HAQN
M+VG\BY09.<H1?XR:+7LN:LR;4$NW)%%2Z9R"LC)KJ%49=N:)2)LT^^\R";B_
MQQY9,IB\"TQNWHK*],<5LHQ.U:!LRBCU(%$DXC+DSDJ8+(L/4+K1-LG,6^)J
MTC[*M'OJ'9EXSDY>GT,.5M["\7<G<F3K/*?E*O3-ADQNC 1ARNBT\I"W93'R
MCC (09AH7R,1[#MW,MEX2<4!;HU]1EZEY)!]7Z4A?EW;I9EROK%5A?2#C5PX
M4,\;<Q>?V&ZK0MF^K9OI%Z:#&NF_BJ+8U:3 2:1$JJ5K6\)LO75;XLTO*%DL
M@AMWA2C+(CT<F715A"8T,.ZM21DD\H!?FI>%&P*V_0SH-"C3D"YO5(+TKS%2
MYNDVF%:)$>IF]1<@I.M\&1DE+P\3X]0ZDW&05J8CU]-[:M-O],.,@ZZ;:!%G
MV5=X)X](#9<G95O67D_27?B::LC%0CRLTD9BJ#1E39$_4VW1?EIX4;"PMRQX
M%:;4*4//U*ZA?E#%]3SD,.VP5G9RB&U*(]2#A0MV@GLKW&E.TTZ,O1_6"9WI
M\S<9"=8Q*UOT93OJ)LTT*(>2Q%O5XS*QG,1<B@U4\GEZ:NP_GD&8USFC6+C=
MPA$K:9$X;8UI&[@(59H;PQ#,[U9(L)<[*W&MY(5Q0U9>H1RHWS=Q:XTT3*&3
M)C.]/U7K4-4D_1Q6%A;ECP*W)@<9:(?S0D:4R@[&Q$8UL3EVJ0Q:Y%RSL2I+
ML**:DKG]3PJ^O0U79_<1MT%BI#+\DVOTM:WJ&3(,&W2K+Q)]Y7.F'TL&-0H+
M<3/C9O\ L8UO3[*"=@N.,0C=!7J6]1C;]R4Y:GJ2,09KT64+_P!-Y4B5*#"O
M,S9N3WI^2)PVOGVF!9M'IITYTTDQFJ#]0EZ>*WZ0:]EX\[EO*_9S#)C---3N
M)M/A&%*FLF%!?*&#ZGK(8=M@K.SE9-T87V6]P4FU",SLXKL8BEE>6"N3!2BE
M5"R46YDDU$BD?#BJU(J=U@IJQ\GLK5*N20R#!MTJR\)F_;A2_P"DZ,ZW[=Q/
MX#<-I"PTS8M,J<[(UW,X;=:N:A%AZ;FOE;8^$8FCUKM@8GKZMNB8J_36RE%D
M<6GINLC= HB,_3"YLSC*9'^(961"U.S*4?= HJK/4@KQ; 4%GAQCO2]^YKD8
MG19&1#U%.!2(PW;S1'<-]&4>_I^[E(\I\&1 '/=A.8/BNH="Q1X%<$Y"04XX
MB<[QEVF0I[F%8U:)I-V.*O7"5:%ZS+UQ$/HZ\I4[3L=7I\S/H%"Q08$<.! N
M)BQ;>HIC]S$OY 547KC^R\7^D.SB(6::9B6DG3U17JC4GI^KZ4\J=AF>KZK+
MY3ID=2,<BJICI[U)V5^I4Q;N1C,6?<),F+?%R2LBDK&@9QUGUFNO%.J>2:2D
M2?J@+IN*W\06>M7A+8]\1>15/D*T<;WJ/8K\[CQ5+0K>N+U$&6(YR[5WEB;#
M8T(#9#/?.P@>;@71Z@NOUJ65OZD&XKGHMIV_Z<:UJ13,>/IN[9IE20R4EVF)
M!]-M?RI2&Q78+C9+VMIN]*+F^J]K(HP4Y+B?D"^MSU#)]6*=5>RC,B'SE?6'
MRS%]1OE>.FQ5;Y;TJ34G<OJ7L\AYQR Q G_+-QW>GRL=2)28>O3WFA1;B2'Z
M18FB8H"6DSX%T'*+5UC826FLB$>IZRFR\N8>9W/,>%@*)4WHX-0C=!7J6]1C
M0;CIRT?4E>G:GY2OVDCP\Z#>&0KTWA#L*+$XD5^&?GJ*")8Q17J0?3M3\I7[
M21X>=!O#(5Z=XJJ0G+$!Z:VW:G7<>?J89S4B[/<?=HD;BVR*E#<-K)#9#:,B
MM>OBJ9I$1(7/4N%6I3J1DU#T]*(SD3*C["Z;U3OU*?I-,K1QD4@3#4=2=*T0
M]?\ 44'18AY7*IYS<-ZB@8 YV1NLV/47O--Q,N2;2?&8TGK:HJH_4EU^%+J,
M]3)CBJ]U&FK?TQL&PY?#0L2+)F/ZCG*\=-BJWRWV=":HKU+BL+QNPO$M85#9
M3JB'T_R.#?K1%^FO*ZAT+%'@54<1LL0_IO?4NK#L9.^-A.Q0TD@$_J F9*Y?
M4[Y1[LOBT,<&+,RTXI>P<O5$W2B],+FPI%!0[@9S(2%&0+@!RP$);3I69_Z)
M2SUGO4#0&&K0%TEF?2D?4EH^QJ%.D@XO3=6G3K\3*E>:D+H]3#GA/V73QB+7
M:1,H2]O^I5/RSS'+A:M.DCSSNS=1DY"5R?)U-#&=5,KQI2RO)_U#)]6*=5>R
M<W66!SYX,X]=IRH%'-NHK5"^JC5W<-.65GZQ@./'SEOL"Y3/GBO)TH+#(0J5
M?4.AJL]0UDOA0CZS'6@1:EU6^H#-I#=D8Y\;V-;$Y=JD,6JOBR+.W,V&:T["
M\5*OO(5CBDUH7+A>7<9N0-&?J-IN!-%CZAXZ:47V,?)(6%5A0VPV:53/0U!^
MH/*6K7@H&_D4VS:YH9_\(!@VF6"^EV(&3=0LZ1Y6(KS-=DQ2D7:PDM^HM]/U
M4Y"WJMBOFX:ULI>4&(\?^7Y6RQ"#1 2I+H\4)DV.:Y%!D59IK?V5]QC["E0>
ME8C4ITQ"J6:$D*?20G:JIELK ABKL@M%))9(%7Q2)-Q%H=1:8J6THD0BXD5E
MXUT=+YAHYQ_I.01:ZT\<2+<AEIIGP2XP4G&VLS'2D-?]O)IQA(Q219Q )R)U
M+9)VQC4199B+ZZG4E+H(E.V$3'*EHV8?IV,2L&I42@4BVZ+5DF$%7%/F(6]C
M&U8Q'X)L9R>#+5_B>0VN@RUFXST<+[F".QJHA37?!.),((@# 2ZDL@48E73<
M::)J40A&X.L;B?S7!&I-(--MR& EDF+D/=.9WX4E&$S@O(=R];!*=.I1$:1A
M3(E2X1Z5B_P@XVRY(U-V%W'@EDWQ0L3Z'[66$JK#CC\62:Z>TS$0E$IJ];](
MNBAE7@DQ?$Y$I:92*HZ>B/P38SD\&6LC&^C+(!,3%*DYN0I_I\,3M)NVII+(
M&LJC6/C*1JO&HE6F9'6*5,N)'$ DY6>+5.B8R*2041NE)8IZ%7&1ZG"92P7^
M'9 1=IF3[A,QSIL-VLUVFT"DX?L;*8\BF/M+J.4V(K*+,D59/XZ<$4WZ?K%[
M<TM52M+FN%R4.!/%^1IDTY)1 TA494(W3L1TXFE,A)(^)%+R32$1D55Q^GRQ
M07->]/IDG2J>LW&>CA?<P1V-5$*:[XJ/IY<3]5KRF\4*&%;0$;X[$@(&H9P8
M(<8IW&V>&/-(*BTOWOA2QXF,3B.\:2,T'3INE)8IZ%7?./5(1DIJ5(E0BUH$
M=)R4M3Y17*(DOKO*Q'F,9("%KE,3 5BN- TSY1(F!3"?E3)/(=:1,*F2:0JU
M2/.5':;%$5Q/>%?'"F Y;E2:0=X*2L])9!6$HFGI,(.E*D4OANQYJY/0BT:I
MJ31>928H4.D4J)-*32$2!9-V^G[Q0WH8RA49II500ZDTTDVKLDK>MRCVI0%B
MH#28OVTEAH:3&O<I3?2Z1A[)]-5'*<#M3):^'Q!-MIN5(E0BUH$=)2$K3I0U
MTHD.>!I7>C=-]_*5CI+(.:50K1$*55V%F2?IZ,3Q#F(4"-DZ$2<:ETDD$L&Q
M%BH*2XO6Q4?X]4B(0H:ITDD"M4G#A)POC\*=OI=<%S7THI!3ZA\E#T($HE,E
M'8&"3%X7A:&0DTAC=/$Z4ED HB^UGXXDD+\D"9QFH>3W>0NC% ARZU?J_P 5
M"(ER7LE!&*9$.E:8Q<6H:Y>60E0B"V347Z5B**I-I;(\3<4J9"UP(XK"KM<R
MD3II-^44BDD@%=VRLI!*7%]6%*8Z\8*'+-008-O9#LSRT\;R0\@5,)3&4AI.
M=XK#Q7HE75=EC8P40%^DU/>-%(2:" +; ?BS*ZTC910F8\K5T,XF=@1Q<FR:
M%F69;9>VBL['\E+(!8Q-XJD&$#<]9KM-H%)P_8V4QY%,?:5T>IN1*4JD,(^.
M!51O1D5I?>2T699V:3I;F-B>0X:"MR<2801 & I#"/C@54;T9%:7WDM.)S*&
M"GDBR)*Y-90G41A3J++$D,.^,=#5Y%,>!9Y6,Y 3V>^(=25A8+2:I=TU8C$S
MD@FPB;>]/KB<MF_CM2>G]1\^1^$K&NGDZ5E(.2TOTLR?Q,(!(BK6TDH@;04L
M%*86\>"JSBIF-Y&5&F&I.(-Y4Y-I,( @# +U)) E4?B9TF$*CVQC"P 8L#)O
M]8F-)'2[J 2F,I#2<[Q*A)1 D@;D:4@S$,J,%V+LEC(N;&JBJ\4?J3323:NR
M2/A'B<%-IZ+_  L8X"ZM5L/BQ96.I(2_;=2!CQ2LABA0/3Y8F(%_GRD5/BG)
M-0J3R%57**12.G]75OWTDXA3(4#?Z3B',\_C)240AO'NL[&ZCI?TNFS&JCU)
MA=I[3P4"52:6'BO1*NJ[*1B-Q_T9-BPT0)C7L4948B\?)+Q:<DH@:0J.X;:H
MMV4*WO3QXF[?N18: $J+R+DG\2: "+J94)G(?)YE_1SC-1H@ZH8W45IIRD5!
M'B#4JH*L>^SEQ8X0K&PII-K]QFB+>2<05JJ5B)+(*,JE7>)Q#:WS!3"C%-B.
M"BI_I\,3M)NU9N/-*"_;>)W%VA8@KK/C!OC@48;)%$ 3B92N/E.Q+J?*<DL4
M&,C'O7TX&[8643.<*$E,A+:4B5:-DWDF=A'I(3^G"[%I8ED"9 JVD["[CF1/
M=Z6$DI\123=XI+( P%$*@PO8ZUA&\5Y2EP2=@Q4F$),*G6[C91ED;M^E>F(P
M=T6JWJ@5+!AK'^XK7&M94+3MNJU/Y;@SW&;ILI4922ITI3I3[,>6@3,*G4BF
MTB4%1H5*JS.'W/F9&6G9>GTBGTJ3_J1Y:!,PJ=2*;2)3^F_+NOLI%!I%!DA4
M+2MFK5%DNZZW^W2=%I=.>%,HM+HLH*A;E%JTPR68ZS^G&E'(T.ET"D4.3_\
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M$N_HTC.F93L:DJ,[2(S5(<C2E#NJH)UZ3$+G02J-'@K;LLMF$/NU4$28=?\
M:)41T2U2(C([J=8/J_J\LZAT[SE$E,;J4F&S78>L';BIH3/Q3#-\MK"<L,R9
M@&2CU#4B2U*$QJ8;TB+8371*H2V6*-*V%L&>N'M;155NB<._HL*^9-GU"/5,
M@7:.IX<XE1F7F2623*5A[^BHI-1-AA"+>U)#F_I'OM^4DD\I&>I;8R<)B8A%
M-\LV)=4F&?UJ*F$5DZ-]A&=>1-6.TP\[#*8F6V-X)!U6,$>^7A(:VC]9A-Q2
M;8#V&@88WL4[.1T13E;-=#>ZU$Y9!Z77Y)=K/Z))L6)35W83[1\"(K&NSSSI
MU]"PHFF1%2:9$3"\4R:TV$T'#OH5T9G(TDD7>E+8.2P(OLNIY3=$UAS,8PL%
MIRL99'_2]!CEL]+_ +G.S4?JSZNH'M<0A-S1D5!K&M,BPF&R?Q3'WFRBK-9Q
MC6[#6%=9L!$-5D.3Z-5A*(V4)3(C/>,-K&L:G4DE!/J\30>V2+=;WQG8%=!1
MO,V1R-;XQ3M.RP.JSCG9/WSYWG*2R:S4(C,RUS)C9&E(0^\W<,E$3XZ9+S/"
M'53U7#^EQ#R=!+H4> MMFU;.0.WO:R#)+AX9->),MZ3/%8;66=\G4([/W_#,
M6DW6<HD<FH5)AW:.P"==E80GADQJZ1$1'.9,-)&<EG6U2#RI8Z$6\CW1D6;)
M1D:C/ZAFEC#,VD<EDS#IUVK@W3M+V8R22F%;D,R/@[(^_8&7BMXUG&_GL/!_
M1EU B([*P5)TN9:C(B:PC81,)MIIFDFZP^ZH&"4\C2-ANR>S22F:LW(132D4
MLQ!U5W:EP3HGQDQ=HCD*0B-LLYTB83&D1!-8Q<JEX*&LI:RF'WA_U!]VN\SX
ME"69K6LFL8+6V&2AU6,)O5+PD-;1V6);BD'<! P9/(Q9LH$IK"81M-6;DE:3
M#9,VR'E>]K2)T\=M8[F)<LC%&9LD984W4F)U6M65<[=N7LQ,)5\Z-\BUQ%UE
M6<,E*C9YM9DIC7N:/?4;$\S+&J(.L'Q)0GQ$I9?W!_[=5:'?U2-NM-KRA]5\
M8Y]&?.?HTZ;93(_H(9*6J-G_ -)W*N,B300::32;2WQ6YF:QR62.4GT8AVY2
M\03$FDR(U6I+3;#3!/8IM(FL([33D+4*8M0A&DN'2Y8?T3U/T2#V'['N4*=.
M?[5<A&7Z)$1D9_I&4X_Z=*$<$_(V&3&LV-:4IM5@J>.?SIS9F@I_-/#>3_G-
MHS-*>68??<55CMW#)PFI:QNL1'KM3)*T??\ 5L,;Y7]T2R(YV'OS2R3]'6;(
MV.B8&&.+.)92(ET#=L:R6B=(BE9(G9%7PZW!O(R.E-U3HYOZU!5(]A 9&U4Z
M?%):3K^,VX6S\"-^T+_6_HRUR[Y? K%Q!1BH+,F9M2DU4I3D.B\=F5J<PFLZ
MWB51RD8)*2:&,U36\;^3!!/4R-L#T-*22X\1.]OR]X11+8WZ+9FL)EX1)/S(
MTM*A3D-K28S9GL&4\@S!O$NGA)-X5)DQ*.B1$TITD3#G+7!5/!56]B#S6;)X
M1F1,L*90-NM2EMB(3',+/FTTVI"*>S(16"%</WZ$J63U2VF7YYM)DTID4M@/
MJVBDYQ;VPVBS98IMP@ZKM;]$,X>S%F\Y=WR"UK>H*S32WSHI[;#58;)/;%;O
M"PB)\5MN;>I=D>HV4]1K)6-$$^23%';EV@]@X<B3#.O[-D^S8N&(E"B;0>T=
M?>I)MYHC?1^-8;->P"\?T@1OV81?V@47*,Y$1DQ4J-#5F529]4/G]>13IRX>
MRF1H(V%KTRN_\Q&J63?/$@I9MZF6]-)KBLXUJ<\Z^D:&MXXSD;(VA;.?4#ZA
M0(G,K%'1;+L,O@JHA*K>K4;J@3V5GZ3*&JUA*EL&(BKHA"L\_-II)1DR0BG8
M;9"*P0BW?9%ZZ=F>$2BWTUB9K=5@@.TG:",@S?)81KIJWQ$VQ0DG.W>%3DHV
M$:DM*VU^2VMV632SC?M+63ND(7,S24^%/>_IXS8];(07V;N[/_I!4Q/DTF[:
M2[QF'T,TC=NOHLGVKXK,H4Z)J-A'.S>D?Y3"-8;'Q':I',6L($C8;XRE8R>D
MEGA$']I/]4Q5AJ;OSAJ1%]$J*I#GLLEDOBKG<"5)PB=5%E+OLNF/O%*"6\SN
M;)W2HZK:3%-UF;(=5H\B$0[A[,6;IL+5WR)?RDF%9J<J9FR(B-C2-F>-L\C:
M%_4EBU*,I2.5DGT;%RR(S.L-#2F^U@\QA,EUK-X0SQ*"4NDJFI)DW".P1'):
MEF$,]AR:N2D16Y6RZVH4EFU5CAZ7'&Y:=K./LV<FH1':GL,:*R=/%$;MXZ?+
M2EC*&;L-;*VVPF6C&_)K7F;GO[E_XSV:^TE^LGX-6&1LSJ5;$J;MX.W5:5S$
M1#E,Z*)II;)O5D6*8]!JY.;*W/>G,]5K1&19)+/(,B2NU):LW1#YQI)6K?$F
M9)453LGE,K4K+(95E801PQ6E'D"L7K\D(>/"(B,E-HF3;92SZ@*DEVRRUK=@
M5/KEWR&RG]8A PBTDE:85T:5LI,-V5B8]\VW(1V1$]GJQ,TQ,,I+&FTU[\BF
M^BS74U@_^W?^E$0DF$IY%$3#.;>INSZ@>0#PTYQ^I+")36,.E8*T1RF96I3,
MB.#<O#89F9S,.4S4R_+\"*_21^L0@_L\+\"-^S#TR!K-<&G.&[H)=K5]9J7[
MNXS9E!QBE*BHG^\5)>:KOM$(YBD4TL*1K/&U-4K@K%P^42T*F)C*-\VW@ZKA
M:97*E[QL^^5(UDEJ8P=;5>:(9Q8.C3.392TIY9-8RE$3Z8^IO2)37J4M:;4R
MT6G-+)2,1?:SLF^-$01MS1$6L>_,S:6H:)R(Y#E'_2O:EUFXPS92:9G;FHVK
M-*>2>01;FHE(*.,VI-;"*8BDV&7PYAJVCH1:'5AJB;P)!#0\0NF\<)(E*EWQ
MD1$<\L]DY3G,B&==*HI\5C;^X*F=?G)_73\*+^T?!K>"@(M4$;8DS4E)J,V1
M,TBW9E*PSEEFLAS'U]%KK!3JP:3=D=U;PROE98T01I)G^9\!B$AX(B=H4ZSA
MDQK=2Q=O"N71$Q!&HF:E)1%>#VK^RR4.S<F9&LR(VL-C6,)DQR--MLA!(KY\
M3Y])(2*+-\FS25K[ <OH5Y0BG/TZ+6[%)++>$'*>U*,ZZ>EAM89;##:RR4C6
MDRT*K=$=-##I*-I);JL,Y+=EC666YI]'P2G/B4U=^AX _JR.21+>J:EAF=$F
M$5DI3DU-D;PFIMM8/^E>R!*>Q1G*HI$D6O\ EWB,W"2)X_5A+F,]1DLA3%*<
MA,E^#_I_@U;"H504]^DQK/.YJ9I-MSE:U0[56];OXEVF=!I45+9-ZMEPQ%P%
M7.\TA+IZLK,CPL&Q@VVRVB$1%N&)?.WQ()3&R44RL;;;=U!53Q)2O"<D;))7
MCU3LSV&D;++&:H<]GJA=D]CGWTC-E&7Q6&UOZ1;()YVAB4K0TO-D5DU$12TC
M;*9?1#FJHQ%)V^=YND?T3\9AE*PYB;/9#Y$*OTNKG)M-)E0(TSG+24:;)%A,
MD-ADTA]XNTF[4[,B>H(VYMBF3L32(_T2D,.BJ".@DN%E*5-1FG7WC)->4/:^
MK1;C./2-I$M1$TV2X!S,.[J2@CK0UJ9_=M\!B$K3LT]-)G*;M9-8PK!RG+9D
M:UGP8+[27>[L[!6-1/S),4B8O&,I#+489:NL0F,]@0"GDJ7F%:*3\K0S57DG
MT7QI.]NBMON_H[54&34::J/!9X!7/^J]:(;/_I!"=E*@=D<38:<EQGALD"B.
MTT43Q,GFJ#-BE2-MK!(%2.4H><&<&9$MJIBI'A&16A"ND2J^F96V'.S4$2<:
MFF<M!ILE84S2.PV^(IU$$DD?04N?8(1E%9T\PJ<FFRD;-AC-@/7SA!)?/S/.
M+GI,,RFD9=#F JYV3Q\_*1IT22<Q2,-LIS-)H?Q%=/T(</",S2QMBP9J+9:3
M.^/,[TFG)/9-E[;$;1)JFS3MD*;4%4^F'_EFIIVJ-)-*\WPC-5@2?1?&D[VZ
M(LW$J/HVIB_*X*SC6ISSKZ1H:WCC.1LC:%LY]06BM=V$^T? K*IHA;8E.](C
M*C2HJ41V39/JC/11$[U&MVA6$; R.D-8IA[YC"U&6? V<+5])*F,M^8)W/LM
MFL,U0]=+*B;U29Y&;XKMX?Z;:$96*T$IX3W-I,[$A2[E\,7*FU,$J<M4:7N=
M86L:669FM,[5BR(-+I14T.LVI)'28R0S.9A_FV#D:&+21*M-;X!%$MC?HMF:
MPF7A$D_,C2TJ%.0VM)C-F>P93R S?--X3A4\DA*51X+.^9V0Z?LWSU2II&;X
M[MY@BWC$DLVRT6E8^BTA!/V-,GM"64SD.5O@O@Z1MZ*()"3HI84A$RQ;%;OT
MI(GJ#515.S?JL;HJQX],C-ZTI"8QN9/5;AZDPJER_/>,.D9S4I&-LVVLVAFH
M>.@EN?$IJ*_0\ ?PT>9(4\/>I)IDDF$36FR5I'(R9DM@HRLB1YY#"2J=FP(,
MGIL32WY%9D.=EV40?W>7^7_1W1&9S :4TW2PYK2(*EF?HM92M;XYFZQ@ZP@'
MB(=S8.A2.XU+6SM$4ZBWA/#2Z4HUH)I&9FEI46G,QF$=JP-G_P!)W*MA4JH*
M>R4IV->YJ9I-FI3E:U1"Q59/7D=!&>_2;7;-EKQA3V-2R"B:M,LQ8HL8S48(
M[7+O"-J,G'IZ))851JM_FG:MM*XQ7:^M'/HDLB6D\D9XQ$B2S*DCU)";4R(@
MJ1-<7%OJ!E<([NH*QAGIDI*W;UXF1E'-6)S:VW(RT8EFSM!GA_*Z*X8PU)(F
M$4K)5?ELB'>N%DZ?.L!XRDW6(E)9L&'*>U*,ZZ>EAM89;##:RR4C6DRT,]#E
M2U)N[&_:%_K?T9:Y=\O@1U81R448LY")4J6F9FV2PVQ/*<DW<<.:J)'F3E-2
MF-*X;/RE[CNN.S[W,Q+LC:JBTEG8:Q142MFQ3)V&';GM/$)*'0S>)+"MRM(B
M-DQF2B:R2VXJXW*GBXEWFW24/,W2_.P%D3+3#!)JVLW+I),85,S_ /\ &7?#
M[LQVA,GSQRV4E$9'-(;$L:;6DS5M".K2-)#(LVDFE*EIF9M-DK&LU9Y)A]V/
MUYL_'92X+4]\.NSCVL'4.Y=S+(VG<:7?DU3E$:M2B6ZB2(D&PR-)$5DC;-,6
M^-I2FPY!&UX\))N(O.L.DRCG7A/99):+*-AN%),'#FJB1YDY34IC2N&S\I0^
M<MHYVRQK.\V\'T%6A)\Z\SC4J:S48R4/G"\%[>V[P?=E:R50>(>YQ/YUBBRQ
M,1M:<[&22OX-M'/.\VV=FJR1NLTM</H*M"3YUYG&I4UFHQDH<O8.2(<S&QM+
M4D,J)&;&L;-98"@Z^BLVX)F]G-3)VRI(FR33RS!_5L>SSKW.$HFR$PB(C([)
MZAL+5$<]C20R*F8IAIXV>27C+=BPT%5D0A;V(CS8Z0EYFVMLF;%66%(1G+,Q
MH(H6LG*4E)AJF9JN[&N'_9SM*9*B'+=\2J1'L$5$I#(RWS66&D8>Q_8YYFW;
MW^SI2))GC6=21.NPF!S&]H8DC<.3XK>[Z0_I&6]E8<RFZ@@ZPJ];(N$F,RPY
M2-LYT3)C2D5?#]]VE?.TDZ8PF-,[;3,R9J2"L.UCAI0KIM YR.U+(R9MF?\
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M+;=P-7(=J<;V4K;/Z'S<OP<V[WQE/^4HS;S>F<WY2?"-ZEM$ISHG8^1':/\
M#HSU9?QB#_U7J@[2_B,5ZU\8JC\./UOXQ"?B)>MG\8KG[.7ZQ?*)ZYJ9P:7R
M'6<3OFTM28KK=@.8/"2L]])@D4MDY6S'-.',75;HFO7F;I$3#)EF2>2Q(16Q
MZ55\*\6BW1(N^9 EUA#&[=G])K6':-A&7"'WBX<FMPUE,K;632V0Z56\,;A;
MV9+25+:)C#/920=+=P32>S><21W#8>-1"5UK#YDE3-61MGL%K#TBKX12T6U*
M2C]8P569@_25&PD&TC/6-E]C"E-K",."JIR40;V??)2PY+!G,=ILEN8/50#D
MWA.IV&4]ENXT9B!0;Q<["8UFR9![5SAP:G[J=#2;^6LT'4Y.C])*2A(VZU@3
M#QL";]]_<FM*3,V',IBB(Y#/6O*=0\)Z.^.0G-(E&1L;*HB24VIL!XX1!JI(
MFE*6ZR\:@=3E"*]*\2D5''P0Z.LW"G27K6&9DR\9WS+OCTJKX5XM%NB1=\R!
M+K"&-V[/Z36L.T;",N$*Q-PX2]6IM%3)4RG-.VZ0>QD3"*2[=3FTCNL:S7)M
MLV"9OR&[1_AT9ZLOXQ!_ZKU0=I?Q&*]:^,51^''ZW\8A/Q$O6S^,5S]G+]8O
ME%5D/@.HETIVHCE)LC#FM-DDUQ7=<QB<V4 W-$9<81FUA*^C(PI"5*5L03Y^
MJFJFZ>-_\4IMBW9M$'4:]K-560;YIM,Z1$1V6TT,;*<A_G-(VD3TDQOWCF9,
M]F\V9V)J;S6E49VY0^B7Y$^0YSV\P6YN7"E92UC9JB$?]I7Q/79&VB9,(B8R
M<FWR.R;6"'?U4^)S!.F2&]WIL.4C)I2J(S)M%3&-D80@8!X]4^A4,)24F;#.
M4Y+!&=)+3E;-88"<(KE%6$7]A0)DK2:9YU#6L,B:EDALEFJZM*@B'9Q#J12W
M9DJE-.1373G$"FIHA;I)I49MDE(TD5G5,1QD94S.TTYB"<T;$T3G)ME+? (N
M/A%47B58)62,F&1LGGD(R8TB.5A ^U:(0GE89K.9NFPY&G1(Z)DV4Y:,MF8@
MXK&*>FMZ\4HV&4S'2E,GU63%;.4P:Y&TFS?]P2[>PW98';BKWN:2BBUA-I--
MFPW\CM0[BKUYLGIO3-1$5-CIA,I&T]\UK289,9*T0=81QDMX6:-K&<;/<EUV
MV ZC7M9JJR#?--IG2(B.RVFAC93D/\YI&TB>DF-^\<S)GLWFS.Q-3>:TJC.W
M*(U]#83'QL/_ +JR>H=ZV8C*OKMYZ2Y87T=>UK?E8?0I'22Z-14IFL,RFE8U
MC9S8WY#=H_PZ,]67\8@_]5ZH.TOXC%>M?&*H_#C];^,0GXB7K9_&*Y^SE^L7
MRB@8ZJGBC.$:W>F1JE29:I-9J@ZNJU9M>&6<71,C46M8-K)S.235$/4<.M1O
MW1.6E1G-W.1:X<5+VG-Z1.)"HM)I$3)R(V;)M,5A4$ [4Y2G E-=*1LK4E1/
M5,S,]4Q$5)$+440])\PJ,QO)BV!#P\,[SJG9D9RT6D1E2MZUF>4BL*<1L5$(
M4F0T(ILDUE,,YR,R)M@YB(JO[0]G7IF2S:9+)E RL-:;6V9"G,I!][=HC>N8
MC\VD=\B(K>LVPTPY+LVAXE+HC::CI-.1C)"9JMDUPXBNT!*0MU]%)'+J4B81
M7Y2U ^AX]+'3YC#:>]V*)M*:TRS./_;7:CI?3-I&1?HJ:9$TIBN!_7M>&:H9
MX;2*B<^K;8<Q,.PJ0R('6KPC."H9LD-.;QC-AV6L*B4C".9H<5W5QFF%=M:5
M$R/BC=MV3WQV93GG'_44I.&VO^Y)WWR;^31]X0AM1(=FP;;)$=X0YU>M1DZS
MS3-)RYPTF3"U&'KAS425&3]UF6DQK<W/=V0XJ7M.;TB<2%1:32(F3D1LV3:8
MK"H(!VIRE.!*:Z4C96I*B>J9F9ZIA[5KZD]>O<Z5!E%F=D:TVMHE*92&=C5?
MO>R:%$]>V%$9L^LQAD6IJR6WBUX3RS:;W[-WY#=H_P .C/5E_&(/_5>J#M+^
M(Q7K7QBJ/PX_6_C$)^(EZV?QBN?LY?K%\HMZPMC=(;TB+8W2#7;"5;9NEWQO
MC)EJCN@UM*BJ<F3[.X&O&&JVS=/OA-9P"F**QKL;+L6KH^\(BI4F]MY\M;^X
M!'%%0=)P79'@_683;A!BB(TVF;H8DR+8W0QX1**TS=#53VPU1$9VV,%%XPTG
M89NGWA0^C:%$V,M,W1.5&TSPM\ WDAVQO6%L;H:IAJML9X?"-\9,M4=T&MI4
M53DR?9W!22PE6V-\+;X8@B25IGR'[1_AT9ZLOXQ!_P"J]4':7\1BO6OC%4?A
MQ^M_&(3\1+UL_C%<_9R_6+YP:VJ.%D>QL,_<)LLSKHW=)DC:+:3&DUC*13CC
M*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>SCC*OZR\]G
M'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY
M[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K
M+SV<<95_67GLXXRK^LO/9PY[4U\4.ERZSLB7M)N=<YJ=DE&>8VS23BMZ]@WD
M)F(V)>Q"?.J:6=>YVAQ9-HX-*1L["F'&5?UEY[..,J_K+SV<<95_67GLXXRK
M^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQ
ME7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>S
MCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>SB"K+L[F
M:$+#9@R6\HFKSV=I326F2VVV!QE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<
M<95_67GLXXRK^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67G
MLXXRK^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^L
MO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLX=?RT:X*LW404
M0S.;PV/C>T*=&3Q:3#MLL#C*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK
M^LO/9QQE7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQ
ME7]9>>SCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9QQE7]9>>S
MCC*OZR\]G'&5?UEY[..,J_K+SV<<95_67GLXXRK^LO/9Q&QW:%+FC%NB0Q#V
MD:6&1MD3OIIM[K_.#&]I*&<^[H=\_-#:.=S3DWIH-3#H4F,I4549V',-"Q7*
M(YH:%BN41S0T+%<HCFAH6*Y1'-#0L5RB.:&A8KE$<T-"Q7*(YH:%BN41S0T+
M%<HCFAH6*Y1'-#0L5RB.:&A8KE$<T-"Q7*(YH:%BN41S0T+%<HCFAH6*Y1'-
M#0L5RB.:&A8KE$<T-"Q7*(YH:%BN41S0T+%<HCFAH6*Y1'-#0L5RB.:#GLQ
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M8!7590P"NJRA@%=5E# *ZK*& 5U64, KJLH8!7590P"NJRA@%=5E# *ZK*&
M5U64, KJLH8!7590P"NJRA@%=5E# *ZK*& 5U64, KJLH50:#5+5YSFW_P W
MK# *ZK*& 5U64, KJLH8!7590P"NJRA@%=5E# *ZK*& 5U64, KJLH8!7590
MP"NJRA@%=5E# *ZK*& 5U64, KJLH8!7590P"NJRA@%=5E# *ZK*& 5U64,
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M0(KD#RAT"*Y \H= BN0/*'0(KD#RAT"*Y \H= BN0/*'0(KD#RAT"*Y \H=
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MTL[P9Y9, [A[0P#N'M# .X>T, [A[0P#N'M# .X>T, [A[0P#N'M# .X>T,
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M9T2,YP]6JB:US'1P=ALMX07:MY5\/6:8-O\ E(I)/(9;29*@R,B9.4BI1_\
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MUX=4-6=)5L&2S8'SMZ;$O?I,FV+-TAYK?%;F'^5E6/\ *-S>J,X[.220OR\
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M/QB,UX7UL=F_PZ%]4/X7I-%!OYLY1)M'Q66MGN*,TH)3Q-%9I31I)MG*>_\
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MZI&\R- 5AU2-YD: K#JD;S(T!6'5(WF1H"L.J1O,C0%8=4C>9&@*PZI&\R-
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M8"L1YD# 5B/,@8"L1YD# 5B/,@8"L1YD# 5B/,@8"L1YD# 5B/,@8"L1YD#
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M[R<II,^C-?E[PS/HM _&IMO4"[XS+)6>$>A^CT]6FR]1/OC[SK8VGXIEX6^
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M'3_]LCG!T_\ VR.<'3_]LCG!T_\ VR.<'3_]LCG!T_\ VR.<'3_]LCG!T_\
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M]E'3*MZP_P#91TRK>L/_ &4=,JWK#_V4=,JWK#_V4=,JWK#_ -E'3*MZP_\
M91TRK>L/_91TRK>L/_91TRK>L/\ V4=,JWK#_P!E'3*MZP_]E'3*MZP_]E'3
M*MZP_P#91TRK>L/_ &4=,JWK#_V4=,JWK#_V7YDYK_<F[DYW#[C6=V27N22B
M83?)*H5NCHDNLH.2=G^:39D;JS# /'>90P#QWF4, \=YE# /'>90P#QWF4,
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MPFL:QK"EA^PSUR^?P%2PT0J(,D[WTB(F69&I)$;LWCDR*D9JW[#31,1?8GM
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MX#KCC+&EX#KCC+&EX#KCC+&EX#KCC+&EX#KCC+&EX#KCC+&EX#KCC+#ZA6\
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MVFX_^]^9_;%B/^7DG]X4_P#MBA?^81W_ 'PS/[8WI?\ +NS_ /<TX_;]]_\
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MY5=(:.D+T0AGK+J'O>SEQ\.!X2&R!,  I]1Q.IEI*!"@.67?ZA,(9:?O\'?
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M)M&R/1(N1DXJ8A)A '$;44#)L2'*X8J#TB K:2B5=)5(29DU#_AMKW[M[/\
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MI!4ITAUB41P;O,BE3Z4>^*8Y2?"H5/4 <[!1Z%0"G_@S#ITJ?^J8!$.V(8,
M@) *94FM4JB9!,3+2(',7(P&_&<*>K+3]_@,?3D4H\!C&(0IB?\ MM1A#O/O
M_@QPAI_#^V>N/_Y?:J_N'KC]C7DK8*,HZ0:6X?P,=4HU15S.G%4G%1H.W$8#
M5-0BO2 8K0^8@(99_>X7<@SM!3E<)LT3+JMJ*N313R2,F0QM?0QLZ[CUE3@4
M"F*DD0RA\\DR'$,2]'UA3-04K5< _=1TW3E20\C SD6[9+@@Z;O8F621<I*$
M,8I!*HD4#''(@F)W^#F#08"$5/WJJ8B8I,](%(80,)C:1X  <=\ !PIZ0$Y
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M*F? !?O@(X,(%,)2_+ BH)#^XN8H$-_\(8V,](:,R#T@*$Z+0HETA3]..2?
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MX<;*^KDMJN#"C* MZ2Y-<-6>A(:CE6*YJ5IB=EB@41Z1U)!4LJY3.H=-5RY
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MS%,&MLLLEF'%KS#BX=HQFZID#%NBU;=(F*I53-WD"[:N$5#E.&93(J'0,
M"F.D0X,\/-O](R+2)FKG'LG!-I1^F==C",BVMC7=03JS%N!5%Q91Z"SD$.D3
MU@CT?2$UZBIV)O+2VY_='>*/IZ&EJ["GZHB*4IJG5J@8%?,A>DB'U/E2=NDD
MTG"+75(&205!1TZ,J7I!VR2MH*-J2W=LY.NK3.J(HNJIAQ/3E/TNO353^(,G
MTV[%8SL#HCFFH(G$43D H%#+*FMC76%V-+=2R%/@G#T;7%/-TY:0IZ"5*N,/
M'SU/$<,WR*T4FLNT;34"]*\29J%;>*CDHJLKOTV!7E?W"L(U4CAJ.B9QX2</
M"14W425+*.:6E7B#5^@K'OWC5)_#3C(SU  ,X4=$% 43[:)'<U;VYERK!BSI
M1.K*:L:^;LI@E5NJ]F'7TG.K*S< EXFA4!52O""]'4^%(H)K<&'UU[#;;=Z%
M*UJ_IF6I1[(OG%)U.F>!F)!K*/&/T9,W*<(&.*[)!0#@F<PFU&,(B;@O]=>C
MXV3B*2N?>VZ=Q::BIYDS8RD/3E<5K(S< PEX^+6<H-W";-P4!0;+K%*),M0:
MLBB&28@(9@44BE(4_2Z\P(EI#+3WNG+[^?8QUG0")P#]%*XUB4V1S%&Q4OF!
M3& <A^_D/[*Q'_+R3^\*?_8]7Y<*_6VJD-T=&RMM-JM(1]NZU:TN]AXRH9';
M,\FF=4(M*LB)ELHN@W8.692^*%-DY,8JA0*8AYRPFT';A0.SZA:ECY:)DGM'
M.(U[42$;-LQ82A*-C*6AH*.A5UTC&(=X#9PNGP&;J(&(0Q;K%$"AIVF5T(9!
MWNI2\%"F$P%$1^4 FX^S][&Z:3EG2LA(/MQ5[%7;ITHJL=44[D/R)(Z5#"7H
M4RIHD02$H@FF3H@$41Z,.K*<.EU'3EQ3%%.%W+@YU5UG"MBHHRZZJIQ$YC',
M<3F$3<)@ 1SRQ:'<IUAU37BKZM;S1L))4M9*TSF-@V[=U,0J-5!3PN5CMW2R
MK!L9N,H]&9:-4CFZ%)!Q^*,KON7V:6,NE9NE(^DC1M5EN17#NKCU1,_U9SRC
M,L>@M)R"#!5FF4R#HI'69^F0$P@(EQ<&'J.WR%U[&W>:12-PZ-\9(PDT74<U
M<-FT_32SY,[!?6V>.49!B\;%1=(]"3QE+H=1ZZK_ *O:NIBPU[X5HM.SMHYU
MC(1]--I!_P!(9 L_0TBHL9BU<JJ$;IRU+2B\>S,;@07'),>L!A9N(DEJRIN5
MMM$U#"T\HDI5ZY(2)JUFK&PJA5T0!P+A%T@R*19,.E,4XB")DM$!5\!M-WPQ
M]14E/1]20;A2IHI<[.2IU\5=LLF*UT3 8I52ZE U]*8HBF)NC[S%O+I6:I.X
ME-Q=(6I;V^GRW)AJ3B)=9XWK*5G&AT34S+S")FI ?*F(!W1%2F,<02$#!D)A
M*&@IA*<0. ="4I-9E%M>0%+\DN0CF;@PEUD76%':4GMVHDJ$[:BV52-".IR]
M=2J%Z>GI4]-K]^\8N52%^AHH2 >351\85$D,0%7*EQJJ0/2U 4N#J%M3;A-X
MJNSI"G)!5-PY=NW:1 3<R<ET*3F1>AHU'!$I4DTVZ1"_L*%_YA'?]\,S^QWJ
M594U.,JQIJC[@7+JB>HV1(U/'U-#P=CXZ7?0+U)=LNB"#Q%'Q8P&:J% !$3$
M.&9!EU-H_5L6.L96\JW415JPHTE"1Z(G3%,#2<);6F8-T_* Z>\^E4LP#(1[
M(63N_=6H7%55[76YVR<Q4,PZ2;I%45_K#C6C5BQ9MRE10:-D2$0;MRD$")!H
M >SBS<&L^65B([:Y3$K&QQSJ TCY.6NK5K27?-4R&#2JX)'QY3'SSTH:>$#=
M[UBQ55%54VU5;CB))+*J*I$*?;U1YW!2%.(B **JJ.#!F(=*8Q^,<7BWA[M+
MFU9;[;C9N0FF[V/HI)F%1SBE$TXUJ6J9A_*.FL@*+5LFX9MT$&#!9TZ5!4$E
M6NA+I[)TSM,VT;DH"ZQRW1/3UV[E7!47AFL=&VLFEIF6EZ>CYV2;N2/V17;-
M/I$2 BLNU.?2<Q2A>K<%;=&*=U/;NO*==IQ4J31&S47-V?AX*J8&4;)*(F%.
M19.72.M#6I_!*E.55+6:'BKI4S5.US>16I&%/Q\VSDFC!S6-3BB2/B8EE6+-
MNM 5$8IB-6S4LW&,'SH?]59AHQ:RPM=5#%5F2+HVXM76YJQ%BO%)5!"3=IIL
ML1)%AW:BH-'B21)%!PS276*FLDNL03)Z3A>R.W5;8MX%87Y93D C7E44K/,V
M],S6NC(P::D:?(%?Q9TVAXHK--JF,>W 1*H3H@',<6WV=[9;87WHUC:BM*(F
MJ2&[D;1SF-AZ2IJFYB!79H3S.JZ@D.D*A(] 4QV^CH]1 .4# )<5[+6"?TQ'
MN[AM(&+J4:II%M4A44J64=*Q9"D<G3%N?-Z8IB%$5#<8DX<@OE:G>G9>@6UT
M+/PE+K4+?*V\9,4U4<8RK4LRQCU4?&W;I4%HN19J/BLW#LT6_*N4QHY($<U)
M:(64(L>)DY"+473$.C669._%BG( "/>G#O\ ,!'+BX>/]AO2_P"7=G_[FG'W
M86<,B"_T-*Q\H5N0_BZBQF3M-R9'QK2?3K*GHU=&.6>>0Y9#LZW'T>DK/VT4
M95K!.)]H3IV+<E?,(:L[=/E%BF A$I-LQD%$#*&)_ E <SB! U"!@#+5F.C+
M1^Z4P]]_HXW9**D9_3:= VT3C# </&DX=>H)566\44$04!$YBQ1ES:C!D1 I
MP Y2B>K5JT4?'K1Q5$\^JSQW+Z1+52LETU0G=%'OU'97W LL@ D^^&.K9?UT
MJ56ZJL1:)>7/)B4\V=\IMV3?UT9<QC])_P#)WB:SLH\)S@D)Q$Q2E/U</_FS
M;E_\SU6F*[_\UM?_ )M>&Q76_G>Q<>M*2L%1;R<0@J0MNBR2FJA0IJ63IUQ)
M2DJY;/3',]EG Q+&.CT4EEERD4%X3@+B)@-GFVW<!1MQVEMJ]<'N1<ZOQFV!
M*80,R(^4>TXA-RC8B[\5&QC*MR$1(IWH"83)&4=%R  '>]7ALB@!<U$)243*
MH;+C,;I,SC\H0S'CQ<$LKTA&"5NK5?HZF[*<4DH96D4 76;D2 0TIR*DGJ$0
M.(JG**8*&S*%Z$JX%<\"5Q<']#/I9-46  2^[(U,DAC$ 1Z+])P4*F!2\#DJ
MA0)D4<K:$HDN44XDXM"OR10D50&/7W,RBTV>0!7O3:YLK(3BKK*<X@4P*HG.
M53:J:E0<I2"U8U0C($9I)H [IQ2@Y(U:-E4U! BA C_&%C]Z*FKHC@8!R#%L
M1B2-@<*WJVK?2PH(@!1E5:*AE%>F%$Q0Z8[8_2',(9B8VH0S#A3I^2EGSJ#H
MRS= ,*;B3N5OHZ)1G3O)R678LM71I.'#@Y3+NDBE65*D@DJ<Z*)$PN[<R\]Q
MY:VU@[%L8Q:KGE-';I5)4$@JV>S+UFVE9M-RU91\>R:F<O7;AJN(E62+T0*]
M*NE8"B-N.W'=!4UQT[STE%T!=FLJ_>Q4&$PTD#>*5>M2[>8,5=LR4(919JM%
M(+&0#-5/6/188D*GTAQI"Q0YIIB58O\ K.GOS%,&8E()\C@(&RTAGD0,]L8=
M(&HUJ*R)T)#K%(9(]5E$/&"DTB7A$IC&,8@%#C$<=93(4&F9*Z*,;=WZ#/%%
M;EJ(TDPVZYT0BD*)RJ@8L@9T=F43ER6.MT1LQ-HI-W1BSDM9M:D@G=)'9*%^
MD$JL3DNEIY9B!?X%V9]P(JF.F3[X\6-IJJ -"U$O0=SD)DA/%B29H<T_$J0!
ME 6S.=N1<9,R9=!=)CK:3&$3%)L#HYO,/RTS43&Z-43<,+@_B4M.4A3='1U.
MR,FF7+IE&J,W)D3$PY9.%2B D4,03!P=^<JAP B9$Q."71&R32 H  @ <'8_
MR_=OO_R\G_O"@/V&R3=31+=:6MXV&>4/(1P+O4&L=N!HV JRCI!=5,A1\67-
M"HH%7.F5,RBJ9#F2,<A3]_D0H@<2&.8"ZBE6\6*8P!GH ZG>E!328O\ \4*G
MC;U9FX":L96]P/ZJ6S&&<@9I)LI">JIU?9['R+#(BQ%&+,AF[P- =$MD!P*8
M2D&B 1;+*@C4KIPJ*91.*21][$P1$52DSR$QS)I&*43&*<P%$.SBTJ[=!1RF
MRHF[<@\,W**A6C!:W3R-3=N-6D2%.X601)J+GJ,8%.C$H :<_P">*U/]+J?Q
M9*AUI1TK2D)MJBJGBX11986#2<JBZ-214Y()MP.!0.Y;0\<FJ !I'Q=$0 .C
M+@VD"%+F4"$*F4I 3 HE,0Q4](#GJ-P@ 99_>Q)PLPN*#ZY&W^X5$TX50Q43
M.)]"IZ?N"JUT]\ F.SIV0T$U!F)0* \.-UL)4S%=LK5E[*\N; +*,G":,K35
MTZE6KR+DX\7 $!9 B,FFV7<I&%,KDIDQ$!*.": *?48P9 8PF,7, (9!(A1.
MKJU   F4>'@QML;T0)24XZF;=%N&6)Z%6/!@>OIQS+%D@_&%$"562/$Z9=8B
MZTE.00 V-MY:?!R NW-RV\RFD"7BRM-C:>=<2I'1 TAT1#(IF+J'I"+HM^^,
M.(=.#!H=L-ZK1+K$99 BTES[?X)[/ 8S4W"N=X9\9UK'/ICB4P9APW/9/7*C
MIM"T+:*-BDE\CD8LU*#;3AT6Y2Y:0,[=.%SZ<M1C_>QM+:-72H-ZCD;.P$FF
M)U !6+:*SD^T; 1,Q2"5)Q'M=!3D,4"E 0*"I4U4[^H%<*E0<;?P<.$ -DBL
MNC<.$\65.0F68H@NX*B)A$2@H(9CEPK\CAJW=.'"0,RE&'GBE*F("&D *4I>
M+L8W:+R3QR\51N8,:B998YBHQ<12[*-CX]-,>]Z-)-,-!1 0 <QQU;4$5TJ,
M=.0UKYB31,=0?&G\#81LC%JG$1'A3^D7)P.'?Z]!M>9>'K$$3*G%NA2]C%TT
M-:H)IJJ0UPRF51(!@*0^22)=8%ST$*4<\@$-[SGH>EGDX.P'T8FV3;?3:T6D
M%:G>HQA%Q "E4,1GD G #F$AC&XQ2;S/_"5OG:5%$3H/O&'=31Q))&9CG^M=
MPN 7/%456[GOU3:>F*?OL\\6@KBS5)W(I="@Z(EZ.GSW*@:0@YETY<SJLXP.
MP5I>8FR]#T0K@5-TN@<-:I0(!CZB[0Z)"9??HNX97>JEY"IKJ(L7T^W<P47'
MRKM),0$ZS9JNY11,8P@F594J92$44*>]3AP1I]+--M\FG'@?2+XC=>Y%.I2)
MB"IGF":AD$P$H@*95=!A/K$0W(KUP#K]+3WXO O5(/2M2KEE3UP^1E0.4X@"
M>8:3@!1*1,/QH FIW^-L Y#P!>HJJA4S)@!?^'BJQ12 ^0 )>_$Y1)V3A\'#
M=3;K2TJS@92YERZ=CEIR0;+O&T)"P=F(JJZIGA8HF3\9%G&L'*R3?ITNG4+T
M72)\O#S;]=*C=TNZ&\5.1T;)5Z^A:PBZ5@J<DJCBF]01R#Y6(?4^B55=%1LX
M21Z%_P!&@J NG8B7(VQB5MK3,_0]N9.Y%A7E"4C44H]EYZGZ.?;<ZS7IV'EY
M1Z85G)DF)TTQ,L&>>@P 42 &*$_\UNO_ )M>9^YO6K]S#-:G0H:N+BU@O34@
MJ"4=4"%,V)CI4T ].=-8"-W)4!1/FBH  <1$ALLAW$6ALS;NW6S/<[%T*^EK
M8K4]'PU20TNFNW^CB54I'GB&!5R0\PJU2DVQT%0%)8BR0J%*82S,;?\ 7J!S
M>2-O(DPN6O5KT)&;5JYK53=M(J.'@BIK,L9+4W. =&?(%$RD1.0H[8_[)JJ_
MI<&-G6ZJXVX"C-D%=K0504^G&;CA84;1U:+K-64G4ZE*NJADF)CQ[-T@9W$2
MB)5DG:"Z!5=!C$-B@.K/VTW7+N0J!*983US+O0$>LRHYL URO<V178/!.JW=
MN'4B=%O'ILU7B*3(HG6<F7-T@=9Q.0SM6-EX."W!2D3(-#&2=,I"-VO)+L':
M2I! 042.0ARF#(0,&8<.-F!DG"R!E-V&W=-11%50BAP<79B&S@HFSX"K)"*:
MY   .4QP'@,.(8 ,(:=O5O#AI*B42G+4M0=&H14"=(!B9G,0>DX#:!RR)D/5
MW<:>5(7Y3-WR:(%)]#6Z,JF G,4NL% ((AWV12B(9XK^&GK>(74LE=UM&-[B
MT8+MDPFV:L,@Y9MZA@EGI5F2@&:NUFSV/D$"^-(E2("R/1YFKJO^KVKJ8L->
M^%:+3L[:.=8R$?33:0?](9 L_0TBHL9BU<JJ$;IRU+2B\>S,;@07'),9BG)I
MMXM,P,M(04LTZ5%3Q:4BWBC%XVUHF-GI.GEGD''][[NV/_EXLK_=S&_X.M?_
M "C47_N(7_8;8+.VTI6ZE/U-9,S3]*I"X4%14? 2H-J%;4J8U,O(&<E%5A,Z
M0'@701[T<\^/'*. "*8'$ILE#$)RB%.8!TZOAR'%^)B]%+74J=M=""H&/I\E
ML8.E)=9HM3#N7=27TP2K9N$Z,?\ 60*4$>ESRSSX>#%8[0-V=J'5^=I]>*OU
MBP<5]%N*GHDDXOXW44:QB9%PS0>M%G  ]: B\:+M7@F<D<',.D*QK78?M.NE
M)7QJ>&D(!C/W2?/R0$:R=@"[5@_GYFH)UPBP3<%(==NS:)+N$]:1G1-0&+/[
MN3W&IBEWEFJG>[A[WW-K:#<5!#K!42[T):$CJ7CEF69I5NF_!$I'39%HU1,X
M;&+H117J^X5PMFU];G5A44D*LO<&'IV(@HZM5H]$D2G4;6,_K$AC*&\53(8I
MUXM!R)0T"GTX]%BQN_O9(RJ.A+97>JQE3$M;V>EIMV@8DLPF)!A.Q:=4/7KE
MLNT?Q#M@\9 \<MSIK%%H5,A=1]G5AK<TM=.#J[;[!4Q'U?)5M"4I&4U**QEM
M6='.?T;D(>:?JK"#MJ/ NW1[TV>?!PTQ?5O305?!HPTQ2-<4RD]+'2DQ1M0"
MFUDS0[DVLH.6;INU>HIF2$#]'T690-K"IMT\'M$OI<J_\S+_ *;#05;K-:4M
M,_N4G_KA96NHV/J"1:)^,./]8D$DF+ILZ5#4NW4$<\;4H-&CJOIF[=JDZI>W
M9?/XJ"8V_F*CJ"#B(]\M;U9A+/W:R*KE@==))VT2Z,A^C$YQ 3CM.V94A2]T
MXNYUAYZTK^K)ZI8.E6M"2B-"VNJ.A9@::DXB:>OU];V2;@@*\:CK*.?!GB_$
MQ>BEKJ5.VNA!4#'T^2V,'2DNLT6IAW+NI+Z8)5LW"=&/^L@4H(]+GEGGP\%N
MZPDTG;B,I2MZ5J9\C'D;JOG+*!J-N\?(L4'"J0'5R0R*0QBYZL^QD-L;DV=I
MRX],0=(6M_0:4;7-AZ<AI-:7+5LE+@I'HTO+3"2B(I/ 'I!6+R>SJX(&IHAT
M+:8IN4CYJ)=:14,WDXQ\D_:NOQ@CF)5$@$/BQLKZQVV:*4A25>T"6V->F8J$
M<*4M,N5SU1!4_+G2',RL=)?I-%O<TR=$Y; D&M5=-+%G+DSJ$B^@J NG;NN9
MAM"H-W<H[AJ0K!O-R*<2@Z60267%)#@3%8O*SS'+(;8W)L[3EQZ8@Z0M;^@T
MHVN;#TY#2:TN6K9*7!2/1I>6F$E$12> /2"L7D]G5P7"4K>BY:NK1WFAX")K
MIG2ZD/\ I?%R=)*O'--U!"QLPNW;2"224E)MEF0KM^D%?I.E+H AGU[-C^TN
MY=2[B1DW<A0;^]LD];6HM6]EQ,#B4IZFPGI$%7+8#G%H@=(JB1A*=-V30 #0
M]Y+1TU<&EZ?IBQM.VWDHJX\;3D9/*S4/7-2U6]?1[:EY27158@VDT,EQ7((F
MX-'#P;4HBT=+73IES8N!N/'56:X\)2D4E**UJRI1K$_HT>F)N7Z<2C /16!?
MH='>\(YX6W,TW6E)VYMWL\B"W%NG6M904I52 TK4=-R\')P#2&9N6ZQEWT.S
MG3)OB.$B,Q1,L!%E2)-UJQKVO-E-]JTJFIJ@7DJBK:-IV&B&54RC54J7TV2.
M:7&CCCT@%'6FK&IK'#@,EQ@.W3?/LJ0G:+M7?2<BH5Q0DM,SCXC=_/TX\K6G
MYV)"J'3M^V6($/(LY)N#MPT 2(>("0I4S+45:+K3]O%9W+K*VQ#-Z>O);15K
M])2RZC5%![.R1FTI NHMT^2;-@E$FCATS=+)$5!LCH2*G<&VVS#:U=2.N[70
MTH*%Y+LO'+T]"1U/5G&U.["%3J.H9QUTKYJR<Q:I&S!LJ"3D3BN<"=&:]ECM
MQ=OJ@N!82^R8K3:-+)1,B]BG#FGW-,3J+NG)=RR*^83;)5!%PKXTB9$$>0IK
M[VV\/U?-GKP4/)DF)I:O)"X+^5DBS@OD6<=2<'3#)]44VY.X353<=*F9N0?Q
MZ>G7KX-F/5X%<HH72JUM'73NO#-#=,O&-V<@^K2J4'.?XPY%ZNDQ^CW!2_CD
MHESDF7,H%_PVU[]V]G_S/E88WC?\PUS/Z1./N_\ SNS]%;K?UV9_SF^A:-_J
MP]JW^N[\M?3WTI^2_P#5OR-_\E_BN3W^-W-M[ITM=.H)R_<%%Q]).;?P=*RT
M9%*M*/GH8?TE6J":BU$!%:20#)!);+X1SQ;NL)-)VXC*4K>E:F?(QY&ZKYRR
M@:C;O'R+%!PJD!U<D,BD,8N>K/L9#;&YEFJ?N52T-1]KRT/)(7+B*<A)1271
MK"1G$%HM"EI:83.F4CHANF%8O)XN^X+?6JZSVP]RJZN!;/H$HRX-NS"X2G91
M)BE&O:F;3$1/0K^.D)%%NB$HQS7;+G 3AH#24E^MO%G]KER[5[>ZAHF0C;7A
M"JP-87!F+B5#!OHFJ*HN\I5-1E\30=(*1:*+=!\]Z'Q50>E.#@J:%<WCO%3M
MP:BIJH[(5+;1A'6WC*<EY\DW)US355MW;EG4\K#HD:^+1:_XSQC/5P:0RX:F
MWB69;+H>-WCN57+"FZJ3*R"8H2X-2O'#ZF:F2CUERMU'+%ZH0#%55%-0I%@(
M(E N&]Z]RNT:^C&\[YLV3JYG33N28-:A<LVQFC1!Y)T15T$C)D2(81*[<,FQ
MS&',X&Q5NZ;;M8U6D]M=54Q%VF<6<*K&1%01EN4*5@6,P_AEX]99@23/.P;:
M=51775Z;4LV%<!4\9"I]TUN-I=Z;D;AYR<7N''TE<9TE3%H4+H/7!I(]4U7'
MQ]0R+;\8^.9\\8HLW#5501$B2(]]C9^$12=9TK<FS]-5\G>!:=B*=84A,5C7
M4+2AY%S;=>.DY!9PQ(^@7_1F?H-1$F@HAF;/$-L7W_6BN/6]'4,]4-2]3T(9
MG*)RT02IG-34^@N];2\0_B9*.%R9F!FRRH*MPZ,1( B&+7;F=OMK;Q4YM9MM
M U3'_HBN#2?N5*3LW:&?H=_-QK.JZD6:F:JNI)%<17ETQ\6_'9:AZ(+A[N[%
MFJNARR->T#7-O5ZB;0\77%.35&4[%MV,@[CX=^_;H]&\8 90!<GZ0HZ!RRS&
M@I[K%MJ=PPOM0<*TI\U96=>ORQ,JS;ZEW)FKV(J"#?),G3A5RJVAGZ+T695U
MR(NC=,J<]-;)-EMFYJQ6V"GG,6,PG,K-6M554U@'PS4-2@0S!Z^3;M#2HEEY
M-RO).7+UXF1<ZJ9C+]-O2VIUW2]TYBX6XB!N^PHV8H^#I21I"+6KBS 6ZA@J
M5[,S<>^1R>ATBX-XY;0CW_#Q8V_WCJAE+/:9M+?"T]RJCCX-!JYGW<)0E<,*
MKEFD.R?+-D5'1V[80136<) 81Y7!D,=>JT<#7=.4PA:REZ%5CKCQM/Q,^68@
MIF7>/5/%*7DYA+H=+DH IT_#E]_@_;'7'_\ +[57]P]<?L=S%(7<I6ZM1R5Y
M!I4*;6MQ#4;+,HHL/3,VR<#42U3SL.*(ZGZ' @5;+/C'!.+\7R,BE+SM/'BG
M)ET"RS:(GXJ0<D:I=*L*#-XFZ,)"&$O'HTY]C//[V+.U?9RE;HTQ&V_HF?IJ
M91N9"TI$O73Q]4?CC9>)0I&;FP62,7Y0F+\.*0OS:U9F:H*97=MY&&E"+*1%
M5TS,)G9U!34X1(P&,FX0.8R2I>%%R!'(%,) )A:\6X[:??FB[S5&U;J5VG1#
MU=*(F9 N12R!I.EJFA6D@(%#\9)K131PH/?&#/AQ049LIV^S=A+;413<G%2P
MU<Y3>5G7$Q(/!<HR,TO])33I0R)#F2*5W+.<@R,D9'++!@.=134?6 J'$X$-
MTHJYIIGS( @)AR'1P8W0V<N;2EUJBJ6]YGGZ,2% PU'2D!%%=4(YI0!J5[4$
M[&*H"5TN' @@MF4!'/$/?6ZL%6\_2;*B:SIM2-H%A3TC4HO:F:IMF*PQU2R<
M2D"(='J,?Q@>/+(./&X"\-+L95G3%V[Y78N;3L=.H-FL\SA:[K*2J6);2S*/
M7<)).R-G9>G31<JE Q,L^^X'5A-S5-W4KR!I.8,ZLY-6Z84I.24-3LH5PYGJ
M4F2UA.PG0M63S\?%B@=7(CD4"@1-%( _XQ?HJJOZM?\ CB_XD_H#Q.'_ $Z_
M0G^O7^M3Z%^C?'OH_P"F/HWO/%OI/H.G_%>,Y\.(NXFX#9_N7N76,+3+*CHN
M;EJ:HB/<-*;CY-U--8TJ5/W+9I&*5V]=+ZC)B.9Q#BRQ*6%ZNW;1";5*5E$W
M;=W7"Y8!K6+4CZ/"/=/*9INE"E:MYPQ2$ 9V2DI!8 STD*<$U$SK+G.NJJ=9
M155=119951P8YUG"RZQC'.J<RBAE%#F$3".8AP?L+.?^5+P?W72&-Z/_ #:;
MC_[WYG]A82]58,9V5IBUETJ2KJH(ZF635U/O(>G99-X]3AV<NNR146R3R*FL
MNEQY\.7#'WJM'3]<T[3*5K*3H9=A<B+IV+J(LQ3DS+O72I&E-R<R@5$ <ADI
MTW#E]_@QN V.U!2UTWMV+M3E=OZ=J"&A*4<V^9HU(TA&T;],2;J:1DT\_$%A
M,*,2IEQ9=G%B[Z5VPJ"5I*VE:M:FFHVDV\0_J9ZS;,U6@(Q,=+/6*1U3=)JT
M+.$LLLN'C"'W^V(I.IVT53+RW$C%T?<YG%0%0RS>FJ*;TG5\&\3I>0E2-_'6
MQ'34KCIC]'T^KHCZ-)VVXN\NV7<C4U[ @XMK,TFPDF5.P=6KPC C&(8U1,0M
M5(IJMVZ296Y7R"*)CI!I524#O0I3;FI:.;MA=*G+NQU0LH^EXN ;V7INW%-%
MG(FC:4@Y,DDG)>.Q\0YBV IIP29%#(F6*")5013ME2VY+;%?BE[UTA1%.4O5
M]PK1.DV457DK!,B-'53"2-J-DP47?&*91;QN&!0-6GIC<>'FPS8)9:MK>V=G
MY5!S7%67.D2N)Z0*VGT:K?,8%A]*RRJKE](M6RJKUX_*B1(%$4VA04*=.KMH
M&[*T;G<#M-JX9%4L#'EAWM24DI/NQD*CCXR%F5FS62CW#O2_;-_&VBK1V)UT
M7&9@*4]5T?LZW"W&J5EJ5@J/JZ5G@I0[_H^D*O4"505FNW!L/%TSUH\$!_\
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MK*.?!GBH^KS5I:ZA[T3<ZG(,ZG2@Z4/; J*6X5A=T!<37TW]*$SC&PH9_0W
M['H>$H=*-<[$M[-J:LKNQU2R<T]A9B@2,WKQ-I44HE4C^$G8YX_BQ068S"'T
MHRD&+D1(H8 Z'O .-*CL\VLW82H6JW4@VO[=NXSEM4%Y:FI5K&.AA*9MC%R4
M\LV1*:5.QDG)W#QFDL1OXOXL4106;+;XEH&NUK4*;B:KN\%/-XVGSW "FIAV
MX=MF0QAI,(SQ_P#'Z?%_I;(=.>OAR"9EMZNT2Y[R.H^4/%63N/0TF[BZWD+?
MF.1Z2E[HP5.U+'BW=IO#/'"8HOG9"%7,DB".MT=U0^S#9O;*=L_MBHT(=Q+!
M.!'1<G4[*EC%>0U/%IN)=/0:Q[.0(25<OC/5W+UXFDL;HAZ<'%<[6-RMK#WV
MVE7(5E32=(L#12U44HXJ$B;>I#T_%3*Z"$DP>II%<&8BZ:&1?B9ZV<(B84L5
M/<K8_M*NW(WQF81[!0\E<:2<$AJ?CW9 RC3U!5%23R[)MK(D1?Z/9&<+( =
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MZ9<V+@;CQU5FN/"4I%)2BM:LJ4:Q/Z-'IB;E^G$HP#T5@7Z'1WO".?["^_\
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M&O7W^G0-8[0-V=J'5^=I]>*OUBP<5]%N*GHDDXOXW44:QB9%PS0>M%G  ]:
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MHUD52S)F4P(GY"0' <\B_#GJ^^&-.28% $\@!,!U&24!4HJ@H)@$HF*740
M! ,LN'' "8"( )@Z),R9SERTG.FH!M6>DFL#".K(W%JX+CI25N8^[]H+UP$9
M3MU;>/7:,8^DF<.F_0@Y)C*NF;HAR-T962;N&"S4Z+A)RJ!M"G1*)JU4SZO/
M<&[DTU1?HTE)77E$Z+5DC(]&9H<%JS<"9$1[[HCIF0S_ /B.6+?T>PH&FK)V
M"LVP,RM=9^C7(NV40J9@WB4GTG-I-F .56[)L1HR*BR;HMDA,"213'4,?(#9
M%!/0!-)=.?2])J,/*#@[W(AB_#@=)A ,L@S$=6?_ +0P@( )_P#2RP;OU,S
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MT@*%*!,RIF%0%5#IE4$P 8PE*&>60%#+3P_=#481#+(<A'5G_P"T*(B( ?\
MTLL% 3"8I 5 A!$0+F?DZ@ <Q OP9_Y0QRS /WLP(7_XVF Y!^'!1$QA$J>C
M+/24!_SRZ,AYPCC+I3AF'?B324PG_P#;%S 0U_?.4V,BCD  (@3-0J8G#ODS
M*$(8-61N^,&89\7!QX$2@0F8B&DJ214] 9]&00* &-EWFH3F-GI[&?!IX@$O
M1FT!T>2??AT:14\B@&DP%[XIN+/&6LP\)PU9$U=&KHZ8FH ^7I'4/W^WETIQ
MR#O!/I,8#_\ MC9  :_OD*7&H2IB80 5,TDQ*HH)LE#G 0S'43O<C&'(>^X>
M+'""8B ")0Z),J9#FSU'(FF!=.6H^@"B&G,O'IX> =/X<  99B30J<" 118/
MA,='3D/WRY8.43%T'XR%*8I29\?1%$P@'^4!QP@F;( $AA23!0B@Y=(<3D -
M6>D,@.!LLNS]PO?G*)1R_%F A='2])D!<AS'+O=2@F^'+L8X!['$8 .77J$W
M3:#<&LPZ!./RA+GP9\!"ZC=&4P'Z,#""8B('%0#)#F00,8P&R,0<LLN'/@'-
M50H!P$!,VGHPZ7I-11-J[_+O<S9A_H]C!,@)WHI\.@"G$B.GHP$Z>G4(:>6I
MJ'OC_P"=P9""9NP&M)(V@FDA-*?!F'>E$F>8]Z.7*[\<9BH<#AITJ$,<BI-"
M6@NA<!UES'@/I,&HG><'*^X8P'$-8*E4#( *<J@:2F$I-("<H<&HP#^YB@+O
M4$Z;,ZSMM5M/UI3;E\U(^9?2M-22<G'MI!D<2E5:J"3HG2!1)TJ8Z=1<LQ9W
M;W<;#[LGOFM#1,35-1VCN:JUB)OZ*9)LD3NW;:9IU1<A"))I(@Z9KJD13214
M75*F C</;/U=&UUMMFH^Z3-Q#7$N96%3JU9<RIX%Y&JQ3MNDNNN]<D=F0<NF
MZ3MY,NRM453$9HMC?C,%*()Z2!WI>B2TE.">G44H  %U#P* 7+43O.#E8R*"
M9"BFDGI32!,NDBAU3$$I! #%S, $!0#"4 RU#GP  ','>D(.0$,44DT13*EI
M4 P9")A,;@X>+&H#F*83G.8Q1S.85.4!SGU"8 ^2!Q-E@H]YJ)F"1A2*<R8
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M%IMR-37RH&LX6W/Z>B\IN!IJHV4G(_I=;68H=#Q=V].9,G0J2O3F[TPF!+0
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MDG,^/'))S/CQR2<SX\<DG,^/'))S/CP @<VH   ..1A -69\@-P9B'!GE_\
M48NKCWSN'2]M*-;+ V++5)) BK(/1;'=A%P<2V(J]DGQTTECI,8UNX74*0QB
MIB4IQ*:.CWMYZF:$5,D,Y#6U3:18Z5-!5 1J61CWV@_&0PLPS#X,+L+$7<B)
M^JV+1-[)T!-MWU*5TQ:G =3LE.5"FW6=MR" @=U'^,(@.0=)PAC0(  ]Z.68
MB;(PB&8% !XA ,^'XY"+>W@JA)W%O5X]Z7^J6YP@DX;+'07* _17#I,F.>7P
MX@ZGIN1:35.5+#1U00,U'KE782D/+M"/XJ0:JEY23A!0BJ1P#(2YCP=FB8S<
M16,Q23RX36;>TLG&4?5%4^.MJ=4;I2RB@TZU<='T8ND  #!PZ@Q1-VK?OEY:
MB+A4S$5=2TDNQ?1RSV$FF1'S%PHRD$DU4Q$AP[TQ/O@(AAO6NX*Y]-6UAGXN
M20R,JX7?3M1K-"%4<-Z7IB&3<R4DHF4Y!5!DT5!/443B!#$,8\7XW>L&1%5$
MQJ$UKE B.C(ETOC(-_'OI#HQX@'Q'5_HXD*LV\W2INY$3#^)!.H1YWT7/TZI
M)$4/'(U)2L^@TDH\ZX)* D5XU3$PD4 ,] X2K7<)<VGK:Q#OQDL2UDSNY"H:
MA6:% [EM3-+0B+F2DE$@,3I@9-503U%$Y@(8AC?1B:U[7C;I>A---[;-$HT@
M_P"<9O(2B#_+]QD.'\GMZNU UT\AVQ'4]2QTI&G:T@$E%/%@6F:2J-!J_10Z
M?_5P=@@9N94!(14QN#$W5$TH+:&IV'D9V6<9"<S>-BV1W[U8J90$3"4A!'3P
M?NX;6=L;<::J:OG4),5 E%2%!5O3B(QD$1,\BMX_/,&Z.904#(->8Y#EV/N"
M(IF$H$$XF Q0+WHB YF/D&0Y=Z.?#QCI#AQ(T54UVUJYK.&6>-)NG+2PCNNS
MPK]B@*KB-DJA:BC#)NBF#H5&OTF*R*@Z7*:.&T$_KJNK9K/')&C:0N/0;YI!
MF75_@O&IRD59AJT3'LK/544P[)L1534G*153T].,FDI#ST%*LI2$E(MZ0CAK
M(QTHP,JDNDLB<%4%$C"0Q1 3&(4=6.^#O0'(QP$3%3'(#9*"4!T]Z.H!'@RX
MQ#$C2=2WH1K6LHDZJ4E2UJ8>0KMTR632Z7Q9S/L"D@TUA'\5T*DJ50%!T"7/
M/)*/EJGNE;Y)90A$Y2LK9RCB-TGXU3*4.K-*: ^$J1O\F(;=5.5DYF;"SXP)
MHZX%%4_/UK&G95*X\2B)=9M339RX(R.XR;*.!1R35,4I@X<PK1OMTKIU6#RW
MP02M51\G3524E(,6=1^,%C'[9I4[1J9RB)VRI%3HZ@(8HE,.H2%/6EX+I3:5
M-4#0$&O4-2S*J:SDK5BBH5!)-!%L4QE5UE3I((HD#,ZBA2AQYXFK?;?:LJBL
M*AIRGU*GG3.K>5Q3T-&0Q7C=@DX<3D\P;M@.X5<D(U;BH"R@E4R3 $SB7_Z@
M7L .689CEF.68A@M%4C)"^A9>YB%D[ T^NY5"GJ:I4DX:)3J)\1J4W1#(*HK
M3,PXR.( !4#F4;))$(R@:\"Z5SJP(R DA7;JMY.D#%E%4 3>OZ=I:FC)L621
MC9G1;. =]%Q=(?+,:)=VCKZJU*<D46ER[$W(5%LQJ^GI"&E^@FH62D(\B*"S
MY@84O&7"2)4W"*Z"@MD14%,MDK_&219R=?TD@K5+-H!BM6=;P#Q6EZT;-TQ*
M&E()1HYZ,F09%RX1X1&_Q*':EE)"V4%<.ZTO$"L[&4?4S2-5H_I8M%MDM8N%
MF+!TO).$2AF5LV5,43F#0$SLQN'-G6K*T\>O45G'\DX$%IRUZCC1,T>@=0OX
MQ:GG?2*-" <5/$'!2]$1)ITBNT$!*<3C25Y"Z]!1(DD,Y39P$I^P)A I1R#B
MQMAKBI796%.T?M5HBI)^14 @?1\#3=!%DY9X)B@' F@W45$/O99]G"$=,U"[
MBG%S*FDG22KX5I2&LQ9.ETU7PQT#&I*(HE^CF ""0%%N>1D% ,X5!5510[>F
M',9>!S4*3-)%:Y 7+<I56N\(CT)Y,8SQ4T"54W".7T,)0^ >/%TX:&K26K".
MEZDG[G5=7M113")G$Z<@Z?*A$PCXL>H=%5*):-G"A5B@F"BRZRO1IZ](14:]
MG%8Z2N_6#J/IT)( D8&T=FZ=9N)M9O&1:71IB2)B47"P F9NI(/!!1=0%EU#
M&&EY&.NY.5"=D#92XKFY#UE4Z:^7?/&,3&H)020B.>131!_W>SA@VMO7$DK+
M42:%N+:>NA;DCUZHM_.JJL31=0Q;17H%D51;NH*7: ;Q9VFGK,W3*;H0D+U4
M\B+*&NIMEEJ]CV/2>,*1R=5VW5E#1+A4Z:?2*ME5#-E!T%S,01TESR"FDP$2
MD"TUTR@4IU2E#HH]NHGD0A@+P=D-/#]RG;46ZFG%/USN5E9^FG<]&G4:2D/;
M2E8ULI7BT4Z1[Y)R^&081G3@8!(@LKH 3% <2>XC<C)U0A;'](Y&GK<T52;U
MO3J]:'@52I5'4<W4!43NOHYNZ-XFFW:&2.+M-P8RI>B JE=75VEDK.CJ^MC2
M\Q5YZ"DJA>5C3=<0T&W-)3\>@K49E9!G)BT(HHS63>*)'.0$@:YG Q:@V8U7
M,N9.@JYA:@KFU+!XH)RTI6M+)#*U5#P*1BF*BUEH_P >>+M43)H)':B=)$%7
M+E52A=L]IJB>4O5U\8R;G*]J&(=.F50Q%LV+@L*UAH=XW$HMOIMV9ZDN[*;6
M1%H=$I1!<3IL-R.YV;JR*MI4CN6_JXM[2KEO3TK63"+E%HN3JBIYQXV.X;L1
M=(* R(T327<  .O&$@$J8NVE!$NO:&?,DL9C-P5>2-6M2/5.0M)Q-=E?F<)%
M_P#8(NF^?^<&'&U5[ E-9QW;!.SXPI19D<)4@C EIYF*#KH@ 'J9-+I)X5,3
M%= "P!J#3A6FKC*NTZ9I*K'=L;GKD;*)LZPLC5SIO(1-;-FP"IJ%-H>.J-ND
M00S<H%0Z4.D7*2@=F%MZ@9.H@&,#=F\+Z/=>,M9-60;G>VNI CIN.DY3(",Z
MH7,R*P*,#"<HE#.#E*GBS,[QWX+%7)N89<JJ3V%9'894'0RB*9C)E+&1RRRS
MHO1D/X\\= 8<P()?_J!9Y.(+G+K0THG$YF$N<@>-,#/,V0Z1%3+&U?Z:(D1H
M$K<IHD5<A"B65=60JAM% H"0CDHH_P"@,0I\Q$V1\P'O<  %,!QR$"\!3"&K
M(X (Y!F <.6>-F2#@K;Z9&8ONJR*4J@JEB@C:0))K#H#O,U0;D()@'4($( 9
MB(EMZK(@?Q-Q<"[*L"<ZJ:I#11*O60<BET)C '^OD? ;AY0#\.)J/>H(NVCJ
MC;_-W;9RBDNV=H.C?CVKI!4!*=$=1_Q9N =:H&$Q3Z2P5Q;-B]BJ/&I"WEL)
M)&%4\2YI-5\=&J[7RA0,8%&[ JRU/R)#'Z=2.79*YIG72 W5Q;C;=N%U8"Z%
M&W^=D9N%R'6@G40^HA*;IJ8(W P@\C)%9S&.B@0,ED3CEI$HBI]$:O&PZM^;
M%;+-%3Z."S2ZDUT?29"!O$_& +]_%R_&3M17-M9KI%B!RD'_ %LEU*(5'HRB
M!1.KXN54#'+D)!*MP" CEC=NW@BG&<<[9+]HPXI"!3%E%K5RI([(QQ+D85A)
ME]_#<D@=J1Y(6-N0WIX3$4-TTF1U$+ DWT%)I4%@VD#C\*1#E,!0/P8V[H$!
MN>H4[)2"LD328KHD.K7KHL,93,0#0*Y9%1+,V61%@'2),C6U3F>G*]#;-=44
MRN52'7^CE33QH,3*)B8!_P!4\7Z,2CEIR$/@Q3?]E%UO_<6W^YM066 _T&K;
M^Y:,;J63!$TLC4L6G-:$SCQ@DZCSJ</"&D. "<.UTT*9+Q<(>XQ'()AQ3 7D
MJ(LV=8@ES!0S[ISJ=C4)^QD.)MW/&;DA&D7(N9H[TAA02AT6J@R:JP% V900
M*L/!\G[V-K:<5T@+I3-R'#HZ*J0)E9!9BI"S"@F PYD.U4.&67&<O'D&=&>.
M&6!H?;%00PFM5,&@,/ZPJL(MT93&#OO&^G,;[VG[PXM94NW=K(N+LP.P:W<I
M;9K25-(U9-JW$:V99+L$XVE5FSQ)X\/)=,"C91FKK6$P' 1*.<'_ %T5W=JT
M/Z3C+%IO^M+:?:BWOTZ,$"!I@(C]+J&9^-^+ [:"MXITNGI0^#AL#>&[M2#5
MMQ:XIZH7U4U#]$0<&$HZ85U+0S93Z(IQLT8H:6[9$FENV( Z<Q#,1'%/[RZ1
M9-D*NLX2.H^YXH@""M26PJ*>*A3SMSF;)96'EWA2I% NHY'JAA.0C<I#158W
M*7=5+;>P#*F:\K%*<>GDW-1.X/2QM-2#PL@*@JL$SLT2J(B)DQ9,2M.B #BL
M3,1+P &G2F!1 =>LPYY]G(O^4,__ *@;//Y0F'@X1'B+D.?8#@^_@+PV\B7L
M11C^ZA[W[?ZU1C'1J234-/*5,>AY=5$2IIKQ2BBD8Y9*J%%1FHDL8J:*N81L
MC=.U-\*5N$FQ(:;IRD(&E:NIM[)HEZ-8:7J.2EXLRB*AN29XU;"7/(=0\(T7
M'VSMI)%**:%M[,VNCG(2CQA&.I$7DS4M53"9TFJ3A58PN9&17!!NS22;@<RJ
M2'3'LSM]C7+5X-N*.:1,M)L4#-F<U5<@=2H*TG6B E*)$GLJY=NR$,8=(* F
M)C"7,9,<AR_1&^XB;4F) R,!1 3E,/9Q4E+04:V5O+;HSRX-F9(2$(X/4[%H
M)9&D7#@3%,#2<:9LUPU"4JQ6KGHU#-DT\0MI)Y:0"GJ"JVL:BA("235;N*1J
M>K6T1#5J9D43AXOXZ,''#(MSAF"B15>$XG$^V.B:D9IR--UCM7HJEIZ/$>B3
M?0=14$6&EV*@HAF *(KJ$$P%'+//+#&2D(3Z3F+5STH>.2=JJQE/WEM%4#=2
M).O&R71N0*A+,55%>D(DX4CWH$%=+IDP2%"4DK8;CF=3"BD#JDV5,4!)"D]/
MRT&\ZI4;=N=(O_MU 2S_ ,S%R[D-K6NJ*I&+NC4UF!IFHYM&I'53PK:A8&I'
MLQ)$:M&Z+?IRSAF9FI#KIEZ'7XR;I!(2+J>,BG*Q+>5A.U9::I)AK+_HO=:U
M4JFX8/6XR34"(F6<1;I6-GT2K"9H[,&6HF1\)S,S:?<#&5L5GFZHIE"T3*1X
M26@1!./JY:::IKL=60>/&9ICEP]!V!3=4C1A&D[6?T73M.4ZU7?2U.6AM#!N
M\P=U7-:2Y,VRB[F1D7AV[<KMXZ.5J0%U$F9Y^TE*)G"FK8;<)F@H0HHI@[5B
MJ3MPM#(.'((FR%=9-$53F W"<XB.8YYP]]K@TQ5U64^RHVM:84A*.1BSSWC=
M0M4VS=3HIERU1 "]'GETO#GEF&68^@?<+S+9>?L65W'V3I.6?5Y2E)T]?JBZ
M'<,T7U;3-M+KT&RG:OHF,91)G":\RDA]'NR-FZBI5SLE$$#'543SGK!7THJI
MZNL\O4CVHZ>D:(&.<UE;ZH)),I*CB/T?GGC5!W%.CID<G(1XF=NX.X6_&]/I
M)6]FMJ-$7 ;5!<BFYBBZEN)<5E"TTQI6F*@:'B9H::BH:2?+N7KI!15NV644
M;^+&,"H%5$ +BH=[%PH%6#IAO2\E0]DT91DJWD:CDIPB+>IZ[C&JA$SHQJ+%
M-1@U65)F[!V8X ET0E/0.Y^U]/.ZGJFQC*9I^X,+$QRLA,O;920_3+:H6C=N
M4YU48-X5VLX;IIF,9%V=P!BD1-KAMNFY*B*RJ>@:0?R86XKVA/HV7J"(B)*3
M4D'5,U! U [9$<)-':[A1-TU>D512,1 &1@3 X[<D+'PMR8Q.T*=W35*ZK^!
MIZGDWQK@_HT:*+"EB9:245!$8%\$@"Z2>@!+IUZLL;43=Z8JE(56HF8AM1%$
MCW,G%4U"#D&8&(8#!P8W5$* "8:5I'("F*"@IJ7.@P.">HW9 Q](FRR'(<N
M,]X  7,?T2LVJ(B(#F5:6J(R ):Q+P9%/P" 9<'_ -01)4#=2C*7N)14P0"R
M=,5A QT]#.3)G$[98K%^0Y$U4#"!VZZ8 JD<I%"'*H75@\R-@'D699=)PYC8
M:ZEW6$0X$CGQDR161)T0;D-R1*S,CP8=QNWVS='6U&1;H,Y28BFCF1JN78-5
M.E:QTS6<^L\EGC=(_?I(NGJA"&S.4 .(F$>_,&8E$>$1$0(/ 4=8B&0AP#D
M9\(X4O#9ZR,)1-RE6LPR5JMC.UD^>J-IX<Y5(R$S).4,EN(WXK]S+ "(AP&
MX#D.K4 :<\\_@X,L5-<2M]M%(S-95E./JEJ:9).5U$FEI^36\8D915E"RS9
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MM/ X]H"OOY:T\#CV@*^_EK3P./: K[^6M/ X]H"OOY:T\#CV@*^_EK3P./:
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M9<LP$PAQB !EF&8Y\.D0 0'++//]D8! H:<N 3@!QSR*7O!#/A-F ?#E]_\
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M9SK$MBL-.0TBXB)B&E]W%@8R5BI9FZ,S?1DC'OJ@(L@X14(<BB*I"G*8H@(
M(#E&UE;BMJ/K^C9H%#0U6T34\+5E-S!$U#I&/%3< LX:N U$,7\4J/"4P?)X
M6%.;E-U^WRQU3RB1'4;2MR[L492E5OH]4NLDJWI>5=IR!F@!EK=^+="4P@4R
M@"(9PUR+/W$H6Z]O:DZ<U.UU;6KJ?KFCY\C5P9LZ4A*FIEPY8NP2.10J@-W!
MQ*8AR9:RF* %R+PFT!F?28QN4 )@8,C9% YA[[,-/$.?!@:YLI<^W-X*&^E9
M*")6MKJXIJX%)GFX1WXA-PI:AI)R\:>.,U\T7+7I>D34R3.4#@<I!#,. 0X<
MQRX3=&4!X.,39@ ?>_R8E[E.-PECF]N*>KH]KI^X#B[5!(43!W-1J@M$K6[F
M*K._^CVTX28,6*&*6<E=>.B#3HO&!Z/#*J-RU^;0V&@)1P9G#R=V+ATQ0:$V
M\3.FFLS@B5*X;*/52"IJ.1J0XD)D<^@A@-APWVU[GK"7V>LF*TE)1-J;KT37
M$]$,4'";91U-0%/O%WC(@'61*/C2*8YJ$#+O@Q+W$O)<*A+26]@!(6;KRY=8
MT[0U&Q/2*=&F>2J:IW#5BW((@(ZUERAV.4!RD0MY8S>EM>NG7KPYDXVB:+OA
M;V:JZ8$AP34-!TVU?"\?$*8R914:(J$S-D!A$,A=OGZR+*/8(*.GK]VLDW9M
M6R)!4<.%W"H@4I4P*;I!,(:<@SX!S!FR8=8WL+?/7[A)JT9,MX6WQT]=+K]X
MBBV:I5 )SG.<=)2Y /%\KO,1E0TU,1-14]-LVDC!ST%),Y6'FHY^W!RRD(J2
M9G,@X05(.M-9!0Y#%R$IAX=,G45FKHVYNY3T+44M1\S/VPKBF:_A(FKJ?,F2
M>I>2EJ5<ND$)%D94@.F*QRN$\PU)!F&(RHKRW1MS:.GIJHHFCX:?N?7%,T!"
M2U75 90D#2\;+54Y:H+R+TR1P:L43F<*9#I2'(<4DYN[=*W5K6M>UK#VVH=U
M<6MJ;HEM65Q:B3<*T_05*.*E<M4Y"9? U<BTBVICN503.)$C:39!\ \7_P #
M%U[3VVNS;ZNKE6)>PL7>>AZ5JN)FZEMA*U&@X<P$;6T2P4.M'K.R,WG1D<E(
M;-%0HE Q1 %;B7ZNY;"R5O$9)A#+5]=VOZ3MI1:<Q*CE%1)ZGK1VR9>,N@ X
MMT@6$3Z#@&6D<2-@8N\%K)&^\/225?3%E65Q*/=W:B*&<+-FR%:2EN&KP\RA
M$'5>LD@DSL@;B9P@ *"*I?V.Y#^P>\']W4C^V+>_[&K_ /H+(8W'_P!OEX_[
MQW_[8M3_ &2%_IB__;%+_P!J[C^\J1_;%Z?_ "'3W])!_8<G(=8$[XQ0 !$<
MBB80SRU9AI#C',.#CRY)^,"\!<QX3@3,2AP@ 9@(B(!D'#_@@-D&@=(B;,1
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MAN0_L'O!_=U(_MBWO^QJ_P#Z"R&-Q_\ ;Y>/^\=_^V+4_P!DA?Z8O_VQ2_\
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M<BK)NCJ5<!P% @9;G-N-^+?M4MWLL>[4/3<%45H)-_6;NKIB 0A;?3B5:/F
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M!22:ZC9VJY-=%M;V;IM=TAF=2,DF<TH1ZS5$$EA3(*J:@  !^T.OY_XLMOM
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M;U)QXQ!/9<BV;,>B34.HET9RD,5I?#;#M8I*TUU&,)+TXVK"'JBY,L\)"SZ
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M",*:I6GXPDA/+DB*?IV#3;M6B!!$3II-T0 N9@(!>,.$HY#I$N68B<ILQ#0
M@&H<@$PE#,W /!Q9XHW?)M&W/5[L;W\V\H4;:L;RT=#L:QH"Y]NFLD:;84!>
MFULL=%I,LB.M)2.%5#D33$@NFTEXC'D:V8ZMSK:;56?+7^XJ#J^2VK;Q=N+J
M89V@O9*T! C,U-2-64=5J23F)GRMLNF,W*S(5RY:-RQO0O&[I3@1,8ND3<!B
M@<3!Q)@4V0 8PB70!C!GPYZ<@SQU[<1MJF*/F]MMC^N,W5WMN5M?$:F"L][5
M8T_=M"7E[%2KFE7+1XA Q].Q9'R#)JX \M(."-D0Z9LU<-[0[@MNC:'IRAY&
MGXZDI>U\:$:S-9*LJ89-V526>DHF-(W(S5ACZ$&I ;H%7:':/44?$G38<=;_
M +WMTEN8.\=V[;[ZKA;.[)L;PTQ&58QLA9>Q1%(^(IVB*?GTEV\8^>D?I%FU
M"-]8*IG!,X"]>F<=5)<;:O0D):&&ZPV#W.[?MT=L;6TY'4;;NO&%KZ>@JCH>
MX3^E:?2;LB2S*4J)L]>2B2":@I1Y-2FI=TH>]]+7RAR5S9JU6PJS%XY^U<P<
MKR@;F5W3M7P]/VWB+HTB)0:SD-'.)9W-IQD@15L9ZR:&52.0@D%C:K;W0XVY
M@=UFZFSNW"NHJPM)TY3,Z[HVN(B6JJL&%/,(HC1(TC,MJ3:T]F?25PDY*U4,
M5,XF)<C9C:;_ *:;?[:QX-H9ZFK"5XUVA6V8S5L[IQ<!_P#<ZN2]KV'?FG%7
M))ANS>5#()NE7LJCXP5TH[,[6 =N4[US$+)1BM860M=8V]%JKM4;4%4W,N_=
M%Q'_ */QM!#;)NFM*S52S2<>I)NVB3<RH@"SM<4DD'!TKWFMGU&>XK:W3MN6
MM!5/:O<=7]@=KFV8]CYQG=&%:DG(BCZ2JL:Q9,GS588WHFL.!SE<B+IHF1!1
M8EA*IJ.17EJAJ6S-KI^<E5](.9&9F:'8R<J^<"7@$RRQS'-P<8CP_M?>%97=
M+'4LPA-QT/#4NW2H^J&=2">#6I&>I:I3JBW3*"1TRRJ1T-0YZP P#WN8.[W[
MD248YB: H2IJ;M#^CU3K5"LUJ&II L:ZEDVJB*7BB 1KB;-T.DQ3+2)U<RBF
M(*;E=X%:1])(6:NF%YU*4>Q]4-WTZJ%:UM&S,&#^&*F4R&M%N<1S..0\ \/
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M3O;>QO1@5"<;I;C;B/+L7HJYU4E6OZQ>2%;5Z^1;F?KI+OSMVQP;)@FV201
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M;DSM,BBB)436BZOO<[&P_P!-#M>J6P=WHR DB5!#$95K#R%.3K1C))D2*O\
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MVW1/J,M;4ZD=H(UK&H;.N(]*I.E< 4572;/Q8!6'4DF@3O!V#W"H*>L*MO\
MMC5[=ONZQY2\B\K&*VPW7N];Z):2%RJ4B%WZ)Y=M$/)Y$J\ :3%!8[0IVKM1
M [@SM"[>VV[%E-K^Q6AY.D$I=]2%-7N&]ER=Q-P*+?(5/1% &JF-13AZ6I1U
M,H,WTHZ,LZ>B5N5L8YT5E\[+T%4:3=&H:'M1;NDIQ)HX\::EF*:H]I"RJ35R
M!2@H4JJ)M)@#(P<7[7X#Y<G+(HYY ?48,\^R&0#^YCE#QY@    4-.G04.P7
MLY?#@W#D)^48.,1T 3/(>#B .UCA/J+V"B4,@$!S*;/CX/OC]_@P "?5IX2:
M@,(D$2Y<!C&$<LQ'@$>+(.Q@O#F).28>,!T"3/(.#B$>WBI[#W45F&4'.NHZ
M8BZAIYPBVJ"EZFA5A7AY^).\(L@8Z>I1)5%9(R:J2BI! NO4#.T5'=;9=2F[
M-1;(L!"Q$7;Z9;S<%3"#</HZGH19*K2JLT&2)$6K,6T@GT:) +I%(>B"I8&W
MDA/UA6=?R+"6N-<NK%$_T@JIW%$.2+9HM69@29L6PJ*J(M2&.;6JJ=1503AI
MRZ0>,.P7@ .,H9=@>W@,M( &0 4"F*4"@'R2@;(!SX<P#[WW\%-JX2B(@82%
M,8,R@42D,;D@.69L@S'X0P'" AT8IB!@.8#!\G4439#V<Q$,Q^''+X $1 !#
M5EF'".9Q$<\Q'ASRRX,L?)[.69<^,.'LX =1<@$O>F)J+P' ^>0"'"&611['
M'PX$X" :A,80$N8:C% @F_=R#\(_#C5J$. 0X,\^$<^//]S+@P  H80#@ !*
M0"@'8  (!>+L8$,^, #LA^[Q#V>SC/6(&',!,'!F&8Z0$!SXL\<)]1>P42AD
M @.939\?!]\?O\&  3ZM/"34!A$@B7+@,8PCEF(\ CQ9!V,<L3=Z(9F+F.>H
M3%'(H@&09\678#,>#'*$>/C#@ 1XS !<LA'AX0^Y1=\9NW])25XK=P=14O15
MS',(U-6M.TO5V@M2TW'U"4 <E8/.C3459])T/3%!8$P4X< .K48.#4=-/,0R
M#(!Z,"\0@ \&-6K4<!'290A#"0AC9F3()0#@^#//+LY\6!$,BB(E$3  :ARR
M P9CGP"!0 0# @'&.D<QS$1.3("F-P\/$&?PY8#B H:0T 4NC(I@,&10[.10
M#]P.+ Y"72?EE$HB!OOB(#F(C\L39ZL=GMCAW?Y.W])%O<\H1M:U6ZZD&T<5
MZ2VC:;/4A*#;5(N!G*,5](*J/Q8HG(B9P)5CIG.4!_;@=^(B4V91,!1T@)A,
M<A<^(! PE#++(,@[&#:39";,<QU&[X2Z0XS9@4.,"E$/W>/_  >H#FSXB\8Z
M2B  (<(\/$(AGP (YY?M7<A_8/>#^[J1_;%O?]C5_P#T%D,;C_[?+Q_WCO\
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M472;4!PZ,!$P& 0SX1RSX>',! ?@#' H(=\ CWI1[W@ Q"]D $,PS <^'//
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MCF&HP"(&, </'P8)PY@F(B4!(0-(BGT8F)H N0CP\(?YQ@[(99B!<]6K,"@
MB/WQ'/ ]\4-7*#HPX<\A$/W!$!SSS'AX!#CQ6ERZ<H&BJ>N/<EM2S.Y%P(.E
M(&*K:X36AV*L91K>N:L9H%D)<D2V<.&\820<K U354(@">H1^X;AX#9:@TD
M!R',PCD&8B;@U9B(?># "&D,A 2Y%RTZ>$O"40'@'/,.(0$0[(Y@40+H " !
M )D!1*(\) SR#C#+(,PRXQ[  !SER+I*)1R$N0"!39#F41 1S #%$O\ HX$!
M',!(8@YB<<P,/!F.KX_OA@#9EU (AGHSTE',0Z(#"(%-GI$P\(#EQ?!KU" 9
M%#(-6H-*@*<!A'Y0@('X.^#(/D\."Z%#IE* E*0@%T@ F V0%. @&66DN0!D
M41#X! H!D $  *7272&0]Z(:<A 0#@+I$,L:-0Z  "E+F<IB@&7(.F8-/9R
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MA.X'Y_IKYF/0G<#\_P!-?,Q3UVH2 DZ9CIY[/M48J6<MUWB 04RXB3'.JUR
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MW,<9O_#W,<9O_#W,<9O_  ]S'&;_ ,/<QQF_\/<QQF_\/<QQF_\ #W,<9O\
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M 5E1-:(IS]/2;T>A3:KJ*BFLLNDD#8C9N\>-]\0Y) <>K)LJ %(4P&$R5RX
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M,J?O!=:V-1;'']I:IVM;DX<M.O[JV^N#9V&&&IRKI-LU;Q[)^"P&%T[:( T
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M+]Z+A8163.C4_6:DN=(JSE3;+VVSI:T9J6;EC6T:WNS&W4"NBUGX^*IU1/'
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M!CVJM\/O+U1X#'M5;X?>7JCP&/:JWP^\O5'@,>U5OA]Y>J/ 8]JK?#[R]4>
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M Q[56^'WEZH\!CVJM\/O+U1X#'M5;X?>7JCP&/:JWP^\O5'@,>U5OA]Y>J/
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MAQCR])1_RAP_>QPAP\8:=1LRZ@+F&0??#/\ ;NDP9&$ACE+GF8Q2B4#&[W,
M !.4#"(\''Q<. $4QU"/ 0!$3:0+J4X #C#A ,LP$<N'AX 4TAI-PAWY1S3X
M]9=.>?>]]D'8^_\ <'44Q0 1R$W#J(!->L=.>D,LP#7D.88S*41#O>$1R+WP
M9E$#CP"'WRB/[GW,LBB.8@( <HCP'T#D <>0@(& .$!X.'CQ\GX. V>9\P+I
M ,L^ > 1'+(<OAX [W(!SXS%*?(!* F ALN NK(^>0@(99#C(QB@8 U"74 "
M!.$P"(&R'/2!C99?)-EGE@>]X<A,4N8"8P%* FR N?" B!1_].,M!L]6@>$
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MWQM>>L2\*0%U  @&HH_!GGEE@"D$AQ$#FR!0NH>B4!-4"EXQ$HCD/!D \ B
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M(^? IT9N, Y(\L.,GR@#&1@ H:@)F)LRB83&)D4P!D(YERRSSX>$ X,P[T1
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M0+F(@40X\&W+[ ]B>U>D=IT^^J!&STEO$O3643>"]=.4W*N(<:OC*=MN@5A
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M9@'#P_>P8-.>0=Z&>1C" ]]P"&67"7(<^SPY98X$SCV<PTZ1+J$"F 0'O@$
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M0'$N8#QAEJ*<@"&9@RS 0+F;/@ !#OL9Z<AX0$H&*82B @42FTYAF CD;(1
M![.#E 2B9,_1G* CJ!02E.0F0@'")3E'[V>-0:3 /1B4"' XB14P%*<=/  #
MF(APY" 9Y\>671&RT"8#9Y]\4<C)Y% <Q#L 7,1R-P<G4(:! ,ATG-F!>]'(
M=1LL@X<@ !'5GGWN09X/ITGT' @@!PSUF*4Y2#GP 8P& 2@(\.8<(9\'W+9[
MO*[H.F[:5%7]1W,@W='TQ+2TS!QQ:%KV0I--1)Y+@58>F(R!?ON1KT=\!=1A
M$0'2 Y&.7,Q2=X4X:QRX,P-F \0!PB(#P8$IB&*(&*4,P,&L>,_1B(9&R#A
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M ZHFI"YNR[?+=V?WJ4.K2LA)G0I*ZM$0]6KO'Z+>IS4=+2%)PQH<D>JHL]9
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M;0TM?2GJ[HF^%1VPHK;:SN;"?IG;6$V^6DH0S6 C6<9%NXI59.1;/3.7B1W
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M(HA@Q>  ,!BCD4O" @!0$0-F B   <(#VN# =^IP!I',0$3E !T%.<0U#EF
M@;5JS !SX39@.L0X  0XPX# ;O2F$0X0S PB FX> P8$3*G. J"H!3$1TE,)
MND "@!?DFR. CF83<)C&R#+2 B !I$N?"!1*.HN0?>'L?N!Q!EB2M'9=.H5(
M6?N9<:\%5U!5THC-UC6-Q+IU(O4E65)5$TW0;$=+',JBU0_U<O1MVZ"??=&
M_</WV0G[)0 #%X=0" CGP@83&#X!'&8&R,/'F4I@-PAQAQ\  )0X>(1SS' !
MJ'C,(YYCJU<!L\LNQP!EQ=C!2$'2F42Y)Z2F*&@/Q0$*?," 3(HD*0 * @(Y
M</ /?B.K,5!'C./$3/+@R*'>\("(@!0,(Y<.C4.0ZBCWRFK0?@, ' P& WP&
M >#L8R$QAX$P <Q$0Z,<RB)S9F$?A$PCG@A]0 )-?"!.^,!U /I$^>>7 /
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MPWYIJ3R/'I1AOS34GD?_ 'C &89& !(("'? (")0 HY#F.1L@ !X SS[&-0
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M:;J@W 2M(W0KY.W\#+MHF(0)%M3RQD5U!*LL@*8BFF(DU ;2;+2-.-ZRZO\
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MJJ)C'TM*"=DR:JQB2")5FW3H&7TJ"(TU1%(1;*GZ1HZ!B:6I>GXY'HHZ#IN
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MP%EN15JNE9G<+5EIZ[LD_:4%6M9'NK3\/2[ID6F:56I)C(N5UVAW94TVH@D
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MK[SUCTO[7_577WGK'I?VO^JNOO/6/2_M?]5=?>>L>E_:_P"JNOO/6/2_M?\
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M1*8QU#&R* "(\ #CVZ.KC_ER7VLQ[='5Q_RY+[68]NCJX_Y<E]K,>W1U<?\
M+DOM9CVZ.KC_ )<E]K,>W1U<?\N2^UF/;HZN/^7)?:S'MT=7'_+DOM9CVZ.K
MC_ER7VLQ[='5Q_RY+[68]NCJX_Y<E]K,>W1U<?\ +DOM9CVZ.KC_ )<E]K,>
MW1U<?\N2^UF/;HZN/^7)?:S'MT=7'_+DOM9CVZ.KC_ER7VLQ[='5Q_RY+[68
M]NCJX_Y<E]K,>W1U<?\ +DOM9CVZ.KC_ )<E]K,>W1U<?\N2^UF/;HZN/^7)
M?:S"-.T7O!V%5E4+HJJC:GZ8CI"I)URV;IBJ\49P\'4ZSH=!<Q-H((  ")A
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M5=?>>L>E_:_ZJZ^\]8]+^U_U5U]YZQZ7]K_JKK[SUCTO[7_577WGK'I?VO\
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MHKI[<7M.HS+!Q.LH2V%>,Y-S!D<]/(LXYRM,J 518OXLIQ*.CCR-Q?L;3_\
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M1NWCE&[>.4;MXY1NWCE&[>.4;MXY1NWCE&[>.4;MXXC\ @ Y&#@^$PZ\N]^
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MS[ 9!@ $XCEF.8@(")NP(Z! .#X!#&0&R^ P%#5\/9X/P8-D<W? &>H3& !
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M$"F-D/ 0H=\7/A$2Y"8!U&$0,(\(Y@(#PX I5#%X"%$P@!\P((9Y$-WH9AF
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M=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\
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MPXY9^<..6?G#CEGYPXY9^<..6?G#CEGYPXY9^<..6?G#CC_?=W''^^[N./\
M?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]
M]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_W
MW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?
M=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\
M?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]
M]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_W
MW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?
M=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\
M?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]
M]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_W
MW=QQ_ON[CC_?=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?
M=W''^^[N./\ ?=W''^^[N./]]W<<?[[NXX_WW=QQ_ON[CC_?=W''^^[N./\
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MF"QEWI6Z9:N,]++_ *=#51I1NB+#Q $8<6?"<%@<J<!.@[\IR@ D,80 PCD
MAGI*8,L\P,.6G+C <\9"32.H0R,8NK(,LC@4/AS+P&R'AXOATE ,PS$^HVGH
MP @*&*IF'>G IB'T'TCH'4 #D( ?,N0$$ $<P'LAKU:,].13%-WV7 .8Y% 1
M N8&#44Q@ <LQ$H:A(4 $=0Y9\C,. >'BS$-.6D0U"8Q=(%T H8Q@+F8O!K
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M-;>S<1#S=30UMX^"EZVD&,S5+"DF_P"C\94LE$,ECE<2*!S=-(HE!/4;7P
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MBT4:@<F@I.>HA]4!"K4R_>SU-I%8RD')$,"+27332_ULR3<R %7;KJ_<OO\
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M_B.T_P#RF43_ 'P5O]S:K1,^DFY@*FO_ &HCY]@Y1!TTD8DM9LG4M'*-Q,0
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M4/HQ25!H15[X@5P+D$"BH)=.>-[>Y2]>Q.M-Y&PW?V_H.[+>ZMHK&4[?NO\
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M2% H:  4P,7B'2( )1  $,@#/CSR Y@#44>#C'(0,.8_?$!U?#GC(QA$.^X
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MOAS # (!D&0"4P'(8 'Y13% P"/:P<1R'6?6/ (#GP=\8V>8F#(  V?
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M] 3SR&>&/T**)%'";R)9@DR?'."SI)107/C6^$I2@4 _X9P#("AP9W  FK2
M9Y8W!W7W2TY4$?1M9O[GO:9K!G!N9Y:-B+DD;5'2-8QB71F7?-R,6JL(Y(P$
MZK<3'3#@25(&T*_^W^EJ@I6BZDN[MZH1E5T_ KTZZNVBTN.:BZWK9LTR*J5
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MF*6JN&R;1MPZ*IVY=&GKBB(BM89)5<&DJ2&D6:SYJ!OQ2AC)B F*8 QU2JG
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M4,"9+:5UMPC5&M:=4W66VC<UM[3T%45B8#:ZHTIAVW>KETCXJQID7,DX*)#
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MZ2 F GR+D(%$0#@$=0Y9FX-89 ;AR,!<C% P@<P%,40-D8Q2F, CPY<."CF
M"4>$=.8B&HIQ*&8Y  B4N?!Q<60\(+OV,-#LW[H!\:D&<6S9OW(GX516=MRE
M..HW?"&88R'(<RY&[T U<?"(!^Z/!Q8XP'X1R',,PX=(YYAV\#K$# )!3TB0
M,@(;,#@7LAJ 0 W#D.09 &%V[DI'#9RDJ@NV7(*S==!=,$ET5T%1$ARG#,#
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M'@SR$#,:@B8J=CA535)'3,:TE&2:A$A0$Y&[TIR@)B&.0V0 &D1#+A/K#OS
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M8,6R31FR:HI-F;1L@D9!NV;-D0 A4R$,)2D$!X +PB(9X !RR#+(NDHE*)1
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M5K4T6[?G4F&;E0.D19-B"0I@#O ''M#U']6J \T8]H>H_JU0'FC'M#U']6J
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M3F)!R#,1#OQ,!0*)N]*4HB8W ("0F8YX/I,0>C/T9PUE$2F#(1*8"YY&R$!
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MZFX0=VTNG-VK?,ZEJ.D*M.9--XM"*/"J-T3'325(44C&*80W74E3E,6,VO\
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M=/8>%5J,':F1R]*"_2@81-PCGC:+J,(%&[-@A6 ATTTA(&VBKA,F0%1 =.H
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M69DP#3\(XV6RS5?QU]5D=>:L*DEU5"N)&8JBH-PM6N)MU*/-.:RI5-#?,_?
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MNJ#];NY_R?'LY=4'ZW=S_D^/9RZH/UN[G_)\1QIPC5O,J,&9I=)B8QV2<H9
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M Z!<A5>EU@ XK)Q;:WU$6^7N+6\U<RX*M%4G!4J:N[DU(@W:U'<*LOH%!O\
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M!=S^Q8W]-XG]O]*&@%! P"<J8 ?2?2<Y0,(B( )RZA*&11S',!'OO\"=0I2
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M (A][AXL<)#%'+A ?DCF :1$N8<8AV< )B@7O1,(&.4,BER$QQ'B H9]\(B
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M=.>H-.8:\PX,P ,\9 00$"@80$0$Q2F4$A3"!-7 8"F$H\7!PY8'236;O>]
MP /#PY#GR1$ $"ZP* F#2(AF X$0 ! F8'-K+I*<H%$2"(\0\/$?3C^#'+O
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M9B&;+(1@OS=*9)>2,@4P$4X>],(,[][L:X>6_MI)UI"6^BI6-I>IZR?R56U
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M%KMMNTXN9!6\VY7KIRN9BBBTJX^GX^E9^7JMVT:/%D<TR++-%0(/?:3<6-L
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MXO2R!N^[(!WV'FP6GKAL'T@2T']6,=<B<IU>)8.EOI'Z0"6=4VV>O5$0XR]
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M86\MY2B4VJHY+"4U"I$:1J"PAT72K% I2&* 9ZAX3 <P@4A3F,!RF#,Q0#C
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M\( 4>QD/PYX+D82Z1 2Z1, "8.P8 '(2_P"C^' B)^'( *)0R$O>:1$ ,(E
M<^$,BA\'#C+,1^$1$QLQ'E .H1'3_HYXRX/E!R2Z= \29B\0@   ?#]_ CF
M"(]\)2E 39 ( (_"/"''P<'$&-&H!#(P" D[T0'4!<RYY".0AJ$>/+L8X3!G
MD8.]+HRU<6G(<PR_=''?'/GJU=X8Y S 1T\ #F(</"4PB4?\W 9G,;A,/&8
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M>6X_F);_ /BZ@\MQ_,2W_P#%U!Y;C^8EO_XNH/+<?S$M_P#Q=0>6X_F);_\
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MS].==)&;,G;@BB# Y#))'4 VDB@D$H%$1 #"/*$"Y" 9")0$,Q'O0 ,Q$0$
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MP9_C!RQ)6WVS6@HNRE!3%8S%?2%(4*P/'0BE7U$W2;2DL@T.)@1$R:"#9)%
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M<2+Y5,HF H&64$N6HV=U S*83=21'F-K*4"@*6\"FA(4 X<SZ2IGS'ARTFX
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M2'B("8@+>L8YJT+&P#=G",48^,-TW0 40!40R *.VK6%>UJ^MC0\M5DQ"KW
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M8^3SOBQ\GG?%CY/.^+'R>=\6/D\[XL?)YWQ8^3SOBQ\GG?%CY/.^+'R>=\6
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MN/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX]
ME/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^
M?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KG
MSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/
M0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/
M?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?Z
MY\ZX] E/?G^N?.N/0)3WY_KGSKCT"4]^?ZY\ZX] E/?G^N?.N/0)3WY_KGSK
MCT"4]^?ZY\ZXO->]YMNA*D;6=M1<2Z3N":U56\:YG6EO:4>5>:%1D"/EP2\8
M*S%N506ZNC5KT'TZ3?JOGOO$37F['ZKY[[Q$UYNQ^J^>^\1->;L?JOGOO$37
MF['ZKY[[Q$UYNQ^J^>^\1->;L?JOGOO$37F['ZKY[[Q$UYNQ^J^>^\1->;L?
MJOGOO$37F['ZKY[[Q$UYNQ^J^>^\1->;L?JOGOO$37F['ZKY[[Q$UYNQ^J^>
M^\1->;L?JOGOO$37F['ZKY[[Q$UYNQ^J^>^\1->;L?JOGOO$37F['ZKY[[Q$
MUYNQ^J^>^\1->;L?JOGOO$37F['ZKY[[Q$UYNQ1NW.'ZO;^KJ0JJ*K"51JM[
M>RH:@8LRTC33BJ 0^B&23/INF! 4 -TY=.>O(V6G&DMB*?+D(& /IZN- G*7
M250Y22I=1@^'//[_ &<>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:
M><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@
M6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U
M:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>
M@6 _/U:><\>@6 _/U:><\>@6 _/U:><\>@2GOS_7/G7'H$I[\_USYUQZ!*>_
M/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_US
MYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'
MH$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2G
MOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]
M<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYU
MQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$
MI[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS
M_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^
M=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ
M!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[
M\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7
M/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<
M>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*
M>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_
MUSYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G
M7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@
M2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_
M/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_US
MYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'
MH$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2G
MOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]
M<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYU
MQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$
MI[\_USYUQZ!*>_/]<^=<>@2GOS_7/G7'H$I[\_USYUQZ!*>_/]<^=<1-1P-C
MX"-FH.39S44^2F:O4,UE&"_C+5V"*TB9,X@?A$IR"4>R'[&@/^7RD_[Q:O\
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M* 9\@!42 ZG$ ]&&?8$0*.8AP_Y,< "(9%',N8@.HHFU%$<@,7++(2".?P8
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MR%N]V^Y&'N1%W.JQ>2)_632CB/D+DU^6H)Z;ETVT"5JNV*D"K]-%NBVX$RF
MQSU-76U'JU^L-W9;5*,GY2 EMS]GK3Q*]/58:!>KL9N4L_0TX^;2E3-FQT!(
MHF M'1#]XJV2X!-UU5X;5U,WK&W%V]_*-RZ,J)&/E(GQZG*[HL]4LT7T9,H-
MW;9VU([*U>MG:)5$7!%$C<(80LUNIM9$7?MBVJ:-K)"DYB3J2$;$JB(;.&D=
M+@_I%]'.]:9';@!)XQH-J 1+F4!QU<FU&E]J5+0U@;U;;-SE;7,MVVK*Z:D=
M5534+3<H[I62?2+N=4?D%J9(N16[M,#99CQ!C=QN<VW;:T[:4C VT_K.O/!6
M[J&IYZH*^BK)Q<S*4]&LBW(FW2"3EJ66DBH@55 H^,&UB<2I@6P^XNF8:8IZ
MF+_6:MC>JFX.?!J,[$0-TJ)95S"Q<P$<=5#QM%L](1<$53E Q1R'(0QN+J*W
M%%UM1[';=NPNWM'J8E:_01%ZBK*ST?#2$]55.)PKMUJB' 32!6IW IKCH-J1
M+F 8I>XFR/J^-\>[R57CI9_=2G;<T53<?#6,?1<VZBDZ(KVOG[U2.7J=VV1:
MS#2!B =K'CW:*YC$,/1C -]K&UG>;N2W.O9&K8>NMGM"VI9M+M6%?4._1B9]
M]N FI-\$'3<:J\5!I&//'W)W:X"W!NFY3<H-[U6"FK(WOVI;J]NZ<+(78VX;
MA(*+AJS94Q4@)G@:WI)]#N7"$M#K NT*=V!$!(+ANIH,V=-'#A'9W9C;]N&W
MP;O"4DC7M461VS4K'S8VLHUX5!2*J"\-:SKEK'P*3XCE([1/)PJ(*("JFB#M
MF+BHMI]Q[$[A-EV[^F:76K?_ (>]T%'-:4FJXHMFX\5DJOM)4T:X<,:BCFJI
M5$U54A14-T:JB22C=)58EU=HM=V^OA5=[Z%MW:^LK=T%:VD&%=5CN,J:[$B>
M/IZUMD*28/2/7\V@5-1Z_P#'B-6J#1-1<S@2D$,5!NUWF;2=R>TZ1+>YA8BU
M^W.HX6%KN_=]*RJ. 83%#,[6TQ3*Z;=VO-+.)%DU;K.DM*D:Z,933T8FMI;6
M[W5 ]9#8BG[O5E3]%TE=67M]1]94)2[JHGH-&TW>=_!2:7Z*1J(#TCERN9P9
M, $.C'C_ &QO=_Y1-RG]S$S^V+-_^4[P?W82_P#VKW)UEMO=Q36_%&V4N/5]
MI FH9*H8U]7U+4LZGH.'=P[DP%63?+MRLP#5^+%37I4 N@=J>ZJ:4AUZSN?:
MQ@I<H85N1C%!=:D7JU#W.\0C$SJ>)MUJ@BWZS=OK-H1$@9FU ;&Y*PEVXZEX
MW;E<6G+MW5ZO.HX^$2B75:VRLA?R3LU4"+J:264))/GS= [\R)2%,V(R7'-4
MI@/CJJMF>V:1III7&\C<+4JMVG4S3+2JW,/MIL[$L*ANJI&MW9T_$GCMFZ<*
MLGQA-D#1;(INP]K"Y]<4=;JE(\Q"/JEKFJ8.E(%H91-18@.9B=70;$'0BL;2
M974/1GTE-EPDJRU-PZ'N;2RJQVZ-2V^JR"K2GU5TEA;K(DF:87=MQ,F<!!0
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M65S5$)2=.,%%EQ;MR/)F=60;)"82F#)14HB.1"@8^90ZG:K=I6XM5Q;B\77
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M&'&Z>[ANBEZ"ZLW9A:O;=3#Q,=4;&WLW#OU[B3$I'J&R*+PL*\J.">%3U"
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M11/_ -+_ &9HIJ#.C+6AOHMQ2C(I01394_0VW"A*7@R)H(:2%,FV;I 72
M@.>H1SQ?O;-NP8.[D[5NK-VR6HJ.BMOLG+2K2W=67TOM#05>N;C5E$QAD/'S
M(Q4T5H+=904U!9M2'S2%TBMU+-TMIEOF.W^G+H=;ULQI2[EI+;/Y>%M#7510
MM?)R-K[@.K=@N>(82T"U5J>/;NXMHW%9&7=>,@MDF!=B>PK=<G?"H-D$;:6=
MW@;BK06$IFL:PJ/<#/#4D_1]F*)JB(H44Y!:"BI.F7<D]236 AD5CFR3<)L5
M4-@^X?J<=GVZ7;3N#H3=1;6B;Y4W#[5+O6<M7>+:769UXJYM/U]%K,W$6]>
MX^CT6;I9%)PF#I5V*HN6C)5O_B*@/^7RD_[Q:O\ \!=S^Q8W]-XG]A>BBH2O
MZBNO!WM/!)U(TK*$AV"*,=#14A$*QA4HTQ@53<I23DJF>D *.G(>/%9WCI"X
M-77$J"IJ.<T/#MZOB81NC2<,^FFTO(J1ZL=_".%RL63<ZPD(.A(0R[\0"\&]
M^+N=5<[5-WOZPO'Z&?P\0VIZ%&X50,IY\+%^@8RYP1,SZ,H&*&K7J'3ITFA
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M57/U>]M-6MB-O&Y>"HAU43WQYU3]J9ZZ4:5_!0S81$C"/(=;H"\ *FQN;O\
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M/YU[\/71+_:3'\Z]^'KHE_M)C^=>_#UT2_VDQ_.O?AZZ)?[28_G7OP]=$O\
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MH7!S.)0.II_2]P!TRBIJ*!1#@RT\&.0G_%I]S'(3_BT^YCD)_P 6GW,<A/\
MBT^YCD)_Q:?<QR$_XM/N8Y"?\6GW,<A/^+3[F.0G_%I]S'(3_BT^YCD)_P 6
MGW,<A/\ BT^YCD)_Q:?<QR$_XM/N8Y"?\6GW,<A/^+3[F.0G_%I]S'(3_BT^
MYCD)_P 6GW,<A/\ BT^YCD)_Q:?<QR$_XM/N8Y"?\6GW/\:FRTCI,!! !'/4
M'+#3EV,!D B.>D0S#,ILLP V7_OL_P!D(#T8#F  &L=60\.1BZ<P-IX0+_\
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M,SDA21146,T:/3NS)$473;J((+JI]020 * C0G64J"8"E W#M>?E$,RY"/)
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MYA#0!\S:,P#64,N^RU%UY<!>'A'+A H$,)C 4Q0 0$IBB;+,#!]X,RYY9A\
M%.)0 Q,A$2@4!.D B)N++,?A$I0'/(3& /OXMIL659SCV\%Q]O\ </<>#AFD
MV^@*7H&A*RB:$:?3JK@Z;@5YB0D7:<>5L@H  Q6Z<4A40!3:PAM#H^S=6T3,
M;@Z2B]WCNZ#^18U#2.W1R<"UE4-J0:23$BDPBETHMTS$=J:^B*1N<HG,GD!>
M .4(ZBY &6HQ> <P#47ASRX\Q#+ )E*!C=\80!1+/HBB4#*E*(YB  <@F#L
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M74DB[4=L%0W&C9:9(\*PE)*OJGIL&D8UF7BI2'6<3+XBJY *90YP*33O/O\
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MN[D5U3EXMM,18JW;V*>Q3 C%T]:N(DCV>4<G;)B"ACI)Y?B\*F$P'!3/20Y
M%(@"4P&**89 8#"83&$>^$3&#5I$"E*4ND"@! R$A1  2+DET8!D!=(Z3!D&
M0"'  ".>#@82B53I-1 (&DP* !>^*81 >#/,!#(1',0P7,XF$-(:C 439!D)
MM/8+J$H"( &7!P  \.#"8YQ 39Z=0Z,M(D$AB .0@)1$!S^'_1)I#O@+EV"D
M+I, B)C%, YCD8<M09\.6!S..0B.8!GEED %$-0CD8! ! 0[/8SX<&$JABB8
MPF 0[&8@)LP[(B  35Q@3@*)1X<9"?,1$NHP%R,8 X1 1S'C'BX. . ,AX<
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M_P#P< />Y@4"9@7(0*/+ HE$!#/(,N'@P("<=1N48H"7(=&@1(&>8?#PB..
MX\.8B E P"/R0'/ATA\ #_EQF @ _#D81$->K(PB.8\'!PCW,!F8P\)39ZA
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MED)0,40'B$VD>QGV>R(%R#,Y3Y9&R$2 4A-0%,&8E*4  ?O /&'#IR+P'.H
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M.MI*.?LX-XLV>Q\C4SEVQ<MU1* &!4@%,4/@, @(]GT0U_\ 5R0^9CT0U_\
M5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\
M5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\
M5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\
M5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\ 5R0^9CT0U_\
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M4CF[V44.T*@(@BLJ&-D>V^V#J@$+@;?+^[/KEUZXJBHI"+I]2G[#TZO%UP6
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M]M%4JU_42*?CL ANCW113JG6-OT)!L"B/CK>GG#>2.D<VM%U$NTEBD%(=/\
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MJ8GT@ &,0#"4AC .0=@3=]@HY9%3*((@4RFI$3J]*H*1CF,!!$>(Q *</\[
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MY0X\N$/AX3 7@[(@&.47G%[N.47G%[N,L@SR*/+#(=0"(:1_R#QY8#,"@!C
M4!$^0"(AGEWP!GG\G3GG][&>0:<N5K+RO\WX/PX'(!$  #9APAI-R3!IS$0'
ML9 /W\L%*8"@)@'(.D*.8@&H2% <A$<N$>#!1 H" B #F<"@ B Y &?9$0 .
M'+CQED&>1AY89!I !'4/^4.+/  )1 QL])3"!=>1=611'LY9\ Y<0_!]S44@
MGS*!B@4> P#Q"!AX,LN'CP4 TYF 1RUE 0TB &[T>$<N'A .Q@1T< &$,]68
M" $$1$-("/*#2(98,7O>#+DG P\>0YEX!#+CXLLN'&0 7,2F$I1.!3&T&TJ
M!39#WHY /P9XST" AD)@,8@:0$,\S" B':$<:@ 1[T3Y" E-EV T&R',>P&6
M!R#,P!F)2B \?"!<QRX<N'(<%*8"@)@'(.D*.8@&H2% <A$<N$>#!1 H" B
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MX.SBR45;2[ES[>QC^PX2<A&417]64E'/I$U>S#8'[IK3KMJ!U@30(0%!'/(
M^#%!7@H7<+7:U&7*I.'K.EG$INRKJ/?*PTZR3?1_C[,'BG0JG*IEH QN+C[
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M--A%](C("#=NW32 FG(0$!S[W++'I]JWWOZX\JQ7OC-75'!7>H*P]FH:<J^
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M*R2CVK=ME625#*INU@5=*4)49U*KH*2#6 "#9,BS^*:ES'HTF(IYCIRQL_\
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MI$U65BRZ0PJIL;@WNEW\1!1[0RH 51K'T^A+H(E  %,HM3@!0TEQ_P#I#?\
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MM8Z$A$>(.,!Q=NL+E7"MO6[*X-&PM,QK:A3U*+EBXCIH9(Z[[Z?8M"Z3%'(
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M**G,<ZAC&4.(T;>.VURK7T9!TM9>G[9NHRMS5463<RL17505.L^;?0,>\3Z
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MG%]P!U"(Z1*(YF Q@^2(B00#,/AR[6-8:0,/&8"B!C9=@39X+PAD7B#07+4
MYE/^Z& #,H@!A-PDX ,(ZLR@ \'#PY_<T@;(,S&S* @;,^>H=0#]_@QJ VD=
M1#F$I"9G,7@$3B(=DO!P998 P]&(Y"&8IYFR,&1LC9\8AI ?W/N#W_ (@.G(
MP% =(E-I#5V<^(<_AX\:@-I'40YA*0F9S%X!$XB'9+P<&66!+J "F+H$N@!+
MHTZ0(!#9AE][+\'W-0FU#J.<HF(3,AC< "00#L%X.'//'8[08R$V8=G@X3<&
M0@;//@_< /N#WP\/P9AE^YPY_AQEF&?PB C_ ._^X(9E !,!N G )@'5F8!'
MAX>'/[FD#9!F8V90$#9GSU#J ?O\&-0&TCJ(<PE(3,YB\ B<1#LEX.#++ #J
M$1TB41S,!C!\D1$@@&8?#EVL .8"(")@$P&-D/\ \,;@X>'@$,!GEF'$8I<A
M#@R'2.>8=O[G*S$ R 1 !$O!EP"/#VQ'!M*F0B \(E'+4/#F;2("/#PY9A@!
M PE$"F*!@ !,75Q"75F&8?? <:AX3!R1$I,R?^H.7_ISP( )<AX!#2;(0^#+
M5CC'@*) S$PCI[&HQA$1'[^?W $=.>91,.0@(Z! P9" AEP@&>>>8!ECL=H,
M9E,)?O!Q=KB^YEJ#+(Y>(P"!3CPE#28 XL@#@['PCCOC9\/'W^O2'"72?5F
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M 0(.11$-61\A-P9@'#EGC@ .(# &9M0D[)M(!GQ\ ?#C/(0^$! Q<A#E".H
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M$34%.2D?/0$^P9RL%.PK]G+PTU$R#<KMA*1,G''517;KI'(LBJ0^1TQUES*
MCAA;._>\+;/9NXDCXB=*B+E7MM[1U4(-9(,V$E(PLV_279M%\\D'CTB*!QS
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MC)5=<Y&:X'S:N>ER. #D''_A;D6BK5$SVC;JT+6%N:P9%!,1?4M6\ YIN>9
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M><YE%" )2 "8&4[X>(,N#CQ?2S+!XE'R5T[45S1$-(N#J$;,)NH::7CH5ZX
MO#T:;E4AE@X!,4HEX-7!=JR76L[>:_@;QTK6KQ>"JLTK>J/2;0I8A-N\H-Y3
M]JIIF)3,G+-9RPD$F:J;@CDJ8KEZ #JW]JCJ^;*UY0<A0%/4!2%:U[5T[<I_
M'U7%5Z\DY-G#TS$UW4<T=,&BT DJ\479-3E,HF(E$-0CN9J>[\!6;FT%?G;4
MO4%74= *U 2D*LA:JEI.D"3:21TB$;O$3SB270KF4$Z>?1FZ)0$ZXWJT+2E2
M0]EJ =/:NDI&:CTFQV<5%V?&REKX^27;&620E9A1 TD=D"Y\V[=VFF)O%S*&
MZ3(V6K+DFRS_ /G>''\.G+@U9<OO./AQ;<0#E!1V66H<A)ME<])K, :0 .2
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M":K2I3T]5DG)V_?T2X3JN[%P%9U\Z/&,XI"+82/1$BFX&X2).2M1,!@W0I@
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M7VOO+J$NQ:FW=>UX;;@YD8A]&UG0%B*FJ!6I:/M+7,P[?//IQS3JCERS;S1
M:],SZ! 6:?BX'4;UE=G;Q8JY]6M01(VJ>X=H;>UI4*"38I4VZ:,Y4D<Y=%*0
MA"$(7IM)0*70!=)=+&WDO;ZAY>@HL6XQ=%2E(4X_I*-\4545:"RIQRV,T(*/
M2&Z,P(Y@/?<)A,)EY2WEI+8T'*.DBH.I&C:"I>F'SA I^D*@J[A&J"AB ;A
MAC"'WL/Z?J:'B:CI^5;F:2L%/QC*8AI5H<N1VLI&/R'0<I"8"GT+)F[X/OY
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M )= E$H& Q>]  /_ )V0 (%$V>6?9XON<8!F42B(%S'(0$/E9@.0B(]\ _\
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M'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V
M]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX
M?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V
M ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<M
MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%
MV ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<
MMX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M
M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4
M<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'
MM%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]
M4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?
M'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V ]4<MX?'M%V
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MNWCE&[>.4;MXY1NWCE&[>.4;MXY1NWCE&[>.4;MXY1NWC/4(]\<V9LQ$!-Q
M40$,@#X/VC1UCK8U-70UY7:\HUIUO4M"2D!%N7<3$.9I=JI*.#'3*=1)JH5
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M<A !^$,\L:@$!#3J#A  ,7(!U%,;(!#A#A <L*)@'"B)@5S$ Z/04#GU!V!
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M9$0, !WHXR$Q2F'D 8Y0 XZ1,7++,V0@4X@.GB*8>(,&*8@E #F3 ^8"!SE
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M;=5!NVM/MXW@[=XVO+@U/:2]-F+E,'S=_..J<K60EDV\[!-HIR$6X;AI36<
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M=9M:AFY:45G?HU%11=&.;-T%W()B0#)F4!1+&Y/>#!=7WO-W8V<NQLHL_9"
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M&U" &*4H@ G$!T!D4QBG,8HFX3:C:<S!I <](#C/6;A',W&&O\6"0 <<\Q
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MK<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO
M8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P
M'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO
M 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2
MP'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<E
MO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G
M2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<
MEO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]
MG2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K
M<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8
M]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'
MK<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO 8]G2P'K<EO
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MCV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+
M>MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\
M!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+
M >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6
M\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=
M+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR
M6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV
M=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >M
MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!C
MV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >
MMR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!
MCV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+ >MR6\!CV=+
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M7"Q4P0'Q9PLFF<2*F#,<RB(</W!+T1LP$H#I,!M(B CJ-\!>++Y0YYB4 #/
M@)0 0 !RU9B(9Y&,  '%_F_#\ 8R,7C'(! <PSS "E$1X $PB&D!'AP F+IS
M$ $!.34&LP$2'+LZA'2&68B;@*!N/ \&66G@,( ;(Q@*'>AF(".>10$,Q'@X
M,<!1X,A'4!PR 1#, $ $!'A'@ >/@_<^Z;@#,O"(9Y !1STB81#@SRXN/ !I
M, YF#LCD!3   82@.DP@)1 ALAR'BX!R'O1R NH1,(%T@)<P$Q1X0#C#/+CP
M8QL@(34!C:PXP[X  #9?)[\1-D !PYB7AQD4@FSTY"75PYZA,.9@ N60 )1
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M*8H>O=PM5/*(LK2<RZ7),7&JJ-\5&3B*<:HI'%0S8'K4ZZA])"$53,)LC8S
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M((B'4L[%/H=R3;^OUM'5U[4G<&P<?1TJK:M];:LK62"",L@ G3>KQ1U 4=@
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M X'#0>S-*'54?VZZJ[9'5%V)1JX(9S',=P&YU<M,1T>9(3F KA>FI.%EFIA
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MX-,S#D8W#EC9!2=C5;IC%U[L@W3STZ-T+R72O7(FDHV:8QC=.)D[FRDNNP;
MF G.FBHF4QN$V8@&/^HC,(B?ONJ2 P:<E *39Y.B J 0,ASS "B'&':QUOU-
M4@1S%0'6 ;88O>7L\:0Z4BNJWWQ554<?M=N-!T\Q05,JYEY.H)V%KB4332(
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M]'** NRBF/5M*&CMMZ;R,4 RHQ;YK-M*9U.!T*BB!PUE5 B74%B*>1PH'K)
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MHJWNX:F9&K*6M]=FBKV4NRC*DGZ5797"MZJX5I25._IUPW7.1 '2Y3I=( '
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M4)KJPUC*9DH4E[KTUON&NI*U!4L_6%0UK=ZXJK=>KJMF9ZI'#AR<[D[5$Q$
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M5/(1, XI:T5I:77K.XU:NG#.F*78R,,Q>2J[.+6EW9$UYEPV0+H1;+F'4J'
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M+^+&=I%*L9#I3]$)M&L^6H?U7.T'_P!V N/L+C]5SM!_]V N/L+C]5SM!_\
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M9$\LBZLR_J@JM][BV_V<PC5=Z[%/=N==&EY1FO;20K>-N,Y;1317HHZ9/4<
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MO'U@-7U TB*X&7A3Q]OK+':_0$#1$TF<OC!W1(YT\;N1:&*FOFD?HTQ0 #;
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M.71BYY>M[6FGG9TH^58^/(3)F;95 @G.*3P'S1X)2F.F#H%BI* F)36XH]_
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MIZ/<2T[3AT(X5$ DV39F[6>1G3^-( D8JJ)%.\_9AJ3.0! =)C9:#& <A+J
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MWINU&H+D<(L+EW2KBN6B*J:@*)'1:5.^=(D$@E 4Q*F&DW"'^ HO_P I4_\
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M-JWD %J3),' )=^*8J&ZL^Q)#G?P>R_:SN9WMUK& 4YX\9.Z)D=O=MW4BKF
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M4_\ /T]_1K]N\&8CF Y*#K3U!R1Z/@XOW<&*4!+K.H8V1U *?6.13J)9Z!4
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MXRX<$;;Z[?;XZCL34M^-R6P>Q.XA_/;=8"KZ;MA,TW9VNFE@J?<M&5=("_\
MI!N11=N[4%\)1%,_1D, "#/KJ=]CEV,FG?#K Y3;W14LIT1DY&U6S:F$Z%H:
M6CE '45JLUE 2*!BE#-L ZCB.1-A&P?;S,L+CVIV WYA=]F^BX]*.DYZ@[>U
MM:=5VRLY9R3GXX#-1J)V\/*,Y&/(Y,HF5Z<#$,K'OTD.MEHVX[Q. KF_&VC9
MI6&V]M/+%9'K:V5 VGC*>NF2B%E])7713R*KA5JU$YS"S?+]'H:.%$"% AA
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MK<ZU=(  Y[1[ ';#'R5H-NUH*%GT#)HE4/5</0C%"K7#A-(I2@=S)BY=.-
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M .IE3>28]&E?_4RIO),>C2O_ *F5-Y)CT:5_]3*F\DQZ-*_^IE3>28]&E?\
MU,J;R3'HTK_ZF5-Y)CT:5_\ 4RIO),>C2O\ ZF5-Y)CT:5_]3*F\DQZ-*_\
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M158TO/4E).HAT+&5;QU0QBD0]<1[[(XI."I*"**V0B0P 8,4[;ZV]0;I]OE
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M1U$UDE"B4Y3"4P"&>9J5&H-VJNV8U9K5]_P-*;K+M?\ !C^DRTH,X+P;,%>
M)B ],9<$#2(I" ]&8AD^]Q:NSET*??,K7V<NM:F[M%T10KM"C8!":LN"GZ!4
M^]81B/1GA6P'(0T8D5-+0DB0@)]& XHVU]^650RU$45=ZWMZV,) 3SFGD96K
MK9O5)&F6-0&:E-XW%].KTKAB8 *H<I#"8!(&(BS5^FM1R- 1%R:#NE]%4W.J
MT^>4J.W,L,Y3;6;63(H#EAXT(+.6AB "HE((B D 1X>5I$NH R'O@#4/X Q4
MVY)W>+>3M_N_7,;3L37M2;7=S-8V@;5LSI*%3I^FRST&@F]9 9JU12(!V:"
MG$NI3481$:HEUKA6LVY2-[W<W4E8W;W&WJ;/KNWS?4>D60D&"%6W&>C)3BC(
M'H+I04,F8.E<**E;'77544WN=>;5=N7-$QV[6KT;=;*:?J.,>Q,XRV]452T1
M;Z8OM)4^]*!(^3N'^CL0X*<@%7132=I@LHC(9J[;MWE;-ZBD;M[3X>[,/9@$
MYH4:5@B7LIQ.DZ_D'L"*1@<.W#!!!%)<52BGH#(!SRQM>OG<U"I)"K]H5;U5
M<:SK&/GEHZFVU959")0#F9J.&(4Q7YVR"8F9ZC$Z(YA, CQ#:R]]75MN"LE?
M>SL-4%)49?+:_>6I;'W42H"JC'/4-O9*IJ=U^,1+DRJYQ1%$% %10H*=$LY3
M7M'N[=C6DU>:R&WE_MFM_)3U5O):'96^EY4)68E9"+>%,+B=>"4$7,L*I3J)
M9D,3+&VS=_6[:HI&[^TZ'NO$68Z*:%O2<'_733B=*5[)/:?!(P.'3ABDFBDL
M*Q13 O9Q;:M[G&N9;J]%F7+MQ:#<1M]N145F;]6W+)ZPE6=.7$I90JPMEP44
M,#1VDLB10YU")@<PB-P*UM>UN'7U[+N*,1NSN2O]<6I+T[@[DMXPQ3L(ZI;E
M5@JJX(S3$A#BQCDFK8ZA$UCHF73(H&X>4M*UJ'Z8W0[B+@;GKMS%3S(3DE*W
M.N05L6>^CG'1(^+1B7BI?$6  8J&HX 8=6-T5\+>MZD-<7>#<" N->F9J">6
ME_I&8I*)6@J6CX)(Q">),&#-=1N@U*8X 4> 0P\C_''3/QQLNU%ZQ."$BW*N
MWZ#IVKD0,!%BCWQ3Z1R$ X,-+?6ZNYOXHBV[-5\H2VU(;V;T4G0)RR[A1S-$
M-2]+O&38OCAU53N#IE*<QC"83"/'7NT3;]:MC9BSERZ8KBFJQ0HB2E_TRFCW
M"I]:F:BJ>4K^I%Y&8D)GQ1<R;63E';I9 "(D*/1)$3"F-D$10;"H-M=-6L/9
MLUOZURJ=O45".8XT;)QU3.'@ +I1Z5199VL!2&.N<52Z#!B@T*CJ+=9>FR-I
M*F9U99W:+?C<Y<BZ>TVU4G%',M!H4M9J>7%LNT8J'.HBTF7#Y-36J1T#A-0Q
M,=4CL-KNE8.NK,4W2NZW=ON#H:<BF,S3LQ1T-;O^K"U;>8BG0:2M5YE9]&&4
M <QZ?O$R"0-5N+Y3-0[EMP]1V+,N;;C36ZG<5<2_E [;1.DFW9?U+TI6;@Z,
M<+))% D<H\,[49F107:G1=)$7"S.]"J$*DD;SV!M]7UM[7&&:T4E3L+<P.AK
M&23I\$N^D7;?2S.\Z<!% H)B40QM6W/7"0J20N3LXD+J3%EFS2;%E2;68O#2
M3>BJMEZF@$DO_E@X38M4OH\YUB@V4#I"E,/!BT5S[BS-Z+2WOL2M,DM9?[;/
M=FH[(WFI>$J/2>?IA*L:>%3IF+E0H*ATS<R[8YEA9K-O&G?C%$7XM!0<W%W/
MH>W5P[?IU74%73M7S]8/+KS\94-P[G7+J>HU7$M4=729X>/9*STM(+JD8I%9
M(E20(F5/=!>ZW;>HS7%W?7 @+CWGFZAFQF#24W2T.M3].,(4@IIBSCV+-=1%
MHT QP3 > 1X<;;MWE;-ZBD;M[3X>[,/9@$YH4:5@B7LIQ.DZ_D'L"*1@<.W#
M!!!%)<52BGH#(!SRQMFW:UXVJ64NQM&8W<9V2!.H'+>E(%:]]+IT;<"5?TX
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M.+\ 8XOP!CB_ &.+\ 8XOP!CB_ &.+\ 8XOP!CB_ &.+\ 8XOP!CB_ &.+\
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MJ<;/K2I;/$J[] OT[7E4&AXU)L,OFS!)1Z5<1 3=%IP(:1X!T\1BB8W'D76
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M@J*N->R1G(BS]"U35<)!U9<^3IB.3EJB9T)!2*R;B4.R061.Y\4(<"=(0#"
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MRO\ 4%U8VQA'>10>U6IY2@+W;@;A;@J:V]6BF;JTJU%[5=G[*/)F(EE:C?L
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M54-<%13+6\8R=.(X[!E#1J*[]17H \6(47(I;CNLLVO55&6OM78.C;J4U?\
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MCW:@J!XR]0B2.!,4NI0#&$1ZZ8FT-NXA^KACMR%G:/V^T_&F>JVT2OC2]!O
MW/C:,QC"U1A49I5N5,6&I!1D,65$QT$$P/6]TKFU)&47;NV]*3]<US6$XOXM
M#TW2=+QRTO/3<@KD)^B:MD%%5-!#&X@(!A$ Q,;W:7ZLFNT.J]ITDC54AN&J
M:^5(0&X.3LA3KHXUAN/IS;!]&KK.Z>BVJ#F4,Q&H2.7,:BH]:F5[Q ;A=;[)
MV#=P]!PAZ[=6SM1(7,%O)W)@XB_:E@[:RC^KEZ<(,*I4[X$'GBXPSWQ-)4H
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M,HF<3$)?^PMS["5OM-W?[59JF(F_.W2O*EIZN!A8ZN(L9NBZVH.XM+E29U#
M2;4HF;22;-L.K1J2!)=JLXW9V'V0;&'E^;S;7=TUS=O\NYG;ZQEN[-1=!VY4
M2B&5\;DW,F:;%*.5J>6),,*7HRGVT](N21+]X[58-4RG->22K^R4QMROMMCW
M"U[M@W$VCDJHC*^AZ9NE;9)HI-/*4KJ'0:MI*,6(\(!5@;)&3527  5;@W=N
MKDW\O14K6C;5VFI64K*MZF>%57)'0D2EK5\69M"G6<.5U!(V9M$2&577.1%,
MHG.4!;;U*OZG[<13_5VKI1E4+7[<7WL^ON 86CF%2 PN](;/TD?I)&)%!1)Z
MITE3 9-F(OE!*P*+H;M7UVRVZ/=2V-]MO[J$_P"(2)N73- Q%JZ8W#,HNWUO
M*[A:=F=<_-R#\*D0<QC2.CB"@*6ITX; .HEJ=N=_-FD)L[&P-O+=V[I%G!W[
MHN]CJ\QF-(IFK:Z=0MZ.B8E*GY&5F?&)&08&.X,=RX./C&DF1K!V,M!8ZH]U
M&\;=;/5'!;?MNE.55#T C*L*'C/IRX-P[@W%GT'3*GZ=@V9BJ.Y!1LX.<P@"
M2!DR.%D4>KUN1U6%JZ2O-$VJIW<)5E3L=_L.:DD=N\W7B%NY.ZM(QA;;N59@
ML?)**-#1I'2*QW*8(G% #]('6L;BWSCIZ5V>[<=M>QFA9IZ=L1@0:U*IN#NX
MQ9*!I*0(J<:Z'O2GUEZ=,#"!<REN'<;JZ^J^NIO6VH6PGZDIR0W+.=P5M+",
M;K/J'<*H5HYVSVXJV.DY6NFK86ZZ#-P@=D#MT3Q0@$6'+%T.LPLHO+M:%I+;
MS>RZ*=/U>P;1U7TI6]HZ;E#S=O:JB"KJH%E&LO'&8@5)RHBN)TU$3J)*I&4L
MG6.U7J]JHW76)L-;2LKW;E+\UQ?:$LA*UI4=4U-+7CO7'6+H6?B)29JXE&-9
M!>+E9UPFT;N'S!PTB4I8Z!C8I;K**FFYT;$UY;JA:WH"GXZ/;/;G5Q/W';HA
M25JJ:I5-?0XJ1=XN$>LS*ZZ-LJDY4<K(MFJZQ)?=)OKZKRH-O^WZIZ<J0UH)
M2$W(4S<FX#"YIJ(>579>V.X2BH2G4G=(IURX:!#)SB)9)*$DE2-91L0!*J/5
MS;696DW= U=UFV\/9;;ZZ=L6TT-1#1E"/EF]YKL0KJ<\49&>HTX_:1A7+PT:
MWZ9%(5A11$>AP1),"$233*F1,I,B$*4O1@4H / 4"\!2AQ??PAL3V/;6YC>M
MN]C:.B[BW7@AN+"V<LOMQH.? JE.SEZ[KS+*2!I)R:*J3R-I]".,Y<-C L4Y
M=:15>L)O_N\VTTUM"NU:^T5V*4MC'4-N IZ_D36TQ4UOF],VWN9#3L+&1(Q3
M=6I9I%F$:]1\=+XJHMT8D40%7J[-MEW-L\#N?_XB@VD;3Y';M5-5_H+ 5?=_
M="<]QZK9R$Z6&FC 2.EU9=]I^BQ,N=$"B=$3ZB[(MEL'M\GJ_0OY;ZZT;05'
M6>.+.I*/;6AI9A!V3M;;"TD?$JMI9>J9A9"FF)',M"Q\*S06D7K[Q5%0I;&;
M(-\>Q)EM7EMW-%72J[;%5]&;BJ6W HRC^RU*FKVOK?W*0IZ'C21DBRA2>-*N
M6SARV,LHDW;G< ITQ*+VJSNU>C*]NGM%V>R^Z2G=V=0SC1><LQ,WBKQ"UDA:
M.FJ.^B%C>-2\3T,HI*+3:1TT@.F1J;4=8UY=N75C;+4-X([::B<4%N*W W(O
MA V"V]T5==B"0R%FJ.J%Q%3CRIY]@)SHS2+-L@FP5)H4.H4Y%!MON#WJ;<*@
MM;N6NM5XVKH#9/:>Y%,;@+AU]>&8JQ_"T+05#UQ3;2-C9#Z1C6[6:?/?%DB,
M$ECMC$7>)IHN$*PWS]5^YM75%WE(R%VHTG;S=32EU8FYMUI:JXJ'1V^71K2"
MI@"4E/H1<DXGF\H#&08OD(V200$KMN5%;J.MDY=2C:X^]J7W<5[%LE2KL5:0
MV04#_6$O'2CK0FH9@]7ECHE!4A06.GWH%.0,M(\ Y@  &8\ @(@/%]X<7CM)
MU8VQ;_C.HS;+6CNWE];_ -:;@J6V\6A7N5# 4]16ALY.341,GJ*4;B!T'DH"
M:#1LN"8#TS9P@Z/NMC*9L?5UG*#VH)V@IJL:MN7439K4:EYJLI62G+VVEF*'
M+'I$C%K=/V!8:4DOI9RB]75Z5N1-N0%#QUY^KZZMAS>&9;/;BL[CDN%N1A;8
MVRH&3I6K'\10]NXFNZJIAHK4=9S\.U9U&]AXR-+&PS64BTGLV9RZZ).+ZS6M
MVLCM_M!&T;7=176@ZW=C+2-MIFV%1OJ2K.G$9&.;)!,"I(1YT8([5JFXD179
MHE9H/5Q9IJ[Z;D]5G7-MNK>5CD:F9W8E;_T9);CF-JY]SIHF_=1[;&<25PVI
MYX95DL^9M9ITZ;,%OI-N#]HGF>P5=UL0QKB[FJBNYNEN"]503;J2LY>JY$C-
MPLT!<A$WC=/I0ZVH1X0R  RQ1=2531]:W?NU>:O(FT>W3;O:MLUD[GWONO4&
M2<735/-'1BD;LD#G1&6EE"G3:$51*":[IPU:N(^FMV?5QVZVW6DJ"E)JI$KE
M4AO,I"]<U1DPQ*W)$6\JZB&%-12S]V\Z90QY!@Z\71!(VH%!$,KIR/5N]6=<
MG?+M^LO5<_0U7;CWFX2V>W2C*_JRCG2C:L8G;="5Q'R3VO :"DJFB[:>*-EU
MBE2!8@+-CKUOUA]$1550]O[96UO!7%RK?5L@UIZN[?5!8N%?REQJ!JYNF9R1
MJ\9GCEB@H 'UHF27!/OP3PAOZVV]6&_N#MPM]:)2[FX*KZQW-PUN6<<SI>"_
M2B[=,;?&T_2B<I6B5%L2.V\]4;B'B62LFQ?,(<DL5N1TK5^]#85U?T]N7V:V
MFMB\NW<Z^=T;Y4SMW3GH2CZ7+5UU:=L?23Z)GGM1'I- DDPJ"8_$MR2D<_C8
MXDDN@7I"]:Q3EOI2XM$3EIK)70H:U4G4[2A*@J)>^4Y!0E/TG*5$DQFB1[ED
M,X15^J2/=%*1!42%.'?!0&ZNK^K_ )B"ZM*KKD6_H>0W/53?JF:>NLE2=R)Q
M*F8/<!';=GT,+YO1[AVH5Q#_ $W*1\D\CSHO'3",,J#<M-;RI'J\*I3ZL&4K
M^B*84W)UC>VFJ.OA.6_N!.MX*$OW3&V!:(=R1:?="L#R#92<HTD7[11!=PWC
M2+ "=M&J-MJSW ;A]P=>)6KVR[9+:.&#:O+RW .W(]?I%EI,#-(>#B&RB;RH
MJA>%.WC6ZB*BI3&62(>G]A>^C9I![6;P7-LE4]_[*S=MMPU/;@:+J6D*5G2P
ME1TO4R\9#PRL;)L^^50<%(N@Y!,Y2]$;0"F[_89M#V15'NDW&;<JBMU 4@VB
M+P0M"T54$?.V_"J;M7#N_5E60B,/14-2$HXCZ;8D&5E7D\_65(W;,RMS&':I
M:>HMIDQ=SK,=V, \?49L1LU<^GY5E OJ=;@ZKNH:]OW(,1B(2EX0,T750JQZ
MQ%5RK^*H.&S1VZ0NR\WY;+;;[5*'MU0C>MX2YEO=TE.7V@JP*B@\D:KI<]*L
MX2(?QBT,R:>,N'C@ZB"W2 1 3Z#&&JNMDJW;536R"W>X*M;H[@;@VVH622N!
M6-S+DU#=*0MY!S!)5"'IX9:I:V<QK=6.;%:)((D=)"LX(V(JZ+*;O]ZO5=5;
MM_VC3U-3$I;VIV.X:F;@7=IVI7=(O):S=-WYM5"T^BO3*==R*+"!1?D=O @Y
M*09MI5$H',J39C:=6DG=JKC=;#?_ &#V2D+?,:@+5$I;K^N.8C[W533_ .E(
ML(T[@D5]"IL7LA]'-BJ .9VZ15!3Q'0T8U091<4Q91D>Q0()6S2.CT2-V;-!
M,PCD0B:9"  B/ &-RNWGJZ=A=.;GH;9U4\=;V_%V;M;E:8L!3;NZCQ@:1>6O
MMW#N86;=/G#,A5"/)%V+=!%5,2*%("K4[F3WU[B=HDE0U\(I[2M,N-FXWNI:
MHI%>O*QO A:^$IB/OC1T3)1+E)9DN%1D>-XHXF:%.ET(+E$N+U[RJ\H1&H'-
MF;<L:K>6S0K$L.WG:PEG[*GX>A&U=#&.^A*YEG[=@61"(5R >D\6'^#QLXW(
M7JM8A&O-TMXMNEI:HH=Q7LLBC9@MXZ96JVX=7.YR*IB0D9UI1C)H\.HV:T^V
M<2(D23(FT57*0NVJI-TO5MUCMZV3;K;U4?8F@+X53?6B)>]=O:KN@LX_JJF[
M][>HMEKI9&3(@9>4CSSSE6(1 2.E32)?HPVS6R55VJJVZ<ENY>7P;,4+?NI2
M2KR%5M-1368I:#HVW,-#R2M2358U!(1M*0L>J_BT4W3CQER\3:H.%$]O6U#?
M=L%)M*A-Y;"X!=L%S*?W(T5?AJO6ELX M33EKKLLJ4BF*43+K,3H=$9J]>-S
MO%TFC11\4%W+?8!9YDD,O";&]E>X[>;-QBYR(PJ]6WSD1VY4HVF794E-+I%1
M!J[9ZBG%(!Z0B>6H34-O(G;<-]OAZ@D;L15:6ZEJ]3K9O;UU:BY$U0\F9_73
MB(@".$U&<2G*JJ&C&X( L= VL$.G5KG<5 65>6ML2O>*O*$VY5=.5JI-U#?Z
MV5"3"E/'O2XI)6$C IUG(/T';1C&B_D5#';+BHL0A4S*;7)VOZ(<ULRW&;FZ
M.L5()L9V6CI*AZ*E(Q[+5K="+@Z>@Y]_43R*3;M&[&F635%61=/4$/'6F>L=
MI-.;LNK?G-O>V7>Q?>E=M=FKHN=PE"5]=^DKK7+,JG::,O-9BF& MXA:8TE4
M>M&E0O CTP7U+N'"'BZEF]K5@[#5-N]WO[@V,K45LMNU*57$T!$P%MZ<6.WJ
M2\=YKI3K5XQI6FVRI%&C9XX:+F>.B&;MTS"54Z>X[95NFVSL-LFZ7;;2]N;A
MS,31%WH>^%L:XMW=-L:1@9ZG:OCX^*69.T!$B3N->LQ, *$5(L8!$I;_ -V.
MKPV!H[I]I&UIW6C*XFYRX>Y2E=O=-7;?VNC5Y2YD;MQ@IB%EW<ZPC4VZY"5*
MX,W9N%TE$D"F$@&-9CK%I:FKA/X#<3#4$PL=8B#C&\O>6YUXKC%6:T]9*EHA
MF8R+B5\<:ODEG!3BD"+5=P36'1)J[C::WB=74]VF'W@6DJ"PFWBJ;=;@Z:W!
MN(ZY%VVA8B3M!>)E3<1%*P4TYI%6=E(UZU!RV<*L%68B@X,3+J\NJFVF;:D=
MU6\24VLTJTB:(>7/IJRMMJ'M58FBF-&57=BY-QI-I)")7SY@Z*Q:,6*BCM5)
MR)ETU1;I.;CL-YFRV%VE3=(.Z81HR7I#<;1FX2C;Q1TTB]&8G*><4Y'Q3Z%"
M,5;-DUVTLS*=7QE-1(PIE,8+G;C;YU0E2%J+1TT\JFLITZ*KQ=%DV7(Q:L8U
M@W 5'+UZ\5;Q[%J3OEG2R2!?QAP#$;N\O=U15_K6]7U(NX"0=7]=7XM/4-]J
M2MW5DFE'T[<VOMH46U+,1<<<%2JNTAGU5VQ<M29P,!L7;GMN]I7=R:%W*6N8
M6S7O[!7/I.F(VAJ?W"/&5 4R^I>D5Q5J&H9&982QRLDHUF@D@13QD[S\5T9K
M9[?[[;.Z;V;J[>*4HVTU"4E3U_Z0O\E<*FZ8HQBWD;GRLS1<3$MX^0E9,7J[
MUHH#Q0ZQEE3NE#+&QM%V/(Y.%]_O6$;4]OE3Q1%#>.%M7&5O_6;<2H!.4%#
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M$7^! #"&>L<^,0,;B$/W/@QU\6[Q\X,Y=+[Q:(V54^T6,H=: A=F%"*T)/\
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M[7<&676.HLJ<YE!'&Q.B:^%16C[&]6U>J^UD&<BKT4.XO=7]QIJU5=K1;=P
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M143,?K<=ZKLQU97<?UF]VK>P6H .X;VBVVPS2BK5I/#K:54UDV\B\040%/O
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M%(Z-.G>$.4IA$ZBS=+HPUG*"FR#JBZ3?M:LN=O)WF[:BWQI*'5&1"@]NE.W
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M-FD8P%Z/I=0%,!>^W@7<E&I)Z&ZN#9/8C;E1JQVS=S&0ETMRYY&[<Q4$4Z2
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MNKPC"L:(N;;EK#SUWKV5-$6YHV\L(YIVY\=99C.U$N6BG,LS>O$%):F/$I!
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M12=N+-6S:R[*B:-1FZEJ8(5M/5$\JR7+]/UB]D)1T9>0?.7!U'SY<XB?+/2
M "%E-MU##;VVK:IZLK(D"O4]95H\6J6N)E2H:HF']3U_(RDLZ6=NU3G.9R^/
MD72F4"E* !5E8NMMLG#1E?5":KJ[M/1M[+\4-8>KJH,ITWTW+V3I&IF=.:A,
M1 3LTF!&1^B+J:CJ4ULHJ.02:1T>T08,V:13=$W9MDP1003U"(]Z0 +F(B(\
M8XMM*[EK8OJDJNS\G)2ELJ_HZNZ^M5<2C%)L"!-,XFN+92<3)>*NNC(=5JJX
M.GT@=*4I51UXMY<BQE@::MO6EK;:U=:2C9J#FJT5\5HJO*E:5=6834=*2;AI
M,3,J_CV2TA4TRW=S"X(D3.^%( ($E)/=O=6GI>:JEY6\W:)+<5N1;61EZL?R
M"DJ[F7MI6U6EA!Z1PITAV96@-!  3!N"6:8VH_K7M \BI2Q%(!;^RM0V?N'<
MJQ$W:ZA021;_ *&TDXL_+PR:<6"3=)$L>X16;D(  1,NE,25A#;7+1,Z!>7%
ME&LY<>LY.HJMKRY5P9EFFH1L^K&XU?/Y.7>%2%991NU,Z!L@HJLHBBF=8YAK
MV]=6V&J"#K.[DLO.WD:6OO??2SU&7>F72AEWDK<&@[6U'$1+QRX657<O'!&B
M:CM=995V9<ZIQ&EMFUV;/1<_MYM_'4'&VVHEE,U-3SJV9;70P4];I_;^JH!Z
MVEHIY#L0%HT=MGP*] 8[=0QVZAT367LE6%JZ^EZ>V]2]PZAL[5QMP^X9M=NB
MJ@NQ*MYJY$LSNVTJA.?<C,.6K91VV?OUVP BB5)%,J*8%K2>VV6D"F*YN4G'
M(W%NA5M85U=*ZM:-XD=4>QF;C7,DY:6!HF)4A^CV[I-F(IICXOJ(4P7%LI<R
M*7G;9W9H2K+9W IQI+3%.GGZ'KB"6IJJ(,)NFG#.1: Z9.%D!68NT52@<1*<
M!X<6EV?5G:)"6VWV--:0UK[9)UG<6*9T^%BVZ#>UR3ZHH68;3,J2.\6;J*EE
MY%SXZH3I'_C)S".*RVW[D*+4N#9>X2D I6M&(U16E%A/#2]4-*SA$UI^@)**
ME$B)23%JY,1!Z36) *;,N8"W8LD$&C1JDBW:M6J)4&S=JV(5!NV00)WI"$3*
M4A2ER  #@  X,$LUNQM/"7?H5K--:EAVTD\FX"=IBIV"*K5C4U(U?23IA+1+
M\B*ZJ)G$<]1$Z9SIF 4CF(-9US8"BZS;7#N'#Q5.5E<.Y%W[KWCK*9IJ"=G>
MPU.$E[I3,MXFR;J*"8J#!- #" "?4( (5;=:IMMJK5Y<2HS5C<JW])75O#0M
MF+CU8+CQX)ZLK.T9/L:>=*BZ 'BI"L$TG"XF4=)KF.(X;;5+RVHAZ@VZL5:$
M%A:.GY2I[<TDR:VSDVLU0\4W;6V?Q"A6$>Z9-%$HWI/%#%13340.4!SJ/;YN
M4HDUQK05;(4O*5)1OZ35C2+6:>T;4S2KZ=&2D:$D8M\HDA(,&:XH@Z*0XI@!
M@$!RQ5^V[<Q12]Q[*5XXIES5E$)596M$IS!J0J=G64 FXGK>R,3* FA)L&CO
M01Z4#'3#5F7O0M!/WOM/3URG%AGM:/[61%1+3*E&4^XN#1#FW%4_2-O6KI.!
MF"JPKQRP;DFHUV#4J@JM01<?CL4[?VU-A'7]:-"LW<9:^<N#=2\-VV%H8E\D
MHW<1UJ*9NA/RT9 %*DJH@V/',TSMT3"B@9-(RA3VUW=5+0ZDQN$M!0M6VUMO
M7SFJZT(2E*,KDYSU3&QU(M9%."%=V!Q24D5XQ1YT7XL%P*  %Y]V%)T*,9N!
MW!4[;^D;LW#4J>L9->I*9M=&%B*(A6=.RT@O#Q:#1$H=*$3'MA='R4>"X.&>
M)S>DPH;HMR]2V>96 FKF+U-63Y9>SC"J4JW;T.RI9[(J0;- 99!%X=PUC".#
M&*)15R,.!W(7PL>\FKNR%/1](5A45+7-NI;=O<RDHE!-G&TS=*%MW-1;.H&B
M3=)-H)9-!4ZK8I&C@ZS5-)$EVJ_L3:BG;8U-?$EK$+DJTPK,MX65962H!&UU
MJ(N$I-T[6B8-E!0")8UBQ@F3-OT>9E4E5C'5-56[ZTEK)NA+OUG4E:UM/-H"
MZ5U6=KW-=7&BU82N*U)9@LT-)DDI%HLJBLN6&  UG.0I5-)B3MN]N]#C0%)5
M1<6L+LU*Q6J6L*S?SEPZ_<)NZQJB1J&OI"5DE%WRB2)E=;L2AIR* 9XJ6X4O
MMC%JUK6K25_6MJ:=NM>6EK!UC7*3H7B52U%8JG:@:TNL<J@(F!HG&)M,TRZF
MXZCZB[8;Y6NC:JL"1>A%26MA9JJ;>4R1O;.5:S5"0Q$K;/XA8L;&N63-1"+*
ML#0>A(0Z)TR@3%>[=-P=**UW9RY[*,CJZI!"I:PHTT\SAY]K5$>V/4=!2,7+
MH)E?,FRBA&K],%2%.@KK14.F,'2].L4(B!IJ'C:?@HUF0"H1D-$,TX^.CVY3
MZLDTD$4DB!V"E#%#4+NYM,A>"D[;UZRN;1T&\J^X-)LHVM6$:O$-Y5U^@,O%
M'?)^+.5T%&<@==L<BABF2'/@9V*W6VY4N?:AC5,76J-)HUG7]!%_26$CWL5%
MOAFK:2L-( 0C>1>I';E= F<%.^+D4 Q4>U>Y=!LY6P-5T9'V\F;=0<K4="QY
MJ(BB-D8VFHV4H%[%R#%J@FS;I)$9.TLDR%3'-,!*+[9Q=&U\)5NVZ1HJF+?.
M;8/G$P2,3I>BS,U:2:L)5!T61;.(U6.8KLGZ+PKM)9$JY5^G_&X3VFN[75E6
M=D O;3VX=W3E?WUOO5\G*77I%E&Q5*SDC5,M4AY)1DP9P\6U1@@=%BA*W*8[
M(RBBYU:RVW[D*+4N#9>X2D I6M&(U16E%A/#2]4-*SA$UI^@)**E$B)23%JY
M,1!Z36) *;,N8"T8,4$6;)@V19,FC=(J3=LR;D*BW;))%X *1,A2% .  #@#
ML8V_WHNC1'Z4W&VM5-4M96(G#U)5\6TH:J:P@BTW/SAJ:A9!O$RBZC,A$VXS
M#!T#80$[<$SB)AM9O K.V,;46XVR-(U-0EJ;ER$O5 NZ-I:L 5)/LV5/(OR0
MZSA0CARFC(N8]1V@194J*Y 55UL-Z[FASNMS,795?;O&W*=516;D(VSKFL1K
MY>D8VBE9$:<0.>4,==25)#_21B&,@+SH!%,0M#NWLM25[:#1D"R\8QJ/Z6C9
MNG9D$Q;FF:0K.F'3&9A'9TAZ%1S#OVJADQ.F8PIG,0:*NS2VW"5JFX-MIR+J
M*WTY=:\][KI,J/EH-^C*0KN(I2LZA=0VIJX0242,M'J& 0$ '(<;@-P=LK?C
M#7JW23L%45]KD2U55M6E2UN\I5HI'TI').:YDI(D3%Q;=46\?#0J;1B@D1%-
M-N4J*8!"6TW$T*-?T73EP:0NG!Q2-35C1KB-KR@I 9&D:B;3%!R,8]!9DID"
M8>,:1+J*<I@,(8I^WVZ*VJ%P(JC*F;5I0,VQGJGH>NK>U:T(5-*>H>X-!/8R
M:C53 1,%R-WP$7*4I7!50(GHJN(VQVBCJ%D+@S"=07)KJ6FJEK^Z=RIE!55P
MS?5]=*X3R4GY0&RJ[A9HV<R MVYUES-T4NG5USM@-S-"FN5:&II6FIFH*,&J
M:SI%I,/:0GFM34]](/Z$D8QXHD@^9MUQ0%ST9S$#44<L7%LA=B%7J:V5V:*J
M>W5P:=:3=04LK45%UC#K4_4L&>=I%VQD6Q';)=1!51D[14R$1(8H\0'_ .!\
M<O\ ,#<QO" H!F!LB 6X(   8 $  ,N/@XLJ<V[[7:");"S])OZBE("D?TDK
M.LA8/JJFEJCGE_TAKR2DY9;QAXL*@E<OU *4 3(!2Y95S8>_-#0=S+1W(BS0
MU845/(N"Q\O'BZ3D4A,Y8*HN47*#I)-RU>-EDUD52)JIG!4@*8K"U+';<-2T
MW732@H>HI"O;J7EK:LCTI;&NHRY5$4)#5Y/U"M,Q5/-)N&C9)6GHI\VC':R!
M/'&CA,.CQMZW(W&H@U2WGVJ.;FN[!5<K4M81[:@'%X:82HVX+@M)Q,@A#2BK
MV.02135FH]V9J8O2LQ;J#GBPUR;R4$%:5?MCN,6[=C9%:IJRA&]#W&(U(S3J
M@8>FI%DQDU4TDB%03F&KI-/OA(0!,.+?-]RUN7U23%IYM[4%L:XI&MJYMA<2
M@9*6*BE.?HS7-N9&,D$D'Z:)2/&RJRB2@Z%=(+))*$M%<&SEA(.AZQL335R*
M5M?.,*GN _<P[*\#IJ\NA-SJ4U+NDIZ?G#LVQ)"J)Y-Y,*(ID0\>!(-(X;;Z
MG%K)N#W'!.T754W4]&W1NG1%-5M5-NB%3HBH;@V\I*990,VYCRD*!#2,>H"V
M7^L@MBEKIW\M7)+W?HJ'5IVF+Q6UN#<*S5U(ZFUA<"--KUO:J3B'KV/3,Z<'
M09R"BZ29E%!*7\8<#-[,[5K1TY9^WI)-Y.OXR$6F9.8J.H'R*;1S4=85A4KI
M[,34B=!)!N+Z6?N%@1101*<J*"*9*XM57+)>6H6X](5'0580S>3E8-:3I&KH
M=6GZBB$)JG5V;]H*[-=5$CAFZ273$VLB@& !Q';0*%HD],;=HFU<C96-M_&5
M/5Z2K*VTK"+T\^@6]8F?C/ N=JY7 TK])_2(JF%?QOI_QF(?:+;NB1I3;W 6
MVD+0Q% Q]2U>J=A;R6B5X23@T*O>R"L]TRR#I?.3-*"^!4XK>,](&K$9LTH:
MU<$QVQQ5"3=LF]H9EW.5C3[FA*F.\/45/S#^LG;^2D"/?'W8N5'[Y90YE!.)
ML\5W1E.[9SRE.U[1E;6U7:UI=N]=;O:)MO<8AT*VHFT,W5%1.G]&M91!15K(
M.*8<LGCI!11%PY53.)<;;8^XMN/T@CMH5QZ$NUMSCB5=7D/'VYK^V<6,/0L^
M5E!RK9*5-&MS'2;MYHCM "F$!2$<Q&B:-W$T$2XU+6YNU0U\*/@UJCK&FF3"
MYEN%W#JD)^3+1LC'#*)-57;@YHN4%Q'+"8OC#-707%.V\W0VX"NXFBZPC[@4
M),QE1U50U:T%6D64I6E1T97-"/8V6CW&12E4%!V!5"@ '*.A,247?R0M3$VV
M@MG\S<C<&SO#4M>W<J28A:KJRCBTA<"ZUT9J1EW[BKY$\0F5!LI4B<GXEEJC
M$F9N+==UBUI';^NMI^WK:E0.Q+;S=;Z.>QE)W*KB?K@EX;U5!0)9E-LHY+"N
MP/&O7_0 5=-4GBYE2!EBW[+<];5W5<I:>>=U);"LZ6K:NK:5_0,M)*(#,+4U
M6EO9*-?I)O2MTBNT%%CIJ&*172"R22A+57 LEM_IVW]9V6@;FT]0%1QM05T^
MDFZ-YG+!U=.=JI6:E7):CGIP8N/2?U-497TN=% J(/BIB)<4?<?<%:EX^NS0
M$:,)1]X[>5Y<*T%V(2GCKN'*M,DKVV$K%2#F,!1X\50CWRRZ""BZIT2$,H?5
M7NQ^&LFUD]M%U7\S,W.H&KZRN%6SZNZAJ$S-:7J>H*XJJ6=SQY-16.CUT7R4
MF15NHV1.V,B8A1"XVV"@+?S=1V5NXWE8^Y5'WAN)<2]C>KH:7I=&C'-/.W%S
MY23.VCBQC=%FE'QXMVQ"%U@ETXBL->43";=92;@[@T'4EIGYJXO5?:M9FEK3
M5:<IJ@MQ:^HY^I5I"E(]Z0OB[Y:GG+1X[;F40=NETSB4-O5#W2MHG4U(;5;J
MVKO98:G4ZMKRGXNA[EV39*QML)]9M3,JS++I1+=8Z24;-@\8J@(^,-EN#(1$
M<\Q V0_),4,@$OP<&+@78J3;].0LY=VH5*KN_3=MKW7XM/;6Z=0J+*.3R];6
MTMM4L7"N5U%U57+@Z3-+QA=595<%#K*"-+4'1L4V@*/HFGH:DZ4@&/2@R@Z;
MIV+2A8.(9BJ8Z@I-VR*:914.8PZ<Q-GBFJ!W36R"O8VB*K:5S0<W%U/5E#5K
M0=7L]/1SU&UO1+YA*1ZQ@(0JQ4'0$5*1,%"GZ)+18ZN;56$C:;KO;Q4-U*OM
MQ72E8W%FJP4K&]E&$M]<ZLKA5!.3#EQ6$M)PQ CRR%6FDE6:0F*P%KF A)SL
MNZ381,*P>RDL^<"8$6$?&HBY?.%>B YAT)@8X%* B;+@[&'.[C=1;6?=73W=
M[R]XV[Z!KRD:]KVT]V*&1NM<P:$>P#&O;92S"1^BI!E2;19>)>KK,5#'(OXL
M*^E<T;8S:Q:BG;.VPBY%Y,)4_3YY20>R4S("7QZ=J>J:C<O9>8D52D32/(2S
M]PX,DFDD90R:92XJ.^EU;'2K.Y=?,6\5=:;M==>[EEV]Y8EKH*FQNQ$VIG(A
MK-G,0A4UGKE+QM0 +FX_%IZ)?9.QM% TWM:G+>S%JI&T%$/9ZW\(I0=1(K(U
M#"-Y>AWD?*H&?E<+^.O$7Y7*YE53J+&466.>@;26VAD:8M]:ZC*7MY05.HN9
M)^A3]%T5$(T]2T"D]E7"[M9-FP;HMDSN'!SB!=1S&'$!OBJ*UL['[CX6>MO5
M$A6-'72NE0D37-0V><LGEKI6Y5&4=,,HB?/"J1L=XN629J%53;(H.BKMTRI!
MN NI:2A34K<#=+73*Y-]ZF5J>L:E>5W64:R4C8N341JR0?(1Z35LJH@VCXI)
MLS3(;(K<,5'?2ZMCI5G<NOF+>*NM-VNNO=RR[>\L2UT%38W8B;4SD0UFSF(0
MJ:SUREXVH %S<?BT]$OLG8VB@:;VM3EO9BU4C:"B'L];^$4H.HD5D:AA&\O0
M[R/E4#/RN%_'7B+\KE<RJIU%C*++'.GM3;4LHQL$A9PFWYM04=4%4Q_BMGTJ
M*_JZ2HYK5+1\6:2 D,!6A9!.2*^ 0Z4'/2=]BWEA[)TNA0]J+5TQ'T;0E)MY
M"9F"0=.121TF+(9>HW+Q^[. &U*.'SI910^HYS"<PCBL;,7PH2G+G6LN!%A#
M5C1%71R4K"S3 BA7385$E<C)K-W":3ELX2,4Z*Q"JI"14 ."&Y:C;,R*54V7
MI.67HFL[LW4O5?$MDJ*AXY1Q(MK5QETIJ=3ABM6HJ%;JQC<'>C-(BHCGG9&_
MVV:IU+P;0^K2VJ762_KFA(V60MRXW9;HU_T-F:-I63ED&OT@Y3HLB+IR[:@J
M5-5/HC 41*H.*XK[_J$*LB5.LEB;@77HZ\EI=SO]<%(H[?Z-A:^DG%N+4[<J
M!HTC6*;TZA">+N#/X0B\D\?NG0/GKH3H&)UEK*S=,[A*2ZG*[LS;^@=D=MKY
MU!=2)>RT0I0LK3&XZ?L^PKUV2K8"DI%^X11AW)W"+I42IY*I/6;I!&CMLUF*
M"CZ2L70--/:/I:WCE_-U=&,Z;DG"[N1BY!]6[J2>R!%U73HZPR#E85!5/KU9
MX95NPVP$=1<36)[A05H)NY]W*@V^0-<*. <'J6*L)-3J]*$5$-:0-SQ1FQ4S
MG3*@4HE EHY"^5N(FY0V+KI>YEL8NHGDX>F(2N5:5D*)3G96D6;M&,F.@C)5
M^V;-YIJZ11%8ZZ:97.E8M*7^MQM\,-Q;<KOG-I#5O<Z[USJ/LLXD3%5='L_;
MZXL_*0M/:5")G:FCV)#L^C3(Q.V(42FC+2[JK8L[CTE3U1Q]94FNA,U'2-6T
M;5\:11-"HZ2KBD'C&6CW E4T+>+/"E6*&E8J@9 %H*EMM8)C&5G9"X-1W8HN
MO9>N+F5/7,C<VKJ,<V^GZ[N+5-033AW5LB>(>O&K(]4*/R1XJF4CDVI@+E<;
M>!3U" QW%W9M_2=K*]N,I4M92"DQ0-$JD6ING&M*R<BM!QR2!TTU3'BXQLHL
MH7I'!UC?<FMP-S;.U#"7DJR,:P=>U[9Z[]W['R]QX-BBBW91EP$[4SD2A* F
MFV:D\8<)"X$J*1!6Z,A2!L_<1EFD67_ 06I?^$YJC7%RACK5+U?$)0=02!HQ
M29,WGG:[9$I0=U*G(*D/FN4X+B*HDWK#0@'W-)6.-MN0N8K4E7JBVLH>NQN6
MK136CU) 8!,3S9CO32A(H)$=0H>-^+?B<7]NI:>@B4Q</=%7+.Y%^*H5J6L:
MC>U]6$<S4CXU^LE5<B^2CV[5!51%M'11&K1(AA*1  QN W/T%0HPE]-T:5LD
M+Z5ZO4U83KNM&]G:74HVW#1M#5'(.XR'1CX]91(Z4&Q9@[-H4>>,'3(8)^V^
MW:A@H"CJGN%5UU9Z-6J.KZP>2MP:[=)O:MJ1_/5Q(24@JJ]511.H!W0@&CO0
M#/@K>OY;;W-T^-T)T]471H*W=[+YVSM)<:H%5SNG$C5=JJ"J..@EA7455.X3
M29)E5$YA,'?J:[8P.XZV#BH5[*2"LK:"KJ1K.N+:W"ML^<E:HO1I2N: D8Z0
M02<)LFI7#<RITSF235$O2ID.6U5P+);?Z=M_6=EH&YM/4!4<;4%=/I)NC>9R
MP=73G:J5FI5R6HYZ<&+CTG]35&5]+G10*B#XJ8B7&X.^]L:%-3=V=U,[2%27
M\K$]4UI.N;@2UOX9>GZ)67C:EDGK*/)&LG*R#="(;-4@ PB)!'"J"Z:2S==,
MZ:S=9,%4EB*E,FLFN17,IR'*82F(8,A#$M<Z@=LK-C*/:BG*P@J6E+B75J&V
M%NZPJ6.4BYNL;7VKG)M>GZ?F#I*"#.6CHY-W'9 6+68D "XI#8145EDG^TFA
M$J20I>SZ=P+K,&+-*A:A)5=+IOZJCIY*>?E;R*:;PX/Y5;IU0U..EQ7NW3<'
M2BM=V<N>RC(ZNJ00J6L*--/,X>?:U1'MCU'04C%RZ"97S)LHH1J_3!4A3H*Z
MT5#IC+[5;XVN@Z\L),P4/3:] .W$Q&-V,93@(_HX:!FH-RVD8URP%NB+1W'N
MT54].13  B&(RE(VP;JH0C[G6HO YJNN[KWEK>XE0UO8U_\ 2EIB59<*HZA7
MEY.!A'(G7:4>]=J4^*AA44BSG$QARS+IR,&G3P  \G( $,LO_>RQ1=/;I[2,
MK@JVUFG-26UJV-GZLH*XMNI]XLV7>2M%7$H!_&3+ [@[-FJ[22>="X5;MU%D
MCBBGE<.#V\T/.1"EVY&.E+H5#7EQ;C7<JNO'<.U<Q\4:H*BNC*RSDY&[=XY1
M(DF<B>1QU$-@:X+M<2-$?IU_6<2S*ET+O*;<4J_X2C4Q-O9YT:1U&((I&8FB
M18BD/0^*@C^+Q9B.OE;Y"MXS;W>V@]Q-H(DM0U?2T-2=W;8$<(T'5"T11TC'
MMY0D>F[<E+&3";M@ITINE:G+I*6U,??RAS5]&V2O=0.XNVT<-45E3+&$N_:X
M[I2@ZID&]'R,>6438&>+&^BY;QF/6$0\8:*Y!E;^EMPU!C<&GK77@H>_5$1)
MJIK:EV49=2W'3_H74D@C1LG'!)I,O&51^BY3QB/6,(&<-%1*739/=-65#!,W
MXVZ0EQ*=LS7"M25@W1HB'NU"A3EQD&U),9%*%=JR;'-NHXD8YPJF&0IF*)0Q
M8K=#6U%'F[Y;:(RYD19"M%:GK%HA0C*\D$G2]S1;4C&R*$&]6E8](C8[B2C'
M"B8!FD8@Y9;>]S%QJ'-4M[-JH7*&P58K516S!"@%;P4VG2%QG!*2B9-"#D5)
M&.0;MQ4E8QR9 4P.V,B?A"A!W06G+6-0VLD7$O;"X--5965L[FV^DGN@7ZU+
MW#MQ(1<LBBN9)%19D=T=J=5))8R(JIIG+=RV5DK;SD%!W\:J-;T34]=2[E<5
M_<@%81S3@N9ZX]:3S^=3739O'1&JS!^W%J=511KT!C<%O]OM@Z02M_9ZUT0K
M!4-1B$M/U"C"1:\@O++(%FJM=R$DX.=TX67.JZ>JG,8PB(_!1]Q]P5J7CZ[-
M 1HPE'WCMY7EPK078A*>.NX<JTR2O;82L5(.8P%'CQ5"/?++H(*+JG1(0RA]
M43M(1L:Z?6&B[P0=_E:2E[K7FE)*H+QT\\0D8ZNJOK1U40S<NOXPU;'49R,@
MLR.5,B0M>B*4@*60W4VS:7,H$DY'U3#M_IFHJ7GJ5JV(040BJII"JZ2=L9*-
M>MP5. &;.BD4()DEDU4CJ$-;"0H:P#0E3VFNFPO?3E>U%7=S*MN++W:BJ1?4
M-#UM7]=U),N9.IE8^,DY!O%,:@</&$=XP<T<T:'!,Q*FWHQM"F0W,5C:.+L/
M4-S%*HK)XH[M)#U"C5C&C6M)NY$\$T3"1;I.E';2+3=', @9<0,.)NF*D8(3
M%/U'$R$'.1;PIC(243*H':2#%R*8E-H424,0-(@)0$<ASXHB7_X<ZAJ.E:;F
MV=24Q9NN;];@:^L- 3K$Y%&[MO9NLZG?0+I H@H 1LBR<,0*J=,&P)%1(C2]
ML-S-LD:R@:#JJ*K>WLK!3M1V_K2W=60I 2CYVA*WH-W'2D6L"94TE"-G0(J$
M(0ITAZ-/19>H;<V$;QE66#KRMKJ6^K*0K^Z5058XN?<2E"T15UP;AS<_..5*
MNE%XLA&S9:JOI K#+7'$9FXNN9J+<9;^.N=9BQ-![0=EMND'3R9A9B+GX&-5
MO1<J:IFK:5>,I.%EH2K6Q2LY:,>IN2@<0*X3(91)2N:BVXVI5@:\N<# EQ;I
M5K6M>W7NM62$8.;!C+7$N=)RTH1HD.1BL6CA%L)R)J&1%4HG-UJFZ_<C0:]:
MM+T=9_<>)L76U/U?6=OKA4O;?:]2Z%KK4U?05S;>R<?,Q:CIB]D6[MNR?E:N
M"%!)?QE$J923EO\ :Q:B,MO#U=4"E6US+JS%3UA6]P:K6)H6J2NZ^K9](S$J
MZ$3*F)XV\.FB90_BZ:)3&*,PQK6MX';# ;DKD7NW'KQDG)77N94=X;LKGA5K
MMU) #**5%(NY%0[Z%!*);*E3#I"@V;  *"3>'UOM]+,NK-7RZPRXKF6M/;.J
M(E.*K.T6TF"!LTM]%U2R4$_BLY59&,=,U$0$R"<6S)8@)](H@&+A[OX.A/%=
MQ=U+>TQ:BN;C+U/6,@M*6ZHUP#NGJ584S(R*L+&-T5BE74/%QK95=4 4<**F
MPVWL.*#*XW.,K)+;=&-S5ZDK%06-FUZT-<)6CV5&'D1IY(QI8ZC@TH2)"1$A
MA;B\\7_%#3%X;\6JEU;T4;!.:5IV\MM+DW)LS=!I2SDZJGZ./JOM7*Q+A^T2
M%=<&Z4CTX)%55*GI!9;I%[$[=[:,J&M<]G)RII>GGTS4M<NJAJ&IVJ3"HIFI
MZAN"]E9&1</6R"39=1XZ4$R10)R<LEZDB]MDK&0#BK3U\>T,=?&_L=89.MC2
M190D^ULDPJ=*FD@34*F"4<2.!@F5-$I&I2I%#%"4]N=MPO6"EK*D4J^U]5T[
M5M8VYN!;JHW)$4I*1HZN;?OXV19@\3;HE=HE6%-4R:"HEZ9LV42L57=I["P]
M*UIMN_KB<6DJ@M4W!EIF)G+_ ,.RIZ\E9U.[G)=R-25%43"-8LI*I*E\?E3-
MT$VZ3Q) @)!7=ZKAVCKUA75V98)>\*EN-Q&XBU5/79<%3*WRKFE+>U3'1RXF
M3+I55:MT%5!$3&.(XI&RE@[>TS:JU-"1YXVE:'I"-1CH6+17='?/7!B!J4<.
MG2YS.';URHHNNL)EEE#J**&/5]C;_6]IRZEJ:[9(1]4475C,SV+?HLW!'D<X
M0$AR*MG319-)PS=MU"*H+$*LB8BG?8D=UU*6I=15167MQ4#N(NK>"Z%X+Y2%
MF+94W"KO9QI;=.YDQ.$@VC2-%PB 0Z!7)T3*($.)#G(HSW<;?:@&Z6SKJ^=F
M$S:>C;R1[&41HJH]UVX6J =5<SH=[*(-1=^+48)F4JNW3,":R1$3<"R1QQ76
M[J&H0&^XBY%N*<M%6%Q'%3UG(GD+<4G*!-P%*LZ7D9%6%8((.P\8Z2/CD%5%
M.^54/B_NXZV%LHNEKW;HI&DY2^]P4Y.HY65KQS1$2:#II,S.=>NF<8B@W.;I
M$(=LT3<JY+NRN%]2AK]5S9F@@I&K-SMUI"]E])Q:J*VJE]7ER))($EYM52L9
M.0"/03+J(UBHH&L<W(8Q4&B8&'.GZPW06#B:NN+2; D53%U*6J.L;871B(M)
MT=XUBSUY;60BI%^T;J+.U6C.47<MVZCITHBD0[A033UR=O=AW=+W7J:DY>B)
M>[LU=:\M;70_1V=;I,I%G!UI650OG<,86[=NV27A#LUB)IE %!$3&&"L!MCM
MRQM?:>G9.?FHZFFTS4]4.E)FIY-27G9>6J>N'TI+/W3E94PJ.'SY932!4RF*
MDF1,ME]U]7T&$ON"V]T]7U*6BN&6IJQC%Z5IZY\:,16\6M3D/(MX>2(\;")"
M_2T>Z%L81.TZ XB.)J^E[K(RKRY58PT93-RYJ@;LW?M&VN[3$-H)%P-V(BUT
M[$M9Y%%-)) %7Z1UA1331%7H4D2)TM:NT-%TQ;:VM#Q"4#1U"49!QU/TO3D2
MB8RA6<;$QJ::9 $YSG.8  QS&,<XBH=0YF>]9Q0PN-S,?95?;Q'W*<5/6BQ8
M^SSJK?TZ=TDPHM22&GDC*RH X/*$B0D1()D!>"@84\4)2N\NT;N\-.VTF)F?
MHN)3N?>&W#6)FI^/)%2D@X):BH(+QTYFZ8))>/\ 3@B4RI403!977&S4=LD*
MG(1,BSEF*R^X[=L]33D8]P1TS<*M7E>G16 IR 8Z:R9R*<2A3%X,6HW[UC;1
M*<W260MW*6NMC<1W4-5@G2])2SB57710I9N_)$+.$RS\\DW=.&*ATB/E0(("
M5(2?]A<M0\8<(E*(Y /%WP#Q_#B/F9."AI&6BC%-&RCZ*8N9&/4(H"R:K!^H
M3I43E.4# 9(Y>WPX I5! H:<LP PE,!=.M,.(H\60 &D!#,"_!^T7D?(MFK]
MA(-UV;]@[;).&3YFZ1%LY;/6Z^H%2*)"*:A3YE,7@$N6&K%@W;LF;)J@R9LV
MJ!&[1FS;(%;-FC-NED5)),A2E(F3(  ,@_9*(.$DUT%DU$5D5B%526153Z)9
M%9-0!*<ARCI,4P" AQX0CXMBQC8]H0R;)A',T&3-FF93I#)MFK< 3(41R,(%
M('?9CV>##8)..CY(K)VS?LB2+)!\DR?L#F,S?LDG &*DNETA^C6*&LHB Y\&
M0C\ \?\ \'_L>NS>HHO&;I%5LZ9N4BK,W+9P@+=PV<-5,R*)J$$Q3)J 8H@/
M"&&\=&,V<?'-$@19L&+1%FS:)$R!%)NV:@1,A2   4"E 0RX!_PJB#A)-=!9
M-1%9%8A54ED54^B61634 2G(<HZ3%, @(<>$(^+8L8V/:$,FR81S-!DS9IF4
MZ0R;9JW $R%$<C"!2!WV8]G@_P 'I$>\$!(9/+\6*8YYEZ,,B\.8 ;4 @(!E
MEPX3CH2,CH9@CF9-E$L4(]F14^73*%;-P @:@ "YY:@#@ WP8CY>5@(64E(@
MVJ)DI&*8/9"*'I2N,XYZNF*J0](0J@F*;/4&>!$@Y!IT%()=2:9-&C0D' )2
MCD344H@7O0$  1$1_P 7/58V.CX]>2=*OY)9DQ;MCR+]8!!5Z].B!3J*CF.:
MACB;L:LON>(1$='13+I7"X,XQBW8L^F>K"Y>J"U0 ":EE3&.H;+,1$1$1'A^
MXP=RD7'2;F)=>/1"\C',7JT4\ 4Q*ZCUUTQ424_%ES.F<##Q"(Y%TZ2G$"YB
M(E-WX!FH*F1->>D S[T XM) #@+D/^#.D<VI-0IR*D4(50BA5"&2/TA#\!\R
M&TY* 8H@'"4>#)O'0D;'P\:U4<+-XV+8M&,<BL\74=/E4F;<A2%,LHJH=0P!
-F(F,.??'U?\ UFG_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774620688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 23, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MACROGENICS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001125345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,918,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774990800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 211,727<span></span>
</td>
<td class="nump">$ 84,098<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">93,394<span></span>
</td>
<td class="nump">192,898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">13,643<span></span>
</td>
<td class="nump">2,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">3,151<span></span>
</td>
<td class="nump">3,483<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other current assets</a></td>
<td class="nump">383<span></span>
</td>
<td class="nump">704<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">322,298<span></span>
</td>
<td class="nump">283,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">49,983<span></span>
</td>
<td class="nump">17,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,602<span></span>
</td>
<td class="nump">1,369<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">373,883<span></span>
</td>
<td class="nump">311,263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,451<span></span>
</td>
<td class="nump">3,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">38,581<span></span>
</td>
<td class="nump">16,134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">7,202<span></span>
</td>
<td class="nump">4,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,319<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveCurrent', window );">Lease exit liability</a></td>
<td class="nump">298<span></span>
</td>
<td class="nump">1,593<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">49,755<span></span>
</td>
<td class="nump">27,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">13,637<span></span>
</td>
<td class="nump">10,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, net of current portion</a></td>
<td class="nump">11,253<span></span>
</td>
<td class="nump">4,867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveNoncurrent', window );">Lease exit liability, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">74,645<span></span>
</td>
<td class="nump">42,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value &#8211; 125,000,000 shares authorized, 36,859,077 and 34,870,607 shares outstanding at December 31, 2017 and 2016, respectively</a></td>
<td class="nump">369<span></span>
</td>
<td class="nump">349<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">611,270<span></span>
</td>
<td class="nump">561,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(61)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(312,340)<span></span>
</td>
<td class="num">(292,714)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">299,238<span></span>
</td>
<td class="nump">268,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 373,883<span></span>
</td>
<td class="nump">$ 311,263<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated appreciation or loss, net of tax, in value of the total of available-for-sale securities at the end of an accounting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6904-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated obligations associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid in the next twelve months or in the normal operating cycle if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of known and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a duly authorized plan, which are expected to be paid after one year or beyond the next operating cycle, if longer. Costs of such activities include those for one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and costs associated with an ongoing benefit arrangement, but excludes costs associated with the retirement of a long-lived asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6760870240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">36,859,077<span></span>
</td>
<td class="nump">34,870,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775098832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue from collaborative agreements</a></td>
<td class="nump">$ 155,516<span></span>
</td>
<td class="nump">$ 86,582<span></span>
</td>
<td class="nump">$ 99,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Revenue from government agreements</a></td>
<td class="nump">2,226<span></span>
</td>
<td class="nump">5,298<span></span>
</td>
<td class="nump">1,486<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">157,742<span></span>
</td>
<td class="nump">91,880<span></span>
</td>
<td class="nump">100,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">147,232<span></span>
</td>
<td class="nump">122,091<span></span>
</td>
<td class="nump">98,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">32,653<span></span>
</td>
<td class="nump">29,831<span></span>
</td>
<td class="nump">22,765<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total costs and expenses</a></td>
<td class="nump">179,885<span></span>
</td>
<td class="nump">151,922<span></span>
</td>
<td class="nump">121,036<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(22,143)<span></span>
</td>
<td class="num">(60,042)<span></span>
</td>
<td class="num">(20,182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income</a></td>
<td class="nump">2,517<span></span>
</td>
<td class="nump">1,514<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,626)<span></span>
</td>
<td class="num">(58,528)<span></span>
</td>
<td class="num">(20,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on investments</a></td>
<td class="num">(21)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Comprehensive loss</a></td>
<td class="num">$ (19,647)<span></span>
</td>
<td class="num">$ (58,605)<span></span>
</td>
<td class="num">$ (20,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare', window );">Basic and diluted net loss per common share</a></td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Basic and diluted weighted average number of common shares</a></td>
<td class="nump">36,095,080<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each basic and diluted share of common stock or unit when the per share amount is the same for both basic and diluted shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicAndDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161450&amp;loc=SL4573702-111684<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569616-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96868048&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775427104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">$ 121,286<span></span>
</td>
<td class="nump">$ 280<span></span>
</td>
<td class="num">$ (19)<span></span>
</td>
<td class="nump">$ 335,071<span></span>
</td>
<td class="num">$ (214,046)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,995,638<span></span>
</td>
<td class="nump">865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">7,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">203,467<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">203,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,976,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (29)<span></span>
</td>
<td class="nump">908<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">373,289<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,790)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(20,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,140)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="nump">313,337<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">547,185<span></span>
</td>
<td class="num">(234,186)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,345,754<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">12,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="num">$ (39)<span></span>
</td>
<td class="nump">1,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,853<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(77)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(58,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(58,528)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">268,751<span></span>
</td>
<td class="nump">$ 349<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">561,198<span></span>
</td>
<td class="num">(292,714)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,870,607<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">14,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering costs</a></td>
<td class="nump">34,244<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,699,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity', window );">Stock plan related activity</a></td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (40)<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity', window );">Stock plan related activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,186<span></span>
</td>
<td class="nump">1,862<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredParValueMethodAmount', window );">Retirement of treasury stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesRetired', window );">Retirement of treasury stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,862)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestments', window );">Unrealized gain on investments</a></td>
<td class="nump">21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(19,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,626)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 299,238<span></span>
</td>
<td class="nump">$ 369<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 611,270<span></span>
</td>
<td class="num">$ (312,340)<span></span>
</td>
<td class="num">$ (61)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,859,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodValueStockPlanActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares issued due to stock plan related activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodValueStockPlanActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredParValueMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the par value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredParValueMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesRetired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common and preferred stock retired from treasury during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesRetired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments, not including unrealized gains or losses on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, held at each balance sheet date and included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775794896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">7,608<span></span>
</td>
<td class="nump">2,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">14,744<span></span>
</td>
<td class="nump">12,165<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(10,878)<span></span>
</td>
<td class="num">(1,540)<span></span>
</td>
<td class="nump">1,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses</a></td>
<td class="nump">332<span></span>
</td>
<td class="num">(1,677)<span></span>
</td>
<td class="nump">2,405<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities', window );">Restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">262<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,544)<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">12,832<span></span>
</td>
<td class="nump">4,659<span></span>
</td>
<td class="nump">3,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRestructuringReserve', window );">Lease exit liability</a></td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
<td class="num">(3,293)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">6,533<span></span>
</td>
<td class="num">(4,191)<span></span>
</td>
<td class="num">(12,223)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">6,115<span></span>
</td>
<td class="num">(1,134)<span></span>
</td>
<td class="nump">4,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities', window );">Other liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(727)<span></span>
</td>
<td class="num">(878)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">14,405<span></span>
</td>
<td class="num">(43,679)<span></span>
</td>
<td class="num">(13,661)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(135,122)<span></span>
</td>
<td class="num">(347,762)<span></span>
</td>
<td class="num">(142,910)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">242,401<span></span>
</td>
<td class="nump">288,894<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and software</a></td>
<td class="num">(29,403)<span></span>
</td>
<td class="num">(11,381)<span></span>
</td>
<td class="num">(9,197)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">77,876<span></span>
</td>
<td class="num">(70,249)<span></span>
</td>
<td class="num">(152,107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="nump">34,244<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">203,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases', window );">Proceeds from stock option exercises and ESPP purchases</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">1,893<span></span>
</td>
<td class="nump">911<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Purchase of treasury stock</a></td>
<td class="num">(40)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">35,348<span></span>
</td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">204,349<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">127,629<span></span>
</td>
<td class="num">(112,074)<span></span>
</td>
<td class="nump">38,581<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">84,098<span></span>
</td>
<td class="nump">196,172<span></span>
</td>
<td class="nump">157,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">$ 211,727<span></span>
</td>
<td class="nump">$ 84,098<span></span>
</td>
<td class="nump">$ 196,172<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Stock Options Exercised And ESPP Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromStockOptionsExercisedAndESPPPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in current liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow for the increase (decrease) associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as operating activities. This may include cash restricted for regulatory purposes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestrictedCashForOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the carrying amount (including both current and noncurrent portions of the accrual) of the liability pertaining to the exit from or disposal of business activities or restructuring pursuant to a duly authorized plan, excluding costs or losses pertaining to an entity newly acquired in a business combination and to asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire debt securities classified as available-for-sale securities, because they are not classified as either held-to-maturity securities or trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale or maturity (principal being due) of securities not classified as either held-to-maturity securities or trading securities which are classified as available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765510640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Nature of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Nature of Operations</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MacroGenics, Inc. (the Company) was incorporated in Delaware on August 14, 2000. The Company is a biopharmaceutical company focused on discovering and developing innovative antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The Company currently has a pipeline of product candidates in human clinical testing that have been created primarily using its proprietary technology platforms, which have broad applicability across other therapeutic domains, including autoimmune disorders and infectious disease. The Company believes its programs have the potential to have a meaningful effect on treating patients' unmet medical needs as monotherapy or, in some cases, in combination with other therapeutic agents.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923368688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> that the Company determined to be other-than-temporary.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's revenue relates to agreements with various collaborators and&#160;contracts and research grants received from U.S. government agencies.&#160;The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incyte Corporation (Incyte)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10% </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Equipment and Software</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> assets held-for-sale.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and DART&#174; technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.  The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license was to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the (FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, ASU 2016-10,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;"> &#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  The Company will adopt the new standard in the first quarter of 2018 using the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has substantially completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Due to the unique contract terms of certain agreements, the Company is still in the process of finalizing its analysis of those agreements.  Upon completion of the Company&#8217;s analysis, it will determine the cumulative effect of initially applying the new standard (if any).  The Company is also finalizing its accounting policy and designing and implementing the necessary changes to processes and controls to account for revenue under the new standard. Based on the Company's timeline and planned resources, the Company anticipates completing its implementation in connection with its first quarter 2018 interim financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company adopted ASU 2016-09 effective January 1, 2017 and has elected to continue to estimate the number of stock-based awards expected to vest, as permitted by ASU 2016-09, rather than electing to account for forfeitures as they occur.  </font><font style="font-family:inherit;font-size:10pt;">The adoption of this standard did not have a material impact on the Company's financial statements or related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765560448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;font-weight:bold;">Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,991</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company's available-for-sale securities held at December 31, 2017 had maturity dates of less than one year.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of December&#160;31, 2016 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All available-for-sale securities in an unrealized loss position as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> were in a loss position for less than twelve months.&#160; There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> that the Company determined to be other-than-temporary.  The Company recorded interest income of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the years ended December 31, 2017, 2016 and 2015, respectively, which is included in other income.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=4738149<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289146<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6611739360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Property, Equipment and Software</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,919</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> consists of the costs incurred for the build-out of a manufacturing suite at our headquarters building in Rockville, Maryland, which is expected to be completed in mid-2018.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We had </font><font style="font-family:inherit;font-size:10pt;">$9.6 million</font><font style="font-family:inherit;font-size:10pt;"> in property, equipment and software at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> that was purchased in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> but was not paid for by year end.&#160; Property, equipment and software balance at December 31, 2016 includes approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> in assets that were purchased in 2016 but were not paid for by year end.  Depreciation and amortization expense related to property, equipment and software for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$7.0 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$6.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765561120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stockholders' Equity</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;The Company's amended and restated certificate of incorporation authorizes </font><font style="font-family:inherit;font-size:10pt;">125,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock, and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares of undesignated preferred stock, both with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;There were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> shares of undesignated preferred stock issued or outstanding as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2014, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">1,800,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">450,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$36.50</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160;&#160;The Company received proceeds of </font><font style="font-family:inherit;font-size:10pt;">$76.7 million</font><font style="font-family:inherit;font-size:10pt;"> from this offering, net of underwriting discounts and commissions and other offering expenses.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2015, the Company's stock purchase agreement and investor agreement, each with Johnson &amp; Johnson Innovation &#8211; JJDC, Inc. (JJDC) became effective (see Note 9 for additional information).&#160; Under these agreements, JJDC purchased </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;"> new shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;"> per share, representing proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, the Company completed an equity offering, in which the Company sold </font><font style="font-family:inherit;font-size:10pt;">3,525,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160; Additionally, the underwriters of the offering exercised the full amount of their over-allotment option resulting in the sale of an additional </font><font style="font-family:inherit;font-size:10pt;">528,750</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock at a price of </font><font style="font-family:inherit;font-size:10pt;">$37.00</font><font style="font-family:inherit;font-size:10pt;"> per share.&#160; The Company received net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$141.0 million</font><font style="font-family:inherit;font-size:10pt;"> from this offering, net of underwriting discounts and commissions and other estimated offering expenses.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2017, the Company entered into a definitive agreement with an institutional healthcare investor to purchase </font><font style="font-family:inherit;font-size:10pt;">1,100,000</font><font style="font-family:inherit;font-size:10pt;"> shares of its common stock at a purchase price of </font><font style="font-family:inherit;font-size:10pt;">$21.50</font><font style="font-family:inherit;font-size:10pt;"> per share in a registered direct offering. Proceeds to the Company, before deducting estimated offering expenses, were </font><font style="font-family:inherit;font-size:10pt;">$23.7 million</font><font style="font-family:inherit;font-size:10pt;">. The shares were offered pursuant to the Company&#8217;s effective shelf registration on Form S-3 that was filed with the SEC on November 2, 2016.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On May 3, 2017, the Company entered into a sales agreement with an agent to sell, from time to time, shares of its common stock having an aggregate sales price of up to </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> through an &#8220;at the market offering&#8221; (ATM Offering) as defined in Rule 415 under the Securities Act of 1933, as amended.  The shares that may be sold under the sales agreement would be issued and sold pursuant to the Company's shelf registration statement on Form S-3 that was filed with the SEC on November 2, 2016. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold </font><font style="font-family:inherit;font-size:10pt;">599,284</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock resulting in net proceeds of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> related to the ATM Offering.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916209440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2017, the Company&#8217;s stockholders approved the 2016 Employee Stock Purchase Plan (the 2016 ESPP). The 2016 ESPP is structured as a qualified employee stock purchase plan under Section 423 of the Internal Revenue Code of 1986, as amended, and is not subject to the provisions of the Employee Retirement Income Security Act of 1974.  The Company reserved </font><font style="font-family:inherit;font-size:10pt;">800,000</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock for issuance under the 2016 ESPP. The 2016 ESPP allows eligible employees to purchase shares of the Company&#8217;s common stock at a discount through payroll deductions of up to </font><font style="font-family:inherit;font-size:10pt;">10%</font><font style="font-family:inherit;font-size:10pt;"> of their eligible compensation, subject to any plan limitations. The 2016 ESPP provides for six-month offering periods ending on May 31 and November 30 of each year.  At the end of each offering period, employees are able to purchase shares at </font><font style="font-family:inherit;font-size:10pt;">85%</font><font style="font-family:inherit;font-size:10pt;"> of the fair market value of the Company&#8217;s common stock on the last day of the offering period.  During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, employees purchased </font><font style="font-family:inherit;font-size:10pt;">38,012</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock under the 2016 ESPP for net proceeds to the Company of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Option Plans</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective February 2003, the Company implemented the 2003 Equity Incentive Plan (2003 Plan), and it was amended and approved by the Company's stockholders in 2005. The 2003 Plan originally allowed for the grant of awards in respect of an aggregate of </font><font style="font-family:inherit;font-size:10pt;">2,051,644</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company's common stock. Between 2006 and 2012, the maximum number of shares of common stock authorized to be issued by the Company under the 2003 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">4,336,730</font><font style="font-family:inherit;font-size:10pt;">. Stock options granted under the 2003 Plan may be either incentive stock options as defined by the Internal Revenue Code (IRC), or non-qualified stock options.  In 2013, the 2003 Plan was terminated, and no further awards may be issued under the plan.  Any shares of common stock subject to awards under the 2003 Plan that expire, terminate, or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised, or resulting in any common stock being issued, will become available for issuance under the 2013 Stock Incentive Plan (2013 Plan), up to a specified number of shares.&#160; As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, under the 2003 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">955,296</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$1.85</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2013, the Company implemented the 2013  Plan.&#160;&#160;The 2013 Plan provides for the grant of stock options and other stock-based awards, as well as cash-based performance awards. The aggregate number of shares of common stock initially available for issuance pursuant to awards under the 2013 Plan was </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;"> shares.&#160;&#160;The number of shares of common stock reserved for issuance will automatically increase on January 1 of each year from January 1, 2014 through and including January 1, 2023, by the lesser of (a) </font><font style="font-family:inherit;font-size:10pt;">1,960,168</font><font style="font-family:inherit;font-size:10pt;"> shares, (b) </font><font style="font-family:inherit;font-size:10pt;">4.0%</font><font style="font-family:inherit;font-size:10pt;"> of the total number of shares of common stock outstanding on December 31 of the preceding calendar year, or (c) the number of shares of common stock determined by the Board of Directors. During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the maximum number of shares of common stock authorized to be issued by the Company under the 2013 Plan was increased to </font><font style="font-family:inherit;font-size:10pt;">6,769,888</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;If an option expires or terminates for any reason without having been fully exercised, if any shares of restricted stock are forfeited, or if any award terminates, expires or is settled without all or a portion of the shares of common stock covered by the award being issued, such shares are available for the grant of additional awards. However, any shares that are withheld (or delivered) to pay withholding taxes or to pay the exercise price of an option are not available for the grant of additional awards. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, under the 2013 Plan, there were options to purchase an aggregate of </font><font style="font-family:inherit;font-size:10pt;">3,549,346</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$24.62</font><font style="font-family:inherit;font-size:10pt;"> per share.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Employee Stock Options</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67% - 68%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Dividend Yield</font><font style="font-family:inherit;font-size:10pt;"> &#8211; The Company has never declared or paid dividends and has no plans to do so in the foreseeable future.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Volatility</font><font style="font-family:inherit;font-size:10pt;"> &#8211; Volatility is a measure of the amount by which a financial variable such as a share price has fluctuated (historical volatility) or is expected to fluctuate (expected volatility) during a period.&#160;&#160;As the Company does not yet have sufficient history of its own volatility, the Company has identified several public entities of similar size, complexity and stage of development and estimates volatility based on the volatility of these companies.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risk-Free Interest Rate</font><font style="font-family:inherit;font-size:10pt;"> &#8211; This is the U.S. Treasury rate for the week of each option grant during the year, having a term that most closely resembles the expected life of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Expected Term</font><font style="font-family:inherit;font-size:10pt;"> &#8211; This is the period of time that the options granted are expected to remain unexercised. Options granted have a maximum term of </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">. The Company uses a simplified method to calculate the average expected term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the assumptions above, the Company estimates the forfeiture rate based on turnover data with further consideration given to the class of the employees to whom the options were granted.&#160;&#160;The forfeiture rate is the estimated percentage of options granted that is expected to be forfeited or canceled on an annual basis before becoming fully vested.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(253,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(326,607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,910,171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,337,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> the Company issued </font><font style="font-family:inherit;font-size:10pt;">253,036</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">526,715</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">374,214</font><font style="font-family:inherit;font-size:10pt;"> net shares of common stock, respectively, in conjunction with stock option exercises and RSU lapses.&#160;&#160;The Company received cash proceeds from the exercise of stock options of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average grant-date fair value of options granted during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$12.53</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$15.17</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20.90</font><font style="font-family:inherit;font-size:10pt;"> per share, respectively. The total intrinsic value of options exercised during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;The total fair value of stock options which vested during </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the total unrecognized compensation expense related to non-vested stock options and RSUs, net of related forfeiture estimates, was </font><font style="font-family:inherit;font-size:10pt;">$20.3 million</font><font style="font-family:inherit;font-size:10pt;">, which the Company expects to recognize over a weighted-average period of approximately </font><font style="font-family:inherit;font-size:10pt;">2.3 years</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765700304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> there was </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> provision for income taxes due to taxable losses generated, fully offset by a valuation allowance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,847</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of realization, management considers (i) future reversals of existing taxable temporary differences; (ii) future taxable income exclusive of reversing temporary difference and carryforwards; (iii) taxable income in prior carryback years if carryback is permitted under applicable tax law; and (iv) tax planning strategies. The Company's net deferred income tax asset is not more likely than not to be utilized due to the lack of sufficient sources of future taxable income and cumulative book losses which have resulted over the years. The net decrease in the valuation allowance in </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;"> is primarily as a result of the legislation enacted in 2017, which lowers the statutory corporate tax rate from 35% to 21%,, which decreased the net deferred tax asset.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has U.S. federal and state NOL carryforwards of approximately </font><font style="font-family:inherit;font-size:10pt;">$239.7 million</font><font style="font-family:inherit;font-size:10pt;"> that will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2025</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2037</font><font style="font-family:inherit;font-size:10pt;">. In addition, the Company has U.S. federal tax credits of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;"> which will expire in various years beginning in </font><font style="font-family:inherit;font-size:10pt;">2025</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">2037</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use of the Company's U.S. federal NOL and tax credit carryforwards in future years are restricted due to changes in the Company's ownership and tax attributes acquired through the Company's acquisitions. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$13.5 million</font><font style="font-family:inherit;font-size:10pt;"> of the Company's U.S. Federal NOLs are limited for use over the years </font><font style="font-family:inherit;font-size:10pt;">2018</font><font style="font-family:inherit;font-size:10pt;"> &#8211; </font><font style="font-family:inherit;font-size:10pt;">2028</font><font style="font-family:inherit;font-size:10pt;"> in which a range of such amounts could be utilized on an annual basis of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">. The remaining </font><font style="font-family:inherit;font-size:10pt;">$226.2 million</font><font style="font-family:inherit;font-size:10pt;"> of NOLs is not limited and can be offset against future taxable income, subject to certain limitations for newly enacted tax legislation.  The Company adopted ASU 2016-09 as of January 1, 2017.  Accordingly, the Company recognized the previously unrecognized excess tax benefits of approximately </font><font style="font-family:inherit;font-size:10pt;">$18.6 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$6.5 million</font><font style="font-family:inherit;font-size:10pt;"> tax effected) recorded as deferred tax assets with a corresponding offsetting full valuation allowance at the beginning of 2017 without any tax impact.&#160;&#160;Further, despite the NOL and tax credit carryforwards, the Company may have a future tax liability due to recent changes in tax legislation or state tax requirements in which net operating losses do not exist.  The Company is still quantifying the impact of these changes.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred federal rate change reduction in corporate rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, of the total gross unrecognized tax benefits, approximately </font><font style="font-family:inherit;font-size:10pt;">$3.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> would favorably impact the Company's effective income tax rate, respectively. Although, due to the Company's determination that the deferred income tax asset would not more likely than not be realized, a valuation allowance would be recorded, therefore, zero net impact would result within the Company's effective income tax rate. The Company's uncertain income tax position liability has been recorded to deferred income taxes to offset the tax attribute carryforward amounts.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company has </font><font style="font-family:inherit;font-size:10pt;">not</font><font style="font-family:inherit;font-size:10pt;"> recognized any interest or penalties related to the uncertain income tax positions due to the fact such position is related to tax attribute carryforwards which have not yet been utilized. The Company does not expect its unrecognized income tax position to significantly decrease within the next twelve months.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's U.S. Federal and state income tax returns from </font><font style="font-family:inherit;font-size:10pt;">2001</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">forward remain open to examination due to the carryover of unused net operating losses and tax credits.</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As more fully described in Note 2 to the consolidated financial statements, the Tax Act was signed into law making significant changes to the Internal Revenue Code on December 22, 2017.  Under ASC 740-10-25-47, the effects of the new legislation are to be recognized in the period of enactment.  As such, recognition of the tax impact of the Tax Act is required in the interim and annual periods that include December 22, 2017.  As a result, the Company has revalued the deferred tax asset as of December 31, 2017, fully offset by a valuation allowance without impact to the financial statements.  The Company does not anticipate that other provisions of the Act would have a material impact on its financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919516192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Lease Exit Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Lease Exit Liability</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2008, the Company acquired Raven Biotechnologies, Inc. (Raven), a private South San Francisco-based company focused on the development of monoclonal antibody therapeutics for treating cancer. The Company undertook restructuring activities related to the acquisition of Raven. In connection with these restructuring activities, as part of the cost of acquisition, the Company established a restructuring liability attributed to an existing operating lease.&#160; During the year ended December&#160;31, 2016, the Company entered into an agreement to sublease a portion of the space subject to this operating lease.&#160; The Company will receive approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in sublease payments over its term, which ends at the same time as the original lease in February 2018.&#160; No sublease income was contemplated when the restructuring liability was recorded in 2008; therefore, the Company adjusted the liability to reflect the future sublease income during the year ended December&#160;31, 2016 and recorded an offset to research and development expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> in the same period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,593</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During 2015, the Company corrected an immaterial error attributed to the estimated lease term that resulted in a reduction of research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$1.9 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920735104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration and License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock', window );">Collaboration and Other Agreements</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Collaboration and Other Agreements</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Incyte</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In October 2017, the Company entered into an exclusive global collaboration and license agreement with Incyte Corporation (Incyte) for MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1). Incyte has obtained exclusive worldwide rights for the development and commercialization of MGA012 in all indications, while the Company retains the right to develop its pipeline assets in combination with MGA012.  The Company received a </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Incyte when the transaction closed in the fourth quarter of 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the collaboration and license agreement, Incyte will lead global development of MGA012.  Assuming successful development and commercialization by Incyte, the Company could receive up to approximately </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in development and regulatory milestones, and up to </font><font style="font-family:inherit;font-size:10pt;">$330.0 million</font><font style="font-family:inherit;font-size:10pt;"> in commercial milestones. The Company determined that each potential future clinical and regulatory milestone is substantive.&#160; Although the sales milestones are not considered substantive, they will be recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160; If commercialized, the Company would be eligible to receive tiered royalties of </font><font style="font-family:inherit;font-size:10pt;">15%</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">24%</font><font style="font-family:inherit;font-size:10pt;"> on any global net sales. The Company retains the right to develop its pipeline assets in combination with MGA012, with Incyte commercializing MGA012 and the Company commercializing its asset(s), if any such potential combinations are approved. In addition, the Company retains the right to manufacture a portion of both companies' global clinical and commercial supply needs of MGA012.  The Company and Incyte have agreed to initiate negotiations for a separate clinical supply agreement that will set forth terms and conditions. Finally, Incyte will fund the Company's activities related to the ongoing monotherapy clinical study until such time as the Company can transfer the Investigational New Drug application (IND) to Incyte. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration and license agreement with Incyte and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&#8217;s substantive performance obligations under the collaboration and license agreement include the delivery of the license and clinical activities through a brief technology transfer period.  The Company evaluated the collaboration and license agreement with Incyte and determined that the license and clinical trial activities each represented separate deliverables and were accounted for as separate units of accounting. The Company concluded that the license had standalone value to Incyte and was separable from the clinical trial activities because the license was sublicensable and Incyte has significant capabilities in performing clinical trials.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative best estimate of selling price (BESP) to each deliverable.  The BESP for the exclusive license was determined using information from other similar collaboration and license agreements.  The BESP for the clinical trial activities was determined using similar arrangements and is estimated at approximately </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;">, which will be recognized over the technology transfer period as work is performed and the expenses are reimbursed by Incyte. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$151.1 million</font><font style="font-family:inherit;font-size:10pt;"> under the Incyte collaboration and license agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, including the </font><font style="font-family:inherit;font-size:10pt;">$150.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> related to clinical trial activities performed. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Roche</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In December 2017, the Company entered into a research collaboration and license agreement with Roche to jointly discover and develop novel bispecific molecules to undisclosed targets.  During the research term, both companies will leverage their respective platforms, including the Company's DART platform and Roche's CrossMAb and DutaFab technologies to select a bispecific format and lead product candidate. Roche would then further develop and commercialize any such product candidate.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of this agreement, Roche received rights to use certain of the Company&#8217;s intellectual property rights to exploit collaboration compounds and products, and paid the Company an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> which was received in January 2018. The Company will also be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$370.0 million</font><font style="font-family:inherit;font-size:10pt;"> in potential milestone payments and royalties on future sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration and license agreement with Roche and determined that it is a revenue arrangement with multiple deliverables, or performance obligations.  The Company&#8217;s substantive performance obligations under the research collaboration and license agreement include the delivery of the license and activities during the research period.  The Company evaluated the collaboration and license agreement with Roche and determined that the license and research activities do not have value on a standalone basis and therefore represented one unit of accounting.   The </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> will be recognized over the expected research period, which is </font><font style="font-family:inherit;font-size:10pt;">30 months</font><font style="font-family:inherit;font-size:10pt;">. Each company will be responsible for their own expenses during the research period.  </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, the Company determined that each potential future development and regulatory milestone is substantive.  Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$4.0 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$6.0 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.&#160;</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:56px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Janssen</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">December 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration and license agreement with Janssen for the development and commercialization of MGD011 (also known as JNJ-64052781 or duvortuxizumab), a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD19 and CD3 for the potential treatment of B-cell hematological malignancies (MGD011 Agreement). The Company contemporaneously entered into an agreement with JJDC under which JJDC agreed to purchase </font><font style="font-family:inherit;font-size:10pt;">1,923,077</font><font style="font-family:inherit;font-size:10pt;"> new shares of the Company's common stock for proceeds of </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;Upon closing the transaction in January 2015, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Janssen as well as the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> investment in the Company's common stock.&#160;&#160; In August 2017, Janssen notified the Company that they were terminating the MGD011 Agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the MGD011 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize duvortuxizumab. Following the Company's submission of the Investigational New Drug (IND) application, Janssen became fully responsible for the development and commercialization of duvortuxizumab.&#160;&#160; </font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the MGD011 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the collaboration and license agreement included the delivery of an exclusive license and research and development services during the preclinical research period (through the filing of the IND for duvortuxizumab). &#160; The Company evaluated the MGD011 Agreement and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the relative BESP method to each deliverable.&#160; The BESP for the exclusive license was determined using a discounted cash flow model that includes Level 3 fair value measurements. The BESP for the research and development services was determined using third party evidence of other similar research and development arrangements, which are Level 2 fair value measurements.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the stock purchase agreement and the collaboration and license agreement as one arrangement and determined that the stock purchase price of </font><font style="font-family:inherit;font-size:10pt;">$39.00</font><font style="font-family:inherit;font-size:10pt;"> per share exceeded the fair value of the common stock by </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;">. This excess was recognized in the same manner as the upfront payment allocated to the license and preclinical research and development activities.&#160; Of the total arrangement consideration of </font><font style="font-family:inherit;font-size:10pt;">$125.0 million</font><font style="font-family:inherit;font-size:10pt;">, the Company allocated </font><font style="font-family:inherit;font-size:10pt;">$62.7 million</font><font style="font-family:inherit;font-size:10pt;"> to equity (representing the fair value of common stock purchased), </font><font style="font-family:inherit;font-size:10pt;">$62.3 million</font><font style="font-family:inherit;font-size:10pt;"> to the license and preclinical research and development activities, and a de minimis amount to the ongoing research and development activities.&#160; The Company submitted the IND application and therefore met its performance obligation during the year ended December&#160;31, 2015.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2015, Janssen dosed the first patient in an open-label Phase 1 study of duvortuxizumab which triggered a </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone to the Company.&#160; </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> revenue was recognized under the MGD011 Agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  During the years ended December&#160;31, 2016 and 2015, the Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$72.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD011 agreement. </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, the Company entered into a separate collaboration and license agreement with Janssen, a related party through ownership of the Company's common stock, for the development and commercialization of MGD015, a product candidate that incorporates the Company's proprietary DART technology to simultaneously target CD3 and an undisclosed tumor target for the potential treatment of various hematological malignancies and solid tumors (MGD015 Agreement). Under the MGD015 Agreement, the Company granted an exclusive license to Janssen to develop and commercialize MGD015.  The Company received a </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment from Janssen upon closing the transaction.&#160;In January 2018, Janssen notified the Company that they were terminating the MGD015 Agreement.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the MGD015 Agreement, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations.&#160; The Company's substantive performance obligations under the MGD015 Agreement included the delivery of an exclusive license and research and development services during the preclinical research period. &#160; The Company evaluated the MGD015 Agreement with Janssen and determined that the license and preclinical research and development activities each represented separate deliverables and were accounted for as two separate units of accounting.&#160; The Company concluded that the license had standalone value to Janssen and was separable from the research and development services because the license was sublicensable, there were no restrictions as to Janssen's use of the license and Janssen or other third parties have significant research capabilities in this field.&#160; Thus, the total arrangement consideration for these two deliverables was allocated using the BESP method to each deliverable.&#160; The BESP for the exclusive license was determined using information from the previous collaboration and license agreement with Janssen as well as other third party collaboration and license agreements, which are Level 2 fair value measurements. The BESP for the research and development services was determined using other similar research and development arrangements, which are also Level 2 fair value measurements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$75.8 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under the MGD015 Agreement.  Revenue recognized in </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> included the </font><font style="font-family:inherit;font-size:10pt;">$75.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront fee for the exclusive license.</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Takeda</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">May 2014</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a license and option agreement with Takeda for the development and commercialization of MGD010, a product candidate that incorporates the Company's proprietary DART technology to simultaneously engage CD32B and CD79B, which are two B-cell surface proteins.&#160;&#160;MGD010 is being developed for the treatment of autoimmune disorders.&#160; Upon execution of the agreement, Takeda made a non-refundable payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company.&#160;&#160;Takeda had an option to obtain an exclusive worldwide license for MGD010 following the completion of a pre-defined Phase 1a study.&#160; Following the announcement of its therapeutic area re-prioritization, Takeda gave formal notification in September 2016 that it did not intend to exercise this option.&#160; As a result of Takeda not exercising the option, the Company regained worldwide development and commercialization rights to MGD010. </font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of the license and option agreement with Takeda, the Company evaluated it and determined that it was a revenue arrangement with multiple deliverables, or performance obligations. The Company's substantive performance obligations under the license and option agreement included exclusivity, research and development services through the Phase 1a study and delivery of a future license for an initial research compound.&#160;&#160;The Company concluded that the MGD010 option was substantive and that the license fee payable upon exercise of the option was not a deliverable at the inception of the arrangement as there was considerable uncertainty that the option would be exercised. The Company determined that each potential future clinical and regulatory milestone was substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time.&#160;&#160;&#160;The Company determined that these performance obligations represent a single unit of accounting, because the exclusivity clause does not have stand-alone value to Takeda without the Company's technical expertise and development through the pre-defined Phase 1a study.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">After identifying the deliverables included within the arrangement, the Company determined its best estimate of selling price.&#160;&#160;The Company allocated </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the exclusivity clause to its technology and the research and development services and </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the exclusive license for the initial research compound.&#160;&#160;The Company's determination of best estimate of selling price for the research and development services relied upon other similar transactions.&#160;&#160;The Company relied upon the income approach (e.g., discounted future cash flows) to determine the value of the license of the to-be-delivered compound along with other similar license transactions with differing indications but similar stage of development. The portion of the up-front fee allocated to the MGD010 option was being recognized over an initial </font><font style="font-family:inherit;font-size:10pt;">24</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected period of development through the completion of a pre-defined Phase 1a study.&#160;&#160;During the first quarter of 2016, the Company determined that the development period would be extended by </font><font style="font-family:inherit;font-size:10pt;">eight months</font><font style="font-family:inherit;font-size:10pt;">, and prospectively adjusted the MGD010 option fee recognition period.&#160; The portion of the up-front fee allocated to the license for the initial research compound was deferred until the research collaboration and license option agreement was executed and the license delivered in September 2014.&#160; Upon the notification that Takeda would not exercise the option to obtain an exclusive worldwide license for MGD010 during the three months ended September 30, 2016, the Company's performance obligation to Takeda ceased, and the remaining deferred revenue under the MGD010 agreement was recognized in full.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> revenue under was recognized under this agreement during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$8.0 million</font><font style="font-family:inherit;font-size:10pt;"> under the MGD010 agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160; Revenue recognized during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> included a </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> milestone payment received upon initiation of a Phase 1a trial of MGD010.&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.&#160; </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Servier</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">September 2012</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a right-to-develop collaboration agreement with Servier and granted it options to obtain three separate exclusive licenses to develop and commercialize DART molecules, consisting of those designated by the Company as MGD006 (or flotetuzumab) (also known as S80880) and MGD007, as well as a third DART molecule, in all countries other than the United States, Canada, Mexico, Japan, South Korea and India.  During 2014, Servier exercised its exclusive option to develop and commercialize flotetuzumab, and during 2016 Servier notified the Company that it did not intend to exercise the option for the third DART molecule.  Servier retains the option to obtain a license for MGD007.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, Servier made a nonrefundable payment of </font><font style="font-family:inherit;font-size:10pt;">$20.0 million</font><font style="font-family:inherit;font-size:10pt;"> to the Company. In addition, the Company will be eligible to receive up to </font><font style="font-family:inherit;font-size:10pt;">$40.0 million</font><font style="font-family:inherit;font-size:10pt;"> in license fees, </font><font style="font-family:inherit;font-size:10pt;">$63.0 million</font><font style="font-family:inherit;font-size:10pt;"> in clinical milestone payments, </font><font style="font-family:inherit;font-size:10pt;">$188.0 million</font><font style="font-family:inherit;font-size:10pt;"> in regulatory milestone payments and </font><font style="font-family:inherit;font-size:10pt;">$420.0 million</font><font style="font-family:inherit;font-size:10pt;"> in sales milestone payments if Servier exercises the remaining available options and successfully develops, obtains regulatory approval for, and commercializes a product under each license. In addition to these milestones, the Company and Servier will share Phase 2 and Phase 3 development costs. The Company has determined that each potential future clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Under this agreement, Servier would be obligated to pay the Company from low double-digit to mid-teen royalties on net product sales in its territories.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the research collaboration agreement with Servier and determined that it is a revenue arrangement with multiple deliverables, or performance obligations. The Company concluded that each option is substantive and that the license fees for each option are not deliverables at the inception of the arrangement and were not issued with a substantial discount. The Company's substantive performance obligations under this research collaboration include an exclusivity clause to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the preclinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the initial upfront license payment was deferred and initially recognized ratably over a </font><font style="font-family:inherit;font-size:10pt;">29</font><font style="font-family:inherit;font-size:10pt;">-month period, which represented the expected development period. During 2014, the Company and Servier further refined the research plan related to the three DART molecules and as such, the development period was extended.&#160;&#160;Based on this revised development period, the Company prospectively adjusted its period of recognition of the upfront payment to a </font><font style="font-family:inherit;font-size:10pt;">75</font><font style="font-family:inherit;font-size:10pt;">-month period. The impact of this change in accounting estimate reduced revenue that would have been recognized in 2014 by </font><font style="font-family:inherit;font-size:10pt;">$3.7 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of Servier exercising its option in 2014, the Company received a </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> payment from Servier for its license to develop and commercialize flotetuzumab in its territories.&#160;&#160;Upon exercise of the option, the Company evaluated its performance obligations with respect to the license for flotetuzumab. The Company's substantive performance obligations under this research collaboration include an exclusive license to its technology, technical, scientific and intellectual property support to the research plan and participation on an executive committee and a research and development committee. The Company determined that the performance obligations with respect to the clinical development represent a single unit of accounting, since the license does not have stand-alone value to Servier without the Company's technical expertise and committee participation. As such, the </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;"> license fee was deferred and was being recognized ratably over a period of </font><font style="font-family:inherit;font-size:10pt;">82 months</font><font style="font-family:inherit;font-size:10pt;">, which represented the expected development period for flotetuzumab.&#160;&#160;During the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company and Servier determined that the expected development period should be extended to </font><font style="font-family:inherit;font-size:10pt;">124 months</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160;The impact of this change in accounting estimate reduced revenue that would have been recognized in 2017 by </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">. In accordance with the agreement, the Company and Servier will share costs incurred to develop flotetuzumab.&#160;&#160;Reimbursement of research and development expenses received in connection with this collaborative cost-sharing agreement is recorded as a reduction to research and development expense.&#160;&#160;During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> the Company recorded approximately </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> as an offset to research and development costs under this collaboration arrangement, respectively.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> the Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;">, and </font><font style="font-family:inherit;font-size:10pt;">$3.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, under this agreement.&#160;&#160;At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$8.5 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$11.1 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$3.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$7.8 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Boehringer</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">October 2010</font><font style="font-family:inherit;font-size:10pt;"> the Company entered into a collaboration and license agreement with Boehringer to discover, develop and commercialize multiple DART molecules that were to be evaluated during a five-year period that ended in </font><font style="font-family:inherit;font-size:10pt;">October 2015</font><font style="font-family:inherit;font-size:10pt;">. Under the terms of the agreement, the Company granted Boehringer an exclusive, worldwide, royalty-bearing, license under its intellectual property to research, develop, and market DART molecules generated under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the agreement, the Company received an upfront payment of </font><font style="font-family:inherit;font-size:10pt;">$15.0 million</font><font style="font-family:inherit;font-size:10pt;">. The Company subsequently received </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> annual maintenance payments. These maintenance payments were being recognized over the estimated period of development. The Company has the potential to earn additional milestone payments of approximately </font><font style="font-family:inherit;font-size:10pt;">$34.0 million</font><font style="font-family:inherit;font-size:10pt;"> related to preclinical and clinical development, </font><font style="font-family:inherit;font-size:10pt;">$88.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to regulatory milestones and </font><font style="font-family:inherit;font-size:10pt;">$82.5 million</font><font style="font-family:inherit;font-size:10pt;"> related to sales milestones for each of the two ongoing programs under this agreement. The Company determined that each potential future preclinical, clinical and regulatory milestone is substantive. Although sales milestones are not considered substantive, they are still recognized upon achievement of the milestone (assuming all other revenue recognition criteria have been met) because there are no undelivered elements that would preclude revenue recognition at that time. Boehringer would be required to pay the Company mid-single digit royalties on product sales.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the deliverables under the Boehringer agreement include the license, the research and development services to be performed by the Company, and the co-promotion/manufacturing services. The Company concluded that the co-promotional activities were optional and were subject to further negotiation upon reaching regulatory approval. As such, the co-promotional period is not included in the expected obligation period to perform services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company concluded that the undelivered element of research and development services had fair value. The Company concluded that the license did not have value on a standalone basis (e.g. absent the provision of the research and development services) and therefore did not represent a separate unit of accounting. The Company concluded that because the drug candidate had not yet been developed, the license was of no value to Boehringer without the ensuing research and development activities using the DART technology, which is proprietary to the Company. Likewise, Boehringer could not sell the license to another party (without the Company agreeing to provide the research and development activities for the other party). Therefore, the upfront license fee and research and development services were treated as a combined unit of accounting and recognized over the expected obligation period associated with the research and development services through October 2015, which represented the estimated period of development.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Boehringer also agreed to establish a joint research committee to facilitate the governance and oversight of the parties' activities under the agreements. Management considered whether participation on the joint committee may be a deliverable and determined that it was not a deliverable. However, had management considered participation on the joint committee as a deliverable, it would not have had a material impact on the accounting for the arrangement as the period of participation in this committee matched the obligation period for the research and development services.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> revenue under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">.  The Company recognized revenue of approximately </font><font style="font-family:inherit;font-size:10pt;">$12.5 million</font><font style="font-family:inherit;font-size:10pt;"> during the year ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> under this agreement, including a payment of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> for the achievement of preclinical milestones.  </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> revenue was deferred under this agreement at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Green Cross</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In </font><font style="font-family:inherit;font-size:10pt;">June 2010</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a collaboration agreement with Green Cross Corp. (Green Cross) for the development of the Company's anti-HER2 antibody margetuximab. This arrangement grants Green Cross an exclusive license to conduct specified Phase 1 and Phase 2 clinical trials and commercialize margetuximab in South Korea. In March 2014, the Company and Green Cross entered into an amendment to the original agreement, causing the terms of the original agreement to be materially modified.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon execution of the amendment, the Company became eligible to receive reimbursement for costs incurred for Phase 2 and Phase 3 clinical trials up to </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> as well as clinical development and commercial milestone payments of up to </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">. The Company determined that each potential clinical development and commercial milestone is substantive. The Company is also entitled to receive royalties on net sales of margetuximab in South Korea. The Company and Green Cross have formed a joint steering committee to coordinate and oversee activities on which the companies collaborate under the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluated the collaboration agreement with Green Cross and determined that it is a revenue arrangement with multiple deliverables or performance obligations. As a result of the material modification to the arrangement in March 2014, the Company reassessed the entire arrangement in accordance with the guidance provided by ASC 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Multiple Element Arrangements (Revenue Recognition)</font><font style="font-family:inherit;font-size:10pt;"> as the original agreement was accounted for prior to adopting ASU 2009-13</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">.</font><font style="font-family:inherit;font-size:10pt;"> The Company's substantive performance obligations under this agreement include an exclusive license to its technologies, research and development services, and participation in a joint steering committee. The Company concluded that the license and the reimbursements for research and development services do not have value on a standalone basis and therefore do not represent separate units of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The initial </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> upfront payment received by the Company upon execution of the original agreement is non-refundable; as such, there is no right of return for the license. Therefore, the upfront license fee and participation on the joint steering committee were treated as a combined unit of accounting and will be recognized over the term of the agreement through </font><font style="font-family:inherit;font-size:10pt;">June 2020</font><font style="font-family:inherit;font-size:10pt;">. Further, due to the fact the research and development services are not deemed to have stand-alone value, revenue for those services will be recognized over the entire term of the agreement (through June 2020). As a result of reassessing the arrangement in accordance with ASC 605-25, the Company was required to record an adjustment on the date of the material modification to reflect the revenue that would have resulted had the entity applied the requirements of ASC 605-25 from the inception of the agreement.&#160;&#160;As a result, the Company recorded an additional </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue during 2014.  The Company has received a total of </font><font style="font-family:inherit;font-size:10pt;">$5.5 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> for reimbursement of research and development services, which is also being recognized over the remaining term of the agreement.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognized revenues of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> milestones were achieved under this agreement during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.&#160; At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.2 million</font><font style="font-family:inherit;font-size:10pt;"> of revenue was deferred under this agreement, </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> of which was current and </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> of which was non-current.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">NIAID Contract</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company entered into a contract with the National Institute of Allergy and Infectious Diseases (NIAID), effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;15, 2015</font><font style="font-family:inherit;font-size:10pt;">,&#160;to perform product development and to advance up to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> DART molecules, including MGD014. Under this contract, the Company will develop these product candidates for Phase 1/2 clinical trials as therapeutic agents, in combination with latency reversing treatments, to deplete cells infected with human immunodeficiency virus (HIV) infection. This contract includes a base period of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;"> to support development of MGD014 through IND application submission with the FDA, as well as up to </font><font style="font-family:inherit;font-size:10pt;">$17.0 million</font><font style="font-family:inherit;font-size:10pt;"> in additional development funding via NIAID options. Should NIAID fully exercise such options, the Company could receive total payments of up to </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">. The total potential period of performance under the award is from September 15, 2015 through </font><font style="font-family:inherit;font-size:10pt;">September&#160;14, 2022</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended December&#160;31, 2017, NIAID exercised the first option in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company recognized revenue of </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in revenue under this contract during the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationAndLicenseAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922082752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Leases</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company leases manufacturing, office and laboratory space in Rockville, Maryland under </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> leases that have terms that expire between </font><font style="font-family:inherit;font-size:10pt;">2019</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2027</font><font style="font-family:inherit;font-size:10pt;"> unless renewed.&#160;&#160;During the year ended December&#160;31, 2017, the&#160;Company entered into an agreement to sublease a portion of the space it leases.  Under the terms of the sublease, the Company will receive a total of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;"> over the </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;"> month term.  </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> The Rockville leases include a lease executed in </font><font style="font-family:inherit;font-size:10pt;">July 2015</font><font style="font-family:inherit;font-size:10pt;"> for space that the Company uses as its headquarters with office and laboratory space and manufacturing space currently under construction.&#160;&#160; Under the terms of the lease, which commenced on </font><font style="font-family:inherit;font-size:10pt;">January&#160;1, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company received an assignment fee from the former tenant and a tenant improvement allowance from the landlord totaling </font><font style="font-family:inherit;font-size:10pt;">$5.1 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;&#160; In July 2017, the Company executed a lease amendment for its headquarters building which extends the term of the lease to August 2027, restructures the rent due under the lease, and provides for an additional tenant improvement allowance from the landlord of </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, which was received during the third quarter.  The assignment fee and tenant improvement allowances have been recorded as deferred rent and are being recognized over the new lease term.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company also leases office and laboratory space in South San Francisco under a lease that expires on </font><font style="font-family:inherit;font-size:10pt;">February&#160;28, 2018</font><font style="font-family:inherit;font-size:10pt;">.  During the year ended December&#160;31, 2016, the Company entered into a sublease agreement for a portion of the South San Francisco space (see Note 8).  As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, future payments to be received by the Company under this sublease total approximately </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">.  In </font><font style="font-family:inherit;font-size:10pt;">April 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company entered into a </font><font style="font-family:inherit;font-size:10pt;">72</font><font style="font-family:inherit;font-size:10pt;">-month lease commencing in </font><font style="font-family:inherit;font-size:10pt;">December 2017</font><font style="font-family:inherit;font-size:10pt;"> for office and laboratory space which will replace our current South San Francisco location.&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the leases contain rent escalation clauses and certain leases contain rent abatements.&#160;&#160;For financial reporting purposes, rent expense is charged to operations on a straight-line basis over the term of the lease.&#160;&#160;As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had recorded a deferred rent liability of </font><font style="font-family:inherit;font-size:10pt;">$12.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$6.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Rent expense for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$3.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,484</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Contingencies</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">From time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company does not believe it is currently subject to any material matters where there is at least a reasonable possibility that a material loss may be incurred.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657620880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Employee Benefit Plan</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2002, the Company established the MacroGenics 401(k) Plan (the Plan) for its employees under Section 401(k) of the IRC. Under this Plan, all employees at least </font><font style="font-family:inherit;font-size:10pt;">21</font><font style="font-family:inherit;font-size:10pt;"> years of age are eligible to participate in the Plan, starting on the first day of each month. Employees may contribute up to </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> of their salary, subject to government maximums.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Employees are </font><font style="font-family:inherit;font-size:10pt;">100%</font><font style="font-family:inherit;font-size:10pt;"> vested in their contributions to the Plan. The Company's contribution to the Plan, as determined by the Board of Directors, is discretionary. The Company's contributions to the Plan totaled </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> for the years ended </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765538592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Information (Unaudited)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:4px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quarterly Financial Information (unaudited)</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762854256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation and Principles of Consolidation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation and Principles of Consolidation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The consolidated financial statements include the accounts of MacroGenics, Inc. and its wholly owned subsidiary, MacroGenics UK Limited.&#160; All intercompany accounts and transactions have been eliminated in consolidation. The Company currently operates in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> operating segment. Operating segments are defined as components of an enterprise about which separate discrete information is available for the chief operating decision maker, or decision making group, in deciding how to allocate resources and assessing performance. The Company views its operations and manages its business in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> segment, which is developing monoclonal antibody-based therapeutics for cancer, autoimmune and infectious diseases.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with generally accepted accounting principles (GAAP) requires the Company to make estimates and judgments in certain circumstances that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. In preparing these consolidated financial statements, management has made its best estimates and judgments of certain amounts included in the financial statements, giving due consideration to materiality. On an ongoing basis, the Company evaluates its estimates, including those related to revenue recognition, fair values of assets, stock-based compensation, income taxes, preclinical study and clinical trial accruals and other contingencies. Management bases its estimates on historical experience or on various other assumptions that it believes to be reasonable under the circumstances. Actual results could differ from these estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents and Marketable Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash, Cash Equivalents and Marketable Securities</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company considers all investments in highly liquid financial instruments with a maturity of 90 days or less at the date of purchase to be cash equivalents. Cash and cash equivalents includes investments in money market funds with commercial banks and financial institutions, securities issued by the U.S. government and its agencies, Government Sponsored Enterprise agency debt obligations and corporate debt obligations. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:33px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company carries marketable securities classified as available-for-sale at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company records unrealized gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as a separate component of stockholders' equity. Realized gains or losses on available-for-sale securities are determined using the specific identification method and the Company includes net realized gains and losses in other income (expense).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. The Company considers factors including: the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value.&#160; An impairment loss is recognized at the time the Company determines that a decline in the fair value below its cost basis is other-than-temporary. There were </font><font style="font-family:inherit;font-size:10pt;color:#252525;">no</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> unrealized losses at </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> that the Company determined to be other-than-temporary.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Accounts Receivable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounts Receivable</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable that management has the intent and ability to collect are reported in the consolidated balance sheets at outstanding amounts, less an allowance for doubtful accounts. The Company writes off uncollectible receivables when the likelihood of collection is remote.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates the collectability of accounts receivable on a regular basis. The allowance, if any, is based upon various factors including the financial condition and payment history of customers, an overall review of collections experience on other accounts and economic factors or events expected to affect future collections experience. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> allowance was recorded as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, as the Company has a history of collecting on all outstanding accounts.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company's financial instruments consist of cash and cash equivalents, marketable securities, accounts receivable, accounts payable and accrued expenses.</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The carrying amount of accounts receivable, accounts payable and accrued expenses are generally considered to be representative of their respective fair values because of their short-term nature.&#160;</font><font style="font-family:inherit;font-size:10pt;"> The Company accounts for recurring and non-recurring fair value measurements in accordance with the Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurements and Disclosures</font><font style="font-family:inherit;font-size:10pt;"> (ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and disclosed in one of the following three categories:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1 &#8211; Fair value is determined by using unadjusted quoted prices that are available in active markets for identical assets and liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2 &#8211; Fair value is determined by using inputs other than Level 1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:12px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3 &#8211; Fair value is determined by inputs that are unobservable and not corroborated by market data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</font></div></td></tr></table><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company evaluates financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them each reporting period. This determination requires the Company to make subjective judgments as to the significance of inputs used in determining fair value and where such inputs lie within the ASC 820 hierarchy.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of Level 2 securities is determined from </font><font style="font-family:inherit;font-size:10pt;color:#252525;">market pricing and other observable market inputs for similar securities obtained from various third-party data providers. These inputs either represent quoted prices for similar assets in active markets or have been derived from observable market data.  There were no transfers between Level 1 and Level 2 investments during the periods presented.  </font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentration of Credit Risk</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, marketable securities and accounts receivable. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">We maintain our cash and money market funds with financial institutions that are federally insured. While balances deposited in these institutions often exceed Federal Deposit Insurance Corporation limits, we have not experienced any losses on related accounts to date.&#160;</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;color:#252525;">Our investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer.</font><font style="font-family:inherit;font-size:10pt;"> The counterparties are various corporations, financial institutions and government agencies of high credit standing.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment and Software</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property, Equipment and Software</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software are stated at cost. Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation or amortization are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the recoverability of its long-lived assets in accordance with the provisions of ASC 360, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Property, Plant and Equipment</font><font style="font-family:inherit;font-size:10pt;">. ASC 360 requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of the long-lived asset is measured by a comparison of the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset or asset group. If carrying value exceeds the sum of undiscounted cash flows, the Company then determines the fair value of the underlying asset group. Any impairment to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. Assets to be disposed of are reported at the lower of the carrying amount or fair value, less costs to sell. As of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company determined that there were </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> impaired assets and had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> assets held-for-sale.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that are expected to be in effect when the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized as income in the period that such tax rate changes are enacted. The measurement of a deferred tax asset is reduced, if necessary, by a valuation allowance if it is more likely than not that some portion or all of the deferred tax asset will not be realized. Financial statement recognition of a tax position taken or expected to be taken in a tax return is determined based on a more-likely-than-not threshold of that position being sustained. If the tax position meets this threshold, the benefit to be recognized is measured as the largest amount that is more likely than not to be realized upon ultimate settlement. The Company's policy is to record interest and penalties related to uncertain tax positions as a component of income tax expense.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company enters into collaboration and license agreements with collaborators for the development of monoclonal antibody-based therapeutics to treat cancer and other complex diseases. The terms of these agreements contain multiple deliverables which may include (i) licenses, or options to obtain licenses, to the Company's technological platforms, such as its Fc Optimization and DART&#174; technologies, (ii) rights to future technological improvements, (iii) research and development activities to be performed on behalf of the collaborator or as part of the collaboration, and (iv) the manufacture of preclinical or clinical materials for the collaborator. Payments to the Company under these agreements may include nonrefundable license fees, option fees, exercise fees, payments for research and development activities, payments for the manufacture of preclinical or clinical materials, license maintenance payments, payments based upon the achievement of certain milestones and royalties on product sales. Other benefits to the Company of these agreements include the right to sell products resulting from the collaborative efforts of the parties in specific geographic territories. The Company follows the provisions of FASB ASC Topic 605-25, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition &#8211; Multiple-Element Arrangements</font><font style="font-family:inherit;font-size:10pt;">, and FASB ASC Topic 605-28, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition&#8211;Milestone Method</font><font style="font-family:inherit;font-size:10pt;">, in accounting for these agreements. In order to account for these agreements, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator. The consideration received is allocated among the separate units of accounting, and the applicable revenue recognition criteria are applied to each of the separate units.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the periods presented, the Company had the following two types of agreements: 1) exclusive development and commercialization licenses to use the Company's technology and/or certain other intellectual property to develop compounds against specified targets (referred to herein as exclusive licenses); and 2) option/research agreements to secure on established terms, development and commercialization licenses to therapeutic product candidates to collaborator-selected targets developed by the Company during an option period (referred to herein as right-to-develop agreements).</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There are no performance, cancellation, termination or refund provisions in any of the arrangements that contain material financial consequences to the Company.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exclusive Licenses</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The deliverables under an exclusive license agreement generally include the exclusive license to the Company's DART technology with respect to a specified antigen target, and may also include deliverables related to rights to future technological improvements, research and preclinical development activities to be performed on behalf of the collaborator. In some cases, the Company may have an option to participate in the co-development of product candidates that result from such agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Generally, exclusive license agreements contain nonrefundable terms for payments and, depending on the terms of the agreement, provide that the Company will (i) at the collaborator's request, provide research and preclinical development services at negotiated prices which are generally consistent with what other third parties would charge, (ii) earn payments upon the achievement of certain milestones, (iii) earn royalty payments, and (iv) in some cases grant the Company an option to participate in the development and commercialization of products that result from such agreements. Royalty rates may vary over the royalty term depending on the Company's intellectual property rights and whether the Company exercises any co-development and co-commercialization rights.  The Company does not directly control when any collaborator will achieve milestones or become liable for royalty payments.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">When entering into a new collaboration arrangement or materially modifying an existing arrangement, the Company must identify the deliverables included within the agreement and evaluate which deliverables represent separate units of accounting based on the achievement of certain criteria, including whether the delivered element has stand-alone value to the collaborator.&#160;&#160;The selling prices of deliverables under an arrangement may be derived using third-party evidence (TPE), or a best estimate of selling price (BESP), if vendor specific objective evidence (VSOE) is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the license agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions, company-specific factors, and factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the license. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In determining the separate units of accounting, the Company evaluates whether the exclusive license has standalone value to the collaborator based on consideration of the relevant facts and circumstances for each arrangement. Factors considered in this determination include the research and development capabilities of the collaborator and the availability of relevant research expertise in the marketplace. In addition, the Company considers whether or not (i) the collaborator could use the license for its intended purpose without the receipt of the remaining deliverables, (ii) the value of the license was dependent on the undelivered items and (iii) the collaborator or other vendors could provide the undelivered items. If the Company concludes that the license has stand-alone value and therefore will be accounted for as a separate unit of accounting, the Company then determines the estimated selling prices of the license and all other units of accounting based on market conditions, similar arrangements entered into by third parties, and entity-specific factors such as the terms of the Company's previous collaboration agreements, recent preclinical and clinical testing results of therapeutic product candidates that use the Company's technology platforms, the Company's pricing practices and pricing objectives, the likelihood that technological improvements will be made, the likelihood that technological improvements made will be used by the Company's collaborators and the nature of the research services to be performed on behalf of its collaborators and market rates for similar services. Total arrangement consideration is then allocated to each of the units of accounting using the relative-selling-price method.&#160;&#160;If facts and circumstances dictate that the exclusive license does not have stand-alone value, then the related payments are deferred and revenue is recognized throughout the period of performance.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management reassesses the period of performance over which the Company recognizes deferred upfront license fees and makes adjustments as appropriate in the period in which a change in the estimated period of performance is identified. In the event a collaborator elects to discontinue development of a specific product candidate under a single target license, but retains its right to use the Company's technology to develop an alternative product candidate to the same target or a target substitute, the Company would cease amortization of any remaining portion of the upfront fee until there is substantial preclinical activity on another product candidate and its remaining period of substantial involvement can be estimated. In the event that a single target license was to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination or through the remaining substantial involvement in the wind down of the agreement.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upfront payments on exclusive licenses may be recognized upon delivery of the license if facts and circumstances dictate that the license has stand-alone value from the undelivered elements, which generally include rights to future technological improvements, research services and the manufacture of preclinical and clinical materials.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue related to research and preclinical development services that represent separate units of accounting as they are performed, as long as there is persuasive evidence of an arrangement, the fee is fixed or determinable, and collection is reasonably assured. The Company recognizes revenue related to the rights to future technological improvements over the estimated term of the applicable license.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company typically performs research activities and preclinical development services, including generating and engineering product candidates, on behalf of its licensees during the early evaluation and preclinical testing stages of drug development under its exclusive licenses. The Company records amounts received for research materials produced or services performed as revenue from collaborative agreements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's license agreements have milestone payments which for reporting purposes are aggregated into three categories: (i) development milestones, (ii) regulatory milestones, and (iii) sales milestones. Development milestones are typically payable when a product candidate initiates or advances into different clinical trial phases. Regulatory milestones are typically payable upon submission for marketing approval with the U.S. Food and Drug Administration (FDA) or other countries' regulatory authorities or on receipt of actual marketing approvals for the compound or for additional indications. Sales milestones are typically payable when annual sales reach certain levels.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the inception of each agreement that includes milestone payments, the Company evaluates whether each milestone is substantive and at risk to both parties on the basis of the contingent nature of the milestone. This evaluation includes an assessment of whether (i) the consideration is commensurate with either (a) the entity's performance to achieve the milestone, or (b) the enhancement of the value of the delivered item(s) as a result of a specific outcome resulting from the entity's performance to achieve the milestone, (ii) the consideration relates solely to past performance and (iii) the consideration is reasonable relative to all of the deliverables and payment terms within the arrangement. The Company evaluates factors such as the scientific, regulatory, commercial and other risks that must be overcome to achieve the respective milestone, the level of effort and investment required to achieve the respective milestone and whether the milestone consideration is reasonable relative to all deliverables and payment terms in the arrangement in making this assessment.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-refundable development and regulatory milestones that are expected to be achieved as a result of the Company's efforts during the period of substantial involvement are considered substantive and are recognized as revenue upon the achievement of the milestone, assuming all other revenue recognition criteria are met. Milestones that are not considered substantive because the Company does not contribute effort to their achievement are generally recognized as revenue upon achievement of the milestone, as there are no undelivered elements remaining and no continuing performance obligations, assuming all other revenue recognition criteria are met.&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Right-to-Develop Agreements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company's right-to-develop agreements provide collaborators with an exclusive option to obtain licenses to develop and commercialize in specified geographic territories product candidates developed by the Company under agreed upon research and preclinical development product programs. The product candidates resulting from each program are all directed to a specific target selected by the collaborator. Under these agreements, fees may be due to the Company (i) at the inception of the arrangement (referred to as "upfront" fees or payments), (ii) the selection of a target for a program, (iii) upon the exercise of an option to acquire a development and commercialization license (referred to as exercise fees or payments earned) for a program, or (iv) some combination of all of these fees.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accounting for right-to-develop agreements is dependent on the nature of the options granted to the collaborator. Options are considered substantive if, at the inception of a right-to-develop agreement, the Company is at risk as to whether the collaborator will choose to exercise the options to secure development and commercialization licenses. Factors that are considered in evaluating whether options are substantive include the overall objective of the arrangement, the benefit the collaborator might obtain from the agreement without exercising the options, the cost to exercise the options relative to the total upfront consideration, and the additional financial commitments imposed on the collaborator as a result of exercising the options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to a product program are considered substantive, the Company does not consider the development and commercialization licenses to be a deliverable at the inception of the agreement, and therefore defers any upfront payments received and recognizes this revenue over the period during which the collaborator could elect to exercise options for development and commercialization licenses. These periods are specific to each collaboration agreement. If a collaborator selects a target for a product program, any substantive option fee is deferred and recognized over the life of the option. For right-to-develop agreements that include multiple deliverables, the Company determines the selling prices of deliverables under the arrangement using TPE or a BESP, if VSOE is not available. The objective of BESP is to determine the price at which the Company would transact a sale if the element within the right-to-develop agreement was sold on a standalone basis. Establishing BESP involves management's judgment and considers multiple factors, including market conditions and company-specific factors, including those factors contemplated in negotiating the agreements, as well as internally developed models that include assumptions related to market opportunity, discounted cash flows, estimated development costs, probability of success and the time needed to commercialize a product candidate pursuant to the right-to-develop agreement. In validating the BESP, management considers whether changes in key assumptions used to determine the BESP will have a significant effect on the allocation of the arrangement consideration between the multiple deliverables. Deliverables under the arrangement are separate units of accounting if (i) the delivered item has value to the customer on a standalone basis and (ii) if the arrangement includes a general right of return relative to the delivered item, delivery or performance of the undelivered item is considered probable and substantially within the Company's control. The arrangement consideration that is fixed or determinable at the inception of the arrangement is allocated to the separate units of accounting based on their relative selling prices. The appropriate revenue recognition model is applied to each element and revenue is accordingly recognized as each element is delivered. Management exercises significant judgment in determining whether a deliverable is a separate unit of accounting.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a collaborator exercises an option and acquires a development and commercialization license to a product program, the Company attributes the exercise fee to the development and commercialization license. The Company determines the selling price of the option license, upon exercise, through management's best estimate using the process for an exclusive license as described above.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Upon exercise of an option to acquire a development and commercialization license, the Company would also attribute any remaining deferred option fee, in addition to the consideration received for the license upon exercise of the option, to the development and commercialization license.&#160;&#160;The Company then applies the multiple-element revenue recognition criteria to the development and commercialization license and other deliverables, if any, to determine the appropriate revenue recognition method. This model is consistent with the Company's accounting policy for upfront payments on exclusive licenses (discussed above).&#160;&#160;In the event a right-to-develop agreement were to be terminated, the Company would recognize as revenue any portion of the upfront fee that had not previously been recorded as revenue, but was classified as deferred revenue, at the date of such termination. The Company's right-to-develop agreements have been determined to contain substantive options.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For right-to-develop agreements where the options to secure development and commercialization licenses to product programs are not considered substantive, the Company considers the development and commercialization licenses to be a deliverable at the inception of the agreement and applies the multiple-element revenue recognition criteria to determine the appropriate revenue recognition. The Company does not directly control when any collaborator will exercise its options for development and commercialization licenses.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Costs</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenditures are expensed as incurred. Research and development costs primarily consist of employee related expenses, including salaries and benefits, expenses incurred under agreements with contract research organizations, investigative sites and consultants that conduct the Company's clinical trials, the cost of acquiring and manufacturing clinical trial materials and other allocated expenses, license fees for and milestone payments related to in-licensed products and technologies, stock-based compensation expense, and costs associated with non-clinical activities and regulatory approvals.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Right-to-develop agreements may contain cost-sharing provisions whereby the Company and the collaborator share the cost of research and development activities.&#160; Reimbursement of research and development expenses received in connection with these agreements is recorded as a reduction of such expenses.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Comprehensive loss represents net loss adjusted for the change during the periods attributed to unrealized gains and losses on available-for-sale securities.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-based Compensation</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock-based payments are accounted for in accordance with the provisions of ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation &#8211; Stock Compensation</font><font style="font-family:inherit;font-size:10pt;">. The fair value of stock-based payments is estimated, on the date of grant, using the Black-Scholes model. The resulting fair value is recognized ratably over the requisite service period, which is generally the vesting period of the option.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For all time-vesting awards granted, expense is amortized using the straight-line attribution method. For awards that contain a performance condition, expense is amortized using the accelerated attribution method. Recognition of stock-based compensation expense is based on the value of the portion of stock-based awards that is ultimately expected to vest during the period.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company utilizes the Black-Scholes model for estimating fair value of its stock options granted. Option valuation models, including the Black-Scholes model, require the input of highly subjective assumptions, and changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss Per Share</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.  </font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Standards</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the (FASB issued Accounting Standards Update (ASU) No. 2014-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606) </font><font style="font-family:inherit;font-size:10pt;">(ASU 2014-09).  ASU 2014-09 will eliminate transaction- and industry-specific revenue recognition guidance under current GAAP and replace it with a principle-based approach for determining revenue recognition. ASU 2014-09 will require that companies recognize revenue based on the value of transferred goods or services as they occur in the contract. The ASU also will require additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, including significant judgments and changes in judgments and assets recognized from costs incurred to obtain or fulfill a contract.  ASU 2014-09 is effective for annual reporting periods beginning after December 15, 2017 and interim periods therein, with early adoption permitted for interim and annual reporting periods beginning after December 15, 2016.  ASU 2014-09 may be adopted either retrospectively or on a modified retrospective basis&#160;whereby ASU 2014-09 would be applied to new contracts and existing contracts with remaining performance obligations&#160;as of the effective date, with a cumulative catch-up adjustment recorded to beginning retained&#160;earnings at the effective date for existing contracts with remaining performance obligations.  In 2016, the FASB issued ASU 2016-08, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">, ASU 2016-10,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing</font><font style="font-family:inherit;font-size:10pt;">, and ASU 2016-12, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;"> &#160;to provide supplemental adoption guidance and clarification to ASU 2014-09.  The effective date for these new standards is the same as the effective date and transition requirements for ASU 2014-09.  The Company will adopt the new standard in the first quarter of 2018 using the modified retrospective method.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has substantially completed extensive contract specific reviews to determine the impact of the new standard on its historical and prospective revenue recognition. Due to the unique contract terms of certain agreements, the Company is still in the process of finalizing its analysis of those agreements.  Upon completion of the Company&#8217;s analysis, it will determine the cumulative effect of initially applying the new standard (if any).  The Company is also finalizing its accounting policy and designing and implementing the necessary changes to processes and controls to account for revenue under the new standard. Based on the Company's timeline and planned resources, the Company anticipates completing its implementation in connection with its first quarter 2018 interim financial statements.</font></div><div style="line-height:120%;padding-bottom:8px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-02) that provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors.&#160; ASU 2016-02 requires a lessee to recognize assets and liabilities on the balance sheet for operating leases and changes many key definitions, including the definition of a lease. ASU 2016-02 includes a short-term lease exception for leases with a term of 12 months or less, in which a lessee can make an accounting policy election not to recognize lease assets and lease liabilities. Lessees will continue to differentiate between finance leases (previously referred to as capital leases) and operating leases, using classification criteria that are substantially similar to the previous guidance. ASU 2016-02 is effective for fiscal years beginning after December&#160;15, 2018, and interim periods within those fiscal years, with earlier application permitted. Entities are required to use a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest comparative period in the financial statements. The Company is currently evaluating the effect of the standard on its consolidated financial statements and related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:6px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March&#160;2016, the FASB issued ASU 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Improvements</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;"> (ASU 2016-09). This amendment addresses several aspects of the accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities and classification on the statement of cash flows. ASU 2016-09 is effective for fiscal years beginning after December 15, 2016, including interim periods within that year. </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The Company adopted ASU 2016-09 effective January 1, 2017 and has elected to continue to estimate the number of stock-based awards expected to vest, as permitted by ASU 2016-09, rather than electing to account for forfeitures as they occur.  </font><font style="font-family:inherit;font-size:10pt;">The adoption of this standard did not have a material impact on the Company's financial statements or related disclosures.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has evaluated all other ASUs issued through the date the consolidated financials were issued and believes that the adoption of these will not have a material impact on the Company's consolidated financial statements.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the Tax Cuts and Jobs Act of 2017 (the Tax Act) was signed into law making significant changes to the Internal Revenue Code, which included how the U.S. imposes income tax on multinational corporations.  Key changes in the Tax Act which are relevant to us, and generally effective January 1, 2018, include a flat corporate income tax rate of 21% to replace the marginal rates that range from 15% to 35% and the elimination of the corporate alternative minimum tax.  The Tax Act also imposes limits on executive compensations and interest expense deductions, while permitting the immediate expensing for the cost of new investments in certain property acquired after September 27, 2017.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On December 22, 2017, the SEC issued Staff Accounting Bulletin No. 118 (SAB 118) to address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Tax Act.  SAB 118 allows registrants to include a provisional amount to account for the implications of the Tax Act where a reasonable estimate can be made and requires the completion of the accounting no later than one year from the date of the enactment of the Tax Act, or December 22, 2018. </font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">ASC 740 requires changes in tax rates and tax laws to be accounted for in the period of enactment in continuing operations.  Accordingly, of significance, we recorded a provisional estimate for the re-measurement of our U.S. deferred tax assets and liabilities to 21%.  This change in value of these deferred tax assets and liabilities, which is provisional, was offset by a corresponding change in our valuation allowance, thus no tax expense or benefit was recorded.  The ultimate impact may differ from these provisional amounts, possibly materially, due to, among other things, additional information necessary to complete the computation and analysis thereof, additional regulatory guidance that may be issued, and actions we may take as a result of the Tax Act.  The accounting is expected to be complete by December 22, 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=SL6953423-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5212-111524<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5093-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775425344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurement Financial Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial assets measured at fair value on a recurring basis were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,990</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,990</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,418</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155,910</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61,512</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">94,398</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$62.5 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:38%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:2%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurement at December&#160;31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Quoted Prices in</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Active Markets for</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Identical Assets</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant Other</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Observable Inputs</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Significant</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unobservable</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inputs</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S Treasury securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets measured at fair value </font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">(a)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">251,666</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,781</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204,885</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Total assets measured at fair value at </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;"> includes approximately </font><font style="font-family:inherit;font-size:10pt;">$50.8 million</font><font style="font-family:inherit;font-size:10pt;"> reported in cash and cash equivalents on the balance sheet.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Summary of Percentage of Customer Concentration</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those collaborators that represent more than 10% of total revenue earned in the periods indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:68%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Incyte Corporation (Incyte)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">96%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen Biotech, Inc. (Janssen)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">85%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">72%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Boehringer Ingelheim GmbH (Boehringer)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table includes those counterparties that represent more than 10% of accounts receivable at the date indicated:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Janssen</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Government</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19%</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">* Balance is less than 10%</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock', window );">Estimated Useful Lives</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.90243902439025%;border-collapse:collapse;text-align:left;"><tr><td colspan="2" rowspan="1"></td></tr><tr><td style="width:50%;" rowspan="1" colspan="1"></td><td style="width:50%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10 years</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Laboratory and office equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5 years</font></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shorter of lease term or useful life</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Loss Per Common Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic and diluted loss per common share is computed as follows (in thousands except share and per share data):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Numerator:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss used for calculation of basic and diluted EPS</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(19,626</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58,528</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,140</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Denominator:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, basic</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effect of dilutive securities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options and restricted stock units</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average shares outstanding, diluted</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36,095,080</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34,685,274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31,801,645</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.54</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.69</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following common stock equivalents were excluded from the calculation of diluted net loss per share because their effect would have been anti-dilutive:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:60%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,146,064</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Property plant and equipment estimated useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentEstimatedUsefulLifeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6442-108592<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6327-108592<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916661104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Available-For-Sale Securities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#252525;">Available-for-sale marketable securities as of </font><font style="font-family:inherit;font-size:10pt;color:#252525;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> and </font><font style="font-family:inherit;font-size:10pt;color:#252525;">2016</font><font style="font-family:inherit;font-size:10pt;color:#252525;"> were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,995</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,989</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,998</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,991</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,462</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77,414</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,455</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(63</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">93,394</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gains</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Gross</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Unrealized</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Losses</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">U.S. Treasury securities</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,826</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,825</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Government-sponsored enterprises</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,764</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(10</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Corporate debt securities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,376</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(127</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">166,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(138</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All of the Company's available-for-sale securities held at December 31, 2017 had maturity dates of less than one year.  </font><font style="font-family:inherit;font-size:10pt;color:#252525;">The contractual maturities of the available-for-sale marketable securities as of December&#160;31, 2016 were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:69%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:4%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Amortized Cost</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature in one year or less</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,985</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">192,898</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Mature between one and five years</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,986</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,966</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">200,884</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6642888960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software consists of the following (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,261</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,520</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Software</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,111</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and office equipment</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">656</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,549</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,208</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,525</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,807</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Construction in progress</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32,800</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">78,902</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43,784</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(28,919</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,823</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property, equipment and software, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49,983</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,961</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6909386400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following stock-based compensation amounts were recognized for the periods indicated (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,388</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,778</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,623</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,356</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,387</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,224</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,744</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,165</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,847</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Employee Stock Options Award Valuation Assumptions</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of each option award is estimated on the date of grant using the Black-Scholes option-pricing model using the assumptions in the following table:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67% - 68%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64% - 69%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">73% - 75%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.9% - 2.3%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.2% - 2.4%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.6% - 2.1%</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.25 years</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Stock Option and Restricted Stock Unit Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option and restricted stock unit (RSU) activity for </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Weighted-Average</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Remaining</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Contractual Term</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(Years)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Aggregate Intrinsic Value</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,838,060</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18.93</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,246,225</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20.05</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options exercised or RSUs vested</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(253,036</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.16</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited or expired</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(326,607</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24.26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding, December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,504,642</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.79</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7.0</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,343</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017:</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercisable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,910,171</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17.65</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,495</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vested and expected to vest</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,337,015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19.60</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.9</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share Based Compensation Stock Options And Restricted Stock Units Activity Table [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ScheduleOfShareBasedCompensationStockOptionsAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6908636224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Company's Deferred Income Tax Assets (Liabilities)</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The significant components of the Company's deferred income tax assets (liabilities) were as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Federal U.S. net operating loss carryforward</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50,346</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">75,377</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State net operating loss carryforward</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,583</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,284</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,829</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,708</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19,855</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred rent</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,385</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,982</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,098</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Depreciation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">155</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,926</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,847</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,085</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113,258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">130,250</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(112,453</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(128,844</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">805</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,406</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenditures</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Gross deferred income tax liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(805</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,406</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net deferred income tax asset/(liability)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Reported Estimated Income Tax Benefit</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the reported estimated income tax benefit to the amount that would result by applying the U.S. federal statutory tax rate to the net income is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">United States federal tax at statutory rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6,869</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,489</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(7,049</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">State taxes (net of federal benefit)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(735</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,116</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(897</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred income tax adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">173</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">661</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred state blended rate adjustments</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(485</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(32</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(493</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred federal rate change reduction in corporate rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39,447</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,455</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,551</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(3,296</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Orphan drug credit, net</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,853</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(571</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(106</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other permanent items</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">276</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">145</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Equity-based compensation</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,067</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,997</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,102</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Change in valuation allowance</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(24,000</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,444</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10,103</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Income tax expense/(benefit)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:62%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Year Ended December 31,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:2px solid #000000;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Beginning balance</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,047</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases for current year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">569</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">308</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">357</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Increases/(decreases) for prior year tax positions</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(268</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></td><td style="vertical-align:bottom;border-bottom:2px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Ending balance</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,395</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,465</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,425</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=96868398&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6611731600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Changes in Lease Exit Liability</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Changes in the lease exit liability are as follows (in thousands): </font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,713</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments </font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,822</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,891</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal payments and other adjustments (net of sublease receipts)</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,593</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrual balance at December&#160;31, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">298</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765538592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock', window );">Schedule of Minimum Future Lease Payments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future minimum lease payments under noncancelable operating leases as of </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2017</font><font style="font-family:inherit;font-size:10pt;"> are as follows (in thousands):</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:88%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,574</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,342</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,775</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2021</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,743</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2022</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,885</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Thereafter</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,484</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45,803</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for lessee's operating leases. Includes, but is not limited to, description of lessee's operating lease, existence and terms of renewal or purchase options and escalation clauses, restrictions imposed by lease, such as those concerning dividends, additional debt, and further leasing, rent holidays, rent concessions, or leasehold improvement incentives and unusual provisions or conditions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 1,3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164451&amp;loc=d3e36991-112694<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=82913245&amp;loc=d3e12069-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLesseeDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918050032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Company's Consolidated Quarterly Results of Operations</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1st Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2nd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3rd Quarter</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:2px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4th Quarter</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(in thousands, except per share data)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,055</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,666</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,663</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">152,359</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37,655</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(40,654</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(47,043</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">105,727</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.87</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.08</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.28</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,846</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80,673</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,255</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,106</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss)</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(30,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,464</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(33,846</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34,783</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, basic</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.17</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net income (loss) per share, diluted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.88</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.12</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.97</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775419856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance recorded</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset', window );">Impaired assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup', window );">Assets held-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84173941&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets held-for-sale that are not part of a disposal group.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 15<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77912953&amp;loc=d3e400-110220<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount on the books of the entity of the impaired asset to be disposed of by a method other than sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairedAssetsToBeDisposedOfByMethodOtherThanSaleCarryingValueOfAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776157968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="nump">$ 50,800<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">155,910<span></span>
</td>
<td class="nump">251,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">46,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">8,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">29,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">78,418<span></span>
</td>
<td class="nump">166,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">46,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">61,512<span></span>
</td>
<td class="nump">46,781<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets for Identical Assets, Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">94,398<span></span>
</td>
<td class="nump">204,885<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">3,990<span></span>
</td>
<td class="nump">8,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">11,990<span></span>
</td>
<td class="nump">29,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs, Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">78,418<span></span>
</td>
<td class="nump">166,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | U.S Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs, Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27232-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776201424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details) - Sales revenue, net - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_IncyteCorporationMember', window );">Incyte Corporation (Incyte)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="nump">96.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember', window );">Janssen Biotech, Inc. (Janssen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember', window );">Boehringer Ingelheim GmbH (Boehringer)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of all significant revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763381408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details) - Customer Concentration Risk - Accounts receivable<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Les Laboratoires Servier and Institut de Recherches Servier (Servier)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">31.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Janssen Biotech, Inc. (Janssen)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of significant accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_ServierMGA271Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgnx_USGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgnx_USGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762848400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember', window );">Laboratory and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Leasehold improvements</a></td>
<td class="text">Shorter of lease term or useful life<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68071081&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_LaboratoryAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762789920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss used for calculation of basic and diluted EPS</a></td>
<td class="nump">$ 105,727<span></span>
</td>
<td class="num">$ (47,043)<span></span>
</td>
<td class="num">$ (40,654)<span></span>
</td>
<td class="num">$ (37,655)<span></span>
</td>
<td class="num">$ (34,783)<span></span>
</td>
<td class="num">$ (33,846)<span></span>
</td>
<td class="nump">$ 40,464<span></span>
</td>
<td class="num">$ (30,363)<span></span>
</td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average shares outstanding, basic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,095,080<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock options and restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average shares outstanding, diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,095,080<span></span>
</td>
<td class="nump">34,685,274<span></span>
</td>
<td class="nump">31,801,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (0.54)<span></span>
</td>
<td class="num">$ (1.69)<span></span>
</td>
<td class="num">$ (0.63)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1500-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661612944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock options</a></td>
<td class="nump">4,504,642<span></span>
</td>
<td class="nump">3,838,060<span></span>
</td>
<td class="nump">4,146,064<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776245856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 93,455<span></span>
</td>
<td class="nump">$ 200,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(63)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">93,394<span></span>
</td>
<td class="nump">200,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">3,995<span></span>
</td>
<td class="nump">4,826<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">3,989<span></span>
</td>
<td class="nump">4,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">Government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">11,998<span></span>
</td>
<td class="nump">29,764<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">11,991<span></span>
</td>
<td class="nump">29,759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule of Available-for-sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">77,462<span></span>
</td>
<td class="nump">166,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(127)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 77,414<span></span>
</td>
<td class="nump">$ 166,300<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized gain in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of unrealized loss in accumulated other comprehensive income (AOCI) on investments in debt securities classified as available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776185504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Available-For-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities', window );">Available-for-sale securities, other than temporary impairment losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Mature in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,985,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Mature between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,981,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">93,455,000<span></span>
</td>
<td class="nump">200,966,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Mature in one year or less</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">192,898,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Mature between one and five years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,986,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">93,394,000<span></span>
</td>
<td class="nump">200,884,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest Income, Other</a></td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the cost of debt securities, which are categorized neither as held-to-maturity nor trading, net of adjustments including accretion, amortization, collection of cash, previous other-than-temporary impairments recognized in earnings (less any cumulative-effect adjustments recognized, as defined), and fair value hedge accounting adjustments, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the second fiscal year through the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after adjustments of available-for-sale debt securities at cost, maturing in the next fiscal year following the latest fiscal year. Adjustments include, but are not limited to, accretion, amortization, collection of cash, previous other-than-temporary impairments (OTTI) recognized in earnings less cumulative-effect adjustments, and fair value hedge accounting adjustments. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of available-for-sale debt securities maturing in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount by which the fair value of an investment in debt and equity securities categorized as Available-for-sale is less than the amortized cost basis or carrying amount of that investment at the balance sheet date and the decline in fair value is deemed to be other than temporary, before considering whether or not such amount is recognized in earnings or other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossesInvestmentsAvailableforsaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762945120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Software (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 78,902,000<span></span>
</td>
<td class="nump">$ 43,784,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">32,800,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(28,919,000)<span></span>
</td>
<td class="num">(25,823,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and software, net</a></td>
<td class="nump">49,983,000<span></span>
</td>
<td class="nump">17,961,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions', window );">Property and equipment purchased but not yet paid</a></td>
<td class="nump">9,615,000<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">7,000,000<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">2,261,000<span></span>
</td>
<td class="nump">2,520,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">5,111,000<span></span>
</td>
<td class="nump">2,352,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">656,000<span></span>
</td>
<td class="nump">897,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">20,549,000<span></span>
</td>
<td class="nump">20,208,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, equipment and software</a></td>
<td class="nump">$ 17,525,000<span></span>
</td>
<td class="nump">$ 17,807,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PropertyPlantAndEquipmentNonCashAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PropertyPlantAndEquipmentNonCashAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=mgnx_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776438320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2017</div></th>
<th class="th"><div>Apr. 26, 2017</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="nump">125,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,525,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption', window );">Additional shares sold under over-allotments option to underwriter (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">528,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 141,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,244<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 203,467<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember', window );">Johnson &amp; Johnson Innovation JJDC, Inc,</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember', window );">Undesignated Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Undesignated preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Undesignated preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Undesignated preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Undesignated preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Common stock purchase price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember', window );">At The Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of shares issued or sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">599,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockMaximumAmountAvailableForIssuance', window );">Common stock maximum amount available for issuance</a></td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockMaximumAmountAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Maximum Amount Available For Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockMaximumAmountAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares to underwriters for exercise of over allotment option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_StockIssuedDuringPeriodSharesToUnderwritersForExerciseOfOverAllotmentOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JohnsonAndJohnsonDevelopmentCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgnx_UndesignatedPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgnx_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762847344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Employee Stock Purchase Plan (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>May 18, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,244<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 203,467<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember', window );">2017 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent', window );">Common stock discount percent</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair market value to purchase shares</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Common stock purchased by employees (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee Stock Purchase Plan, Maximum Annual Contributions Per Employee, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeeStockPurchasePlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share instruments newly issued under a share-based compensation plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_TwoThousandSixteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775598368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">84 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Feb. 28, 2003</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">4,504,642<span></span>
</td>
<td class="nump">3,838,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 19.79<span></span>
</td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 14,744<span></span>
</td>
<td class="nump">$ 12,165<span></span>
</td>
<td class="nump">$ 7,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member', window );">Equity Incentive Plan 2003</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,051,644<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,336,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">955,296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member', window );">Stock Incentive Plan 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation, number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease', window );">Increased number of shares authorized (in shares)</a></td>
<td class="nump">6,769,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Share-based compensation arrangement by share-based payment award, options, outstanding, number (in shares)</a></td>
<td class="nump">3,549,346<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 24.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance', window );">Stock reserved for future issuance (in shares)</a></td>
<td class="nump">1,960,168<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan', window );">Percentage of common stock share outstanding</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,388<span></span>
</td>
<td class="nump">5,778<span></span>
</td>
<td class="nump">3,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 7,356<span></span>
</td>
<td class="nump">$ 6,387<span></span>
</td>
<td class="nump">$ 4,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Capital Shares Minimum Increase In Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CommonStockCapitalSharesMinimumIncreaseInSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of shares of company's common stock outstanding for increase in shares reserved for issuance under stock plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PercentageOfSharesOfCompanysCommonStockOutstandingForIncreaseInSharesReservedForIssuanceUnderStockPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares authorized after increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorizedAfterIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_EquityIncentivePlan2003Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgnx_StockIncentivePlan2013Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776265824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Option Pricing Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">67.00%<span></span>
</td>
<td class="nump">64.00%<span></span>
</td>
<td class="nump">73.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">69.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Options granted, maximum term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776212448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">December 31, 2016</a></td>
<td class="nump">3,838,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Granted</a></td>
<td class="nump">1,246,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised or RSUs vested</a></td>
<td class="num">(253,036)<span></span>
</td>
<td class="num">(526,715)<span></span>
</td>
<td class="num">(374,214)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited or expired</a></td>
<td class="num">(326,607)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">December 31, 2017</a></td>
<td class="nump">4,504,642<span></span>
</td>
<td class="nump">3,838,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable</a></td>
<td class="nump">2,910,171<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest</a></td>
<td class="nump">4,337,015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">December 31, 2016</a></td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted</a></td>
<td class="nump">20.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised or RSUs vested</a></td>
<td class="nump">2.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited or expired</a></td>
<td class="nump">24.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">December 31, 2017</a></td>
<td class="nump">19.79<span></span>
</td>
<td class="nump">$ 18.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable</a></td>
<td class="nump">17.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest</a></td>
<td class="nump">$ 19.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average remaining contractual term, Outstanding</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Exercisable</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-average remaining contractual term, Vested and expected to vest</a></td>
<td class="text">6 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value, Outstanding</a></td>
<td class="nump">$ 18,343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate intrinsic value, Exercisable</a></td>
<td class="nump">17,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value, Vested and expected to vest</a></td>
<td class="nump">$ 18,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">253,036<span></span>
</td>
<td class="nump">526,715<span></span>
</td>
<td class="nump">374,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash proceeds from exercise of stock options</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted (in dollars per share)</a></td>
<td class="nump">$ 12.53<span></span>
</td>
<td class="nump">$ 15.17<span></span>
</td>
<td class="nump">$ 20.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value</a></td>
<td class="nump">$ 4,200<span></span>
</td>
<td class="nump">$ 10,800<span></span>
</td>
<td class="nump">$ 10,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">14,600<span></span>
</td>
<td class="nump">$ 11,600<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost related to non-vested stock-based compensation arrangements</a></td>
<td class="nump">$ 20,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763921664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Provision for federal or state income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal U.S. net operating loss carryforward</a></td>
<td class="nump">50,346,000<span></span>
</td>
<td class="nump">75,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="nump">7,551,000<span></span>
</td>
<td class="nump">6,583,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development credit, net</a></td>
<td class="nump">21,284,000<span></span>
</td>
<td class="nump">12,829,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther', window );">Orphan drug credit, net</a></td>
<td class="nump">21,708,000<span></span>
</td>
<td class="nump">19,855,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Deferred rent</a></td>
<td class="nump">3,385,000<span></span>
</td>
<td class="nump">2,497,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">2,982,000<span></span>
</td>
<td class="nump">5,098,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Depreciation</a></td>
<td class="nump">155,000<span></span>
</td>
<td class="nump">2,926,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5,847,000<span></span>
</td>
<td class="nump">5,085,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred income tax assets</a></td>
<td class="nump">113,258,000<span></span>
</td>
<td class="nump">130,250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(112,453,000)<span></span>
</td>
<td class="num">(128,844,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred income tax assets</a></td>
<td class="nump">805,000<span></span>
</td>
<td class="nump">1,406,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenditures</a></td>
<td class="num">(805,000)<span></span>
</td>
<td class="num">(1,406,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred income tax liabilities</a></td>
<td class="num">(805,000)<span></span>
</td>
<td class="num">(1,406,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset/(liability)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation', window );">Remaining portion of net operating losses</a></td>
<td class="nump">226,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount', window );">Previously unrecognized excess tax benefits</a></td>
<td class="nump">18,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount', window );">Previously unrecognized excess tax benefits, tax effected portion</a></td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember', window );">U.S. Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards</a></td>
<td class="nump">239,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">US Federal tax credits carry forward</a></td>
<td class="nump">42,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount', window );">Net operating loss for limited use</a></td>
<td class="nump">13,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">U.S. Federal Government | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount', window );">Net operating losses limited for use utilized on an annual basis</a></td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Share-based Compensation, Excess Tax Benefit, Tax Effected Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationSharebasedCompensationExcessTaxBenefitTaxEffectedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsAnnualLimitationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss which are limited for use, utilized on a annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsAnnualLimitationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net operating loss carryforward, which are limited for use over the range of years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsLimitationsOnUseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OperatingLossCarryforwardsNotSubjectToLimitation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards not subject to limitation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OperatingLossCarryforwardsNotSubjectToLimitation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible tax credit carryforwards, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=mgnx_DomesticTaxAuthorityandStateandLocalJurisdictionMemberMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6933955616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">United States federal tax at statutory rate</a></td>
<td class="num">$ (6,869)<span></span>
</td>
<td class="num">$ (20,489)<span></span>
</td>
<td class="num">$ (7,049)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes (net of federal benefit)</a></td>
<td class="num">(735)<span></span>
</td>
<td class="num">(3,116)<span></span>
</td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount', window );">Deferred income tax adjustments</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">173<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount', window );">Deferred state blended rate adjustments</a></td>
<td class="num">(485)<span></span>
</td>
<td class="num">(32)<span></span>
</td>
<td class="num">(493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Deferred federal rate change reduction in corporate rate</a></td>
<td class="nump">39,447<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credit, net</a></td>
<td class="num">(8,455)<span></span>
</td>
<td class="num">(2,551)<span></span>
</td>
<td class="num">(3,296)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther', window );">Orphan drug credit, net</a></td>
<td class="num">(1,853)<span></span>
</td>
<td class="num">(571)<span></span>
</td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other permanent items</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Equity-based compensation</a></td>
<td class="nump">2,067<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">1,102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24,000)<span></span>
</td>
<td class="nump">24,444<span></span>
</td>
<td class="nump">10,103<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense/(benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred tax adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxRateReconciliationDeferredTaxAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to deferred state blended rate adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EffectiveIncomeTaxReconciliationStateDeferredTaxesAdjustmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible equity-based compensation costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919739184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 2,465,000<span></span>
</td>
<td class="nump">$ 2,425,000<span></span>
</td>
<td class="nump">$ 2,047,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases/(decreases) for current year tax positions</a></td>
<td class="nump">569,000<span></span>
</td>
<td class="nump">308,000<span></span>
</td>
<td class="nump">357,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases for prior year tax positions</a></td>
<td class="nump">361,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases for prior year tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(268,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">3,395,000<span></span>
</td>
<td class="nump">2,465,000<span></span>
</td>
<td class="nump">2,425,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Gross unrecognized tax benefits</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Unrecognized interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6916805184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability Lease Exit Liability - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 06, 2017</div></th>
<th class="th"><div>May 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ReductionInResearchAndDevelopmentExpense', window );">Reduction in research and development expense</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountOfImmaterialErrorCorrection', window );">Reduction of research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember', window );">Raven Biotechnologies Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountOfImmaterialErrorCorrection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of immaterial error correction made during period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountOfImmaterialErrorCorrection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ReductionInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction In Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ReductionInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgnx_RavenBiotechnologiesIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6637495856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Lease Exit Liability - Changes in Lease Exit Liability (Details) - Contract termination - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual beginning balance</a></td>
<td class="nump">$ 1,891<span></span>
</td>
<td class="nump">$ 4,713<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Principal payments and other adjustments (net of sublease receipts)</a></td>
<td class="num">(1,593)<span></span>
</td>
<td class="num">(2,822)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Accrual ending balance</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 1,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=27011515&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_ContractTerminationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776506800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements Collaboration and Other Agreements,  Incyte Corporation (Details) - Incyte MGA012 Agreement - Incyte Corporation (Incyte) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount', window );">Clinical trial activities selling price amount</a></td>
<td class="nump">$ 4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">151.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount', window );">Clinical trial activities performed, revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement', window );">Potential development and regulatory milestone payments</a></td>
<td class="nump">420.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement', window );">Potential commercial milestone payments</a></td>
<td class="nump">$ 330.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsfromRoyaltiesPercent', window );">Potential proceeds from royalties percent</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Commercial Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Development and Regulatory Milestone Payments Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialDevelopmentandRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsfromRoyaltiesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Royalties, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsfromRoyaltiesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Multiple-deliverable Arrangements, Services Performed, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_RevenueRecognitionMultipledeliverableArrangementsServicesPerformedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 25<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68059916&amp;loc=SL6750900-111635<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_IncyteMGA012AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_IncyteCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_IncyteCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764308000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,202<span></span>
</td>
<td class="nump">$ 4,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637<span></span>
</td>
<td class="nump">$ 10,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement', window );">Potential milestone payments and royalties on future sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 370,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member', window );">F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (Roche) | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential Milestone Payments and Royalties on Future Sales under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialMilestonePaymentsandRoyaltiesonFutureSalesunderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_F.HoffmannLaRocheLtd.andHoffmannLaRocheInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775600880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details) - Janssen Biotech Inc. - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2016</div></th>
<th class="th"><div>Jan. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember', window );">Janssen MGD011 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,923,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds of stock sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of common stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PremiumReceivedOnStockPurchase', window );">Premium received on stock purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalConsideration', window );">Total consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountAllocatedToEquity', window );">Amount allocated to equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AmountAllocatedToLicenseAndRD', window );">Amount allocated to license and R&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ClinicalMilestoneEarnedDuringPeriod', window );">Clinical milestone earned during period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 72.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember', window );">Janssen MGD015 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 75.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountAllocatedToEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of consideration allocated to equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountAllocatedToEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AmountAllocatedToLicenseAndRD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of consideration allocated to license and pre-clinical research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AmountAllocatedToLicenseAndRD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ClinicalMilestoneEarnedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical milestone earned during the period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ClinicalMilestoneEarnedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PremiumReceivedOnStockPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which purchase price exceeds fair value for common stock purchased by collaborator.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PremiumReceivedOnStockPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total consideration received under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD011AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_JanssenBiotechIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=mgnx_JanssenMGD015AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776211792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Takeda (Details) - Takeda Pharmaceutical Company Limited (Takeda) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2014</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Takeda MGD010 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFeeRecognitionPeriod', window );">Option exercise fee recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember', window );">Research Collaboration and License Option Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontFeeAllocatedToAgreement', window );">Amount allocated to agreement</a></td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFeeRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to option exercise fee recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFeeRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontFeeAllocatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of upfront fee allocated to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontFeeAllocatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_TakedaMGD010AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_TakedaMGD010AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ResearchCollaborationAndLicenseOptionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764072144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Servier (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2012</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,202,000<span></span>
</td>
<td class="nump">$ 4,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637,000<span></span>
</td>
<td class="nump">10,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OriginalPeriodOfDevelopment', window );">Original period of development</a></td>
<td class="text">29 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_UpfrontPaymentRecognitionPeriod', window );">Expected period of development</a></td>
<td class="text">75 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact', window );">Change in accounting estimate, current year impact</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_OptionExerciseFeeRecognitionPeriod', window );">Option exercise fee recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">124 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">82 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts', window );">Offset to research and development costs under collaboration arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,500,000<span></span>
</td>
<td class="nump">11,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">3,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,200,000<span></span>
</td>
<td class="nump">$ 7,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember', window );">Servier | Maximum | Servier DART</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialLicenseFee', window );">Potential License Fee</a></td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement', window );">Potential clinical milestone payments under agreement</a></td>
<td class="nump">63,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Potential regulatory milestone payments under agreement</a></td>
<td class="nump">188,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement', window );">Potential sales milestone payments under agreement</a></td>
<td class="nump">$ 420,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ChangeInAccountingEstimateCurrentYearImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the effect of a change in accounting estimate on current year operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ChangeInAccountingEstimateCurrentYearImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to collaboration arrangement offset to research and development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_CollaborationArrangementOffsetToResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment from collaborator upon exercise of option to develop and commercialize product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OptionExerciseFeeRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to option exercise fee recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OptionExerciseFeeRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_OriginalPeriodOfDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Original recognition period for development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_OriginalPeriodOfDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential clinical milestone payments company could earn under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential license fee company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential regulatory milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_PotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total potential sales milestones company could earn under agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_PotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_UpfrontPaymentRecognitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to upfront payment recognition period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_UpfrontPaymentRecognitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_ServierMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_ServierMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=mgnx_ServierDARTMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761050192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Boehringer (Details) - Boehringer Ingelheim GmbH (Boehringer)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>USD ($) </div>
<div>Payment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfAnnualMaintenancePaymentReceived', window );">Number of annual maintenance payments received | Payment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement', window );">Clinical milestone payments</a></td>
<td class="nump">$ 34,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement', window );">Additional potential regulatory milestone payments under agreement</a></td>
<td class="nump">88,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement', window );">Additional potential sales milestone payments under agreement</a></td>
<td class="nump">$ 82,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential regulatory milestone payments available to be earned under a collaboration arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialRegulatoryMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential sales milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialSalesMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfAnnualMaintenancePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of annual maintenance payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfAnnualMaintenancePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_BoehringerIngelheimMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764373760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, Green Cross (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,202,000<span></span>
</td>
<td class="nump">$ 4,261,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,637,000<span></span>
</td>
<td class="nump">10,045,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NonRefundableUpfrontFees', window );">Non-refundable upfront payment</a></td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification', window );">Adjustment to revenue from contract material modification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsFromResearchAndDevelopmentServices', window );">Proceeds from research and development services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue included in current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue included in long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember', window );">Green Cross | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AggregatePotentialFutureCostReimbursement', window );">Aggregate potential future cost reimbursement</a></td>
<td class="nump">5,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement', window );">Clinical and commercial milestone payments</a></td>
<td class="nump">$ 2,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential clinical and commercial milestone payments available to be earned under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalPotentialClinicalAndCommercialMilestonePaymentsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the adjustment to revenue under the accounting standards codification.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdjustmentToRevenueUnderAccountingStandardsCodification</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AggregatePotentialFutureCostReimbursement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate potential future cost reimbursement from collaborator</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AggregatePotentialFutureCostReimbursement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NonRefundableUpfrontFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial fee received from collaboration or license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NonRefundableUpfrontFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromResearchAndDevelopmentServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Research And Development Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsFromResearchAndDevelopmentServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_GreenCrossCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764712256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and Other Agreements, NIAID Contract (Details) - NIAID<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 15, 2015 </div>
<div>USD ($) </div>
<div>Molecule</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement', window );">Commercialization of molecules | Molecule</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_FundedValueOfBasePeriod', window );">Base period value</a></td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement', window );">Proceeds from additional development funding options under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Recognized revenue under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaboration and Other Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement', window );">Additional development funding options</a></td>
<td class="nump">17,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_TotalPotentialValueUnderAgreement', window );">Total potential value</a></td>
<td class="nump">$ 24,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional funding available under agreement at counterparty's option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_AdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_FundedValueOfBasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Funded value of base period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_FundedValueOfBasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of molecules to be developed and commercialized as per collaboration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Additional Development Funding Options Under Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_ProceedsFromAdditionalDevelopmentFundingOptionsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_TotalPotentialValueUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to total potential value under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_TotalPotentialValueUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgnx_NationalInstituteOfAllergyAndInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776248016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 21, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 06, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 30, 2017</div></th>
<th class="th">
<div>Jul. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_NumberOfLease', window );">Number of leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals', window );">Future sublease payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lessee leasing arrangements, term of operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 months<span></span>
</td>
<td class="text">72 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromTenantAllowance', window );">Lease incentives</a></td>
<td class="num">$ (7,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCredit', window );">Deferred rent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,300<span></span>
</td>
<td class="nump">$ 6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Future minimum rental payments required under all non-cancelable operating leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,574<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,803<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_NumberOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of lease during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_NumberOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative difference between the rental payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense over the term of the leased property by the lessor or lessee, respectively.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39896-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractually required future rental payments receivable on noncancelable subleasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueFutureMinimumSubleaseRentals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6911353744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan', window );">Eligible age to participate in plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution to salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage', window );">Percentage of employee vested contribution</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined contribution plan, employer discretionary contribution amount</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage vested of employee's contributions to defined contribution plan</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_DefinedContributionPlanEmployeesContributionVestedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to minimum eligible age of employee to participate in benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgnx_EmployeesEligibleAgeToParticipateInBenefitPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgnx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6764646384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Information (Unaudited) (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 152,359<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
<td class="nump">$ 1,666<span></span>
</td>
<td class="nump">$ 2,055<span></span>
</td>
<td class="nump">$ 5,106<span></span>
</td>
<td class="nump">$ 3,255<span></span>
</td>
<td class="nump">$ 80,673<span></span>
</td>
<td class="nump">$ 2,846<span></span>
</td>
<td class="nump">$ 157,742<span></span>
</td>
<td class="nump">$ 91,880<span></span>
</td>
<td class="nump">$ 100,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 105,727<span></span>
</td>
<td class="num">$ (47,043)<span></span>
</td>
<td class="num">$ (40,654)<span></span>
</td>
<td class="num">$ (37,655)<span></span>
</td>
<td class="num">$ (34,783)<span></span>
</td>
<td class="num">$ (33,846)<span></span>
</td>
<td class="nump">$ 40,464<span></span>
</td>
<td class="num">$ (30,363)<span></span>
</td>
<td class="num">$ (19,626)<span></span>
</td>
<td class="num">$ (58,528)<span></span>
</td>
<td class="num">$ (20,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic (in dollars per share)</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="nump">$ 1.17<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 2.80<span></span>
</td>
<td class="num">$ (1.28)<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (1.08)<span></span>
</td>
<td class="num">$ (1.00)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="num">$ (0.88)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=96948231&amp;loc=d3e4984-109258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>82
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["OO>NKW[Q\870=W KW^AOP!02P,$%     @  8%;3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
MLR+7E$8D19_(+;KD$3BU20TR$S\(G8:8:E < J0),9:AAOBTQJP1X!-]M[X(
MR-^-B/>K;YH]5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J
M-2S%UGB5P/&MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZ<TT#PE"\D^DJ1
MCVFS(Z=T)LWH,QK!1J\;=8=HTCQZ_@7YG#4*')$;'0)G&[-&(81IN_ >KR2.
MFJW"$2M"/F(9-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.
M$9)>-T(^8LZ+D!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]07
M2N0/)J<_Z3(T!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!
M_]':-\*K^(+ .7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7
M<LW(QU2ODRG8.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD
M6R4)RU3393>*$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W
M<DOJMI2^M28X2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-M
MNIW<.CB>F)&Y"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(
M\J(A[J&&F,_#0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R
M4E5@,5O& RN0HGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>
M9;'!51W/55ORL+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4X
MOT4SMA*7&+SCYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5
MYYN<KGHB=OJ7=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(C
ME1P&%A<RY%#NDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>
MTB42%(JP# 4A%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+
MA=OB5,V[&KXF8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y
M,M\Y<-LZW@->YA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,
M?-2K6J5D*Q$_2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:
M,]6+K#F-"F]!U4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_
M 5!+ P04    "  !@5M,TP,7#IH"  "<"0  &    'AL+W=O<FMS:&5E=',O
M<VAE970Q+GAM;'U6[8ZC(!1]%>,#C(*?;=HF_<AF-]E-FMGL[&_:TFI&Q05:
M9]]^ 1W7@>O\4<!S[N'"N<*J8_Q5%)1*[ZVN&K'V"RG;91"(<T%K(IY82QOU
MY<IX3:3J\EL@6D[)Q9#J*L!AF 8U*1M_LS)C1[Y9L;NLRH8>N2?N=4WXWQVM
M6+?VD?\^\%S>"JD'@LVJ)3?ZD\I?[9&K7C!&N90U;43)&H_3Z]K?HN4!99I@
M$"\E[<2D[>E43HR]ZLZWR]H/]8QH1<]2AR#J]:![6E4ZDIK'GR&H/VIJXK3]
M'OV+25XE<R*"[EGUN[S(8NWGOG>A5W*OY#/KOM(AH<3WANR_TP>M%%S/1&F<
M627,TSO?A63U$$5-I29O_;MLS+OKOR3I0(,)>"#@D8#C3PG10(A& OJ<$ ^$
MV"($?2IF;0Y$DLV*L\[C_?:V1+L(+6.U^F<]:!;;?%/+(]3H8Q.N@H<.,R!V
M/0)/$&A$!"KV*( A@1UVZ/BCP-Y%1!\1!Q<1PU.(P!PC0X\F] 2FQR ]-O1X
M0D^M)7(1&2R0@ *)0\\M 1>Q@ 524"!UZ,C>90 RL\T9*)&Y?&N?=STD,9"F
M=T*(9A8J!T5R5\2RR@Z S'AE 4HL7'YB20"0%)9 (5QSH1LALZLN=%8+(9Q$
M\8QUT4QY(U?*-A>$F;$7 FM\B[ 3 3N_$0 SXS $ES&*W BVQR#,G I<[<@M
M9FR;#,+,N S!)8_<BL:VSR#,G-'@ND=N56/+:/L!,S5:E"Y0GB=X1@O^ 2#W
M#X MIQT&3#K16D1V2L'DZ*HIOYEK@?#.[-Z8.\ED=+QZ;+$Y^O[#^WO+#\)O
M92.\$Y/J #7'W)4Q2=5<PB>5<:&N2F.GHE>IFYEJ\_Z^T'<D:X>[4#!>R#;_
M %!+ P04    "  !@5M,?5X$B_X#  #"$@  &    'AL+W=O<FMS:&5E=',O
M<VAE970R+GAM;'V8VXZC1A"&7\7B?A>J^@ ]LBT%1U$B)=)HHTVN&;L]MA:,
M \QX\_9I#F,Y5=5[8P/^J^LOZ/XH]_K6=M_ZD_?#ZGM37_I-<AJ&ZU.:]ON3
M;ZK^<WOUE_#+L>V::@BGW6O:7SM?'::@IDXQRVS:5.=+LEU/UYZ[[;I]&^KS
MQ3]WJ_ZM::KNW]+7[6V30/)QX<OY]32,%]+M^EJ]^C_]\/7ZW(6S]#[*X=SX
M2W]N+ZO.'S?)3_"T4U/ I/CK[&_]P_%J+.6E;;^-)[\=-DDV.O*UWP_C$%7X
M>O<[7]?C2,''/\N@R3WG&/AX_#'Z+U/QH9B7JO>[MO[[?!A.FZ1(5@=_K-[J
MX4M[^]4O!9EDM53_NW_W=9"/3D*.?5OWT^=J_]8/;;.,$JPTU??Y^WR9OF_+
M^!]A<@ N 7@/ /W# +4$*!*0SLZF4G^NAFJ[[MK;JIN?UK4:)P4\J7 S]^/%
MZ=Y-OX5J^W#U?8MNG;Z/XRR2<I;@H^3_BAU7J.PN24/^NPD43> 4KQ[C08Y7
M8KR:XO5C/+%8SA([22YS$0 YYJ02+BMTY@K9C!;-:&Y&$3.SQ#QD<4HY3;QP
M%3@L8F:,:,9P,R1-:7@:936QO.,JS*V6K5C1BN56#+%B61(%!H@30:0+)3O)
M12<Y=V*)DYPG*>@MX9H\B]R10O11<!]D/I8%]X&(#W-@ML)E6(0)E<MNG.C&
M<3<D3>E8&NT<NR]<!;FSD04-F8REC+MA7,I8HHR"B4MR5]B(E0@A@5G1&;4"
MO&:;,4P**F5=Q(V,2D#N!J@;Y+,F5P5[4)(. &UD,8$,7U",WAHC(\C$!(Y,
MRI\2. U1,S8(*N6<B;B1D0F<F9HR$S@.56$*9D=@JP45@03(W 0.3DW!"1R*
M.?+YQU4:HPM39B=P>&H*3^!DA$Q39DDJ!;'5(!,4.$(U12@(<&0 %41@7&PA
MR  %3E!:= D2' TUPT6Q=DJF)W)Z:DI/Y&C4+C?4BR##7&61!8XR0I$CU%"$
MH@A'^D+<2;(LTY$ECI%^DT.4HJ1$#L? 1D,9*LAT82,O7I0)BKQ_-;1_730_
M>MD)$HQUBRB3&#F):<4E<L;FVE(D[0291@.QB2.S& U[MY@(/5&F)W)ZTCE>
MHM!26D?KD?K."*U09B=R=AK*3N14M&'>Y>QA<YT)PNCSEOF)G)^&\A,Y&C]9
M^J:31$7L6<OX1(Y/0_&)G(R?%*"B#=E.$J+#'"*S1\D@51RDAH)4"81T#FGS
MO)-TMLA-[)^NC%+%46HI2A?-X[]8L?^3=%+_ESYL)HR[.W]4W>OYTJ]>VF%H
MFVGWX-BV@P]C9I]#?2=?'>XGM3\.XV$>CKMY5V4^&=KKLF.4WK>MMO\!4$L#
M!!0    (  &!6TP]9SOGZ $  /4$   8    >&PO=V]R:W-H965T<R]S:&5E
M=#,N>&ULC93=CILP$(5?!?D!8O,7T@B0NE15*[52M%7;:P>&@-;&U';"]NUK
M&Q81@MIR$7OL<V:^ <?I(.2+:@"T]\I9IS+4:-T?,59E YRJG>BA,SNUD)QJ
M$\H+5KT$6CD39S@@9(\Y;3N4IV[M)/-47#5K.SA)3UTYI_+W$S Q9,A';PO/
M[:71=@'G:4\O\ WT]_XD383G+%7+H5.MZ#P)=8;>^\<BMGHG^-'"H!9SSW9R
M%N+%!I^K#!$+! Q*;3-0,]R@ ,9L(H/Q:\J)YI+6N)R_9?_H>C>]G*F"0K"?
M;:6;#!V05T%-KTP_B^$33/W$R)N:_P(W8$9N24R-4C#E?KWRJK3@4Q:#PNGK
M.+:=&X=Q)TXFV[8AF S!;/"COQK"R1"N#'@D<ZU^H)KFJ12#)\>/U5-[)OQC
M:%YF:1?=NW-[IEME5F_YWD_QS>:9)$^C)%A(@GM%\:@(R2S!IOX,$6Q"!,X?
M+B&";7^XZ0^=/UKZPU43HR1QDLY)R(ZL.BW^(;HCB39)HD>2:$4R2N)%$3^(
MB7M6./^CO&.*-YGB1Z9XQ10_5 KWA_@=29(5TH8P.B1D3Y(5$5X<0'LA?*7R
MTG;*.PMMSK([<;40&DQ2LC/Y&G,'S0&#6MMI8N9R_">.@1;]=,G@^:;+_P!0
M2P,$%     @  8%;3&'?3M=W P  ZPT  !@   !X;"]W;W)K<VAE971S+W-H
M965T-"YX;6Q]5VUOHS@0_BN([UML8QM3)9&:H-6=="=5N[K;SS1Q$K2 <T":
MO7^_YJ4IG1GZ)8#S/#//C.T9>W5SS<_V;&T7_*K*NEV'YZZ[/$91NS_;*F\?
MW,76_I^C:ZJ\\Y_-*6HOC<T/ ZDJ(\&8CJJ\J,/-:AA[;C8K=^W*HK;/3=!>
MJRIO_M_:TMW6(0_?!KX5IW/7#T2;U24_V>^V^^?RW/BOZ&[E4%2V;@M7!XT]
MKL,G_IAQTQ,&Q+^%O;6S]Z /Y<6YG_W'GX=UR'I%MK3[KC>1^\>KW=FR["UY
M'?]-1L.[SYXX?W^S_G4(W@?SDK=VY\H?Q:$[KT,3!@=[S*]E]\W=_K!30"H,
MINC_LJ^V]/!>B?>Q=V4[_ ;[:]NY:K+BI53YK_%9U,/S-ME_H]$$,1'$G<#U
MIX1X(L3O!/DI04X$"0C1&,J0FRSO\LVJ<;>@&:?WDO>KB#]*G_U]/S@D>_C/
MIZ?UHZ\;K5?1:V]G@FQ'B)A!^!T1>>-W#X+RL!6(+CXZV&%$S#Y",@S1"2TB
M)L.,!WX\YQN:+TF^'/ARSD]!FD:('B#UF":E% ?9W&&8T<J E&08E:;QDF1%
M2E9(<@*RNATA:N9%" $%8Y 2J0%Z,8A+HVFYFI2KL5P.Y&KL1"6)A,L)PU)N
M#%Q1A#'&C)*TYH34G*!5E0B:;TB^P3''(&9#)#81,8R9@ G!4I#!#,-2(Y*%
M[9R2FE.L60+-*?(2"ZU 9#N,\LLJAHH)E$BTHA5S1M<XAC4K6.08SF"2&@-P
M.PJG>"K@!J9P@K-X84_PA>K,L7)4GCGR]$4(+F&^*9QF#&Z?C+3'N%E8V9RL
M^D]<8.4)5"[PY"J>0-T8Y3,NH6J,DDN*Z1;!8ZS80,4QS@U/-:J9%$X9)6#9
MI' ^UY(M**>;$Y>X#J4+%NA>P7&S@ 5SRW&-_R(X#)P P7G/*-#2CJ:;!<?=
MPL!N,6$TF"N)UA>!4T8S!543N'ZNEI33+8,G6+F RD=,,O?$'I2$P@D8?X#G
MDHRVIN,%V72GXKA5&=BJ..XNL6:I8G I[2BDU'Y_P%:244AN&-<H[='LQ%O9
MYC3<)MI@[ZYUUY\<9Z/W&\N3Z$_,8'S;WV2&D_2[F?$:]'?>G(JZ#5Y<Y\_C
MPZGYZ%QGO5 _/6%P]C>O^T=ICUW_FOCW9KQ^C!^=NTQ7J^A^O]O\!E!+ P04
M    "  !@5M,MT&X6@D%  #.&0  &    'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;(U9;6_B2 S^*XCO;&8\;TE%D;90N)/NI&I/=_<Y+=."-B%LDI:]?W^3
MD*7$=H OA:2/Q\_8'C]QF!Z*\GNU\;X>_<RS774_WM3U_BZ*JI>-S]/J2['W
MN_"?UZ+,TSI<EF]1M2]]NFZ-\BP"(6R4I]O=>#9M[SV5LVGQ7F?;G7\J1]5[
MGJ?E?P\^*P[W8SG^=>/;]FU3-S>BV72?OOF_?/WW_JD,5]%IE?4V][MJ6^Q&
MI7^]'W^5=RNE&X,6\<_6'ZJS[Z-F*\]%\;VY^'U]/Q8-(Y_YE[I9(@T?'W[N
MLZQ9*?#XT2TZ/OEL#,^__UI]V6X^;.8YK?R\R/[=KNO-_3@>C];^-7W/ZF_%
MX3??;<B,1]WN__ ?/@OPADGP\5)D5?MW]/)>U47>K1*HY.G/X^=VUWX>CO]Q
MJC/C#: S@).!E!<-5&>@/@TN>]"=@?XT,!<-3&=@3@;@+AK8SL!^&HB+!JXS
M<"<#U7J(CM%MT[5(ZW0V+8O#J#Q6W#YM"EO>N5 0+\W--O_M_T+&JG#W8Q;K
M:?31K--!'HX0.(>8/F3.0&P?LF @K@]Y9"!Q'[)D($D?LJ*01)P@40C&*2+
M1@1:>WUN+U%$CA#;0G8M1(($O.4YA4$L4%@H9B+1CAXI1BDC'&*U9)8"J85&
MM%84-Q ?Q<9'T?@ VO@18LXW[I+$6(72N:# V!J>C&;):$I&H61IXL/%&I?>
M%5"/B6&9&,H$'R1#PR*4MHC+W)#\6%0UC_Q*8H"P90E;2A@?:TO<F,39& ;\
M.-:/HWY013XX6@8QKBE'#P$J)HJ8 #Y*U%,B8GXW,;N;F.X&YR\F/I13@/O4
M@L(2&*C]A*624"KH?#TDQ ?N/PD)FD:+/-)%)GH@9E+P(B,H51R.#M-S(]U0
MZY8#:B:)(RG0EA\Z4,\3JOS594R?"B\CDNJ(P^GI,#TO($+/QJIW%==GQ#=N
M23NW%%C:)&W)2BJE<)%WN-YYU/A$,B#<R1A_1CN)GS"6#&X"2DLLNBL..)0Y
M7E,D%14I<#N25#'"_K5Q1N,@4.10WGAED8RT8)&35!'"(XDU.-K78'T^O'!(
M1CEP1Y=4.D).-0ZBI5*'HT<A$X6[.NLM'E IR<N49'2*%#V5#P,Z-J3N*2X4
M*@SPX85&,DI#^@?5$-S?.TCOG)+PT67.8]QGRVN19,2(='A&2(;# KR4 )42
MVN&!T1*'DKFZ NJ3X>4&J-R0'@^<DL0&\&1S'==G-#"\4-61 C<+H'("-G8&
M:<$<F,%#XZPR(-SC&7_&2HG+><G@PA,<.*EQZAA@/%1'O!@")X:X/P$CACIV
MP@J'HT"10T,G+SIPPR0#5$FD=EKC<%^#]?GPH@,WS#- U41IP'SF0 <:B><O
M?JFA00-X88(;1AI@I,(F"<1#X>'5 FZ8:H!1 :;&K@\V#&2"GQ$?66]:#NR*
MUQRX8;H!*A9AMB'/80L&=Z'9\ZH"-XPX<'W& 6;((>'CIIRA]R*\-*D;IAS%
M33F#85&\[*A;IAQ%]010@U]=QO2I\'JC;IAR%-.M96(!5<SR.J[/:.#U%-?8
M#:9$!Q,(30"_GYHS.&5)3J]/.0PD"" X/.@QN(F28<X1.',,T ZECE<<Q8TY
M^!6F8L8<&YM$X,>I!8/$QR<Z>RG=_-+Q9UJ^;7?5Z+FHZR)OWT*_%D7MPW+B
M2UAHX]/UZ2+SKW7SU87OY?$7AN-%7>R[7T^BTT\XL_\!4$L#!!0    (  &!
M6TS!]-V)T00  /86   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULA9AA
MCZ,V$(;_2I3O.9BQC<TJ&VD35+52*YVN:ON93;R;Z""DP&ZN_[Z&L+ED9GSW
M90/LX^$=8\]K>WENVJ_=WOM^]JVNCMWC?-_WIX<DZ;9[7Y?=I^;DC^$_+TU;
MEWVX;5^3[M3Z<C<VJJL$TS1+ZO)PG*^6X[//[6K9O/75X>@_M[/NK:[+]K^U
MKYKSXQSF'P^^'%[W_? @62U/Y:O_T_=_G3ZWX2ZY1MD=:G_L#LUQUOJ7Q_D3
M/!0*AP8C\??!G[N;Z]F0RG/3?!UN?ML]SM-!D:_\MA]"E.'GW6]\50V1@HY_
MIZ#SZSN'AK?7']%_&9,/R3R7G=\TU3^'7;]_G+OY;.=?RK>J_]*<?_530F8^
MF[+_W;_[*N"#DO".;5-UX]_9]JWKFWJ*$J34Y;?+[^$X_IZG^!_-Y 8X-<!K
M \A^V$!-#=3W!OJ'#?340),&R265L6^*LB]7R[8YS]K+YSV5PRB"!QUZ?SL\
M'#M[_%_HGBX\?5]!:I?)^Q!H8M87!F^9*Y&$Z-=7H/2*-;+F>/^"#2=4>H\4
M',FL+$*)>:JQO;K+T\D!M!A CP'T30#K2#]=D&Q$CB.R@#S#C&0K8,89)-$*
M <,4="J+-J)H(V2=RP$R,4#&L@8@GV9]8<R-4(LTFXT 92E-F4/H,B7KM:)>
MR_3FBLBU["6@K=9$KT A9(8(YI1U.C(NG2C8\2\$D=F5BP%REK$BN:QSIG(1
M!C\=OAL),YI.1$Z!C2F&5*XY*==L:,U)V7N4HG5#@!:065*_"@%#G9J(YDB=
M!&$F(!4-[$4IE?Q3I! 0E4:F/8@E]PF0J:4?<CTQ=[V2L1X6()M1P1Q:H(OU
MKUR?07'%=.9.#!VA=.H*&"(=.X48+%9L0/8$X*9 U:PGYKZ2.#Z4.:8SDU/1
MG%)&QWI:]@0P7#1S?"/U-"VE&PE#AZRK!4QA'NMKV8F 6Y%F18,;2&844\VI
MA88<J&H! PPC*2);-B3@CJ0S*IO;2 9@J&Q.+0!HL2\$+ RD6/F030F<4.S8
M;'0_+W8<65ADY5F@;MWI7K'L@L!M$(!-1<&[]*T13*H%(]0JLVPR2H:ILBRV
M.);-$%-A!1"9T2A[$TK>1 <9<E<):@W0V;J10*6MI=Y0B!$UYA 9;"A[%7*O
M J %"04?TL'$@8H7..=<3F>)P,54RWZ%W*\ Z(8 !8_!7*>T(DE<F'".EB2)
MRR&/+#A1-BWDI@604^7<:*QUU/DW K:P*6HZ520.#-YN->^ER]:%PGX&8]]-
MMA$4=C0(-'M>^E48;72A(6!LVRIL:5*E8WM7E$T$N8FP>;M&8<L"7+- .6KL
MA4#EL44^RAZ"@H<@]1 42C]=J&XD2+$1)D 8V>JB["$H> A2#T%>])51FNZE
M! R<856(4YAJI2.ZE>P@BF^G .G22/$]$(25/))^W A<*$686JI= )4S+C)(
ME.Q<2G N>EZR5MQGG$YSVN4"!GD&EMJ6Q!EK\IARV;64X%IT9;.>H-LS' S>
M1KF-P D9%@)&,KPH3VX._VK?OHX'J]ULV[P=^^$,[>;I]?#V:3R[)<_7\%!<
MCF"_A[F<"/]1MJ^'8S=[;OJ^J<<#Q)>FZ7V0F7X*7;OWY>YZ4_F7?KBTX;J]
MG,1>;OKF-)TR)]>C[M7_4$L#!!0    (  &!6TQ,S34CL0$  -(#   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5-A;YPP#/TK47Y P^6N77<"I%ZG
M:9,VZ=1I[><<&(B:8)J$H_OW2P)'68?ZA=C&[_G9<=(!S;-M !QYU:JU&6V<
MZ_:,V:(!+>P5=M#Z/Q4:+9QW3<UL9T"4$:05XTERP[20+<W3&#N:/,7>*=G"
MT1#;:RW,GP,H'#*ZH9? @ZP;%P(L3SM1PR]PO[NC\1Z;64JIH;426V*@RNC=
M9G_8A?R8\"AAL N;A$Y.B,_!^5YF- F"0$'A H/PQQGN0:E Y&6\3)QT+AF
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MX\O&_C?&>$ INQL<H0X_V&)(:'PXWN+93F,V&=[T\P]BRS<N_P!02P,$%
M  @  8%;3.0<VL>R 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3$N
M>&UL?5-ACYP@$/TKA!]P*&O;RT9-;J]IVJ1--M>T_<SJJ.1 +.!Z_?<=T+.V
M]>X+,,.\-V^&(9^,?70=@"=/6O6NH)WWPY$Q5W6@A;LQ _1XTQBKA4?3MLP-
M%D0=05HQGB1OF1:RIV4>?6=;YF;T2O9PML2-6@O[ZP3*3 5-Z;/C0;:=#PY6
MYH-HX2OX;\/9HL56EEIJZ)TT/;'0%/0N/9ZR$!\#ODN8W.9,0B478QZ#\:DN
M:!($@8+*!P:!VQ7N0:E A#)^+IQT31F V_,S^X=8.]9R$0[NC?HA:]\5]):2
M&AHQ*O]@IH^PU/.&DJ7XSW %A>%!">:HC')Q)=7HO-$+"TK1XFG>91_W:;[A
MZ0+;!_ %P%? ;<S#YD11^7OA19E;,Q$[]WX0X8G3(\?>5,$96Q'O4+Q#[[5,
MLR1GUT"TQ)SF&+Z-62,8LJ\I^%Z*$_\/SO?AAUV%AP@__*7PA?S9+D$6";)7
M2]R+^5<EV_14@VWC-#E2F;&/D[SQK@-[Q^.;_ F?I_V+L*WL';D8CR\;^]\8
MXP&E)#<X0AU^L-50T/AP?(=G.X_9;'@S+#^(K=^X_ U02P,$%     @  8%;
M3!ASKT2T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL?5/;
M;M0P$/T5RQ]0[WI36JV22-TB!!)(JR+HLS>9)%9]";:S*7_/V$E#@(@7VS.>
M<^;,>)R/UKWX#B"05ZV,+V@70G]DS%<=:.%O; \&;QKKM AHNI;YWH&H$T@K
MQG>[=TP+:6B9)]_9E;D=@I(&SH[X06OA?IY V;&@>_KF>))M%Z*#E7DO6O@*
MX5M_=FBQA:66&HR7UA '34$?]L=3%N-3P'<)HU^=2:SD8NU+-#[5!=U%0:"@
M"I%!X':%1U J$J&,'S,G75)&X/K\QOXAU8ZU7(2'1ZN>91VZ@MY34D,C!A6>
M[/@1YGIN*9F+_PQ74!@>E6".RBJ?5E(-/E@]LZ 4+5ZG79JTC]/-73;#M@%\
M!O %<)_RL"E14OY>!%'FSH[$3;WO17SB_9%C;ZKH3*U(=RC>H_=:[K-#SJZ1
M:(XY33%\';-$,&1?4O"M%"?^#YQOPP^;"@\)?OA#8;9-D&T29(D@^V^)6S&W
M?R5AJYYJ<&V:)D\J.Y@TR2OO,K //+W)[_!IVK\(UTKCR<4&?-G4_\;: "AE
M=X,CU.$'6PP%38C'.SR[:<PF(]A^_D%L^<;E+U!+ P04    "  !@5M,W%XI
M>[0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q]4V%OW" ,
M_2N('U#NDJP]G9)(O5;3)FW2J=/6SUSB)*B ,R"7[M\/2)IF6[0O@(W?\[,Q
M^8CFQ78 CKPJJ6U!.^?Z(V.VZD!Q>X,]:'_3H%'<>=.TS/8&>!U!2K)DM[ME
MB@M-RSSZSJ;,<7!2:#@;8@>EN/EU HEC0??TS?$DVLX%!ROSGK?P#=SW_FR\
MQ1:66BC05J F!IJ"WN^/IRS$QX ? D:[.I-0R07Q)1B?ZX+N@B"04+G P/UV
MA0>0,A!Y&3]G3KJD#,#U^8W]8ZS=UW+A%AY0/HO:=04]4%)#PP?IGG#\!',]
M'RB9B_\"5Y ^/"CQ.2J4-JZD&JQ#-;-X*8J_3KO0<1^GFS2=8=N 9 8D"^ 0
M\[ I453^R!TO<X,C,5/O>QZ>>'],?&^JX(RMB'=>O/7>:[G/;G-V#41SS&F*
M2=8Q2P3S[$N*9"O%*?D'GFS#TTV%:82G?RB\VR;(-@FR2)#]M\2MF,-?2=BJ
MIPI,&Z?)D@H''2=YY5T&]CZ);_(>/DW[5VY:H2VYH/,O&_O?(#KP4G8W?H0Z
M_\$60T+CPO'.G\TT9I/AL)]_$%N^<?D;4$L#!!0    (  &!6TP'WXTUM $
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M!;4/Q_=XMM.8388W_?R#V/*-B[]02P,$%     @  8%;3"LU3.NT 0  T@,
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MQ;.;QFPR@NWG'\26;US^ E!+ P04    "  !@5M,WM)>6K4!  #2 P  &0
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MB2!,CD7F4&0."!:>",!D$1;)H$@&"*@G@C 3>Y)#D1P0))X(PJ189 %%%H#
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MLJC6HXJ3O/&N WM/XYO\A<_3_HV9CBN++MKYEXW];[5VX%-);OP(]?Z#K8:
MUH7C)W\V\YC-AM/#\H/(^HVK/U!+ P04    "  !@5M,..0/V[8!  #2 P
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M\1[/=AJSR?"FGW\06[YQ\1=02P,$%     @  8%;3,:''F[3 0  G 0  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL=51ACYP@$/TKA!]P*.ON73=J
M<GM-TR9MLKFFU\^LCDH.Q *NUW]?0,^:+?TBS/#FO1F<(9^4?C4=@$5O4O2F
MP)VUPY$04W4@F;E3 _3NI%%:,NM,W1(S:&!U")*"T"0Y$,EXC\L\^,ZZS-5H
M!>_AK)$9I63Z]PF$F@J<XG?',V\[ZQVDS ?6PG>P/X:S=A9966HNH3=<]4A#
M4^#']'@Z>'P O'"8S&:/?"47I5Z]\:4N<.(3 @&5]0S,+5=X B$\D4OCU\*)
M5TD?N-V_LW\*M;M:+LS DQ(_>6V[ C]@5$/#1F&?U?09EGKV&"W%?X4K" ?W
MF3B-2@D3OJ@:C55R87&I2/8VK[P/ZS2?W&=+6#R +@%T#7@(.F06"IE_9):5
MN583TO/=#\S_XO1(W=U4WAFN(IRYY(WS7DN:?,C)U1,MF-.,H1M,NB*(8U\E
M:$SB1/\)I_'P733#70C?;=6S+$Z010FR0)!M]=/DIL08YC]%[J,B^P@!O1&)
M879QD4-4Y! AR&Y$8IC]C0C9=(<$W8:Y,*A28Q]F<N-=1^^1AN[Z"Y_G]AO3
M+>\-NBCK>C1T4J.4!9=*<N<*[MQ3L1H"&NNW]VZOYX&9#:N&Y2T@ZX-4_@%0
M2P,$%     @  8%;3*IP":3/ 0  G 0  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C0N>&UL;53;CML@$/T5Q <L-DF<;61;VFQ5M5(K15MU^TSL\44+Q@4<
M;_^^@!W7=7D)S/A<9@A#.DKUIAL @]X%[W2&&V/Z$R&Z:$ P_2![Z.R72BK!
MC U5372O@)6>)#BA4900P=H.YZG/752>RL'PMH.+0GH0@JG?9^!RS'",[XF7
MMFZ,2Y \[5D-W\'\Z"_*1F11*5L!G6YEAQ14&7Z*3^?$X3W@M851K_;(=7*5
M\LT%7\H,1ZX@X% 8I\#L<H-GX-P)V3)^S9IXL73$]?ZN_LGW;GNY,@W/DO]L
M2]-D^!&C$BHV</,BQ\\P]W/ :&[^*]R 6[BKQ'H4DFO_BXI!&REF%5N*8._3
MVG9^'6?].RU,H#.!;@AD,O*5?V2&Y:F2(U+3V??,_<7QB=JS*5S2'X7_9HO7
M-GO+:9RDY.:$9LQYPM 5)EX0Q*HO%C1D<:;_T6F8O@M6N//TW=I]?PP+[(,"
M>R^P_Z?%XZ;%$.8Q;'((FAP" A\V)@$,C<(F2= D"0C$&Y,09GO>9'4[!*C:
MSX5&A1PZ/Y.K[#)Z3]3?KK_P:6Z_,56WG497:>P=]3>IDM* +25ZL TW]JE8
M @Z5<=NCW:MI8*; R'Y^"\CR(.5_ %!+ P04    "  !@5M,=-?O&+<!  #2
M P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM4]MNW" 0_17$!P0O
MZVU7*]M2-E'42JVT2M7VF;7'-@H8%_ Z_?L.V''=U"_ #.><N3!DH[$OK@7P
MY%6KSN6T];X_,>;*%K1P=Z:'#F]J8[7P:-J&N=Z"J"))*\:3Y /30G:TR*+O
M8HO,#%[)#BZ6N$%K87^?09DQISOZYGB63>N#@Q59+QKX!OY[?[%HL46EDAHZ
M)TU'+-0YO=^=SFG 1\ /":-;G4FHY&K,2S ^5SE-0D*@H/1!0>!V@P=0*@AA
M&K]F3;J$#,3U^4W]*=:.M5R%@P>C?LK*MSD]4E)!+0;EG\WX">9Z#I3,Q7^!
M&RB$ATPP1FF4BRLI!^>-GE4P%2U>IUUV<1^GF_0XT[8)?";PA7",<=@4*&;^
M*+PH,FM&8J?>]R(\\>[$L3=E<,96Q#M,WJ'W5G"^S]@M",V8\X3A*\QN03!4
M7T+PK1!G_A^=;]/WFQGN(WV_CGY(M@7238$T"J3_E)B^*W$+<W@7A*UZJL$V
M<9H<*<W0Q4E>>9>!O>?Q3?["IVG_*FPC.T>NQN/+QO[7QGC 5)(['*$6/]AB
M**A].'[$LYW&;#*\Z><?Q)9O7/P!4$L#!!0    (  &!6TSL*L-8MP$  -(#
M   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;&U3VV[<(!#]%<0'A%WV
MDM7*MI1-%+52(ZT2M7UF[?%%X>("7B=_GP$[KIOZ!9CAG#,7AJ0W]M75 )Z\
M*:E=2FOOVR-C+J]!"7=C6M!X4QJKA$?35LRU%D0124HROEKMF1*-IED2?6>;
M):;SLM%PML1U2@G[?@)I^I2NZ:?CN:EJ'QPL2UI1P0OXG^W9HL4FE:)1H%UC
M-+%0IO1N?3QM SX"?C70N]F9A$HNQKP&XWN1TE5(""3D/B@(W*YP#U(&(4SC
MSZA)IY"!.#]_JC_&VK&6BW!P;^3OIO!U2@^4%%"*3OIGTW^#L9X=)6/Q/^ *
M$N$A$XR1&^GB2O+.>:-&%4Q%B;=A;W3<^^%FQT?:,H&/!#X1#C$.&P+%S!^$
M%UEB34_LT/M6A"=>'SGV)@_.V(IXA\D[]%XSSO<)NP:A$7,:,'R&64\(ANI3
M"+X4XL3_H_-E^F8QPTVD;^;1=_ME@>VBP#8*;/\I\?9+B4N8PY<@;-93!;:*
MT^1(;CH=)WGFG0;V+CXB^PL?IOU)V*K1CER,QY>-_2^-\8"IK&YPA&K\8),A
MH?3A>(MG.XS98'C3CC^(3=\X^P!02P,$%     @  8%;3/EPJARW 0  T@,
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MY<+QQI_-.&:CX;";?A";OW'^%U!+ P04    "  !@5M,\,7T&1T"  !3!@
M&0   'AL+W=O<FMS:&5E=',O<VAE970R."YX;6R%5>V.FS 0?!7$ YP3DP"-
M"-(EIU,KM5)T5=O?#MD$=#:FMA.N;U]_$ XXB_L3V\OL[,R"-UG+Q:LL 53P
MQF@MMV&I5+-!2!8E,"(?> .U?G+F@A&EC^*"9". G&P2HP@O%C%BI*K#/+.Q
M@\@S?E6TJN$@ GEEC(A_.Z"\W8;+\!YXJ2ZE,@&49PVYP$]0OYJ#T"?4LYPJ
M!K6L>!T(.&_#Q^5FGQJ\!?RNH)6#?6"<'#E_-8=OIVVX,(* 0J$, ]'+#?9
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M$Y6/]]E.\Z@K0#;6%<RTM)F6Y,!08@PES>@*QE#:]S^+H4YS/]WAKC(JZ?O
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M5Z8N%WRIVWHT\?YVDII#U1PNZ^/B^AC]>E+EY^XG O_V.\7F/U!+ P04
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MH,!O/TT^H!:__W1VBUH$M(PFXN#/A")O8#G1*2C^".CB VKQ9T#3_V8QJ,5
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M ]ED !M/.3F8(%^N5@8F8 O4RIQ*"6.V6%U0DF./2% ,&T"\0*PCZ':BV+:
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M@*B@9OD&VT<IT#!VM877/6(7/FIF_U:#1H.4.IK!2QFQ:QEEW&R&V5...PU
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MX!8&8&%LP". J8NMCZ#Q%/+D0T9!#($B+#R=8IXQ3#;%O" 8$>,+INB^TYZ
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M46@FI>-O2^IV/K5A__N#_8L)7@5S)(+N6/$G/\EL[2Y<YT3/Y%K(5W;_2MN
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M'+*Q(4F*10@X3S'&B]D\!4X0P031F"":)8B,0DV8>,34TSPRD;&$8:(8$L6
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M5:WI>(8?NR$]F&Q[;>1FU_:O<?=>C[<X8Z.M3M,-57"])EO]#U!+ P04
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M5F:[U'OAYH$[*-[VHPX-\[;X!U!+ P04    "  !@5M,1:O:58$"  "_"
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MJW9 ;1><E6KX=KK_ !;_ 5!+ P04    "  !@5M,QY8@,Z("  "8"0  &0
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M7 X78DS[7M=/.&EU'P?#QT3V#U!+ P04    "  !@5M,()"_A0T#  !A#
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MNAV3*S2J'.H&6E[3UF%PS-T'?_V4*KP&_*JAYY.YHRK94_JJ%M\.N>NIA(!
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ML"%*&&BKJ0TQGP"G1QL**'2:V5!$N "1SY&@HA#,M\!2)40(>\/&^GX4P?9
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MS'Z%C]Q5Y6Y+6(Z_T-V]+Q_P=F6K53G'^0$E2F#/PL=1F*R)J, TM!X@;R'
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M8[Z4J$2^<%$H(B,32I>/_O;TX.*10](-]H8(9;>.J%3YUMGXOBB; B#ZD+9
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MH<SOD?3!7*_AOZO[O%@G/ZYG?TA._$^G-.@('C\*1@$B'0)2E['>!E08 /5
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M:"[@3\,78NP,9$LY1E"(T?VH=23D)DA03G;@>AT.'/&\ORVR!C(8Q@.@FYD
ML9?4=4A*+G;=&I=(+Z&[@!:.QU#G91F*T^U: I;SJK6T?^-HQ>BE,/"55!TC
M;2%Z8<RR4>C#>F%2952K;O$<>TV#>+1[+:K&-1BOEU,0MAB26VBY0?W6R=Y:
M?L47?V!TZK4W.<S!=,8GOTPYD#H"252A2?.;KL!B_'WC"N,&Q,P92?8:M;@
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MIF2.<VHH*4-\M^H ]\^^<A,4DYYZY2Z#]?^WNW)3D+,NIS_SRL5[Z[QR&^J
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M/G/?%.07G?Z+T%RQ1^YNT?+I]74Z!K6T6P(-J6>;@H6-98.T8'M2W0*Z=*;
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M=V)D+N8HO;X8IJ.+*X<$N)B#2W!R53 O%[[?-24:M.9:G(EH&;)=M=2- OF
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M2I._YE7)1)FW'=#XSO*JO:"(U<3=1F4C\Z"KS.+9*LKV89T]JJ_6@@C;#T1
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M<D'1J56VS8%2SB4>'ZA:PQ'72+RCX!B\: U:&JL06!Y $0<P9AA< FV*+%U
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M?+<2+-$C*O,OL=Q2/<W.P]%<.B/^[S-]I-XLE"8UM5ZAQ%5*\.[,]<02'J"
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M[*CW^)L?ZN%@23 ](M=2L#X1:H=;7=_"=/$<W(!\(VGCOJ>VG )(4/"D7>@
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MS"L".\9V#9IN;C5R4441(T@$%>T;2R3+J""A\*>&P* <[<^$=GUW :HT(5C
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MRM?;@-[&U]N WL;7VX#>QM?;@-YVA;-N=-C-U]N WL;7VX#>QM?;@-[&U]N
MWL;7VX#>QM?;@=[.U]N!WL[7VX'>SM?;@=[.U]N!WGZ%NTIT6<G7VX'>SM?;
M@=[.U]N!WL[7VR=ZYZ8>TO:E#(=VGR]=\FGXMY?>$[AS>3^FRV><IWZ[?Z)T
M&;>D<'Z]N,WGJ1\1X=-_9![_ E!+ P04    "  !@5M,F^CEY-\!  #0(@
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M^6SX(\OB#5!+ 0(4 Q0    (  &!6TP?(\\#P    !,"   +
M  "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    (  &!6TQF\PM@@@   +$
M   0              "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%
M  @  8%;3'?ZMZCO    *P(  !$              ( !F0$  &1O8U!R;W!S
M+V-O<F4N>&UL4$L! A0#%     @  8%;3)E<G",0!@  G"<  !,
M     ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  !@5M,
MTP,7#IH"  "<"0  &               @ 'X"   >&PO=V]R:W-H965T<R]S
M:&5E=#$N>&UL4$L! A0#%     @  8%;3'U>!(O^ P  PA(  !@
M     ( !R L  'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    (
M  &!6TP]9SOGZ $  /4$   8              "  ?P/  !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6Q02P$"% ,4    "  !@5M,8=].UW<#  #K#0  &
M            @ $:$@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#
M%     @  8%;3+=!N%H)!0  SAD  !@              ( !QQ4  'AL+W=O
M<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (  &!6TS!]-V)T00  /86
M   8              "  08;  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q0
M2P$"% ,4    "  !@5M,3,TU([$!  #2 P  &               @ $-(
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @  8%;3!)O@NBS
M 0  T@,  !@              ( !]"$  'AL+W=O<FMS:&5E=',O<VAE970X
M+GAM;%!+ 0(4 Q0    (  &!6TPJJXKIM $  -(#   8              "
M =TC  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  !@5M,
MXU<%>[4!  #2 P  &0              @ '')0  >&PO=V]R:W-H965T<R]S
M:&5E=#$P+GAM;%!+ 0(4 Q0    (  &!6TSD'-K'L@$  -(#   9
M      "  ;,G  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%
M  @  8%;3!ASKT2T 0  T@,  !D              ( !G"D  'AL+W=O<FMS
M:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    "  !@5M,W%XI>[0!  #2 P
M&0              @ &'*P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+
M 0(4 Q0    (  &!6TP'WXTUM $  -(#   9              "  7(M  !X
M;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @  8%;3"LU3.NT
M 0  T@,  !D              ( !72\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-2YX;6Q02P$"% ,4    "  !@5M,WM)>6K4!  #2 P  &0
M@ %(,0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    (  &!
M6TP5J^PYM@$  -(#   9              "  30S  !X;"]W;W)K<VAE971S
M+W-H965T,3<N>&UL4$L! A0#%     @  8%;3).M=)2T 0  T@,  !D
M         ( !(34  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4
M    "  !@5M,E*+! '<"  !T"0  &0              @ $,-P  >&PO=V]R
M:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (  &!6TS7 ^1'Z0$  &8%
M   9              "  ;HY  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL
M4$L! A0#%     @  8%;3%ZT>5NU 0  T@,  !D              ( !VCL
M 'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    "  !@5M,..0/
MV[8!  #2 P  &0              @ '&/0  >&PO=V]R:W-H965T<R]S:&5E
M=#(R+GAM;%!+ 0(4 Q0    (  &!6TS&AQYNTP$  )P$   9
M  "  ;,_  !X;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @
M 8%;3*IP":3/ 0  G 0  !D              ( !O4$  'AL+W=O<FMS:&5E
M=',O<VAE970R-"YX;6Q02P$"% ,4    "  !@5M,=-?O&+<!  #2 P  &0
M            @ '#0P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4
M Q0    (  &!6TSL*L-8MP$  -(#   9              "  ;%%  !X;"]W
M;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @  8%;3/EPJARW 0
MT@,  !D              ( !GT<  'AL+W=O<FMS:&5E=',O<VAE970R-RYX
M;6Q02P$"% ,4    "  !@5M,\,7T&1T"  !3!@  &0              @ &-
M20  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    (  &!6TS1
MH%W5-00  +,8   9              "  >%+  !X;"]W;W)K<VAE971S+W-H
M965T,CDN>&UL4$L! A0#%     @  8%;3#_8WG@D @  RP8  !D
M     ( !35   'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  &!6TS=+I0>( ,  *,-   9              "
M 0I=  !X;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @  8%;
M3.$=TXZ7 @  S @  !D              ( !86   'AL+W=O<FMS:&5E=',O
M<VAE970S-BYX;6Q02P$"% ,4    "  !@5M,_6/=83(#  !&#0  &0
M        @ $O8P  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0
M   (  &!6TRW\=<@J0,   01   9              "  9AF  !X;"]W;W)K
M<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @  8%;3&;PK5]W @  ,@@
M !D              ( !>&H  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q0
M2P$"% ,4    "  !@5M,JW,HMXL#   ,#P  &0              @ $F;0
M>&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (  &!6TS2NY-L
MC (  +8)   9              "  >AP  !X;"]W;W)K<VAE971S+W-H965T
M-#$N>&UL4$L! A0#%     @  8%;3%CAI<GU P  &1(  !D
M ( !JW,  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  !
M@5M,O=!'0P0$   R$P  &0              @ '7=P  >&PO=V]R:W-H965T
M<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    (  &!6TRKZKO8!P,  ,\+   9
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M970T."YX;6Q02P$"% ,4    "  !@5M,P]KCS8L"  ##"   &0
M    @ %QB0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    (
M  &!6TS.!9RS%@,   T,   9              "  3.,  !X;"]W;W)K<VAE
M971S+W-H965T-3 N>&UL4$L! A0#%     @  8%;3,>6(#.B @  F D  !D
M             ( !@(\  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"
M% ,4    "  !@5M,&XA1:6X#  #=#@  &0              @ %9D@  >&PO
M=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    (  &!6TQZ9^=J<@(
M %@(   9              "  ?Z5  !X;"]W;W)K<VAE971S+W-H965T-3,N
M>&UL4$L! A0#%     @  8%;3""0OX4- P  80P  !D              ( !
MIY@  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  !@5M,
M[?@"8CX"   \!P  &0              @ 'KFP  >&PO=V]R:W-H965T<R]S
M:&5E=#4U+GAM;%!+ 0(4 Q0    (  &!6TRRR0WHY (  %@+   9
M      "  6">  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%
M  @  8%;3%B2F_,G @  7 8  !D              ( !>Z$  'AL+W=O<FMS
M:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    "  !@5M,Y<Z6Y5(#  "\#0
M&0              @ '9HP  >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+
M 0(4 Q0    (  &!6TRJ)PV;PZ(  ,.9 @ 4              "  6*G  !X
M;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    (  &!6TP7[#6Z20(  %H+
M   -              "  5=* 0!X;"]S='EL97,N>&UL4$L! A0#%     @
M 8%;3)$G,())!   4"8   \              ( !RTP! 'AL+W=O<FMB;V]K
M+GAM;%!+ 0(4 Q0    (  &!6TPU TT!"0(  #,C   :              "
M 4%1 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (  &!
M6TR;Z.7DWP$  - B   3              "  8)3 0!;0V]N=&5N=%]4>7!E
<<UTN>&UL4$L%!@    !# $, 1Q(  ))5 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>228</ContextCount>
  <ElementCount>311</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/OrganizationAndNatureOfOperations</Role>
      <ShortName>Organization and Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Property, Equipment and Software</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentAndSoftware</Role>
      <ShortName>Property, Equipment and Software</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Lease Exit Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiability</Role>
      <ShortName>Lease Exit Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Collaboration and Other Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreements</Role>
      <ShortName>Collaboration and Other Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2115100 - Disclosure - Quarterly Financial Information (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</Role>
      <ShortName>Quarterly Financial Information (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecurities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Property, Equipment and Software (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables</Role>
      <ShortName>Property, Equipment and Software (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentAndSoftware</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockBasedCompensation</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/IncomeTaxes</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Lease Exit Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityTables</Role>
      <ShortName>Lease Exit Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/LeaseExitLiability</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2315301 - Disclosure - Quarterly Financial Information (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnaudited</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfFairValueMeasurementFinancialAssetAndLiabilitiesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Fair Value Measurement Financial Asset and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfTotalRevenueEarnedDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Total Revenue Earned (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesSummaryOfCollaboratorsThatRepresentMoreThan10OfAccountsReceivableDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Summary of Collaborators that Represent More Than 10% of Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesEstimatedUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesComputationOfBasicAndDilutedIncomeLossPerCommonShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Computation of Basic and Diluted Income (Loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfAntidilutiveSecuritiesExcludedFromCalculationOfDilutedLossPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/MarketableSecuritiesTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Marketable Securities - Available-For-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/MarketableSecuritiesAvailableForSaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Available-For-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Property, Equipment and Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/PropertyEquipmentAndSoftwareDetails</Role>
      <ShortName>Property, Equipment and Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/PropertyEquipmentAndSoftwareTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405401 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/StockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Stock- based Compensation - Employee Stock Purchase Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationEmployeeStockPurchasePlanDetails</Role>
      <ShortName>Stock- based Compensation - Employee Stock Purchase Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Stock- based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock- based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Stock- based Compensation - Option Pricing Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationOptionPricingAssumptionsDetails</Role>
      <ShortName>Stock- based Compensation - Option Pricing Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2406405 - Disclosure - Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/StockBasedCompensationStockOptionAndRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock- based Compensation - Stock Option and Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesComponentsOfCompanysDeferredTaxAssetsLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Components of the Company's Deferred Tax Assets (Liabilities) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationOfReportedEstimatedIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Reported Estimated Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/IncomeTaxesReconciliationOfBeginningAndEndingAmountOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the Beginning and Ending Amount of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Lease Exit Liability Lease Exit Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityLeaseExitLiabilityNarrativeDetails</Role>
      <ShortName>Lease Exit Liability Lease Exit Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Lease Exit Liability - Changes in Lease Exit Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/LeaseExitLiabilityChangesInLeaseExitLiabilityDetails</Role>
      <ShortName>Lease Exit Liability - Changes in Lease Exit Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2412401 - Disclosure - Collaboration and Other Agreements Collaboration and Other Agreements,  Incyte Corporation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsCollaborationAndOtherAgreementsIncyteCorporationDetails</Role>
      <ShortName>Collaboration and Other Agreements Collaboration and Other Agreements,  Incyte Corporation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Collaboration and Other Agreements, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsFHoffmannLaRocheLtdAndHoffmannLaRocheIncDetails</Role>
      <ShortName>Collaboration and Other Agreements, F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsJanssenBiotechIncDetails</Role>
      <ShortName>Collaboration and Other Agreements, Janssen Biotech, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Collaboration and Other Agreements, Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsTakedaDetails</Role>
      <ShortName>Collaboration and Other Agreements, Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CollaborationAndOtherAgreements</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Collaboration and Other Agreements, Servier (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsServierDetails</Role>
      <ShortName>Collaboration and Other Agreements, Servier (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Collaboration and Other Agreements, Boehringer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsBoehringerDetails</Role>
      <ShortName>Collaboration and Other Agreements, Boehringer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2412407 - Disclosure - Collaboration and Other Agreements, Green Cross (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsGreenCrossDetails</Role>
      <ShortName>Collaboration and Other Agreements, Green Cross (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2412408 - Disclosure - Collaboration and Other Agreements, NIAID Contract (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CollaborationAndOtherAgreementsNiaidContractDetails</Role>
      <ShortName>Collaboration and Other Agreements, NIAID Contract (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2414401 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/EmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/EmployeeBenefitPlan</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="mgnx-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2415402 - Disclosure - Quarterly Financial Information (Unaudited) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedDetails</Role>
      <ShortName>Quarterly Financial Information (Unaudited) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://macrogenics.com/role/QuarterlyFinancialInformationUnauditedTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mgnx-20171231.xml</File>
    <File>mgnx-20171231.xsd</File>
    <File>mgnx-20171231_cal.xml</File>
    <File>mgnx-20171231_def.xml</File>
    <File>mgnx-20171231_lab.xml</File>
    <File>mgnx-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>88
<FILENAME>0001125345-18-000022-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001125345-18-000022-xbrl.zip
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M3GE%X8L*L'2NX<5I5& P)N5&=CZ=%1U$@ R&F^"Y590+!C=BHM\D]3RS#83
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MY612X:"B(-B#8\F]M\@Z?'QN^=(K(XE_]CN@PP9@;%;.VX>;#V#1I8F@Y7R
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M#/N=5)_@6H/;V)MAO/:P\WU'2UTKC965P@8J!67&3IM'E/"Y7;+82[$;G(?
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MV2W/^]2!& *T"'>(ZWJ$.B[CAD7+J4V*\!YW<XLC]\^<V/74ZQ#M"R<@TN)
M&;81")M[7FF9XACQ=6GA70[<'!.JQN/%_4)W7G@16,[QKFX0 ZN9@N/& R5M
M!Z1H-?C0MH+NT+=+9H/V%BUT;SK3<R%8.[I162*@E/'  %D)'J@GJT&O@>EU
M!Q1P^&RKAV57"/02'<S)_24->^>B;C"9I 33PW3A="9ZFYXKC3+;K%S2G=@-
M7K79.G#K"#N>;U-!%#$#UP )3*7E\,"GO!J+I$#R=7!J=#GP>>?;-&4T"!S'
MM, _4(YA*4]XU=@S8JCN<%_&V.[X^Q"-D]N9'JWX/IX"AR:SZ'TTOTLFS0]T
M2L_WO-3>)TIQSW' *7 P((T+A<HH@.6['> [U>:[P_=BV-ERX6.K<=SDQ/--
MQ2W%?8=ZQ+494C&NL/1X=S;R::+F((M.I71,[H'I213QB"5X.9G*@X?(CNW0
M&8_V\O@<>B=WJSG?<5R?*]^U!!%& &*)X:)QW_0\XBNY7N>_-&J&7KO:1$U
ME"&!1H@%NLV5S <GIJ0=+KQUDU8&1\UB.H\?II$73>//48IE6#46R;QHOO13
M?KGY&$VG()!_3>-QI.X1*3T5XN*7\9S0>0+_IS:5]V07O!)B*]=@X()YA >,
MPL4I!R<>$>X"O)T0OMB"T9^)])XK?<)H=]#\+ !GPK<],+>"P%VN\6$],T3
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M/J-Z=ZK&K;92F=P7MBL88ZY=[8FFS+"-?E2+;PO5[8'@3Z-JEU";!H0(2:W
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MO0@(Z94GDU<=6Z__9->;Q?1U^Z9 5\9YV_N6VFICW6BM/<6EA)N!YTCF,N*
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M 65@2$L9'G<\4>U\(^ #=V2D2:EMO3BP.]B2)I"J2UWA@%6%>\N=<I>?SRR
MN2LCAS9"=H=N1QGI^HY0GN7XO@_&LDT-1<NT(;@&LC/H\9+93-*>Z,6!P=Q%
M1MHF,:@+WDU@4S#$ BLHF]X\0@+:L=8&!6UM?[^RI4\,7RF%_6A4"*=< 6$#
M[KN^BFTS/C0#[5Y',( 9R0+'%E*!2R:(82NB2LGA@FKP.I+CTAQ:,SP!ZJ?Y
MVRHP!*6"F0R;WFR;EE?L4U=V#683-^L-[9$.7 +3#'ZZ%F>*2@[6!G%\;@E1
M,A<#%ZEC@'!S:!FY.W0[RLC !^&A#.$(YBD&CH%OE#:6LJG7 ?&24RQ'>W$P
M=_*WI?!,BTI@14\8@1*N4^IR7/3>J3G>&K1/X5<WC8!UW#!-'V^2%"M<U3VN
M8EX/8RY(X.O%S/CY8P,X#_Z8S>.Q7NJ</FY886\3Z3H4_D<(3]FX:+4LJ?:(
MY=@=@2-8NS9F#1P-<.LX!SJ+4ZSMS<NGWT< 2"_L6Z32I%(N,3T;U+(MP50&
MN[^<U,=LT5W67#_ZEF<:$HZ#"%=@0P?DJRF4=/W !)%J5OEOP;I]!:*I.T\
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M'9SBUN7<1C,<?MW8DE,S%T^6.3?6A?=G;F>=HH/C'>YWU=[]E47_MX C3VL
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M\3Q3Q1[Y3_CZ3X K9PI_^O.__]L?%]GE;1@^_* ^A_$4_QHDZ<=P&GV,Q@M
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M"T+!//<;[G*$/9SQEV,!WP>Q!K8 3EA78%R/0 _:B-7P('8.%!,8SV+_%6&
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MX?%'-N/?D#XYZ6,V]4Z1R4<^(A0! K$OXD'X,;*M(QAL0%K\I-U6NJS!V&]
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M2BRMFU"#$Y&T$889(2H<E_*\%&ND%=8 >DRZ8U#3B2&'^^.0.T))0KB/VG?
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ME#6<I5+FU,:9%F') :RN,-U#4S"3TLC.?O6>B'*E^F-V.OGBVU:\7(+ )_(
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M<>(N<V)+JF4VV[ JBF<BVECJ;A>CU\WCH,;1Q_&/XQ_'/TU2:[O2+NM_R/K
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MO)[+W.!B\WD2?]?H4D#@9F78YN-^OSX^UC']W@#_5\'5+$EP'6>%X%JK&X2
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MC_^*8B]-6"0G,#AX1'J/3]'-](DN9HU$=,=E.B/&',/T@6S(G'-X83R6GIX
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M9<+2W"!.I['D"X,AI"J,CED,RP_?15ZW\P,N84J>@9DK#"[*D2I7^$!O</X
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M+8LTC]*;L*2'*@'0Q1+F8! <)P@GL[L?$LPL>)&E<DT[#T N"YIEIA2AV+R
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M<V)IW80:G(BDC3"L"%'AN)SG):^05I@#Z#$I1J"FC2&'ZS,F=X2*A' =M>^
MI1*^76!D@UD!<8LX9$&7KGO1V2VJFXDGI4<"U&!"*H;GY E?TNNZR$7!NC(Q
MM+N+S(._IA3PE 0F$BBR#&LW990093=JQ(MQP\(MB_[C%:/Z[[_\F,F#6\;F
M'Z\+VZW0/Y\Q! O,<P."?AZ"6_?7__R/O^1WH)\WC<,Q3^0E.=Z_QRF_R!V9
M_":2,OCPA4]^_G!U@9KO'T?_O+GXX(DQ? &$.>B=#/M79^>=LZ/C3YWSRY.S
MP67_=-@;7%Y].ND/CH\^_'4!KVP4>:(#154)[[.S-$<;KDY=JD6UJ?MG3]&W
MO6!>Q,AN2NX6A96T/X<V)[E=J/M5J(:K!*]EY7LL2Z=Q D^OJ,1]R<BZO8'?
MZ73PGWJB9Z:C_:34K49A0"UOV-AX,?^,BHX689[G._3X*=ME:E-94JB@6H;Q
MI\YAIUO/A/*F/E8>KL1_8,)1+*&6UT7Q6RZ#<10P_5<<F>"I$L1:!K*<(.KK
M<& ]\X21U_*@RFW?+WE0BWW*A4S^4;GFHRA+PC"JCHRCE27PD(T\#6O?(D'?
MU 2K_LEF0$JEU*PV8)A"Q0Q_4",8]8>'@YI&_C@:G>6V)!JRJF +-/X]98AS
M]].L&H9MDD!(KL)#DRS,'5EUI0!8N./) 9KGVDN<ZS) 27&S6^,/2182O3#E
M7MBSM4SY:+"1A5^,TVX+"]@Q<W"4N+@CV(\#SL?UP?J?CH>'QQY<%L)*US,M
M[:M1X9]!%>RLIU48,3%R'*8VR'W317"S&2BQ/-JHW#6+P\F#W%R8'<ONQ>1A
MX\!LHL?8]\%?8%[%M?,L ??:+I?4X5<,DF)@S7SM>QR+(<CV^GL\C20P/O$/
M_I-_\TL4Q7?*1LZ+*KOP\]\O/OGP8W#H[>'?^]3J<&;7#>]A$0[Z;MZIVG!2
MZ3/OVV5-7TVI8JG:TZ>WY1.K396<]OI^Y[@F X1J*]\-54X/ZT)&Z_2#A.NB
M-2J;JA\Z!H>=6J&C_<*=A162_;X65]\?*%>VG1;7<?V"4:K#W$)#:] [\8_K
M,E+>#Q(WO/*5]A7:*?4#9?>H6S-2UFIDF>3$N$YS:]-)TS-@M]#K#>V,J5G.
M<@5H7L]\9YM4*F*%B428?9II^9MR%J;3 ,L!<GL+]VL8DZPFPZ7[ICZP&7S-
M MKKUN\)(3J:+#0MX5@DJH96,>:A]]E(IRX@T6ON@_D*)FE>E( \O)JM_1H#
M?7_J]6OVH%2%L5Y6&BA- -V_+)&9+E%9M5FJL-_EE(>3/.UMZANOP'#WK@_Z
M*B&%:;B)".'9)!"F[B#&RH([G3G2V[5?# 5U2C[>5^LVG$WC%+;6Z*\!4F@/
MR I\8K23&2Z1/ Q]C?MBIC;RP7_]Q^1_RN[4QC1X##SY%C,GZD4Y%F1S?%)#
M'8*\$) 5SFNO\Y,NZYNQY!LOL"&_H(NERC>_>7_H'_8Q#DY*@,CM?<G ]#KJ
M#JR-==<\R!*56M<5;MW3?I_*474J2B=>-;'M9"Z9ZL6CEA;2]!NP2A3IEA7"
MC'& 9<&U*I)?(<+>19:8XBRJ)5%9MC8D"/P-N4>#TU._=[+<2.J5JK@DAB7C
M?T,F9N?PI%[1,Q7(FCMM@7IV#<&Z%0%V&<%-PL;\+!K_@3:J+CV07\A0QP*K
MSVH7V-,E!)?=DXOSSM%P<-*[&AY?#:X&@W-=0M#M#;M7[U)"\,X-K0PYO8*>
M[<UVY9-)\LD8?(Y >Q)H3G53!*QAU?%450&E"WU"W$V@JX"QD0W/MX"5"K]+
MFRVIX4HIVVJJD7#_(BE=4PVE>C/%V2B=9*$IWEG8248A!W+GL(61&I' N133
MTF6:.*Q0?..AF,:J=LU<CEO+D XS$*\6YR]MLIBM J9>DB9JU@[C)Q6K'VLG
M(L/=DM022)':JDY3&_]]))?:D9)A.X([EM".R@D 1YS(A1U(1=E_@&5P>2F8
MV;VDVC'0J$Q'*2HCIY 0H^Y6V.JAO&"J>BL1G#KO1-HESV=%O8C@=?%,!/FP
ML*//'55+VY5?3&TWG&2X^67%&UZ_D8@6Z/>:BAL* ;'+ 5W9PJOL) UU]GX;
M5N)-S1E8$QFI#3@VB!EP>J:.7TM=V_K]J^1_3"ZUCR[74.3'YU?GY]WNL'_^
M:0":?'!YD2ORX^/+\_>I!7QG1?Y5DA.7D['=F*_V#Y3VM53NCQ.J'T"B"FO)
MZRDVZL OG/8RVBT#BD8/>[CY8;]<A6]$!4"4^@WPG"L1?HO6?M;>E$#\_Y5=
MP6[#( R][RNBGA%4VRV:^@6;]@])M2S:&BI"E/;OYV<<8MITTBZ5FB *-N"'
MY?<:VNF$7=,NUT$Y?U-UMX (@00<J+C\VI2UUR+QLFC.+=FI;>9WVKP\(P8Q
MF_7<%H)MR9 2M\9'U#EE4G,+EIBN@'Q"PXR?!P;1>D$RT\S9^H-";ZJNY\3$
M,4D0K2)MR06IA)L"O*T^!@Z@0^?1GF/Y31HEXP.,-@^T9 ]#I$#=9S;$D0P%
MUUZ*%PMW:=:JYD0914'!SY')6]I5+,8TQNEX%7JQ/(K,+J0E&29P%M?D>W9H
MR\Y[7]W0L+Y!,2L<V$KT22,'UD5<\(N B'&<3ND/$=(*[:,B1W*IN"*LK!F,
M8FU;)$22PB,NL3BHD<^XK\O/@_QOY"@# 4($&>V[_O0^#H1CW^A+=>%'P>-$
M^8KQ7#LWS[.]-.''^M"YY_W^Q>&U0\.=M(_7,[5G\2U:D3MT[>[Z/CR].O33
MU_@\_ )02P,$%     @  8%;3*<FSF;/$P  ]](  !$   !M9VYX+3(P,3<Q
M,C,Q+GAS9.U=ZW/;-A+_WK\"IYF;IC.5+=E)>LG4N9%E.5%/MGR2W-Y]NH%)
M4,*%!'0 Z4?_^@- @@_Q3<D16VDFT\HD=K&[O\5B >+Q\]^?'1L\(L8Q)1>=
M_DFO Q QJ(G)\J)S/^\.YL/QN//W3]_]_)=N]U^7LPFXHH;G(.*"(4/0129X
MPNX*_&8B_A58C#K@-\J^XD?8[?I$0/UXYN9';JR0 P%T788?/!==4^9<(0MZ
MMGO1\<C_/&AC"R-3B& C646B0.RU"]D2N;?007P-#7316;GN^N/IJ0,-1I>(
M8(.?&-0Y/>OU?^J?G?<[0&A)^$<;DZ]AX:>GIY/G!V:?4+84)7OGI_+U ^1(
M%W>6Y+DR;T()\9QL[J;+3MV7-3H5A;JB%&+8".G*B9($L@ NT (3[D)BA%H\
MI[1^.E>E^Q\^?#A5;\.BW,PJ*-CV3_]U,YDK_#J?O@- X8F=-64N("D<+,@?
M%*7'NTL(U\I8W5Z_*\WE>\&$&M!5/A?0*"4R"4^1[7+]I!NQ.A$R=,!I/7$8
MM1'?D3R*U[8"28AW)9#BU42@(B_*$2=-(O_J:KJN?-3MGVTG1=0BZTFAZ78A
MQ8=3R P)M8#-<+OH>6U# EW*7J[%W]4DLQE+<!E%3*2('Z2(_?=;B*@X$[24
M ;FZ2'&JG<I1PRR:8NOZLX-L%3'BE+<^X0ZE:29)<S'B@+Q3?YD5X8@1R(K?
MU:N2(^-D21]/#>H1E[U4#FE9=/J/)K$LR=1C3.0S#:2)$X9_;2V/B;#D^+:.
M*)I&_NA&Q,T$0,_&JK8Q0B+U:VLC8/*(N"L9GM>1(D86_.Y&+)I)0J!(YVJ;
M(Z+R?VYM$(X-R:Y?1PA-(W]T(^*& KAK5E\"3:1^%<@ ":&N8B0?Z8?K-286
M]9^(9[++_JC[[1FR@,I,/P:]9G'^>KIF=(V8BT4F%4OB%8,50]9%1Z;R79VR
M_\> ]HG(>'615 7)C$+U4(+$\&REQ"024G.0,?NBPX6Q;11H_LV5,I%55RE!
M@@ENL4XV?*BKDR!!=DO563-45QU!PL5(N)'C208+40!@,:P;4EN8AC+%:4#,
MJ;M";+!D2(VT>0?(TO>S<>Z 5XE3QD4+H$6(/.S36;]_UN_U0!=<86[8E'L,
MB3\2' $D)E \0<3TY]--5AN5>!R94_))_=ZT5T <%"D@W&C@E>F2;2B3+'BH
MX6@.TB5%*X;)$K$KY$)L[PBU--LB&-_VS][VWM>'\4<0U0/>!#7]< 17VZ?D
M]5BDGRX:4K8.BNS4!9I67NHH_?J.4LF7@"\2B,ET=*HT<-=?J&4Y(@&;P!D5
M.=W$-46AC8?"E#MUIKJ5ECK169-H<WT"=)7="02J4B!$.5'ETZ^$0"='%TJC
M^5G\($-&.=^IDZ39EKK!3TW<0-4#5$5'=-,P_ ()%]I=8NHB8[7K2)#+O13K
M\R98!]6!H+X?CVTZ!Y=;#+$YI,1ET'!WBG@FYU*T_]8$[=OQ8'P%=%U'F--@
MS!%[Q#L>+&SP+(7V71-H@TJ.F*;MOX!?D0EW"FF292FB;YL@ZM=QH( Z#G:5
M'83M9;R28V!B8%0=OWP.Q3,NYYDS+B$W!5:"WQ$7:86ZS:N447&C.L\<XA2@
M=&Q'23,OX(.]B]84\"E"Z[Q_?IXUJU&(EL_WL, BG-K8E$L++J$MEX3,5PC5
MF&C.HR\ 1P0[\4\&O+FPF^IZ)#;3V_ET,KX:+$97X'(P&=P.1V#^931:S(^
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M(AL[I2O5 $M+M:[U;2H8K8S-7OU47NP;+AORCW;E8KSNP$_?_1]02P,$%
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M=ITMEK,OV>NPL,<*4:_7;B7[L,HG?U[G\VG8@KK_7L]6=['2'.ZI'0FJ?6_
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M^:R.^_"\7OH<><FX]:HZCTN7LTGX>.QLOMX?0I7>B7=947KIPD=V7=]*[6T
M?>+5JNP#RK$_:?QCF5VMYZ]G7UJ6K<8+^I2WW2]UR"^V#%N<KN=A'ZW"[Z?E
MEQ*PO3\)<%\G\_4TF_HBOS'I?+*>[SZNW4>U^YS:_Y(['%BO^%9/W0>JY,7R
MXW6Z>I_=%MDR[%W?Y&'3>ITN( BR;CLHC_2SV9=RS6X7U)9',V(D/^:K=/X^
M^Y(MUIE+BT7M3>XPHQD$29_.BG^F\W7V)DN7ZV+CC=_OB3=^Q+!ZGN^K['<4
M?2)7TP*/Z.N@%&DQJ039_?A0EGUL^VRQ^G4ZN_EU]\ROZ?Q14,^!Z/DJ(+Z,
MO*>;T3]HV?:@PL]EC$J^^&6:7:7K^2IRB ?[Z7# ^4TZ6S0?[S?=M#[<3>^_
MW&0WG[(B=JS/]='V0*]#?\5D_2G[90]-Y'"/]'1PT($TL["##X^^#O^Z>[H<
M5RNI&=O79E]7V6):GN9V_N(3>1'[D93CJ$8RSR?/X;W!^BI=?MH OE[^\CE-
M;W\M)[=?L_EJ6?UF,]W] N N3>=_[7Z=/!CHETP51>F(KB(Q?\_#]NOY/W\,
M/RW3R>:H+ "3O5IE-WLA0HML_O>?PX"3+EZ3..099UH;K3WTVAI)O!4$> "9
MDU1]"^:\3'G*BYU6NT7SW@)N0>#-:G,$T_9?ECBKM(:6&VD0)IHQ3UR%K/;4
MUD'V_HM1Q>2GO)AFQ=]_AE7+W71RUFI8IKF-@4[YR/ /4(5?;&;7?YW,\V4V
M_?O/JV*=W?\R7ZS"7.+FF]>%B37[7/[0RZ=@2MLI*V[3HHS[N,G4U]GQ">+I
MXXFDE"$"D88&6"V4Y I6<%#&<(]T/+)H/:7GD,S(6\=U0[,>&!-V83O'TGZA
M?#QZ^XTM]@R-:O>12("@!!8:BA@16G''384!Q\0GS]JIG7+LH(W\W 381*UY
MOZ!]GP0:ACC?R'<QO#F7+T\W\.5ODGNS^E7XQ_PZF]V\^693]$#AQQLDC KD
ME/%>4<TX]0K2O5'@)21]:O>Y[=U3U7:@C;P#J**5&Y;+L&==+Z;E>OC';0!@
ML?)9]IQ1<?3Y!(>5$V.#A"50(@6%4'@W7NY=KT9N3=4.:NZV"6:\\M<E0J5C
M8;%.YV\":&&'7.:TO4OO2E&WQ]WWD5A/R%"S?:* M)0YS8V@!F,G 1"5/ "!
M>'*@%TR.;L"-)HN:3C?HI_-W>1C):I;.36A5YCN^F<VSY2I?5$-;_K&8/CB8
M.42?^!X3@Q"#V"N)+";0&^C07N82U6A"X9=+J-[@;I-B[[//I4,S+^[:(UGM
M/I/P 0%.O/ <8 TUE83MYV$JD8BF&?FN:-85X&T2K4R?6+;'L3K=)=P9Y:@C
MF&$D.(38"51)JU&#S0[]KNC5 =9];:Y?SR9EU.ARYQ$_LH5^]&2BM?*48\8]
M44HJ%L0A>WDDBM]*L1?)G79@[._,93.Z]]L\W5+T/;W?9*OK?/KM __SK(D>
MWUGB8?A<C,!02>>E-L@)L$>% !E-+OZBR=4YTGWQK\JB/STM/7HR\<YR12F0
M&#!(I7-,JDH>HX&+9HYXT<QI!N,]+?[MUT<(AJ']V;7?O97:?#^\\T>)I1D)
M3&+:8(>QL101);>$$!)@">M\5S^\\\_Y +US@#D2-A=> 8DT5*9"5FCC^W2'
M]N>=KTVG[KWSY^$_:N_\^U+*$R[Y_3.)PPQ@*"R5+&QML8&0L4IP8U2\D75Y
M?OC:''AL<$6"V9L=7X[OH+/LF:<2 K"W$#AAE>8<<.?\7@Z$X<@=Z!'Z>$ZC
MC;"X7-V.TK?=KTJ'4>6;].OL9GW8J_WL<PD6&%A",25.2DRM,HI4LF"A:)_J
MK.G,CM%$WAX&O>DS8%I+GP^?2W#8LG$$.+3>4HV<PD!5LA#'P?B<E*WHLP$&
M_1V'+;/PKNLRA35LD.?YMM3)O45159O^F+_+BK*"A<^+S2YTJ>\^AJ&>LLG:
MZ#_!A%DIO53&(&@@4 *""CLI2+RSZ'S^7*P]-X B+H#$I60U8NQ:Z#]AUAI8
M.DFP5(J9\"]V/Z$CZMW([<]^^=,>>QMKX >+S\%PG);V=T#>EOSWVR/E-[\I
M -'^H/EX4.J1)@DS2#A+"$+2>Z( <MI5H_:0Q$<3=1B6VJNV\DZ [&O.:B-I
MA@GC)0=66<TQY\'2)J8Z,&6(U\J.:RG@[%*-NQ9P?9DY#X8;8I"4D!HJ$1*<
MT&KK)HD6=-PV5S.U1B<_Q('V?1)HE.;.2'G3JH7RP.E=QSIY\GA"M0GS+'!(
M&*J4IUH2LA\M$FB,EDGKFGAJ?30%:OAT&4&M809(C@%CWDG!>770)C'%O?H"
M!HB3.=?_W":8T<K?!YP^,+G3LB9FPQ#UIOTF4@#/51F63R'4X9O23.S)+UC\
M+'$9Z3519.H9].:D*PLU!KM_%IUN<WY/"0;&A^\'>0=+<)U!QE8R&B7B\[8N
M(\VF&;&Z@CF>2D4^R;+ILD3M?7Z7SLLB8N_"$(^1YDB;Q#!(,7-"*4[*<&E"
M-=V-VSE%>#0]+B,])HX>[0$Z8#1ZV%C-;LLJB/, 5%&NQP_!M%DP]VYFBUTA
MR@_9?%[6>RMFDVQ[$]5YT>H-7Y8@9X@T6BA@*%-0R#!![U#UGH#XX[W+2+.)
MC?4;7!/C3\+!"%A!"9!6.<H(==96WZMW6L5/@)>1A!/+K&8P1J]_APD]?9[0
MF[N?)YOIN3Q"SZ8'9Z]6^T^(<@0 );'EQ$,B-.65#\=KC$PTK2XC_29J71T(
M_(%3+_Q_Y%=7-^EB\3I]GT^NL]>K:7CHT2\/72W_(^7B* VE,91B!2U6C"%K
M-:"[LTC.&8(_"B)&>Y 0%(A*:YW!B% D,=6[TD@<$ 3Z//SJ+^6B-IVZ3[DX
M#_]1IURTX=N%&@!GJ0MF"."08"G5[OB04T9MG^Z3H7V[M9E1Q[=['JXOU#5G
M$!>,"F(U!9(C(2W?8< D(NP"?;NUU1KOHXL"[?LDT.7X=H?G34O[2/^WIU;W
MW]+GS.Z_'??ZGMU14NZ+/*!2"0Z9I$83@BH)A93Q,>9C\ ?7U5[>(X1]32H?
MUI^6V7^O SKN2[DRGTY:.- B";M7Q!R3) #IL%!E,D=E9R)']'>4AA!KS;0#
M[8#4.;G^'&R32(0LU])I8"6%P&A#JZ^0:R/0N V6QIH[S81&.+U,3HS2!AD/
M%49!@9/)D,\^GRCO$"940 F(%AA1)T0EFW=ZA 9'"WHZKODH9(:/.*/,$^0@
MQC(,.=C?DIG=N387!*EXI\)E1)R=>_S6)IC-@W^>1)"4H4I5]$"^\.O5NL@V
M=1#7Y\4"Q7:<:.:HL,PH:KRVR#BJ*C-:<,GCSW O(^8LBDY]HQ[-NQW5[RM-
M5SZU=UDQRP_6 S_1+&% 6:T<TAXQQ0&U807>CQ[+>'?Y982317&F74S[,C[B
M"P@*$0"R5!*N"!9!"%\5Y.0"6!-?%>DR8LIBO43-8!R(%F8=_N5H--CS#1+@
M%,7 (HTPT(QX!O:VEZ!!WA<>T=422>+0'(@K)4CGTN6^34*D!EI 0C$AS .,
MB:YV?4(+'G^,?AF16BTQ)AK0@<-D?@L_+$R1+Y^_,_E'(,Q1\@!97HZGR[I
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MSFBHXX;9.7'8_>#4*$V/<5.I70OD-PL@V"_0M0R2YYHDWAK*K$6>*(^%,2@
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M&-\*UL]Y0,= CH1:D\GZ9KV)F]E7;D[GI5R_!4WH["K,N!_3K_%\J]=_$LP
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MO\^66?$EF_J\\.OR@I$J>^Z06=)6_PDWG IIRTH02#IN)-1@CP<Q+]-U&&6
M# 1Y- 5WR>?A"ZALGTTJYFVZN%L^D.7!AQ.&>D2*:OQ_+()^M^GM86M[B*#]
MO#UA#EJCK3;.602<1+3*5*4*,AGO6>JLD.]0]!VE0OHR.O9%2\+HPRIP0 ?S
M#3_*#."K]]DD_[PHMPE;7__F2J\Z7N>6WY20@!_4C OE#3-&&$/Q'D_':P6H
M=NV";D?F^N[H%M^7.$"5"#,R"KL^"XBGH@H_H@HK.YJ*JH/QZJ"?>C@MC-IG
M':;,_";[L$I7FY>_WHE_PH5]I%4BC::6B_(J.4<$(LQ16H$C?+WBR<-ZM >A
M2MX5PGTM6@=&?-(G>K1=0KV2U&DL)''<:HN1VF^ F,9RW*[P5K18CQF-\'K9
M'!FE&WU\U!B&$J6-'MYUK1;3!W?2[B(^3Z>.GVZ=2.0\)U)+P1"B@GH-]7X*
MMFJ$%6-;TN/C'//6L>J+([]EBZQ(Y^6=8-.;H(?EJ@QL_I+594FM]@G#P;S$
M9>""-(Q"J0&S^P-HYN+]LITYM[KA21=H]<64G56639\WVG8B'*%*O0X2:!7U
MTBE"N=/($,+NL?5"CG!.&<N.K!. !TQ6V![HAX\E3*^K8E9F"FU^_T=XC9J$
M[V:VNNO\UJ/GQ]?++4?ES<)9L=Q&A/7YKJ&S0<P\72[?7FT&5N>H[=GG$Z$8
M,)81CX@O*_X;6%6#EXQB7NM I_.<C0V[[C8"G)&%\;A58H7TS'OC,*8>.<(]
MV]WX)LO;IOLL!G/T\*JAI@ZG2C1$9-0'21_6GY:SZ2PM[CZD>V%/'",=;)-H
M(P1$6*"P!LCP7Z[(SF<@"4*]VNRQ:1'QRGY,H)90ZBUDXGZ496SJVZN/11I6
MI$FMG?[IQHD3 @$-E.<>"^$X0H164ANI_+B/A%K0YF-^= 79]T*849X/C9(G
M+?GZWV>?PZXR*\JJ0D4V6;V]N@I;C,7GX['[QULEM"S6;)##"B!K-?! 5=,K
M95;A/K5<T[?>HD+RKH"*5K):?;S.WJ3%GUE-_1YLD  ## %2 RJ YV7DMJI0
MH B0$9[,=*7:MC#J;6JOSJ8>VM2GK,)#;1+(H--(4@6-M%A1C*&H3'#E<7SX
MS/D\&-XJ; FEOICP<)@G%_6G#X?M%[%2E!,4(0)[2AA3>ZDX'_E5CBUH*^\(
MHI="@'%:<6/0>TL+>ADZMYQ]7I2'M^_"@UE1[,XZCZ_KI]HEP!K#N7,0$@F)
M!U3+_?BIXR-,B&NBA+P[:'K[E/-U60'N-BU6=S4*7CSW> *@MCK@PJB1V$AN
MR3W_N8/QD6SG9]L,OI:W %!_[OK;W?UAZG.1;:>V1Z,_.;G7[B.A%$*H&55:
M(:K"CA<!O\<@;'S'O>@W4^L3[WVWH'V?!!JET3!2WK1D1OPCOUXL-Q[3W4\/
M@E%,7MSFVZ)UQVV*LSI)(*!<2\0P$Y#I8%X!M)=,Z 9IR]W=0M"^UO*>X.O/
M"-EG@9Q1SN%(JP08Z)"#W%H$F5?>:5$=H?!@A?5Z3GR^'=K<4]D>-@-PX%U:
MO"TVVZWIIH+KNZS8"%&/"X=:)TXP)2&4%)#PI2F&";>5W%[A^/ILG1T]=L:)
MEC#JBQO?[J?.F"*.-TP4,P!P+;" F$DA 32XDI81.<+RX^TRHE5XAB%#Q%Q1
MKX-$46ZI8P$ )I5GE&/F*NDM]_$GU)TET7=)CI9@&G+&V-XI?.9LL6V44&:H
M,-Y)ZZA3 #(*>26E]C+^7*NS9/7N9XHH:(8DP(,,XS-9\*!E0@"P'%,.J:+!
MBE9AI;PGO&EP26IGB=_=4R$>G_Z\EV5IO UC[;KTM6XCH;?#_SW[:_.GXZ[,
M.ATD"'/,J98".V+"I(B5K5#E0BD;S0Y^&>SH!*9>*P35*N*S+>D"A9.*".*!
MLU8)'Y8_4DGAPBNBE2TN1-FQ4$2?.!VEU\=\4Q+BKV*VRHJESXNJ ,_;J[=?
MLJ),5UB5QR+;./]#YU$MOB(QFD"HN9 !1*>(+>-"*E24H/$VI!PW008&LC\C
M(Y]DV73I XQ559)@)6\"AK[-HGC6SCC5.-%424]PV(D;@\M[1S&&E=22\ :A
MTV#<_.D,HR'B8+^I KG]'EXM'@21U8R(/=5-@CT/^W5O".-$*XZ%YOLI&#'1
M('?Z0@X].T1K -YLUM4:QQF'FB32"$RU@P9"5(8P"$OV7P94L $?+N3 LR5D
M!M"]R1?+6<!ZX[IYGTVRV9=L^O;\2>-T/XD$PJ@ *B*6 <(T<+#:KHE@QC7(
MY+J00] NX>IUX[*;YFK/&X?:)(0PP+EUCGE+/:%4[9=4021J8'9<R-%G6] ,
M:H=>/?#WG&N&/FR;,,JM 0*9@**&7COAJI52&.SBCS3@Q1Q^M@M1].[WP2MW
M]]BKFS*40'U)9_,R;.U!=<1#V]MS^D@(#R8U=L(+2 1 N-QX57(A[QN$<X[\
ML+-KJ#JO<K"^N4F+NX##[/-B=C6;I&'8DTDY^G(CGL]GDUFG]01JO;^L<+!>
M[8I4Z'0YFY0%;6;S]:JTULN"**_SY3),OCM-E%-P]P48:@U]),-PR]7LIG3*
M_;',KM;SU\%@.3&T7E:CVZQ8W95565=!H>5&?1..]+I&:873C1-$<+G5YX88
M!) %VMIM#!."N@QDJ3,I=62&[0.*#XI1O^C"\2Z"):(IMD9I0(GCP$AGS0X%
M94BO96N.5F!H4Z$'RS&TBM6H:S,<E%3??0RC/W5?Y>G6"<5*$F<)#^LB)%0P
M"D@%E@LP]DBLR&C^MMCPU QL&;P>]P<'  G#.'W3X>G6B;&<*LZ#^0/+VP,M
M143N,662C#NZOU7-UF5-8_2^'_8,PYI3EV>.G#2#A?$&DSXK]B,^6='Q0(M$
M8,"8\II!5:;B!?$0JN0C7O5YG7+=*QS;U-K3X-T64.KM/#*_6OT5-FL!A.K'
M;](2EJOE25[4[B,LZ-0 ;SRR4ELMG%>[>@D! ZEA?$16=Y=]=LB4KG#KBSM^
M701%K#<"^-G7\J?39#G<*,&, Z<-)]IKR\,.@_/][@)Q$Y\QU)E_HTMVM 94
M]"'FZ_13F9.4%W=A"&^OKF:3[/1B4;-E8HUC$#J$.;<(.8:,5Y4,PC1P773F
MN>A"V=V@U=<$\+J\]Z>L#_KJYK;(OVPVV:=G@".M$AOLKD!#@SP+W.:0&80K
M.14B\?9E9PZ,+J> ]I :? =2G7I>'<_W.-DZT8IA0;B4%@$:ICOMV?Y+\ ;%
M!^KU;VPV/U=K'[#!B?+<.7D,99[K)U'>8F(HDUQ+[0R$!-D*"\-L_$V&_=N?
M'9*G!>C&X34;B_?L_L!3A=]/2[=9P/1#-ED7X979TGV=S-=A1*7;VJ3SR7J^
M\[3M/&P[WUH-KUH/Q?Y/2_#05^C28,4N/N^'7\>SU-8K$B,E5, "K(UQ4F/I
M^#8$*,B&N8=U/O>N_4\-A:WOI6KC10FV5G.EE=96""6E!W)W7[37S.L^5]^C
MOJS^*730XS4 [J/VBS7$0]\]W\$)?UJ';TTX5A0A01RG5"$/G32@4@X1IL\B
MN)%^N'XY^OARDM&HIB_C]_D!UZK"=*IIPCGQ7'ABL"+&(N@Q597$'&,[;O_>
M*+A0BY^-(?\>R#9*=^"+Y-A WJ/[RYA.>XD>/YOH8$"5]0B(4HH:*Q#?W7N'
M -"&],J>>KOQ]M3T7#)V W"&G4QJ?SO;J-SNS+1M_PEAEG@$*=>6,,*0(@A4
M1CO79(2EYP;?KPP!_#@.B?9/F7P^KSPQRX_7Z>I]=EMDR]()DP<;]SI=0!!,
MY6T'RVW246GX#GTB8_+%) QREPLU6]:[&.U@HT1:ZH+>/-822,@PQ6Q;]!(A
MS1"NM9WI2=)3IQ_/-TB"% 8#)@0%!# MD:R\:4ACH>./@=N^$ZT%)3V)3FD!
MD5&?+SR1L%:\[9%6B3.2$N2,50(',%Q8V??@((Q&&V?;5->GJ!,-47\A;H\!
MJ!,'>:15X@2E1+$@*>4T++(6>U;)*2!PX]Y=MZ+!DQ-*4[1>+CM&N1T>&RD&
M(L-ZN<IORORU1R,_'15[O&4"9+"(!<4HR(N<9,$F=I6\P4COT]BHFYC9AO8>
M,Z)5E :;(O2=SA:3Z[!A.'6AUJFFY5$1 $ZY\(V%'3XFFDI820PPC+]:I^-[
MM;JW*IK@-!PSJD&?OX(\:IK8\,JP?492&XC#IQ#D)Y7$!H'17\#1ED)/,J45
MW+X'QER*X3$2H@QTMOKD9.FD[7&H22(X]8X*AB0O+[ADP8ZC>\,-67H!1D>T
MTAZ?;+:#45\L>)/^5UY4UM*IJ(:G#R?:EX6Q-# \?#360D&\KZ3B2L;7$NOX
MBJ^6S8K&R/2E[^U-M=\,]^1Z<+!-XK!@R@'MJ"32.\>$V<N(I!+C-AV:*"WO
M%J*728=1V@6C8,&YVC^00N7_]A_YU=5-NEB\3M_GD^OL]6KZMW0Q??3;5XO)
MWXYG5)W=46*=@4 ;3P$(JR6U$JK]CEH)&W_78V<F0 O:RGN$+)H4'[+BRRPK
MWORF$(?'U?[,HXG%1FMO@  *.^.1LV"_)%(I1YC$T+)BFX,2K;I_I(OE,EOH
M6;[*)M>!.B=NS'O^\40@8X#C&EFLD:?8D'NKQE@3'T;=6:9KRRIL!YAH-?[Q
MX;?\2U8L3F>R/GTRD0@#H($E89HP!C++[/X(%!E7*ZN@W\S5EI77&)/!CES>
MA?U(^$7Z.8-'[*ECS1(%N6.(&0^M#Q,-8 ;O<CF1 43T6<TK=F?]NOTH@GB$
M+C((Z&.^2N?OLR_98IV5H5#9]*4% 7$ D =60Z2$P] 22':G+=A(YEY $)!B
M3#MO'6%62P:=9V!W_(.U=[!/9VUL$%!M)=4+ CH/D5$' 34]12,T&!]4<P,Y
M#@8)9HS)"@KE79]Y;FV<HM76[.E3M/.0N<QC$T8 0M)1!+0@G@?L=G?8!!D)
M%_#B3M%J*ZWV^4D<1"^3#I=RBM8_"UK:KH7]X=TJJWU/_8''$TP=+R= 2"#V
M3$@)H=C+SV&?DWKCC5MMY//6@1GZ\(0PJ"7&A &&/-<$4[@772H:OP,;X/PK
M2HWM !.M1IUGU^4E<5GQ*OQC?IW-;HXK\F"#Q&+L*'>> ,,5T]XR!:L10VSB
M;? !SL&B5-D6-"\A( Y2JA'&3".F+'",VNHL*DA,47SMKV$"XF)M[I9Q>@GA
M349BP5UY2SD5"KGR J=J?3((,C]N>[P]A9X;YQ2'V_? F%&:[.,ERC $*>][
M6^Y.67_/3M>G?O;YA M*./-2 AOD<E8BMY<-<]$K%5H*A:NMKF<NT&L*T("6
M1L,T/D D\-Q!SXA2E"DGJP+<V&B.XH-AAHF,:]&^B(3H<A.U/(6*0B\$A@ *
M!:3Q>O\!:0HNSJ X7X-G9&S%H?5RV7$IQL.@I!B(#)VE\7''K2\KG1)@O0.:
MA#FVDI=8WFMN9_,TOMK:.S.-[SR4+CD.A KOD0..,D&8)@IH*/<(VC%>>M*'
M(SD>H9'%@?AT5OPSG:^S-UFZ7!<;%[:?+=+%9);.U7*9E1637\_23[/YIE+.
MT/$?^_%NQK;\=G [&:9ORZNRUT5YX!@>^#U?%-6_EE=Z+E_7"!EI]3V)#3.%
M1%!YH,M34A.VL[MZ030PQ-::5,>+YZG E-;>D0 A*6#8 2P,T\Q9LBL[AHA&
MAO99H>1H+,M ['E\L\I N(\Z8F8/BK[;__@?LZP(@[Z^>UU>2W1BZUVO@P0)
MS47 C2#/H *,.58I#4HLXO/3.HZL&8 TAVC;)L!]F6#/K:?+IV*<W+>=U4\"
M* R8>HPH=A8@;GR5T$$AEW3DQ7#;5O@A/G4(Y?=-KU$>%%P4JP9FTZO%[7JU
MW(!R.%&K1JN$&,^#4,YC3HTL*[LZ5<EIM!AA1=*.]'B(+8TQ&Y(;*(H;NU8)
MU0+;\OI9+XA!PDLB3"6GL&R$\4S#<2,.LR&Y@:.XL6N50(H%-LH(Z;UC/DS)
MS%=R(M[@OI7. J2&XT8<9KUS0]]M=A!FGBY/)28<;),XJ)RBT-(R:K,,-_/5
M@5W@/V'QR=T=QTJ-:A?5"-/>>;-%[!F,-J#\L<@_+;-B4]]F\TV$/^>+24!V
M<S;[4-CZ1G#+KTQL^,B-E ;#\-TCPX 2N$(8$$8N9CL6RYSC!U%# _V#TNTC
M/?8MX*4S>1@&O\D7V=V;M/@S6_GU8GKZSN/G&R02:5W6&"DOBB%, :^QW6]Q
MH!_A#2C#*_IQBF(;R/;%FS\^?"PVB-W=W[%QDCN'&R7 ,40@PV'O8RAS'FA6
M?:Y(XP;;@^ZWCF/A3VOH]L>A^^H;'V[SQ3(/^+G%*BMNB]FR]$1_6IW%KO.[
M2XPT0B%*0$#<<TZ9J$)&*9(*QP<_=+\M'0_O.L>]O_":;4)A=B;UCK9+-.2<
M:XN,XK L)\,1WGMW=8 VFF.=E=D9'<?:!+@O,FVQVT-I9\O251YP5)^6JR*=
M'+T][%3;!%+G9'DS%=$>"86I9?L/"%H^PKJXXPB9:!O9WJ:F='D=$"G_K[S>
M_DLZ_^8X\EZ.8]-4W3X2HP2#&'F )?*"60P1W6. Q @3S%O4Z^.YIR/4>IN'
MOJ2S>3E%^[PH\V;NI\]C$]#!1HDTCI=9.H8BAIC$R&JXGVVUCH][Z<Q4[XX;
MK<$T^*(4LQB%2=@KI&3@?: W-,PXIRL9'<9])B(-3X664!I'^/#&-7$H"+@<
MWFYPY3\^I<OLW__E_P%02P,$%     @  8%;3&U+_-/9RP  #9,* !4   !M
M9VYX+3(P,3<Q,C,Q7VQA8BYX;6SLO6USW#BR)?Q]?P5W]L/MCI"[P7=RXMZ[
M 1) KS?<MAY;/;,;'1L55!4E<;I$:DB6VIY?_P!\JRI)50) @*2\&Q,S(UOE
MPLF3P$D@ 23^_;]_O=\:CVE9947^'W\Q?P)_,=)\76RR_/8__O+;EW?P2_S^
M_5_^^W_^EW__K^_>_:_H\P<#%>O=?9K71ERF29UNC#^S^L[X^R:M_C!NRN+>
M^'M1_I$])N_>M?_(:'[89OD??V7_<YU4J?&UROY:K>_2^^1#L4[JINV[NG[X
MZ\\___GGGS]]O2ZW/Q7E[<\6 /;/P[\Z^0GVIW?]Q]ZQOWIG6N]L\Z>OU>8O
M!K4PKYJV.1KI/_[UV>?_M)M/FV$8_MS\=OAHE;WT0?JUYL__Z]</7QH[WV5Y
M52?Y.OW+?_X7PVCI*(MM^CF],=C___;Y_4ETX<_L$S_GZ2WC^S(MLV+SI4[*
M^D-RG6XIC.;;[LKTYN6OV);ET3<PAD+&D.DQAO[;*U]<?WM(_^,O57;_L*7T
M_#P"OP3@^CE87>@:$C[*@#S'ZM,O5(SWB@[=5"WBYU^I&'/;T7"^T=%_GWZM
M8NQJ(6OM&46=;!7WC&=?>1+SEGWJ _VI^R#[]C/RVS3>B>K!%Z=?ZS3?I)M&
M-(^^VL@V__$7^M-J5[V[39*'U>>TJLO=NMZ5-'3!?/,YW3+(<%UGCUF=I16\
MIA](UO7*CV)(7,]&EN^'P(0D! 0%#B @LKPXME=- ZLT?_?;EQY.\U>Z&OR+
M"$?/V2_3JMB5ZS9T4:0L<K?@__,(HY'D&Z-#:>QA&K_W0/_/O_^\-_:(\6+]
M4A=JX-TDU76#L>.%8C7]G]-M7?5_\X[]S3M@=@'YOPD3^-0)Q5JC$UI.MVQ:
M4I1=ES[J>;!<&T6Y24LZ7>K_45*N7W%>]XF?UP6= SS4[X[\R*9-VNTJ='??
MECEJZ$NL/1NO;%JTV6W33S='2.@?TO(QC;Y=T6_[=!,757U%52"BY/RQ<BWB
MX9 0 '"('1\X&. >"2 ^7-5#Z'IU^.IH7V0@UR>B[)G1'-_1/]$!F^7&AY1-
MB/'7K#8^9,EUMLWJ;R='[W3\\RGGW-2+:6B/UBANC&,][0 ;U]\,!IE]@($V
M?K]*KNGG&7BC03^QL$KP>T9B=7IK&6*KU<)BNKXO)L#OZ3+_/J7+O3IER_E!
M[CT3A!!Z@>E@$R+?!SB.0\^'8>PYT :(<Y#+?KV^@=PB,@9(LTU\3E!S9@R.
M)7,9XVRT%87:+B8V7CZGCVF^.Y@7V;X9NP1X(/"1'P0N"*.@;\:+H2\R&Q'^
M<LU3C1[/7\4F%>(<\:ZU--(CNJ1JH<RX;#KFXNSJ2)*V9>B%//QG:YU1// J
MQ(=LG>952A=37V@PIW^HNH97H>,C%].F(-4E:#H(N&;7GNL1!$2D0KZ5:32C
MW018%UL*NB@3NIQ,C>2V3!N-KL3T9 2C?,(R#9EB"M-A:M(U/2JC@S6MU)QD
MYXSFC&=T&>*CP(Y"=5^3FK 0:MHO94+'WLHF9F""R">>;7EQX)@Q0'T[L04L
MB1F+P+=/*3^WQ6-:YLTL7U9[).@3FLQH8DYJ-M.2UJ*993:S)^/UZ8P$<<N0
ME!'X7Y[02#,ANN99(6 [D6?;)@[]T'9]SR51__5V%))5/6P-<4_F7_U2(<$X
ML35UIN\WNUE&V:&16^B\3HS8 D<I)W(+FWE6,QRK&&YN%C7:!6"?6+4(VLT[
MMEF.L:*3$?SU@4U+]HLCDQ!B(T \9&$3 PL3A/OF3-..168)THWHWDIAN)H9
M=MHA$\QTR+/')PB3$"<F$'O.>E"SY4!.L7-&1483N@Q5&6]&H;BCB<XHJI1^
M]HZVB*B^;8L'-C7O&E]A;&$O"J!O1A$.L.O$9KQ7.E<PI3JF)>V+E19<,YPV
M>WBBLY!19/).3:;B472^<D#A ;)>G28_S'*:I?,'6!2PNPQM4F3+\X,JRACB
M5:E?TCPMDRUM$F[NLSQCDL@2F7VK,?!"WR6A%]J(3L<@I*WWK3K (B(Z-;8M
MS4K5P6M&67($4$RK1E/*IU93LBFF5X=$'F.;1[%>8>J,9JGB>!FJI<R:0D]/
M'+>J6T'BAX'KA#9=01)D13&V@Z$9&/LBF1OA+Y\D@[-^MI8;MY1[G3*Y)9Q2
MML8NW>9=KPFLT[A96X::R,-_95TFR .O7GQZ2)DLY;?M89H/156M,"*^36=3
MD>N"P+1B$".G;PDZKB4B&3+?KUDU&(9VPZ-HP16YH&)(D<8G&KKY$M.- 8W1
M'9[[@0'Z<5KQ>(&2,_HQAL!E2,@H"PIUW4E02.J[M/Q8Y,5QB_ULAT#DVM Q
M21#ZP U<WT=^UZA'H&N+K)A&-J5YP=2@,[(&DJ"LC*204V&F8T]0;!KB#I$-
MJM.!FUIXSC)U3H/44+P0.5)DS%-E4LD1KTA]3.L#(00H),2ATRB3ZIZ#XS (
M[;X-!%P@,L\1^V;-,QP*QMA2'&+R(T@.G]KHXT5,7!@E1W,8 ]9UF5WOZN:N
M3ET8ETEY+@&O16&.V#DC*'(L+D,_)+$7*OJ1Q!0F+NX?RO2.BE#VF.Z;I.U_
MNKE*OEX6)5LP'':>JZ+M.L/.&?)Q9$%,8F %)O0L&+IAC\Z'=B@\UYD TR23
MHO6A'8U"">ZZ3^8A@:G4PIPC,^<Z,N%8)B\,IIS%C4%-N3 Z8TYHYVS' 13Y
MX;49W82>7H9T3V[U2W/$R5E7$2[@8Y)M&192E%^2;?HE7>_*]EK]YA^[JF9;
MF+T%JX 0/P(XMF/H>G1U'D=#9L_SP@"KBA=*06D.&+_E99ILLW^EFR9.&%1T
MLOPQ;4&*INLF<]3XL#&;CY3'C<&2=S=%^:ZBMAA[8XR]-8<19CEA0\0/DG%#
MBZN7'SCTF"T0.33R/M%*8X61#2DJ&[B6'6,[]E#<G_;WXB""0CLTFK%HSG7$
MS]84DRXI7G?%)$L)I5Z8<0FQG # 0;J^]0*W.Y<O]TJM5;L^$&19K+ *P\#N
M9\5%7F?Y+LMO/PV[S9=I&255MF9'&K/MKDXW7^XHHE5L.0&.0.B'@8,:8*'5
MX['-0&B33!\*S3/_!E-[+KI%9>1=.MMX:'-(]U0^*@953.DU^H5/XY?A$C%U
M/\Z9-Z<F]L"-/7(J[-0Y>]]U\(TO9_VDL;R.!,UG]%R_ZY:AY!/8^6(1'_W,
M\JKWW]/L]HX50GRD[=^F'W?WUVGYZ:9I\M.N9D6<67'L)XA6=&7@6B3T+2<.
M7> AY/C].70OLGQ31+HU09A<M__L[#"2UA C;RQA4\%#%1><L.MR$)^&+\ W
M8@+> S8ZQ,;'P0D-Z,HX@'WQ7,&GU6XY>L\(MV9_+4.U=1M93#H&1 ^\W[,3
M(TVH:,K8UEG9E/M 6;6FL\9=F>ZO-(: P-"+S=#&@+B>94$'!7:$G ! "P?<
M![O5-:EOX.]A&5&:IS=9/>=]76[&SAX-5\_[,@:P%LN>'2C7Q=YK0_7^-O^Z
MPO</V^);FE9XF]UF=!4.;]N%>)VMLX>DIDOWKIM>TFZ\HBU:"+D>I/_%Q"4Q
M(K!'$$61RS.?TM&NYDE4#])@D;HNC(<]3E;V^8%^F&^VI(7S\_(X-]UB\C@
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M3C@YTJ(ASYDXHQ\C:%N&=HPQH%#6A01K;B;WZ:>;H^90<9]D^<IS@&6%V+5
M%#C$IX+EHKX]QP^$[LS)MS*9@K1X!#5D!'M\4C(-<;**\AIG>JIRGJ+DC+2,
MIW$9"J/ CJ>5.Q4QPW5$ZWV^_E:G<5$^%.V,Z->474Y;V2[VV4S(=$R;>$$8
MFF8P2)MO<LU21C6@665:6,8!+N.']N].U\Q6R-YYJ9F,.#&5>8&SWUM0G!H]
MCC.!$TM3<"=W&$F&0[[312=L/G5P:"Q%"S@3--J$0F&7$=#<_YGD597F45;4
MZ?J.-MPUY7AF%-JVXP'/(G[DV*XYR'L(7;!Z3,OK@DMU99L0&0"':+C[?P?,
MZ)!=L,I7/QD_='\MHKW2+')H[Q3TB6GO$]X8;3+B*TV:@/A.09Z<^,8LS9R6
M[#[<-W83;EUL*>I>AY/;,DW/OBG+)\0G[#\EQ&/I6H 0CS:A4-A]!(0X*M*[
M,LMOT_(]_9_M79K==XTAV\:NCXD#8A]Z$4$>-/O&3#OFV@H8V83F"? >F#$@
M,WZYO_X?Q@_[7XGH\0@R.11Y&A[%-/E%"B5$>01S K(\#8.R]YD?Z&]9H6HC
M.5#EHJR,/[/ZSOCS+J,QC_Z>'<6X2]C+C'NY-LITF[!C_771'M--UMW;C67_
MXO5MF;#O+M-UFCW23S9EV7[[Z<M/QFU!IS%Y\S7);9JSS<>Q=Z)/$GTJ HSW
MS )B@ (C"J6]=>26</0MHMWA[CXI_VARO:;K1I9M>Y'E002PYZ*8#,VZEC-J
M<UBTL>FWB0=\4AL[X]F5W#G62>SH/61N3J?93'["E<BVLBS-RTCAJC/GM:WF
M<3S):UG?:)='CD,[\''H(]\-H(7-, CZG$9LF9[0:=G1C<VJ95);3./YE54S
MC=2J5+-9-J%>8TM(SR2)7JJ>R9KSJIZ-XHG[&D"R3:O/Z6.:[]*/:=W- _W
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M?WV7;G9;"JDOK/PE+1^S==H@B1B2HW?8MHWSZ$^?;CZGZX+.#O[5%%[.BM:
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MOS-KC<Y<T0S-W.SSK@GGQJEQH;F4#J)G*:O9<>?6QTOI,\N(;\NAX^E*?C'
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MB+[Z,]T^TD\4>7VWS)WJCM?QZBGJH#<EGL+&R6FG'(>*I?-]?O5GP:8 U2K
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M8PK+DG:G#D&^^4B).O'K*_I3Q7;UBKQJ'Q^Q73=V+!_1_T+'(LBC0ML##8-
MJ/S2#/!T'Q8X>&?PR";CT*A&+JE9[]:G/F(<6B;Y?M$,ON=+*BS<[6)Q<!Z/
M:WY04I5?SLU8Y^L$"YGWSDC R0<E9_(%_RL-NYRJ\D-2UM\^)O=I\^",%6 W
M]B (;"L@.,(D=(:F,+&%RI!*-: YIAQB,A@HJ1>IY*CC$W3MK(DN300)T_2
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M7:L)I52G1S=A/%D?F'1AY$/-^ZK!;"0#:..'+._^]L>)0HB\=S5'E$D<.W&
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MA<"7VS90#F.R302VAU"SNQ*[\EL;[.1V#-0[0FS_8!X/C-M-Z#"S706*VCB
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ML-.\*7+^#*)N9PY$#XH=^5/53B-491+J6TDLF5BF>13F$Z\7][K)WC2?(-%
M>4:AOO'DDHI%&_'_SRO$\HKSZJ(AS>#M)1R9AK8.N,YD0Y^[%_(-S3Q++@VC
M!UIL]U.1%"D=C\/R=."$21@@VX.NG1B^[?BNTV.(/--A*G*KQ_)<2Q&#LK2#
M?-MB)?JV.[37]&E)G&U9/97M3Y7M*HHVAM1"\0SMH&L-HH-.&Z,'O\[-P(\9
MYE\BEFRI52\0R_K&MCRLA$%)Q27?0$1(\J8>ZI]O F@F.#&-V(H=QT?0,XW1
MOA^;/MML3KU=[=.V\5&";8OL"A098YJO@60I%=7%KF8%I3] /?<#\%5IYWM>
M^753HFU6K9DR?K'II31SRK2R??9A XTH,-TH=$/7"5T;V:[G#\:#Q/04"R6;
M4>TJ>5T]D;@%=M7A7J-0,C*L2"454CNC1+:H5ZJ/+389<>1KDA]$&3F=XI5%
M$<XD-;$U.7ZKN._>CW>QBTP'$7LFC /7LPUL#A B:%L*)NQBAC7/UUM0]!S^
M8UK0"O,Y!:5$&05YEM)'_13K4LFN'2;008M]55KY(;O\BBG72*O634G7V-13
M!7^2&OI[21?PZ5K>[3[K#^Y^_#X]*NMF@S!)<Z,HM'V$L)4XAA-: S;D!RJ.
MR2I&I%EUN[OT/]^VM;VV$W!*E%=UZTA)\H(-HTNK7[D$>I^NNA*>?9M._0+4
ML54).5^;\"N\IC9?M?3K\IDM)FAE7-$6V?2<4%UG3?V?Z?[0_@:]9OY72MC?
M.-!!INFZM*9(9"1.$AAP !8Z9J1PWTP%',UAXK@_\SQ@:^LLM."4[I@I:1LE
MVVAS-XO^O;77)WU;G\#H%!B]6E6$X&@-\7TXE4V]ZMB@Q6&^'3OU7'-'A=<7
M_#:AET1F['B.Z1NV$=&-PG"R:1AL&EH D%/J.6UPZ?<(AUDM/KT[G/4O/TG>
MC>,ED5.3-?+')[03>4V&<VW1)>KT*N1K;EAD3Y#-E6F9J!>G!$J*%5;5N:[N
MTR+_>Y_R%G6YSW>=W!6[S[0*57]X\_H.YP51O[R[:9QU!\ENZ_;=](WOXM U
MO= +8M<THB0)(&ZQ68%M. ;KU'@>,/H&XQ1_]UK/Z$%[&G7J SW>.GH!CFZ
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M\Z74T<$X)/[?RX>B;H\7]E_%QU?345]"E_3 'H!IN'X46I[M!:87D=34L/
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M1Y#D>&"^?+/;Y72Y(]U_3O/=IP*E3SF9ATRL;P+7-1//<.CQ>^@APP^,X16
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M&6[.=09]H4Y+4UV*<<OVCQ4%MX6)^"BJK:%MM(<S BZOVE_^W)Z3W4 [=.W
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M.F[@N88S6$X()AXI5&%O214D"17Y^T)%[)10S::"<[.L4 #9"-:B@@RLG1%
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MA&H UI5Z'/XP@0E:G NI%S.#YU;5E+?".A1.@U]OU]4T,<>J@OA0%>WCGP0
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M%BGJL'F:1G'%9G93<=LW"]2NW0)FC/IC)G/>+;+'.;V^;DL^,,RSB.0E?;S
M^9HMCKYR/'00F"'T?3,T B.T/=<+_:0"83@N0E+]5R<>6K5SG]#R&O@97MF3
MGZ;E7&PR."/=<H[[+M/+.)E>CLMWYF:*1%G&O$M5</\[;DHAAZ)Y]&']@K/C
M#M]N8KS!18&SQ_0?>#A@#NK+-GVJCZQ^9/G^A";T:29?&6%DVK[I^+YE1M4J
M0]. 3HRD>O^IPJ ^L^Y)SF]WLN%'?T?5B=M_T+N]#J3>^@!H0*"*"/S9">@O
MN02L3"RQ3+P$G>12<H.8"=1*TM&"I>D.;IJ9^4/S;/EY(,/O)&K5FBTC8RN/
MDNB]$X;F<+398/9J!E=IAX*Z3TO^#$]M95<U.K^ 9$/;M5F%*$">EZP\/X+U
MUD C-"THM$Q,"Q#%V?P<&TL8]WA/"G82'3J4VU=^)ETGFX<XQYNM9,E%K5*R
M67QFD8:G\A9X5Q"&'5RHN)Q\+L^U4%)7*.'2,KO*4'O3NW)^Y7/\]_ST?IWB
MJ?/0X9[L=@DI?J9%=@$H2*S(\UW?-:!E)#X*(8P:0 XRI)IS*(2A/;^S)_80
M/V_SG%55^2E:><:^K5Y<L3_A9_^";JC=W"_Y^D2EA+*I?U;UAB?^7B4 0PYJ
MZ M*^[(\"R5]9>(M+>6K"[0WX2OF5JB,_8VGJ'1WD],'S_)84EAPM\/%\R\Z
MN;C)N2.1(WM)A-,#/M3[/GT8!!9:N0:*#=MR0F1[?OU^:&692"C-*QQ><7K_
M=@-O8HD*I2*.!6K+\],KEW\;O* %S#)Q#9G;Y@DT:% /V82O2!*)"O'\T@PM
M!^_I;ZO" UC35)4^D8+E\ /XN2U?P,^7[?H%L(7GY2_PDK+W7B!MM_<7N#IP
MO23T?W/>3O10;TFF<1;T/Y^+E'TVS8R8/@IGU>K@[Y\>/H%G\H:+O-I@6;^[
M_C2RE#Q(A+ZZL5I%%U D5AP@T79WR/CCD7WR[>8K)6E-7?OP2$)<;];$&:^E
M-)M<F(U?[&M)(C.,'=N(8@\&EH^,T+(:0'[H"QV>IP&&AK)P@ZV=$;TVD<AD
M;;5BB!CJ8G20-%:.&]QN0(L</!(ZI0$M> !Y';D+?\3V2<52R1CM8B0;9KBU
M=-U;AMGG$V[:>E"=F(.NSZ5+^7+)CD/3,4?;Y1@J>VU3BSY+L$\]@1+MU[Z$
MG29'.D3&&T7>;D)JW7>XV)+L1P+-Q$I,RTD\RUT%@9T$S8*#%73M^ =]]'LB
M0E8Y= B9.[F+1OA&9EC8/4G!@#?QLS7&\2;@:3H(DW.K"E'5Y)8E/LY<A4H'
M9Q+FHH.[8;91<_C6</ATNOI&ND!/S'WY?2Q%"\C<HT,@$UXR$MD69MFVFD=U
MVLNP\;?Y\^V>_>9R([[E(.AY@1,%H6^M4)0D,6I N"@0WQ@__="*)RDGP&?M
MTC859$ JS!+I1P'Y LE\7M[ETKP8Y>#()R'I@$F( @DDO&%>*8:Y1D>21H:T
MZ0Q^*01(2SJ].++&O?NT*-E2Q$JRD?XBS5N?\Z@38 &>I# XHN4BEO"Q1U*F
MN[:=";?.BT$=*XILQ_#MQ/>"P T]-X'MH$XB=/K31$,I]BD.$.S;WBZR,XD)
MN!2P(;TTRMG.50;9(_(0BYF 3@E+T4OKT +1AE[5[!55>97H"Q<9^T[JMY3T
MN<-T7"[ #28,ABBYW@9T[DIHB/+V$P:V[5O0] V$8B<Q/=OS:D"!;R)3NK67
M&AB*7>*\N5*J^D%;L60"AK,<M>3,J!6* 0>=Q^]N/^$:.ZC!C^EJJ5:H =W)
MYA=L9/LR%<+)M3@;1&&?+>K190&6J2G0:UW4=' K9+51MSK(=Q.M<7[ [9A7
M-X>Z]LJ'R'-BBSH^7"$8F/6+RL#R8UO\G!PEHRM?R]#!S.NN_*RBTSTM\XI0
M#?T";CD[\W(F>4XZY!LI.> .[=*;WG7)(>&)L\LRS H?7S!?\$>9STXB;,C%
MZ@-^M^QJX=JGS-%K^(:0UF=^2@58@.>IC8_HNI0O':Y[!7VAWWW^T/R$?F&%
MS\\?_@-02P,$%     @  8%;3+OV%R#+?0  ;'4& !4   !M9VYX+3(P,3<Q
M,C,Q7W!R92YX;6SLO=F6&SF2)GP_3Y%_SG568E_Z3,T<K#GJD5+Z)677])4?
MBN$1P4X&7>4DE5(]_0 ,.F,EZ73X%I3J5$HAA@.$??8Y8 :8&?['__IZ,__I
M2UXN9\7B[S_#OX&??\H7T^)BMKCZ^\]_?/A%?3"O7OW\O_[G?_L?_]\OO_Q?
M_?[U3[:8KF_RQ>HG4^:357[QTU^SU?5/_[C(EW_^=%D6-S_]HRC_G'V9_/++
M;:.?-C_,9XL__RW^\6FRS'_ZNIS]VW)ZG=],7A?3R6KSW=>KU>=_^_77O_[Z
MZV]?/Y7SOQ7EU:\( /SKKM7>)^*_?JD>^R5^] M$OV#XMZ_+BY]_"A(NEIOO
MKO$EU>-?GSS_%]X\#:64OVY^NWMT.7ONP= M_/7_OGG]82/G+[/%<C593/.?
M_^=_^^FG6SC*8IZ_SR]_BG__\?[5KI.;R;0LKO+%;+K\V[2X^37^_E=3S.>3
M3T6Y04LM+MZNKO-2795Y'I6Q#(/9]'E=YI=___GF:O$UX  Y1+<H_/>:S5??
M/N=__WDYN_D\#U#\VLU8=9%?EX%@>6GSU60V3QW\WOYZD>;(KU\MIM]6N2G*
MS]M'VI$Y\5M[0<;_[^+R\F:R6+R>O"_"6_!Z=1$>>O1A&&D[B#3\MEZ0^"W\
ML#!EL5RV(^O>_GJ1YM\GB^4R7^A9L<JGUZTI\%BWO<CV^VPRNS#%8E5.IJMV
MY#K492\R?<C++[.V)MOG.^M%CH^3/_.+23MB/-M76U+<W,Q6FV\)WQL5']>F
MQ726UQCTT::=C[$VOG5[Z'S$'R>?YDG8/NR@K?$NEL5\=A%-9#V91]/OPW6>
MU['4CC3L>'SO)F7 Z#I?S::3>>/!/MM+^R/_L I_;G3Z]M),EM=^7OQU$L('
M.^AVO&\_Y[>STRT?;SZ7^76^6,Z^Y*_#PMY4B'J]=BO9AU4Q_?.ZF%\$O]+]
M<SU;?6LJS?Z>VI&@<F8#5BY,"*MOKQ:717FS ?#8F.NT;6>4+C0OON6YSA?Y
MY6SU+KQGQP9WH$EG8ZJY<AQOV<X(@P59W.0?)U^/KPW//-KZ&.*[6"RV,TWX
M>;+X%E;*R[PL\XOP@ JV[VKY>C;Y-)O/5O77X?:^H76)W^?3(JRO\]GFE7A[
MJ?.KV6(15MW-&Q.WF-1-L5ZLWE[^%EV9/Q9E:'"UF/UK,]PM/1K@T,GW=H[.
M^SSXZF'Z<\O5[";.@[MGMR-*!^+4KVA=YGJ6VMX&[8SG=3Y9YN[K;%6]"D=7
MI_TMNAJ1N9X$XW3Y:O'T5S5ID-)G5U(]_>3W21FME2]Y8ZGJ]]F55/5(?:Q=
M.Z-[,RG_#%*'CC_DTW6YF>:/C>Q0F^Y&I;X$W<2/?%%^F-S_34TJ)'7:G5P)
MH^]MC/48>[QE.R-\6UY-PN);;=3\/EFMR_R^(W-LH+4[:&>\[\HB]+SZ%OV1
MSUL'X$-QN?HKN+S'AEJG;?>CK,G1$[KH?LSU.%N_AW9&_/^O)\&@*N??_&PQ
M":;69'[/"?QC,5E?S(*9=6S4I_72Y\AK,J519WW*48\]3?IJ1XK-/H<.%L)F
MRR9?+&OM0!QNU>7(*A]^\]MWZW)Z'9XX80\@K=<N)7O[.?[YKIQ-HY^X7*YO
M-A_47=>3.NU2KCV(?XT_UET0TGON7,);I,.L_SY?K@+>F_W$\/D?B]E*38-7
M4-^#:O=;NI2\WNQ6IVV+HSQI_[?K?=ZG_9]"@D,-6QK?^N9F4GY[>_EA=K68
M7<ZFDV"Z3*=QERK,&.^*^:S.\>%IO?0Y\LBX]:K:CYLL9]/P\MC9?+W;A(JG
M$^_R,I[2A9?LNKZ5VML ^L2K5=D'E&.WT_C',K]<SU_/OK0L6XTOZ%/>=M_4
M(=_8&+9XL9X'/UJ%SR_BFQ*PO=L)<%^G\_5%?N'+XL9,YM/U?/MR;5^J[>O4
M_IO<X<!ZQ;=ZZBY0I2B7'Z\GJ_?YYS)?!M_U31&<UNO) H(@ZVT'<4L_GWV)
M:W:[H+8\FA$C^;%83>;O\R_Y8IV[2;FH[>0.,YI!D/236?D?D_DZ?Y-/ENMR
M<QJ_\XDWYXAA]3S]K++?4?2)7$T+O$%?)TOQ.+9=WLJQR*_B,OEZ\BE_%-7S
M7+MY63YH%H/J90RJAVPCR7.]M3S2W_-5NX-]W&'+XPUKRJR(Y\OMCOKY;CL9
M^X?5I&P9\WT=MSS^C\$[R]L=^=,NVQYSG/E;'O.3+ML;<P-BK)X.LR8+M@OE
MQG!['3[8/A_[;25+YO:+\Z^K?!$LQ4U*3O75\V)Z9!:/GV2/O^CU;!JWN^Z^
M2GU:;@*^JZ^<1\'__G/H/CNM@PQX @07P'+I(+ $4Z&L(, #"3UF_*%0\YA0
M591;.-N6RLZ6TWD1%^./ 3T=NOVSL8#/])51++ARC%C$I%3"J2#B5E;$+69U
M9+U/'E5.?RK*B[S\^\_PYY_";VZCH5[?CG5O-MB&2ZLG,\"DG#Z@X-.&VR=^
M_;P)?_UE>CV;[\YM8G)<MP0H^H4_"%N]M;\^^]IV_T(?2?UZ(6^X91X'E)G6
M'ENOO4+0W<(.PV=8-'G#MZ!NZ'DY67[:<'2]_.5J,OG\:Y3VUWR^6E:?;.3_
M!<!MTN1_WWZ<W3G;]Z3YDJNRC+%$53#][\5BNN?7'\-/RR!C/.W8&+;/H-7=
MEV7.*JVAY48:A(EFS),[9#VUW^5\4IMNQ<CT<S?A=,MZ$SVRO R@QVBRFUQ]
MG2T/\/:YQS-)*4,$(@T-L%HHR16L)*.,X?-@WABH4;2NC;YX]C[_O#WDWKVE
MCT=OBYO);'& ?+7[R"1 4 (+#46,"*VXXZ;"@&/BSXN1:30H^@'Y.-'V&"=W
M=L^K\,?\.I_=O,EO/N7E/F-D;X.,48&<,MXKJAFG7D'JJQ%["<EYT:(#318=
MP-S?2I<\6P=S/G^URF\.KY#M?4WFD&<\&"HFV"_0:VLDV2'I)%4)A$7C(^RH
M5M;!M-AXH@SC>I]?KA<74?(_/@=\%RN?Y\^1]>#S&0X886R0L 1*I* 0"F_'
MR[T[%T]B6%47[2NB.7'6<=J.A\R+]63^)JP(JSP>/>7O)M^BJ+='GW=1N4^(
M5+-]IH"TE#G-C: &8R<!$)4\ ($48HUP.AL!L;I13&.BJ8N+691K,G]7A)&L
M9I.Y":UBWOR;V3Q?KHI%-;3E'XN+>[M?^ZC7O,?,(,0@]DHBBPGT!CJTDSFB
MFD!&_(.,3\G8FZK:I.?[_"H&U13EM_8(6KO/++Q\@!,O/ =80TTE8;OYGTI4
M:[-T#T7)#XK6HFA7RFJ3I#'];]D>/^MTEW%GE*..8(:1X!!B)U EK49).RST
M!S5K4;,#/?7EBV\W[)?;:+ #[O2C)S.ME:<<,^Z)4E*Q( [9R2-1RA8.^\&[
M9WWA-!7TM\&\&=W[V_H64?3=J_$F7UT7%P\?^->S[DSSSC(/PZMF!(9*.B^U
M04Z '2H$R 1B\E.)^24O/Q7? S4[UU-?[*UJUQR?$!\]F7EGN:(42 P8I-(Y
M)E4EC]' )?!._)@0GV5=F@I&$$K22D7=%Q)P I41S')C'"+* 0B E[?*$8($
M]_%'P$G3O77O'&".!-?&*R"1#DCOD-7&G\FQ?U=TZS[@Y#3]]&:GQ0$?B3+9
M/9,YS "&PE+)@@^-#82,53(8HU*LJA%Q; PD>&Q9-51!KS3:&P?PS%,9 =A;
M")RP2G,.N'-^)T=8G,XL)J2!_IYC0"/L^N+ F\G7V<UZ?S3(L\]E6&!@"<64
M."DQM<HH4LF"A:)GR(-3M5BTAU]O7)@MZG'A_G,9#H8_1X!#ZRW5R"D,U&ZU
M=AR<UX%D*UQ(P*^_K:!E'K[K.I8]""[:O+@MCW6W3%8W%'PLWN5EK'KDBW+C
M RWUMX]AJ,?,DS;ZSS!A5DHOE3$(&@B4@*#"3@J2<K@S0NZ-R;090'TO@/I1
MLAHAN"WTGS%K#8Q'$E@JQ4SXA]TM(8CZE#VK,2[!_?*M/;8WUECCP\W;G:<W
MORD T<ZY/ASM>Z!)Q@P2SA*"D/2>*("<=M6H/21GDF(WD*:+3I3PDO)>F#!>
M<F"5U1QS'LPIL@V;%I(AGA*=.\((HA&MX"UHXSSS7@PWQ" I(37!UT>"$UI9
M]9)H<6:^;1H-&N>]G 9RXEIX[Q2FSCKXY/&,:A/>+^"0,%0I3[4D9#=:)-!Y
M4:(#+3Y=YU)!_I'QLO],5C-"O&7:8(>QL10152T)$F )SROD<51KZF!:'#[C
M15!KF &28\"8=U)P7NUC24SQF9T-#*/J6ADOIRFB,7%V,93W'*5)+'&<&.V=
MVF\F!?!<Q0AW"J$.ZY-F8K>0"):R6H]P4W!X(O:LL'3"QIJ]>1FK J92M'9/
M&0;&AW</>0<CN,X@8RL9C1(I:5LC]'-'1,JN5-2<AF4QS?.+943M??%M,H^U
M*-^%(1XBW($VF6&08N:$4IS$Z&%"-=V.VSE%:A7\>CGFW@BHU9XR!@SL7H=A
M?XZ%>.<!J#+:$/?!M'G0Y,ULL:V%_"&?SV/)T7(VS6\O0SPM\#OQRS+D#)%&
M"P4,90H*&1:&+:K>$Y"R"7WNF3*G4GPT6AQ_'@U&P I*@+3*44:HL[9ZU[W3
M*F7B/?<\FJ:L3%-!XS5[_\MP\?S+\"$OOX2A+K>'1/G%WEFSU?XSHAP!0$EL
M.?&0"$UY=<+I-4:FSPR:,Z?DD(H;0?Z#_]_%Y>7-9+%X/7E?3*_SUZN+\-"C
M#U\MIB\Y[R$R #LH&)0.>DRYQ-L%BP/OZ^W[_\A[>&Z'%4&!J+36&8P(11)3
M#2MD"0)GLEG8%=VZSWLX33\O*>  :@"<I2Y8#H!#@J54V]U13AFU9W:\.R0U
MZ@0<G*:-,PTX,(@+1@6QF@+)D9"6;S%@$IU;A%4:#9H'')P$<F-'P?_MJ5GT
MM\ES=M'?#H<BG-Q1%HU7#ZA4@D,FJ=&$H$I"(65*+/0(:=2!YHL>X>]K)ONP
M_K3,_[D.Z+@O<38_'IB_IT46W!/$'),D .FP4#%A82L?1X[H\SI5&]&ZV8Y"
M!B3<T:5R;YM,(F2YEDX#*RD$1AM:O;M<FW,+O$K6]''F-,)U(.X<S4-[]OE,
M>8<PH0)*0+3 B#HA*MF\TV>V#K:@X\.L:83JC^B\_?N,TAA*L8(6*\:0M1I0
M4R')$/P1\=Z= SJ8%H>/SJ/,$^0@QC*\PL'%DLQL]Y>Y($BE' R,<%8<1M6U
MHO-.4T1ZL-.3J)<8FE5%+10+OUZMRWQ3!G%]6NQ3TXXSS1P5EAE%C=<6&4=5
MY2D)+NM5$WHYGL3P5.Q;8XTYNWU-[@IK5V=JM]>"[F/DD689 \IJY9#VB"D.
MJ U6]&[T6*8<TX]PP1V>;^WJHR]3LGGU0"$"0)9*PA7!(@CAJUJ>\1)&DU)?
MZ=SC[T[E5SLJ&(A29EV6SR^LAQMDP"F*@44:8: 9\0SL?"]!2;W['MN*?GMQ
M95%;HE@S70S$M C2J62[:Y,1J8$6D%!,"/, 8Z*K_2:A!4\YD#KWN+:6V-98
M&2,(#/HM_+ P9;%<ON30'^ZTEBK>O$9C2>/@M)EM:FOPUI2J5=7J1^C/<]LW
M6(67!&,FE;"0&><HV<Z@P'$)OL^2I[7IUGWHSVGZ>4FA/Y@3#1%5E(4O,=ZZ
M3?3PK616L#/; QN2&G5"?T[3QGF&_GAOJ<76.0R4('$",+C" '*=LC4Q0D:F
MT:!QZ,]I(#?>O;JS>VK7&SG0)+BT5.K@4D@67CDBA<!<5Z/&/FG7:H34Z$";
M12= ]S8/G53BFSKI+">*0 F5D\$UD/=E2"D&.,(M]1&M;$U5T"N-3BKQK4VL
M\13>+:29IYA!@G?O%W/JW.I*GJZ_ R6^3\.N+PXT*_%M %:.< 6)@! P1WVU
M2P^<LDFE=<?*@U.U>+#$]VGX_0B8V;^G!F2\=ES'&MD8>HN!AZA"$@&<XK:-
M\/QN1(O;@%IL;(6KJV _7DU6^>[4^_98VQ3+U?M\=O-I'11X*+ZA=@<9$8A"
MZ$2L):P-(0"3G>?"%3^SE7(8,A0]:*8YU_;?QAQ 2:XRU%+W&6)46BZ-M@@[
M;(VUT%1H@+30KQ$Z!R/@Z2!Z&S[$$*+@F@-%#&'<,<D$='#GF0<!SFN='IYG
M+2DB8?K[K_5RM1&JV)Y;WC)X.HU;-[/%U8=8!VY27BQ-<3&[#"] %'O_=->H
MNTQ!KP%$2 K%L&0<.$IWD[TV9U;M='C:]:.GY/)J/E;G>K::?U6"8V^$:^T>
M,F<YH[<QO"3F%Q+&2"43)3AED_;<ZU(UXEYGJAE_L2EKF0U6+351$$P-]7BW
M/T6,^W%I>WM4:T<% ];VZ_72=NHDD9H*%]"E5@KFY;9N4OB_5BF)P>=><JHI
M,3O7TOB#KA5!G"'KK0S./8<T6!65->$Q0"G;T^=^97M3UJ6IX*4%70<3 5+F
M'.180T&1(FSWP@A/4NH$R;,/NFZ)8LUT\3*#KB73EB'HG%$(!-."$E,9%UXZ
MG501#?R8T>K0K;$V1A!U_>\!E]"QGA6K?'K]TNLN,L^D%EHSJSD$ &&[13^8
M+A37\G5^!%\_=Q3( ZVQ949 A!B2VB#%*V2Y8]]IW<6Z=.L^^/HT_?3G8KZ$
MRZ =U!P#;8G5#B&O"':RP@YB>B:)!6,@7R>709^FOA= _1XO@T: > JP]D!9
M%HP>9ZJ2*-1ZPE-2D$=(_9[YULEET*=IK/%IR-8L?/.;!1#6O WZ4)LLIB8Y
M#81@7%KG!</5Y6+4,B53#GG/BVE-=%UTHX56V$,;L.=QFPQ01:R 89V1*/S)
M&1';H$CJ/*,IYV4C#$49"7L2M?"2,OR0QP(IBTV01@:7W3N-*LD %;6R=E\.
MOT9D K:@C7/-\,.>&&X0L@9X@DB\57N+ 25)F3DC7"_3:)"0X7<*R*G+X=T>
M6ZV5\/'C&2!,.^Z$Y2K.PU0!7+UCCG&1<I(_0DITH,5G%KI$D'^D7^S?7#=4
M"NVLM1QZ)IV!M$JXI"[8#6=6/FU4:^I@6NSK?8C%!M]>?E@5TS]_7\?W-OSC
M.NAI^6JY7.<7KQ;WA#FT47Y"-UF,H988$2M5L'VM4PC8W33C4:_7;;RX@]W:
M-'J\5=Z=A@;@:O#;EK.@\8W^W^?3/$!W\?9TLA[O)Q.<(Z29%%Y"%A9!@P2K
ML,#8]7J9^??(UM95-'R>AI8,4:DL]0XPY*@.0Z[&RS5.<4E&N* /2J@V%3'
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ME0=6 67BWUNIB&8I>?2CW#'O@U#), ]D-\;QNJ^?XW;^[_DA'AULE]$@H95
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M)K44.V;)X7FB/?C[F2H6RV(^NXAGXGHRCX?%'Z[S?#7<%/$A2+&];<#/%F%
ML\G\7;'<I$'4F!GJ-,\,1(A [@GVS$M"J--<0^*I$)(X7.LUZ$9Z%:ASL"SM
M\P]F3FJO.(.((B,5@ ACM).(\#.[SKI=)3^NJI2";&\%NS:#W!X.U*;+H^<S
MX*003#N&O>'.6 8UK63SA"5=;C$^UC15[+/\2(.RMS(VDV6\I27^Y?ZYGGV9
MS#>+X<I,RO);6++^8S(_Z('4:I\9+IS5,+Y5QBH.8AV?2G9%Y)D5IDS4_^,<
MBPX0[FT2^C*9S:-#X8LRWA[[(9^NRS )Y\OC9]!'VV8<8:Z,!X);9./9$O2J
MDIEI=F8U0=IE5=OH]L:HVPL8E^_S:1[>A2# [_FJ!ID.-,N40@9K10&S8?WW
M-!K:NWD>)YURC/ 4KF4>M0=L;T'-9?YY,KO81I@=Y\ZSSV=0(<F(9]0SS+!1
MPIB=\2AL4C&&$=;[:)<T;2#:VR;MYAZ2C?B'=ECNGLH@L0IY)QSWCD,1W N]
M6XJ=2C)V1AATW"XSFN,XB%]5UY_*$$3,&TT]!-1Y J!Q9(>'I2E^U.D'09UO
MP+>\Q"0@V=^:4GS.R]6W=_.85;&XB);ZYL[+PZ'FAYIEAB $A24"$J(-8@Q9
M4$DJO4Q)7ABM>9OL>[>(Z/!.4JTKU^HTSXPGEBBGA058$\X\T[*2'!N>LJT_
M6A,W?1^G?60'L%IJD>C9YS."  ]R<* PMQ8($//"MK)1R5+"%T9KXR:SI@TH
M^S5FCEHQ&>5(RC!K"@@PH=I+A\5V]"J6@._5I.W)?&EI&_A$['I+09]-/LWF
MF\DLK)(?5L7TS^MB'C2RC"OFZEN-$X.Z763,*(VL-RS\:1D#W BR0\#3,]NG
MZ_3HJ2/,!V!=_9.I_8VR,(E*#C@W&B!/'0;:F$I*CWC*SMT(SQ7:5_Y^=J4A
MW?=N\+O)MVBGU=\'?M@@0XR@6!0]+,M<4P&MASO !%5G5J*^#37OV09.PK5'
MUI3KH(TG,!PFSO-M,J4@P<9B30$@&O&PR/M*1JMU2A&5$:YNW7"G%6C[+TIQ
M_Q+W ]S9<^N[#B\ =0!19C'@S'D'=WAQY\ZL^DX'Q&D%U^%*F9Q"G$=MLOA*
M0*NX8O%L%FBDJ:YDC'?3G)=GWBEWTJ#MBS[O\R#P>KI:E[/%5;Q&J_Q28^8Y
MT"H+>G!.,R,9X=0#1=%N(UT!YE*2]D=X3-4!A=H#M]==P9/,GCTM,J )E]Y0
MC"BTV%EM714<H@Q.RKL;86)3!^1I!]CA_/:3_/7,>Z$-#B8_-MXRQS'UU5&N
M4LJFU&$88?Y1!W1)QG0@X[C6X</>-AE%F AA"-",>@((LW<.0 QQ[-.WZB.]
MM_,=GK:@'LYJ/I%13YMEU'HKJ.&4<VXQ=U1 L'MQ0%*UHG'[75U3*AGK(8WI
M6KPZW#!#.$SL5)E@[1D<"V<JA':+-Z,I$1OC]LJZ85:K: ]@*M6SD3*M4:S:
M90@#$DB''# [AQ-KG'+/] @/5_L\Q#@1VKXHTNBT]0!2'@M'M==AJC5  V6<
MK0X3M8$<GJTSU@V!6D.ZMQRNXN:F6&R&?31=Z]&CF89:4V,(AA9Y8>,65V7V
M:8#=F9V@MJ':9Z[ 24"TMS.OBXM-!,)D_FXRNWBU,)//LS#5WQO]H<.OHXTS
M02ET#)!X6J.8 5R *M5#A^4YQ:@>X2E8!SQJ'>,>3U/7-^MYK ^PV=0*(P[J
MNLX7R]F7_-5B6MSDKXOE<G\PI;KXK_5RM8W1?7OY<?+U\#ELV]^62<RXX$)#
M;HP&P7ATK#(D-08VY?J6$3J$77!W<*7TYSFN)K-%?N$FY2(X)<M[D@<_>#8]
M>$'!\<89)\Y+Y[&1$C&,5*SM5TF-I#JS6Z0[H&+K& _G%)SD#&1(:ZF5IP I
MHP4PE""Q>U_23H1'Z$5VP)QD3,<2NIL0LIM9:I@W6""(18 QF!MV)[%T-L6,
M&_=!3>=[$6W@/6B]IW<;2*_SU6PZF3\<UYD5?]**A!<>*\\DEUP30+R2##$4
M?N:^7M7XSCW]H(ZWY4:<BXW?^2XO/UP'%=5S_O>USA!R  JF%8^+(\866%G)
M[D32%O8H]P/:I,/^G8&6X!Y@0VDSS*5:KZZ+,MXC7X]>CUME7@1[7FNK)<!8
M6!83YBHY(? I6Y2CW![HAU:), ]&I[?KU7(U65P$ _T4/MUKEC'D&2*:*^TT
M=(HX 'PEJ?3^S!):^R54<YS[-E!VN"S?7L8"67Y>_#6*PI2[P9QFDSQIEC&F
MA9)20Z:=M![B:('&U E*'!+U;KSN1MI8YR<,]UU9?)D%?/6W/Y;YQ:O%KMBI
MFJYF7VXCEC9U5=?AL^TO@P9KX-+.%V0:B;"R,HLQ$L'U1\P[4R%H'$S)71VW
M19- IF($FNAK=0K"W6U1'J;CW7,9#P(08!SEBE,B&=?<5;(X2U(B&D]F51^1
M:7U3X"D#&X/?WQ%;M8F]_%B\SZ=%6*8WY=#N1OZQJ EBG8*M'7Q=IN,UP)X9
MX[4T!GFG%:N0]1CV&G#9_60Y,*E'H,'^XCB#[H/5&H$+/\_S#3D6%^JF*%>S
M?VT^/QC/>;QYAH.]2^*%PXX+C9C24/E*<NG@F27Q#DN>)S&@K>NGMW.7Z/+H
M28 FGEKFB^4Q+C[?(.,:J%A#2G(N@I >,E)!YZU2*8?((YPY1\6^5C32%]\"
M0&6\!L+FMW_?@V0;\E%C[:_?248M0\IS8'7PX#&'4(GJK?..B3/+,AX5+SO3
MTG!<?5KN]R26/FV>8::E0%1XI!1WDE"(0"6Y%B0E^KG^JBUO^;G(K^*NTL?.
M:=H%,XZ2+QG\X6CWL&#P291[V#03V#(5\:1*D; (&+*SU3UUH)^BF@_I=GY,
M2\)\.)9M\DUFTZ"2S=9943ZS*)S$O3H=9AY*;2#5P#('88"(25BA@VU2'G[]
M!?K<&=F!)@8T&&.,Y9T QVHXUNL@DXA2:#3GU"*"+-.0[-8"0$V* U,_]/#<
M>=@"\L,;?]LB7XTLOVW;S" NC>4(*^:L=YA3)2J9"4XJ+3O"ZB.#VGO-(!^4
M9H_J@9W*M$?-,QGK/E$,)2= >B0E,+N)'6F?X@./,$%N*+*EH3ZPV?<HS?AT
M,^]1!QF40%GOL6>8*VN4I$Q6TBNN4HK>GAY)>YZ<:P'WX5CWJ!+'281[U#;,
M[.'- MQK+@!T\?HW@W=O&DPJ02E^<*T%R(_3[.9J\75#'HBVU(F?'!S(LY4J
M:K3*K) P#-TPZZ ' C!$=_8FLS8E=DY^5W1I'^R!G<IM;:FFIM>>/L*<#!TW
M'%F$>;PM@W) *PRX52GS$P3?%>.ZQK['H*N$R(O.@@8SHH!0D@NB"$ &.$2U
MND6+ D1=BEMZ^FE9Y_E/PP=U]:>K@9G]:O$E6*L=AL6>^ 69\ QAS255GD'#
M-*6"[M##)B6 <83Q"GV&Q7:KB;YX_&[R;7N,KJ;_7,_*?'_VOLT_';SD[K2>
MLGAC $*>$*LH9%Y(!N .#X'ZN7.^[Q/AOKGT^-J\3G74&V?+8IKG%TL?X(V#
M5HN+-Y.X/;#Z]O9ROT2'N-NLQTP" #0W FFU.5)2D.ST8"!+B44<X>PZ-'E[
M4=)@$^_>*RU/F7/W=I(A2X$PVC"@L%1:2.5WKS)6]3*,7M+Y\]!D[4HS+\/
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M00[JWN>K6=#3NTFY>0G>Y*OKXD+=%.N#T=QUN\BLX4I@Y:CPU"&M7# <*P2
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M*%BN@*G@TFWQ9$B>2=6-5IFU[SAK 'WT?I#Z*(CP_H5ZS]P#7Y^]^WK*/.8
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MQIY;.FZK3*C+LL9H]Q=Z=?-Y'<#?C;A&T-6S+3(8!,**:D4$LIHX@0FKY.-
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MJBU7>C+;KE"O99+]E)+P.5].9IV9!E4^'XQDBC&%N54L$D1)QIX=AK16!.$
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M;I]O6?$EOU9&-81P=]4?]NW,,Q:GXPV#8@8 K@46$+-TU1$TN!PM([+..?H
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M'<_'501_U^.#E:I/M(@[ F!,><V@2K<,Q.$A5(Z/>%4G*.*:V'2)Q'^NW=D
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M,C Q-S$R,S$N>&UL4$L! A0#%     @  8%;3*<FSF;/$P  ]](  !$
M         ( !CY(! &UG;G@M,C Q-S$R,S$N>'-D4$L! A0#%     @  8%;
M3!HZG%A6'@  /SH! !4              ( !C:8! &UG;G@M,C Q-S$R,S%?
M8V%L+GAM;%!+ 0(4 Q0    (  &!6TS4ZO6I*TL  'JO P 5
M  "  1;% 0!M9VYX+3(P,3<Q,C,Q7V1E9BYX;6Q02P$"% ,4    "  !@5M,
M;4O\T]G+   -DPH %0              @ %T$ ( ;6=N>"TR,#$W,3(S,5]L
M86(N>&UL4$L! A0#%     @  8%;3+OV%R#+?0  ;'4& !4
M ( !@-P" &UG;G@M,C Q-S$R,S%?<')E+GAM;%!+!08     !@ & (H!  !^
%6@,    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
